NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
NCT04076280,Sodium Watchers Program - Hypertension,SWAPHTN,Recruiting,No Results Available,Hypertension,Behavioral: Sodium Watcher Program-Hypertension|Behavioral: Usual Care,Change in oral salt taste sensitivity|Change in blood pressure over time|Change in adherence to sodium restricted diet over time|Change in dietary quality over time|Change in Depression over time,Misook L. Chung|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,44336,1-Sep-19,Nov-21,Nov-21,3-Sep-19,,9-Nov-20,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04076280
NCT04101630,Activity Monitoring in Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension,Behavioral: Activity Monitoring,Activity Monitoring|Six Minute Walk Distance (6MWD) Test|Intensity of Activity|Quality of Life 36-Item Short Form Survey (SF-36)|emPHasis-10|Minnesota Living with Heart Failure (MLHF),Vanderbilt University Medical Center,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Physical Activity in PH,24-Oct-19,Jun-23,Jun-24,24-Sep-19,,25-Nov-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04101630
NCT02188381,The Role of Gut Microbiota in Hypertension,,Recruiting,No Results Available,Hypertension,Other: Stool Sample and Blood Sample,Characterize gut microbiota composition at phylum level|Characterize gut microbiota composition at genus level|Reduction in BP is associated with changes in gut microbiota composition in RH subjects.|IS hypertension associated with increased sympathetic activity and decreased parasympathetic activity and whether minocycline or other tetracyclines are effective to improve this balance|To determine if characterization of gut microbiota in at risk patients predicts long term care utilization and/or cardiovascular outcomes,"University of Florida|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 80 Years   (Adult, Older Adult)",,426,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB201400233-N|1R01HL132448-01,Jul-14,Oct-20,Oct-20,11-Jul-14,,28-Jan-20,"Cardiovascular Clinic at UF Health, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02188381
NCT04489251,Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,"Diagnostic Test: Protein Elisa analysis, microRNA analysis, whole exome sequencing",Plasma levels of proteins of the TGF-β pathway|Plasma levels of proteins in the TGF- β pathway and PH disease severity|MicroRNA levels in PH vs control subjects|Clinical findings correlation with study proteins/microRNA|Whole exome sequence analysis in PH patients and protein/microRNA levels,Medical College of Wisconsin,All,2 Years to 17 Years   (Child),,40,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,1492809,1-Jul-20,1-Aug-22,1-Jan-23,28-Jul-20,,28-Jul-20,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04489251
NCT04121299,Mechanism of Masked Hypertension - Intervention,,Not yet recruiting,No Results Available,Masked Hypertension,Drug: Carvedilol|Drug: Amlodipine,Out of clinic 24 hour ambulatory blood pressure|Out of clinic awake blood pressure|Out of clinic asleep blood pressure|Out of clinic blood pressure variability|Out of clinic heart rate variability|Out of clinic 24-hour urinary catecholamines|Out of clinic 24-hour urinary metanephrines,University of Alabama at Birmingham,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-300004152,Jul-21,Jun-26,Jun-26,9-Oct-19,,3-Nov-20,"Hypertension Research Clinic at UAB, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04121299
NCT03679117,Prenatal Mindfulness & Hypertension Study,HTN,Recruiting,No Results Available,Hypertension in Pregnancy,Behavioral: Mindfulness Training,Retention and Adherence|Hypertension diagnosis,Lifespan,Female,18 Years to 40 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,1303286,1-Apr-19,31-May-20,1-Jan-21,20-Sep-18,,16-Aug-19,"Women's Medicine Collaborative, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT03679117
NCT03596242,SMS System for Patients With Uncontrolled Hypertension,,Not yet recruiting,No Results Available,Hypertension,Other: SMS System|Behavioral: blood pressure control education,Number of Subjects Screened|Number of Subjects Enrolled|Proportion of Eligible Subjects Enrolled|Number of Subjects who Refuse Participation|Proportion of subjects excluded without SMS capability|Proportion of Participants Continuing myHealth|SMS rate of response|SMS participation|System Usability Scale (SUS)|Medication Adherence|Medication Adherence Questionnaire|Monitoring of SBP|Monitoring of DBP|Initial and follow up BP in office|No Show Rate|Coordinator time,Wake Forest University Health Sciences,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00051763|5UL1TR001420-03,Jan-21,Mar-21,Mar-21,23-Jul-18,,24-Dec-20,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03596242
NCT04029883,Hypertension Control and Remote Blood Pressure Monitoring,,Recruiting,No Results Available,Hypertension,Other: Remote BP Monitoring,Time to Control,Cedars-Sinai Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00057764,9-Nov-19,30-Apr-21,1-Jun-21,23-Jul-19,,16-Jul-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04029883
NCT02425566,Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension,,Recruiting,No Results Available,Hypertension,Drug: Trimethaphan|Drug: Nitroglycerin,Splanchnic venous capacitance|Systolic Blood Pressure|Stroke volume,Vanderbilt University|Vanderbilt University Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,141218,Apr-15,Jul-21,Aug-21,24-Apr-15,,17-Sep-20,"Autonomic Dysfunction Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02425566
NCT03354143,"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)",HIPAC,Recruiting,No Results Available,Hypertension,Drug: Standard Care|Drug: Intensive Treatment,Changes in intracranial pulsatility|Cerebrospinal fluid Amyloid-β and tau|Global and regional brain perfusion via Magnetic Resonance Imaging (MRI)|Regional brain volume via Magnetic Resonance Imaging (MRI)|Regional cortical thickness via Magnetic Resonance Imaging (MRI)|Brain white matter hyperintensity (WMH) via Magnetic Resonance Imaging (MRI)|Brain white matter microstructural integrity via Magnetic Resonance Imaging (MRI)|Brain neural network functional connectivity via Magnetic Resonance Imaging (MRI)|NIH-Toolbox neurocognitive function|NIH PROMIS patient-reported outcome measures of physical health|NIH PROMIS patient-reported outcome measures of mental health,University of Texas Southwestern Medical Center|Texas Health Resources|Michigan State University,All,"55 Years to 79 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",R01AG057571,10-Apr-18,15-May-22,31-Oct-22,27-Nov-17,,7-Feb-20,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03354143
NCT03986931,A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting,,Recruiting,No Results Available,Hypertension,Other: Experimental: Pharmacist-Bidirectional Texting Group|Other: Active Comparator: Control Group,Change in Systolic Blood Pressure- 12 Months|Change in Diastolic Blood Pressure- 12 Months|Number of Medication Changes in 12 Months|Dollars Spent per Patient for 12 Month Bidirectional Texting/Pharmacist Intervention,"Linnea Polgreen|National Heart, Lung, and Blood Institute (NHLBI)|University of Iowa",All,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,420,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,BP Texting and Pharmacist|R61HL144880,25-Feb-20,Dec-21,Jul-22,14-Jun-19,,12-Mar-20,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03986931
NCT04263311,Scaling Community-Clinical Linage Models to Address Diabetes and Hypertension Disparities in the Southeast United States,,Recruiting,No Results Available,Hypertension,Behavioral: CHW,Change in BP control|Change in Hemoglobin A1c (HbA1c)|Change in systolic blood pressure (SBP)|Change in diastolic blood pressure (DBP)|Change in body mass index (BMI)|Physicians Attitudes Regarding the Integrated Intervention|Barriers and Facilitators to Implementation Adoption and Implications for Scalability,NYU Langone Health,All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,162,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-01192,6-Jul-20,Jun-21,Jun-21,10-Feb-20,,24-Aug-20,"NYU Langone, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04263311
NCT01996449,The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension,,Recruiting,No Results Available,Hypertension,Drug: Eplerenone|Drug: Amlodipine|Procedure: Microneurography|Procedure: Rhythmic handgrip exercise|Procedure: Sustained hand grip|Procedure: Forearm blood flow|Procedure: Arm cycling exercise|Procedure: Cold Pressor test,Muscle sympathetic nerve activity during exercise,University of Texas Southwestern Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,R01HL113738,Jul-13,Dec-21,Dec-21,27-Nov-13,,11-Mar-20,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01996449
NCT02922023,Management of Uncontrolled Hypertension (HTN),,Recruiting,No Results Available,Hypertension,Device: Ambulatory blood pressure monitor (ABPM)|Other: Chronotherapy,Changes in blood pressure|Amount of subjects from each group that achieved blood pressure goal,University of Florida,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB201601421,Jan-17,Aug-21,Aug-21,3-Oct-16,,19-Aug-20,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02922023
NCT02245230,Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension,,Recruiting,No Results Available,"Hypertension|Hypertension, Essential",Drug: Angiotensin (1-7)|Drug: Trimethaphan|Drug: Phenylephrine,Systolic Blood Pressure|Hemodynamic Measures|Circulating Renin-Angiotensin System Components,Vanderbilt University|Vanderbilt University Medical Center,All,18 Years to 60 Years   (Adult),Phase 1,34,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,140958,Jan-15,Dec-21,Dec-21,19-Sep-14,,11-Jan-21,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02245230
NCT02034422,Understanding the Exercise-Hypertension Paradox,,Recruiting,No Results Available,Hypertension,Dietary Supplement: Oral Antioxidant|Other: Exercise rehabilitation,Blood Pressure,VA Office of Research and Development,All,40 Years to 60 Years   (Adult),Not Applicable,72,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,O1215-W|1IK2RX001215,1-Feb-14,31-Dec-21,31-Dec-21,13-Jan-14,,14-Jan-21,"VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02034422
NCT03044314,Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension,OVATION,Recruiting,No Results Available,Pulmonary Hypertension,Drug: Illoprost and nitric oxide administration,Change in invasively measured pulmonary artery pressures after challenge with NO and iloprost|Change in echocardiographic and invasively measured parameters after vasodilator challenge|Change in PA pressure and mean pressure determined invasively after vasodilator challenge|Clinical response to vasodilator challenge by echo|Association of change in pressures after vasodilator challenge with clinical outcomes,Duke University|Actelion,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Pro00075840,21-Jul-17,1-Dec-20,1-Dec-20,7-Feb-17,,20-Feb-20,"Duke University Health System, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03044314
NCT04349124,Persistent Postpartum Hypertension Pilot Trial,,Recruiting,No Results Available,Hypertension in Pregnancy,Drug: Nifedipine Extended-Release Tablets|Other: No Antihypertensive Medication,Number of Women with Systolic Blood Pressure of less than 140|Number of participants enrolled as measured by randomization to arm|Number of participants who completed the study as measured by completion logs|Average diastolic blood pressure|Average Systolic and Diastolic Blood Pressure|Change in Percentage of Patients with Blood Pressure Less Than 130/80,Duke University,Female,18 Years to 60 Years   (Adult),Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00104425,25-Aug-20,30-Sep-21,30-Oct-21,16-Apr-20,,30-Sep-20,"Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04349124
NCT03640312,Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension,QUARTET USA,Recruiting,No Results Available,Hypertension,Drug: QUARTET LDQT|Drug: Candesartan,Change in Mean Systolic Blood Pressure|Mean Systolic Blood Pressure|Mean 24-Hour Blood Pressure|Mean Daytime Blood Pressure|Mean Nighttime Blood Pressure|Proportion of dippers|Change in Mean Diastolic Blood Pressure|Mean Diastolic Blood Pressure|Proportion of patients with hypertension control|Proportion of patients requiring step up treatment|Proportion of patients with adverse event free hypertension control|Medication Adherence|Health-related quality of life,Northwestern University|ACCESS Community Health Network|University of Sydney,All,"18 Years and older   (Adult, Older Adult)",Phase 2,364,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STU00205834,30-Aug-19,31-Mar-23,30-Jun-23,21-Aug-18,,15-Jan-21,"ACCESS Martin T. Russo Family Health Center, Bloomingdale, Illinois, United States|Ashland Family Health Center, Chicago, Illinois, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03640312/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03640312
NCT04592783,"Postpartum Hypertension, Tight vs Liberal Control Trial",,Recruiting,No Results Available,Hypertension in the Obstetric Context,Drug: Antihypertensive Agents,"A composite of the following: Development of severe HTN or preeclampsia with severe features, hospitalization > 4 days, use of a second antihypertensive agent, adverse maternal outcomes and emergent treatment of severe HTN.|Hospital readmission secondary to HTN or preeclampsia in the first 14 days postpartum|Persistence of hypertension (CHTN) at/beyond 14 days postpartum|Medication side effects (hypotension|Time to blood pressure control between different antihypertensive therapies",University Hospitals Cleveland Medical Center|MetroHealth Medical Center,Female,18 Years to 55 Years   (Adult),Not Applicable,256,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20200183,23-Sep-20,30-Sep-21,30-Jun-22,19-Oct-20,,19-Oct-20,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Metrohealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04592783
NCT03461003,N-of-1 Trials In Children With Hypertension,NICHE,Recruiting,No Results Available,Pediatric Hypertension,Other: NICHE method|Other: Usual care|Drug: Amlodipine|Drug: Lisinopril|Drug: Hydrochlorothiazide|Drug: Losartan,Ambulatory blood pressure (BP) control|Ambulatory BP reduction from baseline|Side effect experience|Cost-effectiveness,"The University of Texas Health Science Center, Houston",All,"10 Years to 22 Years   (Child, Adult)",Phase 4,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HSC-MS-17-1014,2-Apr-18,May-24,May-24,9-Mar-18,,14-Oct-20,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03461003
NCT03436550,Assessment of Portal Hypertension With Multiparametric MRI,,Recruiting,No Results Available,Portal Hypertension|Clinically Significant Portal Hypertension,Procedure: mpMRI|Procedure: ARFI US,Rate of diagnosis of portal hypertension (PH)|Rate of diagnosis of clinically significant portal hypertension (CSPH)|Rate of prediction of hepatic decompensation|Degree of ascites and TIPS patency,Icahn School of Medicine at Mount Sinai|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",,186,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,GCO 16-1307|1R01DK113272-01A1,20-Mar-18,30-Nov-21,30-Nov-21,19-Feb-18,,30-Sep-20,"Mount Sinai Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03436550
NCT03897777,"Exercise, Hypertension, and Gut Dysbiosis in African Americans",,Recruiting,No Results Available,Hypertension,Behavioral: Exercise Training effect on Hypertension and Gut Dysbiosis,Blood Pressure|Gut Dysbiosis,North Carolina Agriculture & Technical State University,All,30 Years to 50 Years   (Adult),Not Applicable,36,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NCarolinaATSU,1-Jun-19,Jun-21,Jun-21,1-Apr-19,,20-Apr-20,"North Carolina A&T State University, Greensboro, North Carolina, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03897777/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03897777
NCT01712620,Spironolactone for Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Spironolactone|Drug: Placebo,"Change in placebo corrected 6-minute walk distance|Change in placebo corrected VO2 max|Change in right ventricular function|Biomarkers of vascular inflammation|Rate of study drug discontinuation due to hyperkalemia, renal insufficiency, or other side effects such as breast pain and gynecomastia","National Institutes of Health Clinical Center (CC)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania|University of Maryland, College Park|Medstar Health Research Institute|New England Medical Center, Tufts University School of Medicine",All,"18 Years and older   (Adult, Older Adult)",Phase 2,70,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",120211|12-CC-0211,10-Jan-14,1-Oct-21,1-Oct-21,23-Oct-12,,11-Jan-21,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01712620
NCT03480217,Implementing Hypertension Screening Guidelines in Primary Care,,Recruiting,No Results Available,"Hypertension,Essential|White Coat Hypertension",Behavioral: Multifaceted Implementation Strategy,Change in proportion of eligible patients who completed out-of-office BP testing post-implementation|Change in proportion of eligible patients who completed out-of-office BP testing during maintenance period|Change in proportion of scheduled clinic visits with appropriate out-of-office BP test ordering post-implementation|Change in proportion of scheduled clinic visits with appropriate out-of-office BP test ordering during maintenance period|Change in proportion of patients with newly diagnosed white-coat hypertension post-implementation|Change in proportion of patients with newly diagnosed white-coat hypertension during maintenance period,Columbia University|Agency for Healthcare Research and Quality (AHRQ),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,AAAQ1062|1R01HS024262-01,2-Apr-18,2-Apr-19,Apr-21,29-Mar-18,,27-May-20,"Center for Behavioral Cardiovascular Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03480217
NCT04576988,A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR),,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Sotatercept|Drug: Placebo,"Change from baseline in 6MWD.|The proportion of participants achieving the multicomponent improvement endpoint, consisting of all of the following:|Change from baseline in pulmonary vascular resistance (PVR).|Change from baseline in NT-proBNP levels.|Time to death or the first occurrence of any of the following clinical worsening events (TTCW):|Proportion of participants who maintain or achieve a low risk score using the simplified French Risk score calculator.|Change from baseline in EuroQol 5 dimension 5 level (EQ-5D-5L) index score.|Change from baseline in Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®).","Acceleron Pharma, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,284,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A011-11,Dec-20,Dec-22,Dec-22,6-Oct-20,,23-Dec-20,"University of Kansas Medical Center, Kansas City, Kansas, United States|The Linder Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04576988
NCT03783169,SASH Study - Sonographic Assessment for Severe Hypertension in Pregnancy,SASH,Recruiting,No Results Available,Hypertension in Pregnancy,Other: Cardiovascular Sonographic Assessment,Systolic Blood Pressure,TriHealth Inc.,Female,"18 Years and older   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,18-027,11-Dec-18,Dec-20,Dec-20,20-Dec-18,,9-Jan-20,"TriHealth - Good Samaritan and Bethesda North Hospitals, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03783169
NCT03648385,Effects of DHEA in Pulmonary Hypertension,EDIPHY,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: DHEA tablet|Other: Placebo,Right ventricular (RV) longitudinal strain|RV ejection fraction|NT-proBNP|Sex hormone levels|Six minute walk distance (6MWD)|World Health Organization (WHO) Functional Class|Short Form-36|emPHasis-10|Treatment-related side effects and adverse events,Rhode Island Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01HL141268,9-Jan-19,Apr-23,Apr-23,27-Aug-18,,19-Oct-20,"Rhode Island Hospital Pulmonary Hypertension Center, Providence, Rhode Island, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03648385/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03648385
NCT03270332,Effect of Inhaled Albuterol in Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension,Drug: albuterol first then placebo|Drug: placebo first then albuterol,Mean Pulmonary Artery Pressure|Pulmonary Vascular Resistance,University of Miami,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20170552,12-Oct-17,31-Mar-21,30-Jun-21,1-Sep-17,,15-May-20,"Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03270332
NCT03145298,ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy,ALPHA,Recruiting,No Results Available,Pulmonary Arterial Hypertension (PAH),Biological: Allogeneic Human Cardiosphere-Derived Stem Cells|Biological: Placebo,Primary Safety (Early) endpoints including the determination of Gas Exchange and Hemodynamics; Detection of Arrhythmias; Sudden unexpected death and Mortality and Morbidity|Secondary Safety (Long Term) endpoints including ongoing monitoring of events listed for primary safety endpoints as well as long term monitoring for a composite of time to clinical worsening.|Exploratory Secondary Efficacy Endpoints measuring right ventricular function and pressure estimates,Cedars-Sinai Medical Center|California Institute for Regenerative Medicine (CIRM),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IND 16686,1-Oct-17,1-Jan-21,31-Dec-21,9-May-17,,15-Jul-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03145298
NCT04254289,Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension,PaRTAkE-PH,Not yet recruiting,No Results Available,Pulmonary Arterial Hypertension,Behavioral: Usual Care|Behavioral: Home-based exercise program,"Efficacy of a home-based exercise training as measured by change in six-minute walk distance|Change in physical activity as measured by daily activity captured using the pedometer step count|Efficacy of a home-based exercise training as measured by change in treadmill exercise time|Efficacy of a home-based exercise training as measured by change in survey score from the EuroQol five dimension, five level (EQ-5D-5L) questionnaire.|Efficacy of a home-based exercise training as measured by change in survey score The Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)|Efficacy of a home-based exercise training as measured by change in survey score International Physical Activity Questionnaire Short Form (IPAQ-SF)|Efficacy of a home-based exercise training as measured by change in survey score Patient Health Questionnaire (PHQ)-8|Efficacy of a home-based exercise training as measured by change in World Health Organization (WHO) functional class",University of Michigan|Actelion,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,54,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",HUM00150343,Feb-21,Sep-22,Jun-23,5-Feb-20,,8-Dec-20,"The University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04254289
NCT04039464,Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension,MoD,Not yet recruiting,No Results Available,Pediatric Pulmonary Hypertension,Drug: Mono-Therapy with Sildenafil|Drug: Duo-Therapy with Sildenafil + Bosentan,Change in WHO functional class (FC) of Mono vs. Dual Therapy|Time to clinical worsening (TTCW),Johns Hopkins University,All,"4 Months to 18 Years   (Child, Adult)",Phase 3,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Kids Mono vs. Duo Therapy PAH,1-Apr-21,31-Mar-26,31-Mar-26,31-Jul-19,,15-Jul-20,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04039464
NCT04542681,MANP in African Americans With Hypertension,MANP-2,Recruiting,No Results Available,"Hypertension, Resistant to Conventional Therapy",Drug: Placebo - 1st Cycle|Drug: MANP - 1st Cycle|Drug: MANP - 2nd Cycle,Change in Blood Pressure|Urinary cGMP excretion|Urinary sodium excretion|Glomerular filtration rate|Plasma aldosterone,Mayo Clinic,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB # 17-007947,1-May-18,30-Dec-21,30-Jun-22,9-Sep-20,,9-Sep-20,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04542681
NCT01571700,Investigation of Dysynchrony in Patients With Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension,Procedure: Catheterization Pacing,Electrical or Mechanical Dysynchrony,Stanford University,All,"5 Years and older   (Child, Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,DS6901,Sep-06,Dec-21,Dec-21,5-Apr-12,,5-Mar-20,"Stanford Hospital, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01571700
NCT04232124,Nashville - Hypertension Management Model,,Recruiting,No Results Available,Hypertension,Behavioral: Hypertension Management Model,Change in Systolic Blood Pressure,"Vanderbilt University Medical Center|University of California, Los Angeles|Cedars-Sinai Medical Center",Male,"35 Years to 79 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,191470,15-Feb-20,Jun-21,Jun-21,18-Jan-20,,12-Jun-20,"Masters Barbershop, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nash, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04232124
NCT03617458,Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Artery Hypertension,Drug: Metformin|Drug: Placebo|Device: mHealth Intervention|Device: Usual Care,"Change from baseline in six minute walk distance (meters)|Change from baseline to week 12 in World Health Organization Functional Class (WHO FC)|Change from baseline to week 12 in Body Weight (kilograms)|Change from baseline to week 12 in Body Mass Index (BMI)|Change from baseline to week 12 in Absolute Six-Minute Walk Distance (meters)|Change from baseline to week 12 in Borg Dyspnea Score|Change from baseline to week 12 in Emphasis-10 Quality of Life Survey Score|Change from baseline to week 12 in Daily Step Count, as measured by the mean daily step count|Change from Baseline to week 12 in Daily Step Count Goal Attainment, as measured by the percentage (%) of subjects who meet their daily step count goal|Change from baseline to week 12 in Daily Aerobic Time (minutes)|Change from baseline to week 12 in total daily activity assessed in step counts per minute|Change from baseline to week 12 in Resting Heart Rate (beats per minute)|Change from baseline to week 12 in Homeostatic model assessment (HOMA)-Insulin Resistance (IR)|Number of participants with abnormal laboratory values of Plasma Estradiol Metabolites|Number of participants with abnormal laboratory values of Urine Estradiol Metabolites|Number of participants with abnormal laboratory values of Plasma Lipid Profile|Number of participants with abnormal laboratory values of Plasma Free Fatty Acid Profiles|Number of participants with abnormal laboratory values of Plasma Acylcarnitine Profiles|Change from baseline to week 12 in Plasma Brain Natriuretic Peptide (BNP) Laboratory Value measured in pg/ml|Change from baseline to week 12 in Quadriceps Skeletal Muscle Triglyceride Content, as measured by % triglycerides|Change from baseline to week 12 in Quadriceps Skeletal Muscle Fatigue, as measured by total time to muscle fatigue during the muscle strength and function test|Change from baseline to week 12 in Quadriceps Skeletal Muscle Strength During the Muscle Strength and Function Test, as measured by maximum contraction strength|Change from baseline to week 12 in quadriceps skeletal muscle contractile tissue cross-sectional|Change from baseline to week 12 in RV Myocardial Muscle Triglyceride Content, as measured by % triglycerides|Change from baseline to week 12 in Tricuspid Annular Plane systolic Excursion (TAPSE), expressed in mm.|Change from baseline in Right Ventricle (RV) and Left Ventricle (LV) Ejection Fraction values as assessed by echocardiogram results, expressed in percentage (%).|Change from baseline in Right Ventricle (RV) Fractional Area, as assessed by echocardiogram results, expressed in percentage (%).|Change from baseline in Tricuspid Annular Velocity (S'), as assessed by echocardiogram results, expressed in cm/sec|Change from baseline in Tricuspid Regurgitant (TR) Velocity, as assessed by echocardiogram results, expressed in m/sec.|Change from baseline in Estimated Right Ventricle (RV) and Right Atrial (RA) Pressure, as assessed by echocardiogram results, expressed in mmHg|Change from baseline in Right Ventricle (RV) and Left Ventricle (LV) Diastolic Function as assessed by Doppler inflow patterns on echocardiogram.|Change from baseline in Right Ventricle (RV) Free Wall Longitudinal Strain, as assessed by echocardiogram results, and expressed as percent (%) change in myocardial deformation.|Number of participants with a change in Screening Clinical Characteristics|Number of patients with Treatment - Emergent Adverse Events (Safety and Tolerability of mHealth intervention and drug treatment in PAH subjects)|Patient Satisfaction of treatment interventions, as measured by change in emphasis-10 survey score|Dropout Rate Incidence|Number of patients with a PAH-related Hospitalization Incidence|Change from baseline to week 12 in Patient Medication Regimen, as measured by percentage (%) of subjects with a change in medication regimen|Incidence of Death",Vanderbilt University Medical Center|Mayo Clinic|The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 2,130,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",180198,23-Aug-18,Dec-22,Dec-22,6-Aug-18,,16-Jun-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03617458
NCT03558893,Health Disparities in Hypertension,,Recruiting,No Results Available,Hypertension|Cardiovascular Risk Factor,Behavioral: Forced Desynchrony,Blood pressure|Heart rate variability|venous epinephrine|venous norepinephrine|saliva cortisol|saliva melatonin|venous aldosterone|venous endocannabinoids|flow mediated dilation|beat-by-beat blood pressure|24-hr ambulatory blood pressure,Oregon Health and Science University,All,40 Years to 60 Years   (Adult),Not Applicable,52,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,16803,1-Dec-18,1-Jul-22,1-Jul-22,15-Jun-18,,14-Oct-19,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03558893
NCT02133872,Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients,,Recruiting,No Results Available,Hypertension,Drug: Minocycline 100mg Group|Drug: Minocycline 200mg Group,Reduction in High Blood Pressure|Renal function changes,"University of Florida|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,101,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB2015005 -N|RO1HL3361028|2013-00102 Study 1|1R01HL132448-01,Oct-14,May-20,May-20,8-May-14,,5-Jun-19,"UF Health Cardiovascular Clinic, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02133872
NCT03969056,AI Activity Study in Patients With Elevated Blood Pressure,,Not yet recruiting,No Results Available,Hypertension,"Behavioral: Artificial Intelligence (AI) Activity|Behavioral: 10,000 steps",Changes in weekly daily average steps|Duration (minutes) of moderate to vigorous intensity physical activity (MVPA) per day|Changes in Systolic blood pressure (SBP)|Changes in diastolic blood pressure (DBP)|aortic stiffness|sodium intake|Changes in weight|Changes in Body Mass Index (BMI),"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-26452,10-Oct-20,Mar-21,30-Jun-21,31-May-19,,20-Aug-20,"University of California San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03969056
NCT03729544,Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism,CTEPH-DETECT,Recruiting,No Results Available,Chronic Thromboembolic Pulmonary Hypertension,Behavioral: On-screen computerized decision support alert,Frequency of echocardiographic screening for CTEPH in patients with prior PE and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms at 3 months following randomization.|Frequency of CTEPH diagnosis at three months.,Brigham and Women's Hospital|Bayer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,2018P001681,1-Mar-19,30-Jan-21,30-Mar-21,2-Nov-18,,4-Aug-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03729544
NCT02133885,Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients,,Not yet recruiting,No Results Available,Hypertension,Drug: Minocycline Group|Other: Placebo Group,Reduction of ambulatory blood pressure,"University of Florida|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,56,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB201500594-N|RO1HL3361028|2013-00102 Study 2|R01HL132448-01,Dec-20,May-22,May-22,8-May-14,,13-Apr-20,"UF Health Cardiovascular Clinic, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02133885
NCT03312556,Treatment of Supine Hypertension in Autonomic Failure (CPAP),,Recruiting,No Results Available,Supine Hypertension|Autonomic Failure,Device: continuous positive airway pressure (CPAP)|Drug: Placebo,Supine Systolic Blood Pressure|Urinary volume,Vanderbilt University Medical Center,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,010189-1|200124,21-Sep-17,21-Sep-21,21-Dec-21,17-Oct-17,,17-Sep-20,"Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03312556
NCT03892057,Internet-based Positive Psychological Intervention for Hispanic/Latino Adult With Hypertension in a Primary Care Setting,,Recruiting,No Results Available,Uncontrolled Hypertension|Cardiovascular Risk Factor,Behavioral: Internet-based Positive Psychological Intervention,Change from Baseline Ambulatory Blood Pressure at 5- and 12-weeks|Center for Epidemiological Studies Depression Scale: Change from Baseline Depressive Symptoms at 5- and 12-weeks|Life Orientation Test-Revised: Change from Baseline Dispositional Optimism at 5- and 12-weeks|General Well-being Schedule: Change in Baseline Emotional Vitality at 5- and 12-weeks|Life Engagement Test: Change in Baseline Life engagement and Meaning at 5- and 12-weeks|Perceived Stress Scale: Change from Baseline Perceived Stress at 5- and 12-weeks|Modified Differential Emotions Scale: Change from Baseline Positive and Negative Affect at 5- and 12-weeks|Positive Skills: Change in Baseline Positive Skills at 5- and 12-weeks|Medical Outcomes Study Social Support Survey: Change in Baseline Perceived Social Support at 5- and 12-weeks|Medication Adherence: Change in Baseline Medication Adherence at 5- and 12-weeks|12-Item Short Form Survey: Change in Self-Reported Mental and Physical Health at 5- and 12-weeks,University of Illinois at Urbana-Champaign|Rosenfeld Heart Foundation Grant,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,8776,12-Apr-19,Jan-21,Jun-21,27-Mar-19,,5-Jul-19,"UI Health Pilsen Family Health Center Lower West, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03892057
NCT02909608,Actigraphy in Pediatric Pulmonary Hypertension,,Recruiting,No Results Available,Pediatric Pulmonary Hypertension,Other: No interventions / observations only,"Investigate and define the utility of the measurement properties of actigraphy in children with PAH: Baseline|Investigate and define the utility of the measurement properties of actigraphy in children with PAH: Week 26|Use statistical analysis to determine correlations of actigraphy with disease severity, progression, clinical worsening, and survival, based on data from this prospective clinical study.","University of Colorado, Denver",All,8 Years to 14 Years   (Child),,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,16-1422,7-Oct-16,Mar-21,Mar-21,21-Sep-16,,24-Dec-20,"Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02909608
NCT03604289,Angiotensin 1-7 in Obesity Hypertension,,Recruiting,No Results Available,Obesity|Hypertension,Drug: Angiotensin-(1-7)|Drug: Saline,Change in brachial artery diameter with reactive hyperemia|Heart Rate Variability|Circulating catecholamines|Change in coronary blood velocity to the cold pressor test|Change in systolic and diastolic blood pressure to the cold pressor test|Change in muscle sympathetic nerve activity to the cold pressor test,Amy Arnold|American Heart Association|Milton S. Hershey Medical Center,All,18 Years to 60 Years   (Adult),Early Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",STUDY00008170|18POST33960087,1-Apr-19,Jun-22,Jun-22,27-Jul-18,,8-Oct-20,"Penn State College of Medicine, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03604289
NCT03554291,Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension,REHAB-PH,Recruiting,No Results Available,Pulmonary Arterial Hypertension|Right Heart Failure,Drug: Famotidine 20 MG|Other: Placebo,"Six-minute walk distance|nt-pro-BNP|New York Heart Association (NYHA) functional class|Health related quality of life (emPHasis-10 questionnaire)|Frequency of escalation for PAH focused care (increased diuretics, escalating doses of pulmonary vasodilators, and/or adding additional pulmonary vasodilators)|Right ventricular function by echocardiogram","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00005002|1R61HL142539-01,1-May-19,Dec-22,Dec-22,13-Jun-18,,4-Nov-20,"University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03554291
NCT01899495,Blood Pressure Response to Sodium in the Diet,,Recruiting,No Results Available,Hypertension,Other: High sodium diet and low sodium diet,Blood pressure; Change in Mean Arterial Pressure from low salt diet to high salt diet|Urine sodium|Genetic analysis for specified genes associated with hypertension,"University of Virginia|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,400,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,11494|P01HL074940,Jan-05,Aug-21,Aug-21,15-Jul-13,,18-Oct-16,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01899495
NCT01730092,Natural History Study of Biomarkers in Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Disease|Pulmonary Hypertension,,"Examine whether any novel test (inflammatory markers or high resolution cardiac MRI), accurately classifies PAH subjects according to disease severity as assessed by their baseline 6-minute walk distance.",National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,270,NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,130012|13-CC-0012,15-Jul-13,31-Aug-22,31-Aug-22,21-Nov-12,,22-Oct-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01730092
NCT03288025,Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE),,Recruiting,No Results Available,Pulmonary Arterial Hypertension|Insulin Resistance,Behavioral: Nutrition and Exercise,Insulin Sensitivity|Right Ventricular Global Peak Longitudinal Strain,"The Cleveland Clinic|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,44,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-260,27-Sep-17,28-Dec-22,28-Dec-23,19-Sep-17,,23-Jan-20,"Cleveland Clinic Foundation, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03288025
NCT04576897,Liver Incytes for Portal Hypertension,,Recruiting,No Results Available,Portal Hypertension|Chronic Advanced Liver Disease,Diagnostic Test: Liver Incytes,Correlation of Liver Incytes measurements to clinical indicators of compensated advanced chronic liver disease (cACLD)|Correlation of Liver Incytes measurements to FibroScan® measurements for liver stiffness and liver steatosis|Correlation of Liver Incytes measurements to non-invasive blood markers for predicting advanced fibrosis,Indiana University|Sonic Incytes,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,LI for Portal Hypertenstion|2009698702,1-Nov-20,31-Dec-24,31-Dec-25,6-Oct-20,,6-Oct-20,"Indiana University Division of Gastroenterolgy and Hepatology, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT04576897
NCT00710177,PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn,PPHN,Recruiting,No Results Available,Persistent Pulmonary Hypertension of the Newborn,,To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero.,Medical College of Wisconsin,All,up to 12 Months   (Child),,120,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,"CHW 06/02, GC 49",Jan-06,Dec-22,Dec-23,4-Jul-08,,14-Jul-20,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00710177
NCT04454203,Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension,,Recruiting,No Results Available,Tourniquet Hypertension|Intraoperative Hypertension|Total Ankle Arthroplasty|Ankle Fusion,Drug: Mepivacaine|Drug: Saline|Procedure: Perifemoral Injection of Local Anesthetic,Change in tourniquet hypertension as measured by systolic blood pressure|Pain Scores (NRS11)|Opioid consumption|Quadriceps motor function,Duke University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",Pro00104144,Dec-20,30-Mar-21,1-Apr-21,1-Jul-20,,11-Dec-20,"Duke University Hospital, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04454203
NCT03255746,HELP-HY: Health Education and sLeep Program in HYpertension,,Recruiting,No Results Available,Prehypertension|Hypertension,Behavioral: Sleep Enhancement|Behavioral: Health Education,change in 48-hour mean arterial pressure|changes in 48-hour heart rate|changes in baroreflex sensitivity|changes in endothelial function|changes in renin|changes in angiotensin peptides|changes in aldosterone|changes in insulin sensitivity|changes in cortisol|changes in body fat|changes in catecholamines,"Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,94,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",17-004044|R01HL134808,19-Apr-18,30-Jun-22,30-Jun-22,21-Aug-17,,14-Oct-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03255746
NCT03310346,Registry of Preterm Newborns With Severe Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension|Preterm Infant,,Mortality|Cause of death|Number of Days Hospitalized|Number of Days on Ventilation|Classification of Bronchopulmonary Dysplasia (BPD)|Development of Necrotizing Enterocolitis (NEC)|Development of Early Bacterial Sepsis|Development of Late Bacterial Sepsis|Intracranial hemorrhage|Cystic Periventricular Leukomalacia (PVL)|Surgery for Retinopathy of Prematurity (ROP)|Patent Ductus Arteriosus (PDA) Ligation|Pneumothorax|Neurological Exam,"University of Colorado, Denver|Mallinckrodt",All,"up to 45 Years   (Child, Adult)",,500,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,16-2491,1-Aug-17,1-Aug-23,1-Aug-23,16-Oct-17,,18-Jan-20,"University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03310346
NCT04009447,Sleep Quality and Mechanisms of Cardiovascular Risks in Adults With Hypertension,,Recruiting,No Results Available,Hypertension|Insomnia,Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I),Change in blood pressure during the nighttime sleep period|Change in sleep during the nighttime sleep period|Changes in insomnia severity|Change in awake blood pressure|Change in nighttime blood pressure dipping|Change in vascular endothelial function|Change in arterial stiffness|Change in lipid profile|Change in nighttime sympathetic nervous system activity|Change in cardiac structure|Change in cardiac function|Change in sleep fragmentation during the nighttime sleep period|Change in subjective sleep quality|Change in Office Blood Pressure,Duke University|National Institutes of Health (NIH),All,30 Years to 60 Years   (Adult),Not Applicable,150,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,PRO00102036,14-Feb-20,Jun-24,Jun-24,5-Jul-19,,10-Sep-20,"Duke University Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04009447
NCT04402385,Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE),,Recruiting,No Results Available,Pre-Eclampsia|Stage 1 Hypertension|Elevated Blood Pressure,Drug: Aspirin 81 mg|Drug: Placebo,Development of hypertensive disorder|Development of gestational hypertension|Development of preeclampsia|Development of preeclampsia- 37 weeks|Development of preeclampsia- 34 weeks|Development of eclampsia|Development of HELLP syndrome|Spontaneous preterm delivery|Fetal growth restriction|Birthweight|Neonatal ICU Admission|Stillbirth|Neonatal Adverse Events|Placental Abruption,Yale University,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,466,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2000028023,6-Aug-20,31-Jul-22,31-Dec-22,26-May-20,,17-Aug-20,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04402385
NCT01729611,Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension,,Base Line,The Cleveland Clinic,All,"17 Years to 90 Years   (Child, Adult, Older Adult)",,140,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Tonella1,Dec-13,Mar-21,Jul-21,20-Nov-12,,31-Mar-20,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01729611
NCT04570124,STAMPP-HTN in a High-risk Rural Population of Women,,Recruiting,No Results Available,Hypertension in Pregnancy,Device: Home Blood Pressure Telemonitoring,Determine if HBPT decreases the severity of postpartum hypertension complication|Increase awareness and knowledge of postpartum blood pressure control in a group of high-risk women|Assess compliance using HBPT and adherence to blood pressure medication,University of Mississippi Medical Center|University of Chicago,Female,18 Years to 45 Years   (Adult),Not Applicable,211,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2020-0175,14-Dec-20,Sep-21,Jan-22,30-Sep-20,,17-Dec-20,"University of MS Medical Center, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT04570124
NCT04415333,Gut Butyrate and Blood Pressure in African Americans,,Not yet recruiting,No Results Available,Hypertension,Drug: Sodium Butyrate 5 mmol|Drug: Sodium Butyrate 80 mmol,Mean Daytime Blood Pressure|Mean Nighttime Blood Pressure|Blood Butyrate Concentrations,"University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute|North Carolina Agriculture & Technical State University",All,30 Years to 50 Years   (Adult),Phase 1,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",18-1680,May-21,Apr-22,Apr-22,4-Jun-20,,14-Jan-21,"NC A&T State University, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04415333
NCT03683069,MR Antagonist and STRIATIN,,Recruiting,No Results Available,Hypertension|Genetics Hypertension,Drug: Eplerenone vs Amlodipine,Systolic supine morning liberal salt automated blood pressure,Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2018P001888,15-Jan-19,1-Jun-22,31-Aug-22,25-Sep-18,,12-Mar-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03683069
NCT03532750,Splenic Embolization for Portal Hypertension,,Recruiting,No Results Available,Portal Hypertension,Device: Particle|Device: Coil,Change in Quality of Life|Incidence of Treatment Adverse Events|Ascites Production|Splenic Size|Portal Vein Velocity,University of Minnesota,All,"22 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RAD-2016-25151,1-Nov-18,1-Jul-21,1-Jul-21,22-May-18,,4-Sep-20,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03532750
NCT02517697,Oral Nitrite Trial for Hypertension and Metabolic Syndrome,ONPC,Not yet recruiting,No Results Available,Metabolic Syndrome|Hypertension,Drug: 14 Nitrogen (N) Sodium Nitrite|Drug: Placebo,Change in insulin sensitivity (i.e. insulin stimulated glucose disposal)|Change in systolic blood pressure|Change in mean arterial pressure|Change in diastolic blood pressure|Change in methemoglobin level,"Gladwin, Mark, MD|University of Pittsburgh",All,18 Years to 60 Years   (Adult),Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PRO15050540,Oct-20,Jul-24,Jul-24,7-Aug-15,,4-Jun-20,"Montefiore Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02517697
NCT03015402,Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction,PH-HFpEF,Recruiting,No Results Available,Pulmonary Hypertension Secondary|Heart Failure,Drug: Sodium Nitrite|Drug: Placebo Oral Capsule,Pulmonary artery pressure (mPAP) during submaximal exercise as compared between placebo and nitrite|Difference in 6-minute walk test|Change in right heart catheterization (RHC) hemodynamics|Change in severity of heart failure|Change in endurance exercise time,"Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",All,"18 Years and older   (Adult, Older Adult)",Phase 2,26,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STUDY20010014|5P01HL103455,30-Oct-17,Mar-22,Mar-22,10-Jan-17,,21-Dec-20,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03015402
NCT03905083,miRNA and Myokines in Patients With PAH,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Other: Exercise Rehab,To evaluate the impact of released miRNA/myokines on the skeletal muscle in PAH patients.|To evaluate the impact of formal exercise training on the skeletal muscle|To evaluate the impact of formal exercise training on the pulmonary vasculature system,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,STUDY19120032,Dec-20,15-Mar-22,15-Jun-22,5-Apr-19,,24-Jun-20,"Division of Pulmonary, Allergy and Critical Care Medicine, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03905083
NCT04140279,A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension,,Not yet recruiting,No Results Available,Ocular Hypertension,Drug: Latanoprostene Bunod|Drug: Placebo,Change From Baseline in Episcleral Venous Pressure (EVP) at Intervals on Days 1 and 8|Change From Baseline in Diurnal (Daytime) EVP at Days 1 and 8|Change From Baseline in Trabecular Outflow Facility at Intervals on Days 1 and 8|Change From Baseline in Diurnal (Daytime) Trabecular Outflow Facility at Days 1 and 8,Bausch & Lomb Incorporated,All,"18 Years and older   (Adult, Older Adult)",Phase 4,34,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,899,Jan-21,Jan-23,Jan-23,25-Oct-19,,28-Aug-20,"Bausch Site 001, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04140279
NCT04062565,Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Treprostinil Injectable Product|Drug: Riociguat Pill,Change in stroke volume/end systolic volume (SV/ESV)|Change in pulmonary and cardiac pressures|Change in pulmonary blood flow|Change in end-systolic elastance/arterial elastance (Ees/Ea)|Change in Right Ventricle (RV) diastolic stiffness (Beta)|Change in 6 minute walk distance|Change in brain natriuretic peptide (BNP)|Change in magnetic resonance imaging (MRI) right ventricle volumes|Change in Cardio pulmonary Exercise Testing (CPET)|Change in derived VO2 max|Change in derived Ve/VCO2|Change in adverse event profile|Change in composite time to clinical worsening,University of Arizona,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1812168816,25-Mar-19,Dec-20,Dec-21,20-Aug-19,,20-Aug-19,"University of Arizona, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04062565
NCT04371614,PTSC: Improving Hypertension Control Among Poor Midlife African American Women,PTSC-RCT,Recruiting,No Results Available,Uncontrolled Hypertension|BMI|Stress|Medication Adherence,Behavioral: Prime Time Sister Circle,Blood Pressure|Body Mass Index|Waist Circumference|Stress|Medication Adherence|Hypertension Knowledge|Functional Status,"Johns Hopkins Bloomberg School of Public Health|American Institutes for Research|The Gaston & Porter Health Improvement Center, Inc.",Female,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01MD010462,14-Jul-16,20-Dec-21,28-Feb-22,1-May-20,,1-May-20,"Baltimore Medical System, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04371614
NCT04630808,MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Denali,Recruiting,No Results Available,Open Angle Glaucoma|Ocular Hypertension,Drug: NCX 470 0.1%|Drug: Latanoprost 0.005%,Change from baseline IOP|Change from baseline in diurnal IOP|Frequency and incidence of treatment-emergent adverse events|Rate of discontinuation,"Nicox Ophthalmics, Inc.",All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,670,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCX-470-03,9-Nov-20,30-Jun-22,30-Sep-22,16-Nov-20,,18-Nov-20,"Eye Research Foundation, Newport Beach, California, United States",,https://ClinicalTrials.gov/show/NCT04630808
NCT03459716,Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension,BOSS-PH,Recruiting,No Results Available,Scleroderma|Pulmonary Hypertension,Other: No intervention,Composite pulmonary hypertension detection score,Louisiana State University Health Sciences Center in New Orleans|Scleroderma Foundation|Tulane University Health Sciences Center|University Medical Center-New Orleans,All,"18 Years and older   (Adult, Older Adult)",,56,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB 10033SM,1-Jun-18,1-Apr-21,1-Apr-21,9-Mar-18,,27-Jun-18,"University Medical Center-New Orleans, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT03459716
NCT04445519,Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Mont Blanc,Recruiting,No Results Available,Open Angle Glaucoma|Ocular Hypertension,Drug: NCX 470 0.065%|Drug: NCX 470 0.1%|Drug: Latanoprost 0.005%,Reduction from baseline IOP in the study eye|Reduction from baseline in diurnal IOP in the study eye|Frequency and incidence of treatment-emergent adverse events|Rate of discontinuation,"Nicox Ophthalmics, Inc.",All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,670,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCX-470-02,1-Jun-20,Dec-21,Dec-21,24-Jun-20,,24-Jun-20,"Keystone Research, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04445519
NCT04230928,Giving a Low Carbohydrate Diet to Overcome Hypertension,GLOH,Recruiting,No Results Available,"Hypertension|African Americans|Diet, Carbohydrate-Restricted|Risk Reduction Behavior",Other: Very low carbohydrate diet|Other: Standard DPP-GLB diet|Behavioral: Standard DPP-GLB program modules,Changes in Systolic blood pressure|Dietary changes in carbohydrate intake|Changes in Fasting blood glucose|Changes in Hemoglobin A1C|Changes in Cholesterol and lipoproteins|Changes in % Body weight|Changes in Body mass index (BMI)|Dietary changes in fat intake|Dietary changes in caloric intake|Changes in Diastolic blood pressure,Baylor Research Institute,All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,019-268,5-Mar-20,30-Sep-21,14-Dec-21,18-Jan-20,,31-Jul-20,"Baylor Research Institute, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04230928
NCT03857490,Heat Therapy in Older Hypertensive Women,,Recruiting,No Results Available,Essential Hypertension,Behavioral: Lower leg heat therapy,Physiological parameter (awake ambulatory systolic pressure)|Physiological parameter (muscle sympathetic nerve activity)|Physiological parameter (vascular function),University of Texas Southwestern Medical Center,Female,65 Years to 85 Years   (Older Adult),Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STU 072018-091,29-Jul-19,Sep-23,Jan-24,28-Feb-19,,4-Jun-20,"Institute for Exercise and Environmental Medicine, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03857490
NCT04499196,Glucocorticoids and Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension Due to Lung Diseases and Hypoxia|Pulmonary Hypertension|Bronchopulmonary Dysplasia,Drug: GlucoCorticoid,Echo estimation of RV pressure,Washington University School of Medicine,All,up to 1 Year   (Child),,40,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,LD2020,29-Jul-20,29-Jul-22,29-Jul-22,5-Aug-20,,5-Aug-20,"St. Louis Children's Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04499196
NCT03433950,Clinical Characteristics of Parkinson's Disease Subjects With Severe Hypertension During Motor OFFs.,CLIN-HTN-PD,Recruiting,No Results Available,Parkinson Disease|Hypertension|Antiparkinsonism Drugs Causing Adverse Effects in Therapeutic Use,Other: No Intervention,Systolic Blood Pressure Change|Diastolic Blood Pressure Change,Oregon Health and Science University,All,"18 Years to 99 Years   (Adult, Older Adult)",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,17490|VA IRB 4143,6-Feb-18,31-Dec-19,31-Dec-19,15-Feb-18,,1-Apr-19,"VA Portland Health Care System, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03433950
NCT03542812,L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia,,Recruiting,No Results Available,"Infant,Premature|Bronchopulmonary Dysplasia|Pulmonary Hypertension",Drug: L-Citrulline,Plasma L-citrulline levels following administration of a single dose of L-citrulline|Evaluate ability to achieve target trough L-citrulline plasma level|Evaluate incidence of feedings being stopped following L-citrulline administration|Evaluate incidence of hypotension developing following L-citrulline administration|Urinary nitrite and nitrate levels will be measured in subjects enrolled into Group 3.,University of Utah,All,up to 3 Months   (Child),Early Phase 1,36,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,97293,30-Jul-19,30-Jun-22,30-Jun-22,31-May-18,,10-Nov-20,"University of Utah Health, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03542812
NCT03579862,Identification of Heritable CTEPH,,Recruiting,No Results Available,Chronic Thromboembolic Pulmonary Hypertension,Other: Blood Draw,"Rates of family history of VTE in relatives of CTEPH patients compared to PE and PAH patients in Intermountain populations|Characteristics of familial and, apparently, sporadic CTEPH in Intermountain populations|Estimates of prevalence of familial CTEPH in Intermountain populations|Heritability and penetrance patterns of familial CTEPH|Discovery and validation of genetic polymorphisms present in familial CTEPH patients|Identification of gene pathways that may be relevant to the development of CTEPH after actue PE","Intermountain Health Care, Inc.",All,"18 Years and older   (Adult, Older Adult)",,260,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1024723,25-Dec-13,31-Dec-21,31-Dec-21,9-Jul-18,,17-Feb-20,"Intermountain Medical Center, Murray, Utah, United States",,https://ClinicalTrials.gov/show/NCT03579862
NCT03470207,The Prospective Risk Factor Evaluation & Discovery In CTEPH Study,PREDICT PH,Recruiting,No Results Available,Chronic Thromboembolic Pulmonary Hypertension,Procedure: Post-pulmonary embolism follow up protocol,Chronic Thromboembolic Pulmonary Hypertension (CTEPH) diagnosis rate,"Mark W. Dodson|Intermountain Health Care, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,1050516,17-Apr-18,May-21,Aug-21,19-Mar-18,,17-May-19,"Intermountain Medical Center, Murray, Utah, United States",,https://ClinicalTrials.gov/show/NCT03470207
NCT02594917,Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension,,Recruiting,No Results Available,Iron-sulfur Cluster Deficiency|Pulmonary Hypertension|Friedreich Ataxia,Procedure: Right Heart Catheterization|Other: Blood draw,6 minute walk distance (meters)|Pulmonary arterial pressure (mm Hg),University of Pittsburgh,All,18 Years to 60 Years   (Adult),,11,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STUDY19030124,Oct-15,Sep-21,Sep-21,3-Nov-15,,25-Jun-20,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02594917
NCT04401267,Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma,,Recruiting,No Results Available,Hypertension|Osteonecrosis|Osteonecrosis Due to Drug,Drug: Lisinopril|Other: Symptom Survey|Other: Semi-structured interview,Extensive radiographic osteonecrosis|Rate of clinically significant osteonecrosis|Rate of clinically significant osteonecrosis vs. historical control|Blood pressure control on trial|Biomarkers of vascular dysfunction - eNO synthetase (pg/mL)|Biomarker of vascular dysfunction - Von Willebrand Factor (%)|Biomarker of vascular dysfunction - TNF-alpha (pg/mL)|Biomarker of vascular dysfunction - D-dimer (µg/mL)|Biomarker of vascular dysfunction - PAI-1 (AU/mL)|Biomarker of vascular dysfunction - E-selectin (ng/mL)|Biomarker of vascular dysfunction - ICAM-1 (ng/mL)|Biomarker of vascular dysfunction - Arterial elasticity (ml/mmHg)|Biomarker of vascular dysfunction - Pulse Wave Velocity (m/sec)|Magnetic resonance imaging (MRI) of hip and knee,St. Jude Children's Research Hospital|National Cancer Institute (NCI),All,"10 Years and older   (Child, Adult, Older Adult)",Phase 2,180,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HYPERION|1K08CA250418|NCI-2020-03603,15-Oct-20,Mar-23,Mar-25,26-May-20,,30-Oct-20,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04401267
NCT03872856,"Blood Pressure-Improving Control Among Alaska Native People"" (BP-ICAN)",CHAR2,Recruiting,No Results Available,Hypertension,Device: BP-ICAN,Individual-level: within-person change in systolic blood pressure|Provider-level: frequency of antihypertensive medication adjustments|System-level: change in systolic blood pressure for all patients with hypertension,Southcentral Foundation|Washington State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,324,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP-ICAN-1U54MD011240-01|2017-08-038,19-Feb-19,31-Dec-21,31-Dec-21,13-Mar-19,,26-Aug-20,"Anchorage Native Primary Care Center, Anchorage, Alaska, United States|Benteh Nuutah Valley Native Primary Care Center, Wasilla, Alaska, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03872856/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03872856
NCT01884051,"Hormonal, Metabolic, and Signaling Interactions in PAH",,Recruiting,No Results Available,Idiopathic Pulmonary Arterial Hypertension|Heritable Pulmonary Arterial Hypertension|Scleroderma Associated Pulmonary Arterial Hypertension|Appetite Suppressant Associate PAH,,"Ratio of sex hormone metabolites|Evaluation of insulin resistance in pulmonary arterial hypertension patients/Clinical trial of Metformin in Pulmonary Arterial Hypertension|Mechanism, safety, and efficacy of ACE-2 (Angiotensin Converting Enzyme 2) in the treatment of PAH.|Clinical Trial of Metformin in Pulmonary Arterial Hypertension|Mechanism, safety, and efficacy of ACE-2 in the treatment of PAH.",Vanderbilt University Medical Center,All,"up to 90 Years   (Child, Adult, Older Adult)",,1899,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,P01HL108800,Sep-12,Jul-22,Jul-22,21-Jun-13,,16-Jun-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01884051
NCT03612271,mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management,,Recruiting,No Results Available,Hypertension,Behavioral: mGlide,HTN control into guideline specified range,"University of Minnesota|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,450,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,STUDY00003494|1R01HL138332-01A1,1-Mar-19,31-Dec-22,30-Apr-23,2-Aug-18,,10-Nov-20,"Epidemiology Clinical Research Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03612271
NCT03370991,Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure,,Recruiting,No Results Available,Menopause|Elevated Blood Pressure|Hypertension|Endothelial Dysfunction,Dietary Supplement: Blueberry Powder|Dietary Supplement: Placebo Powder,"Endothelium-dependent dilation|Blood pressure|Vascular oxidative stress|Endothelial cell nitric oxide production, oxidative stress, and inflammation|Systemic markers of cardiometabolic health|Plasma blueberry polyphenol metabolites|Endothelium-independent dilation|Augmentation index|Pulse wave velocity|Gut microbiota",Colorado State University|U.S. Highbush Blueberry Council,Female,"45 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1255927,2-Dec-17,31-Dec-20,31-Dec-20,13-Dec-17,,28-Jan-20,"Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03370991
NCT03787082,Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension,,Not yet recruiting,No Results Available,Pulmonary Hypertension|Heart Failure With Normal Ejection Fraction|Pulmonary Heart Disease and Diseases of Pulmonary Circulation,Drug: Nitrates|Drug: Chlorhexidine Gluconate Mouthwash|Drug: Placebo Mouthwash,Change in Plasma Nitrate|Change in Urine Nitrate|Change in Pulmonary Vascular Resistance (PVR),"Gladwin, Mark, MD|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",All,"18 Years and older   (Adult, Older Adult)",Phase 1,45,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRO18080517|5P01HL103455,Jan-21,Apr-21,Apr-21,26-Dec-18,,16-Dec-20,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03787082
NCT03749499,Targeting of UnControlled Hypertension in Emergency Department,TOUCHED,Recruiting,No Results Available,Hypertension|Cardiovascular Diseases|Vascular Diseases,Other: HTN Educational Video|Other: Visual Echocardiogram Image Clips|Other: Mobile Health and Remote BP monitoring|Other: Post-Acute Care HTN Transition consultation (PACHT-c),Mean systolic blood pressure (SBP) difference at 6 months post-intervention compared to usual care.|Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) differences at 3 months post-intervention compared to usual care.|Diastolic blood pressure (DBP) difference at 6 months post-intervention compared to usual care.|Change in cardiovascular risk score/profile.|Change in medication adherence.|Primary care engagement.|Change in hypertension knowledge.,"University of Illinois at Chicago|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,770,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,2017-0118|1R61HL139454-01A1,19-Feb-19,Feb-23,Feb-23,21-Nov-18,,28-Sep-20,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03749499
NCT04615624,Furosemide vs. Placebo for Severe Antepartum Hypertension,,Recruiting,No Results Available,"Pre-Eclampsia|Hypertension in Pregnancy|Pregnancy Complications|Hypertension, Pregnancy-Induced",Drug: Furosemide|Other: Placebo,Change in systolic blood pressure|Change in diastolic blood pressure,"Melanie Maykin, MD|Hawaii Pacific Health",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2020-003,4-Jan-20,May-22,Dec-22,4-Nov-20,,7-Jan-21,"Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT04615624
NCT03814317,Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension,SAPPHIRE,Recruiting,No Results Available,Sarcoidosis|Precapillary Pulmonary Hypertension|Interstitial Lung Disease,Drug: Inhaled Treprostinil,PVR by Right heart catheterization (RHC)|mPAP by Right heart catheterization (RHC)|Change in 6-Minute Walk Test (6MWT)|Change in Cardiac MRI parameters|Change in Pulmonary Function Testing|Change in Brain Natriuretic Peptide (BNP)|Change in WHO Functional Class (WHO FC),University of Florida|United Therapeutics,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,10,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OCR19684|20192572,30-Jan-20,Nov-20,Mar-21,24-Jan-19,,5-Oct-20,"University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03814317
NCT03875768,Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure,,Recruiting,No Results Available,Hypertension|Health Behavior,Behavioral: Tracking plus coaching,Change in Dietary Intake (DASH Score)|Blood Pressure Changes,Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00101689,29-Sep-20,28-Feb-23,28-Feb-23,15-Mar-19,,14-Dec-20,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03875768
NCT03824119,Postpartum NSAIDS and Maternal Hypertension,,Recruiting,No Results Available,Preeclampsia|Gestational Hypertension|Superimposed Preeclampsia|Chronic Hypertension in Obstetric Context,Drug: Ibuprofen 600 mg|Other: Standard Postpartum Care without NSAIDs,Proportion of participants with blood pressure elevation|Number of participants with eclamptic Seizure|Number of participants with stroke|Initiation of anti-hypertensive medication|Pain numerical rating scale (NRS) score|Number of participants with renal failure|Number of participants with pulmonary edema|Number of participants who die|Length of hospital stay,University of Southern California,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS-17-00959,11-Dec-18,11-Dec-22,11-Dec-22,31-Jan-19,,6-Nov-20,"LA County Hospital/University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03824119
NCT03970590,Continuing the Conversation: Using Narrative Communication to Support Hypertension Self-management in African American Veterans,,Recruiting,No Results Available,Hypertension,Behavioral: CTC Intervention|Behavioral: Control,BP Measurement Change at Follow-up,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,IIR 17-185,30-Nov-20,31-Oct-23,31-Oct-23,31-May-19,,2-Dec-20,"Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03970590
NCT03234361,Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate,,Recruiting,No Results Available,Hypertension,Dietary Supplement: High Phosphate Phase|Dietary Supplement: Low Phosphate Phase,24-hour Blood Pressure measured by Ambulatory Blood Pressure Monitor.|Muscle Sympathetic Nerve Activity (MSNA),University of Texas Southwestern Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STU 012017-052,16-Oct-17,30-Sep-21,30-Sep-21,31-Jul-17,,2-Jun-20,"University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03234361
NCT04423627,Sympathetic Regulation of Large Artery Stiffness in Humans With ISH,SELECT,Not yet recruiting,No Results Available,"Hypertension, Systolic|Stiffness, Aortic",Drug: Clonidine|Drug: Hydrochlorothiazide|Drug: Placebo,Change in carotid-femoral pulse wave velocity|Change in carotid distensibility index|Change in carotid flow pulsatility index|Change in carotid intimal medial thickness (IMT),University of Iowa,All,"60 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",202004244,1-Nov-20,30-Jun-25,30-Dec-25,9-Jun-20,,19-Oct-20,"University of Iowa, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT04423627
NCT04598035,Epidural Spinal Cord Stimulation for Hypertension in Patients With Neuropathic Pain,ESCAPE,Recruiting,No Results Available,Chronic Pain|Hypertension|Implanted Stimulation Electrodes,Diagnostic Test: Diagnostic Tests,Change from Baseline Blood Pressure Measurement to 1 week post-op|Change from Baseline Blood Pressure Measurement to 4 week post-op|Change from Baseline Blood Pressure Measurement to 8 week post-op|Change from Baseline PainDETECT Questionnaire to 1 week post-op|Change from Baseline PainDETECT Questionnaire to 4 week post-op|Change from Baseline PainDETECT Questionnaire to 8 week post-op|Baseline Laboratory Tests|1 week post-op Laboratory Tests|4 week post-op Laboratory Tests|8 week post-op Laboratory Tests,University of Kansas Medical Center,All,"30 Years to 89 Years   (Adult, Older Adult)",,72,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,145752,1-Jan-21,1-Nov-23,1-Nov-24,22-Oct-20,,3-Dec-20,"University of Kansas Clinical and Translational Science Unit (CTSU), Fairway, Kansas, United States|The Marc A. Asher Comprehensive Spine Center at the Kansas University Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04598035
NCT03479697,HIRREM for Stage 1 Primary Hypertension,HIRREM,Recruiting,No Results Available,Hypertension|Blood Pressure|Cardiovascular Diseases|Cardiovascular Risk Factor|Autonomic Nervous System Imbalance,Device: HIRREM|Other: Continued Current Care,"Change from baseline in blood pressure, as measured by an automated oscillometric blood pressure device.|Change in Heart Rate Variability|Change in Baroreflex Sensitivity|Change in Insomnia Severity Index (ISI)|Change in Pittsburgh Sleep Quality Index (PSQI)|Change in Epworth Sleepiness Score (ESS)|Change in Center for Epidemiologic Studies Depression Scale (CES-D)|Change in Generalized Anxiety Disorder-7 (GAD-7)|Change in PTSD Checklist for Civilians (PCL-C)|Change in Perceived Stress Scale (PSS)|Change in International Physical Activity Questionnaire (IPAQ-SF)|Change in HIRREM Physical Activity Satisfaction Questions|Change in Quality of Life Scale (QOLS)|Change in Drop Stick Reaction Time|Change in Grip Strength",Wake Forest University Health Sciences,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00047477,8-Aug-18,Jul-21,Jul-22,27-Mar-18,,28-Jul-20,"Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03479697/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03479697
NCT02980068,A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction,PMED,Recruiting,No Results Available,Pulmonary; Hypertension|Heart Failure|Preserved Ejection Fraction,Drug: 15N Nitrate|Drug: 14N Nitrate,Change in nitrate level in urine|Change in nitrate level in plasma|Bacterial content of gut microbiome|Bacterial content of the oral microbiome|Change in nitrite level in urine|Change in nitrite level in plasma|Change in blood pressure|Change in heart rate|Change in respiratory rate|Change in hemoglobin concentration,"Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",All,"18 Years and older   (Adult, Older Adult)",Phase 1,120,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY19120066|5P01HL103455,28-Aug-17,Jan-21,Jul-21,2-Dec-16,,7-Jul-20,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02980068
NCT02796313,Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities,NOSH,Recruiting,No Results Available,Hypertension,Behavioral: DASH Groceries + Weekly Sessions|Behavioral: Groceries + Brochure,Improved blood pressure|Improved urinary sodium/potassium levels|Improved BMI|Improved blood lipids,Washington State University|Oklahoma State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R01HL126578,17-Nov-17,Feb-20,Jun-20,10-Jun-16,,8-Oct-19,"Chickasaw Nation Health Clinic, Purcell, Oklahoma, United States|Seattle Indian Health Board, Seattle, Washington, United States|NATIVE Project, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT02796313
NCT03576885,Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia,,Recruiting,No Results Available,Pulmonary Hypertension|Bronchopulmonary Dysplasia,Drug: inhaled nitric oxide|Drug: Placebo,Death (yes/no)|Bronchopulmonary (BPD) dysplasia (yes/no)|Pulmonary arterial pressure (mmHg)|Oxygen saturation level percentage|SF (SpO2/FiO2) ratio,AdventHealth|Mallinckrodt|Thrasher Research Fund,All,23 Weeks to 29 Weeks   (Child),Phase 1|Phase 2,138,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1170748,15-Jul-19,Aug-21,Aug-21,3-Jul-18,,21-Aug-19,"AdventHealth, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT03576885
NCT04370873,MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006),,Recruiting,No Results Available,Pulmonary Hypertension,Drug: MK-5475|Drug: Placebo,Parts 1 & 2: Number of Participants Who Experience an Adverse Event|Parts 1 & 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event|Part 2: Peak Change from Baseline to Day 28 in Pulmonary Vascular Resistance (PVR)|Part 1: Area Under the Concentration Time-curve from Hour 0 to Infinity (AUC0-inf) of MK-5475|Part 1: Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475|Part 1: Maximum Concentration (Cmax) of MK-5475|Part 1: Concentration of MK-5475 at 24 Hours postdose (C24)|Part 1: Time to Cmax (Tmax) of MK-5475|Part 1: Apparent Terminal Half-life (t1/2) of MK-5475|Part 1: Accumulation ratio of MK-5475|Part 2: Area Under the Concentration Time-curve from Hour 0 to Infinity (AUC0-inf) of MK-5475|Part 2: Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475|Part 2: Maximum Concentration (Cmax) of MK-5475|Part 2: Concentration of MK-5475 at 24 Hours postdose (C24)|Part 2: Time to Cmax (Tmax) of MK-5475|Part 2: Apparent Terminal Half-life (t1/2) of MK-5475|Part 2: Accumulation ratio of MK-5475|Part 2: Percent change from baseline to Day 28 of pulmonary blood volume (PBV),Merck Sharp & Dohme Corp.,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",5475-006|2020-000488-22|MK-5475-006,5-Jun-20,9-Jul-21,9-Jul-21,1-May-20,,21-Dec-20,"University of Rochester Medical Center ( Site 0012), Rochester, New York, United States|Republican Clinical Hospital of Moldova ( Site 0013), Chisinau, Moldova, Republic of",,https://ClinicalTrials.gov/show/NCT04370873
NCT03709771,Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease,,Recruiting,No Results Available,Renal Cell Carcinoma|Hypertension|Melanoma|Cancer,Diagnostic Test: Ambulatory Blood Pressure Measurement,Change in mean blood pressure|Ratio of post-treatment to pre-treatment change in digital pulse amplitude,Vanderbilt University Medical Center,All,"40 Years to 75 Years   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,181796,9-Jan-20,Jan-24,Jan-24,17-Oct-18,,24-Aug-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03709771
NCT03564522,Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension,,Recruiting,No Results Available,Pulmonary Hypertension|Congenital Heart Disease|Pediatric Congenital Heart Disease,Procedure: cardiac catheterization|Radiation: Cardiac MRI,3D volumetric data (mL/m2)|Cardiopulmonary Flow (mL/beat)|Mean Pressure (mmHg),University of Michigan|Michigan State University|Nationwide Children's Hospital,All,"6 Years to 25 Years   (Child, Adult)",,50,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,HUM00117706,1-Apr-17,Dec-21,Dec-21,21-Jun-18,,22-Jul-20,"Mott Children's Hospital University of Michigan, Ann Arbor, Michigan, United States|Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03564522
NCT04226157,Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *On Hold Due to Global Pandemic*,HBPS,Recruiting,No Results Available,Ischemic Stroke|Hypertension,Device: Home Blood Pressure Monitoring Device (Qardio Arm)|Other: Primary Care Provider Blood Pressure Management,Feasibility of blood pressure self management in stroke survivors|Systolic Blood Pressure Difference,MedStar Georgetown University Hospital|Medstar Health Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2018-0718,21-Feb-19,31-Dec-20,31-Mar-21,13-Jan-20,,9-Apr-20,"Medstar Georgetown University Hospital, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT04226157
NCT02102243,Neural Mechanism of Aldosterone-induced Insulin Resistance,,Recruiting,No Results Available,Hypertension,Drug: DEFINITY® infusion|Drug: Human Recombinant Regular Insulin infusion|Drug: Dextrose infusion|Procedure: Flow mediated vasodilation|Procedure: Endothelial cell collection|Procedure: Microvascular perfusion assessment using Definity|Procedure: Microneurography,Increase in muscle sympathetic nerve activity during hyperinsulinemic euglycemic clamp|Change in microvascular blood flow during hyperinsulinemic euglycemic clamp.|Change in microvascular blood flow during saline infusion.|Change in endothelial cell protein expression after hyperinsulinemic euglycemic clamp|Change in endothelial cell protein expression after saline infusion|Increase in muscle sympathetic nerve activity during saline infusion,University of Texas Southwestern Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,STU 102010-063,Nov-10,Dec-20,Dec-20,2-Apr-14,,10-Apr-20,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02102243
NCT04149899,Safety and IOP-Lowering Effects of WB007,,Recruiting,No Results Available,"Glaucoma, Primary Open Angle|Ocular Hypertension",Drug: Study Treatment 1 WB007|Drug: Study Treatment 2 WB007|Drug: Study Treatment 3 WB007|Drug: Timolol 0.5%,Mean change from Baseline in intraocular pressure (IOP) at Day 14|Mean IOP at Day 14,"Whitecap Biosciences, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WB007-001,14-Nov-19,Jan-21,Jul-21,4-Nov-19,,10-Nov-20,"Eye Research Foundation, Newport Beach, California, United States",,https://ClinicalTrials.gov/show/NCT04149899
NCT04229667,Community Models for Hypertension and Diabetes Care for Refugees,,Not yet recruiting,No Results Available,"Hypertension|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Comorbidities and Coexisting Conditions",Other: Improved Community Health Volunteer (CHV) program,"Proportion of diabetes patients at intake (defined as random blood sugar >= 200 mg/dL at intake) demonstrating a change in random blood sugar (mmHg)|Proportion of hypertension patients at intake (defined as blood pressure >=140/90 mmHg at intake) demonstrating a change in systolic blood pressure (mmHg)|Proportion of patients demonstrating a change in self-reported medication adherence behaviors|Proportion of patients demonstrating a change in self-reported medication adherence actions (5-day)|Proportion of patients demonstrating a change in self-reported medication adherence actions (30-day)|Proportion of hypertension patients at intake (defined as blood pressure >=140/90 mmHg at intake) demonstrating a change in diastolic blood pressure (mmHg)|Proportion of patients demonstrating a change in disease control (defined as blood pressure <140/90 mmHg; <150/90 for patients aged ≥80 years), among patients with hypertension at intake (defined as blood pressure >=140/90 mmHg at intake)|Proportion of patients demonstrating a change in disease control (defined as random blood sugar <200 mg/dL mmHg), among patients with diabetes at intake (defined as random blood sugar >=200 mg/dL at intake)",International Rescue Committee|University of Southern California|Jordan University of Science and Technology,All,"18 Years and older   (Adult, Older Adult)",,600,Other,Observational,Observational Model: Other|Time Perspective: Prospective,H 1.00.020,31-Jan-20,28-Feb-21,28-Feb-21,18-Jan-20,,21-Jan-20,"International Rescue Committee, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04229667
NCT03042988,Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension,,Recruiting,No Results Available,Hypertension|Pure Autonomic Failure|Multiple System Atrophy|Autonomic Failure,Other: Heating pad|Other: Sham control,Systolic blood pressure|Orthostatic Tolerance the following morning,Vanderbilt University Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VR22699|141523,30-Jan-17,30-Jan-21,30-Jul-21,3-Feb-17,,17-Sep-20,"Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03042988
NCT04666909,"Take the Pressure Off, NYC!",,Recruiting,No Results Available,Hypertension,Diagnostic Test: blood pressure,Change in Blood Pressure over 6 months,NYU Langone Health,Male,"18 Years to 90 Years   (Adult, Older Adult)",,5000,Other,Observational,Observational Model: Other|Time Perspective: Prospective,20-00978,10-Oct-20,Jun-21,Jun-21,14-Dec-20,,14-Dec-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04666909
NCT04223934,Tailored Drug Titration Using Artificial Intelligence,,Recruiting,No Results Available,Hypertension,Other: optima4BP,Reduction in systolic BP [SBP] (mmHg) measured remotely [Time frame: 0 - 6 months]|Incidence of Adverse Events [Time Frame: full 12 months]|Sustained remote SBP Target during observational period [Time Frame: 6 - 12 months (end of study)],"Optima Integrated Health|University of California, San Francisco",All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,300,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,O4BP-001,18-Feb-20,30-Sep-21,31-Mar-22,13-Jan-20,,9-Jun-20,"University of California San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04223934
NCT04112043,Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial),,Recruiting,No Results Available,Hypertension,Behavioral: Walking Exercise|Drug: Nicotinamide Riboside (NR),Change in SBP|Change in arterial stiffness,University of Florida|National Institute on Aging (NIA),All,65 Years to 105 Years   (Older Adult),Phase 1,74,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",IRB201900746 -N|OCR26682|1R21AG064282-01,28-Jul-20,31-May-21,31-May-21,2-Oct-19,,2-Sep-20,"UF Institute on Aging, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04112043
NCT04110262,Human Sodium Balance Study,MEASURE,Not yet recruiting,No Results Available,Hypertension,Other: High dietary sodium intake|Other: Low dietary sodium intake,"Estimated sodium concentration in skin and muscle|Estimated sodium concentration in bone|Concentration of sodium, potassium, and hormone regulators in excreted urine|Blood pressure|Racial differences in concentrations of sodium in skin, muscle and bone|Racial differences in concentration of urinary potassium excretion","University of California, San Diego",All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,HL140488,Sep-20,Oct-22,Jun-23,1-Oct-19,,23-Jun-20,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04110262
NCT04051034,Heat Therapy and Omega 3 on Cardio-Metabolic Health,,Recruiting,No Results Available,Hypertension,Dietary Supplement: Omega 3|Other: Placebo,Metabolic flexibility|Microbiome|Short chain fatty acids|Vascular Health,Texas Tech University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB2018-1199,20-Aug-19,1-Aug-20,1-Aug-20,9-Aug-19,,14-Aug-19,"Eric Rivas, Lubbock, Texas, United States",,https://ClinicalTrials.gov/show/NCT04051034
NCT04006158,A Controlled Study to Investigate the Effect of Multi-wave Light Emitting Diode (LED) Bed on Blood Pressure and Endothelial Function,,Recruiting,No Results Available,Hypertension,Device: LED bed,Hypertension,"LED Intellectual Properties, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Light bed hypertension,29-Aug-18,31-Dec-20,31-Dec-20,5-Jul-19,,5-Jul-19,"Nitric Oxide Innovations, Rockdale, Texas, United States",,https://ClinicalTrials.gov/show/NCT04006158
NCT03738878,Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1,,Recruiting,No Results Available,Hypertension,Drug: Valsartan|Drug: LCZ696|Drug: Bradykinin|Drug: Substance P|Drug: BNP|Drug: Sitagliptin,forearm blood flow|tissue-type plasminogen activator release|norepinephrine release,Vanderbilt University Medical Center,All,18 Years to 60 Years   (Adult),Phase 4,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRB#170762,15-Nov-18,1-Jul-21,31-Dec-21,13-Nov-18,,19-May-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03738878
NCT03713515,Bridging the Evidence-to-practice Gap,,Not yet recruiting,No Results Available,Hypertension,Behavioral: ALTA,Level of implementation fidelity|Blood Pressure (BP) control|Medication adherence,NYU Langone Health,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,18-01290,15-Dec-20,30-Jun-23,30-Jun-23,19-Oct-18,,2-Dec-20,"NYUMC Langone, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03713515
NCT03484364,Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS),ENACTS,Recruiting,No Results Available,Hypertension,Behavioral: ENACTS,Systolic Blood Pressure|Sodium Potassium Urinary levels|Eating Behaviors|Food Purchasing|Medication Adherence|Social Support|Tobacco Use|Daily Energy Expenditure,Washington State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,270,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U54MD011240 127687|U54MD011240,15-Jun-18,28-Feb-21,28-Feb-21,30-Mar-18,,27-May-20,"Asian Counseling and Referral Service, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03484364
NCT04486170,Assessment of Postpartum Education to Improve Compliance,,Recruiting,No Results Available,Hypertension in Pregnancy|Postpartum Preeclampsia,Other: Education provided via a video format,Compliance with postpartum care|Incidence of postpartum re-admission for hypertension related concerns|Incidence of postpartum labor and delivery triage visits|Incidence of postpartum emergency department visits|Evaluate weight (kg) change|Incidence of stroke|Incidence of maternal death|Participant satisfaction with postpartum education using likert scale|Participant satisfaction with postpartum education,Medstar Health Research Institute,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB STUDY 00001865,14-Sep-20,Jan-21,Jun-21,24-Jul-20,,29-Sep-20,"MedStar Washington Hospital Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT04486170
NCT03298802,Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide,,Recruiting,No Results Available,"Pre-Eclampsia|Gestational Hypertension|Superimposed Pre-Eclampsia|Hypertension, Pregnancy-Induced|Postpartum Pregnancy-Induced Hypertension|Postpartum Preeclampsia",Drug: Hydrochlorothiazide 50mg Tablet|Drug: Placebo Tablet,Rate of readmission and/or triage visits|Need for additional antihypertensive therapy|Length of hospital stay|Total Additional doses of anti-hypertensive therapy|Elevation of blood pressure >150/90|Severe composite maternal morbidity|Use of resources|Adverse Events,"The University of Texas Medical Branch, Galveston",Female,18 Years to 50 Years   (Adult),Phase 3,612,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",16-0280,21-Nov-17,30-Apr-21,30-May-21,2-Oct-17,,29-Apr-20,"St. David's North Austin Medical Center, Austin, Texas, United States|Luis Monsivais, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03298802
NCT03349775,Cardiometabolic Disease and Pulmonary Hypertension,,Recruiting,No Results Available,Obesity,Drug: Metformin|Drug: Placebo,Pulmonary vascular hemodynamics (rest)|Pulmonary vascular hemodynamics (exercise)|Effect on pulmonary artery endothelial cell phenotypes,"Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",All,"30 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,75,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",2017P001020|1R01HL134893-01A1,27-Nov-17,1-Sep-22,1-Sep-24,22-Nov-17,,19-Feb-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03349775
NCT03043963,Mechanisms Underlying the Blood Pressure Lowering Effect of Sleep,,Recruiting,No Results Available,Hypertension,Behavioral: Sleep Extension|Behavioral: Sleep Timing,Reduction in 24 hour blood pressure|Lowering of sleep period blood pressure,Beth Israel Deaconess Medical Center,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,188,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2015P000243,10-Feb-17,30-Jun-21,30-Jun-21,6-Feb-17,,22-Jul-20,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03043963
NCT04194632,Right Ventricular Pacing in Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Artery Hypertension|Right Ventricular Dysfunction,Procedure: Temporary right ventricular pacing,Change in contractility (Ees)|Change in stroke volume|Pressure-volume loop area|Coronary sinus oxygen saturation,"University of California, San Francisco",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-25983,1-Jan-21,5-Dec-21,5-Dec-21,11-Dec-19,,3-Nov-20,"University of California San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04194632
NCT03528902,Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension,T3PAH,Recruiting,No Results Available,Hypertension|Pulmonary Arterial Hypertension|Familial Primary Pulmonary Hypertension|Primary Pulmonary Hypertension|Lung Diseases|Tamoxifen|Estrogen Receptor Antagonist|Hormone Antagonists|Estrogens,Drug: Tamoxifen|Drug: Placebo Oral Tablet,Transthoracic echocardiogram (ECHO)-based change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) measurement|Six minute walk test distance (6MWTD)|Quality of life will be assessed using the SF36 questionnaire. This will be administered at baseline and 12 and 24 weeks.|Quality of life will be assessed using emPHasis-10 questionnaire. This will be administered at baseline and 12 and 24 weeks.,Vanderbilt University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",180241,1-Oct-18,30-Jun-22,30-Jun-23,18-May-18,,18-Jan-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03528902
NCT03179163,Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans,H2SPharm,Recruiting,No Results Available,"Hypertension,Essential",Drug: Captopril Pill|Drug: Enalapril Pill|Drug: Hydrochlorothiazide,laser Doppler blood flow|Systolic Blood Pressure|Diastolic Blood Pressure,"Penn State University|National Heart, Lung, and Blood Institute (NHLBI)",All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,70,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",STUDY3224|5R01HL093238|120058,20-Jul-16,31-Aug-20,31-Aug-20,7-Jun-17,,1-Nov-19,"Pennsylvania State University, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03179163
NCT01815567,DETECT and Retinal Outcomes in Hypertension,,Recruiting,No Results Available,Hypertension|Retinal Disorder|Cognitive Impairment,,"DETECT neurocognitive outcome scores (Z-scores) in association with blood pressure measures and retinal pathology (isolated retinal hemorrhage, grade III/IV hemorrhagic retinopathy)|Variance of DETECT scores (Z-score) attributed to reading level",Emory University,All,"18 Years to 65 Years   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,IRB00060043,Nov-12,Jan-20,Jan-20,21-Mar-13,,8-Feb-19,"Grady Memorial Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01815567
NCT04126629,Association of Hypertensive Disorder of Pregnancy With Sleep-disordered Breathing.,,Recruiting,No Results Available,Hypertensive Disorder of Pregnancy|Sleep-disordered Breathing,,Prevalence of SDB in women with HDP compared to normotensive women.,The Cooper Health System,Female,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,19-028EX,22-Jan-20,1-Sep-20,1-Sep-21,15-Oct-19,,22-Jan-20,"Cooper University Hospital, Camden, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04126629
NCT03611270,TReatment of Pulmonary Hypertension Group II Study,TROPHY-II,Recruiting,No Results Available,Pulmonary Hypertension (PH) Due to Left Heart Disease,Device: Pulmonary Denervation,Procedural related Adverse Events (complications) at up to 30 days post procedure|Changes in cardiopulmonary exercise test|Change in resting mean right atrial pressure|Changes in 6MWD from baseline|Changes in Echocardiography parameters|Change in NT-BNP levels|Procedure related and PH worsening adverse events|Change in exercise mean right atrial pressure|Change in exercise mean pulmonary artery pressure|Change in exercise pulmonary vascular resistance|Change in exercise cardiac index|Change in resting mean pulmonary artery pressure|Change in resting pulmonary vascular resistance|Change in resting cardiac index,SoniVie Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLNS02-001,30-Nov-18,Jul-21,Jul-23,2-Aug-18,,10-Sep-20,"UC San Diego Medical Center, San Diego, California, United States|University of California, San Francisco Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03611270
NCT01913457,Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients,,Recruiting,No Results Available,Pulmonary Hypertension,Radiation: Ultrasound Doppler,Diagnose specific pattern of LDS in children by features as velocity & power in comparison to adult LDS pattern.,Echosense Ltd.,All,"Child, Adult, Older Adult",,200,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,DOP018/25388,Jul-13,Mar-21,Apr-21,1-Aug-13,,22-Jul-20,"Stanford Hospital and Clinics and Lucile Packard Children's Hospital, Palo Alto, California, United States|Stanford university hospital, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT01913457
NCT04286555,Dietary Approaches to Stop Hypertension for Diabetes,DASH4D,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes|Diabetes type2|Type2 Diabetes|Type 2 Diabetes|Type II Diabetes|Hypertension|High Blood Pressure",Other: DASH4D diet|Other: comparison diet|Other: higher sodium|Other: lower sodium,Systolic blood pressure (SBP)|Diastolic blood pressure (DBP)|Glycated albumin level|Fructosamine level|Fasting glucose level|Hemoglobin A1c (HbA1c) level|Cardiovascular disease (CVD) risk percentage|Total cholesterol level|Low-density lipoprotein (LDL) cholesterol level|High-density lipoprotein (HDL) cholesterol level|Triglyceride level|Presence of orthostatic hypotension|Postural change in systolic blood pressure|Postural change in diastolic blood pressure|Symptoms experienced by participants as assessed by a questionnaire,Johns Hopkins University|Beth Israel Deaconess Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00232059,1-Jul-21,31-Mar-23,31-Mar-23,27-Feb-20,,18-Sep-20,"Johns Hopkins ProHealth, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04286555
NCT04442464,Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear,,Recruiting,No Results Available,Ocular Hypertension,Device: Scleral Lens,Intraocular Pressure (IOP),Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,18-004974,1-Jul-20,Dec-21,Dec-21,22-Jun-20,,2-Jul-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04442464
NCT03993184,The Effects of Hot Yoga on Vascular Function,,Recruiting,No Results Available,Hypertension|Elevated Blood Pressure,Behavioral: Hot Yoga,Averages in ambulatory blood pressure and vascular function|Perceived stress|Brachial artery endothelial function|Arterial Stiffness,Texas State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,169,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018381,17-Apr-18,Oct-20,Oct-20,20-Jun-19,,26-Jun-19,"Texas State University, San Marcos, Texas, United States",,https://ClinicalTrials.gov/show/NCT03993184
NCT04554147,Use of an Innovative Mobile Health Intervention to Improve Hypertension Among African-Americans,,Recruiting,No Results Available,High Blood Pressure,Behavioral: FAITH! App-enhanced Hypertension Intervention,"Blood pressure (systolic and diastolic, mmHg)|CV Health Knowledge as measured by module assessment scores|Blood pressure medication adherence (by Morisky Medication Adherence Scale (MMAS-8))|Low-density lipoprotein (LDL) cholesterol|Social Determinants of Health (SDOH, PRAPARE (Protocol for Responding to and Addressing Patient Assets, Risks, and Experiences) tool)",Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,19-009247,Dec-20,Mar-21,Jun-21,18-Sep-20,,20-Oct-20,"North Point Health & Wellness Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Open Cities Health Center, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04554147
NCT03176732,Mechanisms for Individual Differences in Hypertension in Obstructive Sleep,PISA-BP,Recruiting,No Results Available,"Sleep Apnea, Obstructive|Hypertension",Device: Positive Airway Pressure,Nocturnal mean arterial blood pressure (nMAP)|Oxidative stress|Sympathetic activity,"University of Pennsylvania|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 75 Years   (Adult, Older Adult)",,200,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,823172|P01HL094307-06A1,6-Jun-17,30-Sep-21,30-Sep-23,5-Jun-17,,8-Jul-20,"University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Iceland, Reykjavík, Iceland",,https://ClinicalTrials.gov/show/NCT03176732
NCT03427164,Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure,,Recruiting,No Results Available,Portal Hypertension,Procedure: Transjugular Intrahepatic Portosystemic Shunt,Spleen stiffness|Change in spleen stiffness,University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00004361,16-Oct-17,31-Dec-20,31-Dec-21,9-Feb-18,,27-Nov-19,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03427164
NCT03733145,Angiotensin II in General Anesthesia,,Recruiting,No Results Available,Hypertension,Drug: Angiotensin II,Mean dose required to increase the SBP|Mean value of Bradykinin|Mean value of Angiontensin|Mean value of Aldosterone,Wake Forest University Health Sciences,All,"40 Years and older   (Adult, Older Adult)",Phase 1,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00054661,3-Oct-19,Oct-21,Oct-21,7-Nov-18,,4-Aug-20,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03733145
NCT03583866,Adiposity and Endothelin Receptor Function,END-RF,Recruiting,No Results Available,Hypertension,Drug: Candesartan|Drug: Placebo,Percentage Change in Flow-Mediated Dilation (FMD),"Augusta University|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 40 Years   (Adult),Early Phase 1,200,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1148277|5P01HL069999,21-May-18,Jun-20,Jun-21,12-Jul-18,,8-Oct-19,"Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03583866
NCT03224624,Self-management of Blood Pressure Medication for Hypertensive Veterans,,Recruiting,No Results Available,Hypertension,Other: self-management protocol for hypertension care,in-clinic blood pressure change|24-hour ambulatory blood pressure change,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,IIR 15-369,21-Feb-18,1-Jun-21,1-Sep-21,21-Jul-17,,13-Nov-20,"VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03224624
NCT04280523,TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH,TYEGER,Not yet recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: ESR-specific PET scan,To correlate lung ESR density with pulmonary vascular resistance (PVR)|Survival at one year,Vanderbilt University Medical Center,All,"13 Years and older   (Child, Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,191946,1-Jan-21,Oct-24,Oct-24,21-Feb-20,,23-Dec-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04280523
NCT03269630,New Orleans Pulmonary Hypertension Biobank,NO-PH Biobank,Recruiting,No Results Available,Pulmonary Hypertension|Systemic Sclerosis|Mixed Connective Tissue Disease|Heart Failure With Normal Ejection Fraction|Healthy,Other: No intervention. Biospecimen collection only,Collection of biospecimens,Louisiana State University Health Sciences Center in New Orleans,All,"18 Years and older   (Adult, Older Adult)",,450,Other,Observational,Observational Model: Other|Time Perspective: Prospective,LSU,29-Dec-17,Oct-27,Oct-27,1-Sep-17,,11-Mar-19,"University Medical Center-New Orleans, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT03269630
NCT04286568,Wald Outreach for Wellness: Blood Pressure Outreach,WOW,Not yet recruiting,No Results Available,Pre-hypertension|Hypertension,Behavioral: WOW Intervention,Change in actions to control hypertension as assessed by the Behavioral Risk Factor Surveillance System Module 7|Change in blood pressure|Change in usage of BP monitor|Change in knowledge of the signs and symptoms of a heart attack and stroke as assessed by BRFSS Module 8|Change in engagement with healthcare provider as assessed by BRFSS Section 3,Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB00243167,Mar-21,Sep-21,Sep-21,27-Feb-20,,18-Sep-20,"Johns Hopkins University School of Nursing, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04286568
NCT04704336,Integration of Hypertension Management Into HIV Care in Nigeria,TASSH NIMR,Not yet recruiting,No Results Available,Human Immunodeficiency Virus|Hypertension,Behavioral: Task-shifting strategy for HTN control (TASSH) protocol,Change in systolic Blood Pressure|The rate of adoption of TASSH across participating primary health centers (PHCs) at 12- and 24 months respectively.|The rate of sustainability of TASSH across participating primary health centers (PHCs) at 12- and 24 months respectively.|Change in Implementation Climate of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.|Change in Implementation Leadership of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.|Change in Proficiency of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.|Change in Organizational Readiness of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.|Change in implementation process across the primary health centers (PHCs) at 12 and 24 months.|Change in Organizational capacity to change across the primary health centers (PHCs) at 12 and 24 months.,"NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,960,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,20-00009|R01HL147811-01A1,Apr-21,Dec-23,Dec-25,11-Jan-21,,11-Jan-21,"Saint Louis University (SLU), Saint Louis, Missouri, United States|Nigerian Institute of Medical Research (NIMR), Yaba, Lagos, Nigeria",,https://ClinicalTrials.gov/show/NCT04704336
NCT02417740,Natural History of Noncirrhotic Portal Hypertension,,Recruiting,No Results Available,Cystic Fibrosis|Immunologic Deficiency Syndrome|Turner Syndrome|Congenital Hepatic Fibrosis|Idiopathic Non-Cirrhotic Portal Hypertension,,To study the natural history of non cirrhotic portal hypertension. It is an ongoing study,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"12 Years and older   (Child, Adult, Older Adult)",,400,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,150108|15-DK-0108,25-Jul-15,4-Sep-29,4-Sep-29,16-Apr-15,,22-Dec-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02417740
NCT03931317,Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity,,Recruiting,No Results Available,OAG - Open-Angle Glaucoma|OHT - Ocular Hypertension,Drug: Latanoprostene bunod 0.024% QD|Drug: Timolol maleate 0.5% BID,retinal blood vessel density (peripapillary and macular)|best-corrected visual acuity (BCVA),"University of California, San Diego|Bausch & Lomb Incorporated",All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Other,180658,3-Dec-18,Dec-20,Dec-20,30-Apr-19,,9-Jun-20,"UCSD Shiley Eye Institute, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT03931317
NCT03295734,ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension,ACES,Recruiting,No Results Available,Hypertension|Aging|Sedentary Lifestyle,Behavioral: Aerobic exercise|Drug: Perindopril|Drug: Losartan|Drug: HCTZ,Gait speed|Six minute walk test|Body composition|Circulating indices of cardiovascular risk,"University of Alabama at Birmingham|University of Colorado, Denver|Translational Research Institute for Metabolism and Diabetes, Advent Health",All,"60 Years and older   (Adult, Older Adult)",Phase 2,213,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,29-May-18,Sep-22,Sep-22,28-Sep-17,,15-Nov-19,"UAB Center for Exercise Medicine, Birmingham, Alabama, United States|University of Colorado Medical Center, Aurora, Colorado, United States|Translational Research Institute, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT03295734
NCT04610788,Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH,CALIPSO,Recruiting,No Results Available,Scleroderma|Pulmonary Artery Hypertension,,Right Ventricular Function as assessed by RHC|Change in pulmonary vascular resistance|Change in arterial elastance|Myofilament contractility|Calcium sensitivity|Number of genes expressed|Number of proteins expressed,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 100 Years   (Adult, Older Adult)",,100,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NA_00049022|R01HL114910-06,15-Apr-19,31-Dec-23,31-Dec-23,2-Nov-20,,2-Nov-20,"Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04610788
NCT03901781,Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects,,Recruiting,No Results Available,Ocular Hypertension,Combination Product: ST266 via Intranasal Delivery,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],"Noveome Biotherapeutics, formerly Stemnion",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST266-IOPHTN-101,23-Oct-19,1-Feb-21,1-Feb-21,3-Apr-19,,7-Jan-21,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03901781
NCT02910414,TARGET BP I Clinical Trial,TARGET BP I,Recruiting,No Results Available,Hypertension,Drug: Dehydrated alcohol|Device: Peregrine System Kit (Sham Procedure),Change in mean systolic ABPM|Proportion of subjects with major adverse events|Major Adverse Events|Decrease in eGFR > 25%|Changes in eGFR|Adverse event rate|Device success|Procedure success|Change of office systolic blood pressure|Change of diastolic office blood pressure|Change of 24-hour mean diastolic ABPM|Change of 24-hour mean systolic ABPM|Changes in antihypertensive regimen|ABPM responders (5 mmHg)|Office BP responders (10 mmHg)|Change in mean office SBP|Change in mean daytime ambulatory SBP|Change in mean daytime ambulatory DBP|Changes (decreases or increases) in antihypertensive medication regimen from 3 months to 6 months post-procedure|Changes (decreases or increases) in antihypertensive medication regimen from procedure to 6 months post-procedure|Change in mean nighttime ambulatory SBP|Change in mean nighttime ambulatory DBP|Reduction of office SBP and DBP to normal,"Ablative Solutions, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR0002,22-Jul-19,Dec-21,Oct-24,22-Sep-16,,12-Nov-20,"Cardiology PC, Birmingham, Alabama, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02910414
NCT02610413,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer,,Recruiting,No Results Available,Breast Carcinoma,Other: Laboratory Biomarker Analysis,Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension,National Cancer Institute (NCI),All,"Child, Adult, Older Adult",,354,NIH,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,NCI-2013-02289|ECOG-E5103T2|E5103T2|U10CA180820,25-Mar-14,1-Jan-00,1-Jan-00,20-Nov-15,,22-Sep-20,"Eastern Cooperative Oncology Group, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02610413
NCT00932139,Effect of Electro-Acupuncture on Blood Pressure,,Recruiting,No Results Available,Hypertension|Arrhythmias,Procedure: Electro-acupuncture control|Procedure: Electro-acupuncture test,blood pressure|Heart rate|plasma catecholamine|plasma renin,"University of California, Irvine",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1999-2222,Feb-03,Dec-20,Dec-21,3-Jul-09,,26-Sep-19,"Susan Samueli Integrative Health Institute, Costa Mesa, California, United States",,https://ClinicalTrials.gov/show/NCT00932139
NCT03810911,Mechanisms of EPO-induced Hypertension,EPIC,Not yet recruiting,No Results Available,Chronic Kidney Disease|Blood Pressure|Anemia,Drug: Darbepoetin,Change in diastolic blood pressure in EPO treated patients compared to delayed start controls|Change in flow mediated dilatation (FMD)|Oxygen-induced change in forearm blood flow (OIC-FBF)|Predictors of change in flow mediated dilatation (FMD)|Change in systolic blood pressure in EPO treated patients|Between group change in hypertension status|Within group change in hypertension status,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NEPH-005-18S|052387,1-Jan-21,15-Jul-22,2-Jan-23,22-Jan-19,,8-Oct-20,"Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03810911
NCT04585594,Mi Propio Camino Intervention RCT for Blood Pressure Medication Adherence,MPC,Recruiting,No Results Available,Hypertension|Medication Adherence,Behavioral: Mi Propio Camino (MPC)|Behavioral: Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control),Medication Adherence (Objective)|Blood Pressure|Medication Adherence (Subjective)|Reasons for Nonadherence|Medication-related beliefs (Specific)|Medication-related information|Medication-related Behavioral Skills|Activation of behavioral strategies,"University of California, Irvine|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MPCUCI HS# 2017-4025|1R01HL142964,16-Sep-20,31-Dec-23,31-Jan-24,14-Oct-20,,14-Oct-20,"Health Policy Research Institute, Irvine, California, United States",,https://ClinicalTrials.gov/show/NCT04585594
NCT04200573,Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855,,Recruiting,No Results Available,Symptomatic Neurogenic Orthostatic Hypertension|nOH,Drug: Ampreloxetine,Plasma AUC0-t|Plasma AUC0-inf|Plasma Cmax|Number of subjects with clinically significant vital sign abnormalities|Number of subjects with change in C-SSRS scores,Theravance Biopharma,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,179,13-Jan-20,Jun-21,Jun-21,16-Dec-19,,1-Dec-20,"Theravance Biopharma Investigational Site, Miami, Florida, United States|Theravance Biopharma Investigational Site, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT04200573
NCT03778411,Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using Vibration Controlled Transient Elastography,,Recruiting,No Results Available,"Advanced Chronic Liver Disease, NASH",Device: VCTE with splenic stiffness measurement,Risks of decompensation|Risks of decomposition,Indiana University|Echosens,All,"18 Years and older   (Adult, Older Adult)",,300,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,1804223843,1-Dec-20,31-Dec-24,31-Dec-25,19-Dec-18,,15-Jan-21,"Indiana University School of Medicine, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03778411
NCT03821623,Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults,,Recruiting,No Results Available,Hypertension|Aging,Drug: Nicotinamide riboside|Other: Placebo,Systolic blood pressure|Ambulatory blood pressure|Arterial stiffness,"Douglas Seals|University of Colorado, Boulder",All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2,118,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",18-0644,10-May-19,31-Dec-23,31-Dec-23,30-Jan-19,,5-Dec-19,"Integrative Physiology of Aging Laboratory, Boulder, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03821623
NCT03820336,Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women,,Recruiting,No Results Available,Hypertension|Vascular Stiffness,Dietary Supplement: Extra Virgin Olive Oil|Dietary Supplement: Control Oil,Arterial pulse wave velocity|Blood pressure|Arterial distensibility|Arterial Beta Stiffness Index|Flow-mediated vasodilation|Cardiac output|Cardiac output response to volume challenge|C-reactive protein|High Density Lipoprotein (HDL) Cholesterol|Low Density Lipoprotein (LDL) Cholesterol|Triglycerides|Insulin|Hemoglobin A1C|B-type natriuretic peptide (BNP)|Interleukin 6 (IL-6)|Tumor necrosis factor alpha (TNF-α),University of Vermont Medical Center,Female,18 Years to 40 Years   (Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",18-0639,1-Feb-19,Feb-20,Feb-20,29-Jan-19,,17-Apr-19,"University of Vermont Medical Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT03820336
NCT04607876,Family at Risk Study,FAR,Not yet recruiting,No Results Available,Stroke|Hypertension,Other: Technological Facilitator|Other: Standard of Care,Change in Mean Blood Pressure|Time to Target for Designated Risk Factors|Percent of Participants Who Reach Risk Factor Target Goals|Atherosclerotic Cardiovascular Disease Change|Participant Engagement|Motivational Assessment,Vanderbilt University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1800,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,888888,Oct-21,Oct-26,Oct-26,29-Oct-20,,29-Oct-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04607876
NCT03483662,Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS),IMPACTS,Recruiting,No Results Available,Hypertension|Blood Pressure,Behavioral: Multicomponent Intervention|Behavioral: Enhanced Usual Care,Difference in mean change of systolic BP|Proportion of patients with systolic blood pressure <120 mm Hg|Proportion of patients with systolic blood pressure <130 mm Hg|Proportion of patients with a >30 mm Hg reduction in systolic blood pressure|Difference in mean change of diastolic blood pressure|Health-related quality of life (MOS-20),"Tulane University|National Heart, Lung, and Blood Institute (NHLBI)",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,1260,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01HL133790,27-Jun-18,Aug-22,Aug-22,30-Mar-18,,5-Aug-20,"26 FQHC Primary Care Clinics in Louisiana, New Orleans, Louisiana, United States|10 FQHC Primary Care Clinics in Mississippi, Biloxi, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT03483662
NCT04298034,Preeclamptic Postpartum Antihypertensive Treatment,P-PAT,Recruiting,No Results Available,Preeclampsia|Hypertension in Pregnancy,"Drug: Labetalol, Nifedipine",Hospital Readmission|Rate of Healthcare Utilization|percentage of severe range blood pressures at the 7-10 days postpartum visit|percentage of severe range blood pressures at the 6 week postpartum visit|compare mean systolic and mean diastolic blood pressure values at 7-10 days postpartum and at 6weeks postpartum,Medical College of Wisconsin,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PRO36760,17-Jul-20,30-Jun-22,30-Jun-23,6-Mar-20,,21-Jul-20,"Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04298034
NCT03695146,Heart Inflammation and Mental Stress Study,HIMS,Recruiting,No Results Available,Hypertension,Behavioral: Paced breathing|Behavioral: Active relaxation,Change in heart rate variability|Change in cytokine expression in peripheral blood mononuclear cells,"University of Miami|National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,144,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",20180631|K01HL139722-01,19-Aug-19,Feb-23,Feb-23,3-Oct-18,,20-Oct-20,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03695146
NCT01842399,Resveratrol and Cardiovascular Health in the Elderly,,Recruiting,No Results Available,Vascular Resistance|Hypertension,Dietary Supplement: Resveratrol|Drug: Placebo,To determine if oral resveratrol administered for 12 months will blunt the aging associated increase in vascular stiffness as measured by Pulse Wave Velocity (PWV).|To determine if oral resveratrol administered for 12 months will improve exercise capacity as measured by MVO2-treadmill.,National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,300,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",130078|13-AG-0078,14-Jul-15,1-Sep-21,1-Sep-21,29-Apr-13,,25-Nov-20,"National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01842399
NCT04515303,Digital Intervention Participation in DASH,,Recruiting,No Results Available,Hypertension|Dietary Quality|Recruitment|Cardiovascular Diseases,Other: Diverse Intervention Participation in DASH,Barriers and facilitators of recruitment|Barriers and facilitators of diet quality|Comparison of recruitment methods,"University of Connecticut|Duke University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",,30,Other|NIH,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,KFS 5658780|3R01HL146768-01S1,Aug-20,Dec-20,Jun-23,17-Aug-20,,18-Aug-20,"University of Connecticut, Storrs, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04515303
NCT02966665,: Vascular Function in Health and Disease,,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease|Pulmonary Artery Hypertension|Heart Failure|Hypertension,"Other: Maximum Exercise Tests|Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Drug: BQ-123|Drug: Fexofenadine, Ranitidine|Other: Angiotensin-II, Valsartan|Drug: Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Drug: BQ-123, MitoQ, BH4",Change in Limb Blood Flow|Change in Blood Pressure|Change in Maximum Exercise Capacity|Change in Peak Rate of Mitochondrial Adenosine Triphosphate (ATP) Synthesis,Russell Richardson|University of Utah,All,"18 Years and older   (Adult, Older Adult)",Phase 1,420,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB_00030810,Sep-08,Aug-25,Aug-25,17-Nov-16,,30-Sep-20,"George E Wahlen VA Medical Center, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02966665
NCT04346511,Acupuncture Treatment on Cerebral Blood Flow,Amp-HTN,Not yet recruiting,No Results Available,High Blood Pressure,Other: Acupuncture,Cerebrovascular Conductance Index|Middle cerebral artery blood velocity|Mean Arterial Pressure|Heart Rate Variability|End-tidal CO2|Oxygen Uptake|peripheral capillary oxygen saturation|Tissue saturation index|blood glucose levels|blood triglyceride levels|blood high density lipoprotein levels|blood low density lipoprotein levels,University of Oklahoma,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,11943,1-Jul-21,Aug-22,Aug-24,15-Apr-20,,20-Oct-20,"Department of Health and Exercise Science, Norman, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04346511
NCT04114669,Behavioral Economics Trial To Enhance Regulation of Blood Pressure (BETTER-BP),BETTER-BP,Recruiting,No Results Available,High Blood Pressure,Behavioral: Control Condition|Behavioral: Regret Lottery,Change in Systolic Blood Pressure (SBP)|Adherence,"NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,435,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-00952,14-Jul-20,1-Mar-24,31-Jul-24,3-Oct-19,,7-Dec-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04114669
NCT04452331,Assessing Open Access Audio,OAA,Not yet recruiting,No Results Available,Hypertension|Diabetes,"Other: Open Access Audio|Other: No Access, Patient and Provider Aware of Recording|Other: No Access, Provider Unaware of Recording",Blood pressure|Glycosylated Hemoglobin (HgB A1c)|Return Visit Adherence (RVA)|Prescription Refill Rate (PDC -- Proportion of Days Covered)|Patient Activation Measure (PAM)|SEGUE Framework for evaluating and scoring communication behavior.|Contextualization of Care|Emergency department utilization|hospital admission rate,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2308,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research",IIR 19-068,2-Jan-21,30-Jun-24,30-Dec-24,30-Jun-20,,10-Dec-20,"Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04452331
NCT03626363,Mindfulness and Neural Cardiovascular Control in Humans,,Recruiting,No Results Available,Elevated Blood Pressure,Behavioral: Stress Management,Sympathetic nerve activity|Arterial stiffness,Michigan Technological University|Emory University|Texas Tech University,All,18 Years to 45 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,M1690,4-Sep-18,31-Jul-20,Jan-21,13-Aug-18,,13-Mar-20,"Michigan Technological University, Houghton, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03626363
NCT03299816,"Five, Plus Nuts and Beans for Kidneys",,Recruiting,No Results Available,Chronic Kidney Disease|Hypertension,Behavioral: Coaching DASH group (C-DASH)|Behavioral: Self-Shopping DASH group (S-DASH),Change in Albuminuria from Baseline to 1 month|Change in Albuminuria from Baseline to 4 months|Change in Albuminuria from Baseline to end of study|Change in Systolic Blood Pressure,Johns Hopkins University|National Institute on Minority Health and Health Disparities (NIMHD),All,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,150,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00122943|1U01MD010550-01,22-Feb-18,22-Sep-21,22-Sep-21,3-Oct-17,,17-Jul-20,"East Baltimore Medical Campus, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03299816/Prot_SAP_004.pdf",https://ClinicalTrials.gov/show/NCT03299816
NCT02432339,Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress,MMF,Recruiting,No Results Available,"Psychological Stress|Hypertension, Renal",Drug: mycophenolate mofetil (MMF)|Drug: Placebo,Urinary sodium excretion rate|Hemodynamics- change in systolic blood pressure compared to changes in sodium excretion,Augusta University,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",611878,22-Apr-14,Nov-19,30-Nov-19,4-May-15,,20-Jun-19,"Augusta University, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02432339
NCT03741608,B'More for a Peaceful Motherhood Hypertension Control Study,,Recruiting,No Results Available,Hypertension,Behavioral: High blood pressure management education|Behavioral: Home blood pressure measurement,Blood pressure reduction|Stress,"University of Maryland, Baltimore",Female,18 Years to 44 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP-00082822,22-Jan-19,Sep-20,Nov-20,15-Nov-18,,4-Nov-19,"Leonard E. Hicks Community Center, Baltimore, Maryland, United States|Furman L. Templeton Preparatory Academy, Baltimore, Maryland, United States|Pedestal Gardens Apartment Homes, Baltimore, Maryland, United States|Union Baptist Harvey Johnson Head Start Program, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03741608
NCT03980717,Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH,,Recruiting,No Results Available,Congenital Diaphragmatic Hernia,Device: Goldbal Detachable Balloon and delivery microcatheter,Resolution of Pulmonary Hypertension - 6 months|Resolution of Pulmonary Hypertension - 12 months|2-year Survival|Number of participants who undergo a successful completion of surgical procedures/balloon placement|Maternal Outcomes- Maternal Morbidity-incidence of preterm delivery|Maternal Outcomes- Maternal Morbidity-incidence of cesarean section|Maternal Outcomes- Maternal Morbidity-length of hospitalization|Maternal Outcomes- Maternal Morbidity- length of hospitalization after UNPLUG procedure|Maternal Outcomes- Maternal Morbidity- vaginal bleeding|Maternal Outcomes- Maternal Morbidity- Placental abruption|Maternal Outcomes- Maternal Morbidity- Rupture of membranes|Maternal Outcomes- Maternal Morbidity- oligohydramnios|Maternal Outcomes- Maternal Morbidity- chorioamnionitis|Neonatal/Child outcomes- Pulmonary Morbidity - Number of babies that require ECMO|Neonatal/Child outcomes- Pulmonary Morbidity- ventilatory support|Neonatal/Child outcomes- Pulmonary Morbidity- Number of participants that require the use of supplemental oxygen|Neonatal/Child outcomes- gastrointestinal morbidity|Neonatal/Child outcomes-neurologic morbidity|Neonatal/Child outcomes- Survival to discharge from the hospital|Neonatal/Child outcomes- Duration of hospitalization.|Neonatal/Child outcomes- Number of participants that need supplemental oxygen|Neonatal/Child outcomes- recurrent infection|Neonatal/Child outcomes- repeated hospitalization|Neonatal/Child outcomes- Neurodevelopmental,Michael Belfort|Baylor College of Medicine,Female,18 Years to 45 Years   (Adult),Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-42958,9-Aug-19,Dec-28,Dec-30,10-Jun-19,,7-Jul-20,"Texas Childrens Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03980717
NCT03212976,Clinical Efficacy of a Non-Invasive Measure of Intracranial Pressure,MR-ICP,Recruiting,No Results Available,Intracranial Pathology|Intracranial Hypertension,Procedure: Phase contrast magnetic resonance imaging,Intracranial Pressure Measurement|Patency of ventricular catheters,University of Miami,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,20170130,26-Oct-17,Dec-21,Dec-21,11-Jul-17,,16-Sep-20,"Jackson Memorial Hospital, Miami, Florida, United States|University of Miami Hospital, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03212976
NCT03796689,The PCORnet Blood Pressure Home Monitoring Study,BP Home,Recruiting,No Results Available,Hypertension,Device: Smartphone-linked HBPM and associated app|Device: Standard HBPM,Reduction in Systolic Blood Pressure (SBP)|Net Promoter Score,"University of California, San Francisco|Patient-Centered Outcomes Research Institute",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-254-53,15-Aug-19,30-Jun-21,30-Oct-21,8-Jan-19,,17-Nov-20,"University of Florida Health, Gainesville, Florida, United States|University Medical Center, New Orleans, Louisiana, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03796689
NCT04647214,18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA),,Not yet recruiting,No Results Available,Open-angle Glaucoma|Ocular Hypertension,Drug: Bimatoprost intracameral implant (DURYSTA) 10μg,Proportion of treated eyes that did not receive additional Intraocular Pressure (IOP) -lowering intervention/therapy per standard medical care|Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care|Time from bimatoprost intracameral implant to first additional IOP-lowering intervention/therapy|Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy|Proportion of treated eyes achieving predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy|Mean reduction in the number of topical IOP-lowering medications|Proportion of treated eyes achieving complete success|Proportion of treated eyes achieving qualified success|Number of participants experiencing treatment emergent adverse events,Allergan,All,"18 Years and older   (Adult, Older Adult)",,230,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,MED-MA-EYE-0648,31-Dec-20,1-Apr-22,30-Apr-23,30-Nov-20,,30-Nov-20,"El Paso Eye Surgeons, P.A., El Paso, Texas, United States",,https://ClinicalTrials.gov/show/NCT04647214
NCT03868124,Clinical Study Comparing Two Models of a Travoprost Intraocular Implant,,Recruiting,No Results Available,"Glaucoma, Open-Angle|Ocular Hypertension",Combination Product: G2TR intraocular implant containing travoprost|Drug: Sham surgery + active-comparator eye drops,Mean IOP (Control Group vs. Each Implant Group) through 3 months postoperative|Mean IOP (Control Group vs. Each Implant Group) through 12 months postoperative,Glaukos Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",GC-012,2-Aug-18,Jun-21,Jun-23,8-Mar-19,,8-Mar-19,"Center for Sight, Las Vegas, Nevada, United States",,https://ClinicalTrials.gov/show/NCT03868124
NCT04315571,Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents,,Recruiting,No Results Available,"Hypertension, Portal|Ascites",Device: Gore® Viatorr® Endoprosthesis with controlled expansion|Procedure: Large Volume Paracentesis with albumin infusion,Number of Paracentesis|Transplant free survival,"University of California, Los Angeles|W.L.Gore & Associates",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,68,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXTIPSvLVP-v1,24-Mar-20,1-Jan-23,1-Jan-26,19-Mar-20,,26-Mar-20,"UCLA Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04315571
NCT03519386,"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%",,Recruiting,No Results Available,"Glaucoma, Open-Angle|Ocular Hypertension",Combination Product: G2TR intraocular implant containing travoprost|Drug: Sham surgery + active-comparator eye drops,Mean IOP (Control Group vs. Each Implant Group) through 3 months postoperative|Mean IOP (Control Group vs. Each Implant Group) through 12 months postoperative,Glaukos Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",GC-010,22-May-18,Jun-21,Jun-23,9-May-18,,8-Mar-19,"Vance Thompson Vision, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT03519386
NCT04035239,Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma,,Recruiting,No Results Available,Glaucoma|Ocular Hypertension,Device: BGS goggles,Retinal thickness|Retinal vascular density|Retinal fluorescence,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,50800,23-Jul-19,28-Feb-20,28-Sep-20,29-Jul-19,,2-Jun-20,"Byers Eye Institute at Stanford University, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT04035239
NCT02665117,Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate,,Recruiting,No Results Available,Hypertension,Drug: Potassium Magnesium Citrate (KMgCit)|Drug: Potassium Chloride (KCl)|Drug: Chlorthalidone,Change in fasting plasma glucose|Hepatic fat|Muscle magnesium content|Serum Aldosterone|FGF23|Urinary Isoprostanes,University of Texas Southwestern Medical Center,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",STU 092015-058,Jan-15,Jan-23,Jan-23,27-Jan-16,,11-Mar-20,"University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02665117
NCT04295850,Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy),APROACH,Recruiting,No Results Available,Preeclampsia,Drug: Aspirin 81 mg,Aim 1: PFA-100 closure time and risk of hypertensive disorder of pregnancy (HDP)|Aim 2: Pharmacogenomics of aspirin|Aim 3: MicroRNAs and HDP|Aim 4: Aspirin pharmacokinetics in pregnancy|Aim 1: Aspirin response|Aim 1: Prediction of HDP|Aim 1: First trimester serum thromboxane and risk of HDP|Aim 1: Third trimester serum thromboxane and risk of HDP|Aim 2: Pharmacogenomics and Pregnancy outcome|Aim 3: MicroRNA profile and aspirin therapy|Aim 4: Salicylic acid level and Serum Thromboxane,Thomas Jefferson University,Female,"10 Years to 60 Years   (Child, Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19F.887,21-Aug-20,30-Jan-22,30-Jul-22,5-Mar-20,,22-Oct-20,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04295850
NCT03726398,CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH,CRUSADE,Recruiting,No Results Available,Interstitial Lung Disease|Scleroderma|Pulmonary Hypertension,Drug: Opsumit 10 Mg Tablet,Change in exercise pulmonary vascular resistance (PVR)|Change in right ventricular pulmonary vascular hemodynamic coupling (RVPA).|Change in maximal oxygen consumption (V02 max).|Change in pulmonary impedance.,"Franz Rischard, DO|National Jewish Health|University of Pittsburgh|University of Arizona",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,26,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IIS-02801,1-Sep-18,31-Jan-20,1-Dec-20,31-Oct-18,,2-Apr-19,"University of Arizona, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03726398
NCT04255745,The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia,INERTIA,Recruiting,No Results Available,Sarcopenia|High Blood Pressure|Hypertension,Behavioral: progressive resistance training,Change in blood pressure|Short Physical Performance Battery (SPPB)|Timed up and go performance,"University of Illinois at Chicago|National Heart, Lung, and Blood Institute (NHLBI)",All,65 Years and older   (Older Adult),Not Applicable,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2017-0009|1K01HL148503-01,27-Jan-20,Mar-24,Mar-25,5-Feb-20,,21-Jul-20,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04255745
NCT02055209,"Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)",,Recruiting,No Results Available,Hypertension,,Our objective is to develop a community-based cohort and novel genomic science resource for defining the biological significance of ancestry-related genomic variation in African-Americans within the GENE FORECAST(R),National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"21 Years to 65 Years   (Adult, Older Adult)",,2019,NIH,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,140048|14-HG-0048,23-Jul-14,1-Jul-30,1-Jul-30,5-Feb-14,,17-Sep-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02055209
NCT04546126,Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2&3),,Recruiting,No Results Available,Radiotracer|Hypertension|Cholesterol,Drug: Dexamethasone (Group 2)|Drug: Cosyntropin (Group 3)|Combination Product: PET/CT Scan with FNP-59,Change in [18F]FNP-59 chemistry uptake as measured by the standardized uptake value (SUV) based gland segmentation|PET/CT image uptake score as measured by investigator visual assessment for each volume of interest (VOI),Benjamin Viglianti|University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HUM00179097b,Mar-21,Nov-22,Nov-22,11-Sep-20,,12-Jan-21,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04546126
NCT04532489,Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1),,Recruiting,No Results Available,Radiotracer|Hypertension|Cholesterol,Drug: FNP-59,Uptake for [18F]FNP-59 in the adrenal glands using the standardized uptake value (SUV) based on gland segmentation,Benjamin Viglianti|University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HUM00179097a,18-Jan-21,Oct-22,Oct-22,31-Aug-20,,12-Jan-21,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04532489
NCT04656093,Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms,,Not yet recruiting,No Results Available,COPD|Diabetes|Hypertension,Behavioral: Supportive counseling|Behavioral: Education on SMB|Behavioral: Psychoeducation on ATs for maladaptive beliefs (if applicable)|Behavioral: Psychoeducation on emotional response (if applicable),Brief Illness Perception Questionnaire (BIPQ)|Beliefs about Medicines Questionnaire (BMQ scores)|Medication Adherence Rating Scale (MARS)|Dietary Approaches to Stop Hypertension (DASH-Q)|International Physical Activity Questionnaire (IPAQ)|Illness Perceptions Questionnaire (IPQ scores),"Icahn School of Medicine at Mount Sinai|Northwestern University|National Heart, Lung, and Blood Institute (NHLBI)",All,"Child, Adult, Older Adult",Not Applicable,40,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 14-0666|5R01HL126508-05,Dec-20,Mar-21,May-21,7-Dec-20,,7-Dec-20,"Northwestern University, Chicago, Illinois, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04656093
NCT04543656,Personalized Blood Pressure Care Using IoMTs and Artificial Intelligence,,Recruiting,No Results Available,Pre-hypertension,Behavioral: AI-Based Lifestyle Recommendations|Other: No Lifestyle Recommendations,Average change in systolic blood pressure (SBP) in experimental vs. control group|Average change in diastolic blood pressure (DBP) in experimental vs. control group|Number of patients in experimental group that followed lifestyle recommendations,"University of California, San Diego",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,1,1-Oct-20,Jun-21,Jun-21,10-Sep-20,,2-Dec-20,"University of California, San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT04543656
NCT03303391,Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration,IBPS,Recruiting,No Results Available,ESRD|Extracellular Fluid Alteration|Hypertension,Other: Intradialytic Blood Pressure Slope Based Ultrafiltration,Ambulatory Systolic Blood Pressure|Extracellular Volume/Body Weight Ratio,University of Texas Southwestern Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,74,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU 032017-024,1-Nov-17,Jul-22,Jul-22,6-Oct-17,,22-Dec-20,"Davita Dialysis, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03303391
NCT02513914,Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial,OPEN-UP,Recruiting,No Results Available,Pseudotumor Cerebri|Idiopathic Intracranial Hypertension (IIH),Device: Dural Venous Sinus Stenting|Device: Cerebrospinal Fluid Shunting,Perimetric mean deviation (PMD) at six months|Total number of IIH-related surgeries at one year|Resolution of venous stenosis pressure gradient at six months|Papilledema|Visual acuity|Quality of life|Medication usage,"St. Joseph's Hospital and Medical Center, Phoenix|Barrow Neurological Institute",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15BN045,3-Jun-20,Jan-24,Jan-24,3-Aug-15,,24-Jul-20,"Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02513914
NCT04036214,Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT),SLT,Recruiting,No Results Available,"Primary Open-Angle Glaucoma, Unspecified Eye|Ocular Hypertension",Device: Selective Laser Trabeculoplasty,Intraocular Pressure via Goldmann tonometry,Northeastern State University,All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NSUOCO0001,21-Aug-19,31-May-21,31-May-21,29-Jul-19,,9-Sep-20,"Northeastern State University, Tahlequah, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04036214
NCT01959815,Novel Screening Strategies for Scleroderma PAH,,Recruiting,No Results Available,Pulmonary Arterial Hypertension|Scleroderma,,Development of pulmonary arterial hypertension,University of Michigan,All,"30 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HUM00074818,Oct-13,Oct-21,Oct-21,10-Oct-13,,30-Sep-20,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01959815
NCT03961360,Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida,ASPREO,Recruiting,No Results Available,Pre-Eclampsia|Hypertension in Pregnancy|Obesity,Drug: Aspirin 81 mg|Drug: Aspirin 162 mg,Preeclampsia diagnosis|Maternal Outcomes-Incidence of preterm preeclampsia|Maternal Outcomes-Gestational Hypertension|Maternal Outcomes-Placenta Abruption|Maternal Outcomes-Eclampsia|Maternal Outcomes-HELLP syndrome|Maternal Outcomes-Postpartum Hemorrhage|Maternal Outcomes-Other maternal bleeding|Maternal Outcomes-Need for blood transfusion|Neonatal Outcomes- Gestational age at delivery|Neonatal Outcomes-Delivery at < 37 weeks|Neonatal Outcomes-Apgar score at 5 min ≤ 5|Neonatal Outcomes-Small for gestational age|Neonatal Outcomes-Neonatal Intensive Care Unit (NICU) length of stay|Neonatal Outcomes-Intraventricular Hemorrhage Grade III-IV|Neonatal Outcomes-Bronchopulmonary Dysplasia|Neonatal Outcomes-Necrotizing Enterocolitis,"The University of Texas Health Science Center, Houston",Female,18 Years to 45 Years   (Adult),Phase 2|Phase 3,220,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC-MS-18-1073,6-May-19,1-May-20,1-May-20,23-May-19,,23-May-19,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03961360
NCT04530916,Blueberries and Cardiovascular Health in Middle-aged/Older Men,,Recruiting,No Results Available,Hypertension|Aging|Endothelial Dysfunction|Men,Dietary Supplement: Blueberry Powder|Dietary Supplement: Placebo Powder,Blood pressure|Reactive hyperemia index|Augmentation index|Pulse wave velocity|Endothelial cell protein expression|Hemoglobin A1c|Lipid profile|Nitric oxide metabolites|ICAM-1|VCAM-1|Peripheral blood mononuclear cell inflammation and oxidative stress,Colorado State University|Wild Blueberry Association of North America,Male,"45 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",WB2020,1-Jan-20,1-Jun-21,31-Dec-21,28-Aug-20,,28-Aug-20,"Food and Nutrition Clinical Research Laboratory, Fort Collins, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04530916
NCT04051957,Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury,,Recruiting,No Results Available,Kidney Injury|Proteinuria|Hypertension,Drug: Isosorbide Mononitrate|Drug: Placebo oral tablet,Number of participants with a reduction in Urine Protein Creatinine ratio (UPC )of > 500 mg/day from that measured before enrollment|Number of participants with a reduction in UPC of > 500 mg/day from that measured before enrollment|Number of participants with improvement in estimated Glomerular Filtration Rate (eGFR)≥25% from before enrollment|Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment,"The University of Texas Health Science Center, Houston|National Kidney Foundation",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HSC-MS-19-0429,26-Sep-19,30-Jun-21,31-Jul-21,9-Aug-19,,5-Nov-20,"The University Of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04051957
NCT04661813,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,AAIM-High,Not yet recruiting,No Results Available,HIV-1-infection|Hypertension,Other: EXTRA-CVD Virtual Care,"Proportion of eligible participants who agree to participate|Average of home blood pressure values assessed over a 2-week period at 0-, 4-, 8-, and 12-months.|Number of days with at least 1 home blood pressure measurement assessed over a 2-week period at 0-, 4-, 8-, and 12-months.","Case Western Reserve University|Duke University|Metro Health, Michigan|National Heart, Lung, and Blood Institute (NHLBI)|University Hospitals Cleveland Medical Center",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,03-18-16-S1|U01HL142099,Feb-21,Aug-22,Aug-22,10-Dec-20,,10-Dec-20,"Duke Health, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04661813
NCT03016351,Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans,BPVR,Recruiting,No Results Available,Hypertension|Cardiovascular Diseases|Vascular Diseases,Other: Aerobic Training|Other: Resistance Training,Changes in peripheral and central blood pressure|Changes in arterial stiffness|Changes in endothelial function,"University of Illinois at Chicago|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 55 Years   (Adult),Not Applicable,140,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-1091|R01HL130513-01A1,Oct-16,Dec-22,Dec-22,10-Jan-17,,2-Nov-20,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03016351
NCT03437694,"Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)",HIV-MOI,Recruiting,No Results Available,"HIV/AIDS|Diabetes Mellitus, Type 2|Hypertension",Other: Medication optimization intervention,Diabetes mellitus|Hypertension,"University of North Texas Health Science Center|University of California, San Francisco|University of Minnesota|Walgreens, A Boots Alliance",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,U54Proj2,3-Aug-18,30-May-21,30-May-22,19-Feb-18,,9-Nov-20,"Marc Fleming, Fort Worth, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT03437694
NCT04344301,The Impact of Sharing Audio Recorded Clinic Visits on Self-management in Older Adults,,Recruiting,No Results Available,Diabetes Mellitus|Hypertension,Other: Audio recording,Participant retention (Feasibility)|Intervention fidelity (Feasibility)|Feasibility of Intervention Measure (FIM)|Participant recruitment rate (Acceptability)|Intervention use (Acceptability)|Acceptability of Intervention Measure (AIM),"Dartmouth-Hitchcock Medical Center|The University of Texas Medical Branch, Galveston|Vanderbilt University Medical Center|Dartmouth College|National Institutes of Health (NIH)|National Institute on Aging (NIA)",All,65 Years and older   (Older Adult),Not Applicable,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,D20072|1R56AG061522-01A1,31-Aug-20,5-Mar-21,5-Mar-21,14-Apr-20,,30-Sep-20,"Dartmouth-Hitchcock Manchester, Manchester, New Hampshire, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Medical Branch, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04344301
NCT04508049,A Study to Evaluate Renal Fibrosis Using MRI Techniques,,Not yet recruiting,No Results Available,Hypertension|Renovascular,Device: qMT-MRI to detect fibrosis.,Fibrosis assessed by qMT-MRI in the stenotic kidney and contralateral kidneys|Fibrosis assessed by qMT-MRI compared to stenotic kidney function|Fibrosis assessed by qMT-MRI compared to stenotic kidney injury markers,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,15,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,19-008413|R01DK122734,12-Jan-21,1-Sep-22,1-Sep-23,11-Aug-20,,25-Nov-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04508049
NCT03307343,Effect of Reducing Sedentary Behavior on Blood Pressure,RESET-BP,Recruiting,No Results Available,Hypertension|Prehypertension,Behavioral: Intervention,Resting Systolic Blood Pressure|24-hour Ambulatory Blood Pressure|Pulse Wave Velocity|Plasma Renin Activity|Aldosterone|Diastolic Blood Pressure,"University of Pittsburgh|National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01HL134809,3-Jan-18,Jun-22,Jun-22,11-Oct-17,,9-Nov-20,"University of Pittsburgh Physical Activity and Weight Management Research Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03307343
NCT04116684,Digital Home Blood Pressure Monitoring in Type B Aortic Dissection Patients,Dissect-BP,Recruiting,No Results Available,Aortic Dissection|Hypertension,Device: Withings Digital Blood Pressure Monitor,Systolic Blood Pressure at end of 4 weeks|Mortality|Surgical intervention|Hospitalization or Emergency Room Visit for uncontrolled hypertension or symptoms from dissection|Hospitalization or Emergency Room visit for Hypotension|Increase in size or progression of dissection as measured on cardiac CT|Questionnaire describing patient experience in the study,The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,19-723,23-Sep-19,Mar-21,Oct-21,7-Oct-19,,7-Oct-19,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04116684
NCT02841280,Chlorthalidone in Chronic Kidney Disease,CLICK,Recruiting,No Results Available,"Renal Insufficiency, Chronic|Hypertension",Drug: Chlorthalidone|Drug: Placebo,"Change from baseline to 12 weeks in systolic ambulatory blood pressure in the chlorthalidone group compared to placebo.|Changes in albuminuria from baseline at each 4 week visit in the log transformed albumin/creatinine ratio in the chlorthalidone group compared to placebo, as measured by overnight urine collection.|Change from baseline at each 4 week visit in log of aldosterone to renin ratio in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.|Change from baseline at each 4 week visit in log of B-type natriuretic peptide in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.|Change from baseline at each 4 week visit in body volume in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.",Indiana University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1507540384,Jul-16,Jan-21,Jan-22,22-Jul-16,,24-Jan-19,"Indiana University School of Medicine, Division of Nephrology, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02841280
NCT04412096,Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance,,Recruiting,No Results Available,Glaucoma|OHT - Ocular Hypertension,Drug: Timolol 0.5% ophthalmic solution|Drug: Latanoprost 0.005% Ophthalmic Solution,Variation in eye pressures between individuals|Variation in aqueous flow between individuals|Variation in episcleral venous pressure,Ohio State University|University of Nebraska|Mayo Clinic|National Eye Institute (NEI),All,"30 Years and older   (Adult, Older Adult)",Phase 4,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020H0284|R01EY022124,18-Sep-20,31-Dec-23,31-Aug-24,2-Jun-20,,11-Sep-20,"Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04412096
NCT03753204,Salt-Sensitivity and Immunity Cell Activation,,Recruiting,No Results Available,High Blood Pressure|Salt; Excess|Inflammation,Drug: Furosemide 40 mg,The percent of participants with salt sensitive blood pressure|Percent of participants with immune cell activation,Vanderbilt University Medical Center,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,182038,Jan-21,1-Sep-21,15-Sep-21,26-Nov-18,,8-Jan-21,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03753204
NCT04502225,Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure,,Recruiting,No Results Available,Supine Hypertension|Autonomic Failure,Other: Tilt|Other: Elevated trunk|Other: Tilt - In home|Other: Elevated Trunk - In home,Systolic Blood Pressure|Overnight Urine Volume,Vanderbilt University Medical Center,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200124,21-Aug-20,31-May-24,31-May-24,6-Aug-20,,24-Aug-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04502225
NCT03401489,PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor,,Recruiting,No Results Available,Blood Pressure|Hypertension|Mhealth,Device: PACESETTER,Systolic BP|Longitudinal Comparisons of BP,Northern California Institute of Research and Education|University of South Carolina|Medical University of South Carolina,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Pro00070627,14-Jul-20,Aug-21,Jan-25,17-Jan-18,,5-Aug-20,"NCIRE, San Francisco, California, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT03401489
NCT03838445,Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH),RELIEVE-PAH,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Device: V-Wave Interatrial Shunt,Safety-Percentage of Treatment patients experiencing major device-related adverse events|Safety-Percentage of Treatment patients experiencing any major adverse event|Procedure Success-Percentage of patients successfully implanted with study device|Device Success-Percentage of patients implanted with right to left interatrial flow|Freedom from device related MACNE at 1 and 12 months after implantation|Improvement in Exercise Capacity between baseline and 12 months|Improvement in WHO Functional Class between baseline and 12 months|Improvement in Quality of Life between baseline and 12 months,V-Wave Ltd,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL7012,14-Feb-20,31-Dec-21,31-Dec-24,12-Feb-19,,5-Aug-20,"Keck Medical Center of USC, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|The Ohio State University Wexner Medical Center - Davis Heart & Lung Research Institute, Columbus, Ohio, United States|Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada|Instituto Nacional de Cardiologia, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT03838445
NCT03070184,"Race, Natriuretic Peptides and Physiological Perturbations",,Recruiting,No Results Available,Healthy|Pre Hypertension,Other: Exercise capacity VO2 max determination|Dietary Supplement: Standardized meals|Other: Exercise challenge|Drug: Metoprolol Succinate ER,"Change in plasma NTproBNP after 6-weeks of beta-blocker|Change in plasma BNP after Exercise|Change in plasma BNP, NTproANP and MRproANP",University of Alabama at Birmingham,All,18 Years to 40 Years   (Adult),Phase 2,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,IRB-170214001,30-Apr-17,Dec-22,Dec-23,3-Mar-17,,3-Nov-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03070184/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03070184
NCT03221114,Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease,,Recruiting,No Results Available,Uncontrolled Hypertension|Cardiovascular Risk Factor,Behavioral: Positive Psychological Intervention,Change from Baseline Ambulatory Blood Pressure at 8- and 12-weeks|Center for Epidemiological Studies Depression Scale (CESD): Change from Baseline Depressive Symptoms at 8- and 12-weeks|Life Orientation Test-Revised (LOT-R): Change from Baseline Dispositional Optimism at 8- and 12-weeks|General Well-being Schedule: Change in Baseline Emotional Vitality at 8- and 12-weeks|Life Engagement Test (LET): Change in Baseline Life engagement and Meaning at 8- and 12-weeks,"University of Illinois at Urbana-Champaign|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,126,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1K01HL130712-01A1,1-Oct-17,Sep-20,Jul-21,18-Jul-17,,20-Mar-19,"St. Pius V Parish, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03221114
NCT04258332,CARDIA-Salt Sensitivity of Blood Pressure (SSBP),,Not yet recruiting,No Results Available,Salt Sensitivity of Blood Pressure|Hypertension,Dietary Supplement: High Salt Diet|Dietary Supplement: Low Salt Diet,"Salt sensitivity of blood pressure|Immune response to dietary salt loading, IL-6|Immune response to dietary salt loading, Change in circulating levels of IL-17|Immune response to dietary salt loading, IL-10",Vanderbilt University Medical Center|Northwestern University|University of Alabama at Birmingham,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,190622,19-Jan-21,31-Aug-24,31-Aug-24,6-Feb-20,,3-Nov-20,"University of Alabama Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04258332
NCT04433702,Effect of Negative Pressure on Pattern Electroretinography Readings,,Recruiting,No Results Available,"Glaucoma|Open Angle, Low Risk|Ocular Hypertension|Glaucoma Suspect",Device: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle|Device: Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle,Pattern Electroretinography (pERG) Alterations,Vance Thompson Vision,All,"22 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CP-014,1-Oct-20,Dec-20,Dec-20,16-Jun-20,,1-Oct-20,"Vance Thompson Vision, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT04433702
NCT04401982,Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects,,Not yet recruiting,No Results Available,Ocular Hypertension|Suspect Glaucoma,,Change in episcleral venous blood flow with Rhopressa|Change in retinal blood flow in arterioles and venules less than 100 microns with Rhopressa,"University of Maryland, Baltimore|Aerie Pharmaceuticals",All,"18 Years to 88 Years   (Adult, Older Adult)",,10,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,HP-00086248,Jun-20,Jun-21,Jun-21,26-May-20,,26-May-20,"University of Maryland Medical Center, Baltimore, Maryland, United States|University Physicians Inc., Baltimore, Maryland, United States|UM Faculty Physicians, Inc.   5900 Waterloo Crossing, Columbia, Maryland, United States|BWEye Center, Glen Burnie, Maryland, United States|Maryland Eye Consultants and Surgeons, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04401982
NCT04279834,Improving Outcomes for Patients With SDB and Insufficient Sleep,RESTORE,Recruiting,No Results Available,Sleep Apnea|Insufficient Sleep Syndrome|Sleep|Hypertension,Behavioral: PAP Treatment|Behavioral: Sleep Education I|Behavioral: Sleep Education II,Psychomotor Vigilance Test (PVT)|Epworth Sleepiness Scale (ESS)|Multi-dimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)|Reactive hyperemia index|24-hours Ambulatory Blood Pressure,"Wayne State University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,495,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",1809001759|R01HL146059,16-Oct-20,6-Apr-24,31-Jul-24,21-Feb-20,,22-Oct-20,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04279834
NCT04236258,Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period,,Recruiting,No Results Available,Hypertension in Pregnancy|Preeclampsia Severe|Gestational Hypertension|Postpartum Preeclampsia|Postpartum,Drug: NIFEdipine ER|Drug: Enalapril,Prolonged hospitalization|Unscheduled clinic appointment|Visit to Labor and Delivery triage for evaluation|Postpartum readmission|Increase in antihypertensives|Time to blood pressure control|Need for additional antihypertensives|Time to discharge|Clinically significant hypotension or hypertension|Serial creatinine values|Continued need for antihypertensive|Side effects|Compliance,Brigham and Women's Hospital,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019P002981,30-Jan-20,Jan-21,Jun-21,22-Jan-20,,10-Jul-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04236258
NCT04645004,Antenatal Platelet Response on Aspirin and Correlation With Hypertensive Disorders of Pregnancy: a Pharmacokinetic Study Through Pregnancy,APROACH-PK,Recruiting,No Results Available,Preeclampsia,Drug: Aspirin 81Mg Ec Tab,salicylic acid level|serum thromboxane|PFA-100,Thomas Jefferson University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|March of Dimes,Female,"13 Years to 55 Years   (Child, Adult)",Phase 1|Phase 2,20,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,20F.911,31-Dec-20,Dec-21,Jun-22,25-Nov-20,,5-Jan-21,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04645004
NCT04285580,A Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension,,Recruiting,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,Drug: Bimatoprost SR|Drug: LUMIGAN,Change from Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR treated eyes|Number of patients experiencing one or more treatment emergent adverse events (TEAEs)|Change from Baseline in range of IOP for Bimatoprost SR-treated eyes,Allergan,All,"18 Years and older   (Adult, Older Adult)",Phase 3,35,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1698-304-007,11-Jun-20,23-Jul-21,28-May-22,26-Feb-20,,24-Dec-20,"Eye Center South, Dothan, Alabama, United States|Eye Research Foundation, Newport Beach, California, United States|James D. Branch, MD, Winston-Salem, North Carolina, United States|Scott & Christie and Associates, Cranberry Township, Pennsylvania, United States|Keystone Research LTD, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04285580
NCT04360174,"CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension",,Recruiting,No Results Available,Ocular Hypertension|Open Angle Glaucoma,Drug: OTX-TIC,Incidence of treatment emergent adverse events for each subject|Efficacy outcome,"Ocular Therapeutix, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLN-Protocol-0045,25-Apr-18,Oct-20,Mar-21,24-Apr-20,,24-Apr-20,"Ocular Therapeutix, Inc., Petaluma, California, United States|Ocular Therapeutix, Inc., Torrance, California, United States|Ocular Therapeutix, Inc, Roswell, Georgia, United States|Ocular Therapeutix, Inc., Austin, Texas, United States|Ocular Therapeutix, Inc., Racine, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04360174
NCT04163614,Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients,,Not yet recruiting,No Results Available,End Stage Renal Disease|Hypertension|Extracellular Volume Overload|Intradialytic Hypotension,Other: IBPS-Guided Ultrafiltration,Ambulatory Systolic Blood Pressure|Extracellular Volume|Total Peripheral Resistance Index|Intradialytic Hypotension|Association Between intradialytic blood pressure slope with systolic and diastolic dysfunction,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,69,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NEPH-020-19S,1-Oct-20,1-Jul-24,1-Jul-24,15-Nov-19,,7-Aug-20,"VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04163614
NCT03649932,"Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing",,Recruiting,No Results Available,Bronchopulmonary Dysplasia|Bronchopulmonary Dysplasia Associated Pulmonary Hypertension|Pulmonary Hypertension|Premature Birth|Chronic Lung Disease of Prematurity,Dietary Supplement: Enteral L-citrulline,Change in plasma levels of L-arginine and L-citrulline as measured by LCMS approach|Safety of L-citrulline in preterm infants: Measured by at least one adverse event|Dose of enteral L-citrulline required to increase plasma level of > 37 micromol/L,"The University of Texas Medical Branch, Galveston",All,up to 30 Weeks   (Child),Phase 1,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-0194,25-Sep-18,21-Jan-21,30-Jun-21,28-Aug-18,,10-Nov-20,"University of Texas Medical Branch, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03649932
NCT04505618,Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease,OCTA-RVD,Recruiting,No Results Available,"Diabetic Retinopathy|Retinal Vein Occlusion|Hypertension,Essential|Retinal Vascular Disorder",Device: Swept-Source OCT Angiography|Device: Spectral-Domain OCT Angiography|Device: Fundus Imagning|Device: Axial Length Measurement Device,Correlation of Imaging,University of Southern California|National Eye Institute (NEI),All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,1050,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,OCTA-RVD|R01EY030564,10-Aug-20,1-Jun-24,1-Jun-24,10-Aug-20,,17-Aug-20,"USC Roski Eye Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04505618
NCT04669548,Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry,,Recruiting,No Results Available,Intraabdominal Hypertension|Abdominal Compartment Syndrome|Acute Kidney Injury|Cardiovascular Surgery,Device: Accuryn Monitoring System,Urine Output (UO)|Intra-Abdominal Pressure (IAP)|Temperature (T)|Intraabdominal Hypertension (IAH)|Abdominal Compartment Syndrome (ACS)|Acute Kidney Injury (AKI),Potrero Medical,All,"18 Years and older   (Adult, Older Adult)",,5000,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CRD-06-101904,21-Dec-20,31-Dec-26,31-Dec-26,17-Dec-20,,13-Jan-21,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04669548
NCT04465864,"Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert",,Recruiting,No Results Available,"Glaucoma, Primary Open Angle|Cataract","Drug: Intracanalicular Dexamethasone, 0.4 mg insert","Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery|Intracanalicular Dexamethasone, 0.4 mg insertion on day of surgery.",Wolstan and Goldberg Eye Associates,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,DEXTENZA,10-Feb-20,31-Dec-20,31-Jan-21,10-Jul-20,,10-Jul-20,"Wolstan and Goldberg Eye Associates, Torrance, California, United States",,https://ClinicalTrials.gov/show/NCT04465864
NCT03700710,Remote Dietary Counseling to Promote Healthy Diet and Blood Pressure,,Recruiting,No Results Available,Blood Pressure|High Blood Pressure|Dietary Modification|Overweight and Obesity,Behavioral: Self-Guided Approach|Behavioral: Dietitian-led Approach,Change in 24-hour Systolic Blood Pressure|Change in 24-hour diastolic blood pressure|Change in Daytime Systolic Blood Pressure|Change in Nighttime Systolic Blood Pressure|Change in Daytime Diastolic Blood Pressure|Change in Nighttime Diastolic Blood Pressure|Change in Total Healthy Eating Index - 2015 score|Change in Weight|Change in Waist Circumference|Change in Physical Activity (metabolic equivalent of task [MET]-minute per week,Geisinger Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2018-0433,16-Jan-19,30-Mar-21,30-Mar-21,9-Oct-18,,25-Nov-20,"Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03700710
NCT04585555,Physiologic Signals and Signatures With the Accuryn Monitoring System (The Accuryn Registry),,Recruiting,No Results Available,Acute Kidney Injury|Abdominal Compartment Syndrome|Intraabdominal Hypertension|Cardiovascular Surgery,Device: Accuryn Monitoring System,Urine Output (UO)|Intra-Abdominal Pressure (IAP)|Temperature (T)|Intraabdominal Hypertension (IAH)|Abdominal Compartment Syndrome (ACS)|Acute Kidney Injury (AKI),Potrero Medical,All,"18 Years and older   (Adult, Older Adult)",,1000,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CRD-06-2963,29-Mar-19,31-Dec-24,31-Dec-24,14-Oct-20,,11-Dec-20,"Emory University Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04585555
NCT03375918,COmmuNity-engaged SimULation Training for Blood Pressure Control,CONSULT-BP,Recruiting,No Results Available,Hypertension,Other: CONSULT-BP Educational Intervention,Blood pressure|Quality of Communication|Patient Reported Trust in Heathcare Provider|Voils Medication Adherence Scale|Blood Pressure Self Care Scale,"University of Massachusetts, Worcester|National Institute on Minority Health and Health Disparities (NIMHD)",All,"Child, Adult, Older Adult",Not Applicable,205,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,H00012160|1R01MD011532,13-Aug-18,31-Jan-22,31-Jan-22,18-Dec-17,,11-Dec-20,"Barre Family Health Center, Barre, Massachusetts, United States|Tri River Family Health Center, Uxbridge, Massachusetts, United States|Edward M Kennedy Community Health Center, Worcester, Massachusetts, United States|UMass Memorial Hahnemann Family Health Center, Worcester, Massachusetts, United States|UMass Memorial Medical Center -- Benedict Building, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03375918
NCT02587325,"ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension",,Recruiting,No Results Available,Pulmonary Hypertension,"Drug: ABI-009, nab-rapamycin, albumin-bound rapamycin",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,"Aadi, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,25,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PAH-001,1-Apr-17,Dec-20,Dec-20,27-Oct-15,,10-Dec-19,"University of Arizona, Tucson, Arizona, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Indiana University, Indianapolis, Indiana, United States|National Institutes of Health, Bethesda, Maryland, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02587325
NCT04633551,Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes,VIA,Recruiting,No Results Available,Pre-Eclampsia|Pre-Term|Intrauterine Growth Restriction|Hypertension in Pregnancy,Dietary Supplement: Anti-inflammatory supplement,Blood pressure (mmHg)|Arterial stiffness (m/s)|Augmentation index (%)|Endothelial function (reactive hyperemia)|Inflammatory vascular biomarkers (pg/dL)|Acceptability of intervention (Likert scales from 1-5; not likely at all to extremely likely and free text fields)|Perception of intervention (15-20 minute interview),University of South Carolina,Female,18 Years to 45 Years   (Adult),Not Applicable,56,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,10010335,1-Oct-20,30-Jun-21,30-Jun-21,18-Nov-20,,18-Nov-20,"Public Health Research Center, Columbia, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04633551
NCT03874754,Tailored Home-Based Exercise Program for Multiple Chronic Conditions,iHBE,Recruiting,No Results Available,Cancer|Hypertension|Diabetes,Other: Tailored Technology-Enhance Home-based exercise program (iHBE),Change in Fatigue as assessed by self-reported fatigue questionnaire|Change in Resilience as assessed by Connor-Davidson Resilience scale|Change in Physical well being|Change in Mental well being|Physical activity|Change in Brain Derived Neurotrophic Factor level (in serum)|Change in Brain Derived Neurotrophic Factor level (in sweat),Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Institute of Nursing Research (NINR),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,58,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,J1886|P30NR018093-01|IRB00175781,1-Aug-19,30-Sep-21,31-Mar-22,14-Mar-19,,7-Dec-20,"The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03874754
NCT03691701,Pilot to Examine Risk and Feasibility of Remote Management of BP From Childhood Into Early Adulthood,PERFORMANCE2,Recruiting,No Results Available,Chronic Kidney Diseases|Hypertension|Blood Pressure,Other: strict blood pressure control,Achieved Blood Pressure|Number of participants screened who enroll in trial,"University of California, San Francisco",All,"13 Years to 30 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,17-22758,20-Jul-18,Dec-20,Dec-20,2-Oct-18,,27-Aug-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03691701
NCT04467879,A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients,,Recruiting,No Results Available,"Hypertension, Systolic",Device: Zona Plus|Device: Control Device,Change from Baseline in Systolic Blood Pressure to Day 70 ± 2 Days|Change from Baseline in Diastolic Blood Pressure to Day 70 ± 2 Days|Percentage change from Baseline in Systolic Blood Pressure reduction at Day 70 ± 2 Days|Percentage change from Baseline in Diastolic Blood Pressure reduction at Day 70 ± 2 Days|Percentage change from Baseline in Systolic Blood Pressure reduction at Day 160 ± 4 Days|Percentage change in Diastolic Blood Pressure reduction at Day 160 ± 4 Days|Comparison of Heart Rate between Zona Plus nominal device and Placebo controlled device,"Zona Health, Inc",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,230,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1,30-Jun-20,Sep-21,Oct-21,13-Jul-20,,14-Jul-20,"Crystal Biomedical Researc, LLC, Miami Lakes, Florida, United States|Top Endocrine Focused Research Corp, Miami Lakes, Florida, United States|Suncoast Research Group, Miami, Florida, United States|Healthy Life Research, Miami, Florida, United States|Bio-Medical Research, LLC, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04467879
NCT04640519,Telehealth After Stroke Care: Integrated Multidisciplinary Access to Post-stroke Care,TASC,Recruiting,No Results Available,Stroke|Health Care Acceptability|Hypertension,Other: Usual care|Other: TASC intervention,Number of Participants with BP Control|Number of participants who completed 5 visits and satisfaction surveys|Medication adherence percentage,Columbia University|National Center for Advancing Translational Science (NCATS),All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,AAAT2612|UL1TR001873,20-Oct-20,31-May-21,1-Jul-21,23-Nov-20,,27-Nov-20,"The Neurological Institute of New York, Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04640519
NCT04117204,Cardiorenal Protective Diet,CPD,Recruiting,No Results Available,Chronic Kidney Diseases|Cardiovascular Diseases|Hypertension,Other: Fruits and Vegetables,Changes from baseline in fruit and vegetable intake at 6 weeks and 3 months.|Changes from baseline in systolic and diastolic blood pressure at 6 weeks and 3 months.|Change from baseline of urine albumin-to-creatinine ration (ACR) at 6 weeks and 3 months.|Metabolomics will be used to profile how changes in diet effects disease risk.,Baylor Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,018-095,1-Jun-19,May-20,Dec-20,7-Oct-19,,7-Oct-19,"Baylor Scott & White Health and Wellness Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04117204
NCT03686657,Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients,RESILIENCE,Not yet recruiting,No Results Available,Type 2 Diabetes|High Blood Pressure|Arthritis|Obesity,"Drug: Metformin|Drug: Val, Cel and Met XR Low|Drug: Val, Cel and Met XR High",Change in glycosylated Hemoglobin (HbA1c) for metformin background patients|Change in glycosylated Hemoglobin (HbA1c) for treatment naive patients|Change from baseline in acute insulin response to glucose (AIRg) for metformin background patients|Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients|Change in glycosylated Hemoglobin (HbA1c) to <7.0%|Change from baseline in Body weight|Change from baseline in fasting plasma glucose|Change from baseline in Beta-cell function Index|Change from baseline in insulin sensitivity index (ISI or Si)|Change from baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) ratio|Change from baseline in HOMA2-b%|Change from baseline in HOMA-IR|Leptin/Adiponectin ratio|Change from baseline in Atherogenic Index (AI)|Change from baseline in glycosylated albumin (GA)|Change from baseline in Leptin|Change from baseline in Adiponectin,ARKAY Therapeutics|Albany Medical College,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,115,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RK-01 Prototype,11-Oct-21,26-Nov-23,31-Jan-24,27-Sep-18,,29-Dec-20,"Albany Medical College, Albany, New York, United States",,https://ClinicalTrials.gov/show/NCT03686657
NCT02975505,Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD,PERFORMANCE,Recruiting,No Results Available,Chronic Kidney Disease|Bloodpressure|Hypertension,Other: Strict blood pressure control,Hyperkalemia|Achieved Blood Pressure|Falls and syncope by self-report or based on emergency room visits|End-stage Renal Disease|Number of participants screened who enroll in trial,"University of California, San Francisco",All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,16-20978,10-Feb-17,Jul-26,Jul-26,29-Nov-16,,27-Aug-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02975505
NCT04518943,Multiphase Optimization Trial of Incentives for Veterans to Encourage Walking,,Not yet recruiting,No Results Available,Sedentary Behavior|Exercise|Walking|Motivation|Hypertension|Depression|Body Mass Index,Behavioral: Walking,Change in average steps per day from baseline week to week 12|Self-efficacy|Intrinsic/extrinsic motivation|Mental health,VA Office of Research and Development,All,"50 Years to 69 Years   (Adult, Older Adult)",Not Applicable,200,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,IIR 19-450,1-Feb-21,31-Mar-22,31-Oct-22,19-Aug-20,,25-Aug-20,"VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04518943
NCT01280994,Hyperpolarized 129Xe MRI for Imaging Pulmonary Function,,Recruiting,No Results Available,Interstitial Lung Disease|Cystic Fibrosis|Pulmonary Hypertension|NSIP,Drug: Xenon,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Bastiaan Driehuys|Duke University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,445,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Pro00025110,Jan-11,Dec-22,Dec-22,21-Jan-11,,15-Jul-20,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01280994
NCT02977884,Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project,,Recruiting,No Results Available,Cardiovascular Diseases|Diabetes Mellitus|Hypertension|Dyslipidemias|Overweight and Obesity,Behavioral: The Complete Health Improvement Program,Healthcare expenses|Weight|Fasting Glucose|Fasting Lipid Profile|Absenteeism: Sick days on record at Ohio University Human Resources,Ohio University|Touro University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12X81,Aug-12,Nov-20,Dec-20,30-Nov-16,,15-Nov-19,"Ohio University, Athens, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02977884
NCT03152773,Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires,,Recruiting,No Results Available,Pulmonary Artery Hypertension|Congenital Heart Disease|Structural Heart Disease,Procedure: MRI Right and Left Heart guidewire catheterization,"The principal objective of this protocol is to test the safety and feasibility of MRI fluoroscopy catheter navigation using 0.035"" guidewires during right and left heart catheterization guided by low-SAR MRI pulse sequences|Additional objectives are to test and enhanced MRI as an adjunct to routine hemodynamic cardiac catheterization","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,100,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,170095|17-H-0095,2-Aug-17,30-Dec-25,30-Dec-25,15-May-17,,14-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03152773
NCT02299414,Chronic Hypertension and Pregnancy (CHAP) Project,CHAP,Recruiting,No Results Available,Hypertension,Drug: Anti-hypertensive therapy|Other: No anti-hypertensive therapy (unless BP is severe),Composite adverse perinatal outcome|Small for Gestational Age|Composite of maternal death or severe cardiovascular morbidity|Composite of severe adverse perinatal outcome|Adherence to treatment after delivery,"University of Alabama at Birmingham|Columbia University|Drexel University College of Medicine|Rutgers, The State University of New Jersey|Lehigh Valley Hospital|Saint Peters University Hospital|Christiana Care Health Services|Washington University School of Medicine|Duke University|University of Texas Southwestern Medical Center|The University of Texas Health Science Center, Houston|Stanford University|University of Pennsylvania|The University of Texas Medical Branch, Galveston|University of Utah|Intermountain Health Care, Inc.|University of California, San Francisco|Johns Hopkins University|University of Pittsburgh|Ochsner Health System|University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI)|WakeMed Health and Hospitals|San Francisco General Hospital|McKay-Dee Hospital|Winthrop University Hospital|New York Hospital Queens|Latter Day Saints Hospital|Lyndon B Johnson General Hospital|Virtua Medical Group|Bayview Medical Center|Duke Regional Hospital|Utah Valley Regional Medical Center|Northwestern|Brown (WIHRI)|Baylor College of Medicine|Case Western/Metro Health|Ohio State University|University of Iowa|University of California, San Diego|Indiana University|Unity Point Health-Meriter Hospital WI|Weill Medical College of Cornell University|University of Oklahoma|Medical University of South Carolina|Beaumont Hospital|University of Colorado, Denver|University of Kansas Medical Center|Denver Health and Hospital Authority|Gundersen Health System|Aurora Health Care|Oregon Health and Science University|Medical College of Wisconsin|Temple University|New Jersey Medical School|University of South Alabama|Vanderbilt University|University of Arkansas|Miami Valley Hospital|Emory University|St. Luke's Hospital and Health Network, Pennsylvania|Cleveland Clinic Fairview Hospital|University of Tennessee Health Science Center|TriHealth Inc.|Cleveland Clinic Hillcrest Hospital|Tulane University|Yale University|Arrowhead Regional Medical Center|Geisinger Clinic",Female,"12 Years and older   (Child, Adult, Older Adult)",Phase 4,2404,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1U01HL119242-01|U01HL119242-01,Jun-15,Jun-21,Jun-22,24-Nov-14,,18-Jun-20,"University of Alabama at Birmingham, Clinical Coordinating Center, Birmingham, Alabama, United States|University of Alabama at Birmingham, Data Coordinating Center, Birmingham, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Arrowhead Regional Medical Center, Colton, California, United States|University of California, San Diego, San Diego, California, United States|General Hospital of San Francisco, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Boulder, Colorado, United States|Denver Health, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern, Evanston, Illinois, United States|Indiana University, Bloomington, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Lawrence, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane, New Orleans, Louisiana, United States|Ochsner Health System/Medical Center, New Orleans, Louisiana, United States|Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Beaumont Hospital, Royal Oak, Michigan, United States|University of Mississippi Medical College, Jackson, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|St. Peters University Hospital, New Brunswick, New Jersey, United States|New Jersey Medical School, Newark, New Jersey, United States|Virtua Medical Group, Sewell, New Jersey, United States|New York Presbyterian Queens, Flushing, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University, New York, New York, United States|Weill Cornell, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke Regional Medical Center, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|TriHealth, Inc, Cincinnati, Ohio, United States|Case Western/Metro Health, Cleveland, Ohio, United States|Cleveland Clinic Fairview, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Cleveland Clinic-Hillcrest Hospital, Mayfield Heights, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital/Health Network, Allentown, Pennsylvania, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Geisinger Clinic, Danville, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Pittsburg/Magee Women's Center, Pittsburgh, Pennsylvania, United States|Brown (WIHRI), Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|UT Medical Branch, Galveston, Texas, United States|Lyndon B. Johnson Hospital, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|UT Houston, Houston, Texas, United States|McKay Dee Hospital, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Intermountain Healthcare, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Gundersen Health System, La Crosse, Wisconsin, United States|Unity Point Health-Meriter Hospital, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02299414
NCT03934398,Be-HealthY: Behavioral Risk Factors for Poor Vascular Health in Youth,,Recruiting,No Results Available,Prehypertension|Hypertension|Overweight and Obesity|Elevated Blood Pressure|Endothelial Dysfunction|Vascular Stiffness|Sleep,Diagnostic Test: Cardiovascular Assessments|Diagnostic Test: Actigraphy|Diagnostic Test: Laboratory assessments|Diagnostic Test: Emotional/Behavioral Assessments,Arterial stiffness as assessed by Pulse wave velocity|Arterial stiffness as assessed by Ambulatory Arterial Stiffness Index (AASI)|Arterial stiffness as assessed by Augmentation Index|Endothelial function as assessed by Laser Doppler flow perfusion|Mean Blood pressure (mmHg)|Pediatric Adverse Childhood Events (ACEs) score|Children's Emotion Management Scale (CEMS) score|Behavior Assessment for Children (BASC) score,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)",All,"up to 22 Years   (Child, Adult)",,60,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,IRB00196923|1R56HL139620,10-Apr-19,Mar-21,Mar-21,1-May-19,,12-Oct-20,"Johns Hopkins School of Medicine Division of Pediatric Nephrology, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03934398
NCT03229499,Pulmonary Hypertension and Anastrozole Trial,PHANTOM,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Anastrozole|Drug: Placebo Oral Tablet,Difference in changes in distance walked in six minutes between anastrozole and placebo groups|Difference in right ventricular function between anastrozole and placebo groups|Difference in changes in plasma NT-proBNP level between anastrozole and placebo groups|Difference in changes in biomarkers between anastrozole and placebo groups|Difference in changes in SF36 between anastrozole and placebo groups|Difference in changes in emPHasis-10 between anastrozole and placebo groups|Difference in changes in actigraphy-measured physical activity between anastrozole and placebo groups|Difference in time-to-clinical worsening (TTCW) between anastrozole and placebo groups|Difference in changes in bone mineral density between anastrozole and placebo groups|Difference in side effects between anastrozole and placebo groups at twelve months,"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University|University of Colorado, Denver|Rhode Island Hospital|Stanford University|Vanderbilt University|Washington University School of Medicine",All,"18 Years and older   (Adult, Older Adult)",Phase 2,84,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",827486|R01HL134905,7-Dec-17,Sep-21,Sep-21,25-Jul-17,,3-Aug-20,"Stanford University, Stanford, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03229499
NCT03497689,EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil,Oral treprostinil dose|Prostanoid Adverse Events (AEs)|Echocardiograms|Change in 6-minute walk distance (6MWD)|Change in Borg dyspnea score|Change in World Health Organization (WHO) functional class (FC)|Change in serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels|Impact of pulmonary hypertension on a person's life (health-related quality of life)|Treatment satisfaction,United Therapeutics,All,"17 Years to 85 Years   (Child, Adult, Older Adult)",Phase 4,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TDE-PH-402,21-Sep-18,Dec-20,Dec-20,13-Apr-18,,31-Jul-20,"University of California San Francisco - Fresno, Fresno, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Florida Hospital, Orlando, Florida, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|UPMC Presbytarian Hospital, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03497689
NCT03926793,Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension,PAH,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: GB002|Drug: Placebo|Device: Generic Dry Powder Inhaler,Number of participants with Treatment-Related Adverse Events GB002 (Main study)|Number of participants with Treatment-Related Adverse Events GB002 (OLE study)|Pharmacokinetics: Time to Reach Maximum Concentration (Tmax) of GB002 (Main study)|Pharmacokinetics: Maximum Concentration (Cmax) of GB002 (Main study)|Pharmacokinetics: Area Under the Concentration Curve (AUC) of GB002 (Main study)|Changes from baseline in 6-Minute Walk Test (6MWT) (OLE study)|Changes from baseline in WHO Functional Class (OLE study)|Changes from baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP) (OLE study)|Changes from baseline in Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT) Quality of Life questionnaire (OLE study)|Changes from baseline in Right Ventricular function by imaging (OLE study),"GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|Gossamer Bio Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GB002-1101,4-Feb-20,Dec-20,Dec-20,25-Apr-19,,2-Dec-20,"UCSD Medical Center, La Jolla, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke Early Phase Research, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Medical Center Montefiore University Hospital, Pittsburgh, Pennsylvania, United States|VitaLink Research - Anderson, Anderson, South Carolina, United States|Golden Jubilee National Hospital, Glasgow, United Kingdom|Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03926793
NCT04273945,Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension,UNISUS,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Macitentan 10 mg|Drug: Macitentan 37.5 mg|Drug: Macitentan 75 mg|Drug: Placebo,Double-blind Treatment Period: Time to First Clinical Events Committee (CEC)-adjudicated Morbidity or Mortality (M/M) Events|Double-blind Treatment Period: Change From Baseline to Week 24 in 6MWD|Double-blind Treatment Period: Time to First occurrence of either CEC-adjudicated Death or Hospitalization due to PAH|Double-blind Treatment Period: Change From Baseline to Week 24 in PAH Symptoms Based on PAH-SYMPACT Questionnaire- Cardiopulmonary Symptom Domain Score|Double-blind Treatment Period: Change From Baseline to Week 24 in PAH Symptoms Based on PAH-SYMPACT Questionnaire- Cardiovascular Symptom Domain Score|Double-blind Treatment Period: Time to Death Occurring Between Baseline and End of Double-blind Treatment (EDBT)|Double-blind Treatment Period: Number of Deaths|Double-blind Treatment Period: Number of Participants with Intervention-emergent AEs|Double-blind Treatment Period: Number of Participants with AEs Leading to Premature Discontinuation of Study Drug|Double-blind Treatment Period: Number of Participants With Intervention-emergent AEs of Special Interest|Double-blind Treatment Period: Number of Participants With Serious Adverse Events (SAEs)|Double-blind Treatment Period: Number of Participants with Intervention-emergent Electrocardiogram (ECG) Abnormalities|Double-blind Treatment Period: Number of Participants with Intervention-emergent Laboratory Abnormalities|Double-blind Treatment Period: Change from Baseline in Blood Pressure|Double-blind Treatment Period: Change from Baseline in Heart Rate|Treatment Extension Period: Time to Death Occurring Between Baseline and End of Study (EOS)|Treatment Extension Period: Number of Deaths|Treatment Extension Period: Number of Participants With Intervention-emergent AEs|Treatment Extension Period: Number of Participants With AEs Leading to Premature Discontinuation of study Drug|Treatment Extension Period: Number of Participants with Intervention-emergent AEs of Special Interest|Treatment Extension Period: Number of Participants With SAEs|Treatment Extension Period: Number of Participants With Intervention-emergent Laboratory Abnormalities|Treatment Extension Period: Change from Baseline in Blood Pressure|Treatment Extension Period: Change from Baseline in Heart Rate,Actelion,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR108740|2019-002533-11|AC-055-315,30-Jun-20,31-Oct-23,21-Aug-26,18-Feb-20,,23-Dec-20,"Arizona Pulmonary Specialists, Ltd, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Scripps Memorial Hospital, La Jolla, California, United States|USC Keck, Los Angeles, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Ascension   St. Vincent's Lung, Sleep and Critical Care specialists, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Cleveland Clinic, Weston, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|WellStar Health System, Marietta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University Of Iowa - Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Louisiana State University, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Troy Beaumont, Troy, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Morristown Medical Center, Morristown, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Pulmonary Health Physicians, PC, Fayetteville, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai, New York, New York, United States|Columbia University, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Duke, Durham, North Carolina, United States|Lindner Clinical Trial Center/Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Integris Baptist Office, Oklahoma City, Oklahoma, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Pulmonary Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital of Research, Pittsburgh, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|AnMed Health, Anderson, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor College of Medicine (BCM) - Baylor Heart Clinic, Houston, Texas, United States|Baylor Scott White - Plano, Plano, Texas, United States|San Antonio Methodist/TX Transplant Physicians Group, San Antonio, Texas, United States|University of Vermont Medical Center, Colchester, Vermont, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Froedtert & Medical College of Wisconsin - Pulmonary Medicine Outpatient Clinic, Milwaukee, Wisconsin, United States|Hospital Universitario UAI, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Sanatorio Ramon Cereijo, Caba, Argentina|Centro Médico Dra. De Salvo, Caba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Instituto Modelo De Cardiología Privado Srl, Córdoba, Argentina|Hospital Espanol de Rosario, Rosario, Argentina|Instituto Medico de La Fundacion Estudios Clinicos, Rosario, Argentina|Flinders Medical Centre, Bedford Park, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|The Prince Charles Hospital, Chermside, Australia|St Vincent's hospital, Darlinghurst, Australia|Royal Hobart Hospital, Hobart, Australia|Fiona Stanley Hospital, Murdoch, Australia|Westmead Hospital, Westmead, Australia|LKH-Univ. Klinikum Graz, Graz, Austria|Medical University Vienna, Vienna, Austria|The Republican Scientific-Practical Center ''Cardiology'', Minsk, Belarus|Minsk Regional Clinical Hospital, Minsk, Belarus|ULB Hôpital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Brazil|Hospital Universitario Polydoro Ernani de Sao Thiago - UFSC, Florianopolis, Brazil|Hospital das Clinicas - UFG, Goiania, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital São Paulo-UNIFESP, São Paulo, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, São Paulo, Brazil|St. Joseph's Health Centre, Hamilton, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Beijing Anzhen Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|Renji Hospital, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'An, China|Fundacion Santa Fe de Bogota, Bogota, Colombia|Fundacion Neumologica Colombiana, Bogota, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Colombia|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|Århus Universitetshospital, Skejby, Hjertemedicinsk Afdeling B, Arhus, Denmark|CHU de Brest - Hôpital de la Cavale Blanche, Brest, France|Hôpital Côte de Nacre, Caen Cedex, France|Hopital Bicêtre - Aphp Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre cedex, France|CHRU de Lille - Hôpital Claude Huriez, Lille Cedex, France|Centre Hospitalier Universitaire - de Nice - Hopital Pasteur, Nice, France|CHU Saint-Etienne - Hôpital Nord, St Priest en Jarez Cedex, France|Hopital Larrey CHU de Toulouse, Toulouse Cedex 9, France|Ruhr-Universität Bochum / Diabeteszentrum, Bad Oeynhausen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Medizinische Klinik und Poliklinik V Klinikum Grosshadern der LMU, München, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Semmelweis Egyetem,Pulmonológiai Klinika, Budapest, Hungary|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet és rendelő, Szeged, Hungary|Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Kaplan Medical Center, Rehovot, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Yitzhak Shamir Medical Center, Zerifin, Israel|AOU Di Modena, Policlinico Di Modena, Modena, Italy|Policlinico di Modena - Azienda Ospedaliero - Universitaria Modena, Modena, Italy|Ospedale San Francesco, Nuoro, Italy|ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Gemelli Universita Cattolica, Roma, Italy|Kure Kyosai Hospital, Hiroshima, Japan|Kagoshima University Hospital, Kagoshima City, Japan|St.Marianna University School of Medicine, Kanagawa, Japan|Kanazawa University Hospital, Kanazawa, Japan|Kobe University Hospital, Kobe, Japan|University Hospital Kyoto Perfectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Shinshu University Hospital, Matsumoto, Japan|Kyorin University Hospital, Mitaka, Japan|Nagasaki University Hospital, Nagasaki, Japan|Nagoya City University Hospital, Nagoya, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Hokkaido University Hospital, Sapporo, Japan|National Cerebral and Cardiovascular Center Hospital, Suita-Shi, Japan|Juntendo University Hospital, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|University of Tsukuba Hospital, Tsukuba-City, Japan|Severance Hospital - Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hospital Pulau Pinang, George Town, Malaysia|Hospital Serdang, Kajang, Malaysia|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad De México, Mexico|Consultorio Privado del Dr. Gabriel Arturo Ramos Lopez, Guadalajara, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Centro de Investigacion Clinica Chapultepec, Morelia, Mexico|VUMC Amsterdam, Amsterdam, Netherlands|Radboud Umcn, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Akershus Universitetssykehus, Nordbyhagen, Norway|Oslo University Hospital, Oslo, Norway|Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok, Poland|Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Klinika Kardiologii, Bydgoszcz, Poland|SPSK nr 7 SUM w Katowicach Gornoslaskie Centrum Medyczne im. Prof. Leszka Gieca, Katowice, Poland|Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn, Krakow, Poland|Wojewodzki Szpital Specjalist, Osrodek Badawczo-Rozwojowy, Wroclaw, Poland|Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Norte EPE - Hospital Pulido Valente, Lisboa, Portugal|Hospital De Santa Marta, Lisbon, Portugal|Altay Regional Cardiological Dispensary, Barnaul, Russian Federation|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|State Autonomous HealthCare Institution 'Interregional Clinical Diagnostic Center', Kazan, Russian Federation|Scientific and Research Institution of Cardiovascular Diseases Complex Problems, Kemerovo, Russian Federation|Regional State Budgetary Healthcare Organization 'Regional Clinical Hospital', Krasnoyarsk, Russian Federation|FGBU Research Institute of Rheumatology named V.A.Nasonova, Moscow, Russian Federation|Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|State Autonomous Healthcare Institution of Tyumen Region 'Scientific and Practical Medical Center', Tumen, Russian Federation|Tver Regional Clinical Hospital, Tver, Russian Federation|Volgograd Regional Clinical Cardiological Center, Volgograd, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Institute for Pulmonary Disease of Vojvodina, Sremska Kamenica, Serbia|National University Heart Centre, Singapore, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|The Central Slovakia Institute of Cardiovascular Diseases, Banska Bystrica, Slovakia|Narodny ustav srdcovych a cievnych chorob, Bratislava, Slovakia|The Eastern Slovakia Institute of Cardiovascular Diseases, Kosice, Slovakia|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Del Mar, Barcelona, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain|Hosp. Costa Del Sol, Malaga, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Sahlgrenska Universitetsjukhuset, Goteborg, Sweden|Skanes universitetssjukhus, Lund, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Phramongkutklao Hospital and Medical College, Bangkok, Thailand|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Siriraj Hospital Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai hospital - Faculty of Medicine, Chiang Mai, Thailand|Songklanagarind hospital, Songkhla, Thailand|Cukurova University Medical Faculty, Adana, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Ankara Sehir Hastanesi, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Siyami Ersek Training and Research Hospital, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kartal Kosuyolu Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Kartal-Istanbul, Turkey|Mersin University Medical Faculty, Mersin, Turkey|CNE 'Cherkasy Regional Cardiological Center of Cherkasy Regional Council', Cherkassy, Ukraine|Communal Noncommercial Enterprise 'Cherkasy Regional Hospital of Cherkasy Regional Council', Cherkasy, Ukraine|MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery', Dnipro, Ukraine|Ivano-Frankivsk City Central Clinical Hospital, Ivano-Frankivsk, Ukraine|CNE' City Clinical Hospital #8' of Kharkiv City Council, Kharkiv, Ukraine|Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine', Kyiv, Ukraine|State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine, Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine|Municipal Non-commercial Enterprise 'Ternopil University Hospital' of Ternopil Regional Council, Ternopil, Ukraine|Papworth Hospital NHS Trust, Cambridge, United Kingdom|Royal Free Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom|Hanoi Medical University Hospital, Hanoi, Vietnam|Ho Chi Minh City Heart Institute, Ho Chi Minh City, Vietnam|Tam Duc Cardiology Hospital, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT04273945
NCT03904693,Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),A DUE,Recruiting,No Results Available,Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH),Drug: FDC macitentan/tadalafil|Drug: Macitentan 10 mg|Drug: Tadalafil 40 mg|Drug: Placebo FDC|Drug: Placebo macitentan|Drug: Placebo tadalafil,Change in Pulmonary Vascular Resistance (PVR) expressed as the ratio of geometric means of End of Double-Blind Treatment (EDBT) to baseline|Change in 6-minute walk distance (6MWD) from baseline to EDBT|Change From Baseline in Cardiopulmonary Symptom Domain Score in PAH-SYMPACT to Week 16|Change From Baseline in Cardiovascular Symptom Domain Score in PAH-SYMPACT to Week 16|Proportion of subjects with absence of worsening in World Health Organization (WHO) Functional Class (FC) from baseline to EDBT.,Actelion,All,"18 Years and older   (Adult, Older Adult)",Phase 3,170,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-077A301|2014-004786-25,29-Jul-19,15-Dec-23,22-Jul-24,5-Apr-19,,23-Dec-20,"Arizona Pulmonary Specialists, Ltd, Phoenix, Arizona, United States|St. Joseph Hearitage Healthcare, Fullerton, California, United States|University of Southern California, Los Angeles, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Piedmont Healthcare, Austell, Georgia, United States|WellStar Health System, Marietta, Georgia, United States|OSF HealthCare Cardiovascular Institute, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|NYU Langone Health, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Pitt County Memorial Hospital d/b/a Vidant Medical Center, Greenville, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|St. Elizabeth Hospital Mercy Bon Secors, Youngstown, Ohio, United States|Legacy Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott White - Plano, Plano, Texas, United States|WVU Health Sciences Center, Morgantown, West Virginia, United States|University of Wisconsin At Madison, Madison, Wisconsin, United States|Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States|Royal Adelaide Hospital, Adelaide, Australia|Pulmonary Arterial Hypertension Clinic, Hobart, Australia|Core Research Group, Milton, Australia|Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Hospital das Clinicas - UFG, Goiania, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital São Lucas PUCRS, Porto Alegre, Brazil|Hospital São Paulo-UNIFESP, São Paulo, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, São Paulo, Brazil|UMHAT 'Heart and Brain Center for Excellence', Pleven, Bulgaria|National Heart Hospital, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD, Sofia, Bulgaria|Alberta Health Services, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|IKEM, Praha, Czechia|Universitatsklinikum Bonn, Bonn, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitaetsklinikum Giessen, Giessen, Germany|Universitat Greifswald, Greifswald, Germany|Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Kardiologische Praxis Papenburg, Papenburg, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|Semmelweis Egyetem,Pulmonológiai Klinika, Budapest, Hungary|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|SE Pulmonológiai Klinika, Budapest, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szegedi Tudomanyegyetem, Szeged, Hungary|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Cardiologia c/o Spedali Civili, Brescia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Ospedale San Francesco, Nuoro, Italy|IRCCS Policlinico San Matteo, Università degli studi di Pavi, Pavia, Italy|Policlinico Umberto I, Roma, Italy|The University of Tokyo Hospital, Bunkyo, Japan|Chiba University Hospital, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gunma University Hospital, Gunma, Japan|Kure Kyosai Hospital, Hiroshima, Japan|Tokai University Hospital, Isehara, Japan|Kagoshima University Hospital, Kagoshima City, Japan|Kanazawa University Hospital, Kanazawa, Japan|Kobe University Hospital, Kobe, Japan|Kumamoto University Hospital, Kumamoto-City, Japan|Kurume University Hospital, Kurume, Japan|Kyoto University Hospital, Kyoto, Japan|Shinshu University Hospital, Matsumoto, Japan|IUHW Mita Hospital, Minato-Ku, Japan|Kyorin University Hospital, Mitaka, Japan|Tohoku University Hospital, Miyagi, Japan|Nagasaki University Hospital, Nagasaki, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Sapporo Medical University Hospital, Sapporo, Japan|Hokkaido University Hospital, Sapporo, Japan|National Cerebral and Cardiovascular Center Hospital, Suita-Shi, Japan|Juntendo University Hospital, Tokyo, Japan|University of Tsukuba Hospital, Tsukuba-City, Japan|Mie University Hospital, Tsu, Japan|National Heart Institute, Kuala Lumpur, Malaysia|Sarawak Heart Center, Kuching, Malaysia|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Klinika Kardiologii z Oddzialem Intensywnego Nadzoru Kardiologicznego, UM w Białymstoku, Białystok, Poland|Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Klinika Kardiologii, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|GCM SUM, I Oddzial Kardiologii, Katowice, Poland|Oddzial Kardiologii Wojewodzki Szpital Specjalistyczny im. W.Bieganskiego, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Oddzial Kardiologii, Lublin, Poland|ECZ Otwock Klinika Kardiologii, Klinika Krążenia Płucnego Chorób Zakrzepowo-Zatorowych i Kardiologii, Otwock, Poland|SPSK2 PUM, Klinika Kardiologii, Szczecin, Poland|Wojewodzki Szpital Specjalistyczny, Oddzial Kardiologiczny, Wrocław, Poland|Altay Regional Cardiological Dispensary, Barnaul, Russian Federation|Scientific and Research Institution of Cardiovascular Diseases Complex Problems, Kemerovo, Russian Federation|Regional State Budgetary Healthcare Organization 'Regional Clinical Hospital', Krasnoyarsk, Russian Federation|Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|GU 'Moscow Regional Research Clinical Institute n.a. M.F.Vla, Moscow, Russian Federation|E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|State Autonomous Healthcare Institution of Tyumen Region 'Scientific and Practical Medical Center', Tumen, Russian Federation|Abdullah, IA, Durban, South Africa|Dr Kalla, Lenasia, South Africa|Respiratory Research Unit, Parow, South Africa|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Virgen de La Salud, Toledo, Spain|Hosp. Gral. Univ. Valencia, Valencia, Spain|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey|Istanbul University - Cerrahpasa Cardiology Institution, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Ege University School of Medicine, Izmir, Turkey|Dokuz Eylul University Hospital, Izmir, Turkey|Kartal Kosuyolu Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Kartal-Istanbul, Turkey|Konya Selcuk University Medical Faculty, Konya, Turkey|Mersin University Medical Faculty, Mersin, Turkey",,https://ClinicalTrials.gov/show/NCT03904693
NCT03942211,A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag,SPHINX,Not yet recruiting,No Results Available,Sarcoidosis-associated Pulmonary Hypertension,Drug: Selexipag|Drug: Placebo,Pulmonary Vascular Resistance (PVR) on Study Intervention up to Week 26,Actelion,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-065D301|2018-004887-74,15-Jan-21,30-Oct-22,15-Mar-24,8-May-19,,23-Dec-20,"Cedars Sinai Heart Institute, Beverly Hills, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Keck School of Medicine of USC, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|The GW Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|St Vincents Lung, Sleep And Critical Care, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|University Of Il Sarcoidosis Translational Advanced Research Center Star, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|LSU Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Wayne State University/Detroit Medical Center, Detroit, Michigan, United States|Albany Medical Center (AMC) - Pulmonary and Critical Care Medicine, Albany, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Dorothy M. Davis Heart & Lung Research Institute, Columbus, Ohio, United States|Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina (MUSC) - College of Medicine (COM), Charleston, South Carolina, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Houston, Houston, Texas, United States|INOVA, Falls Church, Virginia, United States|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, São Paulo, Brazil|London Health Sciences Centre, London, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hôpital Avicenne, Bobigny, France|GH est - Hôpital Cardiovasculaire et Pneumologie Louis Pradel, Bron Cedex, France|Hôpital Kremlin Bicêtre, Le Kremlin Bicetre Cedex, France|CHR Hôpital Calmette, Lille Cedex, France|Hopital Nord, Marseille cedex 20, France|CHU de Nancy - Hôpital de Brabois, Vandoeuvre les Nancy Cedex, France|Evangelische Lungenklinik Berlin, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Robert-Bosch-Krankenhaus - Klinik Schillerhoehe, Gerlingen, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Thoraxklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Schleswig-Holstein, Luebeck, Germany|Kardiologische Praxis Papenburg, Papenburg, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Wissenschaftliches Institut Bethanien für Pneumologie e.V, Solingen, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|AUSL della Romagna - Ospedale di Forlì, Forlì, Italy|Ospedale S.Giuseppe, Gruppo MultiMedica, Milano, Italy|ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Fondazione Maugeri Montescano, Pavia, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli', Roma, Italy|A.O.U. Città della Salute e della Scienza, Torino, Italy|Hospital Ca' Foncello, Treviso, Italy|Ospedale di Cattinara - Struttura complessa di Pneumologia, Trieste, Italy|VUMC Amsterdam, Amsterdam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT03942211
NCT03492177,A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: selexipag (Uptravi),"Area under the plasma concentration-time curve over a dose interval at steady state of selexipag and its metabolite ACT-333679 combined (AUCτ,ss, combined)|Area under the plasma concentration-time curve over a dose interval at steady state (AUCτ,ss) of selexipag|Area under the plasma concentration-time curve over a dose interval at steady state (AUCτ,ss) of ACT-333679|Maximum observed plasma concentration (Cmax,ss) of selexipag at steady state|Maximum observed plasma concentration (Cmax,ss) of ACT-333679 at steady state|Time to the maximum observed plasma concentration (tmax,ss) of selexipag at steady state|Time to the maximum observed plasma concentration (tmax,ss) of ACT-333679 at steady state|Trough concentration of selexipag at steady state (Ctrough,ss)|Trough concentration of ACT-333679 at steady state (Ctrough,ss)|Treatment-emergent adverse events (TEAEs)|Change from baseline in Tanner stage up to end of treatment (EOT + 3 days)|Change from baseline over time in body mass index (BMI) up to end of treatment (EOT + 3 days)|Change from baseline in thyroid stimulating hormone (TSH) up to end of treatment (EOT + 3 days)",Actelion,All,"2 Years to 18 Years   (Child, Adult)",Phase 2,66,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AC-065A203|2018-000145-39,23-Jul-18,11-Feb-26,21-Jul-26,10-Apr-18,,25-Nov-20,"Children'S Hospital Cardiac Care Center University Of Colorado, Aurora, Colorado, United States|University of Iowa Hospital, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seattle Children's Hospital, Seattle, Washington, United States|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|Centre Hospitalier Sainte Justine, Montreal, Quebec, Canada|Stollery Children's Hospital, Edmonton, Canada|Beijing Anzhen Hospital, Beijing, China|Cardiovascular institute & Fuwai Hospital- Thrombus Center, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Wuhan Asia Heart Hospital, Wuhan, China|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Justus-Liebig-Universität Gießen, Kinderherzzentrum, Giessen, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Münster, Münster, Germany|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|Schneider Children's Medical Center, Petach Tikvah, Israel|Sheba Medical Center, Ramat Gan, Israel|Sarawak General Hospital, Kota Samarahan, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Szpital Kliniczny im. Karola Jonschera, Poznan, Poland|Wojewódzki Szpital Specjalistyczny We Wrocławiu, Wrocław, Poland|Kazan State Medical University, Kazan, Russian Federation|Federal State Budget Scientific Institution, Kemerovo, Russian Federation|Moscow Scientific Research Institute For Pediatrics And Childrens Surgery Of Rosmedtechnologies, Moscow, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Federal State Budgetary Institution, St Petersburg, Russian Federation|Saint Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Institut Za Zdravstvenu Zaštitu Majke I Deteta Srbije ''Dr Vukan Čupić'', Belgrade, Serbia|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Municipal Enterprise Of The Dnipropetrovsk Regional Council, Dnipro, Ukraine|State Institution Of The Ministry Of Health Of Ukraine, Kiev, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Municipal Institution Of The Zaporizhzhya Regional Council, Zaporizhzhya, Ukraine|Great Ormond Street Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03492177
NCT04519658,A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN),,Recruiting,No Results Available,Resistant Hypertension,Drug: CIN-107|Drug: Placebo,Change from baseline in mean seated systolic BP (SBP)|Change from baseline in mean seated diastolic BP (DBP)|The percentage of patients achieving a seated BP response <130/80 mmHg,"CinCor Pharma, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,448,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CIN-107-121,1-Jul-20,30-Dec-21,30-Dec-21,20-Aug-20,,12-Jan-21,"CinCor Site 16, Birmingham, Alabama, United States|CinCor Site 38, Birmingham, Alabama, United States|CinCor Site 61, Saraland, Alabama, United States|CinCor Site 17, Phoenix, Arizona, United States|CinCor Site 25, Lincoln, California, United States|CinCor Site 73, Los Angeles, California, United States|CinCor Site 36, Los Angeles, California, United States|CinCor Site 34, Lynwood, California, United States|CinCor Site 12, Montclair, California, United States|CinCor Site 14, San Dimas, California, United States|CinCor Site 28, Santa Ana, California, United States|CinCor Site 19, Spring Valley, California, United States|CinCor Site 32, Tustin, California, United States|CinCor Site 44, West Hills, California, United States|CinCor Site 66, Whittier, California, United States|CinCor Site 56, Stamford, Connecticut, United States|CinCor Site 30, Clearwater, Florida, United States|CinCor Site 22, Doral, Florida, United States|CinCor Site 13, Fort Myers, Florida, United States|CinCor Site 20, Jacksonville, Florida, United States|CinCor Site 1, Jupiter, Florida, United States|CinCor Site 70, Miami, Florida, United States|CinCor Site 5, Port Orange, Florida, United States|CinCor Site 9, Saint Petersburg, Florida, United States|CinCor Site 23, Tampa, Florida, United States|CinCor Site 71, Suwanee, Georgia, United States|CinCor Site 11, Meridian, Idaho, United States|CinCor Site 15, Addison, Illinois, United States|CinCor Site 49, Chicago, Illinois, United States|CinCor Site 35, Morton, Illinois, United States|CinCor Site 58, Evansville, Indiana, United States|CinCor Site 54, West Des Moines, Iowa, United States|CinCor Site 62, Wichita, Kansas, United States|CinCor Site 29, Lexington, Kentucky, United States|CinCor Site 24, Lexington, Kentucky, United States|CinCor Site 69, New Orleans, Louisiana, United States|CinCor Site 64, Shreveport, Louisiana, United States|CinCor Site 65, Elkridge, Maryland, United States|CinCor Site 52, Roseville, Michigan, United States|CinCor Site 21, Troy, Michigan, United States|CinCor Site 50, Olive Branch, Mississippi, United States|CinCor Site 45, Butte, Montana, United States|CinCor Site 47, Las Vegas, Nevada, United States|CinCor Site 31, Albuquerque, New Mexico, United States|CinCor Site 4, Bronx, New York, United States|CinCor Site 55, Johnson City, New York, United States|CinCor Site 59, Cincinnati, Ohio, United States|CinCor Site 6, Cincinnati, Ohio, United States|CinCor Site 7, Cincinnati, Ohio, United States|CinCor Site 40, Munroe Falls, Ohio, United States|CinCor Site 43, Beaver, Pennsylvania, United States|CinCor Site 63, Providence, Rhode Island, United States|CinCor Site 57, Charleston, South Carolina, United States|CinCor Site 53, Greer, South Carolina, United States|CinCor Site 39, Myrtle Beach, South Carolina, United States|CinCor Site 18, Jackson, Tennessee, United States|CinCor Site 42, Nashville, Tennessee, United States|CinCor Site 27, Austin, Texas, United States|CinCor Site 2, Houston, Texas, United States|CinCor Site 72, Houston, Texas, United States|CinCor Site 60, Houston, Texas, United States|CinCor Site 46, Hurst, Texas, United States|CinCor Site 37, McAllen, Texas, United States|CinCor Site 48, Draper, Utah, United States|CinCor Site 3, Salt Lake City, Utah, United States|CinCor Site 8, Burke, Virginia, United States|CinCor Site 33, Manassas, Virginia, United States|CinCor Site 10, Richmond, Virginia, United States|CinCor Site 41, Olympia, Washington, United States|CinCor Site 51, Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04519658
NCT02932410,A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH),TOMORROW,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Macitentan|Other: Standard-of-care,Time to the first CEC-confirmed disease progression event|Time to first CEC-confirmed hospitalization for PAH|Time to CEC-confirmed death due to PAH|Time to death (all causes),Actelion,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 3,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AC-055-312,28-Nov-17,14-Jul-22,14-Jul-22,13-Oct-16,,23-Dec-20,"Phoenix Childrens Hospital, Phoenix, Arizona, United States|UCLA Children's Heart Center, Los Angeles, California, United States|UCSF Medical Center, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Detroit Medical Center, Detroit, Michigan, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Children's Heart Center, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center - PIN, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Royal Children's Hospital Melbourne - PIN, Parkville, Australia|Lady Cilento Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|Medizinische Universität Graz, Graz, Austria|Landes Frauen Und Kinderklinik Linz, Linz, Austria|Medizinische Universitat Wien, Linz, Austria|Sainte Justine Hospital, Montreal, Canada|Stollery Children's Hospital University of Alberta, Toronto, Canada|Beijing Anzhen Hospital of The Capital University of Medical Sciences, Beijing, China|Beijing Children's Hospital,Capital Medical University, Beijing, China|Fuwai Hospital, Beijing, China|The Children's Hospital, Zhejiang University school of Medicine, Hangzhou, China|Shanghai Children's Medical Center, Shanghai, China|General Hospital of Shenyang Military Region, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|Fundacion Santa Fe de Bogota, Bogota, Colombia|Centro Medico Imbanaco de Cali SA, Cali, Colombia|HUS Uusi lastensairaala, Helsinki, Finland|Hôpital de la Timone Enfants, Marseille, France|Groupe Hospitalier Necker Enfants Malades, Paris cedex 15, France|Hôpital Haut-Lévêque - Hôpital cardiologique, Pessac, France|Hôpital Des Enfants, Toulouse Cedex 9, France|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Rambam Health Corporation, Haifa, Israel|Schneider Children's Medical Center of Israel - PIN, Petah-Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System - PPDS, Seoul, Korea, Republic of|Institut Jantung Negara, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Instituto Nacional de Pediatría, Ciudad De México, Mexico|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad De México, Mexico|CICUM San Miguel, Guadalajara, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Mexico|Makati Medical Center, Makati City, Philippines|Philippine Heart Center, Quezon City, Philippines|Szpital Kliniczny im. Karola Jonschera Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka, Warszawa, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu Osrodek Badawczo-Rozwojowy, Wroclaw, Poland|Centro Hospitalar de Lisboa Ocidental, EPE - Hospital de Santa Cruz, Carnaxide, Portugal|Centro Hospitalar E Universitário de Coimbra EPE, Coimbra, Portugal|Hospital Santa Marta, Lisboa, Portugal|Centro Hospitalar de Sao Joao EPE, Porto, Portugal|Research Institute of Complex Cardiovascular Pathology, Kemerovo, Russian Federation|GBUZ Children's Hospital named after Bashlyaeva Z.A. Moscow, Moscow, Russian Federation|Russian National Research Medical University n.a. N.I.Pirogov, Moscow, Russian Federation|Novosibirsk Research Institue of Blood Circulation Pathology n.a. E.N. Meshalkin, Novosibirsk, Russian Federation|Saint Petersburg State Pediatric Medical Academy, St. Petersburg, Russian Federation|Clinical Hospital №1, Tyumen, Russian Federation|Bashkiria State Medical University, Ufa, Russian Federation|University of The Free State, Bloemfontein, South Africa|Inkosi Albert Luthuli Central Hospital, Durban, South Africa|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|C.H. Regional Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Ramathibodi Hospital Mahidol University, Bangkok, Thailand|Siriraj Hospital Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Chiang Mai University, Chiang Mai, Thailand|MI Dnipropetrovsk Specialized Clin. Med. Center of Mother and Child n.a. prof. M.F. Rudnev of DRC, Dnipro, Ukraine|Municipal Institution of Health Care Regional Children's Clinical Hospital, Kharkiv, Ukraine|MI Scientific Practical Medical Center for Children Cardiology and Cardiosurgery of MOH of Ukraine, Kyiv, Ukraine|Hanoi Heart Hospital, Hanoi, Vietnam|Hanoi Medical University Hospital, Hanoi, Vietnam|Children's Hospital 1, Ho Chi Minh City, Vietnam|Tam Duc Hospital, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT02932410
NCT04193046,A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH),CIPHER,Recruiting,No Results Available,"Hypertension, Pulmonary",Other: Blood Sample,"Expression Levels of miRNAs Biomarkers|Biomarker signatures for miRNA|Biomarker Signature Performance in Identifying Participants with PH|Comparison of Performance of Biomarker Signatures and Transthoracic Echocardiogram (TTE) Based on Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value|Area Under ROC Curve in Participants with PH who are Receiving Therapies Versus not Receiving drug Therapy|Area Under ROC Curve in Participants with PAH, CTEPH, Isolated pre-Capillary and post-Capillary PH","Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,800,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CR108723|NAPUH0001,16-Dec-19,31-Mar-21,31-May-22,10-Dec-19,,23-Dec-20,"Banner University Medical Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of Southern California, Los Angeles, California, United States|UC Davis Health System, Sacramento, California, United States|UCSF, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|University Of Colorado Cardiac And Vascular Center, Aurora, Colorado, United States|Ascension St. Vincent's Lung Institute, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Indiana University School Of Medicine, Indianapolis, Indiana, United States|University Of Iowa - Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|LSU Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Pulmonary Health Physicians, PC, Fayetteville, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Allegheny, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Houston Methodist Research Institute, Houston, Texas, United States|Pulmonary Associates Of Richmond, Richmond, Virginia, United States|ULB Erasme Ziekenhuis, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie, Dresden, Germany|Robert-Bosch-Krankenhaus - Klinik Schillerhoehe, Gerlingen, Germany|Universitaetsklinikum Giessen, Giessen, Germany|Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald, Klinik für Innere Medizin B, Greifswald, Germany|Universitaetsklinik Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie, Hannover, Germany|Thoraxklinik Heidelberg, Heidelberg, Germany|Lungenfachklinik Immenhausen, Immenhaus, Germany|Universitätsklinikum Jena Klinik für Innere Medizin I, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Luebeck, Germany|Medizinische Klinik und Poliklinik V - LMU, München, Germany|VUMC Amsterdam, Amsterdam, Netherlands|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Virgen de La Salud, Toledo, Spain|Royal United Hospital, Bath, United Kingdom|Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom|National Waiting Times Centre Board Golden Jubilee National Hospital, Glasgow, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT04193046
NCT03541174,A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety,PRECISION,Recruiting,No Results Available,Resistant Hypertension,Drug: Aprocitentan 12.5 mg|Drug: Aprocitentan 25 mg|Drug: Placebo,"Change from baseline to Week 4 of DB treatment in trough Sitting Systolic BP (SiSBP) measured by AOBPM|Change from Week 36 (i.e., start of DB-WD) to Week 40 in trough SiSBP as measured by AOBPM|Change from baseline to Week 4 of DB treatment in trough Sitting Diastolic BP (SiDBP) measured by AOBPM|Changes from baseline to Week 4 of DB treatment in 24-h mean SBP and DBP measured by ABPM|Change from Week 36 to Week 40 of DB-WD treatment in trough SiDBP measured by AOBPM|Changes from Week 36 to Week 40 of DB-WD treatment in 24-h mean SBP and DBP measured by ABPM","Idorsia Pharmaceuticals Ltd.|Janssen Biotech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ID-080A301|2017-004393-33,18-Jun-18,Jun-21,Jun-22,30-May-18,,19-Dec-20,"Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|University of Alabama at Birmingham Vascular Biology and Hypertension Program, Birmingham, Alabama, United States|Chrishard Medical Group, Inglewood, California, United States|Clinical Trials Research, Lincoln, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Entertainment Medical Group, Inc., Los Angeles, California, United States|Amicis Research Center, Northridge, California, United States|Empire Clinical Research, Pomona, California, United States|North America Research Institute, San Dimas, California, United States|Orange County Research Center, Tustin, California, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|West Broward Research, Coral Springs, Florida, United States|Century Clinical Research, Inc, Daytona Beach, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Canvas Clinical Research, LLC, Lake Worth, Florida, United States|Southwest Florida Research, LLC., Naples, Florida, United States|East Coast Institute for Research, Saint Augustine, Florida, United States|Premier Medical Associates, The Villages, Florida, United States|Northwest Heart Clinical Research, LLC., Arlington Heights, Illinois, United States|SIU School of Medicine Center for Clinical Research, Springfield, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Cardiovascular Research of Northwest Indiana, L.L.C., Munster, Indiana, United States|Reid Physician Associates, Richmond, Indiana, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States|DelRicht Research, Gretna, Louisiana, United States|Capital Nephrology, Greenbelt, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Washington Nephrology Associates, Takoma Park, Maryland, United States|St Clair Nephrology Research, Roseville, Michigan, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Hypertension and Nephrology Association PA, Eatontown, New Jersey, United States|Renal Medicine Associates, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Scott Research Inc, Laurelton, New York, United States|Great Lakes Medical Research LLC, Westfield, New York, United States|Metrolina Internal Medicine/Internal Medicine Research, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Physician's East Endocrinology, Greenville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center - Neurological Institute, Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Doylestown Health Cardiology, Doylestown, Pennsylvania, United States|Aventiv Research, Inc, Erie, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Drexel University Dept of Nephrology, Philadelphia, Pennsylvania, United States|TLM Medical Services LLC, Columbia, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Stern Cardiovascular Foundation, Inc, Germantown, Tennessee, United States|The University of Tennessee, Memphis, Tennessee, United States|LifeDOC Research PLLC, Memphis, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|San Antonio Kidney Disease Center, PLLC, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Mercury Clinical Research, Webster, Texas, United States|St. George Kidney Care, Saint George, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Salem Veterans Affairs Medical Center, Salem, Virginia, United States|Milwaukee Nephrologists, SC, Wauwatosa, Wisconsin, United States|Central Coast Local Health District, Gosford, New South Wales, Australia|Renal Research, Gosford, New South Wales, Australia|St. George Hospital, Dept. Renal Medicine, Kogarah, New South Wales, Australia|Western Sydney Local Health District, Westmead, New South Wales, Australia|Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia|Core Research Group Pty Ltd, Milton, Queensland, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|CCRE Clinical Trial Centre, SPHPM, Monash University, Caulfield, Victoria, Australia|St Vincent's Hospital (Melbourne), Fitzroy, Victoria, Australia|Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia|Curtin University, Faculty of Health Sciences, School of Public Health, Bentley, Western Australia, Australia|Royal Perth Hospital Unit - The University of Western Australia, Perth, Western Australia, Australia|Grand Hôpital de Charleroi, Site St-Joseph, Gilly, Charleroi, Belgium|Hospital Erasme _Cardiology department, Brussels, Belgium|UZ Brussel, Brussels, Belgium|Clinique Universitaires de Saint Luc, Departement cardio-vasculaires intensives, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium|Clinical Research Solutions Inc., Kitchener, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|The Ottawa Hospital, Renal Hypertension Program, Ottawa, Ontario, Canada|Manna Research (Stoney Creek), Stoney Creek, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|Stephen S. Chow Medicine Professional Corporation, Toronto, Ontario, Canada|Jewish General Hospital - Cardiovascular Prevention Center, Montreal, Quebec, Canada|Hopital MaisonNeuve-Rosemont, Montréal, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|The First Affiliated Hospital of Baotou Medical College of Inner Mongolia, Baotou, China|The Third Xiangya Hospital of Central South University, Changsha, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Province People's Hospital, Hangzhou, China|Lanzhou University Second Hospital, Lanzhou, China|Hainan NO.3 Provincial people's Hospital, Sanya, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|FN U Sv.Anny Brno, kardiologická klinika, Brno, Czechia|Krajska zdravotni, a.s. - Nemocnice Decin, o.z., Děčín, Czechia|Fakultní nemocnice Plzeň, Pilsen, Czechia|Všeobecní fakultní nemocnice Praha, Prague, Czechia|Nefromed s.r.o., Prague, Czechia|Fakultní nemocnice Královské Vinohrady, Praha 10, Czechia|Thomayerova nemocnice, Praha 4, Czechia|Kardio Václavík s.r.o, Přerov, Czechia|Aalborg University Hospital Cardiology, Aalborg, Denmark|Regional Hospital Holstebro Department of Medicine University Clinic in Nephrology and Hypertension at Holstebro, Holstebro, Denmark|University of Oulu, Medical Research Center, Oulu, Finland|TAYS RDI center (Tampere University Hospital,Specialist Internal Medicine, Rare Diseases), Tampere, Finland|Turku University Central Hospital - Turun yliopistollinen keskussairaala Sisätautien klinikka, Turku, Finland|Centre de Recherche Clinique, Bobigny, France|Hôpital Saint-André - Service de Cardiologie et Hypertension Artérielle, Bordeaux cedex, France|CHU Grenoble - Alpes, Grenoble cedex 9, France|Institut Cœur Poumon CHRU LILLE, Lille Cedex, France|Hôpital de la Croix-Rousse - Rhône, Lyon, France|GHRMSA - Hôpital Emile Muller, Mulhouse, France|Hôpital Européen Georges Pompidou- Centre d' Investigation Clinique, Paris, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Medic Trials STUG, Berlin, Germany|Universitätsklinikum Düsseldorf Klinik für Nephrologie, Düsseldorf, Germany|Universitätsklinikum Erlangen Klinische Forschungsstation (CRC), Erlangen, Germany|University Medical Centre Goettingen - Universitätsmedizin Göttingen Klinik für Nephrologie und Rheumatologie, Göttingen, Germany|Clinical Trial Center North GmbH & Co. KG, Hamburg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Herzzentrum der Uniklinik Köln, Köln, Germany|Herzzentrum Leipzig Universitätsklinik für Kardiologie, Leipzig, Germany|Sana Kliniken Lüebeck, Cardiology, Lübeck, Germany|Universitätsklinikum Nürnberg Süd, Nürnberg, Germany|Euroclinic Athens, Athens, Greece|General Hospital of Athens, Ippokrateio, Athens, Greece|National and Kapodistrian University of Athens, School of Medicine Third Department of Medicine, Sotiria Hospital, Athens, Greece|General Hospital of Athens Georgios Gennimatas, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|General Hospital Konstantopouleio -Patision, Nea Ionia, Greece|AHEPA University Hospital, Thessaloniki, Greece|Asklepeion General Hospital, Voula, Greece|Principal SMO Kft., Baja, Hungary|DRC Gyógyszervizsgáló Központ Kft., Balatonfüred, Hungary|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Debreceni Egyetem - Klinikai Központ, Debrecen, Hungary|Pest Megyei Flór Ferenc Kórház, Kistarcsa, Hungary|Pécsi Tudományegyetem Klinikai Központ, Pécs, Hungary|University of Szeged, 1st Dept. of Medicine, Szeged, Hungary|Markusovszky Egyetemi Oktatókórház, Szombathely, Hungary|HaEmek M.C, Afula, Israel|Assuta Medical Center Ashdod, Ashdod, Israel|Cardiovascular Institute, Ashkelon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Galilee Medical Center, Nahariya, Israel|Sheba Medical Center, Tel HaShomer, Israel|University Brescia Department Clinical and Experimental Science, Brescia, Italy|Division of Internal Medicine & Nephrology University of L'Aquila - San Salvatore Hospital V.le San Salvatore, L'Aquila, Italy|Ospedale San Gerardo, Clinica Medica, Monza, Italy|Azienda Ospedaliera S. Andrea di Roma - Division of Cardiology and of Cardiothoracic and Vascular Science Department -, Pisa, Italy|Azienda Ospedaliero Universitaria PisanA - Department Clinical and Experimental Medicine, Pisa, Italy|SCU Medicina Interna e Centro Ipertensione arteriosa. Dipartimento di Scienze Mediche Università di Torino, Aou Citta' Salute E Scienza Torino, Torino, Italy|Veterans Health Service Medical Center Division of Cardiology - Dep. of Internal Medicine, Seoul, Gangdong-gu, Korea, Republic of|Gangnueng Asan Hospital University of Ulsan College of Medicine, Seoul, Gangwon-do, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital Division of Cardiology - Dept. of Internal Medicine, Wonju, Ganwon-do, Korea, Republic of|Seoul National University Hospital Division of Cardiology, Department of Internal Medicine, Seoul, Korea, Republic of|Kaunas Clinical Hospital, Kaunas, Lithuania|JSC ""InMedica"", Kaunas, Lithuania|Clinic of Cardiology and Rehabilitation, Klaipeda, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Zuyderland Medical Center, Geleen, Netherlands|Maastricht University Medical Center, Dept. of Medicine, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Haga Ziekenhuizen-Internal Medicine, The Hague, Netherlands|Klinika Nadciśnienia Tętniczego i Diabetologii, Gdańsk, Poland|Mazowieckie Centrum Badań Klinicznych, Grodzisk-Mazowiecki, Poland|Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w, Kraków, Poland|Diamond Clinic, Kraków, Poland|Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1w Lublinie, Lublin, Poland|KO-MED. CentraKliniczne Sp. Z o.o. Ośrodek Badań Klinicznych w Lublinie II, Lublin, Poland|ETG Lublin, Lublin, Poland|Etyka Ośrodek Badań Klinicznych, Olsztyn, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|KO-MED. Centra Kliniczne Sp. Z o.o. Ośrodek Badań Klinicznych w Puławach, Puławy, Poland|ETG Skierniewice, Skierniewice, Poland|Medycyna Kliniczna, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|ETG Warszawa, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Warszawa, Poland|Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II w Zamościu, Zamość, Poland|ETG Zgierz, Zgierz, Poland|State Budgetary Healthcare Institution of Arkhangelsk Region ""First City Clinical Hospital n.a. E.E. Volosevich"", Arkhangelsk, Russian Federation|Municipal Autonomous Healthcare Institution City Clinical Hospital #6, Gastroenterology Department, Chelyabinsk, Russian Federation|Federal State Autonomous Institution of Higher Education ""Kazan (Volga Region) Federal University"", Kazan, Russian Federation|Federal State Budget Scientific Institution ""Scientific Research Institute for Complex Issues of Cardiovascular Diseases"", Kemerovo, Russian Federation|Scientific Research Institute - Regional Clinical Hospital №1, Krasnodar, Russian Federation|Regional State Budget Healthcare Institution ""Krasnoyarsk Interdistrict Clinical Hospital for Emergency Medical Care n.a. N.S Karpovich"", Nephrology Department, Krasnoyarsk, Russian Federation|Regional Budget Healthcare Institution ""Kursk City Clinical Hospital for Emergency Medical Care"" of Healthcare Committee of Kursk Region/Therapeutic, Kursk, Russian Federation|National Medical Research Center for Preventive Medicine, Moscow, Russian Federation|SBHI of Moscow ""City clinical hospital #52"" of Moscow healthcare department / city nephrology center, Moscow, Russian Federation|State budget healthcare institution of Novosibirsk region ""City clinical hospital #34"", Novosibirsk, Russian Federation|Federal State Budget Scientific Institution ""Federal Research Center Institute of Cytology and Genetics of Siberian Department of Russian Academy of Sciences"", Novosibirsk, Russian Federation|International Medical Center ""SOGAZ"", LLC, Saint Petersburg, Russian Federation|Federal State Military Educational Institution of Higher Professional Education, Military Medical Academy named for S. M. Kirov of the Ministry of Defense of the Russian Federation, Saint Petersburg, Russian Federation|State Healthcare Institution ""Regional Clinical Cardiology Dispensary"", Saratov, Russian Federation|Federal State Budget Educational Institution of Higher Education ""Saratov State Medical University n.a. V.I. Razumovskiy"" of the Ministry of Healthcare of the Russian Federation, Saratov, Russian Federation|State Budgetary Educational Institution of Higher Professional Education Smolensk State Medical Academy, Smolensk, Russian Federation|Federal State Budget Institution ""National Medical Research Center n.a. V.A. Almazov"" of the Ministry of healthcare of the Russian Federation, St. Petersburg, Russian Federation|Federal State Budget Scientific Institution ""Tomsk National Research Medical Center of the Russian Academy of Sciences"", Tomsk, Russian Federation|Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation|Hospital Universitari Germans Trias i Pujol de Badalona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Fundació Puigvert, Barcelona, Spain|Hospital Vall d'Hebron de Barcelona, Barcelona, Spain|Hipertensión Clinic, Internal Medicine, Hospital Clinico, University of Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Virgen de las Nieves - Internal Medicine Department, Granada, Spain|Hospital Clinico San Carlos - Istituto de Investigacion Sanitaria San Carlos (IdISSC), Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen del Rocio Departamento de Medicina Interna, Sevilla, Spain|Hospital Clínic Universitari de València, Valencia, Spain|Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Valencia, Valencia, Spain|Municipal non-profit enterprise ""Clinical hospital of emergency medicine"" of the Dniрro city council, Dnipro, Ukraine|State Institution ""L.T. Malaya Therapy National Institute of the NAMS of Ukraine"", Kharkiv, Ukraine|Municipal non-profit enterprise ""Clinical Hospital # 8""of Kharkiv City Council, Kharkiv, Ukraine|Kyiv City Clinical Hospital # 1, Kyiv, Ukraine|Kyiv Municipal Clinical Emergency Hospital, Kyiv, Ukraine|State Institution ""National Scientific Center ""M.D. Strazhesko Institute of Cardiology"" of the National Academy of Medical Sciences of Ukraine"", Kyiv, Ukraine|State Institution ""D.F. Chebotarev Institute of Gerontology, National Academy of Medical Science of Ukraine"", Kyiv, Ukraine|State Institution ""Institute of Gerontology named after D.F. Chebotarev of National Academy of Medical Sciences of Ukraine"", Kyiv, Ukraine|Municipal Enterprise ""Lutsk City Clinical Hospital"", Volyn Regional Center for Cardiovascular Pathology, Lutsk, Ukraine|Municipal Noncommercial Enterprise ""Lviv City Clinical Hospital #5"", Lviv, Ukraine|Communal Non-profit Enterprise ""Vinnytsya regional Clinical Hospital named after. N.I. Pirogov Vinnytsia Regional Council""/ National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine|Municipal non-profit enterprise ""Regional Clinical Hospital named after AF Gerbachevsky"" of Zhytomyr Regional Council, Zhytomyr, Ukraine|James Paget University Hospitals Foundation Trust, Great Yarmouth, Norfolk, United Kingdom|Aberdeen Royal Infirmary, Clinical Pharmacology Unit, Aberdeen, United Kingdom|Clinical Research Centre The University of Edinburgh Centre for Cardiovascular Science, Edinburgh, United Kingdom|Glasgow Clinical Research Facility (CRF), Glasgow, United Kingdom|University Hospitals of Leicester NHS Trust Dept of Chemical Pathology and Metabolic Diseases, Leicester, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|Queen Mary University of London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03541174
NCT04456998,GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH),,Recruiting,No Results Available,Pulmonary Artery Hypertension,Drug: GB002|Drug: Placebo|Device: Generic Dry Powder Inhaler,Change from Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)|Change From Baseline to Week 24 on the Six-Minute Walk Test (6MWT),"GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|Gossamer Bio Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GB002-2101,14-Dec-20,Mar-22,Apr-22,7-Jul-20,,12-Jan-21,"Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|Pulmonary Associates, PA, Phoenix, Arizona, United States|The University of California San Francisco, San Francisco, California, United States|The Lundquist Institute of Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Central Florida Pulmonary Group, PA, Altamonte Springs, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|New York Presbyterian Hospital - Weill Cornell Medicine, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Hospital Universitario Marqués de Valdecilla, Santander, Spain",,https://ClinicalTrials.gov/show/NCT04456998
NCT04175600,A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension,SALTO,Recruiting,No Results Available,"Hypertension, Pulmonary",Drug: Selexipag|Drug: Placebo,"Time to Disease Progression|Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious AEs|Percentage of Participants with AEs Leading to Premature Discontinuation of Study Treatment|Change from Baseline in Systolic and Diastolic Arterial Blood Pressure|Change from Baseline in Pulse Rate|Change from Baseline in Body Weight|Change from Baseline in Height|Sexual Maturation (Tanner Stage) Change from Baseline to all Assessed Time Points|Percentage of Participants with Treatment-emergent Electrocardiogram Abnormalities|Percentage of Participants with Treatment-emergent Marked Laboratory Abnormalities|Treatment-emergent Change from Baseline in Thyroid Stimulating Hormone|Time to First Clinical Event Committee (CEC)-confirmed Hospitalization and Death for PAH|Trough Plasma Concentration at Steady-state (Ctrough,ss) of Selexipag and its Metabolite ACT-333679",Actelion,All,2 Years to 17 Years   (Child),Phase 3,237,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR108716|2019-002817-21|AC-065A310,16-Jan-20,9-Dec-24,28-Jan-28,25-Nov-19,,23-Dec-20,"UCLA Medical Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Congenital Heart Center of the University of Florida, Gainesville, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Detroit Medical Center, Detroit, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Virginia Division of Pediatric Cardiology, Charlottesville, Virginia, United States|Queensland CHILDREN'S HOSPITAL, South Brisbane, Australia|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao, Blumenau, Brazil|Hospital Pequeno Principe, Curitiba, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|Hospital São Paulo-UNIFESP, Sao Paulo, Brazil|Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead, Sofia, Bulgaria|Hospital For Sick Children, Toronto, Ontario, Canada|Stollery Children's Hospital, Edmonton, Canada|Centre Hospitalier Sainte Justine, Montreal, Canada|Beijing Anzhen Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Guangzhou Women And Children's Medical Center, Guangzhou, China|Qingdao Women and Children's Hospital, Qingdao, China|Shanghai Children's Medical Center, Shanghai, China|Children's Hospital of Fudan University, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|Clinica San Rafael, Bogota, Colombia|Fundacion Neumologica Colombiana, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Colombia|Clinica Vascular las Americas, Medellin, Colombia|Hospital Universidad del Norte, Soledad, Colombia|Rigshospitalet, Copenhagen Ø, Denmark|New Children's Hospital of the Helsinki University Hospital (HUS), Helsinki, Finland|Hôpital Cardiologique - Chru Lille, Lille Cedex, France|Hopital de la Timone, Marseille Cedex 5, France|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital Cardiologique Du Haut-Lévêque, Pessac, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|Universtà Degli Studi Di Padova, Padova, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita, Torino, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital - Yonsei University Health System, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania|National Heart Institute, Kuala Lumpur, Malaysia|CICUM San Miguel, Guadalajara, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Slaskie Centrum Chorob Serca, Zabrze, Poland|Hospital De Santa Marta, Lisboa, Portugal|Centro Hospitalar de São João, EPE, Porto, Portugal|Kazan State Medical University, Kazan, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Children's City Clinical Hospital n.a. Baslyaeva, Moscow, Russian Federation|Veltischev Research and Clinical Institute for Pediatrics of the Pirogov RNRMU, Moscow, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Tyumen Regional Hospital #1, Tyumen, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Drottning Silvias barn- och ungdomssjukhus, Gothenburg, Sweden|Skanes universitetssjukhus, Lund, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chiang Mai University Hospital, Chiang Mai, Thailand|Cukurova Balcali Hospital Application and Research Center, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|CAPA Istanbul University Medical Faculty, Istanbul, Turkey|Mehmet Akif Ersoy Training and Research Hospital, Istanbul, Turkey|Dr. Siyami Ersek Gogus Kalp ve Damar Cerrahisi Training and Research Hospital, Istanbul, Turkey|Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital, Izmir, Turkey|Izmir Tepecik Training and Research Hospital, Izmir, Turkey|Dnipropetrovsk clinical medical center of Mother and Child after prof. Rudnev, Dnipro, Ukraine|MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery', Dnipro, Ukraine|Scientific Practical Medical Center for Pediatric Cardiology and Cardio Surgery of the MOH, Kyiv, Ukraine|Communal Non-commercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine|Sumy Regional Childrens Clinical Hospital, Sumy, Ukraine|MI Zaporizhzhia Regional Clinical Childrens Hospital of Zaporizhzhia Regional Council, Zaporizhzhya, Ukraine|Hanoi Medical University Hospital, Hanoi, Vietnam|Tam Duc Cardiology Hospital, Ho Chi Minh, Vietnam|Children's Hospital 1, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT04175600
NCT04503733,A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension,,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Q4W GMA301 IV injections (300 mg)|Drug: Q4W GMA301 IV injections (600 mg)|Drug: Q4W GMA301 IV injections (1000 mg)|Other: Q4W placebo IV injections,The incidence of Treatment Emergent Adverse Events (TEAE) after the start of GMA301 dosing compared with placebo.|Pharmacokinetics (Area under the serum concentration- time curve from time zero to the last measurable concentration)|Comparison of GMA301 treatment effect at Week 12 versus baseline regarding the pulmonary vascular resistance (PVR) based on right heart catheterization (RHC)|Comparing 6MWT distance,Gmax Biopharm LLC.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GETA_MAD_01,1-Jul-20,3-Sep-21,10-Jun-22,7-Aug-20,,7-Aug-20,"Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute, Louisville, Ohio, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Peking Union Medical College Hospital - Dongcheng District, Beijing, China|Xiangya Hospital, Central South University, Changsha, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, China|Guangdong General Hospital, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04503733/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04503733/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04503733
NCT02610660,Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension,TOPP-2,Recruiting,No Results Available,"Hypertension, Pulmonary",,Death|Transplantation|Adverse events|Hospitalisation related to pulmonary arterial hypertension (PAH)|Use/initiation of i.v./s.c. prostanoids|Atrial septostomy|Potts shunt|Time to clinical worsening|Decline in 6-minute walk test (6MWT)|Type of treatment|Switch in treatment|Escalation of treatment|Reasons for treatment change|Decline in WHO functional class|Decline in Panama functional class|Worsening of echocardiographic parameters (ECHO)|Increase in Brain Natriuretic Peptide (BNP)|Increase in N-terminal-proBNP (NT-proBNP),Association for Pediatric Pulmonary Hypertension,All,"3 Months to 18 Years   (Child, Adult)",,440,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TOPP-2,Aug-15,Dec-21,Dec-21,20-Nov-15,,16-Sep-20,"Stanford Children's Hospital, Palo Alto, California, United States|University of Colorado Denver School of Medicine, Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Boston Children's Hospital, Boston, Massachusetts, United States|St Louis Children's Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Vanderbilt University Children's Hospital, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Royal Children's Hospital, Melbourne, Australia|University of São Paulo, São Paulo, Brazil|The Hospital for Sick Children, Toronto, Ontario, Canada|Fu Wai Hospital, Beijing, China|Hospital Pediátrico La Misericordia, Bogota, Colombia|Université Paris Descartes, Paris, France|University Children's Hospital Ulm, Ulm, Germany|Institute of Cardiology, Budapest, Hungary|Hadassah, Hebrew University Medical Center, Jerusalem, Israel|University of Padova, Padova, Italy|Toho Universit Omori Medical Center, Tokyo, Japan|Keio University, Tokyo, Japan|National Heart Institute, Mexico City, Mexico|Beatrix Children's Hospital, University Medical Center Groningen, Groningen, Netherlands|Children's Memorial, Warsaw, Poland|King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia|The Queen Silvia's Children's Hospital, Gothenburg, Sweden|Hôpital des Enfants, Geneva, Switzerland|University Children's Hospital, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT02610660
NCT04435782,A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging,RESTORE,Not yet recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: JNJ-67896049,Change from Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI)|Change from Baseline to Week 26 in RV End-Diastolic Volume (RVEDV) Assessed by MRI|Change from Baseline to Week 26 in RV End-Systolic Volume (RVESV) Assessed by MRI|Change from Baseline to Week 26 in RV Ejection Fraction (RVEF) Assessed by MRI|Change from Baseline to Week 26 in RV Mass Assessed by MRI|Change from Baseline to Week 26 RV Global Longitudinal Strain (RVGLS) Assessed by MRI|Change of Baseline to Week 26 in World Health Organization Functional Class (WHO FC)|Change form Baseline to Week 26 in N-Terminal-Pro-Hormone Brain Natriuretic Peptide (NT-proBNP)|Change from Baseline to Week 26 in 6-Minute Walk Distance (6MWD)|Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants with AEs Leading to Premature Discontinuation of Selexipag|Number of Participants with AEs of Special Interest|Number of Participants with Treatment-Emergent Marked Laboratory Abnormalities|Change from Baseline to Week 26 in Number of Non-Invasive Low-Risk Criteria Variable,Actelion,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,80,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR108753|67896049PAH4005|2019-004783-22,14-Dec-20,31-Jan-23,20-Apr-23,17-Jun-20,,10-Dec-20,"University of Arizona, Tucson, Arizona, United States|University Of California San Diego, La Jolla, California, United States|University of California at San Francisco, San Francisco, California, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|AnMed Health, Anderson, South Carolina, United States|UT Southwestern, Dallas, Texas, United States|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Sanatorio Ramon Cereijo, Caba, Argentina|Instituto Cardiovascular de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Hospital Moinhos de Vento, Porto Alegre, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, Sao Paulo, Brazil|UNIFESP, Vila Clementino, Brazil|Beijing Anzhen Hospital, Beijing, China|West China Hospital, Sichuan University, Chengdu, China|CHU Grenoble, La Tronche, France|Ruhr-Universität Bochum / Diabeteszentrum, Bad Oeynhausen, Germany|DRK Kliniken Westend, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Robert-Bosch-Krankenhaus - Klinik Schillerhoehe, Gerlingen, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Grantham Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Institut Jantung Negara, Kuala Lumpur, Malaysia|VUMC Amsterdam, Amsterdam, Netherlands|Radboud Umcn, Nijmegen, Netherlands|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|Federal State Budgetary Institution, St Petersburg, Russian Federation|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, Hampstead, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT04435782
NCT04271475,A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension,MACiTEPH,Recruiting,No Results Available,Chronic Thromboembolic Pulmonary Hypertension,Drug: Macitentan|Drug: Placebo,Change From Baseline to Week 28 in 6- minute Walk Distance [6MWD]|Time to Clinical Worsening up to Week 52|Number of Participants with Improvement in WHO Functional Class (WHO FC) From Baseline to Week 28|Change From Baseline to Week 28 in Pulmonary Arterial Hypertension - Symptoms Based on (PAH-SYMPACT) - Cardiopulmonary Symptom Domain Score|Change from Baseline to Week 28 in PAH-SYMPACT - Cardiovascular Symptom Domain Score|Change from baseline to Week 28 in Euro Quality of life-5-Dimension-5-Level (EQ-5D-5L) Utility Score|Change From Baseline to Week 28 in Accelerometer-assessed Proportion of Time Spent in Moderate to Vigorous Physical Activity,Actelion,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR108742|2019-004131-24|67896062CTP3001,7-Jul-20,14-May-24,12-Aug-26,17-Feb-20,,25-Nov-20,"University of California San Diego Medical Center, La Jolla, California, United States|USC Keck, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|St Vincents Lung, Sleep And Critical Care, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|OSF HealthCare Cardiovascular Institute, Peoria, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Syracuse VA Medical Center, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Houston Methodist Research Institute, Houston, Texas, United States|Baylor Scott White - Plano, Plano, Texas, United States|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Instituto Modelo De Cardiología Privado Srl, Córdoba, Argentina|Hospital Provincial Dr. Jose Maria Cullen, Santa Fe, Argentina|Queensland Lung Transplant Service, Chermside, Australia|St Vincent's hospital, Darlinghurst, Australia|LKH-Univ. Klinikum Graz, Graz, Austria|Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria|Medizinische Universität Wien, Vienna, Austria|Military Medical Academy, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD, Sofia, Bulgaria|Alberta Health Services, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Fundacion Neumologica Colombiana, Bogota, Colombia|Fundación Abood Shaio, Bogota, Colombia|Fundacion Clinica Valle de Lili, Cali, Colombia|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Colombia|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Giessen, Giessen, Germany|Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie, Hannover, Germany|Thoraxklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena, Jena, Germany|Krankenhaus Neuwittelsbach, München, Germany|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet és rendelő, Szeged, Hungary|Carmel Medical Center, Haifa, Israel|Tel Aviv Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Ospedale SS. Annunziata, Chieti, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Gemelli Universita Cattolica, Roma, Italy|A.O.U. Città della Salute e della Scienza, Torino, Italy|Kure Kyosai Hospital, Hiroshima, Japan|Hokkaido University Hospital, Sapporo, Japan|Pusan National University Hospital, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Lietuvos sveikatos mokslų universiteto ligoninė Kauno klinik, Kaunas, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad De México, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Centro de Investigacion Clinica Chapultepec, Morelia, Mexico|Slaski Uniwersytet Medyczny, Katowice, Poland|Krakowski Szpital Specjalistyczny im Jana Pawla II, Krakow, Poland|Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego, PZOZ, Lublin, Poland|Europejskie Centrum Zdrowia Otwock Sp. z o.o, Otwock, Poland|Wojewodzki Szpital Specjalistyczny, Oddzial Kardiologiczny, Wrocław, Poland|Institutul de urgenta pentru Boli Cardiovasculare Prof. Dr. C.C. Iliescu Sectia cardiologie III, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta, Tg. Mures, Romania|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|State Autonomous HealthCare Institution 'Interregional Clinical Diagnostic Center', Kazan, Russian Federation|Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Volgograd Regional Clinical Cardiological Center, Volgograd, Russian Federation|King Abdulaziz Medical City, Jeddah, Saudi Arabia|King Fahad Specialist hospital, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|Clinical Center of Serbia, Belgrade, Serbia|Institute for Pulmonary Disease, Sremska Kamenica, Serbia|National University Heart Centre, Singapore, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Narodny ustav srdcovych a cievnych chorob, Bratislava, Slovakia|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Virgen de La Salud, Toledo, Spain|Hosp. Clinico Univ. de Valladolid, Valladolid, Spain|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, LinKou Branch, Taoyuan, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Ankara Sehir Hastanesi, Ankara, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Istanbul University - Cerrahpasa Cardiology Institution, Istanbul, Turkey|Siyami Ersek Training and Research Hospital, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylül University Medical Faculty, Izmir, Turkey|Kartal Kosuyolu Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Kartal-Istanbul, Turkey|Mersin University Medical Faculty, Mersin, Turkey|CNE 'Cherkasy Regional Cardiological Center of Cherkasy Regional Council', Cherkasy, Ukraine|CI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiosurgery', Dnipro, Ukraine|Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine', Kyiv, Ukraine|State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine, Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine|Municipal Non-commercial Enterprise 'Ternopil University Hospital' of Ternopil Regional Council, Ternopil, Ukraine|Papworth Hospital NHS Trust, Cambridge, United Kingdom|Royal Free Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT04271475
NCT04071327,Pulmonary Hypertension Association Registry,PHAR,Recruiting,No Results Available,Pulmonary Arterial Hypertension|Chronic Thromboembolic Pulmonary Hypertension|Pulmonary Hypertension,,Proportion of PAH and CTEPH patients completing all guideline-recommended diagnostics|Impact of clinical predictors of disease worsening on patient outcomes|Survival,"Pulmonary Hypertension Association, Inc.|University of Washington, the Collaborative Health Studies Coordinating Center",All,"Child, Adult, Older Adult",,3000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHAR,Oct-15,Oct-25,Oct-25,28-Aug-19,,3-Apr-20,"Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|UC Davis Health, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|UCSF Benioff Children's Hospital, San Francisco, California, United States|Cottage Health System - Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|UC Health - Anschutz Medical Campus, Aurora, Colorado, United States|University of Connecticut Health, Farmington, Connecticut, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Indiana University Health, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinic, Iowa City, Iowa, United States|KU Medical Center, Kansas City, Kansas, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Ochsner Medical Center, Jefferson, Louisiana, United States|LSU Healthcare Network Clinic, New Orleans, Louisiana, United States|University of MD Medical Group, PA, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Minnesota Health, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Weill Cornell Medical Center, New York, New York, United States|Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|UNC Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|UC Health, Cincinnati, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|AnMed Health, Anderson, South Carolina, United States|Ft. Sanders Regional Medical Center, Knoxville, Tennessee, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Baylor Scott & White, Plano, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Sentara Heart Hospital, Norfolk, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04071327
NCT04088552,Preventing Chronic Disease: ActuaYa,,Recruiting,No Results Available,Healthy Aging,"Other: Go4Life-Physical Activity/Exercise Program ""Workout to Go"" 5|Behavioral: ActuaYa Educational Sessions",Change in mean Hemoglobin A1C (HbA1c) levels|Change in Blood Pressure|Change in Body Mass Index (BMI)|Change in self-efficacy for condom use|Change in nutritional habits|Change in active lifestyle as assessed by daily steps|Change in active lifestyle as assessed by a self-report log|Change in active lifestyle as assessed by the Exercise Survey|Change in active lifestyle as assessed by the Exercise Question Survey|Change in HIV risk behaviors|Change in body fat composition|Change in abdominal circumference|Change in knowledge regarding obesity|Change in risk perception regarding obesity|Change in knowledge regarding diabetes|Change in HIV knowledge|Change in HIV risk perception|Change in self-esteem|Change in depressive symptoms as assessed by the CES-D20|Change in depressive symptoms as assessed by the GDS|Change in health care related habits|Change in technology use|Change in knowledge regarding hypertension,University of Miami|The Community Foundation of Broward,Female,"50 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20190373,7-Mar-20,31-Dec-21,31-Dec-21,13-Sep-19,,23-Oct-20,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04088552
NCT03689244,A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment,SELECT,Recruiting,No Results Available,Chronic Thromboembolic Pulmonary Hypertension,Drug: Selexipag|Drug: Placebo,Percent of baseline Pulmonary vascular resistance (PVR) at Week 20|Change from baseline to Week 26 in 6-minute walk distance (6MWD)|Time to clinical worsening|All-Cause Death or Hospitalizations Related to PH Worsening|World Health Organization Functional Class (WHO FC) improvement at Week 26|Change from baseline to Week 26 in Pulmonary arterial hypertension-symptoms and impact questionnaire (PAH-SYMPACT) Cardiopulmonary and Cardiovascular Symptom Domains|Change from Baseline to Week 26 in Borg Dyspnea index or Borg CR10 Scale|Change from baseline to Week 26 in N-terminal pro b-type natriuretic peptide (NT pro-BNP),Actelion,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,280,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-065B302|2018-002823-41,23-Jan-19,26-Mar-21,23-Apr-25,28-Sep-18,,23-Dec-20,"Mayo Clinic Arizona, Phoenix, Arizona, United States|Cedars Sinai Heart Institute, Beverly Hills, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|University of Southern California, Keck School of Medicine, Los Angeles, California, United States|UCSF, San Francisco, California, United States|University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States|Colorado Springs Pulmonary Consultants, Colorado Springs, Colorado, United States|South Denver Cardiology Associates PC, Littleton, Colorado, United States|St Vincents Lung, Sleep And Critical Care, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare, Austell, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Hospitals - Chicago, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|St. Mary's Cardiology, Reno, Nevada, United States|University of New Mexico Clinical & Translational Science Center, Albuquerque, New Mexico, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Research Institute at The Heart Hospital Baylor Plano, Plano, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Cardiovascular Center, Salt Lake City, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States|Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin, United States|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Sanatorio Ramon Cereijo, Caba, Argentina|Instituto de Cardiología y Cirugía Cardiovascular - Fundación Favaloro, Caba, Argentina|Hospital General de Agudos Dr Cosme Argerich, Caba, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|Hospital General de Agudos Dr. Juan A. Fernández, Caba, Argentina|Centro Médico Dra. De Salvo, Ciudad Autónoma de Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, Australia|Queensland Lung Transplant Service, Chermside, Australia|St Vincent's hospital, Darlinghurst, Australia|Pulmonary Arterial Hypertension Clinic, Hobart, Australia|The Alfred Hospital, Melbourne, Australia|Westmead Hospital, Westmead, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria|Medical University Vienna, Vienna, Austria|ULB Hôpital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Brazil|Faculdade de Medicina de Botucatu - Universidade Estadual Paulista, Botucatu, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Hospital das Clinicas - UFG, Goiania, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital São Lucas PUCRS, Porto Alegre, Brazil|Faculdade de Medicina Do Abc, Santo André, Brazil|Hospital São Paulo-UNIFESP, São Paulo, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, São Paulo, Brazil|UMHAT 'Heart and Brain Center for Excellence', Pleven, Bulgaria|National Cardiology Hospital, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD, Sofia, Bulgaria|University Of Calgary - Peter Lougheed Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire De Cardiologie Et De Pneumologie De Québec, Quebec, Canada|China-Japan Friendship Hospital, Beijing, China|Cardiovascular institute & Fuwai Hospital- Thrombus Center, Beijing, China|Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC), Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Shengjing Hospital of China Medical University, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|Århus Universitetshospital, Skejby, Hjertemedicinsk Afdeling B, Arhus, Denmark|Rigshospitalet Kardiologisk Klinisk, Copenhagen, Denmark|Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie, Dresden, Germany|Universitätsklinikum Giessen Medizinische Klinik Und Poliklinik Ii, Pneumologie, Giessen, Germany|Universität Greifswald - Klinik Für Innere Medizin Bereich Pneumologie/Infektiologie, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf - Pneumologie, Hamburg, Germany|Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätskliniken des Saarlandes / Medizinische Klinik und Poliklinik, Innere Medizin V, Homburg/Saar, Germany|Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Abteilung für Pneumologie, Leipzig, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|Semmelweis Egyetem,Pulmonológiai Klinika, Budapest, Hungary|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|SE Pulmonológiai Klinika, Budapest, Hungary|Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet és rendelő, Szeged, Hungary|Apollo Hospitals, Chennai, India|Govindaswamy Kuppuswamy Naidu Memorial Hospital, Coimbatore, India|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Umberto I, Roma, Italy|Ospedale di Cattinara - Struttura complessa di Pneumologia, Trieste, Italy|Pusan National University Hospital., Busan, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Mexico|CICUM San Miguel, Guadalajara, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|VUMC Amsterdam, Amsterdam, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Krakowski Szpital Specjalistyczny im Jana Pawla II, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland|NZOZ Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Warszawski Uniwersytet Medyczny, Szpital Kliniczny Dzieciątka Jezus, Warszawa, Poland|Wojewodzki Szpital Specjalist, Osrodek Badawczo-Rozwojowy, Wroclaw, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospitais da universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar de Lisboa Norte, Lisbon, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|Altay Regional Cardiological Dispensary, Barnaul, Russian Federation|Irkutsk Regional Clinical Hospital, Irkutsk, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russian Federation|Omsk Regional Clinical Hospital, Omsk, Russian Federation|State Autonomous Healthcare Organization of Permsky Region ""City Clinical Hospital #4"", Perm, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Voronezh Regional Clinical Hospital #1, Voronezh, Russian Federation|National University Heart Centre, Singapore, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Narodny ustav srdcovych a cievnych chorob, Bratislava, Slovakia|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Norrlands Universitetssjukhus, Umea, Sweden|Uppsala Akademiska Sjukhuset, Kardiologkliniken, Uppsala, Sweden|Universitatsspital Zurich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Hacettepe University Medical Faculty, Ankara, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kartal Kosuyolu Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Kartal-Istanbul, Turkey|CI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiosurgery', Dnipro, Ukraine|Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine', Kyiv, Ukraine|SI 'National Institute of Phtisiology and Pulmonology n.a. F.G. Yanovsky of NAMS of Ukraine', Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Papworth Hospital NHS Trust, Cambridge, United Kingdom|National Waiting Times Centre Board Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT03689244
NCT04298944,Association of Mood With Risk for Atherosclerosis,AuRA,Recruiting,No Results Available,Mood Disorders|Hypertension|Overweight and Obesity|Vascular Stiffness|Sleep|Elevated Blood Pressure,Diagnostic Test: Cardiovascular Assessments|Diagnostic Test: Actigraphy|Diagnostic Test: Laboratory assessments|Behavioral: Emotional/ Behavioural assessments,Arterial stiffness as assessed by Pulse wave velocity|Arterial stiffness as assessed by Ambulatory Arterial Stiffness Index (AASI)|Arterial stiffness as assessed by Augmentation Index|Endothelial function as assessed by Laser Doppler flow perfusion|Mean Blood pressure (mmHg)|Pediatric Adverse Childhood Events (ACEs) score|Children's Emotion Management Scale (CEMS) score|Behavior Assessment for Children (BASC) score,Johns Hopkins University|National Institute of Mental Health (NIMH),All,"up to 22 Years   (Child, Adult)",,80,Other|NIH,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,IRB00226838|P50MH115842-01,11-Mar-20,1-Aug-21,1-Aug-21,6-Mar-20,,14-Aug-20,"Johns Hopkins School of Medicine Division of Pediatric Nephrology, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04298944
NCT04046523,Non-Invasive and Non-Contact Intracranial Pressure Waveform Recording Using Dynamic Video Ophthalmoscopy,ICP Waveform,Recruiting,No Results Available,Intracranial Pressure Increase,Device: Video ophthalmoscope,The study will look at whether retinal video-recordings can be used to help estimate intracranial pressure.,University of Minnesota,All,"4 Years and older   (Child, Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PEDS-2019-28052,31-Aug-19,31-Jul-23,31-Jul-24,6-Aug-19,,27-Aug-20,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04046523
NCT04499248,AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension,,Recruiting,No Results Available,Open-angle Glaucoma|Ocular Hypertension,Drug: AGN-193408 SR|Other: Lumigan|Other: Sham Administration|Other: Lumigan Vehicle,Change from Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye|Number of participants experiencing treatment emergent adverse events|Time to Rescue Treatment or Re-Treatment in the Study Eye,Allergan,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1833-201-407,16-Nov-20,30-Apr-24,26-Apr-25,5-Aug-20,,23-Dec-20,"Eye Research Foundation, Newport Beach, California, United States|East West Eye Institute, Torrance, California, United States|Connecticut Eye Consultants P.C., Danbury, Connecticut, United States|Nature Coast Clinical Research, Crystal River, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Midwest Medical Advisors, Inc, Carmel, Indiana, United States|Johns Hopkins Wilmer Eye Institute - Bethesda, Bethesda, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Rutgers/New Jersey Medical School, Newark, New Jersey, United States|Asheville Eye Associates, Asheville, North Carolina, United States|James D. Branch MD, Winston-Salem, North Carolina, United States|Drs Fine Hoffman & Sims, LLC, Eugene, Oregon, United States|Vance Thompson Vision, Sioux Falls, South Dakota, United States|Advancing Vision Research, Smyrna, Tennessee, United States|Southern Utah Medical Research, Saint George, Utah, United States|Vistar Eye Center, Roanoke, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04499248
NCT03286426,Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure,ICP,Recruiting,No Results Available,Intracranial Pressure Increase,Diagnostic Test: Vision/Eye screening,Changes in posterior segment as measured by fundus camera|Changes in visual acuity|Changes in color vision as measured by standard clinical exam (i.e. Ishihara testing),Duke University,All,"up to 21 Years   (Child, Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,Pro00083580,26-Oct-17,31-Dec-21,31-Dec-21,18-Sep-17,,22-Dec-20,"Duke UMC, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03286426
NCT04142138,When the Kidney Reacts to Nutritional Changes,,Recruiting,No Results Available,Prehypertension,Other: DASH,urine exosome protein abundance pattern|urine electrolyte ratio in a spot urine as a surrogate to 24-h urine collection to assess nutritional consumption.|24-h urine collection as a measure of adherence to the DASH diet,Rockefeller University,All,18 Years to 60 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,DBI-1000,22-Feb-20,Jun-21,Aug-21,29-Oct-19,,19-Aug-20,"The Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04142138
NCT04406792,Alternative Lifestyle Interventions in Vulnerable Ethnic Groups,ALIVE,Not yet recruiting,No Results Available,Gestational Diabetes|Pre-Eclampsia|Type2 Diabetes|Chronic Hypertension Complicating Pregnancy|Primary Hypertension After Pregnancy|Obesity,Behavioral: Alternative Lifestyle Interventions in Vulnerable Ethnic groups|Behavioral: Diabetes Prevention Program (DPP) online|Behavioral: Standard of Care,Participants with gestational diabetes that complete the recommended screening for Type 2 Diabetes Mellitus (T2DM)|Participants with gestational diabetes who develop T2DM,"Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,435,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,ALIVE trial|5K01HL140278-02,Jan-21,Jan-23,Jan-24,28-May-20,,5-Jun-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04406792
NCT03581877,Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE,,Recruiting,No Results Available,Pulmonary Embolism|Pulmonary Hypertension|Thromboembolism|Right Ventricular Dysfunction,Drug: Alteplase|Device: EKOS,Right ventricle (RV) to Left ventricle (LV) ratio|Pulmonary pressures|Mortality,Northwell Health,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 4,158,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-0805,28-Jan-19,Dec-21,Dec-22,10-Jul-18,,11-Feb-20,"Southside Northwell Hospital, Bay Shore, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States",,https://ClinicalTrials.gov/show/NCT03581877
NCT01370512,Droxidopa / Pyridostigmine in Orthostatic Hypotension,,Recruiting,No Results Available,Orthostatic Hypotension,Drug: Droxidopa|Drug: Pyridostigmine Bromide,The primary endpoint is the improvement in diastolic BP fall at the end of 5 minutes of standing.|Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine versus placebo on supine NE and its orthostatic increment.|Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine on orthostatic symptoms.,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 2,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10-008810,Nov-11,Jun-21,Jun-21,10-Jun-11,,7-Jul-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01370512
NCT04668664,Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements,,Not yet recruiting,No Results Available,"Liver Cirrhosis|Liver Diseases|Hypertension, Portal",Device: EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™),Portal Pressure Gradient Measurement,Cook Research Incorporated|Cook Group Incorporated,All,"18 Years to 85 Years   (Adult, Older Adult)",,70,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-03,1-Jan-21,2-Jul-22,1-Aug-22,16-Dec-20,,17-Dec-20,"University of California, Irvine, Orange, California, United States|The University of Kansas Health System, Kansas City, Kansas, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|New York-Presbyterian Hospital/Weill Cornell University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04668664
NCT02261883,Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn,,Recruiting,No Results Available,Persistent Pulmonary Hypertension of the Newborn,Drug: IV Remodulin|Drug: Placebo,Evaluate the rate of clinical worsening in neonates with PPHN|Time to discontinuation of inhaled nitric oxide (iNO)|Change in oxygenation index (OI)|Time on mechanical ventilation|Time to initiation of ECMO|Mean treprostinil plasma concentration per dose achieved|Safety|Change in partial pressure of oxygen in arterial blood (PaO2) / fraction of inspired oxygen (FiO2) [P/F ratio]|Change in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP)|Change in pre and post-ductal oxygen saturation (SpO2),United Therapeutics,All,up to 14 Days   (Child),Phase 2,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RIV-PN-201,May-15,Dec-22,Dec-22,10-Oct-14,,20-Oct-20,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Stanford Children's Hospital, Palo Alto, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Nicklaus Children's Hospital, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Boston Children's, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Mississippi Medical Center - Baston Children's Hospital, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Virginia Health Systems(UVA), Charlottesville, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02261883
NCT02249923,Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry,PPHNet,Recruiting,No Results Available,Pulmonary Vascular Disease|Pulmonary Arterial Hypertension,,Time to clinical worsening|Escalation of Pulmonary Hypertension Therapy|Right Heart Failure,"University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI)",All,"up to 21 Years   (Child, Adult)",,1000,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-0018|U01HL121518,Oct-14,Dec-20,Jan-21,26-Sep-14,,18-Jan-20,"Stanford University Medical center, Palo Alto, California, United States|University California San Francisco, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Alberta Edmonton, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02249923
NCT03643705,A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention,EXTRA-CVD,Recruiting,No Results Available,HIV/AIDS|Hypertension|Hyperlipidemias,Other: Multi-component intervention|Other: General prevention education,Systolic blood pressure|Non high density lipoprotein (Non-HDL) cholesterol,"Case Western Reserve University|Duke University|University Hospitals Cleveland Medical Center|MetroHealth Medical Center|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,03-18-16|U01HL142099,20-Sep-19,Jun-22,Jun-22,23-Aug-18,,22-Oct-20,"Duke Health, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03643705
NCT04044248,TIPS Plus Transvenous Obliteration for Gastric Varices,,Recruiting,No Results Available,"Cirrhosis, Liver|Hypertension, Portal|Esophageal and Gastric Varices|Bleeding Gastric|Encephalopathy",Device: TIPS-obliteration,Endoscopic gastric varices eradication rate|Endoscopic esophageal varices aggravation/resolution rate|Imaging gastric variceseradication rate|Gastric varices rebleeding rate|Ascites incidence/improvement rate|TIPS + transvenous obliteration combined technical success rate|TIPS + transvenous obliteration combined hemodynamic success rate|Procedure related adverse event rate|Hepatic encephalopathy rate|Post-TIPS liver failure incidence and degree|Transplant free survival,University of Illinois at Chicago,All,"18 Years and older   (Adult, Older Adult)",,25,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2019-0156,4-Apr-19,4-Apr-21,4-Apr-22,5-Aug-19,,4-Nov-20,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04044248
NCT02020174,The Preeclampsia Registry,TPR,Recruiting,No Results Available,Preeclampsia|Eclampsia|HELLP Syndrome|Toxemia|Hypertensive Disorder of Pregnancy,,Self Reported Diagnosis of Preeclampsia and Hypertensive Disorders of Pregnancy Confirmed by Medical Records,Preeclampsia Foundation,All,"13 Years and older   (Child, Adult, Older Adult)",,20000,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,1,1-Sep-13,May-30,May-30,24-Dec-13,,23-Sep-19,"Preeclampsia Foundation, Melbourne, Florida, United States",,https://ClinicalTrials.gov/show/NCT02020174
NCT03418753,Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure,,Recruiting,No Results Available,Intracranial Pressure Increase,Diagnostic Test: EyeBOX for ICP,Sensitivity and Specificity,"Oculogica, Inc.",All,"4 Years to 70 Years   (Child, Adult, Older Adult)",,60,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ICP001,10-May-18,May-22,May-22,1-Feb-18,,16-Sep-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03418753
NCT03950739,"Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso",BREEZE,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Treprostinil Inhalation Powder,Number of subjects with treatment-emergent adverse events [Safety and Tolerability]|Analysis of treprostinil plasma concentration (pharmacokinetics [PK])|Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 3|Number of subjects with treatment-emergent adverse events [Long-term Safety and Tolerability] during an Optional Extension Phase|Subject satisfaction with and preference for inhaled treprostinil devices|Patient-reported PAH symptoms and impact,United Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TIP-PH-101,17-Sep-19,Jan-21,Jan-21,15-May-19,,24-Dec-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States|USC, Department of Medicine, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Ascension/ St. Vincent's Lung Institute, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville Pulmonary Research, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Univ of MD Medical Center, Baltimore, Maryland, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03950739
NCT03267108,A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension,REBUILD,Recruiting,No Results Available,Pulmonary Fibrosis|Pulmonary Hypertension,Combination Product: INOpulse|Combination Product: Placebo|Combination Product: Open Label Extension,"Change in Moderate to Vigorous Physical Activity (MVPA) as Measured by Actigraphy|Adverse Events and Serious Adverse Events with Long Term INOpulse Therapy|Change in Overall Activity as Measured by Actigraphy|Change in University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)|Change in St. George Respiratory Questionnaire (SGRQ) - Activity, Impacts & Total|Time to Clinical Worsening|Time to Clinical Deterioration|Time to Clinical Improvement|Change in 6 Minute Walk Distance",Bellerophon Pulse Technologies|Bellerophon,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PULSE-PHPF-001,29-Dec-17,Jun-22,Oct-22,30-Aug-17,,24-Dec-20,"Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|Amicus Research, Northridge, California, United States|University of California Davis Health, Sacramento, California, United States|UC Denver Anschutz Medical Center, Aurora, Colorado, United States|St. Franics Sleep Allergy and Lung Institute, Clearwater, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare, Austell, Georgia, United States|Loyola University, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|The Lung Research Center, LLC, Chesterfield, Missouri, United States|The University of North Carolina at Chapel Hill Marsico Clinical Research Center, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Thomas Jefferson University Korman Respiratory Institute, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Utah Health Sciences, Salt Lake City, Utah, United States|Inova Heart and Vascular Institute Advanced Lung Disease Clinic, Falls Church, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03267108
NCT03795428,"Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004",VIP Extend,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Pemziviptadil (PB1046) Injection,Incidence and Severity of Adverse Events|Incidence of Clinical Laboratory Abnormalities|Change in Diastolic Blood Pressure from baseline|Change in Systolic Blood Pressure from baseline|Change in Oral Body Temperature from baseline|Change in Respiratory Rate from baseline|Change in Heart Rate from baseline|12-Lead ECG - Incidence of clinically significant abnormal ECG findings as measured by 12 Lead ECG|Incidence of Immunogenicity|Survival|Change from baseline in 6MWD (6 minute walk distance test)|Change from baseline in NT-proBNP|Change from baseline in NYHA/WHO Functional Class (FC)|Change from baseline in emPHasis-10 (Health Related Quality of Life) score|Change from baseline in Borg Dyspnea Index (BDI)|Incidence of Clinical Worsening|Change in REVEAL Registry Risk Calculator Score,PhaseBio Pharmaceuticals Inc.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,63,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PB1046-PT-CL-0006,10-Apr-19,15-Jan-24,15-Feb-24,7-Jan-19,,6-Oct-20,"University of California San Diego, La Jolla, California, United States|University of California - Davis, Sacramento, California, United States|Emory University, The Emory Clinic, Atlanta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Rochester Medical Center, Rochester, New York, United States|The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03795428
NCT03614260,The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension,RADIANCE-II,Recruiting,No Results Available,Hypertension|Vascular Diseases|Cardiovascular Diseases,Device: Paradise Renal Denervation System|Procedure: Renal Angiogram,Incidence of Major Adverse Events (MAE)|Change in average daytime ambulatory systolic BP|Change in average 24-hr ambulatory systolic BP|Change in average office systolic BP|Change in average home systolic BP|Change in average daytime ambulatory diastolic BP|Change in average 24-hr ambulatory diastolic BP|Change in average office diastolic BP|Change in average home diastolic BP,"ReCor Medical, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,225,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",RADIANCE II Study,14-Dec-18,Feb-22,Dec-26,3-Aug-18,,4-Dec-20,"Cardiology PC, Birmingham, Alabama, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|San Diego Cardiac Center, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|MedStar Washington, Washington, District of Columbia, United States|The Cardiac and Vascular Institute, Gainesville, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Franciscan Health, Indianapolis, Indiana, United States|St. Vincent Center of Indiana, Indianapolis, Indiana, United States|Ochsner Hospital, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|Deborah Heart & Lung Center, Browns Mills, New Jersey, United States|Hackensack University, Hackensack, New Jersey, United States|Columbia University Medical Center/NYPH, New York, New York, United States|Northwell Health Inc. - Lenox Hill, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University, Stony Brook, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|WakeMed Raleigh, Raleigh, North Carolina, United States|Capital Area Research LLC, Camp Hill, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Tennessee Health Science Center, Memphis, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Swedish Medical Center, Seattle, Washington, United States|Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium|Hôpital Civil Marie Curie, Charleroi, Belgium|ZOL Genk Campus Sint-Jan, Genk, Belgium|Hôpital Saint André, Bordeaux, France|CHRU de Lille, Lille, France|Hôpital Européen Georges-Pompidou (HEGP), Paris, France|University Clinic Erlangen, Erlangen, Germany|University Clinic of Saarland - Homburg, Homburg, Germany|UKSH Kiel, Kiel, Germany|Klinikum Konstanz, Konstanz, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Sana Kliniken Lübeck GmbH, Lübeck, Germany|University Hospital Galway, Galway, Ireland|Hartlong Centrum, Alkmaar, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Hôpitaux Universitaires Genève, Geneva, Switzerland|The Cardiothoracic Centre Basildon University Hospital, Basildon, Essex, United Kingdom|Heartlands Hospital Birmingham, Birmingham, United Kingdom|University Hospitals Dorset NHS Foundation Trust, Bournemouth, United Kingdom|Kent & Canterbury Hospital, Canterbury, United Kingdom|The Queen Elizabeth University Hospital, Glasgow, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT03614260
NCT03556020,"Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH",VIP,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Pemziviptadil (PB1046),Incidence and severity of AEs|Incidence of Clinical Laboratory Abnormalities|Changes in Diastolic Blood Pressure|Changes in Systolic Blood Pressure|Changes in Oral Body Temperature|Changes in Respiratory Rate|Changes in Heart Rate|12-Lead ECG - Incidence of clinically significant findings|Immunogenicity|Change in baseline in pulmonary vascular resistance (PVR)|Change from baseline in 6MWD|Change from baseline in NT-proBNP|Change from baseline in cardiac index (CI)|Change from baseline in mean pulmonary artery pressure (mPAP)|Change from baseline in mean right atrial pressure (mRAP)|Change from baseline in wedge pressure|Change from baseline in mixed venous oxygen saturation (SvO2)|Change from baseline in pulmonary artery compliance,PhaseBio Pharmaceuticals Inc.,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PB1046-PT-CL-0004,15-Jul-18,31-Dec-21,31-Dec-21,14-Jun-18,,6-Nov-20,"IMC - Diagnostic & Medical Clinic, LLC, Mobile, Alabama, United States|University of California, San Diego (UCSD), La Jolla, California, United States|University of Southern California, Keck School of Medicine, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of California-Davis, Sacramento, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|The University Miami Health Hospital, Miami, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Dept of Internal Medicine, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Tufts University, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|The Linder Center for Resarch and Education at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Memorial Hermann Hospital CRU affiliated with University of Texas Health Science Center at Houston - McGovern Medical School, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03556020
NCT03850782,Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension,,Recruiting,No Results Available,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: Bimatoprost (SR),Retreatment or rescue administered for IOP|Number of patients experiencing a treatment emergent adverse event.,Allergan,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1698-301-007|2018-002574-52,28-Feb-19,17-Jul-23,17-Jul-23,22-Feb-19,,27-Nov-20,"Walman Eye Center, Sun City, Arizona, United States|Atlantis Eyecare, Huntington Beach, California, United States|Lakeside Vision Center, Irvine, California, United States|Southern Califonria Kaiser Permanente, West Los Angeles, Los Angeles, California, United States|Global Research Foundation, Los Angeles, California, United States|Tayani Institute / American Institute of Research, Mission Viejo, California, United States|Eye Research Foundation, Newport Beach, California, United States|Byers Eye Institute, Stanford, Palo Alto, California, United States|Foothill Eye Institute, Pasadena, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Danbury Eye Physicians and Surgeons PC, Danbury, Connecticut, United States|Segal Drug Trials, Inc., Delray Beach, Florida, United States|International Research Center, Tampa, Florida, United States|Specialty Retina Center, Weston, Florida, United States|Thomas Eye Group, P.C., Sandy Springs, Georgia, United States|Indiana University - Glick Eye Institute at Spring Mall, Indianapolis, Indiana, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Clinical Eye Research of Boston, LLC, Winchester, Massachusetts, United States|Kellogg Eye Center, Ann Arbor, Michigan, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Silverstein Eye Center, Kansas City, Missouri, United States|Moyes Eye Center, PC, Kansas City, Missouri, United States|Clinical Research Center of Nevada LLC, Las Vegas, Nevada, United States|Alterman, Modi & Wolter, Poughkeepsie, New York, United States|The Ohio State University Havener Eye Institute, Columbus, Ohio, United States|AMA Eyes Research Institute, Marysville, Ohio, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|Drs. Fine, Hoffman and Sims, LLC, Eugene, Oregon, United States|Vantage EyeCare, LLC, Bala-Cynwyd, Pennsylvania, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Vance Thompson Vision, Sioux Falls, South Dakota, United States|Eye Specialty Group, Memphis, Tennessee, United States|Advanced Vision Research, LLC, Nashville, Tennessee, United States|Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States|Keystone Eye Research, Austin, Texas, United States|Medical Center Opthalmology Associates - Keystone Medical Research, LTD, San Antonio, Texas, United States|Southern Utah Medical Research, Saint George, Utah, United States|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Sliven, MHAT ""Hadzhi Dimitar"", Sliven, Bulgaria|MHAT Dr. Bratan Shukerov, Smolyan, Bulgaria|Medical Center for eye healt ""Focus"" Ltd, Sofia, Bulgaria|Pentagram Eye Hospital, Sofia, Bulgaria|University Hospital - Lozenets, Sofia, Bulgaria|Specialized Hospital for Active Treatment in Ocular Diseases ""Zrenie"", Sofia, Bulgaria|Diagnostic Consultative Center Alexandrovska, Sofia, Bulgaria|St. Sofia Hospital, Sofia, Bulgaria|Mbal-Trakia, Stara Zagora, Bulgaria|Medical Center -Verea, Stara Zagora, Bulgaria|Medical Center Zara - Med, Stara Zagora, Bulgaria|Specialized Ophthalmological Hospital for Active Treatment - Varna, Varna, Bulgaria|FN Hradec Kralove, Hradec Kralove, Czechia|Ocni klinika Pardubice, Pardubice, Czechia|University Hospital Královské Vinohrady, Prague, Czechia|VFN, Prague, Czechia|Rigshospitalet-Glostrup, Glostrup, Denmark|CHU de Bordeaux Hopital Pellegrin, Bordeaux, Gironde, France|CHU Angers, Angers, France|Ophthalmologie, Polyclinique de la Baie, Avranches, France|Clinique Honore Cave, Montauban, France|Universitaetsklinikum Freiburg, Klinik fuer Augenheilkunde, Freiburg, Baden-Württemberg, Germany|Augenzentrum Dr Hamacher, Starnberg, Bavaria, Germany|Städtisches Klinikum Dresden, Augenklinik, Dresden, Germany|Asklepios Augenklink Nord-Heidberg, Hamburg, Germany|Franziskus Hospital Muenster, Munster, Germany|Bugat Pal Hospital, Gyongyos, Heves, Hungary|Jahn Ferenc Dél-pesti Kórház és Rendelőintézet, Budapest, Hungary|Budapest Retina Associates, Budapest, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Royal Victoria Eye and Ear Research Foundation, Dublin, Ireland|Institute of Eye Surgery, Waterford, Ireland|University of Bari Aldo Moro, Bari, Italy|Eye Clinic, University of Catania, Catania, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Fiorini di Terracina, Roma, Italy|Fondazione Bietti - Ospedale Britannico, Rome, Italy|Profesorskie Centrum Okulistyki, Gdańsk, Poland|Gabinet Okulistyczny Edward Wylegala, Katowice, Poland|Medical Center Julianow, Lodz, Poland|Military Institute of Medicine Warsaw, Warsaw, Poland|Pretoria Eye Institute, Pretoria, Gauteng, South Africa|Somerset Eye Specialist Medical & Surgical Centre, Cape Town, South Africa|Dr Lynette Venter, Westdene, South Africa|Norrlands Universitetessjukhus, Umea, Sweden|Mid Essex Hospitals NHS Trust, Cambridge, Cambridgeshire, United Kingdom|Hinchingbrooke Hospital, Huntingdon, Cambridgeshire, United Kingdom|Colchester Eye Centre, Colchester General Hospital, Colchester, Essex, United Kingdom|Birmingham & Midland Eye Center, Birmingham, United Kingdom|Mid-Cheshire Hospitals NHS Trust, Crewe, United Kingdom|Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom|Royal Liverpool Hospital St Paul's Clinical Eye Research Centre, Liverpool, United Kingdom|Kings College Hospital, London, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom|Oxford University Hospitals, Oxford, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT03850782
NCT03496623,A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD),,Recruiting,No Results Available,Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease,Drug: Inhaled treprostinil solution|Drug: Placebo solution,Change from Baseline to Week 12 in 6MWD at Peak Exposure (10 to 60 minutes after Dosing)|Change from Baseline to Week 12 in Moderate to Vigorous Physical Activity (MVPA)|Change from Baseline to Week 12 in Overall Activity|Change from Baseline to Week 12 in Borg Dyspnea Score|Change from Baseline to Week 12 in 6MWD/Borg Dyspnea Composite Score|Change from Baseline to Week 12 in Quality of Life (QOL) Measured by St. George's Respiratory Questionnaire (SGRQ)|Change from Baseline to Week 12 in QOL measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)|Change from Baseline to Week 12 in Plasma Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels|Change from Baseline to Week 12 in Patient Global Assessment (PGA),United Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,314,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RIN-PH-304,27-Jun-18,31-Jul-22,31-Jul-22,12-Apr-18,,14-Dec-20,"The University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Southern California, Los Angeles, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|St. Francis Medical Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Pulmonary Disease Specialists, Kissimmee, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Advocate Aurora Health Care, Elmhurst, Illinois, United States|Advocate Condell Medical Center, Libertyville, Illinois, United States|Advocate Heart Institute & Pulmonology, Normal, Illinois, United States|Edward Heart Hospital, Oakbrook Terrace, Illinois, United States|Indiana University Healh North Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health, Troy, Michigan, United States|Albany Medical College, Albany, New York, United States|The Mount Sinai Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple Lung Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center - Montefiore, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Pulmonary Associates of Richmond, Inc., Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CardioPulmonary Research Center, Guaynabo, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03496623
NCT02507687,Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension,,Recruiting,No Results Available,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: Bimatoprost SR|Drug: Sham Bimatoprost SR|Procedure: Selective Laser Trabeculoplasty|Procedure: Sham Selective Laser Trabeculoplasty,Change from Baseline in IOP at Week 4|Change from Baseline in IOP at Week 12|Change from Baseline in Intraocular Pressure (IOP) at Week 24|IOP change from baseline at Week 8|IOP change from baseline at Week 15|IOP change from baseline at Week 20|Time to initial use of nonstudy IOP-lowering treatment as determined by the investigator|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 4|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 12|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 24|Percentage of SLT eyes achieving ≥ 20% reduction at Week 4|Percentage of SLT eyes achieving ≥ 20% reduction at Week 12|Percentage of SLT eyes achieving ≥ 20% reduction at Week 24,Allergan,All,"18 Years and older   (Adult, Older Adult)",Phase 3,215,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",192024-093|2015-002131-18,27-Aug-15,1-May-23,1-May-23,24-Jul-15,,11-Jan-21,"Trinity Research Group, Dothan, Alabama, United States|Arizona Advanced Eye Research Institute, Glendale, Arizona, United States|Arizona Glaucoma Specialists, Phoenix, Arizona, United States|M&M Eye Institute, Prescott, Arizona, United States|Walman Eye Center, Sun City, Arizona, United States|Acuity Eye Group, Arcadia, California, United States|Orange County Ophthalmology, Garden Grove, California, United States|Specialty Eye Care, Glendale, California, United States|Lugene Eye Institute, Glendale, California, United States|Lakeside Vision Center, Irvine, California, United States|California Eye Specialists Medical Group, Inc., Pasadena, California, United States|North Bay Eye Associates Inc., Petaluma, California, United States|Pacific Eye Associates, San Francisco, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|WCCT Global, Tustin, California, United States|Glaucoma Specialists of South Florida, Delray Beach, Florida, United States|Eye Associates of South West Florida, Fort Myers, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|University of Florida Eye Institute, Jacksonville, Florida, United States|Ocala Eye, P.A., Ocala, Florida, United States|Logan Ophthalmic Research, LLC, Tamarac, Florida, United States|Carol & Frank Morsani Center for Advanced Health Care, Tampa, Florida, United States|Accusite Surgical Services, Duluth, Georgia, United States|Clayton Eye Clinical Research, Morrow, Georgia, United States|Intermountain Eye Centers, Boise, Idaho, United States|Illinois Eye and Ear Infirmary, Chicago, Illinois, United States|Sabates Eye Centers, Leawood, Kansas, United States|Stiles Eyecare and Glaucoma Institute, Overland Park, Kansas, United States|UK HealthCare Kentucky, Lexington, Kentucky, United States|The Eye Care Institute, Louisville, Kentucky, United States|Advanced Glaucoma Specialists, Reading, Massachusetts, United States|Kresge Eye Institute, Detroit, Michigan, United States|Fraser Eye Center, Fraser, Michigan, United States|Huron Ophthalmology P.C., Ypsilanti, Michigan, United States|Midwest Vision Research Foundation/ Pepose Vision Institute, Chesterfield, Missouri, United States|Wellish Vision Institute, Las Vegas, Nevada, United States|Northern New Jersey Eye Institute, PA, South Orange, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Albemarle Clinical Trials, LLC, Elizabeth City, North Carolina, United States|Cornerstone Eye Care, High Point, North Carolina, United States|BaganStrinden Vision, Fargo, North Dakota, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oklahoma Eye Surgeons, Oklahoma City, Oklahoma, United States|Scott & Christie Eye Associates, Cranberry Township, Pennsylvania, United States|Eye Care Specialists, Kingston, Pennsylvania, United States|Family Eye Group, Lancaster, Pennsylvania, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Carolinas Centers for Sight, PC, Florence, South Carolina, United States|Chattanooga Eye Institute, Chattanooga, Tennessee, United States|Keystone Research Ltd., Austin, Texas, United States|Cross Eye Center, Bellaire, Texas, United States|Houston Eye Associates, Houston, Texas, United States|Alkek Eye Center, Houston, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|R and R Eye Research LLC, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Emerson Clinical Research Institute, Falls Church, Virginia, United States|Piedmont Eye Center, Inc., Lynchburg, Virginia, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|Queensland Eye Institute, South Brisbane, Queensland, Australia|Bendigo Eye Clinic, Bendigo, Victoria, Australia|Eye Surgery Associates East Melbourne, East Melbourne, Victoria, Australia|Essendon Eye Clinic, Essendon, Victoria, Australia|Melbourne Eye Specialists, Fitzroy, Victoria, Australia|Geelong Eye Clinic, Geelong, Victoria, Australia|Waverley Eye Clinic, Glen Waverley, Victoria, Australia|Vision Eye Institute, Melbourne, Victoria, Australia|The University of Western Australia - Lions Eye Institute, Crawley, Western Australia, Australia|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|St. Joseph's Hamilton Healthcare Hospital, Hamilton, Ontario, Canada|Ophthalmic Consultant Centres, Mississauga, Ontario, Canada|Institut de loeil des Laurentides, Boisbriand, Quebec, Canada|Clinique d'ophthalmologie Bellvue Montreal, Montreal, Quebec, Canada|Glostrup Hospital, Glostrup, Denmark|SA IVKH, Kohtla-Jarve, Estonia|East-Tallinn Central Hospital, Tallinn, Estonia|O Dr Kai Noor Silmakabinet, Tallinn, Estonia|Eye Clinic dr. Krista Turman, Tallinn, Estonia|Eye Clinic of Tartu University Hospital, Tartu, Estonia|Charité Universitätsmedizin Berlin, Berlin, Germany|Internationale Innovative Ophthalmochirurgie, Dusseldorf, Germany|Klinik und Poliklinik fuer Augenheilkunde, Greifswald, Germany|Universitaetsaugenklinik, Magdeburg, Germany|Universitaetsaugenklinik LMU, Munchen, Germany|Universitaets-Augenklinik, Munster, Germany|Universitat Augenklinik, Ulm, Germany|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Galilee Medical Center, Nahariyya, Israel|The Rabin Medical Center, Petach Tiqva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Medical Centre, Tel Aviv, Israel|Southern Eye Specialists, Christchurch, Canterbury S, New Zealand|Auckland Eye Limited, Remuera, New Zealand|Capital Eye Specialist - Wellington, Wellington, New Zealand|Asian Eye Institute, Makati City, Metro Manila, Philippines|Peregrine Eye and Laser Institute, Makati City, Metro Manila, Philippines|Asian Eye Center, Makati City, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines|Centrum Diagnostykii Mikrochirurgii Oka LENS ul., Olsztyn, Poland|S..Fyodorov Eye Microsurgery Federal State Institution, Novosibirsk, Russian Federation|Clinical ophthalmology hospital n.a. V.P. Vihodtsev, Omsk, Russian Federation|Samara State Medical University, Samara, Russian Federation|Queen Elisabeth Hospital Birmingham, Birmingham, United Kingdom|Sussex Eye Hospital, Brighton, United Kingdom|Bristol Eye Hospital, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom|Moorfields Eye hospital, London, United Kingdom|Western Eye Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom|Salisbury NHS foundation trust, Salisbury, United Kingdom|Queen Mary's Hospital Sidcup, Sidcup, United Kingdom|Epsom & St Helier University Hospitals NHS Trust, Sutton, United Kingdom|York teaching Hospital NHS Foundation Trust, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT02507687
NCT03630211,Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis,SSc,Recruiting,No Results Available,Systemic Sclerosis|Diffuse Sclerosis Systemic|Interstitial Lung Disease|Pulmonary Hypertension,Drug: Cyclophosphamide|Drug: Mesna|Drug: Rituximab|Drug: Alemtuzumab|Drug: Thiotepa|Drug: GM-CSF|Drug: Intravenous immunoglobulin|Radiation: Total Body Irradiation,High Dose Immunoablative therapy-Safety|Death|Respiratory Failure|Renal Failure|The occurrence of cardiomyopathy|Treatment-related mortality (TRM)|High Dose Immunoablative therapy-Treatment Effect|An increase of mRSS (modified Rodnan skin score ) by ≥5 points for skin score|Increase by ≥25% if the baseline mRSS > 20.|Worsening of > 10% of FVC (pulmonary function testing)|Decrease in DLCO sustained for 3 months or longer on pulmonary function tests (PFT)|Worsening of cardiac involvement|Development of scleroderma renal crisis (hypertensive or non-hypertensive),Paul Szabolcs|University of Pittsburgh,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO18050360,31-Jul-18,1-Aug-23,1-Aug-25,14-Aug-18,,27-Nov-20,"Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03630211
NCT03816462,ReNEW Clinic Cohort Study,ReNEW,Recruiting,No Results Available,Hypertension|Prehypertension|Obesity|Overweight|Left Ventricular Hypertrophy|Elevated Blood Pressure,,Demographic and clinical data obtained via chart review,Johns Hopkins University,All,"up to 22 Years   (Child, Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB00056175,Jan-15,Sep-25,Sep-25,25-Jan-19,,11-Jan-21,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03816462
NCT04439370,Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women,,Recruiting,No Results Available,"Hypertension|Menopause, Premature|Menopause|Blood Pressure",Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA)|Diagnostic Test: Baroreflex sensitivity testing|Diagnostic Test: Sympathoexcitatory Maneuvers|Diagnostic Test: Blood tests,Muscle Sympathetic Nerve Activity (MSNA) (bursts per minute)|Muscle Sympathetic Nerve Activity (MSNA) (bursts/100 heart beats)|Cardiac baroreflex sensitivity|Sympathetic baroreflex sensitivity|Systolic Blood Pressure (mmHg)|Diastolic Blood Pressure (mmHg)|Mean Arterial Blood Pressure (mmHg)|Heart Rate (beats/min)|Respiratory Rate (breaths/min)|Heart Rate Variability (frequency)|Heart Rate Variability (time)|Borg Rating of Perceived Exertion|Numerical Pain Scale Rating|Blood Levels: Estrogens-E1|Blood Levels: Estrogen-E2|Blood Levels: Progesterone|Blood Levels: Testosterone|Blood Levels: Follicle-Stimulating Hormone (FSH)|Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO)|Cold Pressor Test,University of Minnesota,Female,"35 Years to 70 Years   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STUDY00007978,1-Oct-19,1-Jan-23,1-Jan-23,19-Jun-20,,19-Jun-20,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04439370
NCT03325426,Activity Trackers for Improving BP,,Recruiting,No Results Available,Hypertension|Cardiovascular Risk Factor|Physical Activity|Chronic Kidney Diseases,Device: FitBit,Change in mean office systolic and diastolic BP|Enrollment numbers|Weight change,"University of California, San Francisco",All,"8 Years to 30 Years   (Child, Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,16-18605,1-Jun-17,1-Jun-21,1-Aug-21,30-Oct-17,,27-Aug-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03325426
NCT02386293,Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans,Avapro3,Recruiting,No Results Available,"Hypertension|Obesity|Stress, Psychological|Blood Pressure",Drug: Irbesartan|Other: Placebo,Urinary sodium excretion rate|Hemodynamics,Augusta University,All,18 Years to 50 Years   (Adult),Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",611881,Apr-14,30-Nov-19,30-Nov-19,11-Mar-15,,21-Jun-19,"Augusta University, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02386293
NCT04021355,Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans,,Recruiting,No Results Available,Obesity|Hypertension|Circadian Dysregulation|Salt; Excess,Other: Oral sodium supplementation,"24-hour blood pressure|Core Body Temperature|Timing of plasma melatonin increase under dim-light conditions (dim-light melatonin onset)|24-hour urinary sodium excretion|Buccal cell clock gene expression (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2)|Concentrations of plasma melatonin|Concentrations of plasma cortisol|Peripheral blood monocyte clock gene (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2) expression|Flow cytometric analysis of circulating immune cells (CD3+, CD4+, CD8+, CD14+, CD45+)|Concentrations of plasma and urine endothelin 1|Concentrations of plasma and urine aldosterone|Concentrations of plasma vasopressin|Concentrations of plasma cytokine (TNA-alpha, IL-1, IL-6, IL-12, IL-17, IL-18, IL-23, IL-10, TGB-beta)",University of Alabama at Birmingham,All,25 Years to 45 Years   (Adult),Not Applicable,55,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB-300003394,1-Sep-20,30-Mar-24,31-Jul-24,16-Jul-19,,26-Oct-20,"University of Alabama, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04021355
NCT03895580,Supermarket and Web-Based Intervention Targeting Nutrition (SuperWIN) for Cardiovascular Risk Reduction,SuperWIN,Recruiting,No Results Available,Obesity|Hypertension|Hyperlipidemias|Diet Modification,Other: In-store POP education|Other: Online POP education,Dietary Approaches to Stop Hypertension (DASH) score|Systolic arterial blood pressure|Body weight|Low-density lipoprotein cholesterol (LDL-C)|Waist circumference|Triglycerides|Food literacy|Quality of food purchases|Dietitian experience and feedback|Participant experience and feedback,"University of Cincinnati|The Kroger Company|Children's Hospital Medical Center, Cincinnati",All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20168163,18-Mar-19,Apr-21,Jun-21,29-Mar-19,,14-Aug-20,"University of Cincinnati Medical Center - UC Health, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03895580
NCT03748420,Medication Adherence Clinical Decision Support,ADH Wizard,Recruiting,No Results Available,Hyperlipidemia|Hypertension|Diabetes|Medication Nonadherence,Other: Adherence-enhanced clinical decision support|Behavioral: ReachOut Adherence intervention,Change in blood pressure medication adherence|Change in blood pressure control|Change in non-insulin glycemic medication adherence|Change in glycemic control|Change in statin medication adherence|Cost of the intervention|Long-term Health Impact|Long-term cost-effectiveness,"HealthPartners Institute|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,2812,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,A16-691|1R01HL136937-01A1,19-Aug-20,Apr-22,Jul-22,20-Nov-18,,24-Aug-20,"HealthPartners Care System, Bloomington, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03748420
NCT02646475,Metabolic Effects of Angiotensin-(1-7),,Recruiting,No Results Available,Obesity|Insulin Resistance|Hypertension|Metabolic Cardiovascular Syndrome,Drug: Angiotensin-(1-7)|Drug: Saline,Whole-Body Insulin Sensitivity|Blood Pressure|Heart Rate|Cardiac Output|Stroke Volume|Systemic Vascular Resistance,Vanderbilt University|Vanderbilt University Medical Center,All,18 Years to 60 Years   (Adult),Phase 1,19,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",151699,Feb-16,Dec-21,Dec-21,5-Jan-16,,11-Jan-21,"Vanderbilt University School of Medicine, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02646475
NCT04676399,Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction,PASSION,Not yet recruiting,No Results Available,Chronic Pain|Hypertension|Diuretics Drug Reactions|SCS,Drug: Hydrochlorothiazide 12.5mg|Drug: Placebo,Change in Blood Pressure Measurement From Visit 1 to Visit 2|Change in Blood Pressure Measurement From Visit 2 to Visit 3|Change in Blood Pressure Measurement From Visit 3 to Visit 4|Change in Blood Pressure Measurement From Visit 4 to Visit 5|Change from Visit 1 PainDETECT Questionnaire to Visit 2|Change from Visit 2 PainDETECT Questionnaire to Visit 3|Change from Visit 3 PainDETECT Questionnaire to Visit 4|Change from Visit 4 PainDETECT Questionnaire to Visit 5|Visit 1 Catecholamines( Norepinephrine) & Tumor necrosis factor-alpha (TNF-α) and interlukin-6 (IL6) Blood Work|Visit 1 Lipid Panel Blood Work Results|Visit 1 Comprehensive Metabolic Panel Blood Work Results|Visit 1 Stored Plasma Blood Work Results|Visit 2 Comprehensive Metabolic Panel/Electrolyte Check Blood Work Results|Visit 3 Comprehensive Metabolic Panel/Electrolyte Check Blood Work Results|Visit 4 Comprehensive Metabolic Panel/Electrolyte Check Blood Work Results|Visit 5 Comprehensive Metabolic Panel/Electrolyte Check Blood Work Results|Visit 5 Lipid Panel Blood Work Results|Visit 5 Stored Plasma Blood Work Results|Visit 5 Catecholamines( Norepinephrine) & Tumor necrosis factor-alpha (TNF-α) and interlukin-6 (IL6) Blood Work,University of Kansas Medical Center,All,"30 Years to 89 Years   (Adult, Older Adult)",Early Phase 1,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",146604,Dec-20,Dec-22,Dec-22,21-Dec-20,,21-Dec-20,"University of Kansas Clinical and Translational Science Unit (CTSU), Fairway, Kansas, United States|The Marc A. Asher Comprehensive Spine Center at the Kansas University Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04676399
NCT02185417,Diuretic Comparison Project,DCP,Recruiting,No Results Available,Hypertension,Drug: Hydrochlorothiazide (HCTZ)|Drug: Chlorthalidone,Time to major cardiovascular event|Time to event for each component of the composite primary outcome and additional cardiovascular events|All Deaths|Urgent revascularization because of unstable angina|Hospitalization for acute congestive heart failure|Non-cancer death|The primary composite outcome substituting 'all deaths' for 'non-cancer deaths'|Possibly Vascular Deaths|The primary composite outcome substituting 'possibly vascular deaths' for 'non-cancer deaths'|Any revascularization of any artery|Erectile dysfunction (ED),VA Office of Research and Development,All,65 Years and older   (Older Adult),Phase 3,13500,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,597,15-Jun-16,15-Oct-22,15-Apr-23,9-Jul-14,,11-Dec-20,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Alaska VA Healthcare System, Anchorage, AK, Anchorage, Alaska, United States|Veterans Health Care System of the Ozarks, Fayetteville, AR, Fayetteville, Arkansas, United States|Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States|VA Central California Health Care System, Fresno, CA, Fresno, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Grand Junction VA Medical Center, Grand Junction, CO, Grand Junction, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|Wilmington VA Medical Center, Wilmington, DE, Wilmington, Delaware, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|VA Pacific Islands Health Care System, Honolulu, HI, Honolulu, Hawaii, United States|Boise VA Medical Center, Boise, ID, Boise, Idaho, United States|VA Illiana Health Care System, Danville, IL, Danville, Illinois, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|VA Central Iowa Health Care System, Des Moines, IA, Des Moines, Iowa, United States|Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States|Maine VA Medical Center, Augusta, ME, Togus, Maine, United States|Rehabilitation R&D Service, Baltimore, MD, Baltimore, Maryland, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|St. Cloud VA Health Care System, St. Cloud, MN, Saint Cloud, Minnesota, United States|VA Gulf Coast Veterans Health Care System, Biloxi, MS, Biloxi, Mississippi, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States|Manchester VA Medical Center, Manchester, NH, Manchester, New Hampshire, United States|New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States|Albany VA Medical Center Samuel S. Stratton, Albany, NY, Albany, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Syracuse VA Medical Center, Syracuse, NY, Syracuse, New York, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States|Fargo VA Healthcare System, Fargo, ND, Fargo, North Dakota, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Jackson C. Montgomery VA Medical Center, Muskogee, OK, Muskogee, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Roseburg Healthcare System, Roseburg, OR, Roseburg, Oregon, United States|VA Southern Oregon Rehabilitation Center and Clinics, White City, OR, White City, Oregon, United States|Coatesville VA Medical Center, Coatesville, PA, Coatesville, Pennsylvania, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Wilkes-Barre VA Medical Center, Wilkes-Barre, PA, Wilkes-Barre, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia, South Carolina, United States|VA Black Hills Health Care System Fort Meade Campus, Fort Meade, SD, Fort Meade, South Dakota, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States|Hampton VA Medical Center, Hampton, VA, Hampton, Virginia, United States|Huntington VA Medical Center, Huntington, WV, Huntington, West Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States|Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States|Tomah VA Medical Center, Tomah, WI, Tomah, Wisconsin, United States|Sheridan VA Medical Center, Sheridan, WY, Sheridan, Wyoming, United States|VA Caribbean Healthcare System, San Juan, PR, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02185417
NCT03727451,A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis,,Recruiting,No Results Available,"Pulmonary Hypertension|Pulmonary Fibrosis|Sarcoidosis, Pulmonary",Combination Product: iNO,Measurement of mean PAP|Measurement of PCWP|Measurement of PVR|Measurement of CO|Change in 6MWD from Baseline to 16 Weeks|Incidence and Severity of Treatment Emergent Adverse Events|Pulmonary Rebound|Distance Saturation Product (DSP)|Dyspnea|Quality of Life Assessment|Incidence of Adverse Events and Serious Averse Events|Integral Distance Saturation Product (IDSP),Bellerophon,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PULSE-PHPF-002,30-Jan-19,Feb-21,Dec-21,1-Nov-18,,12-Jan-21,"University of Miami, Miami, Florida, United States|University of Cincinnati, Cincinnati, Ohio, United States|Temple University, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Inova Heart and Lung Vascular Institute, Falls Church, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03727451
NCT00001853,Diabetes and Heart Disease Risk in Blacks,,Recruiting,No Results Available,Cardiovascular|Diabetes|Obesity|Hypertension,,Diabetes and Heart Disease Risk,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",,1132,NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,990002|99-DK-0002,21-Oct-98,,,4-Nov-99,,14-Dec-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001853
NCT03697811,DE-117 Spectrum 5 Study,,Recruiting,No Results Available,Primary Open-angle Glaucoma and Ocular Hypertension,Drug: DE-117 Ophthalmic Solution,Intraocular pressure,Santen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,011711IN,27-Sep-18,31-Dec-20,31-Dec-20,5-Oct-18,,10-Jan-20,"Arizona Eye Center, Chandler, Arizona, United States|Global Research Management, Glendale, California, United States|North Valley Eye Medical Group, Mission Hills, California, United States|Eye Research Foundation, Newport Beach, California, United States|North Bay Eye Associates, Petaluma, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Danbury Eye Physicians & Surgeons, Danbury, Connecticut, United States|Shettle Eye Research, Inc., Largo, Florida, United States|International Eye Associates, PA, Ormond Beach, Florida, United States|Dixon Eye Care, Albany, Georgia, United States|Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States|Coastal Research Associates, LEC, Roswell, Georgia, United States|Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Comprehensive Eye Care Ltd, Washington, Missouri, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|South Shore Eye Center, Wantagh, New York, United States|Asheville Eye Associates, PLLC, Asheville, North Carolina, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Cornerstone Health Care, High Point, North Carolina, United States|Apex Eye Clinical Research, LLC, Cincinnati, Ohio, United States|Abrams Eye Center, Cleveland, Ohio, United States|The Eye Institute, Tulsa, Oklahoma, United States|Scott & Christie and Associates PC, Cranberry Township, Pennsylvania, United States|Glaucoma Consultants and Center for Eye Research, PA, Mount Pleasant, South Carolina, United States|Total Eye Care PA, Memphis, Tennessee, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Nashville Vision Associates, Nashville, Tennessee, United States|Texas Eye, PA, Austin, Texas, United States|Eye Clinic of Texas, League City, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03697811
NCT04639947,Reliability and Reproducibility of the Eye Check Tonometer,EyeCheck,Recruiting,No Results Available,"Glaucoma|Glaucoma, Suspect",Device: EyeCheck|Device: Traditional Tonometer (Goldmann and Tonopen),Intraocular pressure (IOP) measurements,Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Pro00106897,6-Jan-21,Jul-21,Jul-21,23-Nov-20,,13-Jan-21,"Duke Eye Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04639947
NCT04709679,Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation,,Recruiting,No Results Available,Glaucoma,Procedure: MicroPulse TransScleral CycloPhotoCoagulation,Changes in intraocular pressure measurements between baseline and postoperative followup visits|Changes in visual acuity measurements measured using a Snellen Vision Chart between baseline and postoperative followup visits|Changes in number of medications between baseline and postoperative followup visits|Rate of post surgical complications,State University of New York at Buffalo|IRIDEX Corporation,All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00003149,1-Jan-21,Jan-24,Jan-24,14-Jan-21,,14-Jan-21,"The Ira G. Ross Eye Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04709679
NCT04676126,Augmented Macular Pigment-containing Nutraceutical and Central Visual Function,,Not yet recruiting,No Results Available,"Glaucoma|Glaucoma Eye|Glaucoma, Open-Angle",Dietary Supplement: Lumega-Z|Drug: Dorzolamide Hcl 2% Oph Soln|Other: Placebo,Pericentral Visual Function|Macular Pigment Optical Density|Dermal Carotenoid Levels|Contrast Sensitivity,"University of the Incarnate Word|Guardion Health Sciences, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,24,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",20-11-005,Jan-21,Jul-21,Jan-22,19-Dec-20,,19-Dec-20,"Ophtalmology Clinic of William E Sponsel, San Antonio, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04676126/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04676126/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04676126
NCT04542616,Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma,B350vsCP250,Recruiting,No Results Available,Glaucoma,Device: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation,Change in intraocular pressure,State University of New York at Buffalo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STUDY00004680,13-Aug-20,31-Aug-23,31-Aug-24,9-Sep-20,,9-Sep-20,"The Ira G. Ross Eye Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04542616
NCT04468633,The Baerveldt Versus ClearPath Comparison Study,,Not yet recruiting,No Results Available,Glaucoma,Device: Baerveldt 350 implant|Device: Ahmed ClearPath 350 implant,"Change in intraocular pressure (IOP)|Complication rate|Change in Best corrected visual acuity (BCVA)|Change in number of individual eyedrop medications that the patient is on (prescribed and actually taking)|Change in Slit lamp exam (SLE) findings|Change in Dilated fundus exam (DFE)|Change in Humphrey visual field (HVF)|Change in Ocular coherence tomography (OCT)|Change in Pachymetry|Change in Motility exam (9 gaze photos)|Change in Motility exam (stereo test)|Change in Motility exam (Worth 4-dot)|Change in Motility exam (Hess Screen Test)|Change in Self-report Dysesthesia Scale questionnaire|Quality of life, as measured by glaucoma utility index|Quality of life, as measured by glaucoma symptom scale|Quality of life, as measured by glaucoma related quality of life 15 questionnaire",Duke University,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,304,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PRO00105781,Nov-20,1-Aug-23,1-Aug-23,13-Jul-20,,25-Sep-20,"Duke Eye Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04468633
NCT02439775,SPYRAL HTN-ON MED Study,,Recruiting,No Results Available,Hypertension|Vascular Diseases|Cardiovascular Diseases,Device: Symplicity Spyral™ multi-electrode renal denervation system|Procedure: Sham Procedure,Acute and chronic safety by evaluating incidence of Major Adverse Events|Change in systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)|Change in systolic blood pressure as measured by 24-hour ABPM|Change in diastolic blood pressure as measured by 24-hour ABPM|Change in office systolic blood pressure|Change in office diastolic blood pressure|Incidence of achieving target office systolic blood pressure|Significant embolic event resulting in end-organ damage|Renal artery perforation requiring intervention|Renal artery dissection requiring intervention|Vascular complications|End-stage renal disease|≥40% decline in eGFR|New myocardial infarction|New stroke|Renal artery re-intervention|Major bleeding according to TIMI definition|Increase in serum creatinine > 50%|New renal artery stenosis > 70%|Hospitalization for hypertensive crisis not related to confirmed nonadherence with medications or the protocol|All-cause mortality,Medtronic Vascular,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,340,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SPYRAL HTN-ON MED,Jul-15,Oct-21,Jul-25,12-May-15,,8-Oct-20,"Heart Center Research, LLC, Huntsville, Alabama, United States|Stanford Hospital and Clinics, Stanford, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Washington DC VA Medical Center, Washington, District of Columbia, United States|Baptist Medical Center Jacksonville, Jacksonville, Florida, United States|Memorial Hospital Jacksonville, Jacksonville, Florida, United States|Tallahassee Research Institute, Tallahassee, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Iowa Heart Center, West Des Moines, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|St Joseph Mercy Oakland, Pontiac, Michigan, United States|Providence Hospital, Southfield, Michigan, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Cardiology Associates Research LLC, Tupelo, Mississippi, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Saint Barnabus Medical Center, Livingston, New Jersey, United States|North Shore University Hospital, Manhasset, New York, United States|Weill Cornell Medical College/The New York Presbyterian Hospital, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|PinnacleHealth Cardiovascular Institute, Harrisburg, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|AnMed Health, Anderson, South Carolina, United States|Centennial Medical Center, Nashville, Tennessee, United States|Baylor Heart & Vascular Hospital, Dallas, Texas, United States|Charleston Area Medical Center, Charleston, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Alfred Hospital, Melbourne, Victoria, Australia|St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|St. George Hospital, Kogarah, Australia|Royal Perth, Perth, Australia|Klinikum Wels-Grieskirchen, Wels, Austria|Hamilton Heath, Hamilton, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Clinique Pasteur, Toulouse, France|Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH, Bad Krozingen, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Herzzentrum Leipzig, Universitätsklinik, Leipzig, Germany|Sana Kliniken Lübeck, Lübeck, Germany|Hippokration General Hospital of Athens, Athens, Greece|University General Hospital of Thessaloniki (AHEPA), Thessaloniki, Greece|Galway University Hospital, Galway, Ireland|Higashi Takarazuka Satoh Hospital, Takarazuka, Hyogo, Japan|Shonan Kamakura General Hospital, Kamakura City, Okamoto, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Mitsui Memorial Hospital, Chiyoda, Tokyo, Japan|Saiseikai Nakatsu Hospital, Osaka, Japan|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Cardiff and Vale University Health Board - University Hospital of Wales, Cardiff, United Kingdom|Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02439775
NCT04421859,Augmented Reality Mobile Application for Glaucoma Education in the South Bronx,,Recruiting,No Results Available,Glaucoma,Other: EyeCU Mobile Application,Change in Questionnaire Scores|Change in Follow Up Adherence|Change in Medication Adherence,Bronx-Lebanon Hospital Center Health Care System|EyeCU Group|VISRE,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,11141902,1-Jan-20,1-Dec-20,30-Jun-21,9-Jun-20,,9-Jun-20,"BronxCare Health System, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04421859
NCT04396002,"Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults",,Recruiting,No Results Available,Primary Open Angle Glaucoma,Diagnostic Test: Life Space Questionnaire|Diagnostic Test: Low Luminance Questionnaire|Diagnostic Test: Contrast sensitivity under dim illumination|Diagnostic Test: Visual field under dim illumination (MAIA)|Diagnostic Test: Macular Pigment Optical Density (MPOD)|Diagnostic Test: Dark Adaptation,Assessment of life space measured with the Life Space Questionnaire|Assessment of vision under low luminance conditions|Differences in contrast sensitivity functions between controls and patients|Differences in dark adaptation between controls and patients|Differences in visual sensitivity under dim illumination between controls and patients|Differences in Macular Pigment Optical Density between controls and patients|Assessment of the relationship between each the measure of visual function and life space|Assessment of the relationship between each the measure of visual function and self-reported visual function under dim illumination,University of Alabama at Birmingham,All,"18 Years to 100 Years   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,300001552,1-Jun-19,30-May-21,30-May-22,20-May-20,,20-May-20,"University of Alabama Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04396002
NCT04178863,CATS Tonometer IOP Reduction Latanoprost Verses Timolol,,Recruiting,No Results Available,Glaucoma; Drugs,Device: CATS Tonometer|Drug: Latanoprost,IOP reduction,"Intuor Technologies, Inc.",All,"18 Years to 101 Years   (Adult, Older Adult)",Phase 4,72,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2019004,1-Jul-18,30-Dec-19,30-Dec-19,26-Nov-19,,26-Nov-19,"Arizona Eye Consultants, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04178863
NCT04007276,"The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients",,Not yet recruiting,No Results Available,"Glaucoma|Glaucoma, Open-Angle|Glaucoma; Drugs|Droopy Eyelid|Ptosis|Glaucoma, Primary Open Angle",Drug: brimonidine tartrate ophthalmic solution 0.025%|Other: sterile balanced saline solution,Ocular redness|Intraocular pressure|Palpebral fissure height|Eye discomfort,Tulane University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Lumify Study,10-Nov-25,1-Jun-30,1-Jun-35,5-Jul-19,,21-Dec-20,"Tulane University Medical Center, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04007276
NCT03959592,Macular Pigment and Visual Performance in Glaucoma Patients,,Recruiting,No Results Available,Glaucoma,"Drug: Lutein, zeaxanthin and mesozeaxanthin|Other: Placebo",Change in the Contrast sensitivity|Change in the Macular pigment optical density|Change in the Speed of dark adaptation|Change in Vision in glare|Change in the quality of life by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25)|Visual field assessment|Change in the Point-spread function,"Felipe Medeiros, MD|Heidelberg Engineering GmbH|MacuHealth LP|Industrial Orgánica S.A. de C.V.|Duke University",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",Pro00093041,21-Aug-19,Dec-20,Jan-21,22-May-19,,16-Dec-20,"Duke University Eye Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03959592
NCT03894631,Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure,,Recruiting,No Results Available,Glaucoma,Procedure: KDB/Phacoemulsification|Procedure: Trabectome/Phacoemulsification,Changes in intraocular pressure measurements between baseline and postoperative followup visits|Changes in visual acuity measurements measured using a Snellen Vision Chart between baseline and postoperative followup visits|Changes in number of medications between baseline and postoperative followup visits|Rate of post surgical complications,State University of New York at Buffalo,All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00002910,6-Mar-19,31-Jan-23,31-Jan-23,28-Mar-19,,31-Aug-20,"The Ira G. Ross Eye Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT03894631
NCT03804684,visuALL Field Analyzer (vFA) Compared to Standard Automatic Perimetry,,Recruiting,No Results Available,"Glaucoma, Open-Angle",Diagnostic Test: Standard Automatic Perimetry Humphrey Field Analyzer|Diagnostic Test: visuALL Field Analyzer,Retinal sensitivity at each location|Mean retinal sensitivity at each quadrant|Mean retinal sensitivity at each hemifield|Mean retinal sensitivity,"Wills Eye|Olleyes, Inc.",All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB Control #18-768E,8-Jan-19,20-Oct-20,31-May-21,15-Jan-19,,2-Nov-20,"Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03804684
NCT03797469,Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin),,Recruiting,No Results Available,"Visual Field Defect, Peripheral|Glaucoma, Open-Angle",Dietary Supplement: Vitamin B3|Dietary Supplement: Pyruvate|Dietary Supplement: Placebo,Change in 24-2 visual field test|Change in Montreal Cognitive Assessment (MoCA) scores,Columbia University,All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",AAAR8208,15-Apr-19,31-Mar-20,31-Mar-20,9-Jan-19,,27-Jan-20,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03797469
NCT03715231,NIDEK Gonioscope GS-1 for Glaucoma,,Recruiting,No Results Available,Glaucoma,Diagnostic Test: NIDEK Gonioscope GS-1|Diagnostic Test: Standard Digital Gonioscopic Images,Inter-Observer Repeatability for NIDEK Gonioscope GS-1|Inter-Observer Repeatability for Standard Digital Gonioscopic images,NYU Langone Health,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,18-00429,12-Jun-19,Dec-21,Dec-21,23-Oct-18,,12-Nov-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03715231
NCT03675412,Caffeine Consumption in Glaucoma Patients and Healthy Subjects,,Recruiting,No Results Available,"Glaucoma, Primary Open Angle",Dietary Supplement: Caffeine tablet,Blood flow change in back of eye before and after caffeine,Wills Eye,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB#18-729,30-Dec-18,30-Dec-20,30-Jun-21,18-Sep-18,,5-Feb-20,"Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03675412
NCT03639870,"Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma",,Recruiting,No Results Available,Glaucoma,Device: Model iS3 three-stent trabecular micro-bypass system,Primary effectiveness endpoint,Glaukos Corporation,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,65,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INFI-106-G2W3 (GC-011),10-Jul-18,Sep-21,Sep-21,21-Aug-18,,8-Mar-19,"Glaucoma Associates of Tx, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03639870
NCT03506568,A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications,,Recruiting,No Results Available,Medication Adherence|Glaucoma,Device: Devers Drop Device (D3) app|Device: Smart phone calendar app,Compliance percentage|Patient Satisfaction,Universal Adherence LLC|National Institutes of Health (NIH)|Oregon State University|National Eye Institute (NEI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Industry|NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,UniversalAdherence|1R41EY028807-01,2-Oct-20,1-Mar-21,1-Mar-21,24-Apr-18,,8-Oct-20,"Robert Kinast, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03506568
NCT03402802,Steroid Eyedrop Adherence After Trabeculectomy,,Recruiting,No Results Available,"Glaucoma|Adherence, Patient",Drug: monitoring of adherence with medication,adherence rate,Johns Hopkins University,All,"21 Years to 100 Years   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB00160532,1-Sep-19,Apr-22,Apr-22,18-Jan-18,,11-Sep-20,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03402802
NCT02157025,A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics,,Recruiting,No Results Available,"Glaucoma, Suspect|Optic Nerve Hypoplasia and Abnormalities of the Central Nervous System|Congenital Coloboma of the Optic Nerve|Optic Nerve Head Pits, Bilateral Congenital",Device: Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|Other: Usual Care procedures during Humphrey perimetry for children,Humphrey Visual Field Test-Retest Variability of Mean Deviation scores (dB)|Humphrey Visual Field Reliability Indices and Ratings,Nova Southeastern University,All,5 Years to 8 Years   (Child),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,KID_VF,Feb-15,Dec-20,Dec-20,5-Jun-14,,10-Feb-20,"Kids in Distress Clinic of The Eye Care Institute, Fort Lauderdale, Florida, United States",,https://ClinicalTrials.gov/show/NCT02157025
NCT03188042,A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma,,Recruiting,No Results Available,Glaucoma,Device: rtACS Stimulation|Device: Sham Intervention,"Change in Optical coherence tomography (OCT)|Change in OCT angiography|Change in Magnetic resonance imaging (MRI)|Change in Visual acuity|Change in Contrast sensitivity|Change in Score on Assessment of Life Habits (LIFE-H), short form 3.1|Change in score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)|Change in score on 36-Item Short Form Survey (SF-36)",NYU Langone Health,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16-02005,14-Dec-17,Mar-22,Mar-22,15-Jun-17,,8-May-20,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03188042
NCT03159481,Glaucoma Management Optimism for African Americans Living With Glaucoma,GOAL,Recruiting,No Results Available,Glaucoma,Behavioral: Usual Care + Health Promotion Intervention,Change in medication rate adherence via an electronic dosing aid|Knowledge of glaucoma management|Glaucoma symptoms|Health beliefs and illness perception|Social problem-solving skills|Depressive symptomatology,University of Alabama at Birmingham,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,9070592,13-Jul-18,31-Aug-21,31-Aug-21,18-May-17,,9-Oct-19,"UAB, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT03159481
NCT02862158,Frequency Doubling Technology (FDT) Mobile Visual Field Testing,,Recruiting,No Results Available,Glaucoma,Device: FDT visual field|Device: Standard HVF,Pattern of visual field loss in FDT visual fields as compared with standard HVF|Mean deviation (MD) in FDT visual fields as compared with standard HVF|Pattern standard deviation (PSD) in FDT visual fields as compared with standard HVF,University of Miami,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,20150968,Aug-16,Nov-22,Nov-22,10-Aug-16,,30-Oct-20,"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02862158
NCT02852057,Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses,,Recruiting,No Results Available,Glaucoma,Drug: timolol maleate and dorzolamide hydrochloride,IOP,University of Florida,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB201602390|OCR19613,18-Jan-18,Oct-20,Oct-20,2-Aug-16,,25-Nov-19,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02852057
NCT02390284,Stop Retinal Ganglion Cell Dysfunction Study,STOP-RGCD,Recruiting,No Results Available,Glaucoma,Drug: Latanoprost|Drug: Bimatoprost|Drug: Travoprost|Drug: Timolol|Drug: Dorzolamide|Drug: Brinzolamide|Drug: Acetazolamide|Drug: Methazolamide,Change in retinal nerve fiber layer thickness|Change in Pattern Electroretinogram Amplitude|Change in Pattern Electroretinogram Phase,University of Miami|National Eye Institute (NEI),All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,500,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20140587|R01EY014957,Sep-15,Jul-24,Jul-24,17-Mar-15,,10-Nov-20,"Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02390284
NCT01957267,Functional and Structural Imaging for Glaucoma,FSOCT,Recruiting,No Results Available,Glaucoma,,Measure of retinal non-perfusion areas in mm2|Measure vessel density in percentage (%)|Determine accuracy of sector visual field progression in OCT-based sector visual field simulation compared to actual visual field results. Measured in dB change over time.,Oregon Health and Science University|National Eye Institute (NEI),All,"40 Years to 85 Years   (Adult, Older Adult)",,160,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,OHSU IRB #00009729|1R01EY023285,Sep-13,Dec-23,Dec-23,8-Oct-13,,7-Jul-20,"Oregon Health & Science University, Casey Eye Institute, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01957267
NCT01931904,Eye Pressure Lowering Surgery,IOP,Recruiting,No Results Available,Glaucoma,,Effects of Intraocular Pressure (IOP) Reduction on Ocular Perfusion,Oregon Health and Science University|National Eye Institute (NEI),All,"18 Years to 80 Years   (Adult, Older Adult)",,46,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB000009745|1R01EY023285,Feb-14,Dec-23,Dec-23,30-Aug-13,,9-Apr-20,"OHSU, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01931904
NCT04402645,Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension,,Recruiting,No Results Available,"Pulmonary Hypertension|Infant, Premature",,Diagnostic test characteristics calculated for TAPSE and PAAT against diagnosis of chronic pulmonary hypertension on standard diagnostic assessment|Composite of Death/ Chronic Neonatal Lung Disease|Duration of need for respiratory support|Length of hospital stay,"Mount Sinai Hospital, Canada|Sunnybrook Health Sciences Centre|Liverpool Women's NHS Foundation Trust|The Rotunda Hospital|University of Iowa|BC Women's Hospital & Health Centre",All,"Child, Adult, Older Adult",,350,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-0111-E,31-Aug-17,Dec-21,Feb-22,27-May-20,,13-Nov-20,"University of Iowa Health Care, Iowa City, Iowa, United States|BC Women's Hospital & Health Centre, Vancouver, British Columbia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Rotunda Hospital, Dublin, Ireland|Liverpool, Liverpool, United Kingdom",,https://ClinicalTrials.gov/show/NCT04402645
NCT03749746,Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia,HH4NM,Recruiting,No Results Available,Preeclampsia|Gestational Hypertension|Hypertension|Obesity|Overweight and Obesity|Pregnancy Complications|Pregnancy Toxemia|Postpartum Preeclampsia,Behavioral: Home Blood Pressure Monitoring|Behavioral: Heart Health 4 New Moms|Other: Usual care,Weight loss|Systolic blood pressure|Diastolic blood pressure|Hypertension,University of Pittsburgh,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,18080007,26-Jan-19,Dec-21,Dec-21,21-Nov-18,,3-Dec-20,"University of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03749746
NCT03450629,Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension,,Recruiting,No Results Available,Open Angle Glaucoma|Ocular Hypertension,Drug: Brimonidine Tartrate Ophthalmic Suspension|Drug: Brimonidine Tartrate Ophthalmic Solution,Change from baseline in mean intraocular pressure,Sun Pharma Advanced Research Company Limited,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 3,666,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CLR_16_33,13-Sep-18,29-Dec-20,29-Dec-20,1-Mar-18,,19-May-20,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",,https://ClinicalTrials.gov/show/NCT03450629
NCT03045029,ADAPT - A Patient Registry of the Real-world Use of Orenitram®,ADAPT,Recruiting,No Results Available,Pulmonary Arterial Hypertension,Drug: Oral treprostinil,"Real-world use and tolerability of Orenitram in new starts and prostacyclin transition patients|To assess treatment-related outcomes during routine clinical care.|To observe the development, timing, severity, frequency, and treatment of prostacyclin-related adverse events (AEs) of interest|Use of concomitant medications|To evaluate information on clinical titration schedules implemented for transition to and from alternative prostacyclin-class therapies|Healthcare resource utilization trends|Health-related quality of life in PAH and treatment satisfaction|To evaluate reasons for discontinuation of Orenitram|To evaluate titration and dosing schedules of Orenitram",United Therapeutics,All,"18 Years and older   (Adult, Older Adult)",,300,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,TDE-PH-401,18-Jul-17,Jun-22,Jun-22,7-Feb-17,,8-Jul-20,"University of California - San Francisco, Fresno, California, United States|University of Southern California - Keck Medical Center, Los Angeles, California, United States|Paloma Medical Group, San Juan Capistrano, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|Pueblo Pulmonary Associates, Pueblo, Colorado, United States|Lung Associates PA, Bradenton, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|USF South Florida Heart Health, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Piedmont Healthcare/Research, Austell, Georgia, United States|Loyola University Chicago, Chicago, Illinois, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|University Of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Mclaren Greater Lansing, Okemos, Michigan, United States|Beaumont Hospital Troy, Troy, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Albany Medical College, Albany, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Pulmonary Health Physicians, PC, Fayetteville, New York, United States|Stony Brook University Medical Center, Islandia, New York, United States|Northwell Health- Long Island Jewish Forest Hills, New Hyde Park, New York, United States|University of Rochester, Rochester, New York, United States|Pinehurst Medical Clinic, INC., Pinehurst, North Carolina, United States|Lima Memorial Hospital, Lima, Ohio, United States|INTEGRIS Nazih Zuhdi Transplant Institution, Oklahoma City, Oklahoma, United States|Oregon Health & Science University (OHSU), Portland, Oregon, United States|University of Pittsburgh - Heart and Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|Center for Biomedical Research, Knoxville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|Carilion Clinic, Roanoke, Virginia, United States|Heart Care Associates, LLC, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03045029
NCT00286637,Novel Diagnostics for Ocular Structure,,Recruiting,No Results Available,Glaucoma|Macular Disease,,Novel Diagnostics for Ocular Structure,NYU Langone Health|National Eye Institute (NEI),All,"18 Years and older   (Adult, Older Adult)",,2767,Other|NIH,Observational,Observational Model: Other|Time Perspective: Other,R01EY013178-06|R01EY011289-21|P30EY008098|16-01302,Jan-95,Jan-24,Jan-25,3-Feb-06,,24-Aug-20,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00286637
NCT00221897,Diagnostic Innovations in Glaucoma Study,DIGS,Recruiting,No Results Available,Primary Open Angle Glaucoma|Myopia,,,"University of California, San Diego|National Eye Institute (NEI)",All,"18 Years and older   (Adult, Older Adult)",,3000,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,RO1-EY08208; RO1-EY11008|R01EY027510,Apr-95,Jul-20,Jul-20,22-Sep-05,,11-Apr-19,"UCSD, Hamilton Glaucoma Center, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00221897
NCT04632589,Losartan for Improved Vascular Endothelial Function After Preeclampsia,LIVE-PE,Recruiting,No Results Available,Preeclampsia Postpartum,Drug: Losartan Potassium|Drug: Placebo,Microvascular endothelial function following systemic AT1 receptor inhibition|Microvascular endothelial function following placebo|Microvascular angiotensin II sensitivity following systemic AT1 receptor inhibition|Microvascular angiotensin II sensitivity following placebo|Central and Peripheral Vascular Stiffness following systemic AT1 receptor inhibition|Central and Peripheral Vascular Stiffness following placebo|circulating inflammatory cytokines|PBMC inflammatory sensitivity,"Anna Stanhewicz, PhD|University of Iowa",Female,18 Years to 50 Years   (Adult),Early Phase 1,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",202006148,22-Nov-20,Jul-22,Jul-23,17-Nov-20,,14-Jan-21,"University of Iowa, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT04632589
NCT04479072,Aspirin and Preeclampsia,,Not yet recruiting,No Results Available,Preeclampsia Postpartum,Drug: Aspirin 81 mg|Drug: Placebo,"Difference in Activin A levels|GLS percentages|Mean Arterial Pressure|Ejection Fraction %|Deceleration Time,|Mitral Annular Motion|Left Atrial Volume Index",University of Chicago,Female,18 Years to 45 Years   (Adult),Phase 4,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",IRB #18-1606,1-Feb-21,1-Jan-26,28-Feb-26,21-Jul-20,,12-Aug-20,"University of Chicago Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04479072
NCT04474704,Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia,,Not yet recruiting,No Results Available,Preeclampsia With Severe Features,Device: Cheetah® non-invasive cardiac monitoring system|Other: Standard of care,Evaluating duration of magnesium sulfate use in the postpartum period defined as the duration in hours between delivery and discontinuation of magnesium sulfate.|Evaluating number of hospital readmission|Evaluating change in arterial blood pressure (systolic and diastolic)|Evaluating change in cardiac output|Evaluating change in heart rate|Evaluating incidence of need to restart magnesium sulfate,Ohio State University,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,2020H0264,1-Dec-20,31-Aug-22,31-Aug-22,17-Jul-20,,14-Oct-20,"The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04474704
NCT04392375,Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor,,Recruiting,No Results Available,Preeclampsia Severe,Drug: Nifedipine 30 MG|Drug: Placebos,Evaluating Nifedipine 30mg XL versus placebo to see the change in blood pressure (both systolic and diastolic) in women with preeclampsia with severe features undergoing induction of labor.|Evaluating number of route of delivery|Evaluating frequency of indications for cesarean delivery|Evaluating frequency of maternal hypotension ( both systolic and diastolic)|Evaluating frequency of postpartum hypertension (both systolic and diastolic),Ohio State University,Female,18 Years to 45 Years   (Adult),Phase 4,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2019H0431,9-Jun-20,Dec-22,Dec-22,18-May-20,,10-Dec-20,"The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04392375
NCT04154332,Exosome Cargo From Preeclampsia Patients,,Recruiting,No Results Available,Preeclampsia,Other: Sample collection,Exosome cargo levels,University of Alabama at Birmingham,Female,18 Years to 45 Years   (Adult),,64,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB-300004235,2-Dec-19,15-Nov-21,15-Nov-22,6-Nov-19,,13-Nov-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04154332
NCT04070573,Low Doses of Aspirin in the Prevention of Preeclampsia,ASAPP,Recruiting,No Results Available,Preeclampsia,Drug: acetylsalicylic acid,Incidence of preterm (<37 weeks) preeclampsia|Incidence of preeclampsia with severe features|Aspirin adherence|Maternal and Fetal Outcomes|Time-to-event for preeclampsia and gestational age at onset of PE|Aspirin compliance,Weill Medical College of Cornell University,Female,18 Years to 60 Years   (Adult),Phase 3,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,19-05020160,21-Oct-19,Aug-24,Aug-24,28-Aug-19,,27-Nov-20,"New York Presbyterian - Weill Cornell, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04070573
NCT04063397,Persistent Postpartum Cardiovascular Dysfunction in Patients With Preeclampsia,ECHO,Recruiting,No Results Available,Preeclampsia|Preeclampsia Severe|Cardiac Complication,Diagnostic Test: Echocardiogram|Diagnostic Test: Blood draw,Cardiac dysfunction,Ohio State University|Roche Diagnostics,Female,"18 Years and older   (Adult, Older Adult)",,60,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2018H0312,19-Aug-19,19-Aug-22,1-Dec-22,21-Aug-19,,16-Sep-20,"The Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04063397
NCT03978767,Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial,PANDA,Recruiting,No Results Available,Preeclampsia Severe|Preeclampsia Postpartum,Drug: Ibuprofen 600 mg|Drug: Ketorolac|Drug: Acetaminophen|Drug: Oxycodone,postpartum antihypertensive requirements|Postpartum pain scores|Postpartum opioid use|Mean arterial blood pressure|End organ damage|Hospital readmission|Continued anti-hypertensive requirement,Washington University School of Medicine,Female,"Child, Adult, Older Adult",Phase 2,286,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201901202,10-Jun-19,27-May-21,27-Jul-21,7-Jun-19,,10-Aug-20,"Barnes Jewish Hospital, Saint Louis, Missouri, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/Prot_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03978767
NCT04274764,Screening and Intervention for Glaucoma and Eye Health Through Telemedicine,SIGHT,Recruiting,No Results Available,Glaucoma,Behavioral: Personalized eHealth Education & Motivational Interviewing,Physician Follow up,University of Michigan|Centers for Disease Control and Prevention,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,400,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HUM00169371,28-Jul-20,1-Mar-25,1-Mar-25,18-Feb-20,,27-Aug-20,"Hamilton Community Health Clinic, Flint, Michigan, United States|Hope Clinic, Ypsilanti, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04274764
NCT03893630,Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia,ASPERIN,Recruiting,No Results Available,Pre-Eclampsia,Drug: Acetylsalicylic Acid 81 mg|Drug: Acetylsalicylic Acid 162 mg|Other: Control,"Change in Pulsatility Index (PI)|Onset of Pre-eclampsia|Severity of Pre-eclampsia|Composite Neonatal outcomes including frequency of Intraventricular hemorrhage (IVH), Bronchopulmonary dysplasia (BPD), Respiratory distress syndrome (RDS), Necrotising enterocolitis(NEC)|Change in s-ICAM levels over time|Change in PIGF levels over time|Change in CRP levels over time|Change in IL-6 over time|Change in TNF over time","John O'Brien, MD|University of Kentucky",Female,18 Years to 45 Years   (Adult),Phase 2,250,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,47841,25-Apr-19,Jun-21,Jun-22,28-Mar-19,,14-Dec-20,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT03893630
NCT03735433,The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia,,Recruiting,No Results Available,Preeclampsia,Drug: 162mg aspirin dose,Incidence of Diagnosis of preeclampsia|Incidence of aspirin resistance based on incomplete inhibition of TBx2,Ohio State University,Female,18 Years to 45 Years   (Adult),Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OBASA,15-Jan-19,Jan-21,Jan-21,8-Nov-18,,25-Feb-20,"The Ohio State Medical Center Labor and Delivery Unit, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03735433
NCT03667326,Postpartum Low-Dose Aspirin and Preeclampsia,,Recruiting,No Results Available,Preeclampsia Postpartum,Drug: Aspirin|Drug: Placebo oral capsule,"Change in Flow-Mediated Dilation (FMD)|Change in Systolic blood pressure|Change in Diastolic blood pressure|Number of subjects with presentation of disease postpartum (symptoms, severe range BPs, lab abnormalities)|Magnesium sulfate re-administration|Number of subjects with initiation of, increase in or addition of blood pressure medication|Rate of hospital readmissions for postpartum preeclampsia",Columbia University,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention",AAAR9439,22-Jul-19,Dec-21,Jun-22,12-Sep-18,,17-Dec-20,"Columbia University Irving Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03667326
NCT03419364,Study of Nicotinamide in Early Onset Preeclampsia,,Recruiting,No Results Available,Preeclampsia,Drug: nicotinamide,Change in Mean Arterial blood Pressure (MAP)|Number of participants with alanine aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)|Number of participants with aspartate aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)|Number of participants with Maternal side effects|Proportion of women maternal abdominal tenderness|Proportion of women with headache unrelieved by oral analgesics|Proportion of women with hematocrit decrease of more than 3%|Proportion of women with less than 500 cc urine output in 24 hours|Proportion of fetuses with Category III non stress test results|Proportion of fetuses with biophysical profile < 6,"University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Female,18 Years to 55 Years   (Adult),Phase 2,25,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-0693|1R03HD092370-01,1-Nov-17,31-Aug-21,31-Aug-21,1-Feb-18,,25-Sep-20,"UNC at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03419364
NCT02989025,Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia,PROGRESS,Recruiting,No Results Available,Pregnancy,Drug: 17 OHPC,Improvement of maternal and perinatal outcomes|Change is being assessed in Maternal Outcomes,Babbette Lamarca|University of Mississippi Medical Center,Female,18 Years to 45 Years   (Adult),Phase 2,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0029,22-May-17,31-Dec-20,31-Dec-21,12-Dec-16,,16-Jul-20,"Winfred L. Wiser Hospital, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT02989025
NCT02935556,Characterization and Epigenetics of Post-Partum Preeclampsia,,Recruiting,No Results Available,Post Partum Pre-eclampsia,Other: no intervention,methylation signature on circulating monocytes,Duke University|New York University|Society for Obstetric Anesthesia and Perinatology,Female,"18 Years to 65 Years   (Adult, Older Adult)",,22,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PRO00104636,1-Feb-17,Feb-21,Feb-21,17-Oct-16,,15-Apr-20,"Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02935556
NCT03660631,Dissemination of the Cardiovascular Risk Service,CVRSLive,Recruiting,No Results Available,Hypertension|Diabetes Mellitus,Behavioral: CVRS Intervention,Factors influencing intervention implementation fidelity|Effect of physician/pharmacist collaboration on implementation fidelity|Adherence to guidelines for primary and secondary prevention of cardiovascular disease|Relationship of physician-pharmacist collaboration survey scores to sustainability themes|Development of payment contracts,Korey Kennelty|University of Iowa,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,201710812,27-Sep-18,1-Aug-21,1-Aug-22,6-Sep-18,,6-Oct-20,"Idaho State University, Pocatello, Idaho, United States|University of Illinois at Chicago: Mile Square Health Center, Chicago, Illinois, United States|Carle Foundation Hospital, Mahomet, Illinois, United States|Carle Foundation Hospital, Rantoul, Illinois, United States|Genesis Family Medical Center, Davenport, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|UIHC River Crossing, Riverside, Iowa, United States|Siouxland Family Medicine Center, Sioux City, Iowa, United States|Northeast Iowa Family Practice Center, Waterloo, Iowa, United States|Henry Ford Health System: Harbortown, Detroit, Michigan, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|Texas Tech University Health Science Center, Amarillo, Texas, United States|Community Health Center of Snohomish County, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT03660631
NCT03215173,Fit After Baby: A Health Intervention to Increase Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease,FAB,Recruiting,No Results Available,Cardiovascular Diseases|Diabetes|Gestational Diabetes|Preeclampsia|Gestational Hypertension|Small for Gestational Age at Delivery|Preterm Birth|Overweight and Obesity,Behavioral: Fit After Baby|Behavioral: Text4Baby Control Group,Change in weight loss from baseline to one year postpartum|Change in postpartum weight retention|Evaluation of Subject Satisfaction|Adherence to self monitoring|Use of app|Number of interactions with lifestyle coach|Change in waist circumference|Change in fasting glucose|Change in HbA1c|Change in fasting insulin|Change in adiponectin|Change in lipids|Change in blood pressure|Change in hsCRP|Change in postnatal depression score|Change in Physical activity|Change in Social Support|Change in Self-Efficacy|Change in Perceived Stress|Change in dietary intake|Change in breastfeeding status|Change in Readiness to Change,"University of Colorado, Denver",Female,18 Years to 45 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,17-0045,1-Sep-17,31-Dec-20,31-Dec-21,12-Jul-17,,22-Jan-20,"University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03215173
NCT04545489,A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention,V-EXTRA-CVD,Not yet recruiting,No Results Available,Cardiovascular Disease|Hypertension|Care Coordination|HIV Treatment Cascade,Behavioral: Nurse-led intervention group|Behavioral: Education control group,Mean Systolic Blood Pressure|Non-HDL Cholesterol,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,350,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IIR 19-418,1-Dec-20,1-May-23,28-Feb-24,11-Sep-20,,16-Sep-20,"Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04545489
NCT04087798,Controlling Hypertension Through Education and Coaching in Kidney Disease,CHECK-D,Recruiting,No Results Available,"Chronic Kidney Diseases|Chronic Disease|Chronic Kidney Disease, Stage 3 (Moderate)|Chronic Kidney Disease, Stage 4 (Severe)|Chronic Kidney Disease Stage 5",Behavioral: Control-EDI|Behavioral: Intervention-EDI and health coaching,Change in Systolic Blood Pressure between baseline and 12 months|Change in Diastolic Blood Pressure between baseline and 12 months|Slope of systolic BP between baseline and 12 months using all available BP values|Slope of diastolic BP between baseline and 12 months using all available BP values|CKD knowledge measured by the Kidney Knowledge Survey (KiKS)|Medication Adherence Self-Efficacy Scale-Revised (MASES-R)|Morisky Medication Adherence Scale (MMAS - 8)|Visit Time with provider|Total time in clinic|Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ)|Satisfaction with CKD care based on Communication Assessment Tool (CAT)|Satisfaction with CKD care based on Consultation Care Measure (CCM)|Perceptions of health coaching for the intervention group|Medication adherence from the electronic medical record (EMR)|Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS)|Self-reported Blood Pressure-Related Behaviors Survey|Provider Adoption based on EMR query and patient survey|Provider Fidelity measured by EMR query|Provider Perception of Usefulness by provider survey|Change in serum creatinine|Change in urine protein-creatinine ratio|Change in estimated glomerular filtration rate (eGFR),University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years to 85 Years   (Adult, Older Adult)",Not Applicable,350,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HUM00136011|R01DK115844-01,4-Feb-20,Jun-22,Jun-22,12-Sep-19,,17-Dec-20,"University of Michigan / Domino's Farms, Ann Arbor, Michigan, United States|University of Michigan / Briarwood Family Medicine, Ann Arbor, Michigan, United States|University of Michigan / Brighton Health Center, Brighton, Michigan, United States|University of Michigan / Chelsea Health Center, Chelsea, Michigan, United States|University Health Center - GMAP/Gen Med, Detroit, Michigan, United States|University Health Center - Med Peds, Detroit, Michigan, United States|University of Michigan / Dexter Health Center, Dexter, Michigan, United States|University of Michigan / Livonia Health Center, Livonia, Michigan, United States|University of Michigan / Northville Health Center, Northville, Michigan, United States|University of Michigan / Ypsilanti Health Center, Ypsilanti, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04087798
NCT04275037,The Hypotensive Effects of Home-Based Isometric Handgrip Training in Older Adults With Pre-Hypertension and Hypertension - The HoldAge Trial,,Recruiting,No Results Available,Hypertension|Pre-Hypertension,Other: Isometric Handgrip Training|Other: Aerobic Exercise Training,24h ambulatory blood pressure|Arterial Stiffness|Endothelial function|Inflamamtion|Endothelial cell repair/damage|Health-related quality of life|Aerobic fitness|Weekly physical activity sleep quality|Intervention quality|Sleep quality,"University Institute of Maia|Aveiro University|Hospital Infante D. Pedro, Centro Hospitalar Do Baixo Vouga|Hospital Pedro Hispano, ULS Matosinhos|Porto University|University of Connecticut|Unidade de Saúde Familiar de Santa Joana|Research Center in Sports Sciences, Health Sciences and Human Development",All,65 Years and older   (Older Adult),Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,POCI-01-0145-FEDER-030646,1-Jan-20,1-Jan-21,1-Jan-21,19-Feb-20,,19-Feb-20,"University of Connecticut, Storrs, Connecticut, United States|Unidade de Saúde Familiar de Santa Joana, Santa Joana, Aveiro, Aveiro, Portugal|University Institute of Maia, Maia, Porto, Portugal|Hypertension Unit, Hospital Pedro Hispano, ULS, Matosinhos, Portugal, Matosinhos, Porto, Portugal|Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal|Institute of Biomedicine, Aveiro, Portugal|University of Aveiro, Aveiro, Portugal|CINTESIS, Faculty of Medicine, Porto, Portugal, Porto, Portugal|Reserach Center in Sports Sciences, Health Sciences and Human Development, Vila Real, Portugal",,https://ClinicalTrials.gov/show/NCT04275037
NCT04636892,Evaluating Infrasonic Hemodynography,,Not yet recruiting,No Results Available,"Aortic Stenosis|Mitral Regurgitation|Pulmonary Hypertension|Heart Failure, Systolic|Cardiovascular Diseases|Coronary Artery Disease",Other: MindMics earbud,Infrasound Hemodynography,"Scripps Health|Rajbir Sidhu MD, Principal Co-Investigator|Steven Romero MD, Principal Co-Investigator|Carly Waldman MD, Principal Co-Investigator",All,"Child, Adult, Older Adult",Not Applicable,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,20-7677,1-Jan-21,1-Jun-21,31-Dec-21,19-Nov-20,,11-Dec-20,"Scripps Health, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT04636892
NCT04364074,Acute Probiotic Supplementation and Endothelial Function,,Recruiting,No Results Available,Coronary Artery Disease|Hypertension|Hyperlipidemias|Peripheral Vascular Diseases|Cerebral Arterial Diseases,Dietary Supplement: Goodbelly|Dietary Supplement: Placebo,change in baseline flow mediated dilation (FMD) after probiotic consumption|Interleukin-6|Interleukin-8|Interleukin-12,Medical College of Wisconsin,All,"21 Years to 89 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",37096,17-Aug-20,30-Sep-21,30-Sep-22,27-Apr-20,,22-Sep-20,"Medical College of Wisconsin, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04364074
NCT03935178,Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities,UVRV,Recruiting,No Results Available,Pulmonary Hypertension|Valvular Heart Disease|Congenital Heart Disease|Congestive Heart Failure|Pulmonary Embolism|Acute Coronary Syndrome,Diagnostic Test: Measuring Right Ventricular Size and Function,Echocardiographic measurement - Right ventricular size|Echocardiographic measurement - Right ventricular function|Echocardiographic measurement - Right ventricular dysfunction severity,Dartmouth-Hitchcock Medical Center,All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Other|Time Perspective: Prospective,D19082 HVC 2019,5-Aug-19,30-Jun-21,Aug-21,2-May-19,,9-Oct-20,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT03935178
NCT03374215,Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks,,Recruiting,No Results Available,"Adrenal Gland Neoplasm|Hypertension|Bone Diseases, Metabolic|Cardiovascular Disease|Hyperinsulinemia",,"To define the germline and/or somatic genetic events causing Primary Aldosteronism (PA) in Blacks.|To define the effects of mutations in Black subjects on adrenocortical tumor formation, function and aldosterone production.|To investigate co-secretion of other steroids in PA.|To investigate the cardiovascular, renal, metabolic, bone, and coagulopathic consequences of PA in AA, as well as any changes after one year of directed therapeutic intervention (e.g. post-adrenalectomy or mineralocorticoid receptor antagonist ...|To investigate the clinical utility of other biomarkers in the subtype classification of PA.",National Human Genome Research Institute (NHGRI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC),All,"7 Years to 70 Years   (Child, Adult, Older Adult)",,1150,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,180031|18-CH-0031,14-Dec-17,31-Dec-25,31-Dec-25,15-Dec-17,,30-Nov-20,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03374215
NCT04105218,"Exercise, Sleep Quality and Nocturnal Fat Oxidation in Metabolic Syndrome",ExerciZzz,Recruiting,No Results Available,Metabolic Syndrome|PreDiabetes|Hypertension|Obesity|Hyperlipidemias,Behavioral: Exercise,Nocturnal FFA concentrations|Nocturnal fat oxidation|Nocturnal glucose and insulin concentrations|Sleep quality (percent time in slow wave sleep [SWS])|Sleep latency|Sleep interruptions,"University of Colorado, Denver",All,19 Years to 45 Years   (Adult),Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,18-0369,15-Aug-19,31-Aug-21,31-Aug-21,26-Sep-19,,30-Sep-20,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04105218
NCT04074954,A (Prospective/Pilot) Study Evaluating the Effect of Cataract Surgery on the Daily Activity Levels of Elderly Patients,,Recruiting,No Results Available,Cataract|Diabetes|Hypertension|Obesity|Vision Disability,Procedure: Cataract surgery,Amount of activity conducted by the patient before receiving surgery|Amount of activity conducted by the patient after receiving surgery,University of Pikeville,All,"60 Years and older   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CataractStudy1,26-Aug-19,31-Jul-20,31-Jul-20,30-Aug-19,,30-Aug-19,"Bennett and Bloom Eye Centers, Louisville, Kentucky, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04074954/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04074954
NCT03742219,Peru Longitudinal Study,,Recruiting,No Results Available,Cardiovascular Diseases|Diabetes Mellitus|Hypertension|Dyslipidemias|Overweight and Obesity,Behavioral: Lifestyle Modification,Weight|Systolic blood pressure|Diastolic Blood Pressure|glycosylated hemoglobin|Total cholesterol|Low-density lipoprotein cholesterol|High density lipoprotein cholesterol|Triglycerides|Herth Hope Index|Household hunger scale|Patient Health Questionnaire - 4 (PHQ-4)|Exercise vital sign|Perceived Stress Scale|24 hour dietary recall,Ohio University,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,1000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-X-88,5-Jun-17,1-Jul-26,30-Jun-27,15-Nov-18,,15-Nov-19,"Ohio University, Athens, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03742219
NCT03404180,Peripheral Nerve Blocks for Above-the-knee Amputations,,Recruiting,No Results Available,"Peripheral Vascular Diseases|Hyperglycaemia (Diabetic)|Hypertension|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive",Procedure: Peripheral nerve block|Drug: Intravenous Sedatives|Procedure: Lateral femoral cutaneous nerve blocks|Procedure: Obturator nerve blocks,Chi-squared tests of peripheral nerve block success as a primary anesthetic|Analysis of pain scores|Mortality,University of Florida|US Department of Veterans Affairs,All,"18 Years and older   (Adult, Older Adult)",Phase 4,36,Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB201702402|OCR18952,9-Feb-18,Sep-21,Sep-21,19-Jan-18,,14-Oct-20,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03404180
NCT04624698,iStent Inject New Enrollment Post-Approval Study,,Recruiting,No Results Available,"Glaucoma, Open-Angle|Glaucoma",Device: iStent Inject Implantation,iStent inject placement and stability|Sight-threatening adverse events,Glaukos Corporation,All,"22 Years and older   (Adult, Older Adult)",Not Applicable,358,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IG2M-105-PASN,22-Sep-20,May-26,May-26,12-Nov-20,,12-Nov-20,"Eye Doctors of Arizona, PLLC, Phoenix, Arizona, United States|Wolstan and Goldberg Eye Associates, Torrance, California, United States|Glaucoma Associates of Texas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04624698
NCT03617302,Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study,INCA,Recruiting,No Results Available,Aging|Arterial Stiffness|Endothelial Dysfunction|Hypertension|Cognitive Decline,Drug: Experimental: Nitrate-containing|Drug: Placebo: Nitrate-depleted,Acute change in carotid artery stiffness|Acute change in cerebral blood flow|Internal carotid artery endothelium-dependent dilation,"Gary L. Pierce|University of Wisconsin, Madison|University of Iowa",All,"50 Years to 79 Years   (Adult, Older Adult)",Early Phase 1,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",201805720,1-Nov-18,30-Jun-22,30-Jun-23,6-Aug-18,,23-Jan-20,"University of Iowa, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03617302
NCT04311086,SPYRAL DYSTAL Clinical Study,,Recruiting,No Results Available,Hypertension|Vascular Diseases|Cardiovascular Diseases,Device: Renal Denervation (Symplicity Spyral™),"Change in systolic blood pressure (SBP) from baseline as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)|Change in office systolic blood pressure|Change in office diastolic blood pressure|Change in office diastolic blood pressure baseline as measured by 24-hour ABPM|Incidence of achieving target office BP|Comparison of BP reduction pattern over 24 hours of ABPM|Procedural characteristics (e.g. Procedure time, contrast media usage, etc.)|Acute and chronic safety by evaluating incidence of Major Adverse Events|Incidence of Myocardial Infarction|Incidence of Stroke|Incidence of Renal artery re-intervention|Incidence of Major bleeding according to TIMI definition|Incidence of Increase in serum creatinine >50%",Medtronic Vascular,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPYRAL DYSTAL,12-Jun-20,14-Mar-21,30-Apr-22,17-Mar-20,,26-Oct-20,"Stanford Hospital and Clinics, Stanford, California, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Baylor Heart & Vascular Hospital, Dallas, Texas, United States|Universitaetsklinikum Erlangen, Erlangen, Germany|Justus-Liebig-Universität Gießen, Gießen, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Herzzentrum Leipzig, Leipzig, Germany|Hippokration General Hospital of Athens, Athens, Greece|Ospedale di Verona Borgo Trento, Verona, Italy|Erasmus Medical Center, Rotterdam, Netherlands|University Hospital of Wales, Cardiff, United Kingdom|Oxford University Hospitals NHS Trust - John Radcliffe Hospital, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT04311086
NCT04200651,Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery,SUSTAIN,Recruiting,No Results Available,Glaucoma|Cataract,Drug: Dexamethasone Ophthalmic Insert|Drug: Prednisolone Acetate 1% Oph Susp,Change in intraocular pressure (IOP) at 1 and 3 months|Change in best-corrected visual acuity (BCVA) at 1 and 3 months|Difference in adverse events between groups|Difference in number of glaucoma medications at 3 months|Percentage of patients requiring supplemental prednisolone acetate 1% eye drops|Incidence of cystoid macular edema (CME) at 3 months as seen on optical coherence tomography (OCT)|Difference in Ocular Comfort Index (OCI) score at 1 month|Difference in Ocular Comfort Index (OCI) score at 3 months|Difference patients with absence of anterior chamber (AC) cells at 1 month,"The New York Eye Surgery Center|Ocular Therapeutix, Inc.",All,"21 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,146602,13-Jan-20,28-Feb-22,30-Apr-22,16-Dec-19,,10-Nov-20,"The New York Eye Surgery Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04200651
NCT03861169,Use of the OMNI® Surgical System in Combination With Cataract Extraction in Open Angle Glaucoma,,Recruiting,No Results Available,Open Angle Glaucoma,Device: Transluminal viscoelastic delivery and trabeculotomy,Change in mean unmedicated diurnal IOP|Change in mean number of IOP-lowering medications|Percent of eyes with a ≥20% reduction in unmedicated diurnal IOP at 12 months|Percent of eyes with unmedicated diurnal IOP between 6 and 18 mmHg inclusive at 12 months,"Sight Sciences, Inc.",All,"22 Years and older   (Adult, Older Adult)",Not Applicable,220,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6213,22-Feb-19,30-Aug-20,31-Dec-20,4-Mar-19,,4-Mar-19,"El Paso Eye Surgeons, El Paso, Texas, United States",,https://ClinicalTrials.gov/show/NCT03861169
NCT03761992,Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG,,Recruiting,No Results Available,Normal Tension Glaucoma,Dietary Supplement: Gingko Baloba|Other: Placebo,Primary Outcome - Measure of Blood Vessel by Optical Cohrence Tomography Angiography (OCTA)|Secondary Outcome - Measure of Blood Flow and Velocity by Nailfold Capillaroscopy (NFC),"Robert Ritch, MD, LLC.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NFC Gingko,19-Nov-18,Nov-20,Dec-20,3-Dec-18,,17-Mar-20,"New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03761992
NCT04454190,Development and Validation of a Model to Predict Fast Progression in Glaucoma,,Not yet recruiting,No Results Available,"Glaucoma|Primary Open Angle Glaucoma|Glaucoma, Suspect",Diagnostic Test: Collection of genetic material,Rates of change,"Duke University|Genentech, Inc.",All,"40 Years to 90 Years   (Adult, Older Adult)",,5200,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00105990,Feb-21,Nov-25,Nov-25,1-Jul-20,,14-Dec-20,"Duke University Eye Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04454190
NCT04530084,A Single Center Proof Of Concept Study To Assess Intra And Perioperative Safety Profile Of OMNI Surgical System,,Recruiting,No Results Available,Open Angle Glaucoma,Device: OMNI Surgical System,Adverse events (intraoperative and perioperative)|Best Corrected Visual Acuity (BCVA)|Mean intraocular pressure (IOP)|Mean number of ocular hypotensive medications,"Mark Gallardo, MD|El Paso Eye Surgeons",All,"22 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1290569,21-Aug-20,22-Aug-21,Dec-21,28-Aug-20,,28-Aug-20,"El Paso Eye Surgeons, El Paso, Texas, United States",,https://ClinicalTrials.gov/show/NCT04530084
NCT04234932,Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation,,Recruiting,No Results Available,"Glaucoma, Open-Angle",Drug: Netarsudil Ophthalmic,Peripapillary capillary perfusion density|Macular capillary perfusion density,University of the Incarnate Word,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",19-12-005,6-Jan-20,Jan-21,Jan-21,21-Jan-20,,14-Apr-20,"University of the Incarnate Word, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04234932
NCT04141865,Effect of Xen Implantation on the Aqueous Humor Proteome,,Recruiting,No Results Available,Primary Open Angle Glaucoma,Device: Xen|Device: Aqueous shunt,Aqueous humor proteome,Price Vision Group,All,"18 Years to 90 Years   (Adult, Older Adult)",,15,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2019-006,24-Oct-19,30-Jun-21,30-Jul-21,28-Oct-19,,7-Jul-20,"Price Vision Group, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT04141865
NCT03352492,Effect of Peripheral Laser Iridotomy Placement on Post-operative Visual Function,,Recruiting,No Results Available,"Glaucoma, Angle-Closure",Procedure: Superior laser peripheral iridotomy|Procedure: Temporal laser peripheral iridotomy,Change in visual acuity|Change in Peli-Robson contrast sensitivity|Change in CSV-1000 contrast sensitivity,University of the Incarnate Word,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,16-02-003,1-Jan-18,Feb-21,Feb-21,24-Nov-17,,14-Apr-20,"University of the Incarnate Word, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03352492
NCT03267849,Lamina Cribrosa Depth Change With Change in Eye Pressure,,Recruiting,No Results Available,"Glaucoma, Open-Angle",Other: wearing swimming goggles or having laser suturelysis,Change in anterior lamina cribrosa depth,Johns Hopkins University,All,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB00133667,1-Jul-17,1-Jul-23,1-Jul-23,30-Aug-17,,15-Jul-20,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03267849
NCT03944512,Pravastatin to Prevent Preeclampsia,Pravastatin,Recruiting,No Results Available,Preeclampsia|Obstetric Labor Complications|Hypertension in Pregnancy,Drug: Pravastatin|Other: Placebo,"Proportion of participants with composite of preeclampsia, fetal loss and maternal death|Proportion of participants with preterm birth < 37 weeks|Proportion of participants with indicated preterm birth < 37 weeks|Proportion of participants with preterm birth < 34 weeks|Proportion of participants with preeclampsia with severe features|Proportion of participants with Postpartum Preeclampsia|Proportion of participants with Gestational hypertension|Proportion of participants with pregnancy associated hypertension|Proportion of participants with Gestational diabetes|Rate of Adherence to study medication|Rate of Adverse Events of Special Interest (AESI)|Gestational age at delivery|Length of maternal hospital stay|Concentrations of angiogenic factors|Concentrations of cholesterol and triglycerides|Proportion of participants with Severe maternal morbidity composite|Percentage of Fetal or neonatal deaths|Birth weight|NICU/intermediate nursery admission|NICU/intermediate nursery length of stay|Proportion of neonates needing Mechanical ventilation|Proportion of neonates needing oxygen support|Proportion of neonates with Respiratory Distress Syndrome|Proportion of neonates with Bronchopulmonary Dysplasia|Proportion of neonates with Necrotizing Enterocolitis|Proportion of neonates with Intraventricular Hemorrhage|Proportion of neonates with Periventricular leukomalacia (PVL)|Proportion of neonates with Retinopathy of prematurity|Proportion of neonates experiencing sepsis|Proportion of neonates with Composite Neonatal Outcome|Proportion of neonates experiencing seizures|Proportion of neonates with a Congenital anomaly / birth defect|Neonatal auditory brain stem response (ABR)/Otoacoustic Emissions (OAE)|BMI for age at 24 corrected months and 5 years|Cognitive, Motor and Language Scale Scores From the Bayley Certified Scales of Infant Development III Edition|Gross Motor Function at 24 months|Proportion of children with Hearing loss or vision problems at 24 months of age|Child Behavior Checklist Total Problems Score and Syndrome Scale at 24 months and 5 years|Cognitive and Achievement Levels From the Differential Ability Scales (DAS II)|Behavior Rating Inventory of Executive Function (BRIEF) Global Executive Composite score at 5 years|Vineland Adaptive Behavior Scales - Adaptive Behavior Composite Score at 5 years|Visual acuity and strabismus at 5 years","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)",Female,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,1550,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",HD036801-Pravastatin|5U10HD036801-20,17-Jul-19,Jun-26,Jun-31,9-May-19,,22-Oct-20,"University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve-Metro Health, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03944512
NCT02682511,Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension,,Recruiting,No Results Available,"Scleroderma, Diffuse|Scleroderma, Systemic|Scleroderma, Limited|Sclerosis, Progressive Systemic|Skin Diseases|Connective Tissue Diseases|Pathologic Processes|Autoimmune Diseases",Drug: Oral Ifetroban|Drug: Oral Placebo,Incidence of adverse events (AEs) and Serious AEs (SAEs)|Change from baseline in forced vital capacity (FVC)|Change from baseline in diffusion capacity for carbon monoxide (DLCO)|Change from baseline in the modified Rodnan skin score (mRSS),Cumberland Pharmaceuticals,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,34,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CPI-IFE-004,Jan-17,Dec-22,Dec-22,15-Feb-16,,31-Aug-20,"UCLA, Los Angeles, California, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Cleveland Clinic - Florida, Weston, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Hospital for Special Surgery, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|KDH - Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India|B. J. Government Medical College, Pune, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT02682511
NCT04616573,"A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, POST-MARKET STUDY OF USE OF THE OMNI® SURGICAL SYSTEM IN COMBINATION WITH CATARACT EXTRACTION IN OPEN ANGLE GLAUCOMA (VERITA)",,Recruiting,No Results Available,"Glaucoma, Open-Angle",Device: OMNI® Surgical System|Device: iStent inject,Mean change in unmedicated DIOP from baseline at 12-month postoperative examination,"Sight Sciences, Inc.",All,"22 Years and older   (Adult, Older Adult)",Not Applicable,762,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7024,31-Oct-20,Nov-25,Dec-25,5-Nov-20,,5-Nov-20,"Eye Center South, Dothan, Alabama, United States|Eye Associates and SurgiCenter of Vineland, Vineland, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04616573
NCT03482440,Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia,,Recruiting,No Results Available,Preeclampsia,Drug: Salsalate Oral Tablet|Drug: Placebo Oral Tablet,change in endothelial function following salsalate treatment compared to placebo treatment|change in inflammatory response to ang II compared to baseline,University of Iowa|Penn State University,Female,"18 Years and older   (Adult, Older Adult)",Early Phase 1,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",HL138133,26-Aug-18,Aug-21,Mar-23,29-Mar-18,,17-Sep-19,"University of Iowa, Iowa City, Iowa, United States|Pennsylvania State University, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03482440
NCT03875911,Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy,,Recruiting,No Results Available,"Glaucoma Open-Angle Primary|Glaucoma|Open Angle Glaucoma|Glaucoma, Open-Angle",Drug: Mitomycin C,Intraocular Pressure Reduction,"University of California, Los Angeles",All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 4,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-000432,30-Mar-19,31-Dec-20,31-Dec-22,15-Mar-19,,10-Dec-20,"Doheny Eye Center UCLA (Arcadia), Arcadia, California, United States|Doheny Eye Center UCLA (Fountain Valley), Fountain Valley, California, United States|Stein Eye Institute - UCLA (Westwood), Los Angeles, California, United States|Doheny Eye Center UCLA (Pasadena), Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT03875911
NCT04072016,Study of the Beacon Aqueous Microshunt in Patients With Refractroy Glaucoma,Beacon,Recruiting,No Results Available,Glaucoma,Device: Beacon Aqueous Microshunt,Effectiveness|Safety|Responder rate defined as achieving at least 20% mean diurnal IOP reduction from baseline|Mean Change from baseline in IOP|Schirmer tear test - mean change from baseline,MicroOptx,All,"22 Years to 85 Years   (Adult, Older Adult)",Not Applicable,90,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4046,29-Apr-20,Jul-22,Dec-26,28-Aug-19,,7-Aug-20,"Icon Eye Care, Grand Junction, Colorado, United States|Minnesota Eye Consultants, Bloomington, Minnesota, United States|iWorks Laser and Vision Center, Dayton, Ohio, United States|Institut de l'oeil des Laurentides, Boisbriand, Qubec, Canada",,https://ClinicalTrials.gov/show/NCT04072016
NCT03739034,Evaluation of a Lifestyle Medicine Practice,,Recruiting,No Results Available,Chronic Lifestyle Related Disease|Diabetes|Overweight and Obesity|Dyslipidemias|Hypertension|Cardiovascular Diseases,Behavioral: Lifestyle Medicine,Weight|Systolic Blood Pressure|Diastolic Blood Pressure|Glycosylated hemoglobin|Total cholesterol|low density lipoprotein cholesterol|triglycerides|high density lipoprotein cholesterol|steps|exercise|fiber|legumes|full plate,Ohio University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-X-220,28-Jun-18,30-Jun-27,30-Jun-28,13-Nov-18,,15-Nov-19,"Ohio University, Athens, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03739034
NCT04084678,A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH,CAPACITY,Recruiting,No Results Available,"PAH|Pulmonary Hypertension|Hypertension|Connective Tissue Disease|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease|Pulmonary Arterial Hypertension",Drug: Ralinepag|Drug: Placebo,Change from Baseline in peak VO2 assessed by CPET|Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change from Baseline in Minute Ventilation (VE)/Carbon Dioxide output (VCO2) slope|Change from Baseline in Health-related quality of life (HRQoL) measured by the Short Form Health Survey (SF-36) Scores|Time to First All-cause Non-elective Hospitalization,United Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,193,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROR-PH-302,29-Oct-20,1-Sep-23,1-Sep-23,10-Sep-19,,15-Jan-21,"Tufts Medical Center, Boston, Massachusetts, United States|New York Presbyterian Hospital, New York, New York, United States|Instituto de Cardiología de Corrientes, Corrientes, Argentina|Macquarie University, North Ryde, New South Wales, Australia|Westmead Hospital, Dept Respiratory and Sleep Medicine, Westmead, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ordensklinikum Linz GmbH, Elisabethinen, Linz, Austria|AKH Wien, Innere Med. II, Kardiologie, Vienna, Austria|Erasme University Hospital - Department of Cardiology, Brussels, Belgium|Gasthuisberg University Hospital - Department of Pulmonology, Leuven, Belgium|Hospital Sao Paulo, São Paulo, SP, Brazil|Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo - InCor-HCFMUSP, São Paulo, SP, Brazil|Centro de Hipertensão Pulmonar, Porto Alegre, Brazil|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego, Białystok, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Oddział Kardiologiczny, Otwock, Poland|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04084678
NCT04670575,Vivity Outcomes in Patients With Early Stage Glaucoma,VIVA,Not yet recruiting,No Results Available,Glaucoma|Cataract|Presbyopia,Procedure: Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL,Uncorrected Distance Visual Acuity|Uncorrected Intermediate Visual Acuity|Uncorrected Near Visual Acuity|Contrast Sensitivity|Patient Satisfaction and Spectacle Independence Survey Results|Mean Refractive Spherical Equivalent,Vance Thompson Vision,All,"45 Years and older   (Adult, Older Adult)",,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,VIVA,Dec-20,Jun-21,Jul-21,17-Dec-20,,17-Dec-20,"Vance Thompson Vision, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT04670575
NCT04202510,IOP and Medication Reduction in MIGS Procedures,,Recruiting,No Results Available,Open Angle Glaucoma|Primary Open Angle Glaucoma|Pigmentary Glaucoma|Pseudoexfoliation Glaucoma in Both Eyes,Procedure: Glaucoma and Cataract Surgery,Intraocular Pressure (IOP)|Visual Acuity|Central Corneal Thickness (CCT)|Endothelial Cell Count,"Wills Eye|Tanta Medical School, Tanta University",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB #19-869,6-Jan-20,31-Dec-21,31-Dec-22,17-Dec-19,,14-Jan-20,"Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04202510
NCT04309383,ShuntCheck in Pseudotumor Cerebri,,Recruiting,No Results Available,Pseudotumor Cerebri,Diagnostic Test: ShuntCheck,Specificity of ShuntCheck test|Negative Predictive Value of ShuntCheck test|Specificity of performing ShuntCheck test twice|Negative Predictive Value of performing ShuntCheck test twice,University of South Florida|NeuroDx Development,All,"18 Years and older   (Adult, Older Adult)",,20,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,Pro00042422,29-Oct-19,Oct-20,Oct-20,16-Mar-20,,16-Mar-20,"University of South Florida Department of Neurological Surgery and Brain Repair, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT04309383
NCT04629521,Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent,COMPASS XXT,Not yet recruiting,No Results Available,Primary Open Angle Glaucoma|Cataract,Device: CyPass Micro-Stent,"Rate of occurrence of sight-threatening adverse events (AEs)|Rate of occurrence of ocular AEs|Central Endothelial Cell Density (ECD) reported by mean and standard deviation|Central ECD reported by mean and 95 percent confidence interval|Central ECD reported by percentile|Peripheral ECD reported by mean and standard deviation|Peripheral ECD reported by mean and 95 percent confidence interval|Peripheral ECD reported by percentile|Central Endothelial Cell Coefficient of Variation reported by mean and standard deviation|Central Endothelial Cell Coefficient of Variation reported by percentile|Central Endothelial Hexagonality reported by mean and standard deviation|Central Endothelial Hexagonality reported by percentile|Change in Central ECD from COMPASS Trial Baseline Visit reported by mean and standard deviation|Change in Central ECD from COMPASS Trial Baseline Visit reported by mean and confidence interval|Change in Central ECD from COMPASS Trial Baseline Visit reported by percentile|Percent change in central ECD from COMPASS Trial Baseline Visit reported by mean and standard deviation|Percent change in central ECD from COMPASS Trial Baseline Visit reported by mean and 95% confidence interval|Percent change in central ECD from COMPASS Trial Baseline Visit reported by percentile|Percentage of Eyes According to Central Endothelial Cell Density <1000 cells per millimeter squared|Percentage of Eyes According to Central Endothelial Cell Density <500 cells per millimeter squared|Percentage of Eyes According to Central Endothelial Percent Change from COMPASS Trial Baseline >30% Loss|Percentage of Eyes According to Peripheral Endothelial Cell Density <1000 cells per millimeter squared|Percentage of Eyes According to Peripheral Endothelial Cell Density <500 cells per millimeter squared|Annualized rate of change in Central Endothelial Cell Density at each year of observation reported by mean and standard deviation|Annualized rate of change in Central Endothelial Cell Density at each year of observation reported by mean and 95 percent confidence interval|Annualized percent rate of change in Central Endothelial Cell Density at each year of observation reported by mean and standard deviation|Annualized percent rate of change in Central Endothelial Cell Density at each year of observation reported by mean and 95 percent confidence interval|Number of corneal sequelae events associated with Endothelial Cell Loss (ECL)|Central ECD Count by Number of Rings Observed at the Visit reported by mean and standard deviation|Central ECD Count by Number of Rings Observed at the Visit reported by percentile|Peripheral ECD Count by Number of Rings Observed at the Visit reported by mean and standard deviation|Peripheral ECD Count by Number of Rings Observed at the Visit reported by percentile|Number of Secondary Surgical Intervention (SSI) events to modify the device position (eg, repositioning, trimming, explantation)|CyPass Micro-Stent movement and/or malposition|Number of corneal adverse events caused by CyPass MicroStent|Number of events of Best Corrected Visual Acuity (BCVA) loss of 10 letters or more|Change in visual field mean deviation from COMPASS Trial Screening Visit reported by mean and standard deviation|Change in visual field mean deviation from COMPASS Trial Screening Visit reported categorically|Change in central corneal thickness from COMPASS Trial Screening Visit reported by mean and standard deviation|Change in central corneal thickness from COMPASS Trial Screening Visit reported by mean and confidence interval",Alcon Research,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,374,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,GLD122-P004,Jan-21,Aug-23,Aug-23,16-Nov-20,,8-Jan-21,"Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT04629521
NCT02547740,Macular Damage in Early Glaucoma and Progression,,Recruiting,No Results Available,Glaucoma,,Change in 10-2 visual field|Change in macular ganglion cell thickness,Columbia University|National Eye Institute (NEI),All,"18 Years to 85 Years   (Adult, Older Adult)",,375,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,AAAO8502|1R01EY025253-01,Oct-15,Oct-20,Dec-20,11-Sep-15,,4-Dec-19,"CUMC Harkness Eye Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02547740
NCT04040959,Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD,,Recruiting,No Results Available,Vascular Diseases|Kidney Disease|Blood Pressure|Oxidative Stress,Drug: Nicotinamide riboside,carotid-femoral pulse wave velocity|Systolic blood pressure,"University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"35 Years to 80 Years   (Adult, Older Adult)",Phase 2,118,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",19-0149|R01DK121516-01,19-Nov-19,15-May-24,15-Sep-24,1-Aug-19,,21-Dec-20,"UColorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04040959
NCT02391519,Effects of High Altitude on AMPK Activation,,Recruiting,No Results Available,Pregnancy|IUGR|Preeclampsia,"Procedure: Collection of myometrial, cord blood, and placental tissue samples",Changes in Myometrial artery dimensions,"University of Colorado, Denver",Female,18 Years to 45 Years   (Adult),,84,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,14-2178,Jan-16,Apr-22,Jun-22,18-Mar-15,,4-Jun-20,"University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02391519
NCT04258813,Onco-primary Care Networking to Support TEAM-based Care,ONE TEAM,Not yet recruiting,No Results Available,"Blood Pressure|Hypertension|Cancer|Cancer, Breast|Cancer of Prostate|Cancer Colorectal|Cancer, Endometrial|Cancer of Head and Neck|Non Small Cell Lung Cancer|CVD - Cardiovascular Disease|Diabetes Mellitus|Hypercholesterolemia|Diabetes",Behavioral: iGuide Intervention (Self-guided)|Behavioral: iGuide 2 Intervention (Tailored/Targeted)|Behavioral: Control,HEDIS quality measure of management hypertension|HEDIS quality measure of management of diabetes|HEDIS quality measure of management of statin use|Patient-Centered Communication in Cancer Care|Medication adherence|Medication adherence defined through patient self-report|Clinical laboratory values|Patient activation|Financial burden|Patient-reported care coordination|Provider-reported care coordination,Duke University,All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,800,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",PRO00104179,1-Jan-21,31-Mar-24,31-Mar-24,6-Feb-20,,27-Oct-20,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04258813
NCT03471117,Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients,,Recruiting,No Results Available,Chronic Kidney Diseases,Drug: Pioglitazone|Other: Placebo,Muscle sympathetic nerve activity (MSNA) will be reduced after 1 month of treatment with pioglitazone,"The University of Texas at Arlington|University of Texas, Southwestern Medical Center at Dallas",All,"35 Years to 70 Years   (Adult, Older Adult)",Phase 4,28,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,CKD-IRB-2016-0005,1-Apr-18,1-Apr-21,1-Jun-21,20-Mar-18,,13-Nov-20,"University of Texas at Arlington, Arlington, Texas, United States|UT Southwestern, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03471117/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT03471117
NCT04300764,Gamification to Increase Mobility in the Hospital,Level Up,Not yet recruiting,No Results Available,Coronary Artery Disease|Coronary Heart Disease|Hypertension|Diabete Mellitus|Dyslipidemias|Obesity|Heart Failure,Behavioral: Gamification Intervention,Change in mean daily step count during hospitalization|Proportion of patients who attain pre-specified step thresholds during hospitalization and after discharge|Hospital length of stay|Discharge to post-acute facilities|30-day acute care utilization|Change in activities of daily living|Change in difficulty with walking|Change in life space assessment,University of Pennsylvania,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",834466,1-Jan-21,30-Apr-21,31-Dec-21,9-Mar-20,,30-Jun-20,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04300764
NCT04705779,The HARMONY Study: A Intervention to Reduce Cardiometabolic Risk in African American Women,,Not yet recruiting,No Results Available,Heart Diseases|Stroke|Pre-diabetes|Hypertension|Obesity|Overweight|Stress,Behavioral: HARMONY|Behavioral: Nutrition and Exercise Education (NEEW),Change in Amount of Moderate to Vigorous Physical Activity|Change in the Dietary Risk Assessment Score|Change in Veggie Meter Score|Change in BMI|Change in Weight|Change in Waist-to-Hip Ratio|Change in Percent Body Fat|Change in Blood Pressure (Systolic Blood Pressure/Diastolic Blood Pressure)|Change in High Sensitivity C-Reactive Protein Amount|Change in IL-6|Change in Glycosylated Hemoglobin,"University of North Carolina, Chapel Hill|National Institute on Minority Health and Health Disparities (NIMHD)",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",20-2193|1R01MD015388-01A1,Feb-21,Oct-24,Oct-24,12-Jan-21,,12-Jan-21,"The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04705779
NCT04684836,Comparative Effectiveness of Telemedicine in Primary Care,,Not yet recruiting,No Results Available,Asthma|Chronic Obstructive Pulmonary Disease (COPD|Congestive Heart Failure|Diabetes|Hypertension,"Other: Exposure to telemedicine, after the onset of the pandemic",Number of avoidable emergency department (ED) admissions|Number of unplanned hospital admissions from the ED|Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index|Continuity of care as assessed by the Breslau Usual Provider of Care measure|Continuity of care as assessed by attendance at follow-up appointment|Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)|Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure|Days at home|Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18)|Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ),Weill Medical College of Cornell University|Patient-Centered Outcomes Research Institute,All,"19 Years and older   (Adult, Older Adult)",,216000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-12023014,Feb-21,Apr-22,Dec-23,28-Dec-20,,28-Dec-20,"University of Florida, Gainesville, New York, United States|Mount Sinai, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04684836
NCT03451630,PCORI Integrated Care (IC) Models for Patient-Centered Outcomes,IC,Recruiting,No Results Available,Diabetes|Arthritis|Asthma|Chronic Obstructive Pulmonary Disease|Hypertension|Anxiety|Atrial Fibrillation|Congestive Heart Failure|Depression|Bipolar Disorder|Schizophrenia,Behavioral: High-Touch|Behavioral: High-Tech|Behavioral: Usual Care/Optimal Discharge Planning,"Patient activation|Change in Health Status|Change in Hospital Readmission Rate|Functional status|Quality of life, enjoyment and satisfaction|Care satisfaction|Emergent care|Engagement in primary, specialty, mental health care|Gaps in care",University of Pittsburgh|Patient-Centered Outcomes Research Institute,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,1927,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1609-36670,23-Apr-18,31-May-21,31-Jan-23,2-Mar-18,,20-Aug-20,"UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03451630
NCT03443635,Cooking for Health Optimization With Patients,CHOP,Recruiting,No Results Available,Cardiovascular Diseases|Cardiovascular Risk Factor|Nutrition Disorders|Diabetes|Hypertension|Cancer|Depression|Obesity|Physical Activity,Behavioral: Treatment,"Mediterranean diet adherence|Hospital readmissions|Composite rate of all cause-mortality, myocardial infarction, and cerebrovascular event|Competencies|Healthcare costs|Food costs",Tulane University,All,"7 Years to 115 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,19500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHOP,1-Feb-18,1-Feb-28,1-Feb-28,23-Feb-18,,3-Dec-18,"The Goldring Center for Culinary Medicine at Tulane University School of Medicine, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT03443635
NCT03815110,Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification,PRAECIS,Recruiting,No Results Available,Preeclampsia and Eclampsia|Preeclampsia Severe|Gestational Hypertension|Chronic Hypertension in Obstetric Context|Superimposed Pre-Eclampsia|Preeclampsia Mild,,Derivation and Performance of Cut-off for sFLT-1/PlGF Ratio (Serum)|Validation of Cut-off and Performance of sFLT-1/PlGF Ratio as Defined in Derivation Cohort (Serum)|Performance in Determining the Risk for Adverse Maternal Outcomes|Performance in Determining the Risk for Adverse Fetal/Neonatal Outcomes|Performance As Compared to ACOG-Guidelines|Performance of sFLT-1/PlGF & ACOG Guidelines|Time to Delivery|sFLT-1 and PlGF Levels in Urine and Saliva,Cedars-Sinai Medical Center|ThermoFisher Scientific Brahms Biomarkers France,Female,"18 Years and older   (Adult, Older Adult)",,1000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00055135,20-Dec-18,Dec-20,May-21,24-Jan-19,,18-Feb-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States|Sharp Mary Birch Hospital for Women & Newborns, San Diego, California, United States|UC San Francisco Medical Center, San Francisco, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|University of South Florida, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of North Carolina Medical Center- Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03815110
NCT03973931,Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications,,Recruiting,No Results Available,"Cardiovascular Diseases|Adherence, Medication|Medication Adherence|Diabetes Mellitus|Hypertension|Hyperlipidemias|Coronary Artery Disease|Atrial Fibrillation",Behavioral: Nudge,"Medication adherence|Blood pressure|Low-density lipoproteins (LDL)|Hemoglobin A1c|Hospitalizations rate (Cardiovascular clinical events)|Emergency Department admission rates (Cardiovascular clinical events)|Percutaneous coronary intervention (PCI) rates, (Cardiovascular clinical events)|Coronary artery bypass graft (CABG) rates, (Cardiovascular clinical events)|Cardioversion rates (Cardiovascular clinical events)|All-cause hospitalizations (Hospitalizations)|All-cause Emergency Department admissions (Hospitalizations)|Implementation costs (Costs)|Healthcare utilization costs (Costs)","University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,5000,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,18-2779|UH3HL144163,1-Jul-19,30-Jun-22,30-Jun-23,4-Jun-19,,4-Nov-20,"Rocky Mountain VA, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|Denver Health and Hospital Authority, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03973931
NCT04311749,Expanded NIPT for Pregnancy Complications,,Recruiting,No Results Available,Fetal Growth Restriction|Preeclampsia Severe,Genetic: Expanded panel cell free DNA testing (non-invasive prenatal testing)|Genetic: Placental biopsy|Genetic: Umbilical cord blood,Composite adverse pregnancy outcome|Preterm birth < 34 weeks|Neonatal intensive care unit admission|Intrauterine fetal demise|Neonatal demise,"University of California, San Francisco",Female,18 Years to 60 Years   (Adult),,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19-27769,12-Feb-20,28-Feb-22,28-Feb-22,17-Mar-20,,17-Mar-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04311749
NCT02951130,Milrinone in Congenital Diaphragmatic Hernia,,Recruiting,No Results Available,Congenital Diaphragmatic Hernia|Persistent Pulmonary Hypertension of the Newborn|Hypoxemic Respiratory Failure|Pulmonary Hypoplasia,Drug: Milrinone|Drug: Placebo (5% Dextrose),Oxygenation Response|Oxygenation Response at 48 and 72 h|Changes in estimated systolic pulmonary arterial pressure on echocardiogram|Vasoactive Inotrope Score and Systemic Blood Pressure|Area Under the Curve for Inspired Oxygen|Oxygenation Response to Additional Inotropes or Pulmonary Vasodilators|Supplemental Continuous Oxygen|Survival to discharge without ECMO|Clinical status (Pulmonary and Nutritional)|Feasibility and sample size calculation to Perform a Definitive Trial (primary outcome - improvement in survival without ECMO|Feasibility to perform a definitive trial (incidence of systemic hypotension)|Feasibility to perform a definitive trial (incidence of intracranial bleeding)|Feasibility to perform a definitive trial (incidence of arrhythmias)|Adjusted Oxygen Response,NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,up to 168 Hours   (Child),Phase 2,66,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NICHD-NRN-0057|UG1HD034216|UG1HD027904|UG1HD021364|UG1HD027853|UG1HD040689|UG1HD040492|UG1HD027851|UG1HD087229|UG1HD053109|UG1HD068278|UG1HD068244|UG1HD068263|UG1HD027880|UG1HD053089|UG1HD087226|U10HD036790,22-Aug-17,Feb-21,Feb-21,1-Nov-16,,22-May-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02951130
NCT02037659,Dermabond Treatment for Gastric Variceal Bleeding,,Recruiting,No Results Available,Gastric Varices,Procedure: DermaBond treatment of Gastric Varices,To determine the clinical impact of endoscopic ultrasound treatment of gastric variceal bleeding.,Indiana University,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Dermabond,Dec-12,Dec-19,Dec-20,16-Jan-14,,22-Apr-19,"Indiana University Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02037659
NCT03973372,ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement,,Recruiting,No Results Available,"Cirrhosis, Liver|Transjugular Intrahepatic Portosystemic Shunt (TIPS)",,To prospectively collect clinical information on the use and outcomes associated with contemporary real-world practice of Transjugular Intrahepatic Portosystemic Shunts (TIPS)|The goals of the ALTA consortium are to answer key clinical questions related to contemporary patterns of TIPS usage as well as clinical outcomes.|Create a database that will serve to inform and answer clinically related questions about the optimization of TIPS and management.,"Northwestern University|University of California, San Francisco|Scripps Health|University of Wisconsin, Madison|University of Florida|University of Arizona|Stanford University|Columbia University|Weill Medical College of Cornell University|Baylor Scott and White Health|Mayo Clinic|University of Chicago|Digestive Health Foundation|Gore",All,"18 Years and older   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STU00208288,10-Jun-19,Jul-24,Jul-24,4-Jun-19,,11-Sep-20,"University of Arizona, Phoenix, Arizona, United States|Stanford, Redwood City, California, United States|Scripps Health, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|Northwestern, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Columbia University, New York, New York, United States|Weill Cornell, New York, New York, United States|Baylor Scott & White Liver Consultants of Texas, Dallas, Texas, United States|University of Wisconsin Madison, Madison, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03973372/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03973372
NCT02780414,Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers,,Recruiting,No Results Available,Preeclampsia|Hypertension|Proteinuria|Thrombocytopenia|Renal Insufficiency|Impaired Liver Function|Pulmonary Edema,,Suspected and Pre-E cases determined by institutional standards,"Progenity, Inc.",Female,18 Years to 45 Years   (Adult),,1791,Industry,Observational,Observational Model: Family-Based|Time Perspective: Prospective,PRO-104-PREECLAMPSIA,Jan-16,May-21,Sep-21,23-May-16,,17-Sep-20,"Center of Research in Women's Health, Birmingham, Alabama, United States|University of Colorado, Aurora, Colorado, United States|Yale Medical, New Haven, Connecticut, United States|Northwestern, Chicago, Illinois, United States|Indiana University Health Physicians Women's Health, Indianapolis, Indiana, United States|Johns Hopkins Medicine, Baltimore, Maryland, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington Univ School of Medicine - Dept of OB-GYN, Saint Louis, Missouri, United States|Winthrop Clinical Trials Center, Mineola, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Regional Obstetrical Consultants, PC, Chattanooga, Tennessee, United States|Austin Maternal Fetal Medicine, Austin, Texas, United States|University of Texas Medical Branch, Galveston, Galveston, Texas, United States|UT Health Medical School, Houston, Texas, United States|University of Utah Hospital, OB/GYN Dept., Salt Lake City, Utah, United States|Medical College of Wisconsin - Department of Obstetrics & Gynecology, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02780414
NCT03626688,A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients,,Recruiting,No Results Available,"PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease",Drug: Ralinepag|Drug: Placebo,"Time from randomization to the first adjudicated protocol-defined clinical worsening event|Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change from Baseline in 6-minute walk distance (6MWD)|Change from Baseline in WHO/New York Heart Association (NYHA) Functional Class|Shift and proportion of subjects who attain all 3 of the following: NT-proBNP level <300 pg/mL, 6MWD >440 meters, and WHO/NYHA Functional Class I or II|Change from Baseline in health-related quality of life as measured by patient-reported outcomes.|Change from Baseline in heart rate recovery (HRR) following completion of the 6MWT|Time to all-cause nonelective hospitalization|Time to all-cause mortality|Safety and tolerability of ralinepag in subjects with PAH",United Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,700,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROR-PH-301|APD811-301,30-Aug-18,Dec-21,Dec-21,13-Aug-18,,21-Dec-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UCSD Health Sciences, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of California Davis Medical Center Sacramento, Sacramento, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Chest Medicine Associates, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Medicine, Omaha, Nebraska, United States|University of New Mexico, Albuquerque, New Mexico, United States|Winthrop Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill-Cornell-New York Presbyterian Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati-Medical Science Building, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NewSTAT, PLLC, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Vermont Lung Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|Hospital Italiano, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Respirar, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|Hospital Italiano de Cordoba, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Instituto de Investigaciones Clinicas, Mar Del Plata, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|Ordensklinikum Linz GmbH - Elisabethinen, Fadingerstrasse 1, Linz, Austria|AKH Wien, Innere Med. II, Kardiologie, Währingergürtel 18-20, Wien, Austria|Cliniques Universitaires de Bruxelles Hopital Erasme, Bruxelles, Belgium|UZ Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, Leuven, Belgium|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, MG, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, R.S, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Sao Paulo, Sao Paulo, SP, Brazil|Instituto do Coracao, Sao Paulo, SP, Brazil|MHAT - ""National Heart Hospital"" EAD, 65, Konyovitza Str., Sofia, Bulgaria|MHAT ""Sveta Anna"" Sofia AD, Sofia, Bulgaria|Peter Lougheed Centre, Calgary, Alberta, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|University Health Network-Toronto General Hospital, Toronto, Ontario, Canada|SMBD Jewish General Hospital d/b/a Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec, Quebec, Canada|Instiuto Nacional del Torax, Providencia, Santiago De Chile, Chile|Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China|Clinical Hospital Dubrava Zagreb, Avenija G.Šuška 6, Zagreb, Croatia|University Clinic for Pulmonary Diseases, Jordanovac 104, Zagreb, Croatia|Vseobecna fakultni nemocnice v Praze, II. interni klinika kardiologie a angiologie VFN a 1. LF UK, U nemocnice 2, Praha 2, Czechia|Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark|Århus Universitetshospital, Århus, Denmark|CHU de Strasbourg - Nouvel Hôpital Civil, Ctre de competence Hypertension Arterielle Pulmona, 1 place de l Hopital, Strasbourg, Bas Rhin, France|CHU de Grenoble - Hôpital Albert Michallon, Clinique de Cardiologie, Boulevrad de la Chantourne, Grenoble, Isere, France|CHU de Saint-Etienne - Hopital Nord, Service de Medecine vasculaire et therapeutique, 81 Avenue A. Raimond, Saint-Étienne, Loire, France|CHU Nancy - Hôpital de Brabois Adultes, Pneumologie- Oncologie Médicale, Rue du Morvan, Vandoeuvre les Nancy, Meurthe Et Moselle, France|CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Service de Pneumologie, 59 Boulevard Pinel, Bron cedex, Rhone, France|Groupement Hospitalier Sud - Hôpital Bicêtre, Le Kremlin-Bicêtre, Val De Marne, France|Universitaetsmedizin der Johannes-Gutenberg-Universitaet Mainz, Zentrum für Kardiologie I, Centrum für Thrombose und Hämostase (CTH), Langenbeckstrasse 1, Mainz, Rheinland Pfalz, Germany|Universitaetsklinikum des Saarlandes, Innere Medizin V, IMED, Kirrberger Strasse 100, Gebäude 41, Homburg, Saarland, Germany|University General Hospital Attikon, 1 Rimini Street, Chaidari, Athens, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|""Onasseio"" Cardiosurgery Hospital, Hemodynamic Research and Interventional Cardiology Dept., 356, Syggrou Avenue, Athens, Greece|AHEPA General Hospital of Thessaloniki, A' Cardiology Clinic, 1 St. Kyriakidi Street, Thessaloniki, Greece|Pecsi Tudomanyegyetem, Szivgyogyaszati Klinika, Ifjusag u. 13., Pecs, Hungary|The Lady Davis Carmel Medical Center, 7 Michal st., Haifa, Israel|Hadassah Ein Kerem Medical Center, Kiryat Hadassah, Jerusalem, Israel|Meir Medical Center, 59 Tshernichovski st., Kfar- Sava, Israel|Rabin Medical Center-Beilinson Campus, Pulmonary Institute, 39 Jabotinsky St Ground floor, Petach Tikva, Israel|Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, S.C. di Cardiologia, Viale Luigi Pinto, 1, Foggia, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, Milano, Italy|Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza, Viale del Policlinico, 155, Roma, Italy|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Gachon University Hospital Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of|VU Medisch Centrum, De Boelelaan 1117, Amsterdam, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Kardiologii z Oddzialem Intensywnego Nazdoru Kardiologicznego, M. Sklodowskiej 24a, Bialystok, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddział Kliniczny Chorób Serca i Naczyń z Pododdziałem Intensywnego Nadzoru Kardiologicznego, Pradnicka 80, Krakow, Poland|NZOZ Europejskie Centrum Zdrowia, ul. Borowa 14/18, Otwock, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Oddzial Kardiologii - F, ul. Dluga 1/2, Poznan, Poland|Premium Clinic Wrocław CM, Podwale 83/17, Wroclaw, Poland|Institutul de Urgenta pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Sos. Fundeni nr. 258, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Sos. Viilor nr. 90, Sector 5, Bucuresti, Romania|Institutul Inimii ""Niculae Stancioiu"" Cluj-Napoca, Cardiologie, Str. Motilor nr. 19-21, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie ""Dr. Victor Babes"" Timisoara, Str. Gheorghe Adam nr. 13, Timisoara, Romania|Clinical Center of Serbia, Koste Todorovica 8, Belgrade, Serbia|Institute for Pulmonary Diseases of Vojvodina, Put Dr Goldmana 4, Sremska Kamenica, Serbia|National University Hospital, Singapore, Singapore|National Heart Centre, Singapore, Singapore|Hospital Universitari Vall d'Hebron, Respiratory Dept., Passeig Vall d'Hebron,119-129, Neumologia, Barcelona, Spain|Hospital Clinic de Barcelona, C/ Villarroel, 170, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Linköping Universitetssjukhuset, Linköping, Sweden|Norrlands Universitetssjukhus, Hjärtcentrum, Umeå, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Uludag Universitesi Tip Fakültesi, Gorukle Kampusu, Bursa, Turkey|Marmara Universitesi Istanbul Pendik Egitim ve Arastirma Hastanesi, Fevzi Cakmak Mahallesi Muhsin Yazicioglu Cad. No: 10, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Mithatpasa caddesi Inciralti Balcova, Izmir, Turkey|CE Dniprop RCC&C Center of Dniprop RC Dept of Card SI DMA of MOHU, Chair of Internal Medicine 3, 28, Knyazya Volodymyra Velykogo St., Dnipro, Ukraine|SI F.H.Yanovskyi National Institute of Phthisiology and Pulmonology of NAMSU, Clinical and Functional Dept, 10, Amosova St., Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council Lviv Clinical Hospital, Dept of Cardiology, D.Halytskyi Lviv NMU, Ch of Internal Medicine #1, 7, Chernihivska str., Lviv, Ukraine|Royal Free London NHS Foundation Trust, Pond Street, London, Greater London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir William Leech Lung Research Centre, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Golden Jubilee National Hospital, Glasgow, West Dunbartonshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03626688
NCT02947750,Neurovascular Transduction During Exercise in Chronic Kidney Disease,NeurovEx,Recruiting,No Results Available,"Renal Insufficiency, Chronic",Drug: 6R-BH4|Other: 6R-BH4 placebo|Dietary Supplement: Folic acid|Other: Exercise training|Other: Stretching|Dietary Supplement: Histidine and beta-alanine supplementation|Other: Histidine and beta-alanine placebo,Change in functional sympatholysis|Change in vascular alpha 1 adrenergic responsiveness|Change in exaggerated pressor responses during exercise|Renal artery resistance during exercise|Change in endothelial function|Change in vascular stiffness,"Emory University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,150,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,IRB00091660|R01HL135183,Oct-16,1-Sep-22,1-Sep-22,28-Oct-16,,3-Nov-20,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02947750
NCT04465630,"A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma",ORION,Recruiting,No Results Available,"Glaucoma, Open-Angle",Device: OMNI® Surgical System,Decrease in intraocular pressure (IOP)|Decrease in number of medications,"Sight Sciences, Inc.",All,"22 Years and older   (Adult, Older Adult)",Not Applicable,110,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6807,19-Jun-20,May-22,May-22,10-Jul-20,,22-Jul-20,"Vold Vision, Fayetteville, Arkansas, United States|North Bay Eye Associates, Petaluma, California, United States|Assil Eye Institute, Santa Monica, California, United States|Grene Vision Group, Wichita, Kansas, United States|Minnesota Eye Consultants, Bloomington, Minnesota, United States|Oklahoma Eye Surgeons, Oklahoma City, Oklahoma, United States|University Eye Specialists, Maryville, Tennessee, United States|El Paso Eye Surgeons, El Paso, Texas, United States|Ophthalmology Associates - Fort Worth, Fort Worth, Texas, United States|Utah Eye Centers, Ogden, Utah, United States",,https://ClinicalTrials.gov/show/NCT04465630
NCT02785042,Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3),,Recruiting,No Results Available,Glaucoma,Device: Heidelberg Spectralis OCT,Bruch-Membrane-Opening - Minimum Rim Width (µm)|Bruch-Membrane-Opening - Minimum Rim Area (µm^2)|Peripapillary Retinal Nerve Fibre Layer Thickness (µm),Heidelberg Engineering GmbH,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,249,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,S-2015-3-hi,Jun-16,Feb-21,Feb-21,27-May-16,,29-Jul-20,"University California San Diego, La Jolla, California, United States|Assil Eye Institute, Santa Monica, California, United States|North Bay Eye Associates, Santa Rosa, California, United States|Mid Florida Eye Center Clinic, Mount Dora, Florida, United States|Illinois Eye Institute, Illinois College of Optometry, Chicago, Illinois, United States|SUNY College of Optometry, New York, New York, United States|Ophthalmic Consultants of Long Island-Valley Stream, Valley Stream, New York, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02785042
NCT02785029,Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1),,Recruiting,No Results Available,Glaucoma,Device: OCT,Bruch-Membrane-Opening - Minimum Rim Width (µm)|Bruch-Membrane-Opening - Minimum Rim Area (µm^2)|Peripapillary Retinal Nerve Fibre Layer Thickness (µm),Heidelberg Engineering GmbH,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,249,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,S-2015-1-aa,Jun-16,Feb-21,Feb-21,27-May-16,,29-Jul-20,"University California San Diego, La Jolla, California, United States|Assil Eye Institute, Santa Monica, California, United States|Mid Florida Eye Center Clinic, Mount Dora, Florida, United States|Illinois Eye Institute, Illinois College of Optometry, Chicago, Illinois, United States|St Albans Community Living, Center, Queens Campus, Jamaica, New York, United States|SUNY College of Optometry, New York, New York, United States|Ophthalmic Consultants of Long Island-Valley Stream, Valley Stream, New York, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02785029
NCT03629912,Bingocize: A Novel Mobile Application for Older Adult Health,Bingocize,Recruiting,No Results Available,"Activities of Daily Living|Accidental Fall|Sarcopenia|Arteriosclerosis|Diabetes Mellitus, Type 2|Hypertension|Cognitive Decline|Executive Function|Cognitive Aging",Behavioral: Socially-Based Exercise Intervention for Older Adults,Changes in Executive Function - Inhibition Measure 1|Changes in Executive Function - Updating|Changes in Executive Function - Shifting|Changes in Executive Function - Fluency|Change in lower-body muscular strength|Change in dynamic balance|Changes in Executive Function - Inhibition Measure 2|Changes in Knowledge of Fall Risks and Proper Diet/Nutrition|Changes in upper body muscular strength|Changes in Fall Efficacy|Changes in Dietary Habits|Changes in Quality of Life|Changes in Weight|Changes in Blood Pressure,Western Kentucky University|National Institute on Aging (NIA),All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,160,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB 18-048|R15AG055906,14-Aug-18,13-Aug-21,13-Aug-21,14-Aug-18,,20-May-20,"Webster County Senior Center, Dixon, Kentucky, United States|Chester County Senior Center, Henderson, Tennessee, United States|Johnson County Senior Center, Johnson City, Tennessee, United States|Scotts Hill Senior Center, Scotts Hill, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03629912
NCT04551807,Natural Versus Programmed Frozen Embryo Transfer (NatPro),NatPro,Recruiting,No Results Available,Pregnancy Related|Pre-Eclampsia,Procedure: Modified natural cycle|Procedure: Programmed cycle,Preeclampsia,JHSPH Center for Clinical Trials,Female,18 Years to 41 Years   (Adult),Phase 3,788,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,IRB00214688,19-Aug-20,Sep-25,Sep-26,16-Sep-20,,20-Nov-20,"Stanford University, Sunnyvale, California, United States|Johns Hopkins, Baltimore, Maryland, United States|Shady Grove Fertility, Rockville, Maryland, United States|University of Rochester, Rochester, New York, United States|Atrium Health, Charlotte, North Carolina, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|CARE Fertility, Bedford, Texas, United States",,https://ClinicalTrials.gov/show/NCT04551807
NCT03206060,Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma,,Recruiting,No Results Available,Pheochromocytoma|Paraganglioma|Neuroendocrine Tumors|Neuroendocrine Neoplasms,Drug: Lu-177-DOTATATE|Drug: Ga-68-DOTATATE|Drug: F-18-FDG|Drug: Amino Acid solution,progression-free survival|safety and tolerability profile|Determine ability to decrease anti-hypertensive medication|Evaluate Quality of Life|Determine changes in plasma biochemical markers|Time to tumor progression|Objective response rate|Overall survival,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,170087|17-C-0087,10-Oct-17,1-Jan-23,1-Jan-25,2-Jul-17,,11-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03206060
NCT04334135,The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function,MAVHS,Recruiting,No Results Available,Racial Disparities|Blood Pressure|Cardiovascular Risk Factor|Renal Function,Dietary Supplement: MitoQ,Changes in flow-mediated dilation (FMD)|Changes in indices of arterial stiffness|Changes in muscle sympathetic nerve activity (MSNA) and sympathetic transduction|Changes in blood pressure reactivity|Changes in circulating reactive oxygen species|Changes in blood biomarkers of nitric oxide bioavailability|Objective sleep duration and quality|Subjective sleep duration and quality|Physical activity|Cardiorespiratory fitness|Mental health - social anxiety|Mental health - depression|Habitual dietary intake,Auburn University,All,"19 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,AU IRB#20-105,5-Oct-20,31-May-22,31-May-23,6-Apr-20,,22-Sep-20,"Kinesiology Building, Auburn, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04334135
NCT04424693,Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36,,Not yet recruiting,No Results Available,"Pre-Eclampsia|Diphtheria, Tetanus and Pertussis Vaccine Reaction",Drug: Tdap Vaccine Administration,"Incidence of preeclampsia in each arm of the study with regards to timing of Tdap vaccination|Incidence of preeclampsia in each arm of the study with regards to the quantitative anti-tetanus toxoid antibody level|Assessment of other potential risk factors for preeclampsia inclusive of BMI, hypertension, prior history of preeclampsia, first pregnancy",Institute of Arthritis Research|Louisiana State University Health Sciences Center in New Orleans|Brigham Young University,Female,18 Years to 42 Years   (Adult),Phase 4,1600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PE-Tdap01,1-Dec-20,1-Oct-23,31-Dec-24,11-Jun-20,,16-Jun-20,"Institute of Arthritis Research, Idaho Falls, Idaho, United States",,https://ClinicalTrials.gov/show/NCT04424693
NCT02221830,Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study),PHP3,Recruiting,No Results Available,Preeclampsia,Drug: Oxytocin|Drug: Placebo,Evaluation of Postpartum hematocrit|Primary postpartum hemorrhage|Estimated blood loss at delivery|Postpartum blood loss,"University of Colorado, Denver",Female,"13 Years to 45 Years   (Child, Adult)",Early Phase 1,124,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",13-2738|UL1TR001082,Feb-15,Dec-20,Dec-20,20-Aug-14,,18-Jan-20,"University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02221830
NCT04278404,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",POPS or POP02,Recruiting,No Results Available,Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Fibrinolysis; Hemorrhage|Attention Deficit Hyperactivity Disorder|Multisystem Inflammatory Syndrome in Children (MIS-C)|Kawasaki Disease|Coagulation Disorder|Down Syndrome,"Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,5-Mar-20,24-Apr-24,24-Apr-24,20-Feb-20,,14-Oct-20,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|University of California, Los Angeles, California, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas-Southwestern Medical Center, Dallas, Texas, United States|University of Texas--Memorial Hermann Texas Medical Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04278404
NCT04615091,Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery,,Recruiting,No Results Available,Advanced Chronic Liver Disease|Surgery--Complications,,Early post-surgical (at +90 days) complications after extrahepatic surgery|The liver-related events and overall survival at +90 days and + 360 days after extrahepatic surgery,Azienda Ospedaliera Universitaria Integrata Verona,All,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,39512,30-Aug-20,Oct-21,Aug-22,4-Nov-20,,4-Nov-20,"Yale New Haven Hospital, New Haven, Connecticut, United States|Medical University of Vienna, Vienna, Austria|University of Alberta Hospital, Edmonton, Canada|McGill University Health Centre, Montréal, Canada|Odense University Hospital, Odense, Denmark|University hospital of Angers, Angers, France|Hopital Jean Verdier, Bondy, France|Hôpital Jean Verdier, Bondy, France|Bordeaux University Hospital, Bordeau, France|Hôpital Beaujon, Clichy, France|Hospices Civils de Lyon Hopital Hotel Dieu, Lyon, France|Centre Hospitalier de Montpellier, Montpellier, France|hôpital Antoine-Béclère, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Paris, France|Hôpital de la Pitié-Salpêtrière, Paris, France|Purpan Hospital Toulouse, Toulouse, France|University Hospital Leipzig, Leipzig, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Aoui Borgo Trento, Verona, VR, Italy|Clinica di Gastroenterologia ed Epatologia Ancona, Ancona, Italy|Gastroenterology Unit - Azienda Ospedaliera Universitaria Sant'Orsola - Malpighi, Bologna, Italy|Ospedale di Bolzano, Bolzano, Italy|Azienda ospedaliero-universitaria Careggi, Firenze, Italy|Policlinico di Milano, Milan, Italy|Policlinico di Modena, Modena, Italy|Gastroenterology Unit, University of Palermo, Palermo, Italy|Università Sapienza, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|ASUGI Clinica Patologie del Fegato, Clinica Chirurgica, Trieste, Italy|Hanyang University Guri Hospital, Hanyang, Korea, Republic of|Boramae Internal Medicine, Seoul, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of|Barcelona Hepatic Hemodynamic Lab. Liver Unit. Hospital Clinic. Barcelona, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Inselspital, Bern, Switzerland|Ente Ospedaliero Cantonale, Lugano, Switzerland|UCL Sheila Sherlock, London, United Kingdom|Room Nottingham Digestive Diseases Centre BRU, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT04615091
NCT04334499,Mitochondrial DNA in Vitreous Fluid and Blood in Patients With Eye Disease or Ocular Trauma.,,Recruiting,No Results Available,Eye Diseases|Ophthalmic Trauma|Mitochondrial DNA|Age Related Macular Degeneration|Glaucoma|Diabetic Retinopathy,Other: Sample collection from tissue discard,Quantitation of mitochondrial DNA in vitreous humor and serum samples|Evaluation of mtDNA quantitation versus ocular comorbities as described in electronic medical record.,"The University of Texas Medical Branch, Galveston",All,"20 Years to 100 Years   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19-0291,21-Sep-20,26-Jan-22,26-Feb-22,6-Apr-20,,26-Oct-20,"University of Texas Medical Branch, Ophthalmology Clinical Research Center, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04334499
NCT04091087,Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis,,Recruiting,No Results Available,Stasis Dermatitis,Drug: crisaborole ointment|Other: vehicle ointment,Percent change from baseline in Total Sign Score|Investigator's Static Global Assessment|Investigators Static Global Assessment|Total Sign Score|Lesional percent body surface area,Pfizer,All,"45 Years and older   (Adult, Older Adult)",Phase 2,92,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C3291038,26-Jun-20,23-Aug-21,23-Aug-21,16-Sep-19,,14-Dec-20,"Lightship, El Segundo, California, United States|Hawthorne Effect, Inc, Lafayette, California, United States|Verily Life Sciences LLC, South San Francisco, California, United States|Onco360 Oncology Pharmacy, Louisville, Kentucky, United States|Onco360 Oncology Pharmacy, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04091087
NCT00081523,Natural History of Sickle Cell Disease,,Recruiting,No Results Available,Pain Crisis,,"gather through clinical experience information regarding the natural history, co-morbid conditions and outcomes, and complicationsrelating to sickle cell disease and other hemolytic disorders in minority/ethnic patients","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years to 99 Years   (Child, Adult, Older Adult)",,3500,NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,040161|04-H-0161,29-Apr-04,,,15-Apr-04,,20-Nov-20,"Childrens National Medical Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00081523
NCT03105661,Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients,,Recruiting,No Results Available,"Obesity, Morbid|Preeclampsia",Drug: Labetalol Hydrochloride 200 mg|Drug: NIFEdipine 60 mg|Drug: Atenolol 25 mg,Rates of preeclampsia in morbidly obese pregnant women,University of Tennessee Graduate School of Medicine,Female,18 Years to 51 Years   (Adult),Early Phase 1,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,4226,4-Apr-17,31-Dec-19,4-Mar-20,10-Apr-17,,22-Feb-19,"University of Tennessee Medical Center, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03105661
NCT03910413,Dual Energy CT as a Noninvasive Method to Screen for Gastroesophageal Varices,,Recruiting,No Results Available,Gastroesophageal Varices,Diagnostic Test: Duel Energy CT,To measure the accuracy of dual energy CT for detecting any varices and high-risk varices in patients with cirrhosis presenting for upper gastrointestinal endoscopy.,University of Alabama at Birmingham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,R18-098,5-Jun-19,Jul-22,Jul-23,10-Apr-19,,17-Sep-20,"UAB Hospital Outpatient Imaging, Leeds and Gardendale locations, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT03910413
NCT04615403,Study of Exchange of Travoprost Intraocular Implant,,Not yet recruiting,No Results Available,Open Angle Glaucoma,Drug: Travoprost,Ocular Safety Measures|Intraocular Pressure|Visual Acuity|Corneal Edema|Corneal Opacity|Corneal Epithelium|Corneal Endothlium|Anterior Chamber Cells|Anterior Chamber Flare|Iris - Neovascularization|Iris - Atrophy|Iris - Pigment Dispersion|Pupil|Lens Status|Gonioscopy|Specular Microscopy|Dilated Fundus Examination|Visual Field,Glaukos Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IDOS-106-EXCH,Nov-20,Feb-22,Feb-22,4-Nov-20,,5-Nov-20,"Inland Eye Specialists, Hemet, California, United States|North Bath Eye Associates, Inc., Petaluma, California, United States|Eye Center of northern Colorado, PC, Fort Collins, Colorado, United States|The Eye Associates of Manatee, Manatee, Florida, United States|Ocala Eye, Ocala, Florida, United States|Center for Sight, Sarasota, Florida, United States|Jones Eye Clinic, Sioux City, Iowa, United States|D'Ambrosio Eye Care, Lancaster, Massachusetts, United States|Northern New Jersey Eye Institute, South Orange, New Jersey, United States|Oklahoma Eye Surgeons, Oklahoma City, Oklahoma, United States|Vance Thompson Vision, Sioux Falls, South Dakota, United States|Texan Eye, Austin, Texas, United States|Lehmann Eye Center, Nacogdoches, Texas, United States|Asian Eye Institute, Makati City, Philippines",,https://ClinicalTrials.gov/show/NCT04615403
NCT04553523,Hydrus(R) Microstent New Enrollment Post-Approval Study,,Recruiting,No Results Available,Primary Open Angle Glaucoma,Device: Hydrus Microstent,Occurrence of clinically significant device malposition|Occurrence of intraoperative ocular adverse events|Occurrence of sight threatening post-operative adverse events|Occurrence of other postoperative ocular adverse events,"Ivantis, Inc.",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,330,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP 18-001,25-Aug-20,May-24,Sep-24,17-Sep-20,,17-Sep-20,"Sacramento Eye Consultants, A Medical Corporation, Sacramento, California, United States|Eye Center of Northern Colorado, Fort Collins, Colorado, United States|Fraser Eye Care Center, Fraser, Michigan, United States|North Suburban Eye Specialists, Coon Rapids, Minnesota, United States|Center for Sight, Las Vegas, Nevada, United States|Carolina Eye Associates, Southern Pines, North Carolina, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|El Paso Eye Surgeons, PA, El Paso, Texas, United States|Texas Eye & Laser Center, Hurst, Texas, United States|The Eye Centers of Racine and Kenosha LTD, Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04553523
NCT04543838,IMMPRES: Intraoperative Monitoring & Management to Reduce Stroke,,Not yet recruiting,No Results Available,Cardiac Surgery,Diagnostic Test: Intervention|Other: Standard of Care BP management,"Proportion of patients with a new clinical stroke, new overt stroke, and death|Proportion of patients with cognitive decline|Proportion of patients with transient ischemic attack|Proportion of patients with delirium|Proportion of patients with clinical stroke|Proportion of patients with composite of clinical stroke|Proportion of patients with MACE (death from any cause, non-fatal MI and stroke)|Proportion of patients with a decrease in quality of life|Proportion of patients with a discrete diffusion-weighted imaging (DWI) lesion|Overall volume of DWI lesion burden",Parthasarathy Thirumala|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,STUDY20070328,31-Jan-21,1-Nov-21,1-Feb-22,10-Sep-20,,4-Dec-20,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04543838
NCT02327312,Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty,,Recruiting,No Results Available,Primary Open-Angle Glaucoma,Device: Stents|Procedure: Laser|Device: Laser Trabeculoplasty,IOP reduction|% IOP reduction,Glaukos Corporation,All,"35 Years and older   (Adult, Older Adult)",Not Applicable,1200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GC-004,Nov-14,Feb-21,Feb-21,30-Dec-14,,8-Mar-19,"Glendale, Arizona, United States|Fayetteville, Arkansas, United States|Hemet, California, United States|Cape Coral, Florida, United States|Elizabeth City, North Carolina, United States|Fayetteville, North Carolina, United States|Memphis, Tennessee, United States|Fort Worth, Texas, United States|San Antonio, Texas, United States|Racine, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02327312
NCT03570632,Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Pregnancy in Diabetes",Drug: Metformin,Rate of hypertensive disorders of pregnancy|Home glucose levels throughout pregnancy|Birthweight|Neonatal morbidity,"Maisa N. Feghali, MD|University of Pittsburgh",Female,18 Years to 50 Years   (Adult),Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PRO18050459,8-Jul-19,Dec-21,Dec-21,27-Jun-18,,8-Jan-21,"Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03570632
NCT02471833,Health Evaluation in African Americans Using RAS Therapy,HEART,Recruiting,No Results Available,Alzheimer's Disease,Drug: Telmisartan 20mg|Drug: Telmisartan 40mg|Drug: Placebo,Change in concentration of cerebrospinal fluid angiotensin metabolites|Change in levels of plasma angiotensinogen|Change in levels of plasma renin|Change in levels of plasma angiotensin converting enzyme|Change in levels of plasma aldosterone|Change in levels of cerebrospinal fluid amyloid β42|Change in levels of cerebrospinal fluid T-tau|Change in levels of cerebrospinal fluid P-tau|Change in arterial function|Flanker Inhibitory Control and Attention Test|Set-shifting Test|Spatial 1-Back Test|Montreal Cognitive Assessment|Mini Mental State Examination (MMSE)|Wechsler Adult Intelligence Scale (WAIS)-Working Memory subtests|Wechsler Memory Scale-III Faces Test|Wechsler Memory Scale-Revised Logical Memory Test|Rey Auditory Verbal Learning Test|Arterial Spin Labeling-Magnetic Resonance Imaging|Structural Magnetic Resonance Imaging and White Matter Hyperintensities,Emory University,All,"30 Years and older   (Adult, Older Adult)",Phase 1,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",IRB00080192,Apr-15,30-Oct-21,30-Oct-21,15-Jun-15,,19-Dec-20,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02471833
NCT03596983,P20 Extending Sleep to Reverse Metabolic Syndrome in Middle-Aged Adults: Acceptability and Feasibility of a Sleep Intervention,,Recruiting,No Results Available,Metabolic Syndrome,Behavioral: Sleep Intervention|Behavioral: Week 2 Intervention,percentage of participants rating SASI|Recruitment rate measured by the percentage of potential participants screened in order to enroll 30 participants|Attrition rate measured by the percentage of enrolled participants completing the 15-week intervention|Protocol adherence rates measured by the percentage of participants completing greater than or equal to 4 daily sleep diary entries per week for 80% or more of the intervention period.,NYU Langone Health,All,35 Years to 60 Years   (Adult),Not Applicable,220,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,18-00707,10-Apr-19,31-Dec-23,31-Dec-23,24-Jul-18,,22-Jul-20,"New York University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03596983
NCT03170375,Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome,,Recruiting,No Results Available,Heart Failure,Behavioral: Performance of WHEELS-I in promoting DASH/SRD adoption|Behavioral: Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors,Carotid-femoral pulse wave velocity|Left ventricular mass index|Ventricular stiffness|Global longitudinal left ventricular strain|Global left atrial strain|Left atrial volume,VA Office of Research and Development,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,130,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CARA-009-16F|9050,2-Jan-19,30-Dec-22,30-Dec-22,31-May-17,,19-Oct-20,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03170375
NCT03774277,Chickasaw Healthy Eating Environments Research Study,CHEERS,Recruiting,No Results Available,Blood Pressure|Body Weight,Behavioral: Packed Promise for a Healthy Heart,Change in systolic blood pressure|Change in body mass index|Food access|Diet|Walking|Change in self-reported physical activity,Oklahoma State University Center for Health Sciences|The Chickasaw Nation|Washington State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7614,10-Jul-18,Feb-21,Feb-21,12-Dec-18,,1-Jul-20,"The Chickasaw Nation, Ada, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT03774277
NCT03376555,Cheese Consumption and Human Microvascular Function,,Recruiting,No Results Available,Microvascular Dysfunction,Drug: Acetylcholine (ACh) Dose Response|Drug: Local Heating (LH)|Drug: Flow Mediated Dilation with nitroglycerin,laser Doppler blood flow|Systolic Blood Pressure|Diastolic Blood Pressure|Flow Mediated Dilation,Lacy M. Alexander|National Dairy Council|Penn State University,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",STUDY4340|129552,Mar-16,30-Jan-21,30-Jan-21,18-Dec-17,,1-Apr-20,"Pennsylvania State University, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03376555
NCT04124848,Obstructive Sleep Apnea Among Somali-Americans,Somali OSA,Recruiting,No Results Available,Obstructive Sleep Apnea,,To assess the prevalence of obstructive sleep apnea|To determine the severity of obstructive sleep apnea|24 hour mean arterial pressure|Vascular endothelial function|Insulin sensitivity|Body composition,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19-000033,25-Oct-19,31-Dec-28,31-Dec-28,11-Oct-19,,8-Dec-20,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04124848
NCT03919136,Wrist Worn Blood Pressure Measurement,,Recruiting,No Results Available,Blood Pressure|Heart Failure|Advanced Heart Failure|Heart Failure，Congestive,Device: Wrist-worn measurement device (LiveMetric),Non-Oscillometric Blood Pressure Wrist Worn Data Acquisition and Analysis,LiveMetric S.A.,All,"18 Years and older   (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB18-1281,1-Aug-18,1-Oct-19,1-Oct-19,18-Apr-19,,19-Apr-19,"University of Chicago, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03919136
NCT03464396,Prematurity-Related Ventilatory Control,PreVent,Recruiting,No Results Available,Respiratory Control in Premature Infants,Other: Bedside Physiology study|Other: Carotid Body Function Test|Other: Room Air Challenge|Other: Hypoxia Challenge Test|Other: Effects of Nasal Cannula Flow|Diagnostic Test: Magnetic Resonance Imaging|Diagnostic Test: Echocardiogram|Other: Blood Sample,Respiratory phenotype based on physiologic testing,"Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",All,up to 14 Days   (Child),,375,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,201611138|5U01HL133700-02,14-May-18,1-Jun-21,30-Jun-21,14-Mar-18,,7-Aug-20,"Washington University, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03464396
NCT00001458,Evaluation of Patients With Heart Disease Not Eligible for Research Protocols,,Recruiting,No Results Available,Cardiovascular Disease,,training of staff,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"up to 99 Years   (Child, Adult, Older Adult)",,99999999,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,950047|95-H-0047,1-Jan-95,,,4-Nov-99,,17-Jul-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001458
NCT03899493,Electromyography in Labor and Parturition,,Recruiting,No Results Available,Labor,Other: Observation,Burst Characteristic RMS|Burst Characteristic Median Frequency|Burst Characteristic Duration|Burst Characteristics Amplitude,University of Arizona,Female,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Other|Time Perspective: Prospective,1809958902,29-Apr-19,Jun-21,Jun-21,2-Apr-19,,25-Sep-19,"Banner University Medical Center Phoenix, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03899493
NCT04373265,Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production,,Recruiting,No Results Available,Adrenocortical Carcinoma,Drug: Relacorilant|Drug: Pembrolizumab,Objective Response Rate (ORR)|Dose-limiting Toxicity (DLT)|Non-Progression Rate (NPR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Duration of response (DOR)|Clinical manifestations of cortisol excess,Corcept Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CORT125134-551,30-Sep-20,Nov-22,Feb-23,4-May-20,,10-Dec-20,"Site #150, Stanford, California, United States|Site #074, Ann Arbor, Michigan, United States|Site #183, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04373265
NCT04365868,Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis,,Recruiting,No Results Available,Prevention of Esophageal Varices|NASH - Nonalcoholic Steatohepatitis|Cirrhosis,Drug: belapectin|Drug: Placebo,"Proportion of patients in the belapectin treatment groups who develop new esophageal varices at 78 weeks [18 months] of treatment compared to placebo|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop varices (esophageal or gastric) requiring treatment|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop variceal bleed requiring hospitalization|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop clinically significant ascites requiring hospitalization|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop spontaneous bacterial peritonitis|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop hepatic encephalopathy (West Haven score ≥2 and requiring hospitalization)|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop mortality (all-cause)|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop liver transplant|Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop model for end-stage liver disease (MELD) score ≥15|Efficacy: Cumulative incidence rate of patients in the belapectin Phase 3 treatment group who progress to large varices (gastric or esophageal) or develop red wales compared to placebo.|Efficacy: Event-free survival by time to first cirrhosis related clinical event, progression to large varices or red wales|Efficacy: Event-free survival by time to first cirrhosis related clinical event, esophageal variceal hemorrhage requiring hospitalization|Efficacy: Event-free survival by time to first cirrhosis related clinical event, clinically significant ascites requiring hospitalization|Efficacy: Event-free survival by time to first cirrhosis related clinical event, spontaneous bacterial peritonitis|Efficacy: Event-free survival by time to first cirrhosis related clinical event, overt hepatic encephalopathy (West Haven score ≥2 and requiring hospitalization)|Efficacy: Event-free survival by time to first cirrhosis related clinical event, Child-Turcotte-Pugh (CTP) score increase of ≥2 points (from baseline)|Efficacy: Event-free survival by time to first cirrhosis related clinical event, model for end-stage liver disease (MELD) score increase to ≥15 as measured on 2 consecutive occasions|Efficacy: Event-free survival by time to first cirrhosis related clinical event, liver transplant|Efficacy: Event-free survival by time to first cirrhosis related clinical event, liver-related death",Galectin Therapeutics Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,1010,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",GT-031,22-Jun-20,Jun-23,Dec-23,28-Apr-20,,6-Jan-21,"The Institute for Liver Health, Chandler, Arizona, United States|Arizona Liver Health - Glendale, Glendale, Arizona, United States|Institute for Liver Health - Tucson, Tucson, Arizona, United States|Liver Wellness Center - Little Rock, Little Rock, Arkansas, United States|Southern California GI & Liver Centers, Coronado, California, United States|Om Research LLC, Lancaster, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC (ICR SITES) - Doral, Doral, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Florida Medical Center & Research, Zephyrhills, Florida, United States|Digestive Healthcare of Georgia, P.C., Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|IU Health University Hospital, Indianapolis, Indiana, United States|Kansas Medical Clinic PA, Topeka, Kansas, United States|Tandem Clinical Research, LLC, Marrero, Louisiana, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|Mercy Medical Center - The Institute for Digestive Health and Liver Disease, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Southern Therapy and Advanced Research (STAR) - Jackson, Jackson, Mississippi, United States|Kansas City Research Institute, Kansas City, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Lucas Research, Morehead City, North Carolina, United States|The Jefferson Digestive Health Institute - Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park, Germantown, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Liver Specialists of Texas, Austin, Texas, United States|South Texas Research Institute, Edinburg, Texas, United States|The Texas Liver Institute, Inc., San Antonio, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Gastroenterology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Bon Secours Liver Institute of Virginia - Newport News, Newport News, Virginia, United States|Bon Secours Liver Institute of Virginia - Richmond, Richmond, Virginia, United States|Soroka Medical Center, Be'er Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Ein Karem Hospital, Jerusalem, Israel|Holy Family Hospital, Nazareth, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|Fundacion de Investigacion de Diego, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04365868
NCT04490005,Outcome pRognostication of Acute Brain Injury With the NeuroloGical Pupil indEx,ORANGE,Not yet recruiting,No Results Available,Acute Brain Injury|Pupillary Reflex Impaired,Other: pupillometry,Correlation between abnormal Neurological Pupil index (NPi) and long-term outcome|Correlation between intracranial hypertension and abnormal NPI values,University of Milano Bicocca|University of Lausanne|Université Libre de Bruxelles,All,"18 Years and older   (Adult, Older Adult)",,420,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ORANGE,Nov-20,Sep-21,Sep-22,28-Jul-20,,27-Oct-20,"Department of Neurology, University of California, San Francisco, California, United States|Parnassus Hospital UCSF, San Francisco, California, United States|John Hopkins, Baltimore, Maryland, United States|Harborview Medical Center, Seattle, Washington, United States|Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium|Department Anesthesia and Critical Care, University Hospital, Grenoble, France|Universitätsklinikum, Erlangen, Germany|Spedali Civili, Brescia, BS, Italy|Policlinico Gemelli, Roma, RM, Italy|Oslo Universitary Hospital, Oslo, Norway|Hospital Clinic Universitari de València, University of Valencia, Valencia, Spain|Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital and University of Lausanne, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT04490005
NCT03624517,Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices,LOVARB,Recruiting,No Results Available,Esophageal Varices|Liver Cirrhoses|Bleeding Esophageal Varices|Upper Gastrointestinal Bleeding,Drug: Octreotide,Esophageal varices rebleed within 72-hours after control of initial bleed|Esophageal varices rebleed at 7 days and 30 days after control of initial bleed|Survival at 7 days and 30 days after control of initial bleed,Medical University of South Carolina|Ohio State University|University of Texas Southwestern Medical Center|University of Florida Health,All,"18 Years and older   (Adult, Older Adult)",Phase 4,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00027015,19-Sep-18,Dec-24,Dec-25,10-Aug-18,,6-Jan-21,"University of Florida Health, Jacksonville, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|The Ohio state University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Texas at Austin, Austin, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Brooke Army Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03624517
NCT03487185,Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy,SLEEP,Recruiting,No Results Available,Obstructive Sleep Apnea of Adult|Preeclampsia|Obstetrical Complications,Device: Continuous Positive Airway Pressure|Other: Sleep Advice Control,Diagnosis of Hypertensive Disorders of Pregnancy|Gestational diabetes|Preterm birth|Cesarean Delivery|Maternal morbidity composite|Maternal adverse cardiovascular outcome composite|Fetal or Neonatal Death|Neonatal respiratory support|Birth weight|Neonatal encephalopathy|Neonatal Seizures|Shoulder dystocia|Birth trauma|Intracranial hemorrhage|Hyperbilirubinemia|Hypoglycemia|NICU Stay,"The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,2700,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",HD36801-SLEEP|U10HD036801|UG1HD087192|UG1HD087230|UG1HD027869|UG1HD034208|UG1HD053097|UG1HD040500|UG1HD040485|UG1HD040544|UG1HD040545|UG1HD040560|UG1HD040512|UG1HD027915,20-Jul-18,Dec-23,Jun-24,3-Apr-18,,26-Oct-20,"University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve-Metro Health, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Brown Univeristy, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03487185
NCT04285554,Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects,DeLIVER,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: iRF System Hepatic Denervation,Rate of Serious Adverse Device Effects|Change in glycemic control: HbA1c|Change in glycemic control - FPG|Change in glycemic control - Insulin|Change in glycemic control - C-peptide|Change in office blood pressure|Change in liver steatosis|Adverse Event rate 365 days,Metavention,All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,15,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,932,28-Jul-20,1-Dec-21,1-Sep-22,26-Feb-20,,6-Jan-21,"Cardiology, P.C., Birmingham, Alabama, United States|Stanford University Medical Center, Stanford, California, United States|AdventHealth Translational Research Institute, Orlando, Florida, United States|Prairie Education & Research Cooperative (PERC), Springfield, Illinois, United States|Metropolitan Cardiology Consultants, Coon Rapids, Minnesota, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|UPMC Pinnacle, Harrisburg, Pennsylvania, United States|Soltero Cardiovascular Research Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04285554
NCT03505723,PeriOperative ISchemic Evaluation-3 Trial,POISE-3,Recruiting,No Results Available,Perioperative Bleeding|Venous Thrombosis|Arterial Thrombosis,Drug: Tranexamic Acid|Drug: Placebo (Saline)|Other: Perioperative hypotension-avoidance strategy|Other: Perioperative hypertension-avoidance strategy,"A composite of life-threatening bleeding, major bleeding, and critical organ bleeding|A composite of myocardial injury after noncardiac surgery, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism.|For patients in the blood pressure management arm: A composite of vascular death, and non-fatal myocardial injury after noncardiac surgery, non-fatal stroke, and non-fatal cardiac arrest.|A net risk-benefit outcome as a composite of vascular death, and non-fatal life-threatening,major or critical organ bleeding,myocardial injury after noncardiac surgery,stroke,peripheral arterial thrombosis,and symptomatic proximal venous thromboembolism|International Society on Thrombosis and Haemostasis (ISTH) major bleeding|BIMS|MINS|MINS not fulfilling the 3rd universal definition of myocardial infarction|Myocardial infarction|For patients in the blood pressure management arm: all-cause mortality|For patients in the blood pressure management arm: MINS|For patients in the blood pressure management arm: Myocardial infarction",Population Health Research Institute,All,"45 Years and older   (Adult, Older Adult)",Phase 3,10000,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2018.02.08,27-Jun-18,Feb-21,Dec-22,23-Apr-18,,21-Apr-20,"Yale New Haven Hospital, New Haven, Connecticut, United States|Cleveland Clinic, Florida, Weston, Florida, United States|Columbia University, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest, Winston-Salem, North Carolina, United States|Cleveland Clinic - Fairview, Cleveland, Ohio, United States|Cleveland Clinic - Main Campus, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Cleveland Clinic - Hillcrest, Mayfield Heights, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Allegheny Health Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Royal Brisbane and Women's Hospital, Brisbane, Australia|Western Health, Footscray, Australia|Mackay Base Hospital, Mackay, Australia|Peter MacCallum Hospital, Melbourne, Australia|John Hunter Hospital, New Lambton, Australia|Royal Perth, Perth, Australia|Princes of Wales Hospital, Randwick, Australia|Redcliffe Hospital, Redcliffe, Australia|Goulburn Valley Health, Shepparton, Australia|Westmead Hospital, Sydney, Australia|Tweed Hospital, Tweed Heads, Australia|Medical University of Vienna, Vienna, Austria|CHU Brugmann, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Vera Cruz Hospital, Belo Horizonte, Minas Gerais, Brazil|Hospital do Coracao de Pocos de Caldas, Poços De Caldas, Minas Gerais, Brazil|Centro de Pesquisas do Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|University of Calgary, O'Brien Institute for Public Health, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Grace Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Cape Breton Regional Hospital, Sydney, Nova Scotia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Juravinski Hospital & Cancer Centre, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|University Health Network (Toronto General Hospital), Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Sherbrooke, Sherbrooke, Quebec, Canada|Royal University Hospital (Saskatoon), Saskatoon, Saskatchewan, Canada|University Hospital, London, Canada|Victoria Hospital, London, Canada|University Health Network (Toronto Western Hospital), Toronto, Canada|Clinica Santa Maria, Santiago, Chile|Clinica Universidad de Los Andes, Santiago, Chile|Hospital Hernan Henriquez, Temuco, Chile|Second Hospital of Anhui Medical University, Hefei, Anhui, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Wuhan Union Hospital, Wuhan, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Beijing Chaoyang Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University First Hospital, Beijing, China|Renji Hospital, Shanghai Jiaotong University, Shanghai, China|Bispebjerg Hospital, Copenhagen, Capital Region, Denmark|Rigshospitalet, Abdominal Centre, Copenhagen, Denmark|Zealand University Hospital, Køge, Denmark|CHU d'Angers, Angers, France|CHU de Brest, Brest, France|Cochin University Hospital, Paris, France|Groupe Hospitalier Paris Saint Joseph, Paris, France|Hopital Ambroise Pare, Paris, France|University Hospital RWTH Aachen, Aachen, Germany|University Hospital Bonn, Bonn, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|University Hospital Düsseldorf, Düsseldorf, Germany|Klinikum Oldenburg AÖR, Oldenburg, Germany|Prince of Wales Hospital, Sha Tin, Hong Kong|Surat Institute of Digestive Science, Surat, Gujarat, India|Sumandeep Vidyapeeth & Dhiraj General Hospital, Vadodara, Gujurat, India|Nanjappa Hospital, Shimoga, Karnataka, India|Rahate Surgical Hospital, Nagpur, Maharashtra, India|Sengupta Hospital & Research Institute, Nagpur, Maharashtra, India|AMAI Charitable Trust's Ace Hospital, Pune, Maharashtra, India|Sidhu Hospital Pvt. Ltd., Doraha, Punjab, India|Christian Medical College, Ludhiana, Ludhiana, Punjab, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India|TD Medical College, Alappuzha, India|Bangalore Baptist Hospital, Bangalore, India|Nizam's Institute, Hyderabad, India|St. John's Medical College Hospital, Kormangala, India|Beaumont Hospital, Beaumont, Dublin, Ireland|Ospedale di Asti, Asti, Italy|PO Busto Arsizio, Busto Arsizio, Italy|Pineta Grande Hospital, Castel Volturno, Italy|University Magna Graecia Catanzaro, Catanzaro, Italy|Ospedale Galliera di Genova, Genova, Italy|Spedali Riuniti Livorno (Ospedale di Livorno), Livorno, Italy|IRCCS Galeazzi Orthopedic Institute, Milano, Italy|Instituto Clinico San Siro, Milan, Italy|IRCCS San Raffaele Scientific Institute, Milan, Italy|Ospedale S. Antonio, Padova, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Ospedale di Rivoli, Rivoli, Italy|Fondazione Policcinico Gemelli A. IRCCS, Rome, Italy|Ospedale Santo Spirito in Sassia, Rome, Italy|Humanitas Research Hospital, Rozzano, Italy|Azienda ULSS 4 Veneto Orientale, San Donà Di Piave, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|ASST Vimercate, Vimercate, Italy|Port Dickson Hospital, Port Dickson, Negeri Sembilan, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Pulau Pinang, Pulau Pinang, Malaysia|Sungai Buloh Hospital, Sungai Buloh, Malaysia|Deventer Ziekenhuis, Deventer, Overijssel, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|Auckland General Hospital, Grafton, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Waikato District Health Board, Hamilton, New Zealand|Shifa International Hospitals, Islamabad, Islamabad Capital Territory, Pakistan|Aga Khan University, Karachi, Pakistan|Jagiellonian University Medical College, Kraków, Poland|Specialistyczny Szpital im. E. Szczeklika w Tarnowie, Tarnów, Poland|Szpital Uniwersytecki im Karola Marcinkowskiego w Zielonej Górze, Zielona Góra, Poland|University Hospital & Educational Center of Medical University in Lodz, Łódź, Poland|City Hospital 1 of Arkhangelsk, Arkhangelsk, Russian Federation|Moscow Regional Research & Clinical Institute (MONIKI), Moscow, Russian Federation|City Hospital N25, Novosibirsk, Russian Federation|E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation|Medical Center 'Avitsenna', Novosibirsk, Russian Federation|Hospital of Saint-Petersburg State University, Saint Petersburg, Russian Federation|Tyumen State Medical University, Tyumen, Russian Federation|King Abdulazzi National Guard Medical City, Jeddah, Saudi Arabia|Groote Schuur Hospital, Observatory, Cape Town, South Africa|Sefako Makgatho Health Sciences University (SMU), Ga-Rankuwa, Gauteng, South Africa|Steve Biko Academic Hospital - University of Pretoria, Pretoria, Gauteng, South Africa|Inkosi Albert Luthuli Central Hospital, Durban, KwaZulu-Natal, South Africa|Grey's Hospital, Athlone, Pietermaritzburg, South Africa|Hospital Clinic - Barcelona, Barcelona, Spain|Hospital de la Sta Creu i Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Alcorcon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario in Valladolid, Valladolid, Spain|University Hospital Zurich Irchel, Zürich, Switzerland|East Kent Hospitals University NHS Foundation Trust, Ashford, United Kingdom|Sandwell and West Birmingham, Birmingham, United Kingdom|East Lancashire Hospitals NHS Foundation Trust, Blackburn, United Kingdom|Medway NHS Foundation Trust, Gillingham, United Kingdom|Royal Liverpool Trust, Liverpool, United Kingdom|Chelsea & Westminster Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Manchester University Foundation Trust, Manchester, United Kingdom|Milton Keynes University Hospital Foundation Trust, Milton Keynes, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom|York Teaching Hospitals NHS Foundation Trust, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT03505723
NCT03888066,Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND),DIAMOND,Recruiting,No Results Available,Hyperkalemia,Drug: Patiromer|Drug: Placebos,Time to first occurrence of CV death or CV hospitalization (or equivalent in outpatient clinic)|Proportion of subjects on ≥ 50% of guideline-recommended target dose of RAASi medications|Total HF hospitalizations|Kansas City Cardiomyopathy Questionnaire (KCCQ),"Relypsa, Inc.|Vifor Pharma",All,"18 Years and older   (Adult, Older Adult)",Phase 3,2388,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Relypsa,25-Apr-19,31-Dec-21,31-Mar-22,25-Mar-19,,5-Jan-21,"Investigator Site 11-080, Alexander City, Alabama, United States|Investigator Site 11-041, Huntsville, Alabama, United States|Investigator Site 11-153, Phoenix, Arizona, United States|Investigator Site 11-097, Tucson, Arizona, United States|Investigator Site 11-052, Bakersfield, California, United States|Investigator Site 11-174, Fremont, California, United States|Investigator Site 11-136, Fresno, California, United States|Investigator Site 11-102, Huntington Beach, California, United States|Investigator Site 11-162, La Jolla, California, United States|Investigator Site 11-048, La Mesa, California, United States|Investigator Site 11-111, Laguna Hills, California, United States|Investigator Site 11-017, Long Beach, California, United States|Investigator Site 11-128, Northridge, California, United States|Investigator Site 11-035, Pasadena, California, United States|Investigator Site 11-044, Sacramento, California, United States|Investigator Site 11-135, San Diego, California, United States|Investigator Site 11-086, San Diego, California, United States|Investigator Site 11-112, Santa Ana, California, United States|Investigator Site 11-101, Stockton, California, United States|Investigator Site 11-047, Thousand Oaks, California, United States|Investigator Site 11-057, Van Nuys, California, United States|Investigator Site 11-058, West Hills, California, United States|Investigator Site 11-095, Aurora, Colorado, United States|Investigator Site 11-007, Littleton, Colorado, United States|Investigator Site 11-168, Altamonte Springs, Florida, United States|Investigator Site 11-106, Boynton Beach, Florida, United States|Investigator Site 11-020, Bradenton, Florida, United States|Investigator Site 11-077, Bradenton, Florida, United States|Investigator Site 11-028, Brandon, Florida, United States|Investigator Site 11-011, Daytona Beach, Florida, United States|Investigator Site 11-003, Doral, Florida, United States|Investigator Site 11-138, Gainesville, Florida, United States|Investigator Site 11-164, Green Acres, Florida, United States|Investigator Site 11-139, Hialeah, Florida, United States|Investigator Site 11-014, Hialeah, Florida, United States|Investigator Site 11-078, Homestead, Florida, United States|Investigator Site 11-004, Jacksonville, Florida, United States|Investigator Site 11-114, Jacksonville, Florida, United States|Investigator Site 11-179, Jacksonville, Florida, United States|Investigator Site 11-122, Medley, Florida, United States|Research Site 11-001, Miami Lakes, Florida, United States|Research Site 11-002, Miami Lakes, Florida, United States|Investigator Site 11-006, Miami, Florida, United States|Investigator Site 11-115, Miami, Florida, United States|Investigator Site 11-125, Miami, Florida, United States|Investigator Site 11-005, Miami, Florida, United States|Investigator Site 11-143, Miami, Florida, United States|Investigator Site 11-032, North Miami Beach, Florida, United States|Investigator Site 11-039, Ocala, Florida, United States|Investigator Site 11-171, Orlando, Florida, United States|Investigator Site 11-025, Orlando, Florida, United States|Investigator Site 11-087, Orlando, Florida, United States|Investigator Site 11-177, Pembroke Pines, Florida, United States|Investigator Site 11-144, Pompano Beach, Florida, United States|Investigator Site 11-099, Tamarac, Florida, United States|Investigator Site 11-090, Tampa, Florida, United States|Investigator Site 11-163, Tampa, Florida, United States|Investigator Site 11-109, Atlanta, Georgia, United States|Investigator Site 11-015, Columbus, Georgia, United States|Investigator Site 11-141, Macon, Georgia, United States|Investigator Site 11-031, Arlington Heights, Illinois, United States|Investigator Site 11-051, Hazel Crest, Illinois, United States|Investigator Site 11-063, Peoria, Illinois, United States|Investigator Site 11-137, Peoria, Illinois, United States|Investigator Site 11-117, Merrillville, Indiana, United States|Investigator Site 11-129, Munster, Indiana, United States|Investigator Site 11-069, Richmond, Indiana, United States|Investigator Site 11-061, Owensboro, Kentucky, United States|Investigator Site 11-026, Baton Rouge, Louisiana, United States|Investigator Site 11-183, Opelousas, Louisiana, United States|Investigator Site 11-022, West Monroe, Louisiana, United States|Investigator Site 11-027, Baltimore, Maryland, United States|Investigator Site 11-023, Columbia, Maryland, United States|Investigator Site 11-132, Boston, Massachusetts, United States|Investigator Site 11-123, Detroit, Michigan, United States|Investigator Site 11-121, Livonia, Michigan, United States|Investigator Site 11-076, Rochester, Michigan, United States|Investigator Site 11-068, Jackson, Mississippi, United States|Investigator Site 11-154, Kansas City, Missouri, United States|Investigator Site 11-094, Saint Louis, Missouri, United States|Investigator Site 11-008, Saint Louis, Missouri, United States|Investigator Site 11-071, Lincoln, Nebraska, United States|Investigator Site 11-049, Las Vegas, Nevada, United States|Investigator Site 11-145, North Las Vegas, Nevada, United States|Investigator Site 11-088, Haddon Heights, New Jersey, United States|Investigator Site 11-054, Linden, New Jersey, United States|Investigator Site 11-148, New Brunswick, New Jersey, United States|Investigator Site 11-107, Newark, New Jersey, United States|Investigator Site 11-116, Albuquerque, New Mexico, United States|Investigator Site 11-127, Bronx, New York, United States|Investigator Site 11-151, Brooklyn, New York, United States|Investigator Site 11-126, Brooklyn, New York, United States|Investigator Site 11-073, Buffalo, New York, United States|Investigator Site 11-040, Manhasset, New York, United States|Investigator Site 11-053, Richmond Hill, New York, United States|Investigator Site 11-093, Rochester, New York, United States|Investigator Site 11-081, Staten Island, New York, United States|Investigator Site 11-021, Stony Brook, New York, United States|Investigator Site 11-120, Charlotte, North Carolina, United States|Investigator Site 11-075, Charlotte, North Carolina, United States|Investigator Site 11-019, Fayetteville, North Carolina, United States|Investigator Site 11-018, Greenville, North Carolina, United States|Investigator Site 11-157, Lumberton, North Carolina, United States|Investigator Site 11-149, Columbus, Ohio, United States|Investigator Site 11-064, Lorain, Ohio, United States|Investigator Site 11-042, Marion, Ohio, United States|Investigator Site 11-074, Bartlesville, Oklahoma, United States|Investigator Site 11-124, Oklahoma City, Oklahoma, United States|Investigator Site 11-056, Hillsboro, Oregon, United States|Investigator Site 11-165, Erie, Pennsylvania, United States|Investigator Site 11-082, Hershey, Pennsylvania, United States|Investigator Site 11-103, Sayre, Pennsylvania, United States|Investigator Site 11-110, Greenville, South Carolina, United States|Investigator Site 11-098, Greenwood, South Carolina, United States|Investigator Site 11-119, Lancaster, South Carolina, United States|Investigator Site 11-133, Rock Hill, South Carolina, United States|Investigator Site 11-152, Chattanooga, Tennessee, United States|Investigator Site 11-091, Jackson, Tennessee, United States|Investigator Site 11-142, Memphis, Tennessee, United States|Investigator Site 11-083, Memphis, Tennessee, United States|Investigator Site 11-134, Tullahoma, Tennessee, United States|Investigator Site 11-104, Allen, Texas, United States|Investigator Site 11-185, Allen, Texas, United States|Investigator Site 11-070, Amarillo, Texas, United States|Investigator Site 11-092, Dallas, Texas, United States|Investigator Site 11-170, Denison, Texas, United States|Investigator Site 11-060, Fort Worth, Texas, United States|Investigator Site 11-072, Gonzales, Texas, United States|Investigator Site 11-140, Houston, Texas, United States|Investigator Site 11-009, Houston, Texas, United States|Investigator Site 11-016, Houston, Texas, United States|Investigator Site 11-033, Houston, Texas, United States|Investigator Site 11-089, Houston, Texas, United States|Investigator Site 11-146, Houston, Texas, United States|Investigator Site 11-079, Houston, Texas, United States|Investigator Site 11-156, Houston, Texas, United States|Investigator Site 11-034, Katy, Texas, United States|Investigator Site 11-029, Lampasas, Texas, United States|Investigator Site 11-010, McKinney, Texas, United States|Investigator Site 11-046, McKinney, Texas, United States|Investigator Site 11-055, Plano, Texas, United States|Investigator Site 11-147, San Antonio, Texas, United States|Investigator Site 11-085, San Antonio, Texas, United States|Investigator Site 11-161, Sugar Land, Texas, United States|Investigator Site 11-100, Webster, Texas, United States|Investigator Site 11-160, Webster, Texas, United States|Investigator Site 11-158, Norfolk, Virginia, United States|Investigator Site 11-065, Morgantown, West Virginia, United States|Investigator Site 11-045, Milwaukee, Wisconsin, United States|Investigator Site 21-006, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|Investigator Site 21-007, Ciudadela, Buenos Aires, Argentina|Investigator Site 21-020, Ramos Mejía, Buenos Aires, Argentina|Investigator Site 21-004, San Nicolás, Buenos Aires, Argentina|Investigator Site 21-011, Córdoba, Cordoba, Argentina|Investigator Site 21-014, Córdoba, Cordoba, Argentina|Investigator Site 21-015, Villa María, Cordoba, Argentina|Investigator Site 21-010, San Miguel De Tucumán, Tucuman, Argentina|Investigator Site 21-003, Ciudad Autonoma de Buenos Aires, Argentina|Investigator Site 21-018, Ciudad Autonoma de Buenos Aires, Argentina|Investigator Site 21-008, Ciudad Autonoma de Buenos Aires, Argentina|Investigator Site 44-002, Mechelen, Antwerp, Belgium|Investigator Site 44-001, Ghent, Oost Vlaanderen, Belgium|Investigator Site 44-005, Aalst, Belgium|Investigator Site 44-009, Brussels, Belgium|Investigator Site 44-003, Genk, Belgium|Investigator Site 44-008, Hasselt, Belgium|Investigator Site 44-007, Leuven, Belgium|Investigator Site 44-006, Liège, Belgium|Investigator Site 44-004, Yvoir, Belgium|Investigator Site 22-021, Salvador, Bahia, Brazil|Investigator Site 22-019, Fortaleza, Ceará, Brazil|Investigator Site 22-013, Fortaleza, Ceará, Brazil|Investigator Site 22-023, Brasília, Distrito Federal, Brazil|Investigator Site 22-012, Vitória, Espirito Santo, Brazil|Investigator Site 22-011, Belo Horizonte, Minas Gerais, Brazil|Investigator Site 22-005, Belo Horizonte, Minas Gerais, Brazil|Investigator Site 22-004, Uberlândia, Minas Gerais, Brazil|Investigator Site 22-010, Campina Grande Do Sul, Paraná, Brazil|Investigator Site 22-008, Canoas, Rio Grande Do Sul, Brazil|Investigator Site 22-009, Porto Alegre, Rio Grande Do Sul, Brazil|Investigator Site 22-003, Porto Alegre, RS, Brazil|Investigator Site 22-015, Porto Alegre, RS, Brazil|Investigator Site 22-002, Porto Alegre, RS, Brazil|Investigator Site 22-017, Blumenau, SC, Brazil|Investigator Site 22-007, Aracaju, Sergipe, Brazil|Investigator Site 22-001, Campinas, São Paulo, Brazil|Investigator Site 22-016, Campinas, São Paulo, Brazil|Investigator Site 22-018, Ribeirão Preto, São Paulo, Brazil|Investigator Site 22-020, São José Do Rio Preto, São Paulo, Brazil|Investigator Site 22-024, Rio De Janeiro, Brazil|Investigator Site 22-014, São Paulo, Brazil|Investigator Site 22-022, São Paulo, Brazil|Investigator Site 61-003, Burgas, Bulgaria|Investigator Site 61-002, Pleven, Bulgaria|Investigator Site 61-004, Plovdiv, Bulgaria|Investigator Site 61-010, Ruse, Bulgaria|Investigator Site 61-009, Sofia, Bulgaria|Investigator Site 61-008, Sofia, Bulgaria|Investigator Site 61-005, Sofia, Bulgaria|Investigator Site 61-006, Sofia, Bulgaria|Investigator Site 12-005, Winnipeg, Manitoba, Canada|Investigator Site 12-008, Cambridge, Ontario, Canada|Investigator Site 12-012, London, Ontario, Canada|Investigator Site 12-010, Newmarket, Ontario, Canada|Investigator Site 12-009, Greenfield Park, Quebec, Canada|Investigator Site 62-019, Brno, Czechia|Investigator Site 62-004, Bílina, Czechia|Investigator Site 62-005, Havlíčkův Brod, Czechia|Investigator Site 62-017, Havířov, Czechia|Investigator Site 62-006, Kolín, Czechia|Investigator Site 62-013, Liberec, Czechia|Investigator Site 62-015, Litovel, Czechia|Investigator Site 62-010, Mariánské Lázně, Czechia|Investigator Site 62-018, Náchod, Czechia|Investigator Site 62-001, Praha, Czechia|Investigator Site 62-011, Slaný, Czechia|Investigator Site 62-016, Uherské Hradiště, Czechia|Investigator Site 32-010, Bordeaux, France|Investigator Site 32-002, La Tronche, France|Investigator Site 32-014, Lille, France|Investigator Site 32-005, Montpellier, France|Investigator Site 32-001, Nancy, France|Investigator Site 32-004, Paris, France|Investigator Site 32-008, Paris, France|Investigator Site 32-017, Paris, France|Investigator Site 32-007, Paris, France|Investigator Site 32-003, Pau, France|Investigator Site 32-015, Poitiers, France|Investigator Site 32-013, Reims, France|Investigator Site 32-019, Rouen, France|Investigator Site 32-018, Saint-Brieuc, France|Investigator Site 32-006, Toulon, France|Investigator Site 32-012, Toulouse, France|Investigator Site 32-009, Tourcoing, France|Investigator Site 32-011, Valenciennes, France|Investigator Site 32-016, Valenciennes, France|Investigator Site 63-012, Batumi, Georgia|Investigator Site 63-007, Tbilisi, Georgia|Investigator Site 63-011, Tbilisi, Georgia|Investigator Site 63-004, Tbilisi, Georgia|Investigator Site 63-002, Tbilisi, Georgia|Investigator Site 63-006, Tbilisi, Georgia|Investigator Site 63-008, Tbilisi, Georgia|Investigator Site 63-010, Tbilisi, Georgia|Investigator Site 63-003, Tbilisi, Georgia|Investigator Site 63-009, Tbilisi, Georgia|Investigator Site 63-001, Tbilisi, Georgia|Investigator Site 63-005, Tbilisi, Georgia|Investigator Site 33-011, Coburg, Bavarian, Germany|Investigator Site 33-008, Greifswald, Mecklenburg-Vorpommern, Germany|Investigator Site 33-006, Homburg, Saar, Germany|Investigator Site 33-023, Bad Oeynhausen, Germany|Investigator Site 33-020, Berlin, Germany|Investigator Site 33-013, Berlin, Germany|Investigator Site 33-015, Bielefeld, Germany|Investigator Site 33-016, Bremen, Germany|Investigator Site 33-004, Erfurt, Germany|Investigator Site 33-001, Essen, Germany|Investigator Site 33-019, Frankfurt, Germany|Investigator Site 33-007, Frankfurt, Germany|Investigator Site 33-018, Gießen, Germany|Investigator Site 33-002, Halle, Germany|Investigator Site 33-005, Hamburg, Germany|Investigator Site 33-022, Hanover, Germany|Investigator Site 33-012, Heilbronn, Germany|Investigator Site 33-017, Kiel, Germany|Investigator Site 33-021, Leipzig, Germany|Investigator Site 33-010, Leverkusen, Germany|Investigator Site 33-024, Minden, Germany|Investigator Site 33-014, Nürnberg, Germany|Investigator Site 33-003, Würzburg, Germany|Investigator Site 64-004, Baja, Hungary|Investigator Site 64-010, Budapest, Hungary|Investigator Site 64-002, Budapest, Hungary|Investigator Site 64-006, Budapest, Hungary|Investigator Site 64-009, Budapest, Hungary|Investigator Site 64-011, Budapest, Hungary|Investigator Site 64-001, Kecskemét, Hungary|Investigator Site 64-007, Kistarcsa, Hungary|Investigator Site 64-008, Miskolc, Hungary|Investigator Site 64-005, Nyiregyhaza, Hungary|Investigator Site 35-008, Ashqelon, Israel|Investigator Site 35-009, Be'er Ya'aqov, Israel|Investigator Site 35-003, Hadera, Israel|Investigator Site 35-006, Haifa, Israel|Investigator Site 35-007, Haifa, Israel|Investigator Site 35-002, H̱olon, Israel|Investigator Site 35-005, Jerusalem, Israel|Investigator Site 35-014, Jerusalem, Israel|Investigator Site 35-001, Jerusalem, Israel|Investigator Site 35-010, Nahariya, Israel|Investigator Site 35-015, Nazareth, Israel|Investigator Site 35-011, Petah tikva, Israel|Investigator Site 35-013, Ramat Gan, Israel|Investigator Site 35-012, Safed, Israel|Investigator Site 35-016, Tiberias, Israel|Investigator Site 34-005, Ancona, Italy|Investigator Site 34-002, Bergamo, Italy|Investigator Site 34-007, Brescia, Italy|Investigator Site 34-001, Caserta, Italy|Investigator Site 34-009, Cona, Italy|Investigator Site 34-004, Milano, Italy|Investigator Site 34-012, Piacenza, Italy|Investigator Site 34-003, Roma, Italy|Investigator Site 23-007, Cuauhtémoc, Ciudad De Mexico, Mexico|Investigator Site 23-005, Delegación Gustavo A. Madero, Ciudad De Mexico, Mexico|Investigator Site 23-004, Guadalajara, Jalisco, Mexico|Investigator Site 23-010, San Pedro Garza Garcia, Nuevo Léon, Mexico|Investigator Site 23-011, Oaxaca de Juarez, Oaxaca, Mexico|Investigator Site 23-001, Santiago De Querétaro, Querétaro, Mexico|Investigator Site 23-002, Culiacán, Sinaloa, Mexico|Investigator Site 23-006, Xalapa, Veracruz, Mexico|Investigator Site 36-003, Rotterdam, South Holland, Netherlands|Investigator Site 36-002, 's-Hertogenbosch, Netherlands|Investigator Site 36-012, Amstelveen, Netherlands|Investigator Site 36-006, Blaricum, Netherlands|Investigator Site 36-009, Dirksland, Netherlands|Investigator Site 36-015, Dordrecht, Netherlands|Investigator Site 36-007, Ede, Netherlands|Investigator Site 36-001, Groningen, Netherlands|Investigator Site 36-013, Helmond, Netherlands|Investigator Site 36-014, Hoorn, Netherlands|Investigator Site 36-010, Schiedam, Netherlands|Investigator Site 36-004, Tilburg, Netherlands|Investigator Site 36-011, Utrecht, Netherlands|Investigator Site 65-007, Białystok, Poland|Investigator Site 65-014, Katowice, Poland|Investigator Site 65-016, Kraków, Poland|Investigator Site 65-002, Kraków, Poland|Investigator Site 65-012, Kędzierzyn-Koźle, Poland|Investigator Site 65-019, Olsztyn, Poland|Investigator Site 65-015, Ostrowiec Świętokrzyski, Poland|Investigator Site 65-013, Oława, Poland|Investigator Site 65-021, Pomorskie, Poland|Investigator Site 65-003, Poznań, Poland|Investigator Site 65-020, Poznań, Poland|Investigator Site 65-008, Rzeszów, Poland|Investigator Site 65-009, Tychy, Poland|Investigator Site 65-010, Wrocław, Poland|Investigator Site 65-005, Wrocław, Poland|Investigator Site 65-011, Zgierz, Poland|Investigator Site 65-001, Łódź, Poland|Investigator Site 65-018, Łódź, Poland|Investigator Site 66-014, Izhevsk, Udmurt Republic, Russian Federation|Investigator Site 66-008, Chelyabinsk, Russian Federation|Investigator Site 66-001, Ekaterinburg, Russian Federation|Investigator Site 66-016, Kazan, Russian Federation|Investigator Site 66-010, Kemerovo, Russian Federation|Investigator Site 66-015, Moscow, Russian Federation|Investigator Site 66-004, Moscow, Russian Federation|Investigator Site 66-011, Moscow, Russian Federation|Investigator Site 66-017, Moscow, Russian Federation|Investigator Site 66-002, Novosibirsk, Russian Federation|Investigator Site 66-005, Penza, Russian Federation|Investigator Site 66-007, Perm, Russian Federation|Investigator Site 66-012, Petrozavodsk, Russian Federation|Investigator Site 66-018, Ryazan', Russian Federation|Investigator Site 66-013, Saint Petersburg, Russian Federation|Investigator Site 66-003, Saint Petersburg, Russian Federation|Investigator Site 66-009, Tver, Russian Federation|Investigator Site 67-010, Belgrade, Serbia|Investigator Site 67-002, Belgrade, Serbia|Investigator Site 67-004, Belgrade, Serbia|Investigator Site 67-007, Niška Banja, Serbia|Investigator Site 67-005, Niš, Serbia|Investigator Site 67-001, Sremska Kamenica, Serbia|Investigator Site 67-006, Zaječar, Serbia|Investigator Site 67-003, Šabac, Serbia|Investigator Site 37-014, Palma De Mallorca, Baleares, Spain|Investigator Site 37-010, Castellón De La Plana, Castellon, Spain|Investigator Site 37-003, Barcelona, Cataluña, Spain|Investigator Site 37-005, Santiago De Compostela, La Coruña, Spain|Investigator Site 37-011, Majadahonda, Madrid, Spain|Investigator Site 37-024, Marbella, Malaga, Spain|Investigator Site 37-016, La Laguna, Tenerife, Spain|Investigator Site 37-001, Manises, Valencia, Spain|Investigator Site 37-012, Alicante, Spain|Investigator Site 37-015, Badalona, Spain|Investigator Site 37-007, Barcelona, Spain|Investigator Site 37-002, Barcelona, Spain|Investigator Site 37-018, Huelva, Spain|Investigator Site 37-025, La Coruña, Spain|Investigator Site 37-023, Lleida, Spain|Investigator Site 37-004, Madrid, Spain|Investigator Site 37-006, Madrid, Spain|Investigator Site 37-021, Madrid, Spain|Investigator Site 37-020, Madrid, Spain|Investigator Site 37-026, Madrid, Spain|Investigator Site 37-022, Murcia, Spain|Investigator Site 37-017, Málaga, Spain|Investigator Site 37-013, Sevilla, Spain|Investigator Site 37-009, Valencia, Spain|Investigator Site 37-008, Valencia, Spain|Investigator Site 68-008, Kharkiv, Novobavarskiy, Ukraine|Investigator Site 68-017, Dnipro, Ukraine|Investigator Site 68-009, Ivano-Frankivs'k, Ukraine|Investigator Site 68-005, Ivano-Frankivs'k, Ukraine|Investigator Site 68-001, Kharkiv, Ukraine|Investigator Site 68-011, Kharkiv, Ukraine|Investigator Site 68-010, Kharkiv, Ukraine|Investigator Site 68-002, Kharkiv, Ukraine|Investigator Site 68-012, Kyiv, Ukraine|Investigator Site 68-003, Kyiv, Ukraine|Investigator Site 68-015, Kyiv, Ukraine|Investigator Site 68-013, Kyiv, Ukraine|Investigator Site 68-007, Kyiv, Ukraine|Investigator Site 68-006, Lviv, Ukraine|Investigator Site 68-014, Vinnytsia, Ukraine|Investigator Site 68-016, Zaporizhzhya, Ukraine|Investigator Site 68-004, Zhytomyr, Ukraine|Investigator Site 39-012, Harlow, Essex, United Kingdom|Investigator Site 39-003, Scunthorpe, North Lincolshire, United Kingdom|Investigator Site 39-005, Dudley, West Midlands, United Kingdom|Investigator Site 39-009, Barnsley, United Kingdom|Investigator Site 39-006, Chesterfield, United Kingdom|Investigator Site 39-016, High Wycombe, United Kingdom|Investigator Site 39-008, Inverness, United Kingdom|Investigator Site 39-011, Leicester, United Kingdom|Investigator Site 39-013, Liverpool, United Kingdom|Investigator Site 39-015, London, United Kingdom|Investigator Site 39-014, London, United Kingdom|Investigator Site 39-010, North Shields, United Kingdom|Investigator Site 39-007, Swansea, United Kingdom|Investigator Site 39-004, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT03888066
NCT04308590,Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas,GRADIENT,Recruiting,No Results Available,Hypercortisolism,Drug: relacorilant|Other: Placebo,"In patients with diabetes/ impaired glucose tolerance (DM/IGT), the mean change in AUC glucose as compared between relacorilant and placebo arm|In patients with systolic hypertension, the change in mean systolic blood pressure (SBP) based on 24-hour ambulatory blood pressure monitor (ABPM) as compared between relacorilant and placebo arms|Rate of safety based TEAEs|In patients with DM at baseline the mean change in HbA1c and fasting glucose|Proportion of patients with IGT at Baseline who achieved normalization of 2-hour oGTT glucose|Proportion of patients with normalization of the mean SBP",Corcept Therapeutics,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CORT125134-456,19-May-20,Jun-21,Jun-21,16-Mar-20,,12-Nov-20,"Site 07, Atlanta, Georgia, United States|Site 09, Metairie, Louisiana, United States|Site 11, Fall River, Massachusetts, United States|Site 06, Jackson, Mississippi, United States|Site 10, Jamaica, New York, United States|Site 01, Wilmington, North Carolina, United States|Site 12, Pittsburgh, Pennsylvania, United States|Site 02, Summerville, South Carolina, United States|Site 03, El Paso, Texas, United States|Site 05, Fort Worth, Texas, United States|Site 08, Houston, Texas, United States|Site 04, Shavano Park, Texas, United States|Site 15, Spokane, Washington, United States|Site 14, Malaga, Spain|Site 13, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT04308590
NCT03697109,A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome,GRACE,Recruiting,No Results Available,Cushing Syndrome,Drug: Relacorilant|Other: Placebo,"In patients with diabetes mellitus/impaired glucose tolerance (DM/IGT), the mean change in area under the curve for glucose from Week OL22 to Week RW12 as compared between relacorilant and placebo|In patients with hypertension, the proportion of patients with a loss of response with respect to hypertension from visit OL22 to RW12|In all patients, assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.|In patients with DM (HbA1c at Baseline >6.5%), the mean change from Visit OL22 to RW12 in HbA1c as compared between relacorilant and placebo.|In patients with IGT at Baseline, the mean change from Visit OL22 to RW12 in the 2 hour glucose value of the oGTT|In patients with hypertension the mean change in SBP or DBP as compared between relacorilant and placebo|The mean change in body weight, body fat measured with DXA scan and Cushing Quality-of-Life (QoL) score as compared between relacorilant and placebo|For patients in either subgroup (DM/IGT or hypertension) the proportion of patients with any increase or modification in diabetes or antihypertensive medication as compared between relacorilant and placebo|Proportion of patients who worsened, as assessed by the Global Clinical Response, from Week OL22 to Week RW12/ET as compared between relacorilant and placebo|Mean change in QoL, body fat composition as determined by DXA, Beck Depression inventory-II (BDI-II) and body weight from Baseline to visit OL22 or end of treatment (ET)|In patients with IGT, the mean change in 2-hour oGTT glucose from Baseline to Visit OL22/ET|In patients with DM (HbA1c ≥6.5% at Baseline), the mean change in HbA1c from Baseline to Visit OL22/ET|In patients with uncontrolled hypertension the mean change in SBP or DBP from Baseline to visit OL22/ET",Corcept Therapeutics,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CORT125134-455,16-Oct-18,Nov-21,Dec-21,5-Oct-18,,19-Dec-20,"Site 21, Phoenix, Arizona, United States|Site 36, Los Angeles, California, United States|Site 42, Santa Monica, California, United States|Site 9, Aurora, Colorado, United States|Site 32, Washington, District of Columbia, United States|Site 52, Gainesville, Florida, United States|Site 10, Miami, Florida, United States|Site 14, Atlanta, Georgia, United States|Site 41, Chicago, Illinois, United States|Site 7, Indianapolis, Indiana, United States|Site 2, Metairie, Louisiana, United States|Site 45, Baltimore, Maryland, United States|Site 46, Boston, Massachusetts, United States|Site 20, Ann Arbor, Michigan, United States|Site 4, Jackson, Mississippi, United States|Site 13, Saint Louis, Missouri, United States|Site 53, Omaha, Nebraska, United States|Site 8, Albany, New York, United States|Site 6, Jamaica, New York, United States|Site 39, New York, New York, United States|Site 57, New York, New York, United States|Site 35, New York, New York, United States|Site 1, Wilmington, North Carolina, United States|Site 44, Cleveland, Ohio, United States|Site 17, Columbus, Ohio, United States|Site 11, Oklahoma City, Oklahoma, United States|Site 62, Philadelphia, Pennsylvania, United States|Site 19, Pittsburgh, Pennsylvania, United States|Site 5, Summerville, South Carolina, United States|Site 51, Dallas, Texas, United States|Site 3, El Paso, Texas, United States|Site 18, Houston, Texas, United States|Site 56, Shavano Park, Texas, United States|Site 31, Everett, Washington, United States|Site 60, Graz, Austria|Site 47, Vienna, Austria|Site 27, Sofia, Bulgaria|Site 55, Vancouver, British Columbia, Canada|Site 58, Montréal, Canada|Site 50, Leipzig, Germany|Site 54, München, Germany|Site 49, Würzburg, Germany|Site 30, Jerusalem, Israel|Site 29, Kfar Saba, Israel|Site 28, Petach Tikva, Israel|Site 43, Ancona, Italy|Site 15, Messina, Italy|Site 26, Milano, Italy|Site 12, Napoli, Italy|Site 40, Roma, Italy|Site 16, Roma, Italy|Site 48, Torino, Italy|Site 38, Turin, Italy|Site 34, Rotterdam, Netherlands|Site 37, Chrzanów, Poland|Site 59, Kraków, Poland|Site 33, Lublin, Poland|Site 61, Barcelona, Spain|Site 25, Girona, Spain|Site 24, Madrid, Spain|Site 22, Málaga, Spain|Site 23, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT03697109
NCT02089217,Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial,CREST-2,Recruiting,No Results Available,Carotid Stenosis,Procedure: Carotid endarterectomy (CEA)|Device: Carotid Stenting (CAS)|Other: Intensive Medical Management - no CEA|Other: Intensive Medical Management - no CAS,Stroke and death|Cognitive Function|Major Stroke|Effect modification,"Thomas G. Brott, M.D.|National Institute of Neurological Disorders and Stroke (NINDS)|Mayo Clinic",All,"35 Years and older   (Adult, Older Adult)",Not Applicable,2480,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,13-004051|U01NS080168|IDE: G130221,Dec-14,Dec-22,Dec-22,17-Mar-14,,13-Jan-21,"The University of Alabama at Birmingham, Birmingham, Alabama, United States|Brookwood Medical Center, Birmingham, Alabama, United States|Huntsville Hospital/ Heart Center Research Alabama, Huntsville, Alabama, United States|St. Joseph's Hospital and Medical Center/ Barrow Neurological Institute, Phoenix, Arizona, United States|Abrazo Arizona Heart Hospital, Phoenix, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Central Arkansas Veteran's Healthcare System, Little Rock, Arkansas, United States|Mission Cardiovascular Research, Fremont, California, United States|Kaiser Permanente Los Angeles, Los Angeles, California, United States|Keck Medical Center of University of Southern California, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|VA Palo Alto Health Care System, Palo Alto, California, United States|Kaiser Permanente, San Diego, California, United States|Kaiser Permanente Division of Research, San Francisco, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|St. Joseph's Medical Center, Stockton, California, United States|St. Mary's Medical Center, Grand Junction, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Washington Hospital Center/Medstar, Washington, District of Columbia, United States|Morton Plant Hospital, Clearwater, Florida, United States|University of Florida Health at Shands, Gainesville, Florida, United States|Lyerly Neurosurgery, Jacksonville, Florida, United States|First Coast Cardiovascular Institute, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Mount Sinai Medical Center of Florida, Miami Beach, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Miami Cardiac and Vascular Institute at Baptist Hospital of Miami, Miami, Florida, United States|Cardiovascular Institute of Northwest Florida, Panama City, Florida, United States|Tampa General Hospital /University of South Florida, Tampa, Florida, United States|Atlanta VA Medical Center, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Southern Illinois Healthcare, Carbondale, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Northwestern University, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Mercy Health Riverside, Rockford, Illinois, United States|Prairie Heart/St. John's Hospital, Springfield, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|The Heart Group, PC, Newburgh, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland VA, Baltimore, Maryland, United States|John Hopkins Medical Institution, Baltimore, Maryland, United States|Adventist HealthCare/ Washington Adventist Hospital, Takoma Park, Maryland, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|University of Massachusetts Memorial Hospital, Worcester, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Michigan Vascular Center/McLaren- Flint, Flint, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Cardiac and Vascular Research Center of Northern Michigan/McLaren Northern Michigan, Petoskey, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Trinity Health/ Michigan Heart, Ypsilanti, Michigan, United States|Minneapolis Clinic of Neurology, Ltd./ North Memorial Medical Center, Golden Valley, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|St. Cloud Hospital, Saint Cloud, Minnesota, United States|John Cochran St. Louis Medical Center, Saint Louis, Missouri, United States|Mercy Hospital, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|SUNY Buffalo, Buffalo, New York, United States|Mount Sinai Hospital New York, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|North Carolina Heart & Vascular Research, Raleigh, North Carolina, United States|Coastal Carolina Surgical Associates PA, Wilmington, North Carolina, United States|Novant Health/Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State Medical Center, Columbia, Ohio, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Jobst Vascular Institute/Toledo Hospital, Toledo, Ohio, United States|Mercy Health St.Vincent Medical Center, Toledo, Ohio, United States|St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital - Network Office of Research, Allentown, Pennsylvania, United States|UPMC Altoona, Altoona, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|UPMC Hamot, Erie, Pennsylvania, United States|PennState Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian University Hospital, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare, Pittsburgh, Pennsylvania, United States|Pinnacle Health Cardiovascular Institute, Wormleysburg, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Berks Cardiologists / St. Joseph's Medical Center, Wyomissing, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|North Central Heart Institute, Sioux Falls, South Dakota, United States|Wellmont CVA Heart Institute, Kingsport, Tennessee, United States|Tennova Healthcare/ Turkey Creek Medical Center, Knoxville, Tennessee, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seton Medical Center Austin, Austin, Texas, United States|Cardiothoracic and Vascular Surgeons, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Fairfax Health Care, Falls Church, Virginia, United States|Winchester Medical Center, Winchester, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medicine-Harborview Medical Center, Seattle, Washington, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Gundersen Clinic, Ltd, La Crosse, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|Vancouver General Hospital, Vancouver, British Columbia, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|St. Boniface Hospital, Winnipeg, Ontario, Canada|CHU de Québec/ Hôpital de l'Enfant-Jésus, Québec City, Quebec, Canada|Soroka University Medical Center, Be'er Sheva, Israel|Soroka University Vascular Surgery, Be'er Sheva, Israel|Shaare-Zedek Medical Center, Jerusalem, Israel|Hospital Clinic Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02089217
NCT02723708,Ventral Tegmental Area (VTA) Self-Activation in Attention Deficit Hyperactivity Disorder (ADHD),,Recruiting,No Results Available,ADHD,Other: Real-Time functional Magnetic Resonance Imaging Feedback (RTFF),"Percent signal change in VTA BOLD activation|Change in VTA BOLD signal following RTFF|Change in goal-directed behavior, as measured by the Effort discounting task|Change in inhibitory control, as measured by the Conners' Continuous Performance Task (CPT)|Change in attention, as measured by reaction time (RT) variability on the CPT",Duke University|National Institute of Mental Health (NIMH),All,18 Years to 45 Years   (Adult),Not Applicable,40,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00070749|1R01MH106751,Aug-16,Apr-21,Aug-21,30-Mar-16,,7-May-20,"Duke ADHD Program, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02723708
NCT04636216,Open Trial of a Program to Support Parents of Children With Attention-deficit/Hyperactivity Disorder (ADHD),,Recruiting,No Results Available,ADHD,Behavioral: COPE parent training,Observations of parenting behaviors during parent-child interaction|Impairment Rating Scale|Disruptive Behavior Disorder Rating Scale|Improvement Rating Scale|Therapy Attitude Inventory rating scale,Florida International University,All,5 Years to 13 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-20-0484,3-Nov-20,30-Sep-21,31-Dec-21,19-Nov-20,,19-Nov-20,"Center for Children and Families, Amherst, New York, United States",,https://ClinicalTrials.gov/show/NCT04636216
NCT02699086,A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD),,Recruiting,No Results Available,Attention-Deficit Hyperactivity Disorder (ADHD),Drug: PDC-1421 Capsule,Attention-Deficit Hyperactivity Disorder-Rating Scale-IV (ADHD-RS-IV)|Conners' Adult Attention- Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S)|Clinical Global Impression-ADHD- Severity (CGI-ADHD-S) and Clinical Global Impression-ADHD- improvement (CGI-ADHD-I),"BioLite, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,6,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Phase II BLI-1008-001,1-Dec-19,10-Aug-20,10-Aug-20,4-Mar-16,,12-Aug-20,"UCSF Medical Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02699086
NCT04402528,Preschool ADHD On-line Behavioral Treatment,,Recruiting,No Results Available,ADHD,Behavioral: Behavioral tools integrated within mehealth for ADHD software,% of days using mehealth behavior tracking system|Acceptability with on-line behavioral treatment assessed by the System Usability Scale|Acceptability with on-line behavioral treatment assessed by the Intervention Acceptability Questionnaire|ADHD Rating Scale-IV-Preschool Version|Impairment Rating Scale,"Children's Hospital Medical Center, Cincinnati|Developmental Behavioral Pediatrics Research Network|HRSA/Maternal and Child Health Bureau|Boston Children's Hospital",All,3 Years to 5 Years   (Child),Not Applicable,20,Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-1274,27-Mar-20,28-Feb-22,28-Feb-22,27-May-20,,27-May-20,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04402528
NCT03324464,Central Executive Training (CET) for ADHD,,Recruiting,No Results Available,ADHD,Behavioral: Central Executive Training: Working Memory|Behavioral: Central Executive Training: Inhibitory Control,ADHD symptoms|Working Memory|Inhibitory control|Actigraph-measured hyperactivity during working memory testing|Actigraph-measured hyperactivity during baseline,Florida State University,All,8 Years to 12 Years   (Child),Not Applicable,250,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH115048,1-Jan-18,31-Dec-22,31-Dec-22,27-Oct-17,,22-Jul-20,"Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT03324464
NCT04386811,Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.,,Recruiting,No Results Available,ADHD,Drug: Calcitriol|Other: Placebo,Enhanced positive neurocognitive effects on the CPT-IP|Enhanced positive neurocognitive effects on the Spatial working memory task|Enhanced positive neurocognitive effects on the PRLT|Enhanced positive neurocognitive effects on the CPT-IP- hits|Enhanced positive neurocognitive effects on the CPT-IP- false alarms|Enhanced positive neurocognitive effects on the CPT-IP- random errors|Spatial working memory task- reaction time|Enhanced positive neurocognitive effects on the PRLT - win-switch / lose-stay rate,Yale University,All,18 Years to 50 Years   (Adult),Phase 1,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2000028035,5-Aug-20,Aug-25,Aug-25,13-May-20,,7-Jan-21,"CMHC, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04386811
NCT04473755,A Naturalistic Study of Functional Impairment for Individuals With ADHD in the Early Morning and Late Afternoon/Evening Hours,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,,Social Impairment|ADHD symptoms|Driving behavior|Percent of Behavioral Goals Met,Florida International University,All,"16 Years to 30 Years   (Child, Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,800012103,4-Aug-20,31-Dec-20,31-Dec-20,16-Jul-20,,23-Sep-20,"Center for Children and Families, Amherst, New York, United States",,https://ClinicalTrials.gov/show/NCT04473755
NCT02293655,The Effects of ADHD Medication (TEAM) Study,TEAM,Recruiting,No Results Available,ADHD,Drug: OROS-Methylphenidate (MPH),ADHD symptom scores|Off-task behavior|Inhibitory control reaction time variability|Math computation|Sluggish cognitive tempo (SCT) ratings|Executive function ratings|Child ratings of depression|Child ratings of anxiety|Child ratings of suicidality|Parent ratings of emotional regulation|Side effect ratings|Sleep ratings|Ecological Momentary Assessment|School observations|Spatial working memory|Math reasoning|Reading fluency and comprehension|Written expression|Spelling,"Children's Hospital Medical Center, Cincinnati|Seattle Children's Hospital",All,7 Years to 11 Years   (Child),Phase 4,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADHDMedTEAMStudy,Jan-15,1-Jun-20,1-Jun-20,18-Nov-14,,15-Apr-20,"Children's Hospital Medical Center, Cincinnati, Ohio, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02293655
NCT02897362,Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,,Objective sleep assessment|Neurocognitive assessment|Executive functioning as measured by neurocognitive assessment,Duke University|National Institute of Mental Health (NIMH),All,13 Years to 17 Years   (Child),,60,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Pro00072033|1K23MH108704-01A1,Aug-16,Jul-21,Jul-21,13-Sep-16,,7-May-20,"Duke Child and Family Study Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02897362
NCT04270812,Treating Sleep in Teens With ADHD,,Recruiting,No Results Available,ADHD|Sleep,Behavioral: Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C),Change in overall sleep quality: Pittsburgh Sleep Quality Index (PSQI)|Change in sleep duration|Change in sleep onset|Change in sleep disturbance|Change in objective sleep functioning|Change in circadian preference,"Children's Hospital Medical Center, Cincinnati",All,13 Years to 17 Years   (Child),Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-0649,16-Oct-18,31-May-20,31-Oct-20,17-Feb-20,,17-Feb-20,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04270812
NCT04189562,A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD,,Recruiting,No Results Available,Attention Deficit/Hyperactivity Disorder,Other: SMS Intervention,Adherence to Stimulants,Massachusetts General Hospital,All,6 Years to 12 Years   (Child),Not Applicable,300,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2016-P-002715,22-Feb-17,Feb-21,Feb-21,6-Dec-19,,20-Jul-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04189562
NCT04002167,A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD),,Recruiting,No Results Available,ADHD,Behavioral: Neurofeedback|Behavioral: Cognitive training,"Change in target frontal-parietal activity|Change in working memory performance|Change in Behavior Rating Inventory of Executive Function (BRIEF), Working Memory t-score|Change in Wide Range Assessment of Memory and Learning 2 (WRAML-2), General Memory Index score|Change in Conners 3rd Edition ADHD Index and Inattention t-score|Change in Developmental NEuroPSYchological Assessment II (NEPSY-II) composite score",Stanford University|National Institute of Mental Health (NIMH),All,7 Years to 11 Years   (Child),Not Applicable,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",328066|R61MH119289,16-Aug-19,31-Jan-21,31-Mar-21,28-Jun-19,,1-Apr-20,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04002167
NCT02848092,Improving ADHD Teen Driving,,Recruiting,No Results Available,Attention Deficit Disorder|Attention Deficit Disorder With Hyperactivity,Behavioral: FOCAL+|Other: Rules of The road,"Number of Extended Glances Away from Roadway during Driving Simulation|Standard Deviation of Lateral Position during Driving Simulation|Number of incidents, crashes, and near-crashes recorded with DriveCam|Number of incidents, crashes, and near-crashes recorded with DriveCam that are preceded by a greater than 2 second glance away from the roadway|Number of motor vehicle crashes","Children's Hospital Medical Center, Cincinnati|St. Louis University|University of Massachusetts, Amherst",All,"16 Years to 19 Years   (Child, Adult)",Not Applicable,136,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",R01HD084430,1-May-16,30-Mar-21,30-Nov-21,28-Jul-16,,11-Feb-20,"Center for ADHD, Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02848092
NCT04175028,Neuromodulation of Executive Function in the ADHD Brain,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Device: Transcranial Direct Current Stimulation,Change in Accuracy and Reaction Time in Attention and Working Memory|Change in Accuracy and Reaction Time in Inhibition/Decision Making|Amplitude of Encephalogram (EEG) Event Related Potentials,Massachusetts General Hospital,All,"18 Years to 66 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",2014P001401,Sep-14,Sep-24,Sep-24,22-Nov-19,,28-Oct-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04175028
NCT04504890,Ocular-vestibular Biomarker Identification for ADHD,,Recruiting,No Results Available,"ADHD - Combined Type|ADHD|ADHD Predominantly Inattentive Type|ADHD, Predominantly Hyperactive - Impulsive",Device: EYE-SYNC,Eye Tracking and ADHD measure correlation|Eye Tracking ADHD Diagnostic ROC|MANCOVA Eye Tracking in ADHD Treatment Population,"Sync-Think, Inc.|Sutter Health",All,"6 Years and older   (Child, Adult, Older Adult)",,240,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EYESYNCOBIADHD2020,16-Jul-20,5-Aug-21,5-Oct-21,7-Aug-20,,23-Oct-20,"Palo Alto Medical Foundation - San Carlos Center, San Carlos, California, United States",,https://ClinicalTrials.gov/show/NCT04504890
NCT03747887,Enhancing IEPs of Children With ADHD Using Daily Report Cards,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Behavioral: Daily Report Card|Other: School as Usual,Student Behavior Teacher Response Observation Rule Violations Count|Academic Performance Rating Scale|IEP Goals/Objectives met|Impairment rating scale - teacher version,State University of New York at Buffalo|Florida International University,All,5 Years to 14 Years   (Child),Not Applicable,216,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R324A180175,3-Jan-19,30-Jun-21,30-Jun-22,20-Nov-18,,20-Nov-18,"SUNY at Buffalo, Buffalo, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03747887/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03747887
NCT02502799,Intervention for Teens With ADHD and Substance Use,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Behavioral: Brief Early Intervention|Behavioral: Parent Training with Adolescent Cognitive Behavioral Therapy|Drug: Methylphenidate,Past 90-day substance use|Evidence of illicit substances in urine screen|Parent-adolescent conflict|Disruptive Behaviors|Likelihood of future substance use|Youth impairment,Florida International University,All,12 Years to 16 Years   (Child),Phase 3,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA034731,Jul-15,Aug-22,Aug-22,20-Jul-15,,25-Sep-20,"Florida International University Center for Children and Families, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02502799
NCT02688959,Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD),,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Behavioral: Tai Chi|Behavioral: Exercise,Change in symptoms of inattention|Feasibility of implementing wireless Electroencephalogram(EEG) to measure the theta beta ratio during performance of tai chi.,"University of Wisconsin, Madison",All,18 Years to 23 Years   (Adult),Not Applicable,145,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2015-0807|A348700|VCRGE\WAISMAN CENTER\WAISMAN|Protocol version 17 July 2019,Feb-16,Jun-21,Jun-21,23-Feb-16,,5-Jan-21,"University of Wisconsin-Madison, Waisman Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02688959
NCT02259517,An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Guanfacine|Drug: Lisdexamfetamine,Changes in brain structure and function produced by stimulant or non-stimulant medications in patients with ADHD,New York State Psychiatric Institute|Columbia University|American Academy of Child Adolescent Psychiatry.|Shire,All,6 Years to 17 Years   (Child),Not Applicable,160,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6961,Sep-14,Sep-21,Sep-22,8-Oct-14,,21-Jul-20,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02259517
NCT03945175,Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening,MYDAYIS,Not yet recruiting,No Results Available,Attention Deficit-Hyperactivity,Drug: MYDAYIS,"total score on the AISRS Adult ADHD Investigator symptom rating scale|Overall inattentive (IA) symptom subset on the Adult ADHD Investigator Symptom Rating Scale (AISRS)|Hyperactive-impulsive (HI) ADHD symptom subset on the AISRS|Overall impairment via the clinical global impression-severity (CGI-S) scale.|Total ADHD symptoms measured via total score on the Time Sensitive Adult ADHD Symptom Scale (TASS)|Total ADHD symptoms measured via total score on the Inattentive (IA) symptom (TASS) subset|Total ADHD symptoms measured via total score on the hyperactive-impulsive (HI) ADHD symptom(TASS) subset|Neuropsychological measurement of Executive Function in the early evening as measured by the Test of Variables of Attention (TOVA)|Neuropsychological measurement of Executive Function in the early evening as measured by the Stroop Color Word Test.|Clinical symptoms of Executive Function, as measured by the The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)",NYU Langone Health,All,18 Years to 60 Years   (Adult),Phase 3,34,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,s19-00046,25-Mar-20,Jun-21,Jun-21,10-May-19,,4-Mar-20,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03945175
NCT04219280,Evaluating Treatment of ADHD in Children With Down Syndrome,DS+ADHD Pilot,Recruiting,No Results Available,Down Syndrome|ADHD,Drug: Quillivant XR|Drug: Placebos,Change from baseline in ADHD Symptoms as measured by parent and teacher report on the Vanderbilt ADHD Parent and Teacher Rating Scales.|Change from baseline in heart rate as measured by an electrocardiogram performed at standard amplitude and speed (10mm/mV and 25mm/sec).|Change from baseline in PR interval as measured by an electrocardiogram performed at standard amplitude and speed (10mm/mV and 25mm/sec).|Change from baseline in QTc interval as measured by an electrocardiogram performed at standard amplitude and speed (10mm/mV and 25mm/sec).|Change in ADHD-symptom severity as measured by parent report and clinical observation on the Clinician Global Impression Severity and Improvement Scales.|Change in child behaviors from baseline as measured by parent and teacher report on the Aberrant Behavior Checklist - Community (ABC).|Change in child behaviors from baseline as measured by parent and teacher report on the Achenbach Child Behavior Checklist (CBCL).|Change in executive-functioning skills from baseline as measured by parent and teacher report on the Behavior Rating Inventory of Executive Function - 2 (BRIEF-2).,"Children's Hospital Medical Center, Cincinnati|University of California, Davis",All,6 Years to 17 Years   (Child),Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",2019-1016,2-Oct-20,Jan-22,Jan-22,7-Jan-20,,27-Oct-20,"University of California Davis MIND Institute, Sacramento, California, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04219280
NCT04240756,Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial,TPAC,Recruiting,No Results Available,ADHD|Parenting,Behavioral: Behavioral Parent Training|Drug: Extended release mixed amphetamine salts (MAS),Change in child ADHD-related impairment,"University of Maryland, College Park|Children's National Research Institute|University of Michigan|Seattle Children's Hospital|National Institute of Mental Health (NIMH)",All,"3 Years to 55 Years   (Child, Adult)",Phase 3,240,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R01MH118320|1R01MH118313,6-Aug-20,30-Mar-24,31-Jul-24,27-Jan-20,,5-Nov-20,"University of Maryland, College Park, Maryland, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04240756
NCT04627415,Project PEAK: Early Intervention for ADHD,PEAK,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Parent-Child Relations|Child Behavior|Parenting,Behavioral: Promoting Engagement with ADHD Pre-Kindergarteners,Post-Treatment Effects (Parent): Intervention Strategies|Post-Treatment Effects (Parent): Behavior|Post-Treatment Effects (Parent): Acceptability|Post-Treatment Effects (Parent): Stress|Post-Treatment Effects (Parent): Optimism|Post-Treatment Effects (Child): Academics|Post-Treatment Effects (Child): Behavior|Post-Treatment Effects (Child): Behavior Observations|Post-Treatment Effects (Child): Self Regulation|Post-Treatment Effects (Child): Bedtime Behaviors|Post-Treatment Effects (Child): Social Behaviors|Maintenance (Child): Behavior Observations|Maintenance (Child): Self Regulation|Maintenance (Child): Bedtime Behaviors|Maintenance (Parent): Acceptability|Maintenance (Parent): Behavior|Maintenance (Parent): Intervention Strategies|Maintenance (Parent): Stress|Maintenance (Parent): Optimism|Mediators and Moderators (Parent): Session Completion|Mediators and Moderators (Parent): Demographics|Mediators and Moderators (Parent): ADHD Symptoms|Mediators and Moderators (Parent): Parent Strategies|Mediators and Moderators (Parent): Stress|Mediators and Moderators (Parent): Media|Mediators and Moderators (Child)|Cost-Effectiveness (money): Face-to-face|Cost-Effectiveness (time): Face-to-face|Cost-Effectiveness (time): Online|Cost-Effectiveness (money): Online,Lehigh University|Institute of Education Sciences (IES),All,3 Years to 5 Years   (Child),Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IES: R324A200010,1-Sep-20,Aug-25,Aug-25,13-Nov-20,,17-Nov-20,"Lehigh University, Bethlehem, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04627415
NCT03511976,Adaptive Response to Intervention (RTI) for Students With ADHD,,Recruiting,No Results Available,Attention Deficit Disorder With Hyperactivity,Behavioral: Tier 1 Classroom Management|Behavioral: Daily Report Card (DRC)|Behavioral: Enhanced DRC (DRC-E)|Drug: Stimulant,Observations of Classroom Behavior|Disruptive Behavior Disorders Rating Scale|Impairment Rating Scale,Florida International University|University at Buffalo,All,"Child, Adult, Older Adult",Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R305A170532,14-May-18,Jun-21,Jun-21,30-Apr-18,,23-Jul-20,"Florida International University Center for Children and Families, Miami, Florida, United States|Center for Children and Families, University at Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT03511976
NCT04104841,School-Based Depression Prevention for Adolescents With ADHD,BEAMS,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Depressive Symptoms,Behavioral: Behaviorally Enhancing Adolescents' Mood in Schools|Behavioral: Usual Care,"Children's Depression Inventory, 2nd Edition (CDI-2)|Affective Reactivity Index|Suicide Behavior Questionnaire|Emotion Regulation Checklist|Difficulties in Emotion Regulation|Mirror Tracing Persistence Task|Tripartite Pleasure Inventory|Reward Probability Index|Behavioral Activation for Depression Scale|Balloon Analog Risk Task|Impairment Rating Scale","University of Maryland, College Park|National Institute of Mental Health (NIMH)",All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,108,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MH117086|R34MH117086,7-Aug-18,1-May-21,Jun-21,26-Sep-19,,26-Sep-19,"University of Maryland, College Park, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04104841
NCT04238403,Peer Professionals to Increase Capacity to Treat ADHD,,Recruiting,No Results Available,Attention Deficit and Disruptive Behavior Disorders,Behavioral: Behavioral Parent Training (MATCH Protocol),Change in Impairment Rating Scale (IRS) immediately after the intervention|Change in Parenting Sense of Competence Scale (PSOC) immediately after the intervention|Change in Alabama Parenting Questionnaire- Short Form (APQ-SF) immediately after the intervention|Change in Beck Depression Inventory-II immediately after the intervention|Change in Parental Stress-Short Form (PSI-SF) immediately after the intervention|Change in IOWA immediately after the intervention Connors Rating Scale (IOWA-CRS),New York University,All,"up to 99 Years   (Child, Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FY20203646,26-Feb-20,Nov-20,Dec-20,23-Jan-20,,28-Feb-20,"New York University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04238403
NCT04577417,Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Attention Deficit Disorder|Attention Deficit Disorder With Hyperactivity,"Drug: ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate",Acoustic reflex|Loudness discomfort level|Speech perception in noise|Tympanogram|Otoacoustic emissions|NIH Toolbox Cognition testing|Hearing screening|Sensory profile questionnaire|Fidgeting,Nemours Children's Clinic,All,"13 Years to 19 Years   (Child, Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,1600804,13-Sep-20,30-Jun-21,30-Jun-21,6-Oct-20,,6-Oct-20,"Nemours Children's Health, Wilmington, Delaware, United States",,https://ClinicalTrials.gov/show/NCT04577417
NCT03154359,Atomoxetine PBPK-PD Clinical Study,,Recruiting,No Results Available,ADHD,Drug: Atomoxetine Hydrochloride,Pharmacodynamic - metabolomic|Pharmacodynamic - activity|Incidence of adverse events|Therapeutic Response (responder vs. non-responder),Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"6 Years to 18 Years   (Child, Adult)",,120,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,16100728|U54HD090258-01,12-Dec-17,30-Jun-22,30-Jun-22,16-May-17,,9-Oct-20,"Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03154359
NCT03136263,Oxytocin and Cognitive Control in Adult ADHD,,Recruiting,No Results Available,Attention Deficit/Hyperactivity Disorder,Drug: Oxytocin nasal spray|Drug: Placebo nasal spray,Stop-signal task|AX-CPT|Category switch task|Global/local task|Simon task,Massachusetts General Hospital,Male,18 Years to 55 Years   (Adult),Early Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2017P000123,14-Dec-17,Dec-20,Dec-20,2-May-17,,30-Sep-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03136263
NCT03242772,Impact of Combined Medication and Behavioral Treatment for ASD & ADHD,,Recruiting,No Results Available,Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder,Drug: Amphetamine|Behavioral: ESDM informed parent coaching|Drug: Placebo Oral Tablet,"Change in amount and quality of joint engagement between the child and parent during a semi-structured 6 minute parent child interaction task|Change in Mean Socialization and Communication Subscales Standard Scores of the Vineland Adaptive Behavior Scale - 3rd edition, Interview Version (VABS-3)|Change in ADHD Symptoms using Preschool or School age ADHD Rating Scale (ADHD-RS)",Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,36 Months to 131 Months   (Child),Phase 2,48,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00085179|1P50HD093074-01,14-Dec-18,Jul-22,Jul-22,8-Aug-17,,10-Feb-20,"Duke Center for Autism and Brain Development, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03242772
NCT03666416,Acute Effects of Exercise in College Students With ADHD,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Effects of; Exertion|Working Memory|Change in Sustained Attention,Behavioral: Sprint Interval Training,"Change in Continuous Performance Test (CPT) from appointment 1 to 2|Change in Digit Span from appointment 1 to 2|Change in Letter-Number Sequencing from appointment 1 to 2|Change in Spatial Span (SS) from appointment 1 to 2|Depression, Anxiety, and Stress Scale-Modified (DASS-M)|Barkley Adult ADHD Rating Scale-Modified (BAARS-M)",University of Wyoming,All,18 Years to 25 Years   (Adult),Not Applicable,48,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20170220PL01463,8-Oct-18,30-Jun-21,30-Jun-21,11-Sep-18,,24-Jul-20,"University of Wyoming, Laramie, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT03666416
NCT03523663,System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Other: no intervention. measure eye movement data,Task choice|Reaction time|Eye position,"University of Wisconsin, Madison",All,8 Years to 12 Years   (Child),,45,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2015-0857|A536200|SMPH\DPT NEUROSCIENCE|Protocol Version 8/1/2019,Jan-16,Dec-21,Dec-21,14-May-18,,16-Dec-20,"Wisconsin Institutes of Medical Research, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03523663
NCT03446885,Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD,,Recruiting,No Results Available,Attention Deficit Disorder With Hyperactivity,Drug: Lisdexamfetamine Dimesylate 40 MG|Drug: Placebo,Ratings of Job Application Quality|Ratings of Job Interview Performance|Objective Observation of Workplace Productivity|Inattentive/Overactive Rating,Gregory Fabiano|State University of New York at Buffalo,All,"16 Years to 25 Years   (Child, Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IIR-USA-001277,1-Apr-18,31-Dec-18,31-Dec-18,27-Feb-18,,14-Aug-18,"SUNY at Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT03446885
NCT01721720,"Genetic, Brain Structure, and Environmental Effects on ADHD",,Recruiting,No Results Available,Attention Deficit Disorder With Hyperactivity,,"Brain MRI|DNA collection, clinical interviews, social network information gathering",National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"3 Years to 80 Years   (Child, Adult, Older Adult)",,1500,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,120202|12-HG-0202,9-Nov-12,,,6-Nov-12,,22-Dec-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01721720
NCT04640766,Process-instructed Self Neuro-Modulation (PRISM) for Attention Deficit/ Hyperactivity Disorder - Adults,,Not yet recruiting,No Results Available,Attention Deficit Hyper Activity,Device: PRISM,Time to achieve learning of feedback paradigm|Change in Score on Adult ADHD Investigator Symptom Rating Scale (AISRS)|Change in Score on Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5 (DSM-5 ASRS)|Change in Score on Behavioral Rating Inventory of Executive Function- Adult version (BRIEF-A) self-report|Change in Score on Patient Health Questionnaire-9 (PHQ-9)|Change in Score on Pittsburgh Sleep Quality Index (PSQI),NYU Langone Health,All,18 Years to 60 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-01086,Mar-21,Mar-21,Mar-22,23-Nov-20,,23-Nov-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04640766
NCT03844269,Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Device: AKL-T01,Midline Frontal Theta Power (MFT),"Akili Interactive Labs, Inc.",All,8 Years to 12 Years   (Child),Not Applicable,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,001S-C,10-May-19,1-Jan-20,1-Feb-20,18-Feb-19,,25-Sep-19,"Cortica Healthcare, San Rafael, California, United States",,https://ClinicalTrials.gov/show/NCT03844269
NCT03935646,Acute Effects of Stimulant Medication in College Students With ADHD,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Stimulant Use|Working Memory|Change in Sustained Attention|Mood,Drug: Adderall IR 10mg|Drug: Placebo,"Change in Continuous Performance Test - Identical Pairs (CPT-IP) for Adderall vs. Placebo|Change in Spatial Span (SS) for Adderall vs. Placebo|Change in Digit Span for Adderall vs. Placebo|Change in Letter-Number Sequencing for Adderall vs. Placebo|Visual Analogue Scales (VAS) for Adderall vs. Placebo|Addiction Research Center Inventory (ARCI) for Adderall vs. Placebo|Intentions to Use Questionnaire (IUQ) for Adderall vs. Placebo|Pittsburgh Sleep Quality Index-Modified (PSQI-M)|Depression, Anxiety, and Stress Scale-Modified (DASS-M)|DSM-5 ADHD Symptoms Checklist - Modified (DSM 5-M)|Side Effects Rating Scale - Modified|Substance Use Day After Questionnaire",University of Wyoming,All,18 Years to 30 Years   (Adult),Phase 2,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20190124JV02251,11-Feb-20,30-Jun-21,30-Jun-21,2-May-19,,24-Jul-20,"University of Wyoming, Laramie, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT03935646
NCT04082234,Reducing Disparities in Behavioral Health Treatment for Children in Primary Care,PASS,Recruiting,No Results Available,ADHD,Behavioral: Partnering to Achieve School Success (PASS)|Other: Treatment as Usual (TAU) plus Family Education,Changes in Homework Performance|Changes in Academic Progress|Changes in Academic Grades|Changes in Behavior Compliance|Changes in Symptoms of ADHD and Emotional and Behavioral Problems|Changes in Peer Relationships|Changes in Life Satisfaction|Changes in Service Use|Changes in Parent-Child Relationship|Changes in Family Empowerment|Changes in Perceptions of Team-Based Care|Changes in Parent-Teacher Involvement|Satisfaction with Treatment,Children's Hospital of Philadelphia|Patient-Centered Outcomes Research Institute,All,5 Years to 11 Years   (Child),Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-016315,1-Nov-19,15-Nov-22,31-Dec-22,9-Sep-19,,27-Aug-20,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04082234
NCT03279952,Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention,,Recruiting,No Results Available,ADHD,Drug: CNS Stimulant,change in parent rated irritability on the DBD irritability score|ADHD symptoms|ODD symptoms|Impairment Rating Scale (IRS)|Modified Overt Aggression Scale (MOAS)|Inventory of Callous Unemotional Traits|Affective Reactivity Index|Pittsburgh Side Effects Rating Scale (PSERS|Event related potentials (ERP)|Error related negativity (ERN) amplitude,Milton S. Hershey Medical Center,All,5 Years to 12 Years   (Child),Phase 4,47,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB: 00008082,1-Jan-18,1-Jul-21,1-Jul-21,12-Sep-17,,19-Jun-20,"Penn State Hershey, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03279952
NCT03221244,Virtual Reality Attention Management,VRAM,Recruiting,No Results Available,ADHD,Device: VR Treatment|Device: VR Active Control,Decrease in the amount of eye movements toward the distractors and/or shorter duration of fixation on distractors.|Decrease in the amount of head movements toward the distractors|Improvement on the Restricted Academic Situations Test (RAST)|Improvement in CGI-S ratings in relation to distractibility|Improvement in distractibility determined by CGI-I|ADHD:RS 5 - Inattentive scale,"University of California, Davis|National Institute of Mental Health (NIMH)",All,8 Years to 12 Years   (Child),Not Applicable,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,883639|R61MH110043-01A1,2-Jun-16,Jul-22,Jul-22,18-Jul-17,,8-Apr-20,"UC Davis MIND Institute, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03221244
NCT04398225,"A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder",,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Centanafadine,Maximal peak plasma concentration (Cmax)|Area under the concentration-time curve from time 0 to 24 hours (AUC0-24h) on day 14|Apparent clearance and apparent volume of distribution of centanafadine on Day 14,"Otsuka Pharmaceutical Development & Commercialization, Inc.",All,4 Years to 12 Years   (Child),Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,405-201-00010,11-Jun-20,Jun-21,Jun-21,21-May-20,,13-Jan-21,"For additional information regarding sites, contact 844-687-8522, Hollywood, Florida, United States",,https://ClinicalTrials.gov/show/NCT04398225
NCT03904498,COMT Inhibition Among Individuals With Comorbid AUD/ADHD,,Not yet recruiting,No Results Available,Alcohol Use Disorder|Attention Deficit Hyperactivity Disorder,Drug: Tolcapone|Drug: Placebo,Change in alcohol-induced stimulation between medication periods|Change in subjective response to alcohol between medication periods|Change in risky decision-making after alcohol administration between medication periods|Change in cognitive-control-associated brain activation (fMRI) between medication periods|Change in selective attention-associated brain activation (fMRI) between medication periods|Change in alcohol cue-elicited brain activation (fMRI) between medication periods,"University of Colorado, Denver|National Institute on Alcohol Abuse and Alcoholism (NIAAA)",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,62,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",19-2335|R01AA026859,15-Jan-21,31-Mar-24,31-Mar-24,5-Apr-19,,3-Dec-20,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT03904498
NCT03480737,rTMS and EF Training for Working Memory Deficits in Adolescent Psychopathology,,Recruiting,No Results Available,ADHD With Working Memory Deficits,"Device: Magstim Super Rapid2 stimulator, 10 Hz condition|Device: Magstim Super Rapid2 stimulator, Sham condition|Device: Magstim Super Rapid2 stimulator, iTBS condition","Compared to sham condition, activation of the left DLPFC prior to EF training will temporarily increase working memory performance as measured by the Sternberg Spatial Working Memory Test|Compared to sham condition, activation of the left DLPFC prior to EF training will temporarily increase fronto-parietal gamma power and theta-gamma coupling during working memory demands.",Bradley Hospital|Thrasher Research Fund|Rhode Island Foundation,All,13 Years to 17 Years   (Child),Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BradleyH,1-Nov-19,30-Jan-21,30-Mar-21,29-Mar-18,,14-Nov-19,"E. P. Bradley Hospital, East Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT03480737
NCT04108273,Brain Plasticity Underlying Acquisition of New Organizational Skills in Children,,Recruiting,No Results Available,ADHD|Attention Deficit Hyperactivity Disorder|Neurodevelopmental Disorders,Behavioral: Organizational Skills Training|Behavioral: Waitlist,Change in parent Children's Organizational Skills Scales (COSS-P) total T-scores following OST intervention,NYU Langone Health|National Institute of Mental Health (NIMH),All,8 Years to 12 Years   (Child),Not Applicable,144,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,s17-00263|R61MH113663,1-Oct-19,Dec-20,Dec-20,30-Sep-19,,10-Nov-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04108273
NCT04647903,"Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)",SEAL,Recruiting,No Results Available,ADHD|Narcolepsy,Drug: ADAIR 10 mg IR tablets|Drug: d-amphetamine sulfate|Drug: Placebo,Drug Liking Emax Visual Analog Scale (VAS)|Take Drug Again Emax VAS|Overall Drug Liking Emax VAS|Plasma concentrations (PK parameters)|Safety (adverse events),"Vallon Pharmaceuticals, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,64,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VAL-104,5-Oct-20,14-Jun-21,21-Jun-21,1-Dec-20,,1-Dec-20,"Vallon Investigational Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04647903
NCT04175041,A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Device: Transcranial Direct Current Stimulation,Change in Accuracy and Reaction Time in Attention and Working Memory|Amplitude of Electroencephalogram (EEG) Event Related Potentials,Massachusetts General Hospital,All,18 Years to 55 Years   (Adult),Not Applicable,104,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",2018P002889,9-Jul-19,Jul-23,Jul-23,22-Nov-19,,28-Oct-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04175041
NCT03420339,Stimulant Effects on Disruptive Behavior,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Problem Behavior,Drug: Stimulant,Change in Behavioral Function|Change in Item Preference|Change in Preference for Social and Non-Social Activities|Changes in Impulsivity in Choice-Making|Rate of Problem Behavior|Item Engagement|Compliance,"Matthew J O'Brien, PhD, BCBA-D|University of Iowa",All,48 Months to 153 Months   (Child),Phase 4,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201709737,1-Oct-18,1-Jan-25,1-Jan-25,5-Feb-18,,20-Nov-20,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03420339
NCT04170738,Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder,,Recruiting,No Results Available,Attention Deficit Disorder With Hyperactivity|Conduct Disorder|Substance Abuse,Drug: Adderall,Change in fMRI Measure,Jeffrey Newcorn|National Institute on Drug Abuse (NIDA)|Icahn School of Medicine at Mount Sinai,All,7 Years to 12 Years   (Child),Phase 4,44,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,GCO 17-1321|1R21DA046029-01A1,5-Nov-19,Dec-21,Dec-21,20-Nov-19,,29-Oct-20,"Boys Town National Children's Hospital, Omaha, Nebraska, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04170738
NCT00001246,"Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers",,Recruiting,No Results Available,Attention Deficit Hyerpactivity Disorder|Schizophrenia|Attention Deficit Disorder With Hyperactivity,,Volumetric MRI Data,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"3 Years and older   (Child, Adult, Older Adult)",,6000,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,890006|89-M-0006,19-Jun-90,,,4-Nov-99,,11-Jan-21,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001246
NCT04553263,Relapse Prevention in Stimulant Use Disorder,,Not yet recruiting,No Results Available,Stimulant Use|Relapse|Cognitive Function|ADHD,Drug: Contrave 8Mg-90Mg Extended-Release Tablet|Drug: Bupropion,Stimulant use 1 month after leaving inpatient treatment (self-report)|Stimulant use 1 month after leaving inpatient treatment (urine toxicology)|Sustained attention|Working memory|Declarative memory|Inhibitory control - stop signal task|Inhibitory control - reversal learning|Reward-based decision-making|Decision making under risk and ambiguity|Loss Aversion,"University of California, Los Angeles",All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",20-001075,11-Jan-21,11-Jan-23,11-Jan-23,17-Sep-20,,10-Nov-20,"University of California Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04553263
NCT04648553,Task-Based Grounding Program,,Recruiting,No Results Available,"Aggressive|Defiant Disorder, Oppositional|Attention Deficit Hyperactivity Disorder",Behavioral: Task-Based Grounding|Behavioral: Connected Care (Enhanced Treatment as usual),Number of referred participants|Number of participants who screen positive|Change from Baseline Session attendance at visit 3|Number of participants enrolled|Number of participants who complete all assessment measures|Fidelity of the training provided|Intervention acceptability as measured by the Treatment Evaluation Inventory Short Form|Intervention Acceptability as measured by the Therapy Attitude Inventory|Intervention Acceptability as measured by the Participant Experiences Questionnaire|Acceptability as measured by qualitative interview|Adherence to the intervention,Dartmouth-Hitchcock Medical Center,All,"9 Years and older   (Child, Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D21019,3-Dec-20,1-Jun-21,1-Aug-21,1-Dec-20,,22-Dec-20,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT04648553
NCT03730194,A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders,,Recruiting,No Results Available,Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Sleep Disturbance,Dietary Supplement: Melatonin|Behavioral: Bedtime Bank,Actigraphy (total sleep time)|Cleveland Adolescent Sleepiness Questionnaire (CASQ)|Sleep Diary|PROMIS Pediatric Item Bank Sleep Disturbance|PROMIS Pediatric Item Bank Sleep Related Impairment|Dim Light Melatonin Onset (DLMO)|Urinary Melatonin|PROMIS Sleep Disturbance (short form v. 1.0 8b)|PROMIS Sleep Related Impairment (short form v. 1.0 8a),University of Nebraska|National Institute of Nursing Research (NINR),All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,775-18-FB|1K01NR017465-01A1,31-May-19,31-Jan-22,31-Jan-22,5-Nov-18,,4-Jun-19,"University of Nebraska Medical Center, Center for Nursing Science, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT03730194
NCT04016779,Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder,,Recruiting,No Results Available,ADHD,Drug: Placebo|Drug: 200-600 mg SPN-812,Efficacy of SPN-812 assessed by adult ADHD Investigator Symptom Rating Scale (AISRS)|Effect of SPN-812 assessed by Clinical Global Impression - Severity of Illness (CGI-S) Scale|Effect of SPN-812 assessed by the Adult ADHD Self-Report Scale (ASRS)|Effect of SPN-812 assessed by Clinical Global Impression - Improvement scale (CGI-I)|Effect of SPN-812 assessed by categorical CGI-I Responder Rate|Effect of SPN-812 assessed by the Generalized Anxiety Disorder 7 Item scale (GAD-7)|Effect of SPN-812 assessed by AISRS subscales of Inattention and Hyperactivity/Impulsivity|Effect of SPN-812 assessed by 50% Responder Rate|Effect of SPN-812 assessed by 30% Responder Rate|Effect of SPN-812 assessed by ASRS|Effect of SPN-812 assessed by the Brown Executive Function/Attention (EF/A) Scales|Effect of SPN-812 assessed by Brown EF/A Scales cluster scale,"Supernus Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,366,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",812P306,20-Nov-19,Aug-20,Nov-20,11-Jul-19,,5-May-20,"Collaborative Neuroscience Network, Garden Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Artemis Research Institue for Clinical Research, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Rearch, San Marcos, California, United States|Collaborative Neuroscience Network LLC, Torrance, California, United States|Gulfcoast Research Center, Fort Myers, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions Inc., Orlando, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Meridien Research, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Psych Atlanta, Marietta, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|St. Charles Psychiatric Associates Midwest Research Center, Saint Charles, Missouri, United States|Alivation Research, LLC, Lincoln, Nebraska, United States|Altea Research Institute, Las Vegas, Nevada, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Hassmann Research Institute, Marlton, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Bioscience Research, Mount Kisco, New York, United States|The Medical Research Network LLC, New York, New York, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|CNS Healthcare, Memphis, Tennessee, United States|BioBehavioral Research of Austin P.C., Austin, Texas, United States|FutureSearch Trials of Dallas, LLP, Dallas, Texas, United States|Houston Clinical Trials, Houston, Texas, United States|Family Psychiatry of the Woodlands, The Woodlands, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|Northwest Clinical Trials, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04016779
NCT04085172,A Study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged Release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attentiondeficit/Hyperactivity Disorder (ADHD),,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder (ADHD),Drug: Guanfacine hydrochloride (SPD503)|Drug: Atomoxetine hydrochloride|Other: Placebo,"Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 10|Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 18|Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 49|Change from Baseline in the Rapid Visual Information Processing (RVP) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points|Change from Baseline in the Spatial Working Memory (SWM) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points|Change from Baseline in the Stop Signal Task (SST) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points|Change from Baseline in the Delayed Matching to Sample (DMS) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points|Tanner Stage in Both Part A and Part B at Specified Time Points|Number of participants with clinically significant changes in Vital signs, ECG, Physical Examination|Brief Psychiatric Rating Scale for Children (BPRS-C)|Columbia- Suicide Severity Rating Scale (CSSRS)|Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale|Pediatric Daytime Sleepiness Scale (PDSS)|ADHD Rating Scale-5 (ADHD-RS-5) Total Score and Subscales|Clinical Global Impression-Improvement (CGI-I)|Child Health and Illness Profile - Child Edition: Parent Report Form (CHIP-CE:PRF)|Academic Performance Rating Scale (APRS)","Shire|Takeda Development Center Americas, Inc.|Takeda",All,6 Years to 17 Years   (Child),Phase 4,288,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPD503-401|2018-000821-29|TAK-503-401,18-Sep-19,7-May-25,7-May-25,11-Sep-19,,15-Jan-21,"Harmonex Neuroscience Research, Dothan, Alabama, United States|Sun Valley Research Center, Imperial, California, United States|Alliance for Wellness dba Alliance for Research, Long Beach, California, United States|PCSD-Feighner Research Institute, San Diego, California, United States|Homestead Medical Research, Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Care Research Center, Inc., Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|AMR Conventions Research, Naperville, Illinois, United States|Phoenix Medical Research, Inc., Prairie Village, Kansas, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Alivation Research, LLC, Lincoln, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cutting Edge Research Group, Inc, Oklahoma City, Oklahoma, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Clinical Research Partners, LLC, Petersburg, Virginia, United States|Medizinische Universität Graz, Graz, Austria|LKH Hall, Hall in Tirol, Austria|Medizinische Universtität Wien, Vienna, Austria|Anima Research Center, Alken, Belgium|ZNA Middelheim, Borgerhout, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|UZ Leuven, Leuven, Belgium|Clinique et Maternite St Elisabeth Namur, Namur, Belgium|Klinikum Frankfurt (Oder) GmbH, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Praxis f Kinder-und Jugendpsychiatrie Dr Reitzle, Muenchen, Germany|Johanniter Zentrum f. Kinder-und Jugendpsychiatrie, Neuwied, Germany|EB FlevoResearch, Almere, Netherlands|Accare, Groningen, Netherlands|EB Utrecht, Utrecht, Netherlands|Hospital de Cascais - Dr. José de Almeida, Alcabideche, Portugal|Andreia Gomes, Braga, Portugal|Centro Hospitalar Cova da Beira, EPE, Covilhã, Portugal|Hospital da Senhora da Oliveira Guimarães, Guimarães, Portugal|Hospital CUF Descobertas, Lisboa, Portugal|Centro Hospitalar do Porto, E.P.E. - Centro Materno Infantil do Norte, Porto, Portugal|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Clinica Dr. Quintero, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Fundacion Alcorcon, Madrid, Spain|Complejo Hospitalario de Palencia, Palencia, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Spain|Barnneuropsykiatriska enheten, Sahlgrenska University hospital, Göteborg, Sweden|Närhälsan Mölnlycke, Mölnlycke, Sweden|PRIMA Barn- och Vuxenpsykiatri AB, Norsborg, Sweden|Ninewells Hospital, Dundee, United Kingdom|Cognition Health Ltd (London), London, United Kingdom|Lister Hospital, Stevenage, United Kingdom",,https://ClinicalTrials.gov/show/NCT04085172
NCT04507204,Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD),RE-DAX,Recruiting,No Results Available,Attention-Deficit/Hyperactivity Disorder,Drug: Adhansia XR|Drug: Concerta,Change in ADHD-Rating Scale 5 Total Score from Baseline to Month 2|Difference in Time Sensitive ADHD Symptom Scale (TASS) Between Treatment Groups|Assessment of Clinical Global Impression-Severity (CGI-S)|Assessment of Clinical Global Impression-Improvement (CGI-I)|Assessment of Treatment Satisfaction|Healthcare Resource Utilization (HCRU)|Adult ADHD Quality of Life Scale - Revised (AAQoL-R)|Work Productivity and Activity Impairment (WPAI) Questionnaire|Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale|Patient Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI),Purdue Pharma LP,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 4,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADA4003,30-Jul-20,30-Mar-21,30-Sep-21,11-Aug-20,,19-Dec-20,"Harmonex, Inc., Dothan, Alabama, United States|Southern California Research LLC, Beverly Hills, California, United States|CT Clinical Research, Cromwell, Connecticut, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|BTC of New Bedford, LLC, New Bedford, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Clinical Research of Southern Nevada, LLC, Las Vegas, Nevada, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Bioscience Research, LLC, Mount Kisco, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|SFM Clinical Trials, Scotland, Pennsylvania, United States|Rainbow Research, Barnwell, South Carolina, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|InSite Clinical Research, LLC, DeSoto, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, Ltd., San Antonio, Texas, United States|Clinical Research Partners, LLC, Petersburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04507204
NCT04631042,"Developing Brain, Impulsivity and Compulsivity",,Not yet recruiting,No Results Available,Typical Development|Attention Deficit Hyperactivity Disorder|Conduct Disorder|Obsessive Compulsive Disorder,,Glutamate concentration measured using Magnetic Resonance Spectroscopy|Heritability of cortical glutamate (proportion of variance explained by additive genetic factors).|Glutamate levels|Structural and functional connectivity,National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"6 Years to 80 Years   (Child, Adult, Older Adult)",,1100,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200147|20-HG-0147,20-Jan-21,31-Dec-30,31-Dec-30,17-Nov-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04631042
NCT04143217,Open-label Study to Evaluate Long-Term Safety and Efficacy of SPN-812 in Adults With ADHD,,Recruiting,No Results Available,Attention-Deficit/Hyperactivity Disorder,Drug: SPN-812,Incidence of adverse events|ADHD symptoms as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score|Global assessment of severity as measured by the Clinical Global Impression - Severity of Illness (CGI-S) scale for ADHD|Clinical response rate of severity of illness as measured by the categorical CGI-S Responder Rate (CGI-S score of 1 or 2)|Global assessment of improvement as measured by the Clinical Global Impression - Improvement scale (CGI-I) for ADHD|Clinical response rate of improvement as measured by the categorical CGI-I Responder Rate (CGI-I score of 1 or 2)|Anxiety symptoms as measured by the Generalized Anxiety Disorder 7-Item scale (GAD-7)|Clinician-rated ADHD symptoms as measured by the AISRS subscales of Inattention and Hyperactivity/Impulsivity|Clinician response rate of ADHD symptom reduction as measured by the 50% responder rate in Adult ADHD Investigator Symptom Rating Scale (AISRS total score)|Clinician response rate of ADHD symptom reduction as measured by the 30% responder rate in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score|Executive functioning as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A; Self Report)|Aspects of executive function and problems of self-regulation as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A; Self Report) Summary Index Scales and subscales,"Supernus Pharmaceuticals, Inc.",All,18 Years to 55 Years   (Adult),Phase 3,400,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,812P311,23-Jan-20,Jul-21,Jul-21,29-Oct-19,,6-May-20,"South California Research LLC, Beverly Hills, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Artemis Research Institue for Clinical Research, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Rearch, San Marcos, California, United States|Collaborative Neuroscience Network LLC, Torrance, California, United States|Gulfcoast Research Center, Fort Myers, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions Inc., Orlando, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Meridien Research, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Psych Atlanta, Marietta, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|St. Charles Psychiatric Associates Midwest Research Center, Saint Charles, Missouri, United States|Alivation Research, LLC, Lincoln, Nebraska, United States|Altea Research Institute, Las Vegas, Nevada, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Hassmann Research Institute, Marlton, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Bioscience Research, Mount Kisco, New York, United States|The Medical Research Network LLC, New York, New York, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, United States|BioBehavioral Research of Austin P.C., Austin, Texas, United States|FutureSearch Trials of Dallas, LLP, Dallas, Texas, United States|Houston Clinical Trials, Houston, Texas, United States|Family Psychiatry of the Woodlands, The Woodlands, Texas, United States|Northwest Clinical Trials, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04143217
NCT01931644,"At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",,Recruiting,No Results Available,All Diagnosed Health Conditions|ADD/ADHD|Alopecia Areata|Ankylosing Spondylitis|Asthma|Atopic Dermatitis Eczema|Beta Thalassemia|Bipolar Disorder|Breast Cancer|Celiac Disease|Cervical Cancer|Chronic Inflammatory Demyelinating Polyneuropathy|Chronic Kidney Diseases|Chronic Obstructive Pulmonary Disease|Colon Cancer|Colorectal Cancer|Crohn's Disease|Cystic Fibrosis|Depression|Diabetes Mellitus|Duchenne Muscular Dystrophy|Endometriosis|Epilepsy|Facioscapulohumeral Muscular Dystrophy|G6PD Deficiency|General Anxiety Disorder|Hepatitis B|Hereditary Hemorrhagic Telangiectasia|HIV/AIDS|Human Papilloma Virus|Huntington's Disease|Idiopathic Thrombocytopenic Purpura|Insomnia|Kidney Cancer|Leukemia|Lung Cancer|Lupus Nephritis|Lymphoma|Melanoma|Multiple Myeloma|Multiple Sclerosis|Myositis|Myotonic Dystrophy|Ovarian Cancer|Pancreatic Cancer|Parkinson's Disease|Polycystic Kidney Diseases|Prostate Cancer|Psoriasis|Psoriatic Arthritis|Rosacea|Scleroderma|Sickle Cell Anemia|Sickle Cell Trait|Sjogren's Syndrome|Skin Cancer|Spinal Muscular Atrophy|Systemic Lupus Erythematosus|Thrombotic Thrombocytopenic Purpura|Trisomy 21|Ulcerative Colitis,,Biospecimen & Clinical Data Collection,Sanguine Biosciences,All,"18 Years to 100 Years   (Adult, Older Adult)",,20000,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,SAN-BB-01,Jul-13,Aug-25,Dec-40,29-Aug-13,,8-Oct-19,"Sanguine Biosciences, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01931644
NCT04296604,Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations,,Recruiting,No Results Available,Traumatic Brain Injury|Major Depressive Disorder|Bipolar Disorder|Schizophrenia|Attention Deficit Hyperactivity Disorder|Borderline Personality Disorder|Substance Use Disorders,Device: Transcranial Direct Current Stimulation,Change in N-Back Task|Change in Flanker Task|Change in Multi-Source Interference with International Affective Picture System Task|Change in Delayed Discounting Task|Change in Stop Signal Task|Change in Iowa Gambling Task,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2014P001428,Sep-14,Sep-22,Sep-22,5-Mar-20,,28-Oct-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04296604
NCT04113304,The Parenting Young Children Check-up: Proof-of-Concept Trial,,Recruiting,No Results Available,Disruptive Behavior Disorders,Behavioral: Parenting Young Children Check-up (PYCC),Perceived ease of use of the Parenting Young Children Check-up Program|Perceived usefulness of the information in the Parenting Young Children Check-up Program|Likeability of the Parenting Young Children Check-up Program|Intentions to use the Parenting Young Children Check-up web-based resource|Suggestions for program improvements|Number of participants that use the web-based parent training resources,Wayne State University,All,"18 Years to 99 Years   (Adult, Older Adult)",,75,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,K01MH110600,22-Oct-19,1-Sep-20,31-Mar-21,2-Oct-19,,17-Dec-19,"Merrill Palmer Skillman Institute, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04113304
NCT04113161,Navigating Resource-Constrained Systems and Communities to Promote the Behavioral Health of Black Youth,,Recruiting,No Results Available,Disruptive Behavior Disorder,Other: Standard Care|Other: Child Behavioral Health Navigator (cbhN),Disruptive Behavior Disorder Rating Scale (DBDRS)|IOWA Connors Rating Scale|Strengths and Difficulties Questionnaire (SDQ)|Impairment Rating Scale (IRS)|Project Reach Care and System Tracking Tools|Electronic Medical Record Abstractions|Service Implementation Checklist|Working Alliance Inventory-Short Form (WAI)|Metropolitan Area Child Study (MACS) Process Records|Beliefs about Mental Illness (BMI) Scale|Semi-structured interview|Implementation and Feasibility Checklists|Texas Christian University (TCU) Survey of Organizational Functioning|Program Sustainability Assessment Tool (PSAT),Washington University School of Medicine,All,"10 Years and older   (Child, Adult, Older Adult)",Not Applicable,405,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,MH116895,1-Jan-20,31-May-24,31-May-24,2-Oct-19,,8-Oct-20,"Brown School at Washington University in St. Louis, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04113161
NCT03927612,Virtual Reality to Improve Social Perspective Taking,,Recruiting,No Results Available,Conduct Disorder|Child|Adolescent|Attention Deficit and Disruptive Behavior Disorders|Child Behavior Disorders|Virtual Reality|Social Perception|Magnetic Resonance Imaging,Device: Virtual reality perspective taking training|Device: Virtual reality control perspective,Change from Pre-intervention on the Virtual Reality Perspective Taking Scale|Change from Pre-intervention on the Acknowledgement of Other Perspective Scale|Change from Pre-intervention in brain activity in response to Self Pain vs. Other Pain,Indiana University,All,9 Years to 12 Years   (Child),Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1902596251,7-Jan-20,Mar-21,Mar-21,25-Apr-19,,16-Jul-20,"IU Health Neuroscience Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03927612
NCT02824627,Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders,,Recruiting,No Results Available,Mood Disorder|Disruptive Behavior Disorders,Drug: Oxytocin|Drug: Placebo,"Affective Reactivity Index Changes|Behavior Assessment System for Children, second version (BASC-2) Changes|Inventory of Callous Unemotional Trait (ICU) Changes|Reactive-Proactive Aggression Questionnaire (RPAQ) Changes|functional MRI (fMRI) BOLD response changes|Magneto-encephalography (MEG) electrical activity changes",University of Nebraska,All,"10 Years to 18 Years   (Child, Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",321-16-FB,27-Jan-17,Jan-21,Jan-21,6-Jul-16,,4-Nov-20,"University of Nebraska Medical Center Department of Psychiatry, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT02824627
NCT04278404,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",POPS or POP02,Recruiting,No Results Available,Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Fibrinolysis; Hemorrhage|Attention Deficit Hyperactivity Disorder|Multisystem Inflammatory Syndrome in Children (MIS-C)|Kawasaki Disease|Coagulation Disorder|Down Syndrome,"Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,5-Mar-20,24-Apr-24,24-Apr-24,20-Feb-20,,14-Oct-20,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|University of California, Los Angeles, California, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas-Southwestern Medical Center, Dallas, Texas, United States|University of Texas--Memorial Hermann Texas Medical Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04278404
NCT03261076,Reading Remediation and Outcomes in Detention,SERIOUS,Recruiting,No Results Available,Specific Learning Disorder (MeSH Unique ID: D000067559)|Dyslexia (MeSH Unique ID: D004410)|Conduct Disorder (MeSH Unique ID: D019955),Behavioral: Strategies Enhancing Reading in Older Underperf. Students,Change in Reading Skills from pre-intervention (baseline) to the week after intervention|Change in Decoding Skills from pre-intervention (baseline) to the week after intervention|Change in Reading Understanding from pre-intervention (baseline) to the week after intervention|Change in Comprehension from pre-intervention (baseline) to the week after intervention|Change in Reading Fluency from pre-intervention (baseline) to the week after intervention|Change in Other Academic Skills from pre-intervention (baseline) to the week after intervention|Recidivism within 1 year post-intervention|Number of days to recidivism within 1 year post-intervention|Detention within 1 year post-intervention|Number of days to detention within 1 year post-intervention|Adjudication within 1 year post-intervention|Number of days to adjudication within 1 year post-intervention,Baylor College of Medicine|University of Houston|Harris County Juvenile Probation Department|Connecticut Court Support Services Division|MindTrust Labs,Male,14 Years to 16 Years   (Child),Not Applicable,192,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-40232,14-May-18,31-Dec-20,31-Dec-20,24-Aug-17,,27-Feb-20,"Burnett-Bayland Rehabilitation Center (BBRC), Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03261076
NCT04372602,Duvelisib to Combat COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo,Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0,"Washington University School of Medicine|Verastem, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,28,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",202007009,12-Oct-20,30-Nov-21,30-Apr-22,4-May-20,,9-Nov-20,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04372602
NCT04482621,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,DART,Recruiting,No Results Available,COVID-19,Drug: Decitabine|Other: Placebo Saline,Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more,Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB00247544,14-Sep-20,May-21,Jul-21,22-Jul-20,,25-Sep-20,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04482621
NCT04343183,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,,Not yet recruiting,No Results Available,COVID-19,Device: Hyperbaric Oxygen Therapy,Decrease incidence of intubation by 30% or greater|Decrease renal injury,Ochsner Health System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STUDY00001051,Apr-20,Jun-20,Jun-20,13-Apr-20,,13-Apr-20,"Ochsner Medical Center, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04343183
NCT04445285,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,DAMPENCOVID,Recruiting,No Results Available,Covid19,Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride,Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function,Jon Simmons|University of South Alabama,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",USAH 1002 000,28-Apr-20,30-Nov-20,28-Feb-21,24-Jun-20,,21-Aug-20,"University of South Alabama, Mobile, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04445285
NCT04663737,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19",,Recruiting,No Results Available,Covid19,Drug: Silmitasertib|Drug: SOC,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) within the CX-4945 Treatment Group assessed by CTCAE v5.0|Clinical Recovery associated with COVID-19 within the CX-4945 Treatment Group|Anti-Viral Activity of CX-4945|Maximum Plasma Concentration [Cmax] of CX-4945|Clinical Benefit of CX-4945 i.e. All-Cause Mortality|Clinical Benefit of CX-4945 i.e. Number of Respiratory Failures|Clinical Benefit of CX-4945 i.e. Number of Hospitalized Days|Clinical Benefit of CX-4945 i.e. Changes in Pulse Oxygen Saturation|Clinical Benefit of CX-4945 i.e. Changes in Clinical Status|Clinical Benefit of CX-4945 i.e. Self-Reported Quality of Life|CX-4945 Inflammatory Marker Outcomes i.e. Plasma IL-6|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CRP|CX-4945 Inflammatory Marker Outcomes i.e. Plasma LDH|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CPK|CX-4945 Inflammatory Marker Outcomes i.e. Plasma Ferritin|CX-4945 Inflammatory Marker Outcomes i.e. Plasma D-Dimer,"Chris Recknor, MD|Senhwa Biosciences, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CX4945 AV01-IIT,3-Dec-20,11-Jan-21,11-Feb-21,11-Dec-20,,11-Dec-20,"Center for Advanced Research and Education, Gainesville, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04663737
NCT04388683,Inhaled Nitric Oxide for Preventing Progression in COVID-19,NO-COVID-19,Recruiting,No Results Available,COVID-19,Drug: Nitric Oxide,"Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with ""Do Not Resuscitate"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level",Tufts Medical Center|Bellerophon,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,42,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000554,12-May-20,30-Apr-21,31-Jul-21,14-May-20,,18-May-20,"Tufts Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04388683
NCT04490174,Serological Surveillance for COVID-19 in Central North Carolina,,Recruiting,No Results Available,COVID-19,,Anti-SARS-COV-2 antibodies|Positive SARS-CoV-2 PCR|Clinical questionnaires and ELISA antibody testing resu|Detection of Anti-SARS-CoV-2 antibodies by ELISA Assay Algorithm|Clinical questionnaires and ELISA antibody testing results,National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,2500,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200143|20-E-0143,8-Jan-20,1-Jun-22,1-Jun-22,29-Jul-20,,12-Jan-21,"NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04490174
NCT04542421,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,,Recruiting,No Results Available,Covid19,Diagnostic Test: Lung ultrasound use in patients hospitalized with COVID,"Adoption of lung ultrasound by hospitalists caring for patients with COVID|Percentage of patients with COVID who receive a lung ultrasound|Chest x-ray utilization|Adequacy of Lung ultrasound images, interpretation and clinical decision-making as measured by a lung ultrasound expert|Inpatient mortality","University of Colorado, Denver",All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,20-0781,1-Jul-20,1-Jul-21,1-Dec-21,9-Sep-20,,28-Sep-20,"University of Colorado, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04542421
NCT04431908,Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,,Recruiting,No Results Available,COVID-19,Device: olfactory device,"sensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracy",Yale University,All,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2000028259,15-Jun-20,1-Sep-20,1-Oct-20,16-Jun-20,,4-Aug-20,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04431908
NCT04473690,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,,Recruiting,No Results Available,Covid19,Biological: Low Dose of KBP-COVID-19|Biological: High Dose of KBP-COVID-19|Biological: Placebo,"Solicited Administration site reactions|Solicited systemic events|Unsolicited Adverse Events and medically attended adverse events|Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae|Vaccine ELISA and neutralizing antibody titers for each treatment group|Seroconversion rates","Kentucky BioProcessing, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,180,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",KBP-201,30-Dec-20,6-May-21,23-Mar-22,16-Jul-20,,14-Jan-21,"ICON CRU, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04473690
NCT04412486,COVID-19 Convalescent Plasma (CCP) Transfusion,,Recruiting,No Results Available,COVID-19,Biological: COVID Convalescent Plasma,Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.,"Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0137,1-Jun-20,31-May-22,31-May-22,2-Jun-20,,2-Jul-20,"University of Mississippi Medical Center, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT04412486
NCT04452669,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,VPCOVID,Not yet recruiting,No Results Available,COVID-19,Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes,Aerogen Pharma Limited|Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APC-VPCOV-CLN-001,15-Aug-20,1-Dec-20,1-Feb-21,30-Jun-20,,31-Jul-20,"Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04452669
NCT04406389,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),IMPACT,Recruiting,No Results Available,COVID-19,Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban,"30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events",Weill Medical College of Cornell University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,186,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-04021936,13-Oct-20,Dec-20,Jun-21,28-May-20,,20-Oct-20,"Weill Cornell Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04406389
NCT04587323,VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease,,Recruiting,No Results Available,COVID-19 Disease,,Laboratory Assays|VEGF-A|VEGF-C|VEGF-D|Tie-2|Flt-1|PlGF|FGF,University of Alabama at Birmingham,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB-300005378,22-May-20,20-Mar-23,20-May-23,14-Oct-20,,14-Oct-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04587323
NCT04347993,"A Prospective ""Universal"" Observational Database for COVID-19",,Recruiting,No Results Available,COVID-19,,Need for hospitalization|Duration of hospitalization|Need for ICU/Ventilator Support|Duration of ICU/Ventilator Support|Overall Survival,Hackensack Meridian Health,All,"Child, Adult, Older Adult",,5000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Pro2020-0342,27-Mar-20,Apr-21,Apr-21,15-Apr-20,,24-Apr-20,"Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04347993
NCT04530474,Outpatient Use of Ivermectin in COVID-19,,Not yet recruiting,No Results Available,Covid19,Drug: Ivermectin Pill|Drug: Placebo,Clinical Improvement,Temple University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1285242,1-Oct-20,30-Jun-21,31-Dec-21,28-Aug-20,,28-Aug-20,"Temple University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04530474
NCT04474483,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,COVID-19,Recruiting,No Results Available,COVID-19,Drug: Melatonin|Other: Placebo (Methylcellulose) capsule,Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality,State University of New York at Buffalo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UBMELCOVID19,6-Nov-20,31-Mar-21,31-Mar-21,16-Jul-20,,10-Nov-20,"University at Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04474483
NCT04363346,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,,Recruiting,No Results Available,COVID-19,Drug: FT516,Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge,"Masonic Cancer Center, University of Minnesota",All,"18 Years to 76 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IDIM-2020-28708|2020LS083,14-May-20,Jan-22,Jan-22,27-Apr-20,,18-May-20,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04363346
NCT04456413,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,,Recruiting,No Results Available,COVID-19,Biological: Convalescent Plasma|Other: Best Supportive Care,"Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.",Hackensack Meridian Health,All,"18 Years and older   (Adult, Older Adult)",Phase 2,306,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro2020-0542,6-Nov-20,Nov-21,Nov-21,2-Jul-20,,20-Nov-20,"Hackensack University Medical Center, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04456413
NCT04479358,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,COVIDOSE-2,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Other: Standard of Care,Time to Recovery|Achievement of Recovery|Overall Survival|Hospital Length of Stay|Clinical Response: Maximum Temperature (Tmax) Response|Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation|Clinical Response: Rate of Vasopressor/Inotrope Utilization|Clinical Response: Duration of Vasopressor/Inotrope Utilization|Clinical Response: Time to Vasopressor/Inotrope Utilization|Clinical Response: Duration of Increased Supplemental Oxygen from Baseline|Biochemical Response: C-reactive Protein Response Rate|Safety: Rate of Secondary Infection,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 2,332,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-1179,10-Sep-20,1-Dec-20,1-Mar-21,21-Jul-20,,23-Sep-20,"University of Chicago Medicine, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04479358
NCT04341506,Non-contact ECG Sensor System for COVID19,,Recruiting,No Results Available,COVID-19,Device: Non-contact ECG,ECG changes associated with COVID-19,Northwestern Medicine,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-0407,8-Sep-20,15-Jul-21,15-Dec-21,10-Apr-20,,9-Sep-20,"Northwestern Medicine, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04341506
NCT04401423,TXA127 for the Treatment of Severe COVID-19,,Recruiting,No Results Available,COVID-19,Drug: TXA127|Drug: Placebo,Change of serum creatinine|Number of participants requiring intubation and ventilatory support|Change in number of deceased participants|Number of participants requiring dialysis|Number of participants requiring a vasopressors|Change in blood inflammatory markers|Percent change in supplemental oxygen requirements,Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AAAT0535,Aug-20,Jun-21,Dec-21,26-May-20,,20-Aug-20,"Columbia University Irving Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04401423
NCT04379284,Risks of COVID19 in the Pregnant Population,,Recruiting,No Results Available,COVID19,Other: Biospecimen collection,Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages,Mayo Clinic,Female,18 Years to 45 Years   (Adult),,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,20-003251,8-May-20,30-Apr-21,31-Jul-21,7-May-20,,13-Jul-20,"Mayo Clinic Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04379284
NCT04708236,A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia,,Recruiting,No Results Available,COVID-19,Drug: ORTD-1 low dose|Drug: ORTD-1 mid dose|Drug: ORTD-1 high dose|Other: Vehicle control,Incidence of adverse events|Incidence of laboratory abnormalities|Incidence of anti-drug antibodies|Proportion of patients requiring intubation|Percentage of days requiring supplemental oxygen|Overall survival (OS),"Oryn Therapeutics, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORTD1-COV-001,Jan-21,May-21,Jul-21,13-Jan-21,,13-Jan-21,"UC Irvine Medical Center, Orange, California, United States",,https://ClinicalTrials.gov/show/NCT04708236
NCT04381052,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,,Not yet recruiting,No Results Available,COVID-19,Drug: Clazakizumab|Other: Placebo,Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative Incidence of Intubation|Time to Extubation|Length of Intensive Care Unit (ICU) stay|Number of Patients who Present a Decrease in C-reactive protein (CRP)|Number of Patients with Acute Kidney Injury (AKI)|Number of Patients with a Need for Renal Replacement Therapy (RRT)|Duration of Renal Replacement Therapy (RRT)|Patient Survival|Number of Patients with Hemodialysis|Number of Patients with Continuous Renal Replacement Therapies (CRRT)|Number of Patients with Peritoneal Dialysis,Columbia University|NYU Langone Health|CSL Behring,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAT0142,May-20,1-Aug-20,1-Aug-20,8-May-20,,8-May-20,"Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04381052
NCT04486001,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,CoronaStem1,Recruiting,No Results Available,Covid19,Biological: PSC-04,Frequency of all adverse events|Frequency of infusion related serious adverse events|Frequency of serious adverse events|Mortality|Ventilator Free Days|ICU Free Days|Total Hospital Days|Total ICU Days|Improvement in Oxygenation,"Sorrento Therapeutics, Inc.|VetStem Biopharma, Inc.|Fresno Community Hospital and Medical Center",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSC-CP-004,15-Dec-20,15-Jan-22,15-Jan-22,24-Jul-20,,8-Jan-21,"Fresno Community Hospital, Fresno, California, United States",,https://ClinicalTrials.gov/show/NCT04486001
NCT04604678,Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19,,Not yet recruiting,No Results Available,Covid19,Drug: Metformin|Drug: Naltrexone,Reduction of COVID-19 symptoms after 1 week of treatment with metformin and LDN|Reduction of COVID-19 symptoms after 2 weeks of treatment with metformin and LDN|Reduction in recovery time from COVID-19|Reduction in hospitalizations|Reduction in requirement of additional treatment due to COVID-19|Reduction in mortality,AgelessRx,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALRx003,Feb-21,Aug-21,Oct-21,27-Oct-20,,7-Jan-21,"AgelessRx, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04604678
NCT04340232,Safety and Efficacy of Baricitinib for COVID-19,,Not yet recruiting,No Results Available,COVID-19,Drug: Baricitinib,"Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","University of Colorado, Denver",All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-0738,Nov-20,Aug-21,Oct-21,9-Apr-20,,25-Aug-20,"University of Colorado, Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04340232
NCT04595773,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",,Recruiting,No Results Available,COVID-19,Other: Aerobic Exercise Training|Other: Education,6 minute walk test distance|Patient reported outcomes and quality of life|Free-living physical activity and sleep quality,National Institutes of Health Clinical Center (CC),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,90,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,10000102|000102-CC,20-Jan-21,31-Dec-23,31-Dec-23,22-Oct-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04595773
NCT04705597,"Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Participants ≥ 60 Years of Age and Hospitalized With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure",,Not yet recruiting,No Results Available,Covid19,Drug: BGE-175|Other: Placebo,"Proportion of participants who have died or progressed to respiratory failure|Proportion of participants experiencing treatment-emergent adverse events|Survival|Viral load|Clinical worsening on a 9-point ordinal scale|Clinical improvement|Time to extubation|Time to discharge from hospital intensive care unit|Incidence of supplemental oxygen administration|Duration of supplemental oxygen administration|Duration of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Incidence of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Duration of mechanical ventilation plus additional organ support using vasopressors, and/or renal replacement therapy and/or ECMO|Incidence of mechanical ventilation plus additional organ support using vasopressors, and/or renal replacement therapy and/or ECMO|Daily ratio of oxygen saturation (SpO2) to fractional inspired O2 (SpO2/FiO2)|Time to discharge from the hospital|Time to re-hospitalization|Proportion of participants requiring intensive care unit admission","BioAge Labs, Inc.",All,"60 Years and older   (Adult, Older Adult)",Phase 2,132,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BGE-175-201,Feb-21,Feb-22,Apr-22,12-Jan-21,,12-Jan-21,"University of Maryland Medical System, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04705597
NCT04344015,COVID-19 Plasma Collection,,Recruiting,No Results Available,COVID-19,Other: Plasma Donation,Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures,Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,20D.346,13-Apr-20,12-Apr-21,12-Apr-21,14-Apr-20,,11-May-20,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04344015
NCT04428008,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,Ta1,Recruiting,No Results Available,COVID-19,Drug: Thymalfasin,"Reduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets (CD4, CD8)|Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parameters","Inova Health System|Davita Clinical Research|Clinical Research Consultants, LLC",All,"60 Years and older   (Adult, Older Adult)",Phase 2,240,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACW-1221958-1,12-Jan-21,Apr-21,Jan-22,11-Jun-20,,13-Jan-21,"Clinical Research Consultants, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04428008
NCT04411147,A Longitudinal Study of COVID-19 Sequelae and Immunity,,Recruiting,No Results Available,COVID-19,,Medical Sequelae in COVID- 19 Survivors|Risk Factors for Medical Sequelae in COVID-19 Survivors|Antibody and cell-mediated immune responses to SARSCoV-2|Antibody and cell-mediated immune responses to SARSCoV-2 over time|Incidence of reinfection with COVID-19|Incidence of clinical silent infection|Mental health status in COVID-19 survivors and contacts,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,900,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200123|20-I-0123,17-Jun-20,31-Dec-27,31-Dec-27,2-Jun-20,,12-Nov-20,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04411147
NCT04536298,Vitamin D and COVID-19 Trial,VIVID,Not yet recruiting,No Results Available,COVID-19,Dietary Supplement: vitamin D|Dietary Supplement: Placebo,Hospitalization or death in index cases|Self-reported disease severity in index cases|Time to hospitalization or death in index cases|ICU admission/ventilation support in index cases|SARS-CoV-2 infection in close household contacts|Self-reported disease severity in close household contacts,Brigham and Women's Hospital|Harvard Medical School|Harvard School of Public Health|Harvard Pilgrim Healthcare Institute|Fenway Health and Beth Israel Deaconess Medical Center|Tishcon Corporation|Takeda|Quest Diagnostics|Karolinska Institutet|Philanthropic donations,All,"30 Years and older   (Adult, Older Adult)",Phase 3,2700,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020J-009152,1-Dec-20,1-Mar-21,1-Mar-21,2-Sep-20,,20-Nov-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04536298
NCT04524507,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,UNC CCP RCT,Recruiting,No Results Available,COVID-19,Biological: High-titer Convalescent COVID-19 Plasma (CCP1)|Biological: Standard-titer Convalescent COVID-19 plasma (CCP2),Cumulative Incidence of Serious Adverse Events (SAEs) at study Day 14|Days to hospital discharge (or discharge equivalent) following first dose of CCP,"University of North Carolina, Chapel Hill",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-1544,27-Aug-20,May-21,May-21,24-Aug-20,,5-Oct-20,"University of North Carolina Health Care, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04524507
NCT04374279,Trial to Promote Recovery From COVID-19 With Endocrine Therapy,RECOVER,Not yet recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Bicalutamide 150 Mg Oral Tablet,Percentage of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV2003|IRB00249425,5-Feb-21,Jan-22,Jan-22,5-May-20,,12-Jan-21,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04374279
NCT04701515,Cardiovascular Manifestations of COVID-19,,Recruiting,No Results Available,COVID-19,Other: Chart review,Heart failure|Tamponade|Pericardial Effusion|Myocarditis|Pericarditis|Arrythmias|Troponin I|N-terminal prohormone BNP|Stroke|Myocardial infarction|Shock|Deep venous thrombosis|Discharge disposition|Primary diagnosis|Rate of ICU admission/transfer|Total hospital length of stay|ICU length of stay|Percentage of patients in cohort that had EKG testing or Echocardiography,Methodist Health System,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Other,030.CVS.2020.D,10-Jun-20,31-Dec-22,31-Dec-22,8-Jan-21,,8-Jan-21,"Methodist Dallas Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04701515
NCT04603794,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,,Recruiting,No Results Available,COVID-19,Drug: 0.5% Povidone Iodine|Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse|Drug: 1% Hydrogen Peroxide|Drug: 0.9% Normal Saline,real time reverse transcriptase quantitative PCR|ct values,Ohio State University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",2020H0346,1-Oct-20,Nov-20,Nov-20,27-Oct-20,,27-Oct-20,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04603794
NCT04365257,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),PREVENT,Recruiting,No Results Available,COVID-19,Drug: Prazosin|Other: Standard of care,"Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma",Johns Hopkins University|Fast Grants,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,220,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00246659|COV2001,13-May-20,30-Jun-21,30-Jun-21,28-Apr-20,,10-Dec-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04365257
NCT04399356,Niclosamide for Mild to Moderate COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring,Change in respiratory viral clearance (by PCR)|Fecal viral clearance (by PCR)|Reduction (change) in respiratory viral shedding (by PCR)|Reduction (change) in GI viral shedding (by PCR)|Progression to severe COVID-19 Disease|Time to resolution of a fever,Tufts Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STUDY00000605,1-Oct-20,1-Jan-21,12-Feb-21,22-May-20,,12-Nov-20,"Tufts Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04399356
NCT04700163,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,RU,Recruiting,No Results Available,Covid19,Biological: C144-LS and C-135-LS,Grade 2 and higher adverse events 4 weeks after administration.|Grade 3 and higher adverse events 4 weeks after administration.|Related Serious adverse events (SAEs) throughout the study period|Elimination half-life (t1/2) of C135-LS and C144-LS|Clearance rate of C135-LS and C144-LS|Area under the curve of C135-LS and C144-LS|Investigational product (IP)-related adverse events during study follow up.|Anti-C144-LS and anti-C135-LS antibodies in all study groups.|Serum neutralizing activity against SARS-CoV-2,Rockefeller University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RUCOV1|CGA-1015,15-Jan-21,15-Jun-21,15-Apr-22,7-Jan-21,,12-Jan-21,"The Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04700163
NCT04705116,COVID-19 Vaccines International Pregnancy Exposure Registry,C-VIPER,Not yet recruiting,No Results Available,Covid19,Biological: COVID-19 vaccine,Obstetric outcomes|Neonatal outcomes|Infant weight|Infant developmental milestones|Infant COVID-19 diagnosis|Infant height,Pregistry|Harvard School of Public Health,Female,18 Years to 50 Years   (Adult),,5000,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PR004,15-Jan-21,31-Dec-25,31-Dec-25,12-Jan-21,,13-Jan-21,"Pregistry, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04705116
NCT04350073,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),,Recruiting,No Results Available,COVID-19,Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy,"Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency",Duke University,All,"18 Years and older   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00105221,20-Apr-20,1-Oct-21,1-Dec-21,16-Apr-20,,14-Dec-20,"Duke University Medial Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04350073
NCT04452942,Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19),,Not yet recruiting,No Results Available,COVID-19,,Changes on eicosanoid lipid mediators|Changes on plasma levels of a panel of 40 human cytokines and chemokines|Severe clinical outcome,EicOsis Human Health Inc.,All,"18 Years and older   (Adult, Older Adult)",,30,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,EC1153-2-01,Jul-20,Sep-20,Apr-21,1-Jul-20,,21-Jul-20,"Stony Brook University Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04452942
NCT04347954,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),,Recruiting,No Results Available,COVID-19,Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%,Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT),Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB-56134,15-Aug-20,Dec-20,Jan-21,15-Apr-20,,23-Oct-20,"Stanford Health Care, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04347954
NCT04499391,COVID-19 Project ECHO in Nursing Homes,,Recruiting,No Results Available,Covid19,Other: Project ECHO,Infection rate|Hospitalization|Death,Milton S. Hershey Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PCORI Nursing Homes,4-Dec-20,Jul-22,Jul-22,5-Aug-20,,23-Dec-20,"Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04499391
NCT04456153,Atovaquone for Treatment of COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Experimental Group|Drug: Placebo Group,Viral Load,University of Texas Southwestern Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STU-2020-0707,22-Jul-20,Dec-20,Mar-21,2-Jul-20,,30-Jul-20,"University of Texas Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04456153
NCT04681079,Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19,,Not yet recruiting,No Results Available,COVID-19,Drug: albuterol sulfate (MDI)|Drug: albuterol sulfate (nebulizer),Viral Load,Theravance Biopharma,All,"18 Years and older   (Adult, Older Adult)",,10,Industry,Observational,Observational Model: Other|Time Perspective: Other,192,Jan-21,Feb-21,Feb-21,23-Dec-20,,23-Dec-20,"Theravance Biopharma Investigational Site, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04681079
NCT04382625,Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial,,Not yet recruiting,No Results Available,SARS-CoV-2 Pneumonia|COVID-19,Drug: Hydroxychloroquine,Change from Baseline Oxygenation on Day 1 to Day 5|Change from Baseline Oxygenation at Day 5|Intensive Care length of stay|Required Mechanical Ventilation|Required Oxygen supplementation|Hospitalization length of Stay|Mortality|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc,Kootenai Health|Washington State University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18244,Oct-20,1-Jan-22,1-Jun-22,11-May-20,,2-Sep-20,"Kootenai Health, Coeur d'Alene, Idaho, United States",,https://ClinicalTrials.gov/show/NCT04382625
NCT04498325,"Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)",,Not yet recruiting,No Results Available,COVID-19|SARS-CoV-2,"Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody (ADA)",Safe and tolerable dose of NT-I7 (Phase I only)|Percent change in absolute lymphocyte count (ALC)|Change in SARS-CoV-2 viral load|COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement|Time to resolution of COVID-19 symptoms|Incidence of treatment-emergent adverse events|Number of participants by PCR result status (positive or negative),Washington University School of Medicine|NeoImmune Tech,All,"18 Years and older   (Adult, Older Adult)",Phase 1,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",202009065,31-Dec-20,30-Sep-21,30-Sep-21,4-Aug-20,,25-Nov-20,"Saint Louis University Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04498325
NCT04581863,COVID-19 Watch + COVID-19 Pulse,,Recruiting,No Results Available,Covid19,Device: pulse oximeter|Other: COVID Watch,Difference in Days Alive and Out of Hospital,University of Pennsylvania|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,850,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,844043,30-Nov-20,21-Feb-21,31-Oct-21,9-Oct-20,,19-Dec-20,"Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04581863
NCT04501796,A Trial of NT-I7 in COVID-19 (SPESELPIS),,Recruiting,No Results Available,COVID-19,Drug: Double-Blind NT-I7|Drug: Double-Blind Placebo,Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.,NeoImmuneTech,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIT-116 (SPESELPIS),Aug-20,Oct-21,Dec-21,6-Aug-20,,6-Aug-20,"Nih/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT04501796
NCT04659759,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",COVID-PRICE,Recruiting,No Results Available,Covid19,Other: COVID-19 exposure,Maternal COVID-19 serology (IgG and IgM)|Maternal/neonatal IgG and IgM concordance,Thomas Jefferson University|Nemours,Female,"Child, Adult, Older Adult",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20F.1043,17-Nov-20,31-Dec-21,30-Jun-22,9-Dec-20,,9-Dec-20,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04659759
NCT04485130,DISulfiram for COvid-19 (DISCO) Trial,DISCO,Not yet recruiting,No Results Available,Covid19,Drug: Disulfiram|Drug: Placebo,"Immunologic impact of 5 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).|Virologic impact of 5 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8)","University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DSF151837,1-Dec-20,30-Nov-21,1-Jun-22,24-Jul-20,,27-Nov-20,"University of California San Francisco, Fresno, Fresno, California, United States|San Francisco General Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04485130
NCT04477889,Methodist Health System COVID-19 Patient Registry,,Recruiting,No Results Available,COVID-19,Other: Treatment for COVID-19,Patient Characteristics|Treatment Measures and Intervention strategies|Clinical and survival outcomes,Methodist Health System,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Other|Time Perspective: Prospective,024.CRI.2020.A,20-Jun-20,Dec-25,Dec-26,20-Jul-20,,24-Sep-20,"Clinical Research Institute Methodist Health System, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04477889
NCT04400890,Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Plant Polyphenol|Dietary Supplement: Vitamin D3,Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates,"Marvin McCreary, MD|Mount Carmel Health System",All,"45 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",McCreary2020,12-Sep-20,Nov-20,Jan-21,26-May-20,,24-Sep-20,"Mt Carmel HealthSystems, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04400890
NCT04361214,Leflunomide in Mild COVID-19 Patients,,Recruiting,No Results Available,COVID-19,Drug: Leflunomide,Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-0622,5-May-20,Feb-21,Feb-21,24-Apr-20,,29-Oct-20,"University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04361214
NCT04487691,Nebulized PL for Post-COVID-19 Syndrome,,Recruiting,No Results Available,Covid19,Biological: Nebulized Platelet Lysate|Other: Nebulized Sterile Saline,Spirometry-FVC and FEV1/FVC tests|6 Minute Walk Distance test (6MWD)|Distance-desaturation product from 6MWD|San Diego Shortness of Breath Questionnaire (SOBQ)|Short Form-36 (SF-36)|Modified Single Assessment Numeric Evaluation (SANE)|Medications|Incidence of adverse events|Incidence of surgical/other treatment interventions,"Regenexx, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",RGX2020-RCT01,8-Dec-20,1-Jun-21,30-Dec-21,27-Jul-20,,4-Dec-20,"Centeno-Schultz Clinic, Broomfield, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04487691
NCT04390503,Convalescent Plasma for COVID-19 Close Contacts,,Recruiting,No Results Available,SARS-CoV 2|COVID-19,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%),Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA,Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AAAT0052,May-20,Apr-21,Apr-21,15-May-20,,15-May-20,"Columbia University Irving Medical Center/NYP, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04390503
NCT04337762,Beat COVID-19 - Observational Trial,JUPITER,Recruiting,No Results Available,COVID-19,,Health Outcomes,Beat COVID LLC,All,"18 Years to 110 Years   (Adult, Older Adult)",,100000,Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20200835,6-Apr-20,Dec-20,Jul-21,8-Apr-20,,9-Apr-20,"Beat COIVD, LLC, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04337762
NCT04368234,Duke COVID-19 Shared Data and Specimen Repository,,Recruiting,No Results Available,COVID-19,,"Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens",Duke University,All,"Child, Adult, Older Adult",,100000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00105316,18-Apr-20,30-Apr-25,30-Apr-25,29-Apr-20,,23-Jul-20,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04368234
NCT04623047,Using Smart Watches to Detect and Monitor COVID-19,CovIdentify,Recruiting,No Results Available,Covid19,,Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by self-reports of symptom questionnaire.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by COVID-19 and influenza test result.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by hospital admission questionnaire.|Accuracy comparison of symptom-only model to sensor-only model to symptom + sensor model to predict Covid-19 symptoms.,Duke University,All,"18 Years and older   (Adult, Older Adult)",,100000,Other,Observational,Observational Model: Other|Time Perspective: Prospective,PRO00106404,2-Apr-20,1-Feb-22,1-Feb-22,10-Nov-20,,10-Nov-20,"Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04623047
NCT04600895,The Prevent Severe COVID-19 (PRESECO) Study,PRESECO,Recruiting,No Results Available,Covid19,Drug: Favipiravir|Drug: Placebo,Time to sustained clinical recovery|Time of Negative Conversion of SARS-CoV2 RNA|Proportion of Negative Conversion of SARS-CoV2 RNA|Proportion of patients showing Alleviation of Symptoms|Proportion of patients that progress to severe COVID-19|Reduction in Death Related to COVID-19|Reduction in Patient Hospitalization|Reduction in incidence of hospitalization for respiratory distress or O2 saturation,Appili Therapeutics Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,826,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ATI0220,30-Nov-20,Aug-21,Oct-21,23-Oct-20,,17-Dec-20,"Elixia Clinical Research Collaborative, Hollywood, Florida, United States",,https://ClinicalTrials.gov/show/NCT04600895
NCT04446377,A Study of LAM-002A for the Prevention of Progression of COVID-19,,Recruiting,No Results Available,COVID-19 Disease,Drug: Apilimod Dimesylate Capsule|Other: Placebo,Viral Load Change|Safety and Tolerability|Clinical Efficacy|Change in COVID-19 Clinical Status|Oxygen Saturation,"AI Therapeutics, Inc.|Yale University",All,"18 Years and older   (Adult, Older Adult)",Phase 2,142,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LAM-002A-CVD-CLN01,15-Jul-20,31-Mar-21,30-Apr-21,24-Jun-20,,4-Nov-20,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04446377
NCT04662086,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,,Not yet recruiting,No Results Available,Covid19,Drug: Acebilustat|Drug: Camostat,"For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus|For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period|Time to first resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2",Stanford University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",COPPS-Master Protocol,Jan-21,Jan-22,Jan-22,10-Dec-20,,11-Dec-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04662086
NCT04662073,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,COPPS,Not yet recruiting,No Results Available,Covid19,Drug: Camostat|Drug: Placebo,"For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus|For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period|Time to first resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2|Time to event from randomization to worsening of symptoms or disease progression",Stanford University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",COPPS-Camostat,Jan-21,Jan-22,Jan-22,10-Dec-20,,10-Dec-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04662073
NCT04568122,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",,Recruiting,No Results Available,Covid19,Device: Saliva test kit,"An indicator for discrepancy in interpretation of findings by participant versus by technician via photo (interrater reliability)|An indicator for whether the home saliva test is positive as determined by the patient (to assess sensitivity and specificity by the patient)|An indicator for ambiguous findings as measured by percent confidence (if < 80% confident) in interpretation of results by participant and by technician (ease of interpretation)|An indicator that the participant appropriately followed instructions for using the kit (≥ 80% confident) (ease of use)|An indicator for whether participant called technical support and by reason (e.g., processing was not possible due to broken part) (ease of use)|An indicator by participant that the sample was sufficient and reached the indicated line for sample integrity (sample integrity)|An indicator for whether the home saliva test is positive as determined by the technician (to assess sensitivity and specificity by the technician)",Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3015,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,58629,20-Nov-20,Jan-21,Apr-21,29-Sep-20,,11-Dec-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04568122
NCT04494893,ImmuneRACE - Immune Response Action to COVID-19 Events,,Recruiting,No Results Available,Covid19,,Comparison of disease-specific TCR signatures in patients and controls|Identify the immunodominant antigens that elicit a T-cell response to COVID-19|Risk Stratification based on an individual's immune signature|Determine whether an immune signature can be detected in individuals exposed to SARS-CoV-2 earlier than currently available tests|Explore whether additional research assays could potential identify and/or confirm antigenic binding,Adaptive Biotechnologies|Covance,All,"18 Years to 89 Years   (Adult, Older Adult)",,1000,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ADAP-006,24-Apr-20,31-Dec-20,31-Jan-21,31-Jul-20,,31-Jul-20,"Adaptive Biotechnologies, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04494893/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04494893/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04494893
NCT04662060,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,COPPS,Not yet recruiting,No Results Available,Covid19,Drug: Acebilustat|Drug: Placebo,"For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus|For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period|Time to first resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2|Time to event from randomization to worsening of symptoms or disease progression",Stanford University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",COPPS-Acebilustat,Jan-21,Jan-22,Jan-22,10-Dec-20,,10-Dec-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04662060
NCT04524715,LLLT Treatment of Lung Inflammation in COVID-19,,Not yet recruiting,No Results Available,Covid19,Device: Non-invasive red LLLT treatment to chest of patient.|Device: Sham Device Treatment,Inflammation of the lungs - O2|Inflammation of the lungs - CRP|Inflammation of the lungs - IL6,Ward Photonics LLC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CP19-02,31-Mar-21,31-Mar-22,31-Mar-22,24-Aug-20,,4-Dec-20,"Wellness Junction, Millsboro, Delaware, United States",,https://ClinicalTrials.gov/show/NCT04524715
NCT04365699,Cardiovascular Effects of COVID-19,,Recruiting,No Results Available,COVID-19,Drug: AT-001,Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization,NYU Langone Health,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-00416,8-Apr-20,31-Dec-20,31-Dec-20,28-Apr-20,,28-Apr-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04365699
NCT04494867,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,,Recruiting,No Results Available,Covid19,Device: Core Warming|Other: Standard of Care,PaO2/FiO2 ratio|Viral Load Measurement|Duration of mechanical ventilation|Mortality,"Sharp HealthCare|Advanced Cooling Therapy, Inc., d/b/a Attune Medical",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19 Core Warming,19-Aug-20,Dec-20,Dec-20,31-Jul-20,,25-Sep-20,"Sharp Memorial Hospital, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04494867
NCT04539795,COVID-19 Study of Safety and Tolerability of Alvelestat,COSTA,Recruiting,No Results Available,Covid19,Drug: Alvelestat|Drug: Placebo,Numbers and % of subjects who experience at least 1 treatment-emergent adverse event|Mortality rate|Adverse events of special interest|Effect of alvelestat on blood pharmacodynamic biomarkers of inflammation,University of Alabama at Birmingham|Mereo BioPharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-300005845,1-Nov-20,30-Sep-21,30-Sep-21,7-Sep-20,,19-Oct-20,"UAB Lung Health Center, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04539795
NCT04353284,Camostat Mesylate in COVID-19 Outpatients,,Recruiting,No Results Available,COVID-19,Drug: Camostat Mesilate|Other: Placebo,Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature,Yale University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2000027971,19-Jun-20,31-May-21,31-May-21,20-Apr-20,,24-Nov-20,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04353284
NCT04389710,Convalescent Plasma for the Treatment of COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Convalescent Plasma,Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma,Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20D.379,15-Apr-20,14-Apr-21,14-Apr-21,15-May-20,,25-Jun-20,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04389710
NCT04418544,Vocal Feature Analysis Algorithm for COVID-19 Detection,,Recruiting,No Results Available,COVID-19,Device: Device used to record voice for screening,Sensitivity and Specificity,Soniphi LLC|UserWise,All,"18 Years and older   (Adult, Older Adult)",,400,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,002 Soniphi,1-Jun-20,Dec-20,Dec-20,5-Jun-20,,30-Oct-20,"Soniphi, Sebastopol, California, United States",,https://ClinicalTrials.gov/show/NCT04418544
NCT04619706,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,,Recruiting,No Results Available,COVID-19,Drug: FSD201|Drug: Placebo,"Percentage of Participants With Disease Progression at Day 28|Percentage of Participants With Disease Resolution at Day 28|Percentage of Participants Requiring Invasive Mechanical Ventilation or ExtraCorporeal Membrane Oxygenation (ECMO) or who are not Alive on Day 28|Change From Baseline in Oxygen use|Change From Baseline in Saturation of Oxygen (SpO2) percent (%)|Change From Baseline in Clinical Status Related to COVID-19|Percentage of Participants who Die (Mortality Rate) at Day 28|Percentage of Participants Testing Negative for COVID-19 at Day 28|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters, Electrocardiogram Findings and Physical Examination Findings|Plasma Concentrations of FSD201|Maximum Observed Plasma Concentration (Cmax) of FSD201|Area Under the Concentration-Time Curve (AUC) of FSD201|Elimination Half-Life (t1/2)|Apparent Total Body Clearance (CL/F) of FSD201|Apparent Volume of Distribution (Vz/F) of FSD201|Average Observed Plasma Concentration at Steady State (Cav) of FSD201","FSD Pharma, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,350,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FSD201-03,14-Dec-20,14-Aug-21,5-Dec-21,6-Nov-20,,24-Dec-20,"Idaho Falls, Idaho, Idaho Falls, Idaho, United States|Mesquite, Texas, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04619706
NCT04703036,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",,Recruiting,No Results Available,Covid19,Dietary Supplement: Glycine|Dietary Supplement: N-acetylcysteine|Dietary Supplement: Alanine,Change in Glutathione concentrations|Change in Interleukein 6 concentrations|Change in Ordinal scale|Change in oxidative stress|Change in marker of damage due to oxidative stress|Change in inflammatory cytokines|Change in mitochondrial energetics|Change in immune function|Change in cognition|Change in function|Change in fatigue|Change in circulating marker of memory,Baylor College of Medicine,All,"55 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,64,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",H48057,11-Jan-21,31-Dec-21,31-Dec-21,11-Jan-21,,11-Jan-21,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04703036
NCT04388527,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,,Recruiting,No Results Available,Covid-19,Biological: COVID-19 Convalescent Plasma,"Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.",University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,842996 (PennCCP-01),30-Apr-20,30-Apr-21,30-Jun-21,14-May-20,,4-Dec-20,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04388527
NCT04487444,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Ta1,Recruiting,No Results Available,Covid19,Drug: Thymalfasin,"Time to recovery (free of respiratory failure)|Lymphopenia|Survival|Hospital length of stay|Requirement for high flow oxygen supplementation|Duration of high flow oxygen supplementation|ICU admission|ICU length of stay|Mechanical ventilation|Duration of mechanical ventilation|Change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections (other respiratory, urinary tract, cellulitis, etc.)|AEs/SAEs|Changes to vital signs|Changes in laboratory parameters",Rhode Island Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCN-16130571-2,10-Sep-20,Mar-21,Jun-21,27-Jul-20,,14-Sep-20,"The Miriam Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT04487444
NCT04338828,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,NO COV-ED,Recruiting,No Results Available,COVID19,Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen,Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality,"Massachusetts General Hospital|Department of Anesthesia, MGH",All,"18 Years and older   (Adult, Older Adult)",Phase 2,260,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2019P00XXXX,18-Apr-20,Apr-21,Apr-22,8-Apr-20,,20-May-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04338828
NCT04356690,Etoposide in Patients With COVID-19 Infection,,Recruiting,No Results Available,COVID-19,Drug: Etoposide,Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2),Boston Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,H-40102,8-May-20,Dec-21,Jun-22,22-Apr-20,,5-Jan-21,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04356690
NCT04634799,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,,Recruiting,No Results Available,Covid19,Drug: TM5614|Other: Placebo,Clinical improvement|Sequential organ failure assessment (SOFA) score change|PAI-1 Levels|Ventilator free days,Northwestern University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STU00213262,16-Nov-20,30-Nov-21,30-Jun-22,18-Nov-20,,20-Nov-20,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04634799
NCT04412785,Cyclosporine in Patients With Moderate COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Cyclosporine,"Safety-oxygen, ICU transfer and ventilation|Safety-changes in absolute lymphocyte count|Safety-changes in creatinine clearance|Safety-secondary bacterial infections|Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions|Laboratory measurements-D-dimer levels|Laboratory measurements-ferritin|Laboratory measurements- IL-6",University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,842998,30-Jun-20,Apr-21,Dec-21,2-Jun-20,,23-Oct-20,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04412785
NCT04410328,Aggrenox To Treat Acute Covid-19,ATTAC-19,Recruiting,No Results Available,Covid19,Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Other: Standard of care,Covid (Coronavirus Disease-19) Ordinal Scale|Mortality|Supplemental Oxygen|Invasive-ventilator|ICU stay|Hospital stay|Inflammatory markers|Thromboembolic complications|COVID ordinal scale,"Rutgers, The State University of New Jersey|Boehringer Ingelheim",All,"19 Years and older   (Adult, Older Adult)",Phase 3,132,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro2020001469,21-Oct-20,15-Mar-21,15-Dec-21,1-Jun-20,,23-Oct-20,"Rutgers New Jersey Medical School University Hospital, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04410328
NCT04509999,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,,Recruiting,No Results Available,COVID-19,Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo,Proportion x 100 = percent of patients with improved COVID-19 symptoms,University of Florida,Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB202001669-A|OCR38162,26-Oct-20,Sep-22,Sep-22,12-Aug-20,,8-Dec-20,"University of Florida Clinincal Research Vehicle, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04509999
NCT04494724,Clazakizumab vs. Placebo - COVID-19 Infection,,Recruiting,No Results Available,COVID-19 Infection,Drug: Clazakizumab|Drug: Placebo,Primary Endpoint|Requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO)|Infusion-related reactions during 24 hours from the time of infusion|Patient survival at 28 days|Patient survival at 60 days|Requirement for open-label clazakizumab|Time in the intensive care unit (ICU)|Time in the hospital|Time to mechanical ventilation|Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14|Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28|Change in Radiologic Assessment of Lung Edema (RALE) at day 14|Change in Radiologic Assessment of Lung Edema (RALE) at day 28,The Methodist Hospital System,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00025969,13-Jul-20,31-Dec-20,31-Jul-21,31-Jul-20,,31-Jul-20,"Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04494724
NCT04575610,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),,Recruiting,No Results Available,COVID-19,Drug: PF-06650833|Drug: Placebo,All-cause mortality at Day 29|Disease Severity (8 point scale)|Mortality|P/F ratio|Change of the SOFA score.|Duration (days) of mechanical ventilation|Ventilator free days.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Yale University|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,68,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2000028042,30-Nov-20,31-Mar-21,31-Mar-21,5-Oct-20,,3-Dec-20,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04575610
NCT04470999,Changes in Cellular Immune Profile During COVID-19 Infection,,Recruiting,No Results Available,Covid19|SARS-CoV-2,Other: Leukapheresis,Cellular immune system profiling|Innate immune system profiling|Expansion of virus-specific innate immune cells,"Serhat Gumrukcu, MD PhD|The Scripps Research Institute|Seraph Research Institute",All,18 Years to 60 Years   (Adult),Not Applicable,25,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SRPH-CVD-01,15-Apr-20,30-Sep-20,31-Dec-20,14-Jul-20,,20-Jul-20,"Seraph Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04470999
NCT04338074,TXA and Corona Virus 2019 (COVID19) in Outpatients,TCOutpatient,Recruiting,No Results Available,COVID-19,Drug: Tranexamic acid tablets|Drug: Placebo oral tablet,Hospitalization,University of Alabama at Birmingham,All,"19 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TXACOVID1,1-Jun-20,15-Dec-20,31-Dec-20,8-Apr-20,,12-Jun-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04338074
NCT04342689,The Role of Resistant Starch in COVID-19 Infection,,Recruiting,No Results Available,COVID-19,Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch,Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score,Yale University|University of Michigan|University of Minnesota,All,"19 Years and older   (Adult, Older Adult)",Phase 3,1500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2000027887,3-Jun-20,1-Jun-21,1-Jun-21,13-Apr-20,,17-Jun-20,"Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04342689
NCT04652115,A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19,DF in COVID19,Not yet recruiting,No Results Available,Covid19,Drug: Defibrotide,The rate of adverse event of special interest (bleeding and hypotension),Brigham and Women's Hospital|Jazz Pharmaceuticals,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,42,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020P003203,1-Jan-21,1-Nov-22,1-Nov-23,3-Dec-20,,3-Dec-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04652115
NCT04628039,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs",LAUREL,Not yet recruiting,No Results Available,COVID-19,Other: Rehabilitation-focused program,EuroQol 5 Dimension 5 Level (EQ-5D-5L) visual analog score|WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)|EuroQol 5 Dimension 5 Level (EQ-5D-5L) overall utility index,VA Office of Research and Development,All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,506,U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,F3666-R|1I01RX003666-01,1-Nov-21,1-Aug-24,31-Oct-24,13-Nov-20,,13-Nov-20,"VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04628039
NCT04561193,Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19),,Recruiting,No Results Available,COVID-19,Other: Observational,Prevalence of subsequent and co-infections|In-hospital mortality|Hospital length of stay (LOS),Methodist Health System,All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,033.PHA.2020.A,30-May-20,Dec-20,May-21,23-Sep-20,,23-Sep-20,"Methodist Dallas Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04561193
NCT04338126,Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients,TCInpatient,Not yet recruiting,No Results Available,COVID19,Drug: Tranexamic acid|Drug: Placebo oral tablet,Admission to Intensive Care Unit,University of Alabama at Birmingham,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TXACOVID2,30-Sep-21,15-Dec-21,31-Dec-21,8-Apr-20,,20-Nov-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04338126
NCT04394416,Trial of Imatinib for Hospitalized Adults With COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Imatinib|Drug: Placebo oral tablet,The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events,"University of Maryland, Baltimore",All,"18 Years and older   (Adult, Older Adult)",Phase 3,204,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2038GCCC,2-Jun-20,1-Jun-22,1-Jun-23,19-May-20,,4-Jun-20,"University of Maryland Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04394416
NCT04374461,A Study of N-acetylcysteine in Patients With COVID-19 Infection,,Recruiting,No Results Available,Covid-19,Drug: N-acetylcysteine|Other: Peripheral Blood,Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,84,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-168,1-May-20,May-22,May-22,5-May-20,,27-Nov-20,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04374461
NCT04665752,Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors,,Recruiting,No Results Available,COVID-19,,Percentage of participants|Correlation of findings|Proportion of patients,National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,150,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,10000078|000078-EI,20-Jan-21,30-Jun-23,30-Jun-23,14-Dec-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04665752
NCT04397757,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,,Recruiting,No Results Available,COVID-19,Biological: COVID-19 Convalescent Plasma,"Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms",University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,843003 (PennCCP-02),13-May-20,30-Apr-21,30-Jun-21,21-May-20,,4-Dec-20,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04397757
NCT04506229,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,GenCov,Recruiting,No Results Available,Covid19,Genetic: Whole exome sequencing,Genetic variants with vs without COVID-19|Cognitive function at baseline|Change in cognitive function at 1 month|Genetic analysis,Texas Cardiac Arrhythmia Research Foundation,All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,TCAI_GenCov,20-Aug-20,Aug-21,Sep-21,10-Aug-20,,27-Aug-20,"Texas Cardiac Arrhythmia Institute, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04506229
NCT04412772,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,ARCHITECTS,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Placebo,Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation,Queen's Medical Centre,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RA-2020-019,12-Jun-20,31-Dec-21,31-Dec-21,2-Jun-20,,17-Nov-20,"Queen's Medical Center, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT04412772
NCT04493307,The Evaluation of Hemostasis in Hospitalized COVID-19 Patients,TARGET-COVID,Recruiting,No Results Available,COVID-19,Diagnostic Test: Phlebotomy,"Frequency of Hypercoagulability as measured by thromboelastography measured by TEG and platelet aggregation.|Frequency of High Platelet Reactivity (HPR)|Frequency of thrombo-inflammatory syndrome|Correlation between TEG6s parameters and clinical outcomes|Correlation between HPR and clinical outcomes|Determine response to anticoagulation therapy|Determine level of platelet aggregation|Determine platelet thrombi and fibrin rich platelet thrombus Area Under the Curve|Determine short and long IgG, IgM and IgG antibody levels","LifeBridge Health|Haemonetics Corporation|Inflammatory Markers Laboratory|Chronolog Corporation|Precision Biologics, Inc",All,"3 Years and older   (Child, Adult, Older Adult)",,100,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,1602903,30-Jun-20,Feb-21,Jun-21,30-Jul-20,,22-Oct-20,"Sinai Center for Thrombosis Research, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04493307
NCT04519411,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,,Recruiting,No Results Available,COVID 19,Diagnostic Test: Transpulmonary pressure measurements,Transpulmonary pressure,Mayo Clinic,All,up to 17 Years   (Child),Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,20-003743,21-May-20,31-Dec-20,31-Jan-21,19-Aug-20,,19-Aug-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04519411
NCT04514627,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,PENFS COVID-19,Recruiting,No Results Available,COVID-19,Device: Auricular percutaneous neurostimulation,"Hypoxemia via oxygen level, or saturation (SpO2) in percent|Progression to mechanical ventilation, ECLS or death|Oxygen requirements|Days of hospitalization|Time to hospital discharge|Time to resolution of fever|Days of resting respiratory rate|Serious adverse events or patient or worsening condition|Erythrocyte Sedimentation Rate (ESR)|C-Reactive Protein (CRP)|Ferritin|D-Dimer|Creatine Phosphokinase, Total (CK)|Troponin|Lactate Dehydrogenase (LDH)|Procalcitonin (PCT)|B-Type Natriuretic Peptide (BNP)|N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP)|Interleukin-6 (IL-6), High Sensitive ELISA|Complete Blood Count (CBC) with Differential|Comprehensive Metabolic Panel (CMP)|7-Point Ordinal Scale of Clinical Status|Modified Borg Dyspnea Scale (MBS)",Olive View-UCLA Education & Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1600899,13-Jul-20,31-Jul-21,31-Jul-21,17-Aug-20,,19-Aug-20,"Olive View-UCLA Medical Center, Sylmar, California, United States",,https://ClinicalTrials.gov/show/NCT04514627
NCT04570501,Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients,,Not yet recruiting,No Results Available,Covid19,Drug: Angiotensin-(1-7)|Drug: Placebo,"Time to recovery|Incidence of mortality at Day 29|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29",Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",58189,Jan-21,Jun-21,Jun-21,30-Sep-20,,27-Nov-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04570501
NCT04351620,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine,Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-0572,Apr-20,Jun-20,Jun-20,17-Apr-20,,17-Apr-20,"University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04351620
NCT04372004,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),CATCH COVID-19,Recruiting,No Results Available,COVID-19,Diagnostic Test: diagnostic tests for COVID-19 infection,detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood,Texas Cardiac Arrhythmia Research Foundation,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,TCAI_CATCH COVID-19,8-May-20,May-21,Jun-21,1-May-20,,11-Aug-20,"Texas Cardiac Arrhythmia Institute, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04372004
NCT04360278,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,,Recruiting,No Results Available,COVID-19,,Collection of convalescent plasma,National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,1500,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200092|20-CC-0092,21-Apr-20,14-Apr-30,14-Apr-30,24-Apr-20,,11-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04360278
NCT04339426,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,,Recruiting,No Results Available,Covid19,Drug: Atovaquone/Azithromycin,Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity,HonorHealth Research Institute,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2,25,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HRI-COVID-19-Anti-Malarial-001,20-Apr-20,Jul-21,Dec-21,9-Apr-20,,2-Dec-20,"HonorHealth, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04339426
NCT04403386,"Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",,Recruiting,No Results Available,COVID-19,,Levels of senescent CD16+CD8+ T cells prior to COVID-19 disease and time to COVID-19 disease morbidity (antibody positvity).,National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC),All,30 Years to 55 Years   (Adult),,200,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200108|20-E-0108,1-Jun-20,31-May-22,31-May-22,27-May-20,,23-Dec-20,"NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04403386
NCT04438057,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,,Recruiting,No Results Available,COVID-19,Biological: CCP,Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days,Metro Infectious Disease Consultants,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIDC-CCP,12-Aug-20,12-Aug-20,12-Aug-21,18-Jun-20,,21-Aug-20,"Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04438057
NCT04570462,Mild Hypothermia for COVID-19 ARDS,,Recruiting,No Results Available,COVID19 ARDS,Other: Hypothermia Via Cooling Machine- Arctic Sun 5000,Changes in metabolic requirement during and after hypothermia|Changes in oxygen requirements and levels during and after hypothermia|length of intubation|Changes in carbon dioxide levels during and after hypothermia|does application of hypothermia reduce pro inflammatory response,Northwell Health,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Protocol 5.18.2020 Approved,18-May-20,31-Dec-20,31-Dec-20,30-Sep-20,,30-Sep-20,"North Shore University Hospital, Manhasset, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04570462/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04570462
NCT04623671,Intravenous Infusion of CAP-1002 in Patients With COVID-19,INSPIRE,Recruiting,No Results Available,Covid19,Biological: CAP-1002|Biological: Placebo,Safety of CAP-1002|Efficacy of CAP-1002 on Cytokine|Efficacy of CAP-1002 on Laboratory Biomarker,Capricor Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CAP-1002-COVID-19-02,15-Nov-20,30-Apr-21,30-Jun-21,10-Nov-20,,24-Nov-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States|PharmaTex Research, LLC, Amarillo, Texas, United States",,https://ClinicalTrials.gov/show/NCT04623671
NCT04490824,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,,Recruiting,No Results Available,Covid19,Device: KELEA Excellerated Water|Device: Water Without an Elevated Level of KELEA,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Institute of Progressive Medicine,All,"Child, Adult, Older Adult",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,KELEA-1,1-Oct-20,31-Oct-20,30-Nov-20,29-Jul-20,,18-Sep-20,"Institute of Progressive Medicine, South Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT04490824
NCT04524663,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,COPS-2002,Recruiting,No Results Available,Covid19,Drug: Camostat Mesilate|Drug: Placebo|Other: Standard of Care Treatment,"Time until cessation of shedding of SARS-CoV-2 virus|Clinical worsening of COVID-19 disease in symptomatic patients|Development of antibodies to SARS-CoV-2|Time until resolution of symptoms|Time until progression of symptoms|Drug level on day five, one hour after a dose taken on an empty stomach",Stanford University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",56029,19-Dec-20,Jun-21,Jun-21,24-Aug-20,,7-Jan-21,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04524663
NCT04606784,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,,Recruiting,No Results Available,Covid19,Biological: Ampion|Other: Standard of Care,Incidence and severity of adverse events|Clinical status using 8-point ordinal scale,Ampio Pharmaceuticals. Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AP-014,28-Oct-20,31-Jan-21,31-Mar-21,28-Oct-20,,2-Dec-20,"Research Site, Colorado Springs, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04606784
NCT04393311,Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients,,Not yet recruiting,No Results Available,COVID-19,Drug: Ulinastatin|Drug: Placebo,"Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation",Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",56639,Dec-20,Jun-21,Jun-21,19-May-20,,27-Nov-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04393311
NCT04368260,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,,Recruiting,No Results Available,COVID19,Device: Control swab|Device: Prototype swab,Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result,University of Virginia,All,"up to 99 Years   (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HSR200127,24-Apr-20,31-Jul-20,31-Jul-20,29-Apr-20,,29-Apr-20,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04368260
NCT04442191,Convalescent Plasma as a Possible Treatment for COVID-19,,Recruiting,No Results Available,COVID-19,Biological: Convalescent plasma|Biological: Placebo,"Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit (ICU)|Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein (CRP)|Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase (LDH)|Ferritin|D-Dimer|White Blood Cell (WBC) Count",University of Illinois at Chicago,All,"40 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-0441,5-May-20,5-May-21,5-May-21,22-Jun-20,,22-Jun-20,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04442191
NCT04621149,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,PROFACT-01,Recruiting,No Results Available,COVID-19,"Other: chlorine dioxide|Dietary Supplement: zinc acetate|Drug: Famotidine|Other: placebo|Dietary Supplement: lactoferrin, green tea extract",Reduction in Participant Symptoms of COVID-19|Incidence of Treatment-Emergent Adverse Events|Rate of Hospitalization|Change in Oxygen Saturation|Change in Body Temperature,"Profact, Inc.",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Profact-01,15-Nov-20,31-Mar-21,31-Mar-21,9-Nov-20,,29-Dec-20,"AZ Good Health Center, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04621149
NCT04555096,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,,Recruiting,No Results Available,Covid19|SARS-CoV-2 Infection,Drug: GC4419|Drug: Placebo,28 day all-cause mortality,"Galera Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COV-4419-201,9-Sep-20,Nov-21,Dec-21,18-Sep-20,,10-Dec-20,"University of Iowa, Iowa City, Iowa, United States|Mercy Research, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04555096
NCT04498377,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,,Recruiting,No Results Available,Covid19,Biological: F-652|Biological: Placebo,NIAID 8-point ordinal scale,Generon (Shanghai) Corporation Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GC-652-04,Dec-20,30-Sep-21,31-Dec-21,4-Aug-20,,16-Dec-20,"Tulane University School of Medicine, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04498377
NCT04363502,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,,Recruiting,No Results Available,Covid19,Drug: Clazakizumab|Drug: Placebo,Change in C-reactive protein (CRP) level,Johns Hopkins University,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB00247932,7-May-20,Feb-21,Feb-21,27-Apr-20,,31-Dec-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04363502
NCT04601077,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans,,Recruiting,No Results Available,COVID-19,"Drug: Nitric Oxide lozenges, 30 mg|Drug: Placebo","Low blood pressure|dizziness|Incidence of hospitalization, ICU admission, intubation, dialysis and death",Nitric Oxide Innovations LLC,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IND150758 Pilot,1-Nov-20,1-Jun-21,31-Jul-21,23-Oct-20,,9-Dec-20,"American Institute of Therapeutics, Lake Bluff, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04601077
NCT04478019,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,SHIELD,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse,Number of Participants with COVID-19 diagnosis|SARS-Cov-2 Viral Load|Fidelity of the treatment regimen|Feasibility of the treatment regimen,"University of Wisconsin, Madison",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,94,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2020-0540|A534265|SMPH/MEDICINE/INFECT DIS|Protocol Version 6/1/2020,7-Jul-20,30-Apr-21,30-Apr-21,20-Jul-20,,20-Jul-20,"University of Wisconsin-Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04478019
NCT04502472,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Inova-CCP,Recruiting,No Results Available,Covid-19,Biological: Convalescent plasma transfusion,"Change is clinical status|Transfusion related events|SOFA score at days 0, 7, 14, 21, 28|Length of Hospital Stay|Supplemental oxygen|Mechanical Ventilation|Change in mechanical ventilation status|Mortality|Change in inflammatory markers",Inova Health Care Services,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Inova COVID-19 CCP,6-Jun-20,31-Dec-21,31-Dec-21,6-Aug-20,,6-Aug-20,"Inova Fairfax Medical Campus, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04502472
NCT04667442,Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects,,Recruiting,No Results Available,Covid19,Diagnostic Test: Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional),Demonstrate clinical agreement between an EUA RT-PCR methodology and the Nanomix eLab® COVID-19 Rapid Antigen Panel,Nanomix,All,"18 Years and older   (Adult, Older Adult)",,60,Industry,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Nanomix CVAG-202,1-Dec-20,Mar-21,Mar-21,14-Dec-20,,14-Dec-20,"Nanomix, Emeryville, California, United States",,https://ClinicalTrials.gov/show/NCT04667442
NCT04427566,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,VENTED,Recruiting,No Results Available,COVID-19,Radiation: Radiation therapy,"Mortality rate of subjects treated with whole lung low-dose radiation|Survival rate of subjects treated with whole lung low-dose radiation|Change in number of Intensive care unit days|Change in number of days using supplemental oxygen|Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated|Quantitation of Lung Involvement using Chest CT|Quantitation of Lung Opacities using Chest CT|SARS-CoV2 viral titers|Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs|Change in performance status after low dose radiation to lungs",Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VENTED,23-Jul-20,31-Dec-21,31-Dec-21,11-Jun-20,,25-Sep-20,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04427566
NCT04476602,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,CROWN,Recruiting,No Results Available,Covid-19 (SARS-CoV-2),,Hospital Admission,Northwell Health,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-0618,27-Apr-20,31-Dec-20,31-Dec-20,20-Jul-20,,16-Sep-20,"410 Lakeville Road, Suite 107, New Hyde Park, New York, United States",,https://ClinicalTrials.gov/show/NCT04476602
NCT04432766,A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients,,Not yet recruiting,No Results Available,COVID-19,Drug: BAT2020,Incidence of adverse events (AEs),Bio-Thera Solutions,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,174,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BAT-2020-001-CR,20-Oct-20,20-Jan-21,18-Aug-21,16-Jun-20,,29-Sep-20,"Snake River Research, Idaho Falls, Idaho, United States",,https://ClinicalTrials.gov/show/NCT04432766
NCT04344236,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse,Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient,NYU Langone Health,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,s20-00444,9-Apr-20,1-May-20,9-May-20,14-Apr-20,,14-Apr-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04344236
NCT04582903,Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence,,Recruiting,No Results Available,COVID-19 Infection,,"Characterization of the dynamic changes of innate and adaptive immune responses during SARS CoV 2 infection and convalescence.|Identification of genetic variants that are associated with either severe/lethal COVID-19 or resistance to SARS CoV 2 infection.|Measurement of proinflammatory/anti inflammatory cytokines produced during SARS CoV 2 infection and convalescence, including the IFN signature response.|Survey of other potential blood proteomic biomarkers of disease.|Characterization of serological responses against SARS CoV 2, other viruses or microbiota, and host antigens.|Characterization of intrapatient SARS-CoV-2 genetic variation andevolution during infection and convalescence.",National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"up to 99 Years   (Child, Adult, Older Adult)",,500,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,10000044|000044-I,20-Jan-21,31-Aug-25,31-Aug-25,12-Oct-20,,15-Jan-21,"Niaid/Lcim, Rockville, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04582903
NCT04434131,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Convalescent Plasma,Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples,University of New Mexico,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20-227,28-Apr-20,28-Apr-21,28-Apr-25,16-Jun-20,,16-Jun-20,"University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04434131/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04434131
NCT04591717,Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers,,Recruiting,No Results Available,COVID-19,Biological: hAd5-S-Fusion+N-ETSD vaccine,"Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of abnormal changes of laboratory safety examinations|Vital Signs - Fever|Vital Signs - Tachycardia|Vital Signs - Bradycardia|Vital Signs - Hypertension|Vital Signs - Hypotension|Vital Signs - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus|Percentage of subjects who seroconverted|GMFR in neutralizing antibody|GMT|Seroconversion rate of neutralizing antibody|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein","ImmunityBio, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,35,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QUILT-COVID-19-hAd5-Vaccine,19-Oct-20,19-Nov-21,19-Nov-21,19-Oct-20,,19-Dec-20,"Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",,https://ClinicalTrials.gov/show/NCT04591717
NCT04352764,ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,,Recruiting,No Results Available,Covid19,Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test,prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms,Texas Cardiac Arrhythmia Research Foundation,All,"Child, Adult, Older Adult",,5000,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,TCAI_COVID-19,27-Mar-20,31-Dec-20,31-Jan-21,20-Apr-20,,27-Apr-20,"St. David's Medical Center, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04352764
NCT04377711,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,,Recruiting,No Results Available,COVID-19,Drug: Ciclesonide|Drug: Placebo,"Percentage of patients hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30|Time to hospital admission or death|Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM/PM assessments)|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30|Safety will be assessed based on adverse events.",Covis Pharma S.à.r.l.,All,"12 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALV-020-001,8-Jun-20,1-Sep-20,1-Dec-20,6-May-20,,11-Jun-20,"University of Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04377711
NCT04360551,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,,Recruiting,No Results Available,COVID-19,Drug: Telmisartan 40mg|Drug: Placebo,Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers,University of Hawaii,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",H051,1-Jul-20,30-Jun-21,30-Jun-21,24-Apr-20,,3-Aug-20,"University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT04360551
NCT04482699,RAPA-501-Allo Off-the-Shelf Therapy of COVID-19,,Recruiting,No Results Available,Severe COVID-19 Disease,Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19|Other: Placebo,Dose-Limiting Toxicity (DLT)|Mortality Rate|Ventilation Support|Days of Hospitalization|Number of Deaths|Incidence of Infection|GVHD Incidence,Rapa Therapeutics LLC|Hackensack Meridian Health,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,88,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAPA-501-ALLO-COVID-19,30-Dec-20,30-Dec-21,1-Jun-22,22-Jul-20,,13-Jan-21,"Hackensack University Medical Center, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04482699
NCT04481685,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",,Recruiting,No Results Available,Covid19,Drug: ATI-450|Drug: Placebo,Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1β|Change in serum cytokine Tumor Necrosis Factor (TNF-α),University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",IIT-2020-ATI-450-COVID-19,20-Jul-20,Jul-21,Jul-22,22-Jul-20,,21-Aug-20,"The University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04481685
NCT04527315,COVID-19 Survivorship Registry,,Recruiting,No Results Available,Covid19,Other: Questionnaires,Level of Inflammatory Markers|Score on St. George's Shortness of Breath Questionnaire (SGSQ)|Score on Short Form Zarit Burden Interview (ZBI-12),NYU Langone Health,All,"18 Years and older   (Adult, Older Adult)",,350,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20-00909,17-Jul-20,Aug-23,Aug-23,26-Aug-20,,17-Nov-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04527315
NCT04545541,Nebulised Heparin in Patients With Severe COVID-19,CHARTER-MT,Recruiting,No Results Available,Covid19|Respiratory Failure,Drug: Nebulised unfractionated heparin (UFH),Alive and Ventilator Free Score,Australian National University,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,202,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CHARTER meta-trial,1-Nov-20,Apr-22,Jun-22,11-Sep-20,,17-Nov-20,"Frederick Health Hospital, Frederick, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04545541
NCT04474288,The COVID-19 PUI Reality Check (CPRC) Study,CPRC,Recruiting,No Results Available,Covid19 Immunology,Diagnostic Test: SARS-CoV-2 antibody testing,SARS-CoV-2 IgG|host immune response|pathogen protein expression,"Bassett Healthcare|Bioreference, Inc",All,"18 Years and older   (Adult, Older Adult)",,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,1613182,16-Jul-20,Jul-21,Jul-21,16-Jul-20,,20-Aug-20,"Bassett Medical Center, Cooperstown, New York, United States",,https://ClinicalTrials.gov/show/NCT04474288
NCT04364802,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,PIIPPI,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Povidone-Iodine Nasal Spray and Gargle,Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|Percent of community participants testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort,Alexandra Kejner|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,58748,29-Apr-20,May-21,May-21,28-Apr-20,,24-Nov-20,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04364802
NCT04358029,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),,Recruiting,No Results Available,COVID 19 Cardiac|COVID 16 Arrhythmia|COVID 19 Death,,Frequency of cardiac arrhythmias|Mode of death,Vivek Reddy|Icahn School of Medicine at Mount Sinai,All,"Child, Adult, Older Adult",,10000,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,GCO 20-0931,9-Apr-20,May-21,Dec-21,22-Apr-20,,13-May-20,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04358029
NCT04491292,Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce,,Recruiting,No Results Available,COVID-19 Infection,Other: Questionnaire Administration,Change in psychosocial outcomes|Change in stress-related outcomes|Demographic and occupational factors associated psychological and stress-related outcomes,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",,20000,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2020-0428|NCI-2020-04259,18-May-20,30-Apr-21,30-Apr-21,29-Jul-20,,29-Jul-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04491292
NCT04482647,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,,Recruiting,No Results Available,COVID-19 Infection,Other: Media Intervention|Procedure: Meditation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Yoga,Study recruitment|Acceptability of study|Adherence to the practice|Change in resilience|Perceive stress and psychological impact|Breath holding time,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1,50,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2020-0483|NCI-2020-04931,17-Jun-20,1-Jul-21,1-Jul-21,22-Jul-20,,23-Sep-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04482647
NCT04391309,IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19),,Not yet recruiting,No Results Available,SARS-CoV2,Biological: IC14|Other: Placebo,Acute respiratory failure|Time to clinical improvement|Invasive mechanical ventilation|Hospitalization|Sequential Organ Failure Assessment|Ordinal Scale|Time to clinical improvment|Time to recovery|Change in C-reactive protein|Adverse events|Serious adverse events,Implicit Bioscience|University of Washington,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COV04,Jul-20,Jul-21,Sep-21,18-May-20,,24-Jun-20,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04391309
NCT04383444,Surveillance of Individuals Following SARS-CoV-2 Infection,,Recruiting,No Results Available,COVID-19,,"Results of SARS-CoV-2 RT- PCR testing, antibody assay, and culture|SARS-CoV-2 culture and RT-PCR results|Symptom checklist and RT-PCR cycle threshold",National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,1050,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200117|20-I-0117,7-Jul-20,1-Aug-23,1-Aug-23,12-May-20,,17-Dec-20,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04383444
NCT04359602,COVID-19 Recovered Volunteer Research Participant Pool Registry,,Recruiting,No Results Available,Recovered From COVID-19,,Serological testing of COVID patients|Immune response,"University of California, Los Angeles",All,"18 Years and older   (Adult, Older Adult)",,10000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,20-000625,8-Apr-20,20-Apr-22,20-Apr-42,24-Apr-20,,4-May-20,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04359602
NCT04562285,Sustained Immunity to SARS-CoV-2,,Recruiting,No Results Available,Covid19,Diagnostic Test: Serologic immunoassays to SARS-CoV-2 antibodies,Detection of antibodies to SARS-CoV-2 in human serum and plasma,Henry Ford Health System,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,13978,23-Jun-20,Jun-21,Jun-21,24-Sep-20,,24-Sep-20,"Henry Ford Health System, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04562285
NCT04332107,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,ACTION,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Azithromycin|Drug: Placebos,Day 14 Binary Assessment of Symptoms|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)|Death|Hospitalization,"Thomas M. Lietman|Bill and Melinda Gates Foundation|Pfizer|Stanford University|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 3,2271,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20-30504,22-May-20,30-Sep-21,30-Dec-21,2-Apr-20,,8-Dec-20,"University of California San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04332107
NCT04449042,The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry,,Recruiting,No Results Available,Airway Management|COVID19,Procedure: airway management during sedation or general anesthesia,airway complications|airway device|PPE|First pass success|induction techniques|failed intubation|complication risk factors,Boston Children's Hospital|Children's Hospital of Philadelphia|Children's Hospital Colorado|Istituto Giannina Gaslini|The Hospital for Sick Children|Perth Children's Hospital of Western Austrailia|Lurie Children's Hospital of Chicago,All,"up to 18 Years   (Child, Adult)",,15000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB-P00035427,1-Apr-20,Dec-25,Dec-25,26-Jun-20,,26-Jun-20,"Boston Children's Hopsital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04449042
NCT04528771,S-Nitrosylation Therapy of COVID-19,,Not yet recruiting,No Results Available,SARS-CoV2 Infection|Covid19,Drug: SNO|Drug: Nitrogen gas,Length of Hospital Stay|Number of Ventilator Days|Length of Intensive Care|All-Cause Mortality|Treatment Emergent Adverse Events|Time to Respiratory Status Improvement|Clinical Status|Respiratory Clinical Status,Robert Schilz|Case Western Reserve University|University Hospitals Cleveland Medical Center,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 1,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STUDY20200453,31-Oct-20,31-Mar-21,30-Apr-21,27-Aug-20,,27-Aug-20,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04528771
NCT04370821,"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers",CHAMPS,Recruiting,No Results Available,Occupational Exposure to SARS-CoV-2|COVID-19,,"Sample Size of enrolled CHAMPS Study participants by demographic characteristics during the first two years of the study|Exposure to SARS-CoV-2 based on models computed from participant baseline data and community variables, if available.|Infectious disease and chronic disease incidence rates by demographic characteristics|Completeness of data by demographic characteristics.|Participation rates in ancillary and sub-studies within the CHAMPS registry.|Number of participants enrolled in randomized trials based on the CHAMPS registry",Villanova University,All,"18 Years and older   (Adult, Older Adult)",,20000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB FY2020-215,9-May-20,27-Apr-40,27-Apr-40,1-May-20,,28-Sep-20,"Villanova University, Villanova, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04370821
NCT04603924,Study of Niclosamide in Moderate Hospitalized Coronavirus-19 (COVID-19) Patients,,Recruiting,No Results Available,COVID-19,Drug: Niclosamide|Drug: Placebo,Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2)|Efficacy as measured by median time to hospital discharge (Part 2)|Efficacy as measured by median time to hospital discharge (Part 1)|Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1)|Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2)|Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2),ANA Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,436,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANA001-001,7-Oct-20,Jun-21,Jun-22,27-Oct-20,,4-Nov-20,"Helen Keller Hospital, Sheffield, Alabama, United States|Baptist Health Research Institute, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04603924
NCT04393558,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,,Recruiting,No Results Available,COVID-19|Healthy Control,Device: ADAM Sensor,Body temperature|Cough Frequency|Respiratory frequency|Heart Rate Instantaneous heart rate every 15 minutes.,Shirley Ryan AbilityLab,All,"18 Years to 95 Years   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STU00212522,20-Apr-20,31-Dec-22,31-Dec-22,19-May-20,,21-May-20,"Shirley Ryan AbilityLab, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04393558
NCT04413955,Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA,,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Device: Seraph®-100 Microbind® Affinity Blood Filter,"Rate of known, expected, or unanticipated adverse device effects|Change in cardiovascular hemodynamic stability|Change in cardiovascular hemodynamic support|Change in pulmonary/respiratory status|Change in laboratory measures of cytokine reactions and/or viral sepsis: IL-6|Change in laboratory measures of cytokine reactions and/or viral sepsis: CRP|Change in laboratory measures of cytokine reactions and/or viral sepsis: Ferritin|Change in laboratory measures of cytokine reactions and/or viral sepsis: D-Dimer|Change in laboratory measures of cytokine reactions and/or viral sepsis: ALC","Children's Hospital Medical Center, Cincinnati|ExThera Medical Corporation",All,"18 Years and older   (Adult, Older Adult)",,100,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,001-Seraph®-100 for SARS-CoV-2,1-Jun-20,31-Dec-21,31-Dec-21,4-Jun-20,,1-Sep-20,"AdventHealth Orlando, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT04413955
NCT04397614,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,,Recruiting,No Results Available,Sars-CoV2|Covid-19,Other: mHealth Assessments,Percentage of ecological momentary assessments completed|Percentage of satisfied mHealth app users|Proportion of manifestation of severe disease|Proportion of treatment-related toxicity|Proportion of hospitalization|Proportion of COVID-19 related mortality,University of Oklahoma,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-19 Mobile Health,22-Jul-20,Dec-21,Dec-21,21-May-20,,19-Oct-20,"Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04397614
NCT04548895,Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19,,Recruiting,No Results Available,Covid19|Community-Acquired Respiratory Tract Infection,Device: Observational measurement of biometric data. No change to health care provided.,Proportion of quality signals obtained out of all monitoring time for each device|Predictive characteristics of the algorithm for respiratory tract infection,"Health Stream Analytics, LLC",All,"Child, Adult, Older Adult",,30,Industry,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,HSA-001,30-Dec-20,30-Jun-21,26-Oct-21,16-Sep-20,,6-Jan-21,"Avalon Health & Rehabilitation Center, Pasco, Washington, United States",,https://ClinicalTrials.gov/show/NCT04548895
NCT04565665,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,,Recruiting,No Results Available,COVID-19 Infection|COVID-19-Associated Acute Respiratory Distress Syndrome,Other: Best Practice|Biological: Mesenchymal Stem Cell,"Incidence of composite serious adverse events (Pilot)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Pilot)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot)|Overall survival rate (Pilot)|Survival rate in patients who present intubated on ventilator support (Pilot)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot)|Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters|Hospitalization stay (Pilot)|Intensive care unit stay (Pilot)|Incidence of infusion-related adverse events (Pilot)",M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,70,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0365|NCI-2020-06741,29-Jul-20,30-Apr-21,30-Apr-21,25-Sep-20,,23-Oct-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04565665
NCT04610801,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,,Recruiting,No Results Available,Covid19,Drug: Nasal Spray,Change from baseline reactive to non-reactive on COVID 19 RT PCR in 7 days|Change of time to clinical recovery from baseline within 7 days,Larkin Community Hospital|Ferrer Medical Innovations|Xlear,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,LCH-3-082020,8-Aug-20,8-Aug-21,8-Aug-21,2-Nov-20,,10-Nov-20,"Larkin Community Hospital Palm Springs Campus, Miami, Florida, United States|Larkin Community Hospital, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04610801
NCT04353206,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,,Recruiting,No Results Available,Covid-19|Sars-CoV2,Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma,Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.,Noah Merin|Johns Hopkins University|Cedars-Sinai Medical Center,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Acute Care CP Consortium Trial,27-Jun-20,May-21,May-21,20-Apr-20,,15-Jul-20,"8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04353206
NCT04355897,CoVID-19 Plasma in Treatment of COVID-19 Patients,,Recruiting,No Results Available,COVID 19,Biological: Convalescent COVID 19 Plasma,Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.,The Christ Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-23,28-Apr-20,Jul-20,Aug-20,21-Apr-20,,20-May-20,"The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04355897
NCT04403035,Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19,,Recruiting,No Results Available,Covid-19,Diagnostic Test: ID NOW vs. Accula,Test characteristics,Ascension South East Michigan,All,"18 Years to 95 Years   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1599159,10-May-20,1-Jul-20,9-May-21,27-May-20,,9-Jul-20,"Ascension St. John Hospital, Detroit, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04403035/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04403035/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT04403035
NCT04371432,Genetics of COVID-19 Susceptibility and Manifestations,,Recruiting,No Results Available,COVID-19|Coronavirus 2019,,Molecular etiology of host susceptibility to severe COVID-19|Mechanisms of disease,National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"3 Years and older   (Child, Adult, Older Adult)",,2500,NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,200090|20-HG-0090,20-Jan-21,1-Jun-25,1-Jun-25,1-May-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04371432
NCT04639466,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",,Recruiting,No Results Available,COVID-19,Drug: Placebo Administration|Biological: Vaccine Therapy,Incidence of adverse events|Humoral immunity|Level of SARS-CoV-2-specfic neutralizing antibodies|Th1 vs Th2 polarization|SARS-CoV-2- antigen specific T cell responses to the COH04S1 vaccine|Evolution of activated/cycling and memory phenotype markers on the surface of SARS-CoV-2- specific T cells elicited as a result of the COH04S1 vaccination|Comparison of one vaccine injection vs two vaccine injections for immunogenicity|Comparison of one vaccine injection vs two vaccine injections for adverse events,City of Hope Medical Center|National Cancer Institute (NCI),All,18 Years to 55 Years   (Adult),Phase 1,129,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20447,11-Dec-20,10-Nov-22,10-Nov-22,20-Nov-20,,7-Jan-21,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT04639466
NCT04540406,NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes,,Not yet recruiting,No Results Available,Suspected or Confirmed COVID-19,Drug: NBT-NM108|Other: Usual Care Only,"Gut Microbiota Composition|Outcome of COVID-19 related illnesses|Proportion of participants who are ""alive and not admitted to the hospital""|Proportion of participants who have complete resolution of all objective symptoms|Proportion of participants who have complete resolution of subjective symptoms|Illness severity based on the categorization from FDA COVID-19 Guidance Document|Illness severity based the Ordinal Scale for Clinical Improvement from the World Health Organization|Body temperature (F)|Oxygen saturation SpO2 level|Pulse rate per minute|Respiratory rate per minute|Fasting blood glucose (mg/dl)",Notitia Biotechnologies Company|University of South Florida|Rutgers University,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,100,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NBTNM10810012020,22-Jan-21,1-May-21,1-Jun-21,7-Sep-20,,14-Jan-21,"University of South Florida Morsani College of Medicine, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT04540406
NCT04348240,Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,,Recruiting,No Results Available,COVID-19,,To determine SARS-CoV-2 viral load and infectivity insaliva that may contribute to asymptomatic transmission,National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,90,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200094|20-D-0094,16-Apr-20,1-Jul-21,1-Jul-21,16-Apr-20,,13-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04348240
NCT04476940,COVID-19 Breastfeeding Guideline for African-Americans,COVID-BF,Not yet recruiting,No Results Available,Covid19|Exclusive Breastfeeding,Behavioral: COVID-19 Breastfeeding Support,COVID-19 breastfeeding guidance adherence at birth.|COVID-19 breastfeeding guidance adherence at 1-month postpartum.|COVID-19 breastfeeding guidance adherence at 3-months postpartum.|Exclusive breastfeeding at birth.|Exclusive breastfeeding at 1-month.|Exclusive breastfeeding at 3-months.|COVID_Status|COVID-19 Immunoglobulin G|COVID-19 Immunoglobulin M,Meharry Medical College,Female,18 Years to 45 Years   (Adult),Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,330875,Sep-20,Oct-21,Jun-22,20-Jul-20,,20-Jul-20,"Meharry Medical College, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04476940
NCT04486482,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,,Recruiting,No Results Available,Mild-to-Moderate COVID-19,Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone,Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)|Relative abundance of microbial taxa in fecal samples as assessed by shotgun profiling based on shotgun sequencing.,Kaleido Biosciences,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,K032-120,Jul-20,Mar-21,Mar-21,24-Jul-20,,24-Jul-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04486482
NCT04667247,Mushroom-based Product for COVID-19,MACH19,Recruiting,No Results Available,COVID-19,Drug: FoTv,Adverse Events|Creatinine|Aspartate transaminase|Alanine transaminase|Prothrombin time|Partial Thromboplastin Time|Duration of viral illness|Hospitalization rate|ICU admission|Ventilatory requirement|Lymphocyte count|Neutrophil count|Ferritin|D-Dimer|Lactate Dehydrogenase|C-Reactive Protein|Troponin|Mid-turbinate nasal swabs|Peripheral Blood Mononuclear Cell (PBMC) immune profiling,"Gordon Saxe|University of California, Los Angeles|University of California, Irvine|University of California, San Diego",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",200633,3-Dec-20,1-Apr-21,1-Aug-21,14-Dec-20,,14-Dec-20,"University of California, Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04667247
NCT04512079,FREEDOM COVID-19 Anticoagulation Strategy,FREEDOM COVID,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Enoxaparin|Drug: Apixaban,Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism,Valentin Fuster|Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Phase 4,3600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 20-2115,8-Sep-20,Mar-21,Jun-21,13-Aug-20,,14-Oct-20,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04512079
NCT04497389,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,,Recruiting,No Results Available,SARS CoV-2,Biological: Human Amniotic Fluid,C-reactive protein,University of Utah,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",132922,28-Oct-20,15-Sep-21,15-Sep-21,4-Aug-20,,6-Nov-20,"University of Utah Health, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04497389
NCT04565067,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans,,Recruiting,No Results Available,COVID-19,,Determine CD8 T cells that are responsive to SARS-CoV-2.,National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,120,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,10000140|000140-AG,20-Jan-21,31-Dec-21,1-Sep-22,25-Sep-20,,15-Jan-21,"National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04565067
NCT04495816,COVID-19 Anosmia Study,,Recruiting,No Results Available,Anosmia|Covid19,Drug: Omega-3 Fatty Acid Supplement|Drug: Placebo/Control,Brief Smell Identification Test (BSIT)|Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)|Sinonasal Outcomes Test (SNOT-22),Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Phase 2,126,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GCO 20-1132,15-Jul-20,Apr-21,Jun-21,3-Aug-20,,6-Jan-21,"Mount Sinai Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04495816
NCT04619719,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Respiratory Distress,,Not yet recruiting,No Results Available,Covid19,Device: Hyperbaric Oxygen Therapy (HBOT),Time to Patient Mortality|Time to Mechanical Ventilation|Number of Participants Displaying Presence of Any Pulmonary Function Abnormality,NYU Langone Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-00897,16-Nov-20,15-May-21,15-Dec-21,6-Nov-20,,10-Nov-20,"Greenwich Hospital - Yale New Haven Health, Greenwich, Connecticut, United States|NYU Winthrop Hospital, Mineola, New York, United States",,https://ClinicalTrials.gov/show/NCT04619719
NCT04341675,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,SCOPE,Recruiting,No Results Available,COVID-19,Drug: Sirolimus|Drug: Placebo,"Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies",University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-0337,24-Apr-20,Jul-20,Sep-20,10-Apr-20,,20-May-20,"Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04341675
NCT04584710,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,,Recruiting,No Results Available,Covid19,Drug: RTB101|Drug: Placebo,"To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years|To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population|To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population|To assess the incidence of treatment-emergent of AEs and SAEs in subjects assigned to RTB101 as compared to placebo|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop symptomatic laboratory-confirmed COVID-19 from first dose through Day 14|To determine the percentage of subjects treated with RTB101 as compared to placebo who die from any cause from first dose of study drug through Day 14 and 21|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop laboratory-confirmed COVID-19 from first dose through Day 14 and are subsequently hospitalized for any reason through Day 21|To determine the percent of subjects treated with RTB101 or placebo who have laboratory-confirmed SARS-CoV-2 infection regardless of symptoms from first dose of study drug through Days 7, 14, 21.",Restorbio Inc.|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),Phase 2,60,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",RTB101-211|3R01AG064802-02S1,13-Oct-20,Jan-21,Feb-21,14-Oct-20,,26-Oct-20,"University of Connecticut, UConn Center on Aging, Farmington, Connecticut, United States|Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04584710
NCT04355143,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),COLHEART-19,Recruiting,No Results Available,COVID-19,Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians,"Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality","University of California, Los Angeles",All,"18 Years and older   (Adult, Older Adult)",Phase 2,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-000685,1-May-20,25-Apr-21,25-Apr-21,21-Apr-20,,21-May-20,"UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States",,https://ClinicalTrials.gov/show/NCT04355143
NCT04334382,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,HyAzOUT,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days,"Intermountain Health Care, Inc.|University of Utah|Utah Department of Health",All,"45 Years and older   (Adult, Older Adult)",Phase 3,1550,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051360,2-Apr-20,31-Dec-20,31-Dec-21,6-Apr-20,,9-Apr-20,"Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04334382
NCT04330521,Impact of the Coronavirus (COVID-19) on Patients With Cancer,,Recruiting,No Results Available,Cancer|COVID-19,,Number of participants who fill out the survey and participate in the semi-structured interviews.,Stanford University,All,"18 Years to 99 Years   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,55596,8-Apr-20,May-22,May-22,1-Apr-20,,24-Aug-20,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04330521
NCT04542993,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,Reszinate,Recruiting,No Results Available,Covid19|SARS-CoV Infection,Dietary Supplement: Zinc Picolinate|Dietary Supplement: Resveratrol|Dietary Supplement: Zinc Picolinate Placebo|Dietary Supplement: Resveratrol Placebo,Reduction in SARS-CoV-2 Viral load|Reduction in Severity of COVID-19 Disease,Swedish Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,SHS KAPH NSWE 20090,8-Sep-20,Sep-21,Jun-22,9-Sep-20,,19-Oct-20,"Swedish Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04542993
NCT04486313,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,,Recruiting,No Results Available,COVID-19,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,Reducing the Time to Sustained Response|Reducing the Rate of Progression,Romark Laboratories L.C.,All,"12 Years to 120 Years   (Child, Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RM08-3008,13-Aug-20,30-Dec-20,30-Dec-20,24-Jul-20,,29-Oct-20,"Invesclinic US LLC, Fort Lauderdale, Florida, United States|RH Medical Urgent Care, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04486313
NCT04497779,Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,,Recruiting,No Results Available,Asymptomatic COVID-19 Infection Laboratory-Confirmed|Symptomatic COVID-19 Infection Laboratory-Confirmed,Procedure: Biospecimen Collection|Other: Diagnostic Laboratory Biomarker Analysis|Other: Electronic Health Record Review|Other: Questionnaire Administration,Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients|All-cause mortality|Donor antibody levels|Incidence of adverse events|CCP recipient outcomes,City of Hope Medical Center|National Cancer Institute (NCI)|California Institute for Regenerative Medicine (CIRM),All,"18 Years and older   (Adult, Older Adult)",,800,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20204|NCI-2020-04000|P30CA033572|TGen,13-Jul-20,21-Aug-21,21-Aug-22,4-Aug-20,,21-Sep-20,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT04497779
NCT04440007,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,SOC,Recruiting,No Results Available,Covid-19,Drug: Abivertinib|Other: Standard of Care,Proportion of subjects alive and free of respiratory failure at Day 14|Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)|Proportion of subjects alive and free of respiratory failure at Day 28|Change in clinical status|Discharge from ICU|Time to respiratory failure or death,"Sorrento Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STI-5656-2001,9-Oct-20,Jan-21,Mar-21,19-Jun-20,,11-Dec-20,"MedStar Washington Hospital Center, Washington, District of Columbia, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04440007
NCT04662671,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",,Recruiting,No Results Available,COVID19,Device: RD-X19,Primary Safety Measure|Primary Efficacy Measure|Geometric Mean Viral Load|Viral Load Reduction|Time to Clearance of Viral Infection|Proportion of Subjects Demonstrating Clearance of Viral Infection|Median Time to Alleviation of Symptoms,EmitBio Inc.|KNOWBio Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EB-P12-01,18-Nov-20,15-Mar-21,30-Apr-21,10-Dec-20,,10-Dec-20,"Site 2, Miami, Florida, United States|Site 1, College Station, Texas, United States",,https://ClinicalTrials.gov/show/NCT04662671
NCT04402840,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|COVID-19,Procedure: Stellate Ganglion Block,Adverse events related to SGB|All Adverse events|Death|Assessment of respiratory/ pulmonary function|Radiographic criteria|Cardiac function,West Virginia University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004963113,24-Apr-20,Dec-21,Dec-21,27-May-20,,3-Nov-20,"West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT04402840
NCT04488575,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,,Recruiting,No Results Available,Covid19,Drug: EDP1815|Drug: Placebo,Change from baseline to the lowest S/F oxygen ratio|Change in S/F Ratio|Percentage change in S/F Ratio|Percentage of participants at each level on the WHO OSCI score|Percentage of participants with shifts from each level of the WHO OSCI score at baseline|Percentage of participants remaining at their baseline score on the WHO OSCI (or lower)|Percentage of participants reporting each level of the WHO OSCI score at their worst post-baseline day|The time in days spent at each participant's worst reported WHO OSCI score (excluding death).|Intubation and mechanical-ventilation free survival|Overall survival|Number of days requiring oxygen therapy|Number of days with pyrexia|Maximum daily temperature|SpO2 level|Time to discharge|Time to oxygen saturation (SpO2) ≥94%|Time to recovery|Number of participants experiencing AEs by seriousness and relationship to treatment|Incidence of clinically significant abnormal lab parameters,"Evelo Biosciences, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EDP1815-205,26-Aug-20,21-Dec-20,21-Dec-20,28-Jul-20,,13-Nov-20,"Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04488575
NCT04377308,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,,Recruiting,No Results Available,COVID-19|Cytokine Storm,Drug: Fluoxetine,"Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale",University of Toledo Health Science Campus,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FRIDA COVID19,1-May-20,20-Apr-21,20-Oct-21,6-May-20,,6-May-20,"University of Toledo, Toledo, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04377308
NCT04360824,Covid-19 Associated Coagulopathy,,Recruiting,No Results Available,COVID 19 Associated Coagulopathy,Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis,"Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions",University of Iowa,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,202004235,6-May-20,16-Apr-21,16-Apr-21,24-Apr-20,,19-Jun-20,"University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04360824
NCT04342884,COVID-19 Community Research Partnership,,Recruiting,No Results Available,Coronavirus|COVID,,Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae,Wake Forest University Health Sciences,All,"Child, Adult, Older Adult",,150000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB00064912,8-Apr-20,Dec-21,Dec-21,13-Apr-20,,11-Jun-20,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04342884
NCT04458363,Convalescent Plasma in Pediatric COVID-19,,Recruiting,No Results Available,COVID,Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies,"Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer",Emory University,All,"up to 22 Years   (Child, Adult)",Early Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000789,Jul-20,Jun-22,Jun-22,7-Jul-20,,7-Jul-20,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04458363
NCT04604704,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,,Not yet recruiting,No Results Available,Covid19|Long COVID-19|Post-COVID-19 Syndrome,Drug: Naltrexone|Dietary Supplement: NAD+,Reduction of fatigue in post-COVID-19 syndrome by treatment with LDN and NAD+|Improvement of quality of life in post-COVID-19 syndrome by treatment with LDN and NAD+.,AgelessRx,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALRx004,Feb-21,Aug-21,Oct-21,27-Oct-20,,7-Jan-21,"AgelessRx, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04604704
NCT04562246,SARS-CoV-2 IgG and IgM Serologic Assays,,Recruiting,No Results Available,Covid19,Diagnostic Test: Serologic assays for antibodies to SARS-CoV-2,Prevalence of antibodies to SARS-CoV-2,Henry Ford Health System,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,13839,14-Aug-20,Aug-21,Aug-21,24-Sep-20,,24-Sep-20,"Henry Ford Health System, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04562246
NCT04424446,Saliva as Source of Detection for SARS-CoV-2,,Recruiting,No Results Available,COVID-19,,Saliva SARS-CoV-2 RT-PCR test results|Saliva and midturbinate swab SARS-CoV-2 RT-PCR test results,National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,5000,NIH,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,200128|20-CC-0128,13-Jul-20,1-Jun-21,1-Jun-21,11-Jun-20,,17-Sep-20,"Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04424446
NCT04349371,Saved From COVID-19,,Recruiting,No Results Available,COVID,Drug: Chloroquine|Drug: Placebo oral tablet,Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance,Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,350,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AAAS9992,Apr-20,Apr-21,Apr-21,16-Apr-20,,21-Apr-20,"Columbia University Irving Medical Center/NYP, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04349371
NCT04354701,COVID-19 and Cancer Consortium Registry,CCC19,Recruiting,No Results Available,COVID-19|Invasive Malignancy (Any Type),Other: Web-based REDCap survey,Web-based REDCap survey,Vanderbilt-Ingram Cancer Center,All,"18 Years and older   (Adult, Older Adult)",,10000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,VICC MD 2032,17-Mar-20,Dec-21,Dec-22,21-Apr-20,,19-Nov-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04354701
NCT04559009,COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,,Recruiting,No Results Available,Covid19|Amyotrophic Lateral Sclerosis,,COVID-19 incidence and prevalence in the ALS population,Atrium Health,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,AH-NSI-COVID19-ALS,15-Oct-20,31-Dec-23,30-Apr-24,22-Sep-20,,4-Nov-20,"Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04559009
NCT04681950,Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program,,Recruiting,No Results Available,Subjects Possibly Exposed to COVID-19,,Matching results from different collection types,Biocerna LLC,All,"Child, Adult, Older Adult",,500,Industry,Observational,Observational Model: Case-Only|Time Perspective: Other,47586,24-Nov-20,30-Dec-20,31-Dec-20,23-Dec-20,,23-Dec-20,"Biocerna LLC, Fulton, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04681950
NCT04537299,COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,COVID-FIS,Not yet recruiting,No Results Available,Covid19|SARS-CoV Infection,Drug: Fisetin|Drug: Placebo,Change in COVID-19 Severity,Mayo Clinic|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),Phase 2,150,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-008867|1R01AG072301-01,Dec-20,Dec-23,Dec-23,3-Sep-20,,3-Sep-20,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04537299
NCT04393948,Lung Irradiation for COVID-19 Pneumonia,,Recruiting,No Results Available,SARS-CoV 2,Radiation: Phase 1|Radiation: Phase 2,Phase 1: Feasibility and safety of treating hospitalized patients with SARS-CoV-2 pneumonia with single or bilateral whole lung irradiation|Phase 2: Proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization|Improvement or worsening on the 7-point ordinal scale over additional intervals|Rate and duration of use of supplemental oxygen|Rate and duration of fever > 38ºC|Rate and duration of invasive mechanical ventilation|Duration of hospitalization|Proportion of participants with overall survival up to 30 days after randomization|Improvement in radiographic findings related to infection/inflammation; comparisons include on study versus baseline scans and irradiated vs. unirradiated lung in subjects randomized to receive single lung irradiation|Treatment-emergent adverse events,Brigham and Women's Hospital,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020P001494,Jun-20,Oct-20,Nov-20,19-May-20,,25-Jun-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04393948
NCT04522830,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,BTL-TML-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: BTL-TML-COVID|Drug: Placebo,Mean duration and severity of disease|Incidence/Safety of Adverse Events,"Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.|Curavit Clinical Research",All,"50 Years and older   (Adult, Older Adult)",Phase 2,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-04-0311,30-Jul-20,31-Jan-21,1-Feb-21,21-Aug-20,,30-Dec-20,"Intermountain Clinical Reserach, Draper, Utah, United States",,https://ClinicalTrials.gov/show/NCT04522830
NCT04592354,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,AEO,Recruiting,No Results Available,Treatment of Fatigue After Resolution of COVID-19 Infection,Dietary Supplement: Oxaloacetate Medical Food/Dietary Supplement,Fatigue|Depression,Terra Biological LLC,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TB-AEO-2020 Post Covid Fatigue,15-Oct-20,15-Apr-21,15-Jun-21,19-Oct-20,,19-Oct-20,"Energy Medicine research Institute, Boulder, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04592354
NCT04393155,Longitudinal COVID-19 Cohort Study,,Recruiting,No Results Available,COVID-19|Acute Respiratory Failure,Other: COVID-19+ observational,Six minute walk distance (6MWD)|Hospital Anxiety and Depression Scale (HADS)|EuroQol Group standardized measure of health status (EQ-5D-5L)|MoCA-BLIND|Health Care Utilization Survey (HUS)|Death|Forced vital capacity (FVC)|Forced expiratory volume in 1 second (FEV1)|4-meter timed walk|Peripheral blood mononuclear cell type: CD4+ T cells (#cells/ml)|Peripheral blood mononuclear cell type: CD8+ T cells (#cells/ml)|Peripheral blood mononuclear cell type: B cells (#cells/ml)|Peripheral blood mononuclear cell type: NK cells (#cells/ml)|Peripheral blood mononuclear cell type: monocytes (#cells/ml)|Circulating markers of inflammation: C-Reactive Protein (CRP) (mg/l)|Circulating markers of inflammation: Interleukin 6 (IL-6) (pg/ml)|Circulating markers of inflammation: Interleukin 8 (IL-8) (pg/ml)|Circulating markers of inflammation: Interferon gamma (IFNg) (pg/ml)|Circulating markers of inflammation: Interferon alpha (IFNa) (pg/ml)|Circulating markers of inflammation: Tumor necrosis factor alpha (TNFa) (pg/ml)|Circulating markers of inflammation: Interleukin 1 beta (IL-1b) (pg/ml),University of Vermont,All,"18 Years and older   (Adult, Older Adult)",,225,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHRMS 16-540,16-Apr-20,30-Sep-22,31-May-23,19-May-20,,8-Dec-20,"University of Vermont College of Medicine, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT04393155
NCT04606069,Treat COVID-19 Patients With Regadenoson,,Not yet recruiting,No Results Available,COVID-19|Lung Inflammation,Drug: Regadenoson|Other: Placebo Control,"Proportion of patients alive and free of respiratory failure through the 30-day trial.|Change of the levels of the inflammatory cytokines prior, during and post drug infusion.|Change of the levels of MMP-2 and MMP-9 prior, during and post drug infusion.","University of Maryland, Baltimore",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HP-00091372,1-Nov-20,30-Nov-21,31-Jan-22,28-Oct-20,,28-Oct-20,"University of Maryland Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04606069
NCT04573634,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition,START,Recruiting,No Results Available,Covid19|SARS-CoV Infection,,Prevalence of COVID-19|PCR Conversion in Exposed Individuals,Jill M Kolesar|University of Kentucky,All,"18 Years and older   (Adult, Older Adult)",,960,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHARM-20-COVID19-START,15-May-20,31-Dec-23,31-Dec-23,5-Oct-20,,5-Oct-20,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04573634
NCT04401410,Anti-SARS Cov-2 T Cell Infusions for COVID 19,BATIT,Recruiting,No Results Available,SARS-CoV 2|Viral Infection|COVID 19,Biological: Dose Finding Phase (MTD)|Biological: Partially HLA-matched SARS-CoVSTs|Other: Routine care (no SARS-CoVSTs),Dose Escalation Phase: Rate of Dose Limiting Toxicities by CTCAE 5.0 [14 days post infusion]|Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge]|Randomized Trial: Rate of Treatment-related adverse events (tAE) by CTCAE 5.0 [14 days post-randomization],"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|AlloVir",All,"18 Years and older   (Adult, Older Adult)",Phase 1,58,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-47739 BAT IT,4-Nov-20,15-Aug-21,15-Aug-21,26-May-20,,9-Nov-20,"Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04401410
NCT04640038,Contrast Enhanced Ultrasound in COVID-19,,Recruiting,No Results Available,Covid19|MIS-C,Drug: Sulfur hexafluoride lipid-type A microspheres,Estimate the proportion of patients with normal perfusion versus area(s) of hypoperfusion in heart and kidneys,Children's Hospital of Philadelphia,All,up to 17 Years   (Child),Phase 3,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,20-017501,Dec-20,Dec-22,Dec-22,23-Nov-20,,7-Dec-20,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04640038
NCT04530539,The Effect of Melatonin and Vitamin C on COVID-19,,Not yet recruiting,No Results Available,Covid19|SARS-CoV Infection,Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey,Symptom Severity|Symptom progression,Lancaster General Hospital,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",2020-68,18-Sep-20,1-Sep-21,1-Dec-21,28-Aug-20,,16-Sep-20,"Lancaster General Health, Lancaster, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04530539
NCT04344600,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,PROTECT,Recruiting,No Results Available,Sars-CoV2,Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline,Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples,Johns Hopkins University|Eiger BioPharmaceuticals,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,164,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,IRB00248163,29-May-20,Jun-21,Dec-21,14-Apr-20,,20-Aug-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04344600
NCT04344457,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",COVID-19,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product,Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement,"Perseverance Research Center, LLC|Athena Medical Group",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIZ-PRC-COVID-19,16-Apr-20,20-Jun-20,30-Sep-20,14-Apr-20,,1-Jul-20,"Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04344457
NCT04510194,MET-COVID -- Outpatient Metformin Use for COVID-19,,Recruiting,No Results Available,Covid19|SARS-CoV Infection,Drug: Metformin|Drug: Placebo,Change in C-Reactive Protein|Change in Albumin|Change in Viral load|Emergency Department Utilization|Incidence of Possible COVID-19 Symptoms|WHO Disease Progression Scale,University of Minnesota,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GIM-2020-29324,1-Jan-21,Sep-21,Sep-21,12-Aug-20,,15-Jan-21,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04510194
NCT04547283,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,,Recruiting,No Results Available,Covid19|Respiratory Failure,Other: Usual Care|Other: APPS,Average S/F ratio|Time spent with S/F ratio < 315|Highest oxygen support|Number of patients requiring ICU admission during study period|Number of patients requiring ICU admission during hospitalization|Number of patients experiencing who die prior to discharge|Number of patients requiring intubation|Hospital length of stay,Atrium Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,06-20-03E,14-Jun-20,20-Sep-20,30-Sep-20,14-Sep-20,,14-Sep-20,"Carolinas Medical Center, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04547283
NCT04399889,hCT-MSCs for COVID19 ARDS,,Recruiting,No Results Available,COVID|Corona Virus Infection|COVID19,Biological: human cord tissue mesenchymal stromal cells,Safety of the Investigational Product|Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00105410,18-Jun-20,1-Apr-21,31-Jul-21,22-May-20,,22-Jun-20,"Duke Hospital, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04399889
NCT04362111,Early Treatment of Cytokine Storm Syndrome in Covid-19,,Recruiting,No Results Available,Cytokine Storm|COVID-19,Drug: Anakinra|Drug: Normal saline,Percentage of patients discharged from the hospital alive and without the need for mechanical ventilation.|Percentage of subjects with 25% change (decrease) in cytokine storm markers at 48 hours|Percentage of subjects without increase in oxygen requirement and no increase in oxygen delivery/respiratory support measures after 48 hours.|Average time in days to achieve sustained ≥93% oxygen saturation without oxygen/respiratory support|Percentage of subjects with resolution of laboratory markers of Cytokine Storm syndrome|Percentage of subjects who develop bacterial or fungal or non-Covid-19 viral infection|Percentage of subjects who develop neutralizing antibody to Covid-19,University of Alabama at Birmingham,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Chatham-Cytokine Covid-19,29-Jul-20,Jan-21,Mar-21,24-Apr-20,,11-Sep-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04362111
NCT04397796,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,,Recruiting,No Results Available,COVID,Biological: BM-Allo.MSC|Biological: Placebo,Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs,"NantKwest, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",QUILT-COVID-19-MSC,3-Aug-20,Jun-21,Jun-21,21-May-20,,7-Aug-20,"St. Francis Medical Center, Lynwood, California, United States",,https://ClinicalTrials.gov/show/NCT04397796
NCT04628000,Baseline Vitamin D Deficiency and COVID-19 Disease Severity,,Recruiting,No Results Available,Vitamin D Deficiency|Covid19,Other: Vitamin D,LOS duration in days|Supp O2 flow volume in L/min,Parkview Medical Center,All,"18 Years to 100 Years   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PIRB78,27-Oct-20,14-Oct-21,14-Apr-22,13-Nov-20,,16-Nov-20,"Parkview Medical Center, Pueblo, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04628000
NCT04616001,IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation,,Not yet recruiting,No Results Available,Covid19|SARS-CoV Infection,Drug: IVIG,Hospital length of stay|Human metabolome and proteome,Sharp HealthCare,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-IVIG VENT|2010902,1-Nov-20,30-Jun-21,30-Jun-21,4-Nov-20,,4-Nov-20,"Sharp Memorial Hospital, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04616001
NCT04700137,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",MHAPPS,Not yet recruiting,No Results Available,Covid19|Mental Health,Other: Caring Contacts Plus Introductory Phone Call (CC+)|Other: Caring Contacts without an introductory phone call (CC),Loneliness as measured by the National Institutes of Health (NIH) Toolbox Social Relationship Scale for Loneliness|Suicidal Ideation & Behavior as measured by the Columbia Suicide Severity Rating Scale|Suicide Attempts & Self-Harm as measured by the Columbia Suicide Severity Rating Scale|Perceived Burdensomeness & Thwarted Belongingness as measured by the Interpersonal Needs Questionnaire (INQ15)|Psychological Stress as measured by the National Institutes of Health (NIH) Toolbox Stress and Self-Efficacy Scales Perceived Stress measure|Alcohol and Illicit Drug Use as measured by questions adapted from Youth Risk Behavior Survey and related to COVID-19|Depression as measured by the Patient Health Questionnaire (PHQ-9)|Anxiety as measured by the Generalized Anxiety Disorder 7 Item Scale (GAD-7)|Attendance at Mental Healthcare Appointments: Self-Report,"St. Luke's Health System, Boise, Idaho|Patient-Centered Outcomes Research Institute|Idaho Suicide Prevention Hotline (Jannus, Inc.)|University of Washington",All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,660,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,20-0052|PCORI HIS-2018C3-14695,4-Jan-21,3-Jan-22,3-Jan-22,7-Jan-21,,8-Jan-21,"St. Luke's Health System, Boise, Idaho, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04700137/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04700137
NCT04480411,Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients,,Not yet recruiting,No Results Available,Diagnoses Disease|Covid19,Behavioral: Doctorgram Patient Kit,Patient provider experience survey score|Provider experience survey score|Use of personal protective improvement|Number of in-patient encounters with COVID patients as a measure of provider exposure to high risk illness,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,56472,Jan-21,Dec-21,Dec-21,21-Jul-20,,25-Nov-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04480411
NCT04318444,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),,Recruiting,No Results Available,COVID-19|Corona Virus Infection,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of participants with symptomatic, lab-confirmed COVID-19.",Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AAAS9676,29-Mar-20,Mar-21,Mar-22,24-Mar-20,,27-Apr-20,"Columbia University Irving Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04318444
NCT04389671,The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19,,Not yet recruiting,No Results Available,COVID-19|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS),Drug: Lucinactant,Oxygenation index (OI) area under the curve (AUC)0-12|FiO2|PaO2|Oxygenation from pulse oximetry (SpO2)|P/F ratio|Ventilation Index (VI)|Lung compliance,Windtree Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,02-CL-2001a,Oct-20,Mar-21,Apr-21,15-May-20,,8-Oct-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04389671
NCT04513990,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),END CoV-2,Recruiting,No Results Available,COVID-19 Infection,Procedure: Biospecimen Collection|Other: Questionnaire Administration,Sensitivity of diagnostic test|Specificity of diagnostic test|Concordance of the novel point-of-care diagnostic test|Positive predictive value (PPV) of the novel point-of-care diagnostic test|Negative predictive value (NPV) of the novel point-of-care diagnostic test|Viral load metrics|Disease progression,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|William Marsh Rice University,All,"Child, Adult, Older Adult",Not Applicable,1500,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2020-0318|NCI-2020-03470,9-Apr-20,30-Apr-21,30-Apr-21,14-Aug-20,,17-Aug-20,"Lyndon Baines Johnson General Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04513990
NCT04682548,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,,Not yet recruiting,No Results Available,Multiple Sclerosis|Covid19,,Seropositivie Rate Against SARS-CoV-2|T Cell Response,NYU Langone Health,All,18 Years to 60 Years   (Adult),,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-01799,Jan-21,Dec-21,Dec-21,23-Dec-20,,23-Dec-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04682548
NCT04402944,Pulmozyme to Improve COVID-19 ARDS Outcomes,,Recruiting,No Results Available,COVID,Drug: Pulmozyme|Drug: Placebo,Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality.,Boston Children's Hospital|Brigham and Women's Hospital,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P00035140,5-Jul-20,31-May-21,31-Dec-21,27-May-20,,26-Oct-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04402944
NCT04390191,Early CPAP in COVID-19 Confirmed or Suspected Patients,PAP-COVID,Recruiting,No Results Available,COVID-19|COVID|Coronavirus,Device: Continuous Positive Airway Pressure,Efficacy Endpoint composite score|Time to ICU admission|Time to Intubation and mechanical ventilation|14 day and 28 day mortality|Conversion rate of COVID household members in CPAP vs control|Clinical COPD Questionnaire (CCQ)|Percentage of patients electing to continue CPAP for greater than 72 hours|Degree of improvement in oxygen saturation|Time to hospital admission or ED,"Icahn School of Medicine at Mount Sinai|Itamar Medical LTD|Community Surgical Supply of Toms River, Inc|Philips Healthcare",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 20-0900,7-May-20,Apr-21,May-21,15-May-20,,15-May-20,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04390191
NCT04393961,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,,Recruiting,No Results Available,COVID19|COVID-19|Coronavirus,Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette,Does Participant Accurately Read Result|Acceptability and Usability of Tests|Social Distancing Behavior Change|COVID-19 Related Anxiety,ProofPilot|Radish Health|Sanesco,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,600,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,2458,5-Apr-20,29-Jul-20,29-Aug-20,19-May-20,,19-May-20,"ProofPilot Online App (https://p.proofpilot.com), New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04393961
NCT04581161,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,,Recruiting,No Results Available,Acute Respiratory Failure|Covid19,Device: Life2000® Ventilator,Life2000® Compared to HFNC (AIRVO)|PEEP level,Hill-Rom,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-RR-2020-004,28-Aug-20,Oct-20,Oct-20,9-Oct-20,,9-Oct-20,"Park Nicolette, Bloomington, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04581161
NCT04445220,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,,Recruiting,No Results Available,COVID-19|Acute Kidney Injury,Biological: SBI-101,Safety and tolerability as measured by incidence of IP-related serious adverse events,"Sentien Biotechnologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SBI-101-02,19-Nov-20,Feb-21,Jul-21,24-Jun-20,,23-Nov-20,"University of New Mexico School of Medicine, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT04445220
NCT04359329,Estrogen Patch for COVID-19 Symptoms,,Recruiting,No Results Available,COVID,Drug: Estradiol patch,Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death,Sharon Nachman|Stony Brook University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,110,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SBU-EstrogenPatch-COVID19,20-Apr-20,15-Nov-20,15-Nov-20,24-Apr-20,,24-Apr-20,"Stony Brook University Hospital, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT04359329
NCT04389294,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,,Recruiting,No Results Available,COVID,Diagnostic Test: SARS-CoV2 serum antibody testing,Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation,"Hospital for Special Surgery, New York",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2020-0850,5-May-20,30-Sep-20,30-Oct-20,15-May-20,,15-May-20,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04389294
NCT04447222,Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors,,Recruiting,No Results Available,COVID-19 Infection|Malignant Solid Neoplasm,Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Survey Administration,"Coronavirus disease-2019 (COVID19)-specific psychological distress|The extent to which COVID-19 experiences are associated with COVID-19 specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and health-related quality of life (HRQoL)|Resiliency factors|Group differences in the outcomes assessed in the protocol relative to prior group assignment in the behavioral clinical trials|Health-related quality of life (HRQOL)|General quality of life (QOL)|Sleep disturbances|Depression|Changes in anxiety|Perceived availability of social support|Elements of mindfulness|Non-judgmental physical and emotional sensations associated with eating|The degree to which participants exercise compassion towards themselves under difficult circumstances and how this impacts their emotions|Physical activity|Intrusive thoughts, or the tendency to ruminate on or avoid thoughts about stressors|Basic fruit/vegetable intake|Usual intake of percentage energy from fat|Engagement in the core mind-body practices that the patients learned",M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",,1242,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2020-0425|NCI-2020-03900|P30CA016672,12-May-20,21-Jul-21,21-Jul-21,25-Jun-20,,25-Jun-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04447222
NCT03376854,Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS,CHILL-pilot,Recruiting,No Results Available,"Respiratory Distress Syndrome, Adult|Sars-CoV2",Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care,Targeted temperature compliance|Adverse event|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel|Complete blood count with differential count and platelet count|Biomarkers|Serum electrolytes|Blood glucose|28-day ventilator-free days,"University of Maryland, Baltimore",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP-00078506,1-May-18,30-Nov-20,31-Dec-20,19-Dec-17,,16-Jun-20,"University of Maryland Medical Center, Baltimore, Maryland, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/ICF_011.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/SAP_012.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/Prot_013.pdf",https://ClinicalTrials.gov/show/NCT03376854
NCT04425720,Use of Remote Monitoring for COVID-19 Patient,RPM,Recruiting,No Results Available,COVID,Device: LifeSignals Biosensor 1AX*|Other: Standard of Care,Monitored versus Non-Monitored in-patient admission|Emergency Department Visits|Length of stay|patient satisfaction|the incidence of mechanical ventilation and ECMO|serious adverse events,Montefiore Medical Center,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2020-11824,1-Sep-20,1-Jun-21,1-Jun-21,11-Jun-20,,12-Nov-20,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04425720
NCT04388709,Interferon Lambda Therapy for COVID-19,,Not yet recruiting,No Results Available,SARS-CoV-2,Drug: Peginterferon Lambda-1A,Number of participants with resolution of hypoxia|Number of adverse events.|Days with fever|Time to resolution of fever|Rate of progression to requiring critical care|Overall survival|Time to discharge,Icahn School of Medicine at Mount Sinai|Eiger BioPharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 20-0820,Sep-20,May-21,May-21,14-May-20,,16-Jun-20,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04388709
NCT04474301,Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic,,Recruiting,No Results Available,COVID-19 Infection|Melanoma,Other: Survey Administration,Experiences during the COVID-19 pandemic|COVID-19-specific psychological distress|COVID-19-specific health|COVID-19-specific financial and social disruptions|COVID-19-specific perceived benefits and social support|COVID-19-specific health related quality of life (HRQoL)|Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL|Prior lifestyle data,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",,1152,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,2020-0470|NCI-2020-04587|P30CA016672,11-Jun-20,1-Jul-21,1-Jul-21,16-Jul-20,,16-Jul-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04474301
NCT04374019,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,,Recruiting,No Results Available,COVID|Sars-CoV2,Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua|Drug: Artesunate,Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function,Susanne Arnold|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-20-COVID-01-PMC,1-May-20,May-21,May-21,5-May-20,,6-Nov-20,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04374019
NCT04630015,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth,,Recruiting,No Results Available,COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Other: Survey Administration,Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Anxiety Short Form over time|Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Depression Short Form over time|Changes in the Functional Assessment of Cancer Therapy (FACT-G) scores,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20805|NCI-2020-08530,31-Aug-20,1-Aug-23,31-Dec-23,16-Nov-20,,17-Nov-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04630015
NCT04424901,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,TOLD,Recruiting,No Results Available,COVID-19 Pneumonia|Vascular Complications,Drug: Dipyridamole,Coagulation system|Viral Detection,UConn Health,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-192-2.F,3-May-20,1-May-21,30-May-21,11-Jun-20,,11-Jun-20,"UConn Health, Farmington, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04424901
NCT04373044,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",,Recruiting,No Results Available,Symptomatic COVID-19 Infection Laboratory-Confirmed,Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration,Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events,University of Southern California|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,144,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0S-20-3|NCI-2020-02685|P30CA014089,1-May-20,1-May-21,1-May-22,4-May-20,,2-Jun-20,"Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04373044
NCT04408040,Use of Convalescent Plasma for COVID-19,,Recruiting,No Results Available,COVID,Biological: Convalescent Plasma,Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection|Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate,"Northside Hospital, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,700,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NSH 1281,14-Jul-20,31-Jul-22,31-Jul-22,29-May-20,,28-Jul-20,"Northside Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04408040
NCT04584684,Mouth Rinses for Inactivation of COVID-19,MOR,Recruiting,No Results Available,Covid19|Coronavirus Infection|SARS-CoV-2 Infection,Drug: 1.5-2% w/v Hydrogen Peroxide|Drug: 0.12% Chlorhexidine Gluconate|Drug: 21% Ethanol plus essential oils|Drug: 1% w/v Povidone-iodide|Drug: 0.075% Cetylpyridinium Chloride|Other: Saline,Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 15 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 30 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 45 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 60 Minutes,"University of North Carolina, Chapel Hill",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,480,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",20-2040,18-Dec-20,Sep-22,Sep-23,14-Oct-20,,11-Jan-21,"General and Oral Health Center, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04584684
NCT04472611,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,COLSTAT,Not yet recruiting,No Results Available,SARS-CoV-2,Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin,COVID 19 Severity,Yale University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,466,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2000027950,1-Aug-20,1-Aug-21,1-Aug-22,15-Jul-20,,31-Jul-20,"Yale New Haven Hosptial System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04472611
NCT04646044,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,,Recruiting,No Results Available,Covid-19|Coronavirus Disease 2019,Drug: Bempegaldesleukin|Drug: Standard of Care|Other: Placebo,"AUC of BEMPEG/standard of care (SOC) (PK).|Cmax of BEMPEG /SOC (PK).|Tmax of BEMPEG /SOC (PK).|Incidence of adverse events.|Incidence of treatment emergent adverse events (TEAEs).|Incidence of serious adverse events (SAEs).|Incidence of dose limiting toxicities (DLT) for BEMPEG.|Presence and levels of anti-drug antibodies directed to BEMPEG.|Fold change from baseline in absolute lymphocyte count by Central Laboratory.|Percentage of patients who require supplemental oxygen.|Change from baseline on the daily collection World Health Organization (WHO) Clinical Progression Scale, an 11-point clinical status ordinal scale.",Nektar Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-214-34,13-Nov-20,28-Jan-21,27-Mar-21,27-Nov-20,,27-Nov-20,"Investigator Site, Hialeah, Florida, United States|Investigator site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04646044
NCT04482673,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,VitD-COVID19,Recruiting,No Results Available,COVID-19|Vitamin D Deficiency|Respiratory Viral Infection,Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo,"Change in total circulating 25(OH)D concentration|Change in total circulating 25(OH)D concentration in COVID-19 positives|Change in SARS-CoV-2 antibody titers|Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha|Respiratory symptoms|Signs and symptoms of rhino/sinusitis|NCI Dietary Intake|Charlson Comorbidity survey|Paffenberger Physical Activity Assessment|Perceived stress|Pandemic stress|NEO-Personality Inventory|GrassrootsHealth Monthly Health assessment",Medical University of South Carolina|Grassroots Health Nutrition Institute|ZRT Laboratory,All,"50 Years and older   (Adult, Older Adult)",Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",99939,31-Jul-20,31-Dec-21,31-Dec-21,22-Jul-20,,4-Aug-20,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04482673
NCT04328012,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,COVIDMED,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: lopinavir/ritonavir|Drug: Losartan|Drug: Placebos,National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival,Bassett Healthcare|Reid Health|Goshen Health System,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,4000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1581969,6-Apr-20,1-Jan-21,1-Apr-21,31-Mar-20,,20-Aug-20,"Bassett Medical Center, Cooperstown, New York, United States",,https://ClinicalTrials.gov/show/NCT04328012
NCT04379089,Neurologic Manifestations of COVID 19 in Children,,Recruiting,No Results Available,COVID|Neurologic Manifestations,Other: Observational study only,Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19|Associations between prescription of empiric COVID-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed COVID-19,University of Pittsburgh|University of Utah|Johns Hopkins University,All,up to 17 Years   (Child),,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STUDY20040154,29-Apr-20,31-Dec-21,31-Dec-22,7-May-20,,7-May-20,"UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04379089
NCT04421391,QuadraMune(TM) for Prevention of COVID-19,,Recruiting,No Results Available,Covid19|Coronavirus|SARS-CoV 2,Dietary Supplement: QuadraMune(TM),Prevention of COVID-19|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events,Therapeutic Solutions International,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,500,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QuadraMune002,8-Jun-20,1-Nov-20,8-Nov-20,9-Jun-20,,9-Jun-20,"Therapeutic Solutions International, Oceanside, California, United States",,https://ClinicalTrials.gov/show/NCT04421391
NCT04392323,Incidence of COVID-19 Test Conversion in Post-surgical Patients,,Recruiting,No Results Available,Sars-CoV2,Diagnostic Test: COVID-19 PCR and Serology,COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19,Northwell Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB #20-0404,13-May-20,1-Jul-20,31-Jul-20,18-May-20,,18-May-20,"North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States",,https://ClinicalTrials.gov/show/NCT04392323
NCT04652674,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial,,Recruiting,No Results Available,"Covid19|Satisfaction, Patient|Telemedicine",Behavioral: Telemedicine visit|Behavioral: In-person postoperative visit,Patient satisfaction|Safety score|Length of visit|Patient willingness to recommend provider to peers rated from 1 to 5|Combined patient satisfaction score from 1st and 2nd postoperative visits|Distance (in kilometers) of patient's primary residence to the clinic location,Cedars-Sinai Medical Center,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,STUDY00000944,28-Sep-20,30-Jun-21,30-Jun-21,3-Dec-20,,3-Dec-20,"Cedars Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04652674
NCT04367831,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,IMPROVE,Recruiting,No Results Available,COVID-19|Venous Thromboses|Arterial Thrombosis,Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose,Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU|Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events|ICU Length of Stay|Total Number of Patients with the Need for Renal Replacement Therapy in the ICU|Total Number of Patients with Major bleeding in the ICU|Hospital Length of Stay,Columbia University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AAAS8980,2-May-20,Nov-20,Apr-21,29-Apr-20,,19-May-20,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04367831
NCT04603742,"Anakinra, COVID-19, Cytokine Storm",SOBI,Not yet recruiting,No Results Available,Covid19|Cytokine Storm|Mechanical Ventilation Complication,Drug: Anakinra|Drug: 0.9% Saline,Number of subjects alive without having required mechanical ventilation|60-day mortality|Patient Hospitalization|Patient Mechanical Ventilation,Weill Medical College of Cornell University|Swedish Orphan Biovitrum,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-07022396,Nov-20,Dec-21,Feb-22,27-Oct-20,,3-Nov-20,"Weill Cornell Medcine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04603742
NCT04517695,Blood Volume Assessment in COVID-19 ICU Patients - BVAC19,,Recruiting,No Results Available,Covid19|Acute Respiratory Distress Syndrome,Device: BVA-100,Total blood volume (absolute and relative to ideal body weight)|Red blood cell volume (absolute and relative to ideal body weight)|Plasma volume (absolute and relative to ideal body weight)|Transudation rate of the 131I albumin tracer|Incidence of new onset renal injury (failure) and requirement for renal replacement therapy,NYU Langone Health,All,"18 Years to 95 Years   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-00896,1-Aug-20,1-Feb-21,1-Feb-21,18-Aug-20,,18-Aug-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04517695
NCT04565080,Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD),,Recruiting,No Results Available,Parkinson's Disease|Functional Movement Disorders|COVID-19,,Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients.,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,150,NIH,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,10000159|000159-N,20-Jan-21,31-Dec-21,31-Dec-21,25-Sep-20,,15-Jan-21,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04565080
NCT04505592,Tenecteplase in Patients With COVID-19,,Recruiting,No Results Available,COVID-19|Respiratory Failure|ARDS,Drug: Tenecteplase|Drug: Placebo,Number of participants free of respiratory failure|Number of occurrences of bleeding|Number of participants with in-hospital deaths at 14 days|Number of participants with death at 28 days|Number of ventilator-free days|Number of respiratory failure-free days|Number of vasopressor-free days|Vasopressor doses at 24 hours|Vasopressor doses at 72 hours|P/F ratio at 24 hours|P/F ratio at 72 hours|Number of ICU-free days|Hospital length of stay|Number of participants with new-onset renal failure|Number of participants with need for renal replacement therapy,"Hooman Poor|Genentech, Inc.|Icahn School of Medicine at Mount Sinai",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GCO 20-1764,25-Sep-20,Jun-21,Dec-21,10-Aug-20,,24-Dec-20,"Mount Sinai Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04505592
NCT04568148,COVID-19 Biorepository,,Recruiting,No Results Available,Covid-19|SARS-CoV 2|Coronavirus|COVID,,Biospecimen Collection|Establishing Connections|Continuing COVID Research,University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Other|Time Perspective: Other,STUDY#00145602,15-Apr-20,31-Dec-21,31-Dec-21,29-Sep-20,,29-Sep-20,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04568148
NCT04385199,Convalescent Plasma for Patients With COVID-19,,Recruiting,No Results Available,Coronavirus Infection|Coronavirus|COVID,Biological: Convalescent plasma,Improvement in respiratory disease|ICU Length of Stay|Length of Stay|Ventilator days|Tolerability of convalescent plasma|Radiographic improvement,Henry Ford Health System,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13807,4-May-20,1-Aug-20,1-Aug-20,12-May-20,,12-May-20,"Henry Ford Hospital, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04385199
NCT04333953,COVID-19 in Patients With HIV,,Recruiting,No Results Available,HIV/AIDS|COVID-19|SARS-CoV-2,Other: No intervention,Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury,University of Missouri-Columbia,All,"Child, Adult, Older Adult",,500,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,262095,1-Apr-20,1-Oct-20,1-Oct-20,3-Apr-20,,7-Apr-20,"University of Missouri-Columbia, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04333953
NCT04349202,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,BLAST COVID-19,Recruiting,No Results Available,COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2,Diagnostic Test: EUROIMMUN assay,Prevalence COVID antibodies in employees of Beaumont Health|COVID-19 re-infection in participants positive for antibodies to SARS-CoV-2|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgA antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgA antibodies|Reproducibility of SARS-CoV-2 IgG antibody detection from dried blood spots|Stability of dried blood spots for SARS-CoV-2 IgG antibody detection|Effect of shipping on dried blood spot samples for SARS-CoV-2 IgG antibody detection|Accuracy of participant-performed blood spot collection for SARS-CoV-2 IgG antibody detection|Ease of participant-performed blood spot collection|Correlation of SARS-CoV-2 antibodies between immediate family members,William Beaumont Hospitals,All,"18 Years and older   (Adult, Older Adult)",,56000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-134,10-Apr-20,Jun-21,Jun-21,16-Apr-20,,25-Aug-20,"Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04349202
NCT04319731,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,,Recruiting,No Results Available,SARS CoV-2 Infection,Biological: Human Amniotic Fluid,Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation,University of Utah,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,131618,20-Mar-20,20-Mar-21,20-Mar-21,24-Mar-20,,17-Apr-20,"University of Utah Health, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04319731
NCT04448145,Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,,Recruiting,No Results Available,COVID-19|Corona Virus Infection|SARS-CoV 2,,Duration of SARS-CoV-2 viral persistence in naso/oropharyngeal samples|Duration of SARS-CoV-2 viral persistence in stool or rectal swab samples|Duration of SARS-CoV-2 viral persistence in semen samples|Duration of SARS-CoV-2 viral persistence in breast milk samples|Prevalence of cell immune responses|Duration of COVID-19 Symptoms|Prevalence of post-viral sequelae|Prevalence of SARS-CoV-2 persistence and bacterial/viral community structures,Columbia University,All,"7 Years and older   (Child, Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAS9722,26-Mar-20,1-Mar-21,1-Mar-21,25-Jun-20,,25-Jun-20,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04448145
NCT04492514,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,,Recruiting,No Results Available,COVID 19|SARS-CoV 2|Pneumonia,Drug: Mavrilimumab|Drug: Placebo,Primary Outcome Measure:|Secondary Outcome Measures:,"Kristin Hudock|Kiniksa Pharmaceuticals, Ltd.|University of Cincinnati",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IND 149353,20-May-20,31-May-21,31-May-21,30-Jul-20,,30-Jul-20,"University of Cincinnati, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04492514
NCT04540484,COVID-19 IgG Formation in Physicians at ALGH and Their Household Members,,Recruiting,No Results Available,Covid19|SARS-CoV Infection|Communicable Disease,,Identifying positive COVID-19 IgG formation|Physician Prevalence of COVID-19 serum IgG|Household Member Prevalence of COVID-19 serum IgG|Physician Risk of Exposure|Physician and Household Member Transmission|Asymptomatic Infection|PPE Use and Positivity|Antibody Persistence,Advocate Health Care|Terika Richardson- President's Fund|Medical Staff Fund- Dr. John Ruge|Advocate Foundation- Ally Regnier and Chrisy Santos,All,"18 Years and older   (Adult, Older Adult)",,900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1606472-1|M5500436,26-Aug-20,24-Sep-21,24-Sep-21,7-Sep-20,,9-Sep-20,"Advocate Lutheran General Hospital, Park Ridge, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04540484
NCT04463004,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,,Recruiting,No Results Available,COVID-19|Sars-CoV2|Pneumonia,Drug: Mavrilimumab|Drug: Placebos,Proportion of subjects alive and off of oxygen at day 14|Proportion of subjects alive and without respiratory failure at 28 days,"Virginia Commonwealth University|Kiniksa Pharmaceuticals, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HM20019145,2-Sep-20,Aug-21,Aug-21,9-Jul-20,,10-Sep-20,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04463004
NCT04366986,International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,IRCEP,Recruiting,No Results Available,Covid-19,Other: Tested for SARS-CoV-2 (regardless of the result)|Other: Clinical diagnosis of COVID-19 by a health care professional,Pregnancy outcomes|Birth outcomes,Pregistry|Harvard School of Public Health,Female,"18 Years and older   (Adult, Older Adult)",,25000,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1,23-Jun-20,30-Apr-24,30-Apr-24,29-Apr-20,,25-Jun-20,"Pregistry, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04366986
NCT04381013,Emergency Ventilator Splitting Between Two or More Patients (COVID-19),,Not yet recruiting,No Results Available,COVID-19,Device: Emergency Ventilator Splitter,Completion of 1-minute test|Completion of 24-hour test,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,57573,Mar-21,Apr-21,Apr-21,8-May-20,,14-Dec-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04381013
NCT04652765,Camostat With Bicalutamide for COVID-19,COMBO,Not yet recruiting,No Results Available,Covid19|SARS-CoV Infection|Coronavirus Infection,Drug: Camostat Mesilate|Drug: Bicalutamide 150 mg,Number of participants requiring hospitalization|Number of participants experiencing symptoms|Number of drug-related adverse events|Number of drug-related serious adverse events|All-cause mortality,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"60 Years and older   (Adult, Older Adult)",Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV2005|IRB00254142,Jan-21,Jan-23,Jan-23,3-Dec-20,,3-Dec-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04652765
NCT04345601,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),,Not yet recruiting,No Results Available,Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19,Biological: Mesenchymal Stromal Cells|Other: Supportive Care,Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-47561 MSC for COVID-19,Dec-20,Sep-22,Sep-22,14-Apr-20,,12-Nov-20,"Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04345601
NCT04465981,Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins,SARS-CoV-2,Recruiting,No Results Available,COVID-19|Corona Virus Infection,Diagnostic Test: Sampling,Detection Test of COVID-19,INanoBio Inc.|TMC HealthCare,All,"18 Years and older   (Adult, Older Adult)",,80,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Other,INANO-CV1,Jul-20,Dec-20,Jun-21,10-Jul-20,,27-Jul-20,"TMC HealthCare, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04465981
NCT04418557,COVID-19 and Obstetric Transmission,COVIDOB,Recruiting,No Results Available,COVID|Pregnancy Complications,Diagnostic Test: RT-PCR and antibody testing,Presence of COVID-19 virus|Presence of antibodies to COVID-19 virus,University Hospitals Cleveland Medical Center|Cuyahoga County Board of Health|The Cleveland Clinic|MetroHealth Medical Center|Case Western Reserve University,Female,18 Years to 50 Years   (Adult),,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20200479,28-Apr-20,31-Jul-21,31-Jul-21,5-Jun-20,,9-Jun-20,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04418557
NCT04397939,Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19,,Recruiting,No Results Available,COVID-19|Myocardial Reperfusion Injury|Cardiovascular Diseases,,Number of In-Hospital Death|Length of Stay|Number of Successful Treatment,Icahn School of Medicine at Mount Sinai,All,"Child, Adult, Older Adult",,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,GCO 20-0965,8-May-20,Mar-21,Mar-22,21-May-20,,16-Jun-20,"Mount Sinai Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04397939
NCT04435522,Maraviroc in Patients With Moderate and Severe COVID-19,,Recruiting,No Results Available,COVID,Drug: Maraviroc,Rate of Completion|Clinical improvement at Day 7|Change in Chitinase 3-like 1(Chi3l1) (ng/mL)|Change in Interleukin-6 (IL-6) (pg/mL)|Change in CCL5 (RANTES) (ng/mL)|Mortality|Time to Discharge|Days on mechanical ventilation,Rhode Island Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1611471-1,21-Sep-20,31-Dec-20,Jan-21,17-Jun-20,,25-Sep-20,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT04435522
NCT04565392,Study of Famotidine With Vitamins C and D for Pandemic Coronavirus,CDFCOV19,Not yet recruiting,No Results Available,Covid19,Drug: Famotidine 20 MG,Negative outcome|Positive response|Relapse|tolerability of ascorbic acid|Unexpected serious adverse event,drpykessupplements.com,All,"18 Years and older   (Adult, Older Adult)",Phase 4,216,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pykonsult 201,1-Dec-20,30-Jun-21,31-Jul-21,25-Sep-20,,25-Sep-20,"Pykonsult headquarters, New Fairfield, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04565392
NCT04570397,Ravulizumab and COVID-19,,Recruiting,No Results Available,Covid19|Thrombotic Microangiopathies|Acute Kidney Injury,Drug: Ravulizumab,Assess the efficacy of ravulizumab to ameliorate SARS-CoV-2 (COVID-19)-induced acute kidney injury manifesting as thrombotic microangiopathy.|Evaluation of pharmacokinetics of ravulizumab in participants with COVID-19,Brigham and Women's Hospital,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,92420,18-Dec-20,May-21,Nov-21,30-Sep-20,,14-Jan-21,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04570397
NCT04639375,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),,Recruiting,No Results Available,SARS-CoV-2,Biological: Vaccinated with polio vaccine (IPV),Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination|Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine,E-MO Biology Inc,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,25,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,EMO-001,15-Nov-20,15-Jan-21,15-Jan-21,20-Nov-20,,27-Nov-20,"Rac Ii Md, National City, California, United States",,https://ClinicalTrials.gov/show/NCT04639375
NCT04408183,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,,Recruiting,No Results Available,SARS-CoV 2|Infection,Drug: GLS-1200|Drug: Placebo,"Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0|Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group|Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome.","GeneOne Life Science, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,225,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",T2R-002,1-Jun-20,Feb-21,Mar-21,29-May-20,,3-Dec-20,"Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04408183
NCT04574869,A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure,,Not yet recruiting,No Results Available,Acute Lung Injury|ALI|COVID-19,Drug: RLS-0071|Drug: Placebo,"Frequency and severity of Adverse Events, including Serious Adverse Events, by treatment group and dose level, including the frequency of premature discontinuation of study intervention due to Adverse Events.|Incidence of clinically significant changes from baseline in clinical laboratory values, ADA, autoantibody panel, vital signs, physical examination, ECG, radiography, and concomitant medications.|Number of patients with positive ADA titers after receiving a single dose (Part A) or multiple doses (Part B) of RLS-0071.|Estimates of single-dose maximum plasma concentration (Cmax) for RLS-0071.|Estimates of single-dose time to maximum plasma concentration (Tmax) for RLS-0071.|Estimates of single-dose minimum plasma concentration (Cmin) for RLS-0071.|Estimates of single-dose area under the plasma concentration-time curve (AUC) for RLS-0071.|Estimates of single-dose apparent total volume of distribution for RLS-0071.|Estimates of single-dose apparent total body clearance for RLS-0071.|Estimates of single-dose apparent first-order terminal elimination half-life for RLS-0071.|Estimates of multiple-dose maximum plasma concentration (Cmax) for RLS-0071.|Estimates of multiple-dose peak time to maximum plasma concentration (Tmax) for RLS-0071.|Estimates of multiple-dose area under the plasma concentration-time curve (AUC) for RLS-0071.|Estimates of multiple-dose average plasma drug concentration observed (Cavg) for RLS-0071.|Estimates of multiple-dose trough concentration prior to dose administration (Ctrough).|Estimates of multiple-dose apparent total volume of distribution for RLS-0071.|Estimates of multiple-dose apparent total body clearance for RLS-0071.|Estimates of multiple-dose apparent first-order terminal elimination half-life for RLS-0071.|Assessment of dose response relationship of single and multiple doses of RLS-0071 on C1q levels and the complement activity assay.|Overall survival.|Incidence of progression to respiratory failure requiring mechanical ventilation.|Incidence of transfer to the ICU.|Duration of hospitalization after treatment (days).|Incidence, severity, and duration after treatment (days) of fever (≥ 39.0°C).|Incidence, severity, and duration after treatment (days) of cough per investigator assessment of CTCAE's latest version.|Duration of requirement for supplemental oxygen after treatment (days).|PaO2/FiO2|Incidence, severity, and duration after treatment (days) of new cardiovascular events as assessed by the investigator (e.g. myocardial infarction, stroke, TIA, ischemic limb) with CTCAE's latest version.|Incidence, severity, and duration after treatment (days) of respiratory acidosis as assessed by the investigator with CTCAE's latest version.|Incidence and duration after treatment (days) of dialysis.|Levels of complement activity (eg, CH50).|Levels of C1q (free and bound to RLS-0071).","ReAlta Life Sciences, Inc.",All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,42,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RLS-0071-102,Oct-20,Mar-21,Jul-21,5-Oct-20,,5-Oct-20,"Prestige Clinical Research Center, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT04574869
NCT04627675,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),CORVax12,Not yet recruiting,No Results Available,SARS-CoV-2,Drug: CORVax|Drug: IL-12 plasmid|Device: Cliniporator,Toxicity|Medically Attended Adverse Events (MAAEs),Providence Health & Services|OncoSec Medical Incorporated,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2020000320 CORVax12,Dec-20,May-21,May-22,13-Nov-20,,13-Nov-20,"Providence Portland Medical Center, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT04627675
NCT04526769,Detecting SARS-CoV-2 in Tears,,Not yet recruiting,No Results Available,COVID|COVID-19|Corona Virus Infection|SARS-CoV-2,Diagnostic Test: Tear Collection,COVID-19 Virus Detection in Tears|COVID-19 Virus Detection in Nasopharyngeal Swabs|Expression of ACE2 in Lacrimal Gland Samples|Expression of ACE2 in Ocular Surface Samples,University of Minnesota,All,"18 Years and older   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,STUDY00009512,Sep-20,Apr-21,Apr-21,26-Aug-20,,26-Aug-20,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04526769
NCT04498442,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",,Recruiting,No Results Available,Covid19|Stress|Anxiety Depression,Behavioral: Simha Kriya|Behavioral: Reading a Book,Change in Perceived Stress Levels|Changes in Resilience Levels|Changes in Covid-19 Prevalence|Changes in self-reported duration of fever and respiratory symptoms in COVID-19 positive participants|Changes in self-reported readiness to return to work in COVID-19 positive participants,Beth Israel Deaconess Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2020P000433,22-May-20,31-Oct-20,31-Dec-20,4-Aug-20,,8-Oct-20,"Beth Israel Deaconess Medical Centre, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04498442
NCT04664309,Understanding Immunity to the COVID-19 Vaccines,,Not yet recruiting,No Results Available,COVID-19|Immunity|Vaccine,Other: No intervention,Percentage of participants with immunity to COVID-19 vaccines over time,Stanford University|National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 64 Years   (Adult),,1000,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB-59566|5U19AI057229-17,Jan-21,Jan-23,Jan-23,11-Dec-20,,22-Dec-20,"Stanford University, Hospital, and Clinics, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04664309
NCT04331509,COVID-19 Symptom Tracker,,Recruiting,No Results Available,COVID-19,Other: No Intervention,Physical health symptoms|Lack of physical health symptoms|Fever,King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University,All,"18 Years and older   (Adult, Older Adult)",,10000000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-19 Symptom tracker,23-Mar-20,23-Mar-22,23-Mar-22,2-Apr-20,,7-Apr-20,"Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04331509
NCT04354155,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,,Recruiting,No Results Available,"Infection Viral|Thromboses, Venous|COVID-19",Drug: Enoxaparin Prefilled Syringe [Lovenox],Safety of in-hospital thromboprophylaxis|Median twice-daily enoxaparin dose,Neil Goldenberg|Johns Hopkins All Children's Hospital,All,"up to 18 Years   (Child, Adult)",Phase 2,38,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,COVAC-TP,2-Jun-20,Sep-22,15-Oct-22,21-Apr-20,,27-Jul-20,"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT04354155
NCT04551911,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,,Recruiting,No Results Available,Covid19|Coronavirus|SARS-CoV-2 Infection,Drug: Rayaldee 30Mcg Extended-Release (ER) Capsule|Drug: Placebo,Severity and duration of disease as evidenced by COVID-19 symptoms using the FLU-PRO© questionnaire.|Concentration of serum total 25-hydroxyvitamin D maintained at or above 50 ng/mL.,"OPKO Health, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTAP101-CL-2014,26-Oct-20,Feb-21,Apr-21,16-Sep-20,,29-Oct-20,"OPKO Investigative Site, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04551911
NCT04587258,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,,Recruiting,No Results Available,Breast Cancer|Colorectal Cancer|Covid19,Behavioral: Informational videos and social media campaigns encouraging cancer screening.,Increase screening rates for breast and colorectal cancer|Impact of screening on cancer care|Community Engagement|Barriers to cancer screening during COVID19.,Rhode Island Hospital|Blackstone Valley Community Health Care,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,1613494-3,28-Aug-20,1-Sep-22,1-Sep-22,14-Oct-20,,14-Oct-20,"Blackstone Valley Community Health Center, Pawtucket, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT04587258
NCT04705831,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,,Recruiting,No Results Available,Post-Viral Fatigue Syndrome|Post-Viral Disorder (Disorder)|Covid19,Drug: Ruconest,Neuropsychological Measures (BRIEF-A)|Neuropsychological Measures (RBANS)|Neuropsychological Measures (BDI II)|Neuropsychological Measures (MoCA)|Patient-Rate Questionnaires (FSS)|Patient-Rate Questionnaires (MIDAS)|Patient-Rate Questionnaires (HIT)|Patient-Rate Questionnaires (Activities)|Patient-Rate Questionnaires (SF)|Patient-Rate Questionnaires (GSRS)|Patient-Rate Questionnaires (SF-36)|Neurological Exam (0)|Neurological Exam (9)|Neurological Exam (17)|Immunological Biomarkers (Toll)|Immunological Biomarkers (GAD)|Immunological Biomarkers (Com)|Immunological Biomarkers (Ig)|Immunological Biomarkers (IgG)|Immunological Biomarkers (TH/TH),IMMUNOe Research Centers,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",IIS202001-Neuroimmune,30-Dec-20,Jan-22,Jan-22,12-Jan-21,,12-Jan-21,"IMMUNOe Research Centers, Centennial, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04705831
NCT04495842,The Effect of Aromatherapy on COVID-19-induced Anxiety,,Recruiting,No Results Available,Stress|Covid19|Anxiety,Other: Essential Oil Blend|Other: Control Blend,Change from baseline in state anxiety on the State portion of the State Trait Anxiety Scale (STAI-S) at 15 minutes,Franklin School of Integrative Health Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,20-7-5600,1-Oct-20,31-Mar-21,30-Jun-21,3-Aug-20,,19-Oct-20,"Franklin School of Integrative Health Sciences, Franklin, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04495842
NCT04342195,Acquiring Convalescent Specimens for COVID-19 Antibodies,,Recruiting,No Results Available,COVID-19|Coronavirus Infection|Corona Virus Infection,Procedure: Blood draw,Number of antibodies against coronaviruses isolated and identified from patient samples,Columbia University,All,"18 Years to 65 Years   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,AAAS9517,25-Mar-20,Mar-21,Mar-21,10-Apr-20,,9-Jul-20,"Columbia University Irving Medical Center/NYP, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04342195
NCT04476589,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,PREDICT-COVID,Recruiting,No Results Available,Covid19|Coma|Consciousness Disorder,Diagnostic Test: Functional MRI,Disability Rating Scale score,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020P001616,1-Jul-20,30-Jun-22,30-Mar-23,20-Jul-20,,19-Oct-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04476589
NCT04661839,Phase 1 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered as a Single Dose or a Repeat Dose in Healthy Adults,,Recruiting,No Results Available,SARS-CoV-2,Biological: COVID-HIGIV|Other: Placebo (saline),Number of Subjects with Adverse Events (AEs) post-dosing|Number of Subjects with Adverse Events that Led to Discontinuation or Temporary Suspension of IV Infusion|Number of Subjects with AEs after a Single IV Infusion|Number of Subjects with SAEs after a Single IV Infusion|Number of Subjects with AEs after a Repeat IV Infusion|Number of Subjects with SAEs after a Repeat IV infusion|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies plus the additional area extrapolated to infinity (AUC0-inf) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after a single dose of COVID-HIGIV|Pharmacokinetics parameter of time at which Cmax occurs after a single dose of COVID-HIGIV|Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after a single dose (Cmin28d) of COVID-HIGIV|Pharmacokinetics parameter of terminal elimination constant after a single dose of COVID-HIGIV|Pharmacokinetics parameter of apparent terminal elimination half-life after a single dose of COVID-HIGIV|Pharmacokinetics parameter of systemic clearance after a single dose of COVID-HIGIV|Pharmacokinetics parameter of volume of distribution after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after initial dose and repeat dose of COVID-HIGIV.|Pharmacokinetics parameter of time at which Cmax occurs after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of accumulation ratios after repeat dose over initial dose of COVID-HIGIV,Emergent BioSolutions|United States Department of Defense,All,18 Years to 60 Years   (Adult),Phase 1,56,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EBS-CVH-003,Dec-20,Sep-21,Sep-21,10-Dec-20,,10-Dec-20,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04661839
NCT04685213,Electrical Stimulation for Critically Ill Covid-19 Patients,COVID-19,Recruiting,No Results Available,Covid19|Pain|Muscle Atrophy,Device: Electrical Stimulation|Device: Electrical Stimulation - Sham,Change in muscle function|muscle fatigue|Change in tissue oxygen saturation|Ankle circumference|Thigh circumference|Foot circumference|Venous Return Flow|Frailty|Length of stay|Major adverse events|instrumental activities of daily living scale|Community engagement Scale|Depression scale|Weight loss|Neuropathy|Change in muscle strength,"Baylor College of Medicine|Avazzia, Inc",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",H-47781,18-Aug-20,18-Aug-21,18-Aug-21,28-Dec-20,,28-Dec-20,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04685213
NCT04531618,Mother-infant Bonding During COVID-19,,Recruiting,No Results Available,Child Development|Mother-Infant Interaction|COVID-19,Behavioral: Family Nurture Intervention (FNI),Change in Welch Emotional Connection Score|Change in Maternal Caregiving Behavior Score (Acceptance versus Rejection)|Change in Maternal Caregiving Behavior Score (Sensitivity versus Insensitivity)|Change in Maternal Caregiving Behavior Score (Consideration versus Intrusiveness)|Change in Maternal Caregiving Behavior Score (Quality of Physical Contact)|Change in Maternal Caregiving Behavior Score (Quality of Vocal Contact)|Change in Maternal Caregiving Behavior Score (Effectiveness of Response to Baby's Crying)|Right and Left Frontal Mother & Infant EEG Synchrony|Heart Rate Variability (HRV),Columbia University,All,up to 72 Hours   (Child),Not Applicable,280,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AAAT0140,13-Aug-20,Dec-21,Dec-21,28-Aug-20,,31-Aug-20,"Morgan Stanley Children's Hopspital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04531618
NCT04464395,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,,Recruiting,No Results Available,COVID-19,Drug: CPI-006|Other: Standard of Care,Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19|Immunoglobulin Anti-SARS CoV-2 Levels|Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests|Duration of symptoms|Time to discharge|Rate of medical procedures|Difference in changes in serum/plasma immunoglobulin anti-SARS CoV-2 levels,"Corvus Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPI-006-002,1-Jul-20,31-Mar-21,31-Aug-21,9-Jul-20,,17-Dec-20,"El Centro Regional Medical Center, El Centro, California, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04464395
NCT04482712,Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS,RAPA-CARDS,Not yet recruiting,No Results Available,Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Respiratory Failure|Sars-CoV2,Drug: Rapamycin|Drug: Placebo,Survival rate|Change in Clinical Status assessed by the World Health Organization (WHO) scale|Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale,The University of Texas Health Science Center at San Antonio|Claude D. Pepper Older Americans Independence Center,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HSC20200489H,Jan-21,Jan-22,Jan-23,22-Jul-20,,30-Nov-20,"University Hospital System, San Antonio, Texas, United States|Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04482712
NCT04581811,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),,Recruiting,No Results Available,ARDS|Covid19|Acute Hypoxemic Respiratory Failure,Other: Prolonged Proned Positioning|Other: Traditional Proning Arm,Duration in prone position|Change in P:F ratio|Change in Drive Pressure|Unplanned extubations|Pressure ulcers|Line displacement|Duration of mechanical ventilation|Mortality|Rescue Interventions,University of Alabama at Birmingham,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-300005979,10-Nov-20,May-21,Jun-21,9-Oct-20,,13-Nov-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04581811
NCT04361253,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,(ESCAPE),Recruiting,No Results Available,COVID|Infectious Disease,Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP),Modified WHO Ordinal Scale (MOS) score,Brigham and Women's Hospital,All,"12 Months and older   (Child, Adult, Older Adult)",Phase 3,220,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2020P001215,30-Apr-20,Jun-21,Dec-21,24-Apr-20,,18-May-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04361253
NCT04385901,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,,Recruiting,No Results Available,SARS-CoV 2|SARS Pneumonia,Behavioral: Therapy Intervention,Change in 6 Minute Walk Test|Change in Short Form 35 (SF-36) Questionnaire|Change in Strength testing|Change in Peak Flow Meter Test,University of Missouri-Columbia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COVID19Recovery,19-May-20,19-Apr-22,19-Apr-22,13-May-20,,5-Jun-20,"Missouri Orthopedic Institute, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04385901
NCT04513314,Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium,,Not yet recruiting,No Results Available,"Covid19|Hyperactive Delirium|Pneumonia, Viral",Drug: Valproate|Drug: Quetiapine|Other: Standard of Care,Change from baseline RASS score of +3 or greater|Total dose of dexmedetomidine administered|Incidence of Treatment Emergent Adverse Events,University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",20200851,1-Nov-21,1-Nov-22,1-Nov-22,14-Aug-20,,10-Nov-20,"Jackson Memorial Hospital, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04513314
NCT04409834,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,COVID-PACT,Recruiting,No Results Available,COVID-19|Venous Thromboembolism|Arterial Thrombosis,Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution,Primary endpoint: Venous or arterial thrombotic events|Key secondary endpoint: Clinically evident venous or arterial thrombotic events,The TIMI Study Group,All,"18 Years and older   (Adult, Older Adult)",Phase 4,750,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CCCTN/TIMI COVID-PACT,5-Aug-20,May-21,May-21,1-Jun-20,,18-Aug-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04409834
NCT04347226,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,,Recruiting,No Results Available,Solid Tumor|Sars-CoV2|Hematological Malignancy,Drug: BMS-986253,Time to Improvement in the 7-point ordinal scale|Time to Death|Time to Intubation|Proportion of patients requiring ICU admission|Percentage Rate of Mortality at 1 month,Matthew Dallos|Bristol-Myers Squibb|Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,138,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAS9881,16-Apr-20,Sep-21,Sep-22,15-Apr-20,,8-Oct-20,"Columbia University Irving Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04347226
NCT04523181,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,,Recruiting,No Results Available,Covid-19,Drug: Antroquinonol|Drug: Placebo,recover ratio|Time to 2-point improvement|Duration of hospitalization|Time to virological clearance,Golden Biotechnology Corporation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,174,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GHCovid-2-001,8-Oct-20,31-Dec-20,31-Mar-21,21-Aug-20,,8-Dec-20,"Franciscan Health Michigan City, Michigan City, Indiana, United States|Ascension.Via Christi Research, Wichita, Kansas, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04523181
NCT04654481,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease|Chronic Cough|Covid19,Device: HCFWO|Other: Standard Care Plus Monitoring,Change in forced expiratory volume in one second (FEV1)|Change in Oxygen Saturation level|Change in Presence of Fever|Change in Presence of pneumonia symptoms via Community Acquired Pneumonia (CAP) Symptom Questionnaire|Change in Quality of life via Quality of Life Questionnaire-Respiratory (QOL-B)|Change in Mental health screening via Personal Health Questionnaire Depression Scale (PHQ-8)|Change in Mental health screening via General Anxiety Disorder-7 (GAD-7)|Change in COVID Symptom Checklist|AffloVest Usage,Icahn School of Medicine at Mount Sinai|International Biophysics Corporation|SPARK Healthcare,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,GCO 20-2667|ISMMS-AFF-20,Dec-20,Feb-21,Nov-21,4-Dec-20,,4-Dec-20,"Mount Sinai Beth Israel, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04654481
NCT04551378,The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors,,Recruiting,No Results Available,COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Other: Quality-of-Life Assessment|Other: Survey Administration,Coronavirus disease 2019 (COVID-19) specific psychological stress|Survey responses|Patient reported outcomes|Changes of survey responses|Changes in discrete responses|Incidence of survey question non-response,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,18 Years to 39 Years   (Adult),,600,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-0504|NCI-2020-06609,13-Jul-20,31-Dec-21,31-Dec-21,16-Sep-20,,16-Sep-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04551378
NCT04340479,The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,,Recruiting,No Results Available,COVID|Trauma|Ultrasound,Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation,Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients,"University of Colorado, Denver",All,"Child, Adult, Older Adult",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-0751,30-Jul-20,May-22,May-22,9-Apr-20,,24-Aug-20,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04340479
NCT04500600,Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,,Recruiting,No Results Available,COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Other: Quality-of-Life Assessment|Other: Questionnaire Administration,Experiences during the coronavirus disease 2019 (COVID-19) pandemic|COVID-19-specific psychological distress|COVID-19-specific health|COVID-19-specific financial and social disruptions|COVID-19-specific perceived benefits and social support|COVID-19-specific health related quality of life (HRQoL)|Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",,50000,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,2020-0473|NCI-2020-04604,11-Jun-20,1-Jul-21,1-Jul-21,5-Aug-20,,5-Aug-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04500600
NCT04490486,Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19,COVID-19,Not yet recruiting,No Results Available,COVID-19|Acute Respiratory Distress Syndrome|Corona Virus Infection,Biological: UCMSCs|Other: Placebo,Percent of participants with treatment related Serious Adverse Events (SAE)|Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptoms,Joshua M Hare|University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20200575,1-Mar-21,1-Jun-24,1-Jun-24,29-Jul-20,,9-Sep-20,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04490486
NCT04433949,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,RESCUE1-19,Recruiting,No Results Available,Pneumonia|Severe Acute Respiratory Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed,Other: Best Practice|Radiation: Low Dose Radiation Therapy,Time to clinical recovery|Freedom from ICU admission|Temperature|Heart rate|Systolic Blood pressure|Oxygen saturation|Supplemental oxygenation need|Respiratory rate|Glasgow Comma Scale from minimum of 3 to maximum of 15.|Performance status|Survival|Serial chest x-rays severe acute respiratory syndrome (SARS) scoring|Changes on computed tomography (CT) scans pre and post RT|CRP|Serum chemistry + complete blood cell (CBC) with differential|Blood gases pH(when available)|Albumin|Procalcitonin|Aspartate aminotransferase (AST)|Creatine kinase|Prothrombin time (PT)/partial thromboplastin time (PTT)|Troponin|Lactate|NT-pBNP (cardiac injury)|Gamma-glutamyl transferase (GGT)|Triglycerides|Fibrinogen|Changes in CD8 T cells|Changes in CD4 T cells|Changes in serum antibodies against COVID-19 epitope|LDH|D-Dimer|IL-6|Myoglobin|Potassium|Ferritin|ALT,Emory University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000781|NCI-2020-04061|RAD5049-20|P30CA138292,12-Jun-20,30-May-22,30-May-22,16-Jun-20,,16-Jun-20,"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04433949
NCT04652505,"Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study",,Recruiting,No Results Available,COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Other: Questionnaire Administration,Patient-reported severity of depression|Patient-reported severity of anxiety|Patient-reported severity of distress|Patient-reported physical symptoms|Substance use|Patient-reported coping strategy|Patient-reported levels of apathy|Patient-reported engagement in the 5 health behaviors endorsed by World Health Organization intended to curb the spread of the coronavirus,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",,700,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2020-0451|NCI-2020-06556,13-Jul-20,31-Mar-21,31-Mar-21,3-Dec-20,,3-Dec-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04652505
NCT04418505,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,COVIDLight,Recruiting,No Results Available,COVID-19,Device: Vielight RX Plus,Time to recovery|Time to elimination of COVID-19 related symptoms|Mean number of days with mild COVID-19 related symptoms|Mean number of days with mild overall respiratory symptoms|Time to symptom reduction|Time to elimination of symptoms|Average number of days with mild respiratory symptoms|Oxygen saturation|Hospitalization rate|Mortality,Vielight Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,280,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VL-2020-02,2-Sep-20,1-Mar-21,1-Mar-21,5-Jun-20,,14-Sep-20,"Progressive Medical Research, Port Orange, Florida, United States|Dr. Michael Zahavi, Oshawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04418505
NCT04506528,The C3I COVID-19 Project,,Recruiting,No Results Available,Covid19|Cancer|Nicotine Dependence|Pulmonary Disease|Cardiovascular Diseases|Immunosuppression Disorders,,Mortality due to COVID-19|COVID-19 Severity,"University of Wisconsin, Madison|National Cancer Institute (NCI)",All,"Child, Adult, Older Adult",,170000,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Other,2020-069|OISE-20-66590-1|A534253|SMPH/MEDICINE|CTRI,10-Aug-20,31-Jan-21,31-Dec-21,10-Aug-20,,12-Aug-20,"University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04506528
NCT04394884,Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND),,Recruiting,No Results Available,COVID-19,,"To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.|1. Characterization of TLR3 and TLR7/8-dependent immunologic phenotypes in COVID-19 patients before and after BTK inhibition.|2. Evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in COVID-19 patients before and after BTK inhibition.|3. Transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in COVID-19 patients before and after BTK inhibition.|4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.|5. Characterization of SARS- CoV-2 serological responses in COVID-19 patients with and without BTK inhibition.|6. Characterization of genetic variants that correlate with disease severity and/or response to BTK inhibition treatment.|7. Evaluation of soluble biomarkers as surrogate markers of hyper- inflammation/prognosis and of response to BTK inhibition therapy in COVID-19 patients",National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,120,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200114|20-I-0114,20-Jan-21,30-Apr-23,30-Apr-23,20-May-20,,15-Jan-21,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04394884
NCT04525443,Endothelial Function and COVID-19,,Recruiting,No Results Available,COVID-19,,Reactive hyperemia index (RHI)|Percentage of COVID-19 patients with impaired endothelial vasodilator function.|Percentage of non-COVID-19 patients with impaired endothelial vasodilator function.,"Hospital San Carlos, Madrid|Mayo Clinic",All,"Child, Adult, Older Adult",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20/451,3-Jun-20,31-Aug-20,30-Sep-20,25-Aug-20,,25-Aug-20,"Mayo Clinic, Rochester, Minnesota, United States|Hospital Clínico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04525443
NCT04334512,A Study of Quintuple Therapy to Treat COVID-19 Infection,HAZDpaC,Recruiting,No Results Available,COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy,ProgenaBiome|DSCS CRO,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRG-044,22-Jun-20,Jun-21,Sep-21,6-Apr-20,,20-Jul-20,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04334512
NCT04368065,COVID-19 Active Research Experience (CARE),,Recruiting,No Results Available,COVID-19,,COVID-19 symptom occurrence and severity|COVID-19 treatments|Hospitalization,Iqvia Pty Ltd,All,"18 Years and older   (Adult, Older Adult)",,100000,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,IQVIA_COVIDREGISTRY_2020,2-Apr-20,31-Dec-22,1-Jun-23,29-Apr-20,,6-Jan-21,"IQVIA, Cambridge, Massachusetts, United States|IQVIA, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04368065
NCT04611230,"A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois",CONTACT,Recruiting,No Results Available,Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2),,Percentage of Participants With Evidence of Prior SARS-CoV-2 Infection|Percentage of Participants With Current SARS-CoV-2 Infection|Percentage of Participants With Incidence of SARS-CoV-2 Infection|Percentage of Participants With COVID-19 Hospitalization|Percentage of Participants With Influenza and COVID-like Illness|Time to Infection|Time to Symptom Onset|Time to Symptom Resolution|Change in Quality of Life (QOL),AbbVie,All,"18 Years and older   (Adult, Older Adult)",,1250,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,H20-308,5-Nov-20,24-Sep-21,24-Sep-21,2-Nov-20,,6-Jan-21,"Great Lakes Clinical Trials /ID# 224874, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04611230
NCT04362995,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,,Recruiting,No Results Available,COVID-19|Coronavirus Infection|Coronavirus|SARS-CoV-2,,Proportion of asymptomatic subjects|Positive CD4 and CD8 cell epitope positive response|Proportion of seroprevalence|T-cell response,St. Jude Children's Research Hospital,All,"18 Years and older   (Adult, Older Adult)",,1517,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SJTRC,23-Apr-20,20-Apr-21,20-Mar-25,27-Apr-20,,9-Dec-20,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04362995
NCT04537650,Swallowing Impairment After COVID-19 Infection,,Not yet recruiting,No Results Available,Covid19,Diagnostic Test: Videofluoroscopic Swallowing Study (VFSS),Swallowing safety|Swallowing efficiency|Time-to-Laryngeal-Vestibule-Closure|Laryngeal Vestibule Closure duration|Pharyngeal Constriction,"University Health Network, Toronto|National Institute on Deafness and Other Communication Disorders (NIDCD)|McMaster University|University of Florida",All,"18 Years and older   (Adult, Older Adult)",,75,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,CAPCR 20-5477|3R01DC011020-08S1,15-Nov-20,31-Aug-21,31-Dec-21,3-Sep-20,,3-Nov-20,"University of Florida, Gainesville, Florida, United States|McMaster University, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04537650
NCT04418518,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,CONCOR-1,Recruiting,No Results Available,COVID-19,Biological: Convalescent plasma,Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE),Weill Medical College of Cornell University|Hamilton Health Sciences Corporation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-04021981,24-Jun-20,Jun-21,Dec-21,5-Jun-20,,7-Jul-20,"Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lower Manhattan Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04418518
NCT04397900,Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,,Recruiting,No Results Available,Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection|Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types,,Identify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection.|Determine which SARS-CoV-2 proteins are frequently recognized by T cells in patients with varying HLA types.,"TScan Therapeutics, Inc.",All,"Child, Adult, Older Adult",,80,Industry,Observational,Observational Model: Other|Time Perspective: Retrospective,1586788,9-Apr-20,1-Jul-20,Jul-20,21-May-20,,16-Jun-20,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Atlantic Health System, Morristown, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04397900
NCT04477902,Long-Term Experience and Health Effects of COVID-19,,Recruiting,No Results Available,Covid19|Corona Virus Infection|Quality of Life|Risk Reduction,Other: none - observational,Longitudinal survey,Altura,All,"18 Years to 100 Years   (Adult, Older Adult)",,50000,Industry,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,altcovid-192020,1-Jul-20,1-Jul-22,1-Jul-22,20-Jul-20,,29-Jul-20,"Altura, Mission Viejo, California, United States",,https://ClinicalTrials.gov/show/NCT04477902
NCT04367857,ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,,Recruiting,No Results Available,Covid-19|Coronavirus Infection|Coronavirus,Other: COVID-19 Serology|Behavioral: Health Care Worker Survey,Proportion seropositive,Columbia University,All,"18 Years and older   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAS9998,18-Apr-20,Oct-21,Oct-21,29-Apr-20,,30-Apr-20,"NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04367857
NCT04575168,Clinical Study Spartan COVID-19 V2 System,,Recruiting,No Results Available,Covid19,Diagnostic Test: Spartan COVID-19 Test,Percent Agreement between SOC test and Spartan COVID-19 test,Spartan Bioscience Inc.|Beaufort,All,"18 Years and older   (Adult, Older Adult)",,100,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,VNV-00615,30-Oct-20,Nov-20,Nov-20,5-Oct-20,,13-Nov-20,"Wake Research Mt. Vernon, Sandy Springs, Georgia, United States|Clinical Chemistry Research Lab, University of Maryand-Baltimore, Baltimore, Maryland, United States|Wake Research ClinSearch, Chattanooga, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04575168
NCT04344561,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPSAT,Recruiting,No Results Available,COVID|Hypoxic Respiratory Failure,Other: Postural Positioning,Incidence of Mechanical Ventilation|Number of participants with supplemental oxygen requirements|Mean oxyhemoglobin saturation|Mean Nocturnal Oxyhemoglobin Saturation|Heart Rate|Respiratory Rate|Percentage of time in the assigned position,Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00246834,25-May-20,1-May-21,1-May-21,14-Apr-20,,24-Jun-20,"Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04344561
NCT04655586,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19",ASPEN,Recruiting,No Results Available,Covid19,Drug: rNAPc2|Drug: Heparin,Change in D-dimer level from Baseline to Day 8 (Phase 2b)|Number of major or non-major clinically relevant bleeding events within thirty (30) days of randomization (Phase 2b)|Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)|Change in D-dimer level from baseline to Day 10 (Phase 2b)|Number of major or non-major clinically relevant bleeding events with rNAPc2 vs. heparin (Phase 2b and 3)|Number of bleeding events in subjects treated with higher vs. lower dose rNAPc2 at Day 10 (Phase 2b)|Time to first occurrence of a composite of thrombotic events and all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Time to first occurrence of thrombotic events within thirty (30) days of randomization (Phase 3 only)|Time to all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Change in Tissue Factor laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b)|Change in interleukin-6 laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b)|Change in high sensitivity C-reactive protein laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b),"ARCA Biopharma, Inc.|Colorado Prevention Center",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,100,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",NAPc-201/301,10-Dec-20,30-Apr-21,31-May-21,7-Dec-20,,6-Jan-21,"ARCA Investigational Site #104, Aurora, Colorado, United States|ARCA Investigational Site #101, Jacksonville, Florida, United States|ARCA Investigational Site #103, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT04655586
NCT04320511,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,,Recruiting,No Results Available,SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19,Device: CT-V,"Predictive association between CT-V, PBM score and disease progression",William Beaumont Hospitals,All,"18 Years and older   (Adult, Older Adult)",,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-087,24-Jun-20,Jun-21,Jun-22,25-Mar-20,,24-Jul-20,"Beaumont Health, Royal Oak, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04320511
NCT04582214,Oscillation and Lung Expansion Therapy in Patients With COVID-19,,Recruiting,No Results Available,COVID-19|Oscillation and Lung Expansion|Ventilation,Device: MetaNeb® System,Time on mechanical ventilation,Hill-Rom|Emory University|Northwestern University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-RR-2020-002,28-Sep-20,1-Jan-21,1-Jan-21,9-Oct-20,,9-Oct-20,"Emory University, Atlanta, Georgia, United States|Northwestern University, Evanston, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04582214
NCT04424797,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,,Recruiting,No Results Available,COVID-19,Other: Prone Positioning|Other: Supine Positioning,Incidence of intubation|Maximum oxygen requirement|Length of Stay|Ventilator-free days|Treatment failure of prone positioning due to worsening SpO2 status while prone|Mortality,Poudre Valley Health System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-6034,13-Jul-20,Dec-20,Dec-20,11-Jun-20,,16-Jul-20,"UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|UCHealth Medical Center of the Rockies, Loveland, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04424797
NCT04392232,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,,Recruiting,No Results Available,Coronavirus|COVID-19|Convalescent Plasma,Drug: Convalescent Plasma,Survival Rate,TriHealth Inc.,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-045,5-May-20,31-Dec-20,31-Dec-20,18-May-20,,20-May-20,"Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04392232
NCT04532372,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,,Recruiting,No Results Available,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed,Other: Best Practice|Drug: Leflunomide|Drug: Placebo Administration,"Incidence of toxicity, graded according to the NCI CTCAE version 5|Maximum tolerated dose (MTD) (Phase 1)|Clinical activity (Response)(Phase 2)|Time to Clinical activity (Response)|Overall Survival|Oxygen Saturation improvement|SARS-CoV-2 resolution|Hospitalization|Mechanical Ventilation required|Mechanical Ventilation duration|Vital status (alive/dead)|Vital status (cause of death)",City of Hope Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20291|NCI-2020-05746|P30CA033572,18-Jan-21,18-Sep-22,18-Sep-22,31-Aug-20,,17-Dec-20,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT04532372
NCT04535128,"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications",CORONA-VTE NET,Recruiting,No Results Available,Covid19|Thrombosis Embolism|DVT|Pulmonary Embolism|Myocardial Infarction|Stroke,Other: No intervention,"Frequency of arterial or venous thromboembolism over 30 days|Frequency of arterial or venous thromboembolism over 90 days|Frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days|Frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days","Brigham and Women's Hospital|Bristol-Myers Squibb|University of Colorado, Denver|Anne Arundel Medical Center|Beth Israel Deaconess Medical Center|Jefferson Medical College of Thomas Jefferson University",All,"18 Years and older   (Adult, Older Adult)",,10000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2020P000848,24-Mar-20,31-Dec-20,30-Mar-21,1-Sep-20,,1-Sep-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04535128
NCT04346615,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,,Recruiting,No Results Available,COVID-19 Infection,Drug: Zavegepant (BHV-3500)|Drug: Placebo,"To compare the efficacy of zavegepant (BHV-3500) to placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a six-point rating scale at Day 15. .|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 29.|Proportion of subjects who have a 6-point severity rating of 2 or 3, or use any ventilation or high-flow nasal cannula as procedures, on any day through Day 29.|Proportion of subjects admitted into an ICU on any day through Day 29 from AE eCRFs.|Proportion of subjects who have a 6-point severity rating of 3, 4, 5, or 6, are alive, and do not use invasive mechanical ventilation as a procedure at Day 15. The analogous definition is applied to Day 29.|Proportion of subjects who have a 6-point severity rating of 4, 5 or 6, or use a low- or high-flow nasal, are alive, and do not use any ventilation at Day 15. The analogous definition is applied to Day 29.|Difference between treatment groups in the mean 6-point severity rating at Day 29|Number of days from baseline to the first day through Day 29 with any 6-point severity rating greater than baseline.|Number of days from baseline to the first of any 2 consecutive days through Day 29 with all SpO2/FiO2 ratios > 400 on both days.|Number of days from baseline to the first day through Day 29 with ≥ 1-point decrease in any NEWS2 score from baseline.|Number of days from baseline to the first day through Day 29 with all NEWS2 scores < 2 on that day.|Mean change from baseline in NEWS2 score at Days 15 and 29 for subjects who are alive at these time points|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 15.|Proportion of subjects who are discharged from the hospital, have a 6-point severity rating of 6 on any day after discharge, and use supplemental oxygen on any day after discharge.|Mean number of days with respiratory rate > 24 breaths/minute through Day 29 for subjects who are alive at Day 29 and do not use invasive mechanical ventilation.|Mean number of days with supplemental oxygen use through Day 29 for subjects who are alive at Day 29. A day in which any 6-point severity rating is 2, 3, or 4, or supplemental oxygen is used as a procedure counts.|Number of days from baseline to the first day through Day 29 on which any SpO2 ≥ 90%, any 6-point severity rating is 5 or 6, and no supplemental oxygen is used as a procedure.|Mean number of ventilator-free days through Day 29 for subjects who are alive at Day 29.|Mean SOFA total scores at ICU admission and Day 29 (if still in ICU), from SOFA and AE eCRFs.|Mean number of days of hospitalization through Day 29 for subjects who are alive on Day 29. All days on study on or before hospitalization discharge are days of hospitalization, from 6-point severity rating scale eCRFs|Number of days from baseline to the first of any 2 consecutive days through Day 29 in which all temperatures show lack of fever on both days and no antipyretics are used on either day.|Number of subjects with deaths, SAEs, severe AEs, and Grade 3 or 4 laboratory test abnormalities at any time on study.|Number and percentage of subjects with severe or life-threatening bacterial, invasive fungal, or opportunistic infections at any time through Day 29 from AE/SAE eCRFs.|Number and percentage of subjects with intranasal administration reactions at any time through Day 29 from AE/SAE eCRFs.|Proportion of subjects with ≥ 50% reduction in eGFR from baseline at any time on study from laboratory test eCRFs.","Biohaven Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BHV3500-203,25-Apr-20,Apr-21,Apr-21,15-Apr-20,,25-Sep-20,"Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Roper Hospital, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04346615
NCT04455958,Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year,,Not yet recruiting,No Results Available,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed,Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration,Severity of symptoms|Clinical benefit rate of lopinavir/ritonavir|Time to symptom progression|Time to improvement of participants|Time to hospital admission for those who develop severe of critical symptoms|Intensive care unit (ICU) admission: yes or no|Receiving ventilator support: yes or no|Overall survival,OHSU Knight Cancer Institute|Oregon Health and Science University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00021444|NCI-2020-02877,1-Nov-20,1-Nov-21,1-Nov-21,2-Jul-20,,18-Sep-20,"OHSU Knight Cancer Institute, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT04455958
NCT04391179,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,DICER,Recruiting,No Results Available,COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection,Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet,Change in D-dimer|Global composite rank score,University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HUM00179783,31-May-20,Feb-21,Feb-21,18-May-20,,23-Dec-20,"North Shore UniversityHealth, Evanston, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04391179
NCT04605965,WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19,WEAICOR,Recruiting,No Results Available,Covid19|Cardiovascular Complication|Behavioral Changes,,Incidence of major cardiovascular events|Incidence of atrial arrhythmia|Mental health effect of COVID-19 measured by incidence of Generalized Anxiety Disorder (GAD) using Generalized Anxiety Disorder 7-item (GAD-7) Scale|Mental health effect of COVID-19 measured by incidence of depression using Beck Depression Fast Screen Scale|Mental health effect of COVID-19 measured by incidence of Post Traumatic Stress Syndrome (PTSD) using the Post Traumatic Stress Disorder Checklist- Standard Form (PCL-S) scale|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of alcohol survey|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of drugs survey|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of nicotine products survey,Tulane University|Biostrap,All,"18 Years to 120 Years   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2020-678,9-Jun-20,Jun-22,Jun-22,28-Oct-20,,7-Dec-20,"Tulane University, TRIAD Center, New Orleans, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04605965
NCT04530604,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),,Recruiting,No Results Available,COVID|Sars-CoV2|COVID-19|Acute Respiratory Distress Syndrome,Drug: Defibrotide,Number of major hemorrhagic complications within 14 days of initiation of treatment|Overall survival|Ventilator free survival|Number of ventilator free days within 14 days of study entry|The time to improvement in oxygenation|Mean change in the WHO COVID-19 Ordinal Scale during therapy,Gregory Yanik|Jazz Pharmaceuticals|University of Michigan,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HUM00182089,1-Oct-20,1-Oct-21,1-Oct-21,28-Aug-20,,14-Oct-20,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04530604
NCT04339998,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),,Recruiting,No Results Available,Coronavirus Infection|COVID|Covid-19|SARS-CoV-2,Diagnostic Test: Point-of-Care Ultrasonography (POCUS),POCUS Score - Lungs|POCUS Score - Heart,University of Minnesota,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GIM-2020-28740,15-Apr-20,Oct-20,Oct-20,9-Apr-20,,3-Sep-20,"University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04339998
NCT04565249,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|SARS-CoV-2,Drug: PLN-74809|Drug: Placebo,"Number of participants with treatment-related adverse events and laboratory abnormalities, assessed by CTCAE V5.0|Assessment of PLN-74809 plasma concentrations","Pliant Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PLN-74809-ARDS-204,22-Oct-20,31-Aug-21,31-Oct-21,25-Sep-20,,7-Jan-21,"Valleywise Health Medical Center, Phoenix, Arizona, United States|Advent Health, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT04565249
NCT04570488,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,,Recruiting,No Results Available,COVID|Corona Virus Infection|Adverse Event,Other: EPIC risk score display,Reduction in days from first low-risk score to discharge|Reduction in length of stay (LOS)|Reduction in GTD vs. LOS|No change in 30 day re-ED presentation or hospital admission rate for cohort,NYU Langone Health,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research",PAU COVID19 RCT,15-May-20,30-Dec-20,15-May-21,30-Sep-20,,14-Oct-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04570488
NCT04435457,Cardiovascular Implications of COVID-19,,Recruiting,No Results Available,SARS-CoV 2|SARS Pneumonia|COVID-19|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|Cardiac Complication,,Prevalence of Myocarditis|Prevalence of cardiac abnormalities by cardiac magnetic resonance imaging|Prevalence of molecular and genetic immune system abnormalities,University of Texas Southwestern Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",,70,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,STU-2020-0359,1-Sep-20,31-Dec-20,31-Dec-20,17-Jun-20,,8-Oct-20,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04435457
NCT04644172,Improving Thinking in Everyday Life After Covid-19,,Recruiting,No Results Available,Covid-19|Cognitive Impairment,Behavioral: Speed of Processing Training|Behavioral: Instrumental Activities of Daily Living Shaping|Behavioral: Transfer Package from CI Therapy|Other: Usual Care,Canadian Occupation Performance Measure (COPM)|Improved and New Cognitive Ability (INCA)|Cognitive Task Activity Log (CTAL) How Well Scale|Cognitive Task Activity Log (CTAL) Independence Scale|Assessment of Motor and Process Skills (AMPS),University of Alabama at Birmingham,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB-300002814C,1-Nov-20,Nov-23,Nov-24,25-Nov-20,,25-Nov-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04644172
NCT04592705,Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients,,Recruiting,No Results Available,COVID-19,Device: Therapeutic plasma exchange,Time to clinical status downgrade or discharge.,Larkin Community Hospital,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,LCH-1-092020,11-Sep-20,30-Aug-21,30-Aug-21,19-Oct-20,,19-Oct-20,"Larkin Community Hospital, South Miami, Florida, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04592705/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04592705
NCT04469179,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",,Recruiting,No Results Available,COVID-19|SARS-CoV2,Biological: SAB-185|Other: Normal Saline,Number of Participants Having Adverse Events|Number of Participants Having Transfusion-Related Adverse Events|Assesment of the PD of SAB-185 administered intravenously|Immune response elicited by SAB-185|Concentration of subject anti-SAB-185 antibodies elicited by SAB-185|Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens|Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens,"SAb Biotherapeutics, Inc.|Biomedical Advanced Research and Development Authority|Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)",All,18 Years to 60 Years   (Adult),Phase 1,21,Industry|U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SAB-185-102,20-Aug-20,Sep-20,Dec-20,13-Jul-20,,9-Sep-20,"Quantum Clinical Trials, Miami Beach, Florida, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Sanford Health, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT04469179
NCT04360538,Long Term Outcomes of Patients With COVID-19,COVID19 LTFU,Recruiting,No Results Available,Critical Illness|Corona Virus Infection|Respiratory Failure|Covid-19,Other: Quality of Life|Other: Impact Event Score|Other: Hospital anxiety and depression scale,Quality of Life score|cognitive dysfunction|Functional Status Score|Physical Disability|Psychological Sequelae,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-0538,8-Apr-20,1-Jul-21,30-Dec-21,24-Apr-20,,24-Apr-20,"University of Chicago Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04360538
NCT04638673,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,,Recruiting,No Results Available,Coronavirus|Covid19,Device: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Device: Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group,Change in Score of Patient Health Questionnaire-9,Medical University of South Carolina|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00101270|U54GM104941-08,19-Nov-20,Jun-21,Jun-21,20-Nov-20,,7-Dec-20,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04638673
NCT04365985,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,SINK COVID-19,Recruiting,No Results Available,COVID-19|Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections,Drug: Naltrexone|Drug: Ketamine|Other: Placebo,Progression of oxygenation needs|Renal failure|Liver failure|Cytokine Storm|Mortality|Length of hospital stay|Intensive Care Unit (ICU) admission|Intensive Care Unit (ICU) duration|Intubation|Intubation duration|Time until recovery,William Beaumont Hospitals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2020-097,29-Apr-20,May-21,Aug-21,28-Apr-20,,2-Jul-20,"William Beaumont Hospital, Royal Oak, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04365985
NCT04473183,Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,,Recruiting,No Results Available,Covid19|SARS-CoV Infection|SARS-CoV-2|Corona Virus Infection,Diagnostic Test: Specimen Collection|Diagnostic Test: Surveys,Prevalence of Symptomatic Infection|Prevalence of Subclinical Infection,University of Minnesota,All,"18 Years and older   (Adult, Older Adult)",,3000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SURG-2020-28863,21-Jul-20,Jan-22,Jan-22,16-Jul-20,,13-Aug-20,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04473183
NCT04605588,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,TriACT,Recruiting,No Results Available,SARS-CoV Infection|Covid19,Drug: Nitazoxanide|Drug: Placebo Nitazoxanide|Drug: Ribavirin|Drug: Placebo Ribavirin|Drug: Hydroxychloroquine|Drug: Placebo Hydroxychloroquine,Rate of decline in viral load over the 10 days after randomization,"Rutgers, The State University of New Jersey|SynaVir",All,"21 Years and older   (Adult, Older Adult)",Phase 2,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro2020001862,2-Dec-20,Apr-21,Apr-21,28-Oct-20,,7-Dec-20,"Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04605588
NCT04374656,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic,,Recruiting,No Results Available,"Conjunctivitis|SARS-CoV-2|COVID-19|Ocular Infection, Viral|Ocular Inflammation",,Proportion of conjunctival samples tested positive for SARS-CoV-2|Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples|Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples|Rate of development of COVID-19 in the study patient population|Positive conjunctival sample rate in patient developed COVID-19,Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB00249598,18-May-20,May-21,May-21,5-May-20,,22-May-20,"Wilmer Eye Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04374656
NCT04363268,ACCESS A Master Digital Surveillance Protocol for COVID-19,ACCESS,Recruiting,No Results Available,Coronavirus|COVID|COVID-19|COVID19|Corona Virus Infection|Coronavirus Infection,,Development of population-based models of disease risk|Relation between disease burden and geolocation|Effect of medications on symptoms of COVID19|Effect of medications on disease severity of COVID19|Rate of COVID19 infection and disease outcomes|Effect of COVID19 on health outcomes|Long-term follow up and recontact,Medable Inc.|Datavant|American Heart Association|BioIntelliSense|PWNHealth,All,"18 Years and older   (Adult, Older Adult)",,1000000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00041635,20-Apr-20,20-Apr-30,1-Oct-31,27-Apr-20,,28-Apr-20,"Medable Inc., Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT04363268
NCT04466098,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|ARDS (Moderate or Severe)|COVID-19 Pneumonia,Biological: Mesenchymal stromal cells|Other: Placebo,Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen,"Masonic Cancer Center, University of Minnesota",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2020LS075|MT2020-12,30-Jul-20,1-Dec-21,1-Dec-21,10-Jul-20,,14-Aug-20,"University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04466098
NCT04342806,"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",,Recruiting,No Results Available,Health Care Worker (HCW)|COVID-19,,"Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis|Distribution of COVID-19 risk factors by participant characteristics|Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)|Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study|Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment",Duke University|Patient-Centered Outcomes Research Institute,All,"18 Years to 89 Years   (Adult, Older Adult)",,100000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00105284,10-Apr-20,31-Dec-99,31-Dec-99,13-Apr-20,,7-May-20,"Duke Clinical Research Institute, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04342806
NCT04352946,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,HERO,Not yet recruiting,No Results Available,Prophylaxis|COVID-19|Health Care Worker|Hydroxychloroquine,Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet,Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost,GeoSentinel Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,374,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",GFICOVID-19-1,24-Apr-20,24-Jun-20,24-Aug-20,20-Apr-20,,22-Apr-20,"The New York Center for Travel and Tropical Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04352946
NCT04706533,"Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19",M2C2,Recruiting,No Results Available,Covid19|Kidney Diseases|Inflammation|SARS-CoV Infection,Diagnostic Test: Biomarkers of inflammation,"Death, need for mechanical ventilation or need for dialysis|All-cause death|Need for mechanical ventilation|Need for dialysis",University of Michigan,All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HUM00178971,23-Mar-20,Jun-21,Jun-21,13-Jan-21,,13-Jan-21,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04706533
NCT04412330,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,OPTIMAL,Recruiting,No Results Available,Covid-19|Critical Illness|Post Intensive Care Unit Syndrome|Muscle Weakness,Other: ICU Recovery + Physical Therapy,"Adverse events (safety)|Feasibility (success of consent process, adherence, and attrition)|Six minute walk test|Short Performance Physical Battery|Quality of life (EQ-5DL)|Cognitive function|Anxiety and Depression|PTSD and distress|Return to work|Secondary complication",University of Kentucky|Ashley Montgomery-Yates,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,59097,1-May-20,1-May-21,1-May-21,2-Jun-20,,24-Jun-20,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04412330
NCT04381923,COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia,COVIDNOCHE,Not yet recruiting,No Results Available,"Severe Acute Respiratory Syndrome Coronavirus 2|Hypoxemic Respiratory Failure|Pneumonia, Viral|COVID",Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO),Ventilator-Free Days (VFD)|ICU and Hospital Length of Stay|Intubation|Renal Replacement Therapy (RRT)|Mortality,University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,843124,15-Feb-21,15-Feb-22,15-May-22,11-May-20,,10-Nov-20,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04381923
NCT04650178,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,,Recruiting,No Results Available,COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Neuropathy,Other: Quality-of-Life Assessment|Other: Questionnaire Administration,Health-related quality of life and coronavirus disease 2019 (COVID-19)-specific domains of interest|COVID-19 experiences and COVID-19 specific distress|Differences in outcomes between neuropathic pain patients|Coping and resilience factors,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",,274,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Other,2020-0508|NCI-2020-06014,26-May-20,1-Jul-21,1-Jul-21,2-Dec-20,,2-Dec-20,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04650178
NCT04487886,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),DAMPEN-CI,Recruiting,No Results Available,COVID-19,Drug: Duvelisib|Drug: Placebo,Number of Participants Requiring Mechanical Ventilation or Dying|Days to Recovery|Duration of Hospitalization|Incidence of Death|Proportion of Participants Transferred to ICU|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Incidence of Grade III-V Adverse Events|Incidence of Secondary Bacterial or Viral Infections|Change in Th1 T Cell Frequency|Change in Th17 T Cell Frequency|Change in Interleukin-2 (IL-2)|Change in Interleukin-2 receptor (IL-2R)|Change in Interleukin-6 (IL-6)|Change in Interleukin-7 (IL-7)|Change in Interleukin-8 (IL-8)|Change in Interleukin-10 (IL-10)|Change in Interferon gamma-induced Protein 10 (IP-10)|Change in Macrophage Inflammatory Protein 1alpha (MIP-1a)|Change in Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Granulocyte Colony-stimulating Factor (G-CSF)|Change in Tumor Necrosis Factor (TNF)-alpha|Change in Vasoactive Intestinal Peptide (VIP)|Change in Gene Expression Profile of Regulatory T Cells (Tregs)|Change in Gene Expression Profile of cluster of differentiation 8 (CD8)+Interferon Gamma (IFNg)+ Granulocyte-macrophage colony-stimulating factor (GM-CSF)+|Change in Gene Expression Profile of CD8+ T cell immunoglobulin and mucin domain-containing protein 3 (Tim3)+ Programmed cell death protein 1 (PD-1)+|Change in Gene Expression Profile of cluster of differentiation 14 (CD14)+ cluster of differentiation (CD16)+ monocytes|Change in SARS-CoV-2 Viremia|Change in Immunoglobulin G (IgG) Antibodies|Change in Immunoglobulin M (IgM) Antibodies|Overall Survival,"Emory University|Verastem, Inc.|University of Pennsylvania",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",STUDY00000701,18-Nov-20,Feb-22,Feb-22,27-Jul-20,,16-Dec-20,"Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04487886
NCT04566965,Serology to Covid for Recording Exposures and Evaluating Needs,SCREEN,Recruiting,No Results Available,Covid19|Coronavirus|SARS-CoV Infection,Diagnostic Test: SARS-CoV-2,The 12-month cumulative incidence of acquired COVID infection in the study cohort.,"Children's Hospital Medical Center, Cincinnati",All,"18 Years and older   (Adult, Older Adult)",,230,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,SCREEN,18-Aug-20,31-Dec-22,31-Dec-23,28-Sep-20,,28-Sep-20,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04566965
NCT04402970,Dornase Alfa for ARDS in Patients With SARS-CoV-2,DORNASESARS2,Recruiting,No Results Available,SARS-CoV 2|ARDS,Drug: Dornase Alfa Inhalation Solution,Improvement in PaO2/FiO2|Change in static lung compliance|Duration of mechanical ventilation|Length of ICU stay|Length of hospitalization|Secondary bacterial infections|Mortality,University of Missouri-Columbia,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2022206,19-Jun-20,31-May-21,31-May-22,27-May-20,,26-Jun-20,"University of Missouri Hospital and Clinics, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04402970
NCT04359836,A Study to Explore the Role of Gut Flora in COVID-19 Infection,,Recruiting,No Results Available,Gut Microbiome|Gastrointestinal Microbiome|COVID|COVID-19|Corona Virus Infection|Coronavirus|Coronaviridae Infections|Coronavirus 19|Coronavirus-19|COVID 19,Other: There is no intervention in this study,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing|Validation of Sequencing Methods,ProgenaBiome,All,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Other|Time Perspective: Other,PRG-041,16-Apr-20,30-Apr-21,31-Jul-21,24-Apr-20,,5-Oct-20,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04359836
NCT04632537,BCG Vaccination to Prevent COVID-19,NUEVA,Recruiting,No Results Available,COVID-19,Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Drug: Preservative-free saline,Incidence of symptomatic rt-PCR-confirmed SARS-CoV-2 infection|incidence of Serology-confirmed infection with SARS-CoV-2|severity of COVID-19 disease|symptomatic respiratory infection|effect of prior adult immunization with other vaccines associated with trained immunity,"Henry M. Jackson Foundation for the Advancement of Military Medicine|Harvard Medical School|Uniformed Services University of the Health Sciences|United States Department of Defense|Immunization HealthCare Division, Defense Health Agency",All,18 Years to 64 Years   (Adult),Phase 3,550,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",USUHS.2020-062,7-Dec-20,Nov-22,Apr-23,17-Nov-20,,12-Jan-21,"Uniformed Services University, Bethesda, Maryland, United States|Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04632537
NCT04402814,IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.,,Recruiting,No Results Available,SARS-CoV 2,Diagnostic Test: Clungene rapid test cassette,IgG/IgM antibodies,"Fadi Haddad, M.D.|Sharp HealthCare",All,"18 Years and older   (Adult, Older Adult)",,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IgG/IgM COVID19|2005801,5-May-20,1-Oct-20,1-Dec-20,27-May-20,,27-Jul-20,"Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04402814
NCT04665258,COVID-19 Vaccine and Impact on Fertility Study,,Recruiting,No Results Available,"Infertility, Male",,Sperm concentration|Sperm motility,University of Miami,Male,18 Years to 50 Years   (Adult),,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,20201451,14-Dec-20,14-Jun-21,14-Jun-21,11-Dec-20,,31-Dec-20,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04665258
NCT04401449,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons,,Recruiting,No Results Available,Acute and Long Term Effects of COVID-19:on Systemic Inflammation|Acute and Long Term Effects of COVID-19 on Lung Function|Acute and Long Term Effects of COVID-19 on Mrain Function|Acute and Long Term Effects of COVID-19 on Cardiac Function|Acute and Long Term Effects of COVID-19 on Kidney Function,,Inflammatory responses of cells in lung and circulation,National Institutes of Health Clinical Center (CC),All,"18 Years to 80 Years   (Adult, Older Adult)",,180,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200113|20-CC-0113,8-Jan-20,1-May-24,1-May-24,26-May-20,,13-Jan-21,"MedStar Health Research Institute /MedStar Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04401449
NCT04661657,COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry,,Not yet recruiting,No Results Available,Covid19|Cardiac Disease|Cardiac Arrhythmia|Myocarditis|Left Ventricular Dysfunction,Other: Transthoracic echocardiogram (TTE)|Other: Cardiovascular Magnetic Resonance (CMR) Imaging,Percentage of myocardium demonstrating late gadolinium enhancement|Extracellular Volume (ECV) Fraction|Left Ventricular Ejection Fraction,Columbia University|GE Healthcare,All,"18 Years and older   (Adult, Older Adult)",,70,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAT0787,Dec-20,31-Dec-21,30-Sep-22,10-Dec-20,,10-Dec-20,"Columbia University Irving Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04661657
NCT04710394,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,VOLT,Not yet recruiting,No Results Available,Anosmia|Covid19|Ageusia|Hyposmia|Hypogeusia|SARS-CoV-2 Infection|COVID-19 Pandemic,Behavioral: Smell Training,University of Pennsylvania Smell Identification Test (UPSIT)|Clinical Global Impression Severity (CGI-S) Scale|Clinical Global Impression Improvement (CGI-I) Scale|Olfactory Dysfunction Outcomes Rating (ODOR),Washington University School of Medicine,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",7011897206,11-Jan-21,11-Mar-22,11-Mar-22,14-Jan-21,,14-Jan-21,"Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04710394
NCT04384445,Zofin (Organicell Flow) for Patients With COVID-19,,Recruiting,No Results Available,Corona Virus Infection|COVID-19|SARS|Acute Respiratory Distress Syndrome,Biological: Zofin|Other: Placebo,Incidence of any infusion associated adverse events|Incidence of Severe Adverse Events|All Cause Mortality|Survival Rate|Cytokine Levels|D-dimer Levels|C-reactive protein Levels|Quantification of the COVID-19|Improved Organ Failure|Chest Imaging Changes,Organicell Regenerative Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",19881,8-Sep-20,31-Dec-20,31-Dec-20,12-May-20,,31-Dec-20,"Larkin Community Hospital, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04384445
NCT04395911,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,,Recruiting,No Results Available,AKI|ARDS|COVID,Device: SCD,Mortality at Day 60|Dialysis Dependency|Ventilation at Day 28|Mortality at Day 28|Urinary output change|P02/FiO2 change|Safety Assessments|SCD Integrity,SeaStar Medical,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCD-005,10-Sep-20,Jan-21,Dec-21,20-May-20,,11-Dec-20,"University of Kentucky, Lexington, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04395911
NCT04348864,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,,Recruiting,No Results Available,Communicable Disease|COVID-19|Sars-CoV2|Infectious Disease|Coronavirus|Virus,"Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine",Clinical accuracy of the antibody and antigen rapid tests compared to LAMP/PCR-based test result|Clinical accuracy of the antibody and antigen rapid tests based on Clinical diagnosis|Self-test interpretation of result vs expert clinical image interpretation of result|Ease of self-testing procedure,Neuroganics LLC|Neuroganics Diagnostics LLC,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,200,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,3/18/20,16-Apr-20,Apr-21,Apr-21,16-Apr-20,,10-Dec-20,"Neuroganics, Northglenn, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04348864
NCT04431869,In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,,Recruiting,No Results Available,Pregnancy Related|COVID|Intestinal Atresia|Limb Anomaly,,"Rates of intestinal atresias and limb abnormalities|Rates of preterm labor, fetal growth restriction and spontaneous abortions|Rates of maternal SARS-CoV-2 infection among mothers to infants born with intestinal atresias or limb anomalies","University of Colorado, Denver",All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-1399,18-Aug-20,Jul-22,Jul-22,16-Jun-20,,24-Aug-20,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04431869
NCT04629105,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER),RECOVER,Recruiting,No Results Available,"ARDS, Human|Covid19",Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography,Longeveron LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",00-006,24-Jul-20,Aug-21,Jul-25,16-Nov-20,,16-Nov-20,"Miami VA Healthcare System, Miami, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04629105
NCT04582201,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,,Recruiting,No Results Available,"Respiratory Distress Syndrome, Adult",Drug: agenT-797,Incidence of Treatment-Emergent Adverse Events|Number of Dose Limiting Toxicities|To assess time to improvement in pulmonary function.|Amount of virus detected in respiratory tract samples.|To assess longevity of agenT-797 infusion.,"AgenTus Therapeutics, Inc.|Agenus Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,55,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-1300-01,21-Sep-20,24-Apr-21,15-Oct-21,9-Oct-20,,29-Oct-20,"Weill Cornell Medicine New York Presbyterian, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04582201
NCT04452695,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,,Recruiting,No Results Available,COVID-19|Telemedicine|Robotics|Emergencies|Emerging Infectious Disease,Device: Doctor Spot,Acceptance of robotic telehealth system|Willingness to interact with robotic telehealth system|Satisfaction of interacting with a robotic telehealth system|Use of robotic system versus in-person triage,Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020P000957,10-Mar-20,31-Jul-20,31-Jul-20,30-Jun-20,,31-Jul-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04452695
NCT04363450,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),HCQPreP,Recruiting,No Results Available,COVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|Hydroxychloroquine,Drug: Hydroxychloroquine|Drug: Placebo,Incidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infection,Louisiana State University Health Sciences Center in New Orleans|Lafayette General Health|University of Louisiana at Lafayette,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1700,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LSU NO HSC IRB 20-050,27-Apr-20,31-Mar-21,1-Jun-21,27-Apr-20,,2-Sep-20,"Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT04363450
NCT04397692,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),,Recruiting,No Results Available,"Corona Virus Infection|COVID-19|SARS-CoV 2|Nitric Oxide|Respiratory Disease|Pneumonia, Viral|Inhaled Nitric Oxide",Device: Nitric Oxide delivered via LungFit™ system,Time to deterioration|Time to NIV|Time to HFNC|Time to intubation|Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93%,Beyond Air Inc.,All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,BAI_COV19_01_US,13-Jun-20,30-Sep-20,30-Sep-20,21-May-20,,8-Jul-20,"Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT04397692
NCT04514016,Cross Sectional CFAR HIV/COVID Study,,Recruiting,No Results Available,SARS-CoV Infection|Covid19,,Number of participants who tested positive with SARS COV-2 Infection|Number of participants who tested positive with SARS COV-2 antibody,University of Miami|Miami Center for AIDS Research,All,"3 Years to 25 Years   (Child, Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,20200802,12-Aug-20,31-Mar-21,31-Mar-21,14-Aug-20,,14-Aug-20,"Batchelor's Children's Research Institute, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04514016
NCT04409873,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),AMPoL,Not yet recruiting,No Results Available,COVID-19|SARS-CoV 2|Severe Acute Respiratory Syndrome Coronavirus 2|Virus Disease|Coronavirus Infections|Pharyngeal Diseases,Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS mouthwash|Drug: Distilled water|Drug: Listerine Mouthwash Product,Change in SARS-Cov-2 viral load|Change in self-reported clinical symptom onset|Change in healthcare utilization and hospitalization,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 2,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",20-30874|R00RG2901,7-Dec-20,30-Jun-21,30-Nov-21,1-Jun-20,,20-Nov-20,"University Of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04409873
NCT04494386,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,ULSC,Recruiting,No Results Available,Covid19|Corona Virus Infection|SARS-CoV Infection|ARDS|Coronavirus,Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control),"Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline","Restem, LLC.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ULSC-CV-01,23-Jul-20,30-Oct-20,30-Nov-21,31-Jul-20,,13-Aug-20,"Sanford Research, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT04494386
NCT04433078,RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,STORM,Recruiting,No Results Available,Cytokine Storm|SARS-CoV-2,Drug: Doxycycline|Drug: Placebo,"Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death|NP SARS-CoV-2 PCR|SARS-CoV-2 Serum Quantitative Viral Load|SARS-CoV-2 IgM/IgG Antibodies|White Blood Cell Count (WBC)|Absolute Lymphocyte Count (ALC)|C-Reactive Protein (CRP)|N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP)|High Sensitivity Troponin I (hsTnT)|Tumor Necrosis Factor Alpha (TNF-a)|IL-1|IL-1B|IL-6",Temple University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",The STORM Trial,22-Jun-20,Jan-21,Jul-21,16-Jun-20,,24-Jun-20,"Temple University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04433078
NCT04356443,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,,Recruiting,No Results Available,"Respiratory Failure|Ventilatory Failure|COVID-19|Pneumonia|ARDS, Human",Device: AirGo Respiratory Monitor,"Endotracheal intubation during present hospitalization, recorded through chart review|Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review|Premature need for removal of the band, recorded through investigator report|In-hospital mortality, recorded through chart review",Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020P000881,15-Apr-20,31-Dec-20,31-Dec-20,22-Apr-20,,22-Apr-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04356443
NCT04395716,A Study of ResCure™ to Treat COVID-19 Infection,,Not yet recruiting,No Results Available,COVID|Covid-19|Corona Virus Infection|Sars-CoV2|Coronavirus-19|SARS Pneumonia|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere,Biological: ResCure™,The rate of recovery of mild or moderate COVID-19 in patients using ResCure™|Reduction or progression of symptomatic days|Assess the safety of ResCure™ via pulse|Assess the safety of ResCure™ via oxygen saturation|Assess the safety of ResCure™ via EKG|Assess Tolerability of ResCure™,"ProgenaBiome|Rinati Skin, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRG-048,Jul-20,Jun-21,Nov-21,20-May-20,,10-Jul-20,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04395716
NCT04659928,Evaluation of Aerosol in a Dental Clinic,,Not yet recruiting,No Results Available,Covid19,Device: High volume evacuation (HVE)|Device: Extraoral vacuum aspirator (EVA)|Device: External evacuation device (EED)|Drug: Hydrogen Peroxide,Number of bacterial colony forming units (CFUs) .|Change in number of CFUs,"The University of Texas Health Science Center, Houston",All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",HSC-DB-20-1017,1-Dec-20,1-Dec-22,1-Dec-22,9-Dec-20,,9-Dec-20,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04659928
NCT04644328,The Doctors for Coronavirus Prevention Project Thanksgiving Messaging Campaign,,Not yet recruiting,No Results Available,Covid19,Behavioral: Facebook Ads on the importance of staying safe during the Thanksgiving holiday,"Covid Case Rate|Population count|Facebook mobility rate|Knowledge of COVID-19 thanksgiving prevention message (recall of ad, intent to travel, mask wearing and beliefs about travel)|average number of tiles people occupy (Mobility measure)|percentage of eligible participants only observed in a single level-16 Bing tile (no change in movement)","National Bureau of Economic Research, Inc.|Massachusetts Institute of Technology|Harvard University|Massachusetts General Hospital|Yale University|Stanford University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20000000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2003000118A010,14-Nov-20,26-Nov-20,26-Nov-21,25-Nov-20,,25-Nov-20,"JPAL North America, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04644328
NCT04592549,"This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19",,Recruiting,No Results Available,SARS-CoV-2,Drug: ADM03820|Other: Placebo,The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit|The number of participants with AEs from administration of ADM03820 to the final visit|The assessment of Peak Plasma Concentration (Cmax) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|The assessment of Tmax for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|The assessment of the Area under the plasma concentration (AUC(0-t)) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|To assess the anti-drug antibody levels,Ology Bioservices|Enabling Biotechnologies (EB),All,18 Years to 55 Years   (Adult),Phase 1,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADM03820-001,4-Dec-20,30-Sep-21,30-Sep-21,19-Oct-20,,10-Dec-20,"PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|ICON Early Phase Services, LLC, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04592549
NCT04595175,Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW),CONSERVE-HCW,Recruiting,No Results Available,COVID-19 Infection,,Baseline IgG Assay Information|Change in IgG Assay Information|Compare seroprevalence of anti-SARS-CoV-2 IgG antibodies between groups|Impact of COVID-19 Pandemic on Perceived Wellness and Job Satisfaction,"Brian Tiffany, MD|Chandler Regional Medical Center|Arizona General Hospital|Mercy Gilbert Medical Center|St. Joseph's Hospital and Medical Center, Phoenix",All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-510-157-66-21,10-Jun-20,30-Jun-21,30-Dec-21,20-Oct-20,,20-Oct-20,"Chandler Regional Medical Center, Chandler, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04595175
NCT04472793,Repeated Employee Testing for Understanding Our Recovery to Normal,RETURN,Recruiting,No Results Available,COVID-19,Diagnostic Test: SARS-CoV-2,The 6-month cumulative incidence of acquired COVID infection in the study cohort.,"Children's Hospital Medical Center, Cincinnati",All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RETURN,11-May-20,Dec-22,Dec-23,15-Jul-20,,15-Jul-20,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04472793
NCT04706299,"Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing",,Recruiting,No Results Available,Prevention of COVID-19,Other: Resistance Exercise,Evaluate the effects of wearing a surgical face mask while performing resistance exercise on average peak force and total work performed.|Identify changes in the level of discomfort experienced while wearing a surgical mask during resistance exercise.,The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20-1303,12-Jan-21,1-Apr-21,1-Apr-21,12-Jan-21,,14-Jan-21,"Cleveland Clinic Sports Health, Garfield Heights, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04706299
NCT04459702,A Study of Combination Therapies to Treat COVID-19 Infection,,Not yet recruiting,No Results Available,COVID|COVID-19|Corona Virus Infection|Coronavirus Infection|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|Coronavirus-19|SARS-CoV 2|SARS Pneumonia,Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir,Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores|Efficacy of Treatment by Time to Non-Infectivity|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.|Safety of Dual Therapy as Measured by Complete Blood Count|Safety of Quadruple Therapy as Measured by Complete Blood Count|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT|Safety of Dual Therapy as Measured by Metabolic Panel ALT|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein|Safety of Dual Therapy as Measured by Treatment Related SAE|Safety of Quadruple Therapy as Measured by Treatment Related SAE,ProgenaBiome|Big Corona Ltd.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRG-043,Jul-20,Jul-21,Dec-21,7-Jul-20,,7-Jul-20,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04459702
NCT04482686,Trial of Combination Therapy to Treat COVID-19 Infection,,Recruiting,No Results Available,COVID|Covid-19|Corona Virus Infection|Coronavirus Infection|Coronavirus-19|SARS-CoV2|SARS-CoV Infection,Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C,Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events,ProgenaBiome|Topelia Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PRG-049,9-Dec-20,May-21,Jul-21,22-Jul-20,,16-Dec-20,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04482686
NCT04636021,Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era,RECIPE,Recruiting,No Results Available,Corona Virus Infection,Diagnostic Test: COVID-19 testing,Number of subjects who contract COVID-19 while hospitalized for elective outpatient procedures|Patient perception of the effect of pre and post procedure COVID-19 testing on risk of contracting COVID-19 while hospitalized for an elective outpatient procedure.,Pinnacle Health Cardiovascular Institute,All,"Child, Adult, Older Adult",,1000,Other,Observational,Observational Model: Other|Time Perspective: Prospective,UPMCP # 20-007,1-Aug-20,31-Dec-21,30-Jun-22,19-Nov-20,,19-Nov-20,"UPMC Pinnacle Harrisburg, Harrisburg, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04636021
NCT04399252,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,,Recruiting,No Results Available,Microbiome,Dietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG Placebo,Change in Shannon Diversity|Change in Shannon Diversity in patients that develop COVID-19,Duke University,All,"1 Year and older   (Child, Adult, Older Adult)",Not Applicable,1000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",Pro00105674,24-Jun-20,25-May-22,25-May-22,22-May-20,,1-Jul-20,"Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04399252
NCT04621461,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,,Not yet recruiting,No Results Available,Corona Virus Infection,Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo,Number of participants hospitalized and/or requiring repeat emergency room visits|Number of participants admitted to the Intensive care unit (ICU)|Number of participants on a ventilator|All-cause mortality|Time to resolution of COVID-19 symptoms|Severity of symptoms,"St. Francis Hospital, New York",All,"30 Years and older   (Adult, Older Adult)",Phase 4,750,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-19,20-Dec-20,May-21,May-21,9-Nov-20,,17-Dec-20,"St. Francis Hospital - The Heart Center, Roslyn, New York, United States",,https://ClinicalTrials.gov/show/NCT04621461
NCT04335084,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",HELPCOVID-19,Recruiting,No Results Available,COVID-19|Coronavirus Infection|Sars-CoV2|Corona Virus Infection|COVID|Coronavirus|Coronavirus-19|Coronavirus 19,Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events,ProgenaBiome|DSCS CRO,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",PRG-042,22-Jun-20,Jun-21,Sep-21,6-Apr-20,,20-Jul-20,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04335084
NCT04690816,Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases,,Recruiting,No Results Available,Systemic Autoimmune Diseases,,"Primary Objective: Characterize how COVID-19 modulates systemic inflammation, autoimmunity features, organ damage and vasculopathy in adult and pediatric patients with a previous diagnosis of systemic autoimmunity. Assess how subjects with syste...|Understand prevalence and severity of COVID-19 in individuals with autoimmune diseases, and the variables that associate/predict these responses.",National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC),All,"15 Years and older   (Child, Adult, Older Adult)",,350,NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,10000207|000207-AR,20-Jan-21,31-Dec-24,31-Dec-24,31-Dec-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04690816
NCT04492891,Cyclosporine For The Treatment Of COVID-19(+),,Recruiting,No Results Available,SARS (Disease),Drug: Cyclosporine|Other: Standard of Care Treatment,WHO COVID-19 clinical severity scale,"Bryan Burt, MD|Brigham and Women's Hospital|Baylor College of Medicine",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-48163,23-Nov-20,23-Nov-25,23-Nov-25,30-Jul-20,,27-Nov-20,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04492891
NCT04478071,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|Coronavirus Infection,Drug: vadadustat|Drug: placebo,"Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale|Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale","The University of Texas Health Science Center, Houston|Akebia Therapeutics Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-MS-20-0395,22-Aug-20,1-Aug-22,1-Aug-22,20-Jul-20,,10-Sep-20,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04478071
NCT04414371,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,,Recruiting,No Results Available,Stress|Anxiety|Depression|Resilience|Wellbeing|Mood,Other: Yoga,Stress|Wellbeing|Anxiety|Depression|Resilience|Positive Affect|Negative Affect,"Rutgers, The State University of New Jersey|Harvard Medical School",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro2020000953,20-May-20,31-Dec-20,31-Dec-20,4-Jun-20,,4-Jun-20,"Rutgers University, New Brunswick, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04414371
NCT04335630,Cardiovascular Manifestations of COVID-19,,Recruiting,No Results Available,Cardiovascular Diseases|COVID,"Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications",Memorial Hermann Health System,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,HSC-MS-20-0286,30-Mar-20,Mar-21,Mar-22,6-Apr-20,,7-Apr-20,"Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04335630
NCT04334954,SARS-COV2 Pandemic Serosurvey and Blood Sampling,,Recruiting,No Results Available,SARS-COV2 Virus,,Number of people with detectable antibodies to SARS-COV2,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,15000,NIH,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,200083|20-I-0083,26-Aug-20,31-Mar-22,31-Mar-22,6-Apr-20,,8-Oct-20,"University of Alabama, Birmingham, Alabama, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04334954
NCT04668209,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),CX4945,Not yet recruiting,No Results Available,Coronavirus,Drug: Silmitasertib,Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]|To compare time to clinical recovery in CX-4945 treatment group evaluated from randomization through Day 28 as compared to the control arm.|To compare changes in clinical status of patients enrolled to CX-4945 treatment arm as compared to the control arm at Day 14 and Day 28.|To evaluate preliminary evidence of anti-viral activity of CX-4945 as compared to the control arm.|Number of Days Hospitalized|To evaluate changes in IL-6 level|To evaluate changes in CRP|To evaluate changes in LDH|To evaluate changes in CPK|To evaluate changes in Ferritin|To evaluate changes in D-dimer|Number of Days of Supplemental Oxygen Use|All-cause Mortality Status|Number of days of on-invasive ventilation/high flow oxygen|Number of days of invasive mechanical ventilation/ECMO|Number of patients returned to room air|Change in pulse oxygen saturation|Number of thrombosis events|Changes in EQ-D5-5L,"University of Arizona|Senhwa Biosciences, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CX4945-AV02-IIT,15-Dec-20,31-Dec-22,31-Dec-22,16-Dec-20,,16-Dec-20,"Banner University Medical Center Phoenix, Phoenix, Arizona, United States|Banner University Medical Center Tucson, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04668209
NCT04665115,Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19),,Not yet recruiting,No Results Available,Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia,Drug: Ibrutinib|Other: Quality-of-Life Assessment,"Proportion of patients who require hospitalization for their COVID-19 disease or die (Cohort 1)|Proportion of patients who require mechanical ventilation and/or die (Cohort 2)|Rate of ""flare phenomena"" (Cohort I)|Patient-reported health and symptom status (Cohort I)|Patterns on ibrutinib therapy during COVID-19 infection (Cohort I)|Reasons for hospitalization (Cohort I)|Mortality (Cohort II)|Time to hospital discharge (Cohort II)|Intubation and oxygen supplementation (Cohort II)|Incidence of ""flare phenomena"" (Cohort II)|Viral clearance|Development of COVID-19 antibodies|Coagulopathy and thrombosis measures|Cytokine measures|Immune subset measures",Academic and Community Cancer Research United|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,134,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACCRU-LY-2001|NCI-2020-11785|P30CA015083,31-Dec-20,1-May-22,1-May-25,11-Dec-20,,11-Dec-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04665115
NCT04321811,"Behavior, Environment And Treatments for Covid-19",BEAT19,Recruiting,No Results Available,Coronavirus,"Other: Observation of patients with known, suspected, or at risk for COVID-19 infection",Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery,xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud,All,"18 Years and older   (Adult, Older Adult)",,100000,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,XC-PCOR-COVID19,21-Mar-20,20-Mar-21,20-Mar-22,25-Mar-20,,2-Apr-20,"BEAT19.org, San Francisco, California, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04321811
NCT04341935,Effects of DPP4 Inhibition on COVID-19,,Not yet recruiting,No Results Available,Coronavirus Infection|Type 2 Diabetes,Drug: Linagliptin|Drug: Insulin regimen,Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures,University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20200384,30-Jun-21,30-Dec-21,30-Dec-21,10-Apr-20,,12-Jan-21,"University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04341935
NCT04694638,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",,Recruiting,No Results Available,Prone Positioning|Covid19|Hypoxemic Respiratory Failure|ARDS|Non Invasive Ventilation|High Flow Nasal Cannulla,Other: Body position change,Rate of intubation|Incidence of hypotension and cardiac arrhythmias and other nursing-related risks of combining prone positioning with high-flow nasal cannula and non-invasive positive pressure ventilation,Mayo Clinic,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20-003191,21-May-20,May-21,May-21,5-Jan-21,,5-Jan-21,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04694638
NCT04465552,Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,,Recruiting,No Results Available,Coronavirus Infections,Other: Patients received standard of care treatment during hospitalization,"To better characterize arrhythmic manifestations, employed treatment strategies and long- term outcomes in hospitalized COVID-19 patients in the US through a multicenter retrospective chart review.",Kansas City Heart Rhythm Research Foundation,All,"18 Years and older   (Adult, Older Adult)",,750,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,KCHRF-COVID-19-0001,10-Jul-20,Oct-20,Dec-20,10-Jul-20,,1-Sep-20,"Kansas City Heart Rhythm Institute, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04465552
NCT04438967,Brain Health in the Time of COVID-19,,Recruiting,No Results Available,Brain Health,,Test the hypothesis that COVID-19 infection will lead to increased risk of neurological impairment|Determine cognitive and behavioral functional patterns that predict susceptibility to neurological impairment due to COVID-19,Miro Health|Johns Hopkins University|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",,10000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,MIRO_001_2020,16-Jun-20,31-Dec-21,31-Dec-21,19-Jun-20,,6-Jan-21,"Miro Health, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04438967
NCT04646616,CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.,CRISOL Contigo,Not yet recruiting,No Results Available,Covid19|Mental Health Issue|Violence,Other: Community popular opinion leader (POL) based intervention,Risk of exposure to COVID-19|Access to health care and testing|SAVAME-related factors and access to SAVAME services,Drexel University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,3R21MD012352-02S1,6-Jan-21,31-Oct-21,31-Oct-21,30-Nov-20,,2-Dec-20,"Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04646616
NCT04342169,University of Utah COVID-19 Hydrochloroquine Trial,,Recruiting,No Results Available,Coronavirus Infection|Coronavirus|Infectious Disease,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition,University of Utah,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB_00131893,4-Apr-20,Apr-21,Apr-22,10-Apr-20,,13-Nov-20,"University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04342169
NCT04513158,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,,Recruiting,No Results Available,Covid19,Biological: Convalescent Plasma,Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19).|Determine the immunologic effects of convalescent plasma infusion|Absolute lymphocyte count (10*3/uL)|reatinine kinase (mg/dL)|C-reactive protein (mg/dl)|D-Dimer (ng/ml FEU)|Interleukin-6 (pg/ml)|Ferritin (ng/mL),"Joseph M. Flynn, D.O., MPH|Norton Healthcare",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-N0124,14-Aug-20,1-Aug-21,31-Dec-21,14-Aug-20,,19-Oct-20,"Norton Hospital, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audubon Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04513158
NCT04341012,Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,,Recruiting,No Results Available,Liver Diseases|Liver Cancer|COVID19,Diagnostic Test: Collection of breath sample,Breath volatile organic compound profiles|Utility of breath profiles for disease diagnosis or prognosis,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19-001971,10-Sep-19,31-Dec-21,31-Dec-21,10-Apr-20,,13-Apr-20,"Mayo Clinic Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04341012
NCT04411602,Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,,Recruiting,No Results Available,Severe Acute Respiratory Syndrome|COVID,Drug: SARS-CoV-2 plasma,Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.|Ventilatory free days|Patient mortality (including death from any cause),Ascension South East Michigan,All,"18 Years and older   (Adult, Older Adult)",Phase 1,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1589349,7-Apr-20,31-Dec-20,31-Dec-20,2-Jun-20,,2-Jun-20,"Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04411602
NCT04585945,Pregnancy Outcomes During the Pandemic: Using Placental Pathology and Gene Expression to Understand Fetal Risk,PROSPER,Recruiting,No Results Available,COVID-19|SARS-CoV-2 Infection,Biological: SARS-CoV-2,"Inflammatory biomarkers in umbilical cord blood between women with COVID-19 disease in the first, second and third trimester of pregnancy and determine if differences are mediated by severity of the illness.|Differences in placental pathology (inflammatory processes, vasculopathy, and villous maturity) for women with COVID-19 disease and determine of differences are mediated by gestational age at infection or severity of illness.|Differences in gene expression analysis for women with COVID-19 disease and determine if differences are medicated by gestational age at infection or severity of illness.",Prisma Health-Upstate,Female,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Pro00101090,4-Aug-20,31-Mar-21,30-Sep-21,14-Oct-20,,14-Oct-20,"Prisma Health Upstate, Greenville, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04585945
NCT04432298,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease",,Recruiting,No Results Available,COVID-19,Drug: Pamrevlumab|Drug: Placebo,"Proportion of subjects who never received mechanical ventilation and/or ECMO and alive|Proportion of subjects alive, discharged home, and not on supplemental oxygen|Time to recovery based on a Modified 8-Point Ordinal Scale|Days in ICU/CCU (either on or off mechanical ventilation and/or ECMO)|Days on mechanical ventilation and/or ECMO|Time to death from any cause|Changes in PaO2/FiO2 ratio, both as categorical and continuous variable|Change in (non-invasive) oxygen supplementation requirements",FibroGen,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FGCL-3019-098,20-Jun-20,Dec-20,Jan-21,16-Jun-20,,2-Dec-20,"Research Center, Detroit, Michigan, United States|Research Center, Greensboro, North Carolina, United States|Research Center, Philadelphia, Pennsylvania, United States|Research Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04432298
NCT04664101,"REmotely Monitored, Mobile Health Supported High Intensity Interval Training for Survivors of COVID-19",REMM-HIIT-ICU,Not yet recruiting,No Results Available,Covid19|Critical Illness|High Intensity Interval Training|ICU|Intensive Care Units|Fitness Trackers,"Behavioral: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)",Percentage of exercise session completed daily as measured by smart device monitoring.|Percentage of adherence to personal heart rate goal as measured by smart device monitoring.|Change in 6 minute walk distance,Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00105798,1-Jan-21,1-Feb-23,1-Feb-23,11-Dec-20,,11-Dec-20,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04664101
NCT04439006,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,,Recruiting,No Results Available,Aplastic Anemia|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Monoclonal B-Cell Lymphocytosis|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed,Other: Best Practice|Drug: Ibrutinib,"Proportion of patients with diminished respiratory failure and death|Death|Time from study initiation to 48 hours fever-free|Duration of hospitalization|Time in intensive care unit (ICU)|Time to ICU admission|Number of days requiring supplemental oxygen|Total days of mechanical ventilation|Time to mechanical ventilation|Shock and need for pressure support|Incidence of any infection (viral, fungal, bacterial)|Time to clinical resolution|Incidence of grade 3 or higher adverse events|At the end of therapy (day 14)|Time to viral clearance|Survival","Jennifer Woyach|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Ohio State University Comprehensive Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 2,72,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-20135|NCI-2020-03341|P30CA016058,22-Jul-20,31-Dec-21,31-Dec-22,19-Jun-20,,19-Aug-20,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04439006
NCT04597047,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,CAPTURE-2,Recruiting,No Results Available,Covid19,Diagnostic Test: Capillary Collection & Testing|Diagnostic Test: Venous Draw & Testing,Performance Evaluation,LumiraDx UK Limited,All,"2 Years and older   (Child, Adult, Older Adult)",Not Applicable,200,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,S-CLIN-PROT-0031,20-Aug-20,31-Oct-22,31-Dec-22,22-Oct-20,,22-Oct-20,"Eclipse Clinical Research, Tucson, Arizona, United States|Centura Health Physician Group, Northglenn Office, Northglenn, Colorado, United States|Professional Research Network of Kansas, Wichita, Kansas, United States|Physicians Quality Care of Jackson, Jackson, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04597047
NCT04447404,"DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",,Recruiting,No Results Available,SARS-CoV 2,Drug: DUR-928|Drug: Placebo,Composite endpoint of alive and free of organ failure|Occurrence of serious adverse events following treatment|Alive at days 28 and 60|Alive and out of ICU|Alive and out of hospital,Durect,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C928-020,21-Sep-20,Sep-21,Oct-21,25-Jun-20,,11-Jan-21,"Site 02, Chicago, Illinois, United States|Site 01, Detroit, Michigan, United States|Site 03, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04447404
NCT04362865,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,,Recruiting,No Results Available,COVID-19,,Characterize immune response|B- and T-cell arm immune response|Immune response and outcome,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,180,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200103|20-C-0103,27-Apr-20,1-Dec-23,1-Dec-24,27-Apr-20,,14-Jan-21,"Medstar Washington Hospital Center, Washington, District of Columbia, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Medstar Montgomery Medical Center, Olney, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04362865
NCT03183570,"Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT",,Recruiting,No Results Available,Idiopathic Pulmonary Fibrosis|Primary Sclerosing Cholangitis|Covid19 Pneumonia,Drug: [18F]FP-R01-MG-F2,"SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung|Time Activity Measurements|Incidence of Study Completion (Safety and Tolerability)","Stanford University|Pliant Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB Protocol: 40450,8-Nov-17,14-Apr-22,14-Apr-23,12-Jun-17,,27-Nov-20,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03183570
NCT04391816,COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study,,Recruiting,No Results Available,Alcohol Drinking|Alcohol-Related Disorders|Pandemic|Psychological Stress,,AUDIT Score|ADS Score|Life Events Questionnaire (LEQ) Score|UCLA Loneliness Scale (UCLALS) Score|Perceived Stress Scale (PSS) Score,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,700,NIH,Observational,Observational Model: Other|Time Perspective: Prospective,200115|20-AA-0115,20-Jan-21,31-Dec-22,31-Dec-24,18-May-20,,15-Jan-21,"NIAAA Section on Human Psychopharmacology, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04391816
NCT04409743,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,,Recruiting,No Results Available,Sleep Disturbance|Insomnia,Behavioral: Remote Cognitive Behavioral Therapy for Insomnia,Change in Insomnia Clinical Diagnosis Over Time|Change in Patient Health Questionnaire-9 (PHQ-9) Scale Score as a Measure of Depression Symptoms Over Time|Change in Generalized Anxiety Disorder-7 (GAD-7) Scale Score Over Time|Change in Insomnia Severity Index (ISI) Scale Score Over Time|Change in Quality of Life (SF-36) Scale Score Over Time|Change in Sheehan Suicidality Tracking Scale (S-STS) Score Over Time|Change in UCLA Loneliness Scale Score Over Time|Change in Social Network Index (SNI) Scale Score Over Time|Change in Perceived Stress Scale Score Over Time|Change in Screen Time- Self Report Over Time|Change in International Physical Activity Questionnaire (IPAQ) Scale Score Over Time|Change in Sleep Onset Latency (SOL) as a Measure of Sleep Continuity Over Time|Change in Number of Awakenings as a Measure of Sleep Continuity Over Time|Change in Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity Over Time|Change in Total Sleep Time (TST) as a Measure of Sleep Continuity Over Time|Change in Sleep Efficiency (SE) as a Measure of Sleep Continuity Over Time|Change in Beck Depression Inventory-II (BDI) Scale Score Over Time|Change in Beck Anxiety Inventory (BAI) Scale Score Over Time,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,IRB-55940,7-Jun-20,May-21,Nov-21,1-Jun-20,,11-Dec-20,"Stanford University, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT04409743
NCT04558320,COVID-19 and Lactating Mothers,,Recruiting,No Results Available,Coronavirus Infection,,mean change in SARS-Cov-2 viral load in breast milk,University of Rochester|National Institute of Allergy and Infectious Diseases (NIAID)|New York University,All,"Child, Adult, Older Adult",,100,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,STUDY00004889|3U01AI131344-04S1,2-Jul-20,1-Apr-21,1-Apr-21,22-Sep-20,,22-Sep-20,"University of Rochester Medical Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT04558320
NCT04398264,Characteristics of COVID-19 Infection Among PREGnant Women,CCOVID-PREG,Recruiting,No Results Available,Corona Virus Infection|Pregnancy Related,Other: COVID-19 positive via testing,Asymptomatic COVID-19 positive pregnant women|Asymptomatic Hispanic COVID-19 positive pregnant women|Follow up of asymptomatic COVID-19 positive pregnant women|COVID-19 positive newborns|Severe COVID-19 disease in pregnant women,Inova Health System,Female,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Other,U20-05-4055,22-Jul-20,30-Sep-20,31-Mar-21,21-May-20,,29-Jul-20,"INOVA Health System, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04398264
NCT04555122,COVID-19 Ad Intervention,,Not yet recruiting,No Results Available,Social Distance,Behavioral: Social Distancing Advertisements,Mobility,"University of California, Irvine|City University of Hong Kong|University of California, Los Angeles",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,52500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",COVID-Ad,29-Sep-20,28-May-22,28-Jul-22,18-Sep-20,,23-Sep-20,"UC Irvine, Irvine, California, United States",,https://ClinicalTrials.gov/show/NCT04555122
NCT04603781,CBD Oil for Reducing Emotional Impact of COVID-19,CBDOIL,Recruiting,No Results Available,Anxiety Depression|Alcohol Abuse|Substance Abuse|Anger|Sleep Disturbance|Stress Reaction,Dietary Supplement: CBD Isolate|Dietary Supplement: Full Spectrum CBD Oil|Dietary Supplement: Placebo Oil,PROMIS Emotional Distress Index|PROMIS Depression Scale|PROMIS Anxiety Scale|PROMIS Anger Scale|PROMIS Alcohol Negative Consequences Scale|PROMIS Sleep Disturbance Scale|COVID-19 Coping Self-Efficacy,University of Texas at Austin|Way West Hemp Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-07-0138,4-Dec-20,31-Dec-21,31-Dec-21,27-Oct-20,,8-Dec-20,"University of Texas at Austin, Laboratory for the Study of Anxiety Disorders, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04603781
NCT04489628,Tele-health Enabled Clinical Trial for COVID-19,,Not yet recruiting,No Results Available,SARS-CoV Infection,Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring,Patients requiring admission to the hospital or experiencing death,University Hospitals Cleveland Medical Center|Northwestern University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STUDY20200461,1-Aug-20,1-Aug-21,1-Aug-21,28-Jul-20,,31-Jul-20,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04489628
NCT04382391,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,SAVIORII,Recruiting,No Results Available,"COVID|Corona Virus Infection|Respiratory Failure|Respiratory Distress Syndrome, Adult|ARDS, Human|SARS (Severe Acute Respiratory Syndrome)",Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies,change in initiation of mechanical ventilation in patients with CoViD-19 compared to the control group.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of CoViD-19 patients|delay onset of ventilation,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)|ElectroCore INC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-132-AGH,8-May-20,1-Mar-21,30-Dec-21,11-May-20,,22-Oct-20,"AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AHN West Penn Hospital, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04382391
NCT04587245,The Provider Insurance Revenue Study in Healthcare Providers in the United States of America,,Recruiting,No Results Available,Covid19|Financial Disclosure,Other: Online questionnaire and interviews,"Change in monthly income of healthcare Providers from baseline to 6, 9 and 12 months after the beginning of the COVID-related events|Differences in Accounts Receivable (AR) due to claim denials over 4 quarters: Differences in recoveries of AR.","ND Sciences, LLC|University of California, Irvine",All,"Child, Adult, Older Adult",,100,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PIRStudy,1-Oct-20,15-Oct-21,15-Oct-21,14-Oct-20,,19-Oct-20,"University of California Irvine Beall Applied Innovation, Irvine, California, United States",,https://ClinicalTrials.gov/show/NCT04587245
NCT04429555,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",,Not yet recruiting,No Results Available,"Pneumonia, Viral",Drug: Ibudilast|Drug: Placebo,"Proportion of subjects free from respiratory failure|Mean change from baseline in clinical status using the NIAID 8-point ordinal scale at Day 7|Percentage of patients with improvement in clinical status|Change in cytokine levels from baseline|Adverse event Incidence, severity, relationship to study drug, and study discontinuations|Changes in laboratory values from baseline|Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 14|Mean change from baseline in clinical status|Incidence of mechanical ventilation or intubation|Intensive care unit admission|Plasma concentrations of Ibudilast|All cause mortality",MediciNova,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MN-166-COVID-19-201,Jan-21,30-Jun-21,1-Dec-21,12-Jun-20,,24-Dec-20,"Denver Health and Hospital Authority, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04429555
NCT04370236,INB03 for the Treatment of Pulmonary Complications From COVID-19,,Recruiting,No Results Available,COVID-19,Drug: INB03|Drug: Placebo,"Proportion of participants with disease progression from randomization to 28 days post-randomization|Proportion of participants with all-cause mortality|Proportion of participants who transfer to ICU level care by Day 28 (ICU level care is defined as a hospital setting where patient to nurse ratio is < 4);|Proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by Day 28;|Proportion of participants with evidence of new CHF or new MI requiring medical intervention by Day 28;|Proportion of participants with a new onset embolus or thrombus by Day 28;|Proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by Day 28;|Proportion of participants with an increase in the WHO Ordinal Scale of Clinical Improvement score at any time during the study;|Length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;|Change from baseline in inflammation markers over time.","Inmune Bio, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,366,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INB03-COVID-19_01,21-Oct-20,Feb-21,Feb-21,30-Apr-20,,26-Oct-20,"NEA Baptist, Jonesboro, Arkansas, United States|Jewish Hospital, Louisville, Kentucky, United States|Mississippi Baptist, Kosciusko, Mississippi, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04370236
NCT04707703,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Isavu-CAPA,Not yet recruiting,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2|Aspergillosis Invasive,Drug: Isavuconazonium Injection [Cresemba]|Drug: Placebo,The incidence of SARS-CoV-2-associated invasive aspergillosis at time of ICU discharge|The incidence of SARS-CoV-2-associated non-Aspergillus invasive fungal infections at time of ICU discharge|Survival|Length of ICU stay|Length of Hospital stay|Mortality|Adverse events,"Jeffrey Jenks, MD, MPH|Astellas Pharma Global Development, Inc.|University of California, San Diego",All,"18 Years and older   (Adult, Older Adult)",Phase 3,162,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",200639,Jan-21,Jan-22,Mar-22,13-Jan-21,,13-Jan-21,"University of California Irvine, Orange, California, United States|University of California Davis, Sacramento, California, United States|University of California San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04707703
NCT04626050,"General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19",,Not yet recruiting,No Results Available,Post-traumatic Stress Disorder|Moral Injury,Behavioral: Medical Music|Behavioral: Narrative Writing|Behavioral: Prolonged Exposure Therapy|Behavioral: Interpersonal Psychotherapy,Feasibility Indicator: Recruitment (Phase I)|Feasibility Indicator: Recruitment (Phase II)|Feasibility Indicator: Enrollment (Phase I)|Feasibility Indicator: Enrollment (Phase II)|Feasibility Indicator: Retention (Phase I)|Feasibility Indicator: Retention (Phase II)|Acceptability Indicator: Satisfaction (Phase I)|Acceptability Indicator: Satisfaction (Phase II)|Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase I)|Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase II)|Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale (Phase I)|Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale (Phase II)|Change in Depressive Symptoms measured by the Beck Depression Inventory-II (Phase I)|Change in Depressive Symptoms measured by the Beck Depression Inventory-II (Phase II)|Change in score on the Pittsburgh Sleep Quality Index (PSQI) (Phase I)|Change in score on the Pittsburgh Sleep Quality Index (PSQI) (Phase II)|Change in score on the Moral Distress Scale (Phase I)|Change in score on the Moral Distress Scale (Phase II)|Change in score on the Modified Moral Injury Events Scale (Phase I)|Change in score on the Modified Moral Injury Events Scale (Phase II)|Change in score on the PTSD Checklist for DSM-5 (PCL-5) (Phase I)|Change in score on the PTSD Checklist for DSM-5 (PCL-5) (Phase II)|Change in score on the Sheehan Disability Scale (SDS) (Phase I)|Change in score on the Sheehan Disability Scale (SDS) (Phase II)|Change in score on the World Health Organization Quality of Life Scale - Brief (Phase I)|Change in score on the World Health Organization Quality of Life Scale - Brief (Phase II)|Change in score on the Social Adjustment Scale (SAS) (Phase I)|Change in score on the Social Adjustment Scale (SAS) (Phase II)|Change in Score on the Occupational Stress Inventory Revised (OSI-R) (Phase I)|Change in Score on the Occupational Stress Inventory Revised (OSI-R) (Phase II)|Change in Score on the Multidimensional Scale of Perceived Social Support (MSPSS) (Phase I)|Change in Score on the Multidimensional Scale of Perceived Social Support (MSPSS) (Phase II)|Change in score on the Posttraumatic Cognitions Inventory (Phase I)|Change in score on the Posttraumatic Cognitions Inventory (Phase II)|Change in score on the Difficulties in Emotion Regulation Scale (DERS) (Phase I)|Change in score on the Difficulties in Emotion Regulation Scale (Phase II),Weill Medical College of Cornell University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,20-04021913,Jan-21,Jan-22,Jan-22,12-Nov-20,,23-Dec-20,"Weill Cornell Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04626050
NCT04661540,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,,Not yet recruiting,No Results Available,Pneumonia,Drug: CM4620-IE (Injectable Emulsion)|Drug: Placebo,Decrease in interferon-gamma producing T-cells in Broncoalveolar lavage (BAL) fluid|Number of Days in the Hospital after randomization|Number of Days in the Intensive Care Unit (ICU) after randomization|Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Intensity and relationship of TEAEs and SAEs|Pre-defined changes in cardiac conduction assessed by ECG|Mortality|Plasma Levels of CM4620,"CalciMedica, Inc.|Northwestern University",All,"18 Years and older   (Adult, Older Adult)",Phase 2,36,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CM4620-205,Dec-20,Apr-21,Apr-21,10-Dec-20,,10-Dec-20,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04661540
NCT04595903,Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device,,Not yet recruiting,No Results Available,SARS (Severe Acute Respiratory Syndrome),Device: Hemopurifier,"Incidence of treatment emergent adverse events|Incidence of device related adverse events|Incidence of serious adverse events|Length if Stay in ICU|In-hospital mortality|Days free of ventilatory dependency|Vasopressor-free days|Sequential Organ Failure Assessment (SOFA)|Acute Physiology and Chronic Health Evaluation (APACHE)|SARS CoV-2 RNA levels in plasma and nasopharyngeal samples|Total lymphocyte count|C-reactive protein (CRP), IL-1, IL-6, and TNF alpha Tests|D-dimer|Troponin-T|Evaluation of SARS-CoV-2 RNA levels post-treatment Hemopurifier cartridges|Evaluation of viral particle load post-treatment Hemopurifier cartridges",Aethlon Medical Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AEMD-2020-02,Jan-21,Aug-21,Aug-21,22-Oct-20,,14-Jan-21,"Hoag Hospital - Irvine, Irvine, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",,https://ClinicalTrials.gov/show/NCT04595903
NCT04615416,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,ERT-P,Recruiting,No Results Available,"Distress, Emotional|Emotional Dysfunction|Anxiety|Depression",Behavioral: Emotion Regulation Training via Telehealth,"Changes in Anxiety, Depression, and Distress|Changes in Worry|Changes in Rumination|Changes in Functional Impairment|Changes in Life Satisfaction|Semi-Weekly Measures of Treatment Changes in Anxiety|Semi-Weekly Measures of Treatment Changes in Depression|Semi-Weekly Measures of Treatment Changes in Depression Symptoms|Semi-Weekly Measures of Treatment Changes in Distress|Semi-Weekly Measures of Treatment Changes in Worry|Semi-Weekly Measures of Treatment Changes in Rumination|Semi-Weekly Measures of Treatment Changes in Metacognitive Regulation|Semi-Weekly Measures of Treatment Changes in Attentional Regulation|Satisfaction and Usability of Treatment","Teachers College, Columbia University|University of Michigan",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-269,1-May-20,Jan-21,Jan-23,4-Nov-20,,4-Nov-20,"Teachers College, Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04615416
NCT04426318,COVID-19 and the Healthy Minds Program for Educators,CAHMP-ED,Recruiting,No Results Available,Anxiety|Depression|Psychological Stress|Psychological Distress|Well-being,Behavioral: Healthy Minds Program Foundations Training,Change from baseline on an aggregate measure of Psychological distress that averages the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depressive Measures and the NIH Perceived Stress Scale|Change from baseline on the Five Facet Mindfulness Questionnaire Act with Awareness subscale|Change from baseline on the Drexel Defusion Scale (DDS)|Change from baseline on the Meaning in Life Questionnaire|Change from baseline on the NIH Toolbox Loneliness scale|Change from baseline on the Conway COVID Questionnaire|Change from baseline on the Self-Compassion Scale Short Form|Change from baseline on the Perseverative Thought Questionnaire|Change from baseline on the World Health Organization 5-item (WHO-5) well-being scale|Change from baseline on the Neutral Face Rating task|Change from baseline on the Growth Mindset Scale for Well-Being,"University of Wisconsin, Madison|Chan Zuckerberg Initiative|Healthy Minds Innovations|Center for Healthy Minds",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2020-0533|A171600|EDUC/COUNSELING PSYCH|Protocol Approval 10/15/2020,14-Jun-20,30-Jan-21,30-Jun-22,11-Jun-20,,27-Nov-20,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04426318
NCT04582331,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,,Recruiting,No Results Available,Covid19,Other: Smartphone-based voice and self-reported symptom collection,Vocal biomarker performance in COVID-19 positive vs. healthy controls|Vocal biomarker vs. symptom burden correlation in COVID-19 positive|Vocal biomarker performance in COVID-19 positive vs. COVID-19 negative symptomatic,Sonde Health,All,"12 Years and older   (Child, Adult, Older Adult)",,300,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,SH2020.COV01,10-Sep-20,31-Dec-20,31-Dec-20,9-Oct-20,,9-Oct-20,"UC San Diego Medical Center, San Diego, California, United States|Brigham & Woman's Hospital, Boston, Massachusetts, United States|Montefiore Medical Center, New York, New York, United States|Deenanath Mangeshkar Hospital & Research Centre, Pune, India",,https://ClinicalTrials.gov/show/NCT04582331
NCT04416919,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,,Recruiting,No Results Available,Coronavirus Infection|Disease Prevention,Other: Assembled mask,Success Percentage|End-tidal CO2 Variation. Description: mmHg.|Oxygen Pulse Oximetry Variation. Description: mmHg.|Mask Visibility. Description: Likert Scale.|Willingness of usage. Description: Likert Scale.,University of Oklahoma|US Department of Veterans Affairs,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,11887,15-Jul-20,May-25,May-25,4-Jun-20,,1-Jul-20,"Oklahoma City VA Health Care System, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04416919
NCT04388605,Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,ASPIRE,Recruiting,No Results Available,Corona Virus Infection|COVID|Pregnancy Related|Early Pregnancy,,"Prevalence of SARS-CoV-2 infection throughout pregnancy in women|Incidence of SARS-CoV-2 infection throughout pregnancy in women|Risk ratios of adverse obstetric in women infect with SARS-CoV-2 during early pregnancy onward compared to non-infected pregnant women|Risk ratios of adverse neonatal outcomes in women infected with SARS-CoV-2 during early pregnancy onward compared to non-infected pregnant women|Clinical, behavioral, and sociodemographic determinants","University of California, San Francisco",Female,"18 Years and older   (Adult, Older Adult)",,11000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-30559,21-Apr-20,Sep-21,Sep-22,14-May-20,,15-May-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04388605
NCT04579393,Fostamatinib for Hospitalized Adults With COVID-19,,Recruiting,No Results Available,Coronavirus Disease 2019,Drug: Placebo|Drug: fostamatinib,"Cumulative Incidence of SAEs|Number of days in the ICU|Change in CRP, IL-6, d-dimer, ferritin, fibrinogen, absolute lymphocyte count, absolute neutrophil count, and platelet count from baseline|Ordinal scale|Days of hospitalization|Time to recovery|Number of days free of mechanical ventilation [entire hospitalization cohort 1]|Number of days on oxygen|Change in SOFA score from baseline|Days free of renal failure|Clinically relevant deep vein thrombosis|Relative change in PaO2/FiO2 or SpO2/FiO2 ratio","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",10000110|000110-H,8-Oct-20,31-Jan-21,31-Jan-21,8-Oct-20,,30-Dec-20,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States|INOVA Health Systems, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04579393
NCT04377672,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),,Recruiting,No Results Available,Corona Virus Infection,Biological: Anti-SARS-CoV-2 Human Convalescent Plasma,Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection,Johns Hopkins University,All,"1 Month to 18 Years   (Child, Adult)",Phase 1,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00247557,28-May-20,28-May-21,28-May-22,6-May-20,,2-Jun-20,"Johns Hopkins Hospitals, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04377672
NCT04343248,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),,Recruiting,No Results Available,COVID-19|Viral Respiratory Illnesses,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI,Romark Laboratories L.C.,All,"55 Years to 120 Years   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",RM08-3006,12-May-20,31-Dec-20,31-Dec-20,13-Apr-20,,18-Sep-20,"The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04343248
NCT04497415,The COVID-19 and Healthcare Workers: An Active Intervention,,Recruiting,No Results Available,Brief Video-based Intervention|Non Intervention Control,Other: Video-Based intervention,Help-seeking behavior|GAD-7|PHQ-9|PC-PTSD|Moral Injury,"Research Foundation for Mental Hygiene, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,8032,21-Oct-20,30-Nov-20,30-Jan-21,4-Aug-20,,23-Oct-20,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04497415
NCT04484207,Addressing COVID-19 Mental Health Problems Among US Veterans,,Recruiting,No Results Available,Brief Video-based Intervention|Vignette Based Intervention|Non Intervention Control Arm,Other: A short video intervention|Other: A vignette intervention,Help seeking behavior|Generalized Anxiety Disorder (GAD-7)|Patient Health Questionnaire-9|The Primary Care PTSD Screen for DSM-5 (PC-PTSD),"Research Foundation for Mental Hygiene, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,8006,6-Jul-20,20-Oct-20,26-Oct-20,23-Jul-20,,14-Oct-20,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04484207
NCT04565509,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,,Recruiting,No Results Available,Covid19|Intellectual Disability|Developmental Disability|Child Development Disorder,Behavioral: General Communication Message|Behavioral: Focused/Targeted Message|Behavioral: Best Message Alone|Behavioral: Best Message + Augmented Message or Implementation Strategy,Adoption of weekly testing by each participant|Acceptability of Messaging/Implementation Strategy|Feasibility of Messaging/Implementation Strategy|Appropriateness of Messaging/Implementation Strategy|Number of missed school days by students or work days by staff|Students and staff positive SARS-CoV-2 virus|School-based SARS-CoV-2 transmission events,"Washington University School of Medicine|University of Missouri, Kansas City|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institutes of Health (NIH)",All,"5 Years to 90 Years   (Child, Adult, Older Adult)",Not Applicable,2500,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,202009060,20-Nov-20,30-Jun-22,21-Sep-22,25-Sep-20,,30-Nov-20,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Baltimore, Maryland, United States|University of Missouri, Kansas City, Missouri, United States|Special School District, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04565509
NCT04614844,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),,Not yet recruiting,No Results Available,Physician Stress Levels,Behavioral: Simulation Intervention|Behavioral: Control,Change in end-of-shift heart rate variability|Change in STAI S-Anxiety|Change in STAI T-Anxiety,Yale University|Agency for Healthcare Research and Quality (AHRQ),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,2000029372|1R01HS028340-01,15-Dec-20,15-Sep-22,15-Nov-22,4-Nov-20,,2-Dec-20,"Yale New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04614844
NCT04517123,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",PRONE,Recruiting,No Results Available,"Covid19|Pneumonia, Viral",Other: Prone Positioning,Occurrence of an escalation in respiratory related care (yes vs no)|Oxygen Saturation|Respiratory Effort as assessed by Respiratory Rate,"Johns Hopkins University|Duke University|University of North Carolina|University of Miami|University of Pittsburgh|Smith & Nephew, Inc.|Nox Medical Iceland",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00249663,1-Sep-20,31-Dec-21,31-Dec-21,18-Aug-20,,12-Oct-20,"Johns Hopkins Univeristy, Baltimore, Maryland, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04517123
NCT04380870,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,,Recruiting,No Results Available,Coronavirus Infection,Dietary Supplement: Chinese Herbal Medicine,Patient reported main complaint|Conduct qualitative analyses of data,"Center for Integrated Care|University of Utah|University of California, San Francisco",All,"18 Years to 114 Years   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,1/4/20,11-Apr-20,11-Apr-21,11-Apr-25,8-May-20,,8-May-20,"Seattle Intstitute of East Asian Medicine, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04380870
NCT04526912,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,ALI,Recruiting,No Results Available,Acute Lung Injury,Drug: VIB7734|Drug: Placebo,"The proportion of patients who achieve treatment success through Day 28, defined as avoidance of death and critical illness|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent fatal and life-threatening SAEs, Treatment-emergent Serious Adverse Events|Change in safety laboratory parameters",Viela Bio,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VIB7734.P1.S2,28-Aug-20,Apr-21,Jul-21,26-Aug-20,,13-Jan-21,"Research Site, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04526912
NCT04619680,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,ENDCOV-I,Recruiting,No Results Available,Pulmonary Fibrosis|Interstitial Lung Disease|Respiratory Disease,Drug: Nintedanib|Drug: Placebo,Change in Forced Vital Capacity (FVC)|Number of deaths due to respiratory cause|Chest CT visual score|St. George's Respiratory Questionnaire (SGRQ)|King's Brief Interstitial Lung Disease (KBILD)|King's Brief ILD (KBILD)|Leicester Cough Questionnaire (LCQ)|Leicester Cough Questionnaire|Short Form (SF) 36 Health Survey|SF 36 Health Survey|Hospital Anxiety and Depression Scale (HADS)|Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal|Number of participants with Thrombotic events|Number of participants with 10% weight loss over 90 days|Number of participants with GI events,Icahn School of Medicine at Mount Sinai|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GCO 20-2147,18-Nov-20,Jul-21,Jul-21,6-Nov-20,,17-Dec-20,"Mount Sinai Beth Israel, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04619680
NCT04652596,Reducing Food Insecurity During COVID-19,,Not yet recruiting,No Results Available,Food Insecurity,Other: Produce prescription program|Other: Grocery store gift cards,Change in Food Security|Change in fruit & vegetable consumption|Depression Symptoms|Symptom Relief|Changes of behavioral activation for depression|Perceived Stress|Social Support|Medical outcomes social support|Mastery Control|Self-Esteem|Unmet needs|Self-Reported Food Assistance Program Participation|Change in Self-Reported Health Status|Maternal attitudes and safe infant care practices|Impact of COVID-19|Program Experience|Change in adult acute healthcare utilization|Total adult patient-level cost of care|Child healthcare utilization|Child weight|Child height,Boston Medical Center|Patient-Centered Outcomes Research Institute|United States Department of Agriculture (USDA)|Krupp Family Foundation|Waldron Charitable Fund,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,H-41052|6007145|Pending,Jan-21,Jun-22,Oct-22,3-Dec-20,,3-Dec-20,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04652596
NCT04678778,Virtual Reality Study - COVID-19 Protocol,NRVR,Recruiting,No Results Available,Healthy Aging,Behavioral: Physical and Cognitive Activity,Magnetic Resonance Image (MRI) brain scan of hippocampal volume (cubic mm)|Mnemonic Similarity Task for visual memory performance - discrimination index,University of Southern California,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,HS17-00354,19-Mar-19,17-Feb-21,17-Feb-21,22-Dec-20,,11-Jan-21,"Mark and Mary Stevens Neuroimaging and Informatics Institute of the University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04678778
NCT04650191,Surfactant Protein Genetic Variants in COVID-19 Infection,,Recruiting,No Results Available,Coronavirus Infection,Other: Identification of genetic variants,Correlation of surfactant protein genetic variants with severity of COVID-19 infection,Milton S. Hershey Medical Center,All,"up to 90 Years   (Child, Adult, Older Adult)",,300,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,15456,1-Mar-20,Jun-21,Dec-21,2-Dec-20,,2-Dec-20,"Milton S. Hershey Medical center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04650191
NCT04312243,NO Prevention of COVID-19 for Healthcare Providers,NOpreventCOVID,Recruiting,No Results Available,Coronavirus Infections|Healthcare Associated Infection,Drug: Inhaled nitric oxide gas,COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test,Massachusetts General Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,470,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NOpreCOVID-19,7-Apr-20,7-Apr-21,7-Apr-22,18-Mar-20,,16-Jun-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04312243
NCT04406064,Viral Specific T-cells for Treatment of COVID-19,,Not yet recruiting,No Results Available,Viral Infection,Biological: Viral Specific T-cells (VSTs),Successful production of viral specific T-cells|Presence of viral-specific T-cells,"Children's Hospital Medical Center, Cincinnati|Hoxworth Blood Center",All,"Child, Adult, Older Adult",Phase 2,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0353,Jan-21,Jun-24,Jun-25,28-May-20,,4-Nov-20,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04406064
NCT04482595,BIO 300 Oral Suspension in Discharged COVID-19 Patients,,Recruiting,No Results Available,Pulmonary Fibrosis,Drug: BIO 300 Oral Suspension|Drug: Placebo,Change in DLCO|Change in 6 Minute Walk Test|Change in FVC|Change in St. George's Respiratory Questionnaire (SGRQ) Scores|Change in Pulmonary Fibrosis on HRCT Scan|Incidence of Re-Hospitalization|All-Cause Mortality|Change in FEV1|Change in FEV1/FVC Ratio|Change in Pulse Oximetry at Rest and During the 6MWT|Adverse Events Related to BIO 300 Oral Suspension|Change in Clinical Laboratory Values|Change in Clinical Laboratory Values for Albumin|Change in Clinical Laboratory Values for Serum Enzymes|Change in Complete Blood Counts with Differential,Humanetics Corporation|NYU Langone Health|National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years and older   (Adult, Older Adult)",Phase 2,66,Industry|Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL0105-01|272201800011C-P00005-9999-1,11-Nov-20,Aug-21,May-22,22-Jul-20,,17-Nov-20,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04482595
NCT04417673,Living With Sickle Cell Disease in the COVID-19 Pandemic,,Not yet recruiting,No Results Available,Isolation|Anxiety|Health Care Utilization|Sickle Cell Disease|Pain,,"Stress|Anxiety|Depressive symptomology|Pain episodes, and severity|Healthcare utilization (primary care, emergency department, telehealth other)|Receptivity to future health recommendations and medical treatment(s).",National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,1000,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,999920125|20-HG-N125,20-Jan-21,31-Dec-24,31-Dec-24,5-Jun-20,,15-Jan-21,"National Human Genome Research Institute (NHGRI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04417673
NCT04373148,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",,Recruiting,No Results Available,Coronavirus,Other: There is no intervention,Testing Immunity to SARS-CoV-2 over time|Testing the virus over time,Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)|National Cancer Institute (NCI),All,"2 Years and older   (Child, Adult, Older Adult)",,1000,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,IRB-55689|2U19AI057229|20-006-ACTT|1U54CA260517-01,8-Apr-20,30-Apr-22,30-Apr-22,4-May-20,,16-Nov-20,"Stanford University, Hospital, and Clinics, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04373148
NCT04501445,Psychological Symptoms and Families of COVID-19 Patients,,Recruiting,No Results Available,Family Members|Post Intensive Care Unit Syndrome|Post Traumatic Stress Disorder,Behavioral: Written Summary of Rounds,Symptoms of Post-Traumatic Stress Disorder (PTSD) initial|Symptoms of Anxiety and Depression initial|Surrogate Satisfaction with the Patient's ICU Care:|Symptoms of Post-Traumatic Stress Disorder (PTSD) final|Symptoms of Anxiety and Depression final|Interview initial|Interview final,Rush University Medical Center|Central Michigan University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20071101,14-Sep-20,1-Aug-21,15-Sep-21,6-Aug-20,,15-Jan-21,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04501445
NCT04431297,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,,Not yet recruiting,No Results Available,Chronic Stress,Other: Mindfulness Rounds,Change in Perceived Stress Scale,Icahn School of Medicine at Mount Sinai,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,GCO 20-1022,Jan-21,30-Jun-21,Jun-22,16-Jun-20,,10-Dec-20,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04431297
NCT04704544,Effectiveness of Tele-rheumatology During the COVID-19 Crisis,,Not yet recruiting,No Results Available,Rheumatic Diseases,Other: Tele-rheumatology,Patient satisfaction|Patient preference,"University of Alabama at Birmingham|University of California, San Francisco|Tulane University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,320,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,IRB-300006553,1-Mar-21,30-Nov-22,30-Nov-22,11-Jan-21,,11-Jan-21,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04704544
NCT04632368,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,,Recruiting,No Results Available,"Burnout, Professional|Stress, Psychological",Behavioral: Transcendental Meditation,change in self reported Stress symptoms|Change in self reported resilience|Change in symptoms of depression|Change in insomnia symptoms|Change in anxiety symptoms|Change in psychological distress|Change in self reported burnout symptoms,Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00106191,20-Nov-20,Apr-21,Apr-21,17-Nov-20,,16-Dec-20,"Duke University health system, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04632368
NCT04460677,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,,Recruiting,No Results Available,"Psychological Distress|Stress, Psychological|Autism Spectrum Disorder",Behavioral: Emotional Support Plan|Behavioral: Daily Monitoring,Decreased distress on Patient Health Questionnaire (PHQ-9)|Decreased distress on EMA reports|Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)|Adult Self Report (ASR),"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Pro2020001593,12-Aug-20,31-Mar-21,31-Mar-21,7-Jul-20,,9-Sep-20,"Rutgers University, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04460677
NCT04377100,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,,Recruiting,No Results Available,Anxiety|Healthy Volunteers,Behavioral: Computer task questionnaires,Patterns of neural connectivity as predictors,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5000,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,999920112|20-M-N112,20-Jan-21,28-Feb-21,28-Feb-21,6-May-20,,15-Jan-21,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04377100
NCT04661410,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,,Recruiting,No Results Available,Bulimia Nervosa|Bulimia; Atypical|Binge Eating|Binge-Eating Disorder,Behavioral: Reward Re-Training|Behavioral: Supportive Therapy,Binge eating frequency assessed by the Eating Disorder Examination|Global Eating Pathology|Remission Status|Compensatory behavior frequency assessed by the Eating Disorder Examination (EDE)|Depressive symptoms as assessed by the Beck Depression Inventory-II|Substance Use assessed by the NIDA-Modified ASSIST|Quality of Life assessed by the Quality of Life Inventory (QOLI),Drexel University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2009008088|R01MH122392-01S1,1-Dec-20,1-Dec-21,30-Mar-22,10-Dec-20,,10-Dec-20,"Drexel University, Stratton Hall, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04661410
NCT04417270,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,,Recruiting,No Results Available,Diabetes Mellitus,Device: Freestyle Libre 14 day CGM system|Device: Accuchek Inform II platform,Comparison of values between two devices,Northwell Health,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,20-0455,12-Jun-20,30-Nov-20,31-Dec-20,4-Jun-20,,21-Dec-20,"Lenox Hill Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04417270
NCT04453514,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,,Recruiting,No Results Available,Anxiety,Behavioral: Trauma-informed yoga video recording,Number of participants enrolled over 3 months|Number of participants enrolled per week over 3 months|Proportion of participants who enroll in the study over 3 months|Proportion of participants who complete the study over 3 months|Proportion of missing data over 3 months|Proportion of participants who complete the 45-minute video over 3 months|Mean change in state anxiety from immediately before to immediately after yoga using the State Trait Anxiety Scale - 6 item short form|Mean change in state mindfulness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Mind subscale)|Mean change in body awareness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Body subscale),National University of Natural Medicine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Tibbitts_TIYoga_COVID,21-Jul-20,Oct-20,Oct-20,1-Jul-20,,24-Jul-20,"National University of Natural Medicine, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT04453514
NCT04360850,Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic,,Recruiting,No Results Available,Online Therapy,Behavioral: online survey,responses to the survey questions,University of Washington,All,"18 Years and older   (Adult, Older Adult)",,10000,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,STUDY00010090,24-Apr-20,Oct-25,Oct-25,24-Apr-20,,28-Apr-20,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04360850
NCT04363437,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COMBATCOVID19,Recruiting,No Results Available,Coronavirus Infection,Drug: Colchicine|Drug: Usual Care,Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula|Percentage of patients who will require mechanical ventillation|Hospital length of stay|Mortality|Maximum CRP|Maximum troponin elevation,Maimonides Medical Center,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4/12/20,26-Apr-20,31-May-20,14-Jun-20,27-Apr-20,,8-May-20,"Maimonides Medical Center, Brooklyn, New York, United States",,https://ClinicalTrials.gov/show/NCT04363437
NCT04327804,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,,Recruiting,No Results Available,SARS-CoV Infection,Diagnostic Test: Odd/Even birth year intervention groups,Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development,Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group,All,"Child, Adult, Older Adult",,120,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,20-002,25-Mar-20,3-Apr-20,10-Apr-20,31-Mar-20,,14-Apr-20,"Everett Clinic, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04327804
NCT04325906,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,,Recruiting,No Results Available,Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection,Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP),Treatment failure|Intubation rate|Efficacy of PP,Rush University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,346,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19-HFNC+PP,2-Apr-20,30-Mar-21,30-Jun-21,30-Mar-20,,21-Dec-20,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04325906
NCT04524598,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,,Recruiting,No Results Available,Depression,Device: Limbix Spark|Other: Psychoeducation,Change in depressive symptoms|Change in anxiety symptoms|Change in parent report of child depressive symptoms,"Limbix Health, Inc.",All,"13 Years to 21 Years   (Child, Adult)",Not Applicable,410,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Limbix Spark 02,20-Jul-20,31-Dec-20,31-Dec-20,24-Aug-20,,18-Sep-20,"Limbix Health, Inc., San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04524598
NCT04558411,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",,Recruiting,No Results Available,Emotional Regulation|Affect,Behavioral: Dialectical Behavioral Therapy (DBT) Skills,Distress|Emotion regulation|Distress (within-person change)|Maintenance of improvement in emotion regulation,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Pro2020002008,12-Sep-20,15-Dec-20,15-Dec-20,22-Sep-20,,22-Sep-20,"Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04558411
NCT04379518,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,,Recruiting,No Results Available,Malignant Neoplasm|SARS Coronavirus 2 Infection,Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod,Incidence of adverse events (AEs)|Kinetics of viral load in nasopharyngeal swabs|Kinetics of viral load in the peripheral blood and nasopharyngeal swabs|Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood|30-day mortality|Hospitalization due to infection|Determine known mediators of antiviral immunity,Roswell Park Cancer Institute|National Cancer Institute (NCI)|AIM ImmunoTech Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,44,Other|NIH|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,I 659920|NCI-2020-02317|P30CA016056,4-Sep-20,4-Sep-21,4-Sep-21,7-May-20,,25-Nov-20,"Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04379518
NCT04369378,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,,Recruiting,No Results Available,Anxiety|Well-being,Behavioral: Meditation app usage,Anxiety|Well-being|Future outlook & hopefulness|Sleep habits|Nutrition habits|Meditation app continued usage,Lake Erie College of Osteopathic Medicine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,27-126,19-Aug-20,28-Feb-21,30-Apr-21,30-Apr-20,,13-Nov-20,"LECOM, Erie, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04369378
NCT04371315,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",,Recruiting,No Results Available,Corona Virus Infection|Pediatric Cancer|Adult Children|Cancer,,Characteristics and outcomes of acute respiratory infections due to COVID-19 in children.|Clinical risk factors of acute respiratory infection due to COVID-19 in children.|Immunologic response to acute respiratory infection due to COVID-19 in children.|Duration of viral shedding and evolution in children longitudinally.,St. Jude Children's Research Hospital,All,"up to 24 Years   (Child, Adult)",,400,Other,Observational,Observational Model: Other|Time Perspective: Prospective,COVID-19,27-Apr-20,1-Jun-21,30-Jun-22,1-May-20,,29-Jun-20,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04371315
NCT04604743,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,,Not yet recruiting,No Results Available,Vaccine Refusal,"Behavioral: Intervention, TBN",HPV Vaccination|Reduction in Vaccine Hesitancy,University of Alabama at Birmingham,All,15 Years to 17 Years   (Child),Not Applicable,4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MISP #60590,1-Jan-21,30-Jun-23,30-Jun-23,27-Oct-20,,27-Oct-20,"University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04604743
NCT04419870,"Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic",,Recruiting,No Results Available,Mitochondrial Disease,,"We will perform whole blood transcriptomic analysis, humoral response profiling and soluble mediator profiling.|Patient Medical Records for Data Abstraction|Patient centered outcomes data via questionnaires",National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"2 Months and older   (Child, Adult, Older Adult)",,200,NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,200120|20-HG-0120,20-Jan-21,1-May-25,1-May-25,9-Jun-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04419870
NCT04519216,Breastfeeding Education in the Time of COVID-19,,Recruiting,No Results Available,"Breastfeeding|Breastfeeding, Exclusive|Breastfeeding Jaundice|Educational Problems",Behavioral: Telesimulation,Change in practice patterns|Self efficacy|Satisfaction with simulation,"University of California, Davis",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,1613611-2,31-Jul-20,30-Jun-21,30-Sep-21,19-Aug-20,,19-Aug-20,"University of California - Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT04519216
NCT04530136,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,,Recruiting,No Results Available,Confirmed Coronavirus Disease,Drug: Ruconest,Disease Severity on the 7-Point WHO Ordinal Scale|Clinical improvement|Invasive or non-invasive ventilation|Acute Lung Injury,Pharming Technologies B.V.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,C1 6201,30-Nov-20,15-Aug-21,30-Nov-21,28-Aug-20,,10-Dec-20,"The Valley Hospital, Ridgewood, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04530136
NCT04326036,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,GARM-COVID19,Recruiting,No Results Available,Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease,Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use,Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry,"Black Tie Medical, Inc.|Robert W. Alexander, MD",All,"18 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,10,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GARM COVID19,25-Mar-20,1-Nov-21,31-Dec-21,30-Mar-20,,12-Oct-20,"Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States",,https://ClinicalTrials.gov/show/NCT04326036
NCT04523246,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,NH-Shingrix,Recruiting,No Results Available,Herpes Zoster|Allergy and Immunology|Corona Virus Infection,"Biological: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|Drug: Normal Saline",Evidenced of active and trained innate immunity|Respiratory Disease Severity (6 month),Barbara Carlson|Oklahoma Medical Research Foundation|University of Oklahoma,All,65 Years to 100 Years   (Older Adult),Early Phase 1,250,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",OUHSC IRB#12394,1-Sep-20,1-Jul-21,1-Sep-21,21-Aug-20,,10-Nov-20,"Fran and Earl Ziegler College of Nursing, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04523246
NCT04699903,"Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood",,Not yet recruiting,No Results Available,"SARS-Cov-2, Covid19",Diagnostic Test: POC SARS-Cov-2 IgG Antibody test,PPA (positive percent agreement) and NPA (negative percent agreement) of POC compared to SARS-CoV-2 reference PCR|PPA (positive percent agreement) of POC compared to SARS-CoV-2 reference PCR,"Rapid Pathogen Screening|Lumos Diagnostics, Inc",All,"1 Year and older   (Child, Adult, Older Adult)",,215,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-1106,28-Dec-20,22-Jan-21,5-Feb-21,7-Jan-21,,7-Jan-21,"Benchmark - SoCal, Colton, California, United States|Comprehensive Clinical Research, West Palm Beach, Florida, United States|Great Lakes Clinical Trials (GLCT), Chicago, Illinois, United States|UCCT- AFC Urgent Care Throgs Neck, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04699903
NCT04398277,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,,Recruiting,No Results Available,Psychological Stress,Behavioral: Daily Coping Toolkit,Patient Health Questionnaire - 4|World Health Organization Well Being Questionnaire|Affective Experience|Treatment Acceptability Questionnaire,Kent State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",20-183,1-May-20,Apr-21,Apr-21,21-May-20,,21-May-20,"Akron Children's Hospital, Akron, Ohio, United States|Summa Health Systems, Akron, Ohio, United States|Kent State University, Kent, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04398277
NCT04613739,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,AFFORD COVID,Recruiting,No Results Available,Asthma,Behavioral: insurance navigation,Insurance coverage|Medication adherence|Financial burden|Delayed/forgone care due to cost,"Harvard Pilgrim Health Care|Patient-Centered Outcomes Research Institute|Asthma and Allergy Foundation of America|University of North Carolina, Chapel Hill|Harvard School of Public Health",All,"4 Years to 64 Years   (Child, Adult)",Not Applicable,430,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IHS-1602-34331,8-Dec-20,1-Sep-21,31-Jan-23,3-Nov-20,,17-Dec-20,"Harvard Pilgrim Health Care, Wellesley, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04613739
NCT04539821,Virtual Pain Care Management (COVID-19),VCPM,Recruiting,No Results Available,Chronic Pain,Other: VCPM,the percent of patients who agree to Buprenorphine transfer|percent of complete tapering or BUP transition,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,C19 20-397,1-Oct-20,31-Mar-21,30-Jun-21,7-Sep-20,,2-Nov-20,"Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04539821
NCT04705766,KIDney Injury in Times of COVID-19 (KIDCOV),KIDCOV,Not yet recruiting,No Results Available,SARS-CoV Infection|Covid19|Corona Virus Infection|Acute Kidney Injury|Kidney Injury,Other: Urine Collection,"Continuous, Quantitative KIT Score|Number of participants with a level of Kidney Injury Molecule-1 (KIM1) above 1 ng/ml|Number of participants with a level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) above 1 ng/ml|Number of participants with a level of soluble urokinase-type plasminogen activator receptor (suPAR) above 1 ng/ml","University of California, San Francisco|Rush University Medical Center|University of Michigan|University of California|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",All,"18 Years and older   (Adult, Older Adult)",,2000,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,KIDCOV2020|R01DK109720,Jan-21,Jan-22,Jan-22,12-Jan-21,,12-Jan-21,"University of California, San Francisco, California, United States|Rush University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04705766
NCT04570384,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,,Recruiting,No Results Available,Acute Hypoxemic Respiratory Failure,Drug: L-Citrulline|Drug: Placebo,Primary Biochemical Objective to measure levels of citrulline and arginine in the Blood|The primary safety objective is a beneficial effect of intravenous L-Citrulline on hemodynamic status.|Primary Clinical Objective|Evaluate the Safety of L-Citrulline|Evaluate the effect of intravenous L-Citrulline compared to placebo as measured by the total length of all mechanical ventilation|Evaluate the Effect of IV L-Citrulline to Placebo for Hospital all cause mortality|Evaluate the Effect of IV L-Citrulline to Placebo on length of ICU and Hospital Stay|Evaluate overall difference in intubation rates|Evaluate overall duration of mechanical ventilation from consent and post-infusion,"Asklepion Pharmaceuticals, LLC",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CIT-COVID19-002-01,15-Oct-20,28-May-21,28-Dec-21,30-Sep-20,,16-Dec-20,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT04570384
NCT04386291,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,,Recruiting,No Results Available,Generalized Anxiety|Health Anxiety,Behavioral: Anxiety Reduction Training|Behavioral: Kundalini Yoga and Anxiety Reduction Training|Behavioral: Meditation and Anxiety Reduction Training,GAD-7|Whiteley 8|PHQ-8|SS-8|Applied Cognition 1.0|PROMIS-4 Sleep Disturbance|ERQ|Perceived Stress Scale|Brief Hypervigilance Scale,"Research Foundation for Mental Hygiene, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7987,25-May-20,19-May-21,30-Jan-22,13-May-20,,1-Jul-20,"ProofPilot (Virtual Study: https://proofpilot.com/covid-anxiety/), New York, New York, United States|Columbia University Department of Psychiatry, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04386291
NCT04666025,SARS-CoV-2 Donor-Recipient Immunity Transfer,,Recruiting,No Results Available,"Accelerated Phase CML, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Phase CML, BCR-ABL1 Positive|COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma",Procedure: Biospecimen Collection|Other: Diagnostic Laboratory Biomarker Analysis|Other: Electronic Health Record Review|Other: Questionnaire Administration,Severe acute respiratory syndrome (SARS)-Coronavirus 2 (CoV-2) Spike protein (S)-specific IgG concentration and T cell levels|SARS-CoV-2 nucleocapsid protein (N) -specific IgG concentration and T cell levels|SARS-CoV-2 neutralizing antibodies|SARS-CoV-2 IgA concentration,City of Hope Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",,36,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20153|NCI-2020-11156|P30CA033572,23-Sep-20,23-Sep-22,23-Sep-22,14-Dec-20,,14-Dec-20,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT04666025
NCT04331886,An Observational Study of Patients With Coronavirus Disease 2019,COVID-19,Recruiting,No Results Available,COVID-19|Coronavirus,,Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response,"Target PharmaSolutions, Inc.",All,"18 Years and older   (Adult, Older Adult)",,5000,Industry,Observational,Observational Model: Cohort|Time Perspective: Other,TARGET-COVID-19,13-Apr-20,Mar-21,Mar-21,2-Apr-20,,14-May-20,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04331886
NCT04353037,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,,Recruiting,No Results Available,Coronavirus|Corona Virus Infection,Drug: Group A HCQ|Drug: Group B Control,Sub Study 1: Patients|Sub Study 2: Health Care Workers|Sub Study 1: Patients: Rate of secondary infection of co-inhabitants|Sub Study 1: Patients: Adverse Events|Sub Study 1: Patients: Negative for COVID-19|Sub Study 2:Health Care Workers:Number of shifts missed|Sub Study 2:Health Care Workers:Rate of adverse events|Sub Study 2:Health Care Workers:Rate of hospitalization,UnitedHealth Group|ProHealth Care Associates|University of Pennsylvania Perelman School of Medicine,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,850,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2020-0003,7-Apr-20,Apr-21,15-Jun-21,20-Apr-20,,24-Apr-20,"ProHealth New York, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04353037
NCT04644276,Mask Adhesive Institutional Study,,Not yet recruiting,No Results Available,Respiratory Failure|Covid19,Device: Mask with Mask Adhesive/Arm 1|Device: Mask without Mask Adhesive / Arm 2,Medical Adhesive-Related Skin Injury (MARSI) and Ease of Use|Leak Change,Philips Clinical & Medical Affairs Global,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,SRCHRCMask Adhesive 2020_11130,18-Jan-21,15-Feb-21,15-Feb-21,25-Nov-20,,8-Jan-21,"Sleep Disorder Center of Alabama, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04644276
NCT04025580,Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine,,Recruiting,No Results Available,Healthy Volunteer|COVID-19,Biological: Flucelvax|Biological: Fluvirin|Biological: Fluzone High Dose,Microneutralization titers,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,190126|19-I-0126,2-Oct-19,31-Dec-25,31-Dec-25,19-Jul-19,,13-Nov-20,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04025580
NCT04376034,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,,Recruiting,No Results Available,COVID19|Coronavirus Infection|Coronavirus|Virus Diseases|RNA Virus Infections,Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care,Plasma Donor|Plasma Recipient,West Virginia University,All,"31 Days and older   (Child, Adult, Older Adult)",Phase 3,240,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004965705,16-Apr-20,30-Mar-21,30-Mar-21,6-May-20,,6-May-20,"WVU Medicine, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT04376034
NCT04320862,COVID-19 Pandemic Response Network,,Recruiting,No Results Available,COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection,,Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants,Duke University,All,"Child, Adult, Older Adult",,200000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00105189,3-Apr-20,31-Dec-21,31-Dec-21,25-Mar-20,,27-Apr-20,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04320862
NCT04367077,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),MACoVIA,Recruiting,No Results Available,ARDS,Biological: MultiStem|Biological: Placebo,Ventilator-Free Days|Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0.|All-cause mortality|Ranked hierarchical composite outcome of alive and ventilator-free|Ventilator-free days,"Athersys, Inc",All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B04-03,28-Apr-20,Sep-21,Aug-22,29-Apr-20,,29-Sep-20,"Athersys Investigational Site 103, Akron, Ohio, United States|Athersys Investigational Site 101, Cleveland, Ohio, United States|Athersys Investigational Site 102, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04367077
NCT04524962,Study of Descartes-30 in Acute Respiratory Distress Syndrome,,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|Covid19,Biological: Descartes 30,To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.,Cartesian Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DC30-1A,15-Sep-20,25-Sep-21,25-Sep-22,24-Aug-20,,22-Oct-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04524962
NCT04378595,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,,Recruiting,No Results Available,Food Insecurity,Other: During COVID-19 Pandemic|Other: After COVID-19 Pandemic,Food Insecurity Score,University of Texas at Austin,All,"18 Years to 100 Years   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-004-0019,10-Apr-20,30-Dec-20,30-Jul-21,7-May-20,,8-May-20,"Dell Medical School, Austin, Texas, United States|CommUnity Care Clinic - Southeast Health and Wellness Clinic, Austin, Texas, United States|CommUnity Care Clinic - Rundberg, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04378595
NCT04462848,Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions,,Not yet recruiting,No Results Available,Corona Virus Infection,Biological: anti-SARS-CoV-2 human convalescent plasma,"Cumulative incidence of Grade 3 and Grade 4 adverse events|Cumulative incidence of serious adverse events|Proportion of participants with disease worsening event.|Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies|Percentage of participants with a natural antibody response to SARS-CoV-2 infection","University of California, Los Angeles",All,1 Month to 17 Years   (Child),Phase 1,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB#20-001263,Aug-20,Sep-24,Dec-24,8-Jul-20,,8-Jul-20,"University of California, Los Angeles (UCLA), Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04462848
NCT04407546,Role of Children in Transmission of COVID-19 to Immunocompromised Patients,,Recruiting,No Results Available,Immunosuppression,,To define the role of household contact with children or siblings in the transmission of SARS-CoV-2 to immunocompromised patients.|To characterize secondary cases of SARS-CoV-2 in immunocompromised participants|To describe the exposure factors such as pets and travel and how those factors are related to immunocompromised patients to estimate risk profiles by household characteristics,Jonsson Comprehensive Cancer Center,All,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-000517|NCI-2020-03669,27-May-20,28-May-22,28-May-23,29-May-20,,23-Jul-20,"University of California at Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04407546
NCT04468958,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",,Recruiting,No Results Available,COVID-19|SARS-CoV2,Biological: SAB-185|Other: Normal saline,Number of Participants Having Adverse Events|Number of Participants Having Transfusion-Related Adverse Events|Pharmacokinetics from screening to day 90,"SAb Biotherapeutics, Inc.|Department of Health and Human Services|Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)",All,18 Years to 60 Years   (Adult),Phase 1,28,Industry|U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SAB-185-101,5-Aug-20,Sep-20,Dec-20,13-Jul-20,,27-Aug-20,"Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|SUNY Upstate Medical University, Syracuse, New York, United States|ICON Early Phase Services, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04468958
NCT04401436,COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO),,Recruiting,No Results Available,Corona Virus Disease 2019,,"Evaluation of lymphocyte subsets in patients with COVID-19 at various stages of disease, including recovery.|Evaluation of inflammatory pathways that may contribute to COVID-19 disease pathogenesis.",National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,350,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,200111|20-I-0111,22-May-20,30-Jun-22,30-Jun-22,26-May-20,,7-Jan-21,"MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04401436
NCT04590430,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults",,Recruiting,No Results Available,Healthy,Drug: HFB30132A|Other: Placebo,"Number of participants with treatment emergent serious adverse events (TESAEs)|Number of participants with treatment emergent adverse events (TEAE) of special interest|Number of participants with treatment-emergent adverse events (TEAE)|Maximum observed serum concentration (Cmax)|Minimum observed serum concentration (Cmin)|Time of maximum serum concentration (Tmax)|Area under the concentration vs. time curve (AUC0-last), AUC0-∞)|Terminal half-life (T1/2)|Systemic clearance (CL)|Steady-state volume of distribution (Vss)|Number of participants with treatment-emergent adverse events (TEAEs)|Number of participants with treatment-emergent serious adverse events (TESAEs)|Maximum observed serum HFB30132A concentration (Cmax) in nasal and oral secretions|Minimum observed serum HFB30132A concentration (Cmin) in nasal and oral secretions|Time of maximum serum HFB30132A concentration (Tmax) in nasal and oral secretions|Area under the concentration vs. time curve (AUC0-last), AUC0-∞) in nasal and oral secretions|Terminal half-life (T1/2) of HFB30132A in nasal and oral secretions|Systemic clearance (CL) of HFB30132A in nasal and oral secretions|Steady-state volume of distribution (Vss) of HFB30132A in nasal and oral secretions|HFB30132A Anti-drug antibodies",HiFiBiO Therapeutics,All,18 Years to 60 Years   (Adult),Phase 1,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HFB30132A-101,20-Oct-20,Dec-20,Jul-21,19-Oct-20,,28-Dec-20,"Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04590430
NCT04419025,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,,Recruiting,No Results Available,COVID|Sars-CoV2|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|Oxidative Stress,Drug: N-acetylcysteine,Decrease in Respiratory Rate|Hospital length of stay (LOS)|Need for mechanical ventilation|Length of time intubated|Need for hospitalization|Recovery disposition,Cambridge Health Alliance,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHA-IRB-1139/05/20,23-Sep-20,31-Jan-21,31-May-21,5-Jun-20,,25-Sep-20,"CHA Cambridge Hospital, Cambridge, Massachusetts, United States|CHA Everett Hospital, Everett, Massachusetts, United States|CHA Respiratory Clinic, Somerville, Massachusetts, United States|CHA Somerville campus, Somerville, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04419025
NCT04581200,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,LIFTCOVID,Not yet recruiting,No Results Available,COVID-19|Cardiorespiratory Failure,Behavioral: Lift,Change in Patient Health Questionnaire-9 Item scale (PHQ-9)|Change in Generalized Anxiety Disorder 7-item scale (GAD-7)|Change in EuroQOL-5DL scale|Cardiopulmonary symptoms,Duke University|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",Pro00106306|3U01AT009974-03S1,11-Jan-21,31-May-21,30-Sep-21,9-Oct-20,,12-Jan-21,"University of Colorado - Denver, Aurora, Colorado, United States|University of Michigan, Ann Arbor, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health & Sciences University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT04581200
NCT04425252,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,CRISIS,Recruiting,No Results Available,COVID-19,Drug: Brequinar|Other: Standard of Care,Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration,"Clear Creek Bio, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCB-CRISIS-01,25-Jun-20,Mar-21,Apr-21,11-Jun-20,,28-Oct-20,"Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida/Tampa General, Tampa, Florida, United States|University of New Mexico, Albuquerque, New Mexico, United States|Temple University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04425252
NCT04498273,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,,Recruiting,No Results Available,COVID-19,Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo,Hospitalization for cardiovascular/pulmonary events,"Frank C Sciurba|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 3,7000,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ACTIV4-Outpatient,7-Sep-20,Sep-21,Sep-21,4-Aug-20,,5-Nov-20,"University of Florida at Gainesville, Gainesville, Florida, United States|University of Floridia at Jacksonville, Jacksonville, Florida, United States|Bond Community Health Center, Tallahassee, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Intermountain Healthcare, Murray, Utah, United States",,https://ClinicalTrials.gov/show/NCT04498273
NCT04458298,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,PRANA,Recruiting,No Results Available,COVID-19,Drug: OP-101|Drug: Placebo,"Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0|Time to Improvement (2 points) in Clinical Status Assessment Using the World Health Organization 7-Point Ordinal Scale (WHO 7OS)|Time to Resolution of Fever for at least 48 hours Without Antipyretics for Patients with Documented Fever (>=37.2 degree celsius [oral], or >=37.8 degree celsius [rectal], or >=38.0 degree celsius [tympanic])|Time to Improvement in Oxygenation for at least 48 hours|Change from Baseline in the World Health Organization (WHO)-7 Point Ordinal Scale|Time to Discharge from Clinic or Hospital or to National Early Warning Score 2 (NEWS2) of <=2 and maintained for 24 hours|Percentage of Patients Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital/Clinic or Day 30|Number of Days of Resting Respiratory Rate of more than 24 breath/min|Number of Days with Hypoxemia|Number of Days of Supplemental Oxygen use|Number of Ventilator-free Days|Number of Days in Intensive Care Unit (ICU)|Number of Days of Hospitalization for Survivors|Number of Participants with all cause deaths|Percent change from baseline in Proinflammatory Cytokines|Incidence of Drug-related Serious Adverse Events (SAEs)","Orpheris, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OP-101-004,1-Jul-20,31-Jan-21,31-Jan-21,7-Jul-20,,19-Nov-20,"Research Site, Loma Linda, California, United States|Research site, Fort Lauderdale, Florida, United States|Research Site, Atlanta, Georgia, United States|Research site, Baltimore, Maryland, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04458298
NCT04391920,Registry of CytoSorb Therapy in COVID-19 ICU Patients,CTC REGISTRY,Recruiting,No Results Available,COVID-19,Device: CytoSorb 300 mL device,ICU mortality|Duration of ECMO after start of CytoSorb|Duration of mechanical ventilatory support after start of CytoSorb|Duration of pharmacologic hemodynamic support after start of CytoSorb|Change in serum concentrations of inflammatory biomarkers after start of CytoSorb,"CytoSorbents, Inc",All,"18 Years and older   (Adult, Older Adult)",,500,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-001|FDA EUA,28-Aug-20,Aug-21,Oct-21,18-May-20,,5-Oct-20,"Medical Center of Aurora, Aurora, Colorado, United States|University of Chicago Medicine, Chicago, Illinois, United States|Baptist Memorial Hospital, Southaven, Mississippi, United States|New York University Medical Center, New York, New York, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04391920
NCT04364763,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),,Recruiting,No Results Available,COVID-19,Drug: RBT-9 (90 mg)|Drug: 0.9% sodium chloride (normal saline),"Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale|Time to first occurrence of death from any cause or new/worsened organ dysfunction|All-cause survival|Oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio|Fever incidence|Acute kidney injury (AKI) incidence|New or worsening congestive heart failure (HF)|Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit (ICU) status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status","Renibus Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,252,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REN-005,5-Aug-20,30-Jun-21,31-Dec-21,28-Apr-20,,14-Jan-21,"New Smyrna Beach, FL, New Smyrna Beach, Florida, United States|Berkley, MI, Berkley, Michigan, United States|El Paso, TX, El Paso, Texas, United States|Fort Worth, TX, Fort Worth, Texas, United States|Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04364763
NCT04326452,Treating COVID-19 With a Bidirectional Oxygenation Valve,,Recruiting,No Results Available,Coronavirus Infection,Device: bidirectional oxygenation mouthpiece,Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide,"TMC HealthCare|PEEP Medical, LLC",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID19PEEP2020|GO2 PEEP Study,27-Mar-20,27-Mar-21,27-Mar-21,30-Mar-20,,6-Oct-20,"TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04326452
NCT04473599,Stay Well at Home: a Text-messaging Study Social Distancing,,Recruiting,No Results Available,Depressive Symptoms|Anxiety|COVID-19,Behavioral: Uniform random message delivery|Behavioral: Reinforcement learning message delivery,Depression scores|Anxiety scores|Self reported mood ratings,"University of California, Berkeley",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,2020-04-13162,17-Apr-20,1-Apr-21,1-Apr-21,16-Jul-20,,28-Jul-20,"University of California Berkeley, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT04473599
NCT04564274,COV2Base-A Rare Disease by COVID Study,,Recruiting,No Results Available,Chronic Health Conditions|Older Age is Associated With Increased Pathogenicity,,"To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.|To identify gene-, tissue- or sociodemographic level features that increase risk of severe COVID outcomes that may inform future genetic modifier studies.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"1 Month and older   (Child, Adult, Older Adult)",,120000,NIH,Observational,Observational Model: Other|Time Perspective: Other,10000091|000091-H,20-Jan-21,1-Sep-21,1-Sep-21,25-Sep-20,,15-Jan-21,"National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04564274
NCT03907891,Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations,Heart Up!,Recruiting,No Results Available,Ischemic Heart Disease|Hopelessness|Physical Activity|Motivation|Social Support|Covid19,Behavioral: Motivational social support from nurse|Behavioral: Motivational social support from nurse with additional support from significant other|Behavioral: Attention control,ActiGraph GT9X Link Accelerometer|State-Trait Hopelessness Scale|Exercise Self-Regulation Questionnaire|ENRICHD Social Support Inventory,University of Illinois at Chicago|National Institute of Nursing Research (NINR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,225,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2018-1485|R01NR017649|3R01NR017649-04S1,1-Aug-19,May-23,May-23,9-Apr-19,,30-Oct-20,"Spectrum Health, Grand Rapids, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03907891
NCT04661813,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,AAIM-High,Not yet recruiting,No Results Available,HIV-1-infection|Hypertension,Other: EXTRA-CVD Virtual Care,"Proportion of eligible participants who agree to participate|Average of home blood pressure values assessed over a 2-week period at 0-, 4-, 8-, and 12-months.|Number of days with at least 1 home blood pressure measurement assessed over a 2-week period at 0-, 4-, 8-, and 12-months.","Case Western Reserve University|Duke University|Metro Health, Michigan|National Heart, Lung, and Blood Institute (NHLBI)|University Hospitals Cleveland Medical Center",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,03-18-16-S1|U01HL142099,Feb-21,Aug-22,Aug-22,10-Dec-20,,10-Dec-20,"Duke Health, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04661813
NCT04323787,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,COVID-19,Recruiting,No Results Available,Coronavirus,Other: observational,ICU and hospital mortality of COVID-19 patients|30 days mortality,Mayo Clinic|Society of Critical Care Medicine|Boston University,All,"Child, Adult, Older Adult",,50000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,20-002610,30-Mar-20,30-Apr-21,30-Apr-21,27-Mar-20,,11-Aug-20,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04323787
NCT04470544,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,RECOVER,Recruiting,No Results Available,Severe Acute Respiratory Syndrome,Drug: Camostat Mesilate|Other: Standard of Care,Change in the proportion of patients alive and free from respiratory failure|Change in the proportion of patients alive and free of ventilator use or ECMO|Mortality Rate|Clinical Change|Adverse Events,Alan Bryce|Academic and Community Cancer Research United,All,"18 Years and older   (Adult, Older Adult)",Phase 2,264,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAM20CV,28-Jul-20,15-Sep-22,15-Sep-22,14-Jul-20,,11-Jan-21,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Tucson Medical Center, Tucson, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04470544
NCT04468971,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,RESOLVE,Recruiting,No Results Available,COVID19|ARDS,Biological: CK0802|Drug: Placebo,"Regimen related ≥ grade 3 toxicity within 48 hours of first infusion|28-day treatment success, defined as S28|Time to extubation|Oxygenation improvement|Ventilator free days|Organ failure free days|ICU free days|All-cause mortality","Cellenkos, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CK0802.501.1,29-Sep-20,30-Sep-21,30-Sep-21,13-Jul-20,,16-Nov-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Baylor College of Medicine, St Luke's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04468971
NCT04540120,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,,Recruiting,No Results Available,Covid19|Cytokine Release Syndrome,Drug: dapansutrile capsules|Drug: placebo capsules,"Proportion of subjects with complete resolution of fever symptoms and shortness of breath|Cumulative incidence of SAEs|Cumulative incidence of Grade 3 and Grade 4 Adverse Events|Discontinuation or temporary suspension of participation|Changes in white cell count|Changes in hemoglobin|Changes in platelets|Changes in creatinine|Changes in glucose|Changes in total bilirubin|Changes in ALT|Changes in AST|Incidence of new infection that occurs during the study|Incidence of opportunistic infections|Complete resolution of fever symptoms and shortness of breath|Time to clinical improvement|Time to sustained absence of fever|Clinical improvement in symptoms relevant to COVID 19|Incidence of composite endpoint of hospitalization, supplemental oxygen, mechanical ventilation, or death|Clinical improvement in symptoms|Improvement in oxygenation|Change in ALT|Change in AST|Change in blood glucose|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Hemoglobin A1c (HbA1C)|Change in Lactate dehydrogenase (LDH)|Change in Lymphocyte, Absolute count|Change in Monocyte, Absolute count|Change in Neutrophils, Absolute count|Change in Eosinophil, Absolute count|Change in CRP|Change in D-Dimer|Change in Ferritin|Change in Fibrinogen|Change in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)|Change in IL-1β|Change in IL-6|Change in IL-18|Change in granulocyte colony-stimulating factor (G-CSF)|Change in interferon-γ-induced protein 10 (IP-10)|Change in C3a",Olatec Therapeutics LLC|CTI Clinical Trial and Consulting Services,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",OLT1177-10,25-Sep-20,Jun-21,Jul-21,7-Sep-20,,13-Jan-21,"National Jewish Health, Denver, Colorado, United States|Atrium Health/Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States|PanAmerican Clinical Research LLC, Brownsville, Texas, United States|J & S Studies, Inc., College Station, Texas, United States|University Hospital Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT04540120
NCT04540939,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,,Recruiting,No Results Available,Trauma,Behavioral: Mindfulness-Based Cognitive Therapy|Behavioral: Muscle Relaxation Therapy,Patient-Reported Outcomes Measurement Information System (PROMIS-adult short form level 2) Anxiety survey|Penn State Worry Questionnaire (PSWQ-16) Worry survey|PROMIS (adult short form) Emotional Depression survey|Working Alliance Inventory- short revised (WAI-SR)|Patient-Reported Outcomes Measurement Information System (PROMIS-adult short form level 2) Anxiety survey group differences (MBCT and PMR)|Penn State Worry Questionnaire (PSWQ-16) Worry survey group differences (MBCT and PMR)|PROMIS (adult short form) Emotional Depression survey group differences (MBCT and PMR)|Working Alliance Inventory- short revised (WAI-SR) group differences (MBCT and PMR),University of Michigan|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HUM00152509-COVID Substudy|1R61AT009867,19-Oct-20,Dec-21,Dec-21,7-Sep-20,,2-Nov-20,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT04540939
NCT04388813,Predictors of Severe COVID-19 Outcomes,PRESCO,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|COVID-19,,Performance (discrimination / calibration) of models,Verily Life Sciences LLC,All,"18 Years and older   (Adult, Older Adult)",,1500,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,102293,28-May-20,Feb-21,Mar-21,14-May-20,,19-Nov-20,"University of Illinois at Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Inova Health Care Services, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04388813
NCT04169542,"Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery",,Recruiting,No Results Available,Breast Ductal Carcinoma In Situ|COVID-19 Infection|Hereditary Breast Carcinoma|Invasive Breast Carcinoma,Other: Questionnaire Administration,Prevalence of financial toxicity|Correlation between economic disruption from coronavirus disease 2019 (COVID-19) and financial toxicity|Relationship between financial toxicity and patient reported quality of life|Relationship between financial toxicity and patient reported satisfaction with breast reconstruction,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Older Adult)",,600,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,PA18-1077|NCI-2019-07463,21-May-19,31-Mar-22,31-Mar-22,20-Nov-19,,9-Dec-20,"MD Anderson in The Woodlands, Conroe, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|MD Anderson League City, League City, Texas, United States|MD Anderson in Sugar Land, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT04169542
NCT04668950,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),,Recruiting,No Results Available,Covid19|Coronavirus,Drug: Fluvoxamine|Drug: Placebo,Clinical deterioration|Post Covid Functioning,Washington University School of Medicine|Covid-19 Early Treatment Fund,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",202011101,22-Dec-20,Jul-21,Sep-21,16-Dec-20,,24-Dec-20,"Northwestern University, Evanston, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson, Seattle, Washington, United States|McGill University Health Center, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04668950
NCT04442178,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),ILIAD-7-US-I,Recruiting,No Results Available,COVID-19|Lymphocytopenia,Drug: CYT107|Drug: Placebo,"Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|""clinical improvement"" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|Length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo a|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm",Revimmune|Washington University School of Medicine|Amarex Clinical Research,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ILIAD-7 COVID US INFECTIOUS,15-Sep-20,30-Dec-20,31-Mar-21,22-Jun-20,,12-Oct-20,"University of Florida College of Medicine, Gainesville, Florida, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Rutgers Health, New Brunswick, New Jersey, United States|Stony Brook Medicine, Stony Brook, New York, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04442178
NCT01306084,Viral Infections in Healthy and Immunocompromised Hosts,,Recruiting,No Results Available,Anogenital Herpes|COVID-19|Herpes Labialis,,"Sample collection, analysis of immune function, or review of tissue bx or clinical rpts from outside labs in designated pop. w/ viral, suspected, or recovered from a viral infection or a close contact of people w/or suspected to have a viral inf...",National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",,1000,NIH,Observational,Observational Model: Other|Time Perspective: Prospective,110109|11-I-0109,15-Mar-11,,,1-Mar-11,,28-Dec-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01306084
NCT04359901,Sarilumab for Patients With Moderate COVID-19 Disease,,Recruiting,No Results Available,COVID,Biological: SARILUMAB,Intubation or death,Westyn Branch-Elliman|VA Boston Healthcare System,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 3305,10-Apr-20,Apr-22,Apr-23,24-Apr-20,,11-Sep-20,"VA Connecticut Healthcare System, West Haven, Connecticut, United States|VA Maine Healthcare System, Augusta, Maine, United States|VA Boston Healthcare System, Boston, Massachusetts, United States|Providence VA Medical Center, Providence, Rhode Island, United States|VA Medical Center - White River Junction, White River Junction, Vermont, United States",,https://ClinicalTrials.gov/show/NCT04359901
NCT04596657,Vitamin D3 Supplementation to Prevent Respiratory Tract Infections,,Recruiting,No Results Available,Respiratory Tract Infections|Covid19|Flu Like Illness,Dietary Supplement: Vitamin D supplementation,Respiratory tract infection,The Cooper Health System|The Won Sook Chung Foundation,All,"52 Years and older   (Adult, Older Adult)",Not Applicable,2099,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20-455,27-Oct-20,Oct-21,Nov-21,22-Oct-20,,20-Nov-20,"Cooper University Hospital, Camden, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04596657
NCT04359810,Plasma Therapy of COVID-19 in Severely Ill Patients,,Recruiting,No Results Available,SARS-CoV-2 Infection,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma),"Day 28 severity outcome|Proportion of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital and 28-day mortality|Time-to-clinical improvement in-hospital|Host genetic differences at day 0|Host transcriptomic differences at days 0,7,14","Max R. O'Donnell|New York Blood Center|Amazon.com, Inc.|Columbia University",All,"18 Years and older   (Adult, Older Adult)",Phase 2,219,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AAAS9924,21-Apr-20,Dec-20,Apr-21,24-Apr-20,,13-Nov-20,"Columbia University Irving Medical Center/NYP, New York, New York, United States|Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil|Hospital Geral de Nova Iguaçu, Rio De Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT04359810
NCT04344184,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),,Not yet recruiting,No Results Available,"COVID-19|Lung Injury, Acute|Kidney Injury",Drug: L-ascorbic acid|Other: Placebo,Change in COVID disease status|Renal safety biomarkers - serum oxalate|Renal safety biomarkers - urine oxalate stones|Renal safety biomarkers - 24-hour urine oxalate levels|Acute Kidney Injury-free days|Number of deaths|Change in plasma ferritin levels|Change in plasma D-dimer levels|Change in serum lactate dehydrogenase (LDH) levels|Change in plasma IL-6 levels|Proportion of patients alive and free of respiratory failure|Proportion of patients alive and free of invasive mechanical ventilation,Virginia Commonwealth University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HM20018977,Jan-21,May-21,May-21,14-Apr-20,,9-Dec-20,"Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04344184
NCT04470622,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),,Recruiting,No Results Available,COVID-19,Drug: Aprepitant injectable emulsion|Drug: Saline Placebo,"Proportion of subjects alive and discharged from the hospital.|Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).|Time to discharge from hospital.|Change from Baseline in Interleukin 6 (IL-6).|Incidence of treatment-emergent adverse events.",Heron Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HTX-019-202,20-Jul-20,Feb-21,Mar-21,14-Jul-20,,12-Nov-20,"Helen Keller Hospital, Sheffield, Alabama, United States|University of California, Irvine Medical Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States|Ponce Medical School Foundation, Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04470622
NCT00571389,Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products,,Recruiting,No Results Available,"Solid Tumor, Adult|Healthy Donors|COVID-19 Donors",,,"BioCytics, Inc.",All,"18 Years and older   (Adult, Older Adult)",,1000,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BioCytics 0001|WIRB Protocol # 20070969,Nov-07,Feb-25,Feb-25,12-Dec-07,,10-Sep-20,"Carolina BioOncology Institute, Huntersville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00571389
NCT04471051,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,,Recruiting,No Results Available,Covid19,,Inpatient Mortality|Requirement for mechanical ventilation|Transfer to ICU|ICU Mortality|ICU Length of Stay (LOS)|Hospital Mortality|Hospital Length of Stay (LOS),"University of Colorado, Denver",All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-0986,30-Apr-20,Apr-21,Apr-21,14-Jul-20,,14-Jul-20,"Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04471051
NCT04361838,The COVID-19 ICU PRAYER Study,,Recruiting,No Results Available,Coronavirus Infection,Behavioral: prayer,Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.|Difference in patient outcomes - Acute Physiology and Chronic Health Enquiry. APACHE II score.|Difference in patient outcomes - Sequential Organ Failure Assessment - SOFA Score|Difference in patient outcomes - Length of stay in ICU.|Difference in patient outcomes - Length of ventilator support|Difference in patient outcomes - length of vasopressor support,Kansas City Heart Rhythm Institute,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",Covid Prayer Study,1-Jun-20,31-Aug-20,31-Aug-20,24-Apr-20,,4-Jun-20,"Research Medical Center, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04361838
NCT04452474,Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).,,Not yet recruiting,No Results Available,COVID-19,Drug: Olokizumab 64 mg|Drug: Placebo,"Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the ""Not hospitalized"" category|Subjects' clinical status distribution based on 5-point clinical status scale during the study|28-day case fatality rates","R-Pharm|Cromos Pharma, LLC|Covance",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,376,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041080,30-Jun-20,16-Nov-20,29-Jan-21,30-Jun-20,,30-Jun-20,"George Washington University Medical Center, Washington, District of Columbia, United States|Center For Haptitis C/ Atlanta Medical Center, Atlanta, Georgia, United States|PMG Research of DuPage Medical Group, Downers Grove, Illinois, United States|Northwest Indiana Center for Clinical Research, Portage, Indiana, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|PMG Research, Inc., Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04452474
NCT04372628,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,TREATNOW,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo,"Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29",Vanderbilt University Medical Center|AbbVie,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",200827,1-Jun-20,1-Apr-21,1-May-21,4-May-20,,16-Dec-20,"University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04372628
NCT04385251,International SARS-CoV-2 (COVID-19) Infection Observational Study,ICOS,Recruiting,No Results Available,COVID|COVID19|SARS-CoV 2|Dyspnea,Other: Data Collection,Time to Hospitalization|Time to Expiration|Rate of Death at 7 Days|Rate of Death at 14 Days|Rate of Death at 28 Days|Rate of Hospitalization at 7 Days|Rate of Hospitalization at 14 Days|Rate of Hospitalization at 28 Days|Participant Health at 7 Days|Participant Health at 14 Days|Participant Health at 28 Days|Modified Borg Dyspnea Scale at 7 Days|Modified Borg Dyspnea Scale at 14 Days|Modified Borg Dyspnea Scale at 28 Days,University of Minnesota|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years and older   (Adult, Older Adult)",,10000,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ICOS|75N91019D00024,18-Jun-20,30-Jun-21,30-Jun-21,12-May-20,,19-Oct-20,"Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London Medical School Centre for Sexual Health and HIV Research, London, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT04385251
NCT04593940,Immune Modulators for Treating COVID-19,ACTIV-1 IM,Recruiting,No Results Available,Covid19,Drug: Infliximab|Drug: Abatacept|Drug: Remdesivir|Drug: cenicriviroc,Number of patients that recovered from COVID-19|Change in number of patients hospitalized on invasive mechanical ventilation|number of patients that improved clinically|Number of patient deaths|Number of patients with decreased supplemental oxygenation needed|Change in number of patients needing non-invasive ventilation/ high flow oxygen|Number of days patients are in the hospital|Number of SAEs and AEs of grade 3 and 4|Number of patients with changes in abnormal WBC counts,Daniel Benjamin|National Center for Advancing Translational Science (NCATS)|Biomedical Advanced Research and Development Authority|Duke University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2160,Other|NIH|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00106301,15-Oct-20,Feb-21,Sep-21,20-Oct-20,,12-Jan-21,"University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|Scripps Clinical Medical Group, La Jolla, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers New Jersey Medical School, New Brunswick, New Jersey, United States|Weill Cornell Medicine, New York, New York, United States|St Lawrence Health System, Potsdam, New York, United States|University of Rochester Medical Center-Strong Memorial Hospital, Rochester, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Trinity Mother Frances Hospital, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|Gundersen Health System, La Crosse, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04593940
NCT04401293,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,,Recruiting,No Results Available,Sars-CoV2|COVID,Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin,"Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.|Major bleeding|Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4|Sepsis-induced coagulopathy (SIC) score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization",Northwell Health,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-0340,26-Apr-20,26-Apr-21,26-Apr-21,26-May-20,,3-Dec-20,"Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States",,https://ClinicalTrials.gov/show/NCT04401293
NCT04357977,A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device,,Not yet recruiting,No Results Available,Coronavirus|COVID,Diagnostic Test: RBA-2,Covid +,"Kaligia Biosciences, LLC|University of South Florida",All,"18 Years and older   (Adult, Older Adult)",,300,Industry|Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,KBS005,Apr-20,Aug-20,Dec-20,22-Apr-20,,22-Apr-20,"Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT04357977
NCT04582266,PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US,,Not yet recruiting,No Results Available,COVID-19,Drug: Remdesivir,"PK Outcome: Area under the plasma concentration-time curve (AUC) of RDV|PK Outcome: Half-life (t1/2) of RDV|PK Outcome: Trough concentration (Ctrough) of GS-441524|Safety Outcome: Maternal renal adverse event (AE) of any grade|Safety Outcome: Maternal hepatic AE of any grade|Safety Outcome: Maternal hematologic AE of any grade|Safety Outcome: Maternal Grade 3 or higher AE|Safety Outcome: Serious AE|Safety Outcome: Maternal Grade 3 or higher AE assessed as related to RDV by the Clinical Management Committee (CMC)|Safety Outcome: Pregnancy loss|Safety Outcome: Congenital anomalies|Safety Outcome: Preterm birth, defined as < 37 weeks|Safety Outcome: Preterm birth, defined as < 34 weeks|Safety Outcome: Small for gestational age, defined as < 10th percentile|Safety Outcome: Newborn birth weight|Safety Outcome: Newborn length|Safety Outcome: Newborn head circumference|PK Outcome: AUC of RDV|PK Outcome: t1/2 of RDV|PK Outcome: Ctrough of GS-441524|Safety Outcome: Renal AE of any grade|Safety Outcome: Hepatic AE of any grade|Safety Outcome: Hematologic AE of any grade|Safety Outcome: Grade 3 or higher AE|Safety Outcome: Grade 3 or higher AE assessed as related to RDV by the CMC",International Maternal Pediatric Adolescent AIDS Clinical Trials Group,Female,"Child, Adult, Older Adult",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IMPAACT 2032|DAIDS Study ID 38746,15-Oct-20,15-Jan-22,15-Jan-22,9-Oct-20,,9-Oct-20,"USC/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States|University California, San Diego (CRS 4601), San Diego, California, United States|Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States|University of Florida (5051), Jacksonville, Florida, United States|Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Ann & Robert H Lurie Children's Hospital of Chicago (4001), Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|University of Puerto Rico Pediatric HIV/AIDS CRS (6601), San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04582266
NCT04340557,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,,Recruiting,No Results Available,SARS-CoV Infection,Drug: Losartan,Mechanical ventilation|ICU transfer|Oxygen therapy,Sharp HealthCare,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,COVID-ARB|2003902,27-Mar-20,6-Oct-20,31-Dec-20,9-Apr-20,,2-Jun-20,"Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT04340557
NCT04625972,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",STORM CHASER,Recruiting,No Results Available,COVID-19,Drug: AZD7442|Drug: Placebo,"The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARSCoV- 2 nucleocapsid antibodies|The incidence of COVID-19-related death occurring after dosing with IMP|The incidence of all-cause mortality occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum",AstraZeneca|QuintilesIMS,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,1125,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",D8850C00003,2-Dec-20,21-Jan-22,21-Jan-22,12-Nov-20,,11-Jan-21,"Research Site, Birmingham, Alabama, United States|Research Site, Guntersville, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Corona, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Modesto, California, United States|Research Site, Coral Springs, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Mount Dora, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Buford, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Greenwood, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Waxahachie, Texas, United States|Research Site, Riverton, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Wakefield, United Kingdom",,https://ClinicalTrials.gov/show/NCT04625972
NCT04625725,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",PROVENT,Recruiting,No Results Available,COVID-19,Drug: AZD7442|Drug: Placebo,"The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP|The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring after dosing with IMP through Day 366|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 nucleocapsid antibodies|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of COVID-19-related Emergency Department visits occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum.",AstraZeneca|QuintilesIMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,5000,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",D8850C00002,21-Nov-20,3-Feb-22,3-Feb-22,12-Nov-20,,10-Dec-20,"Research Site, Birmingham, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Cerritos, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fresno, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Lancaster, California, United States|Research Site, Modesto, California, United States|Research Site, Victorville, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Middlebury, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Wesley Chapel, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Noblesville, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Jamaica, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Alken, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozée, Belgium|Research Site, Namur, Belgium|Research Site, Wetteren, Belgium|Research Site, Clermont-Ferrand cedex, France|Research Site, Dijon cedex, France|Research Site, La Roche S/ Yon Cedex 9, France|Research Site, Lille, France|Research Site, Limoges cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Nimes, France|Research Site, Paris cedex 10, France|Research Site, Paris cedex 14, France|Research Site, Saint Etienne Cedex 2, France|Research Site, Tours cedex 9, France|Research Site, Alcobendas, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella (Málaga), Spain|Research Site, Pozuelo de Alarcón, Spain|Research Site, Enfield, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, London, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Rochdale, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Torpoint, United Kingdom|Research Site, Wakefield, United Kingdom",,https://ClinicalTrials.gov/show/NCT04625725
NCT04590586,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,,Recruiting,No Results Available,COVID-19,Drug: Standard of care|Drug: Apremilast|Drug: Apremilast placebo|Drug: Lanadelumab|Drug: Lanadelumab placebo|Drug: Zilucoplan|Drug: Zilucoplan placebo,"Time to confirmed clinical recovery|Number of participants who achieve oxygen-free recovery at Day 29|Number of participants who experience ≥2-point improvement from baseline or assessed as fit-for-discharge on the ordinal scale at Day 29|Incidence of all-cause mortality|Distribution of participants across the 8-point ordinal scale of clinical severity status scores at Day 8, Day 15 and Day 29|Worst post-baseline score on the 8-point ordinal scale of clinical severity status|Number of intensive care unit (ICU) days|Number of invasive mechanical ventilator days|Number of participants who achieve clinical recovery at Day 8, Day 15, and Day 29|Number of participants who achieve sustained clinical recovery at Day 60|Number of participants who experience one or more treatment-emergent adverse events (TEAEs)|Number of participants who experience one or more serious adverse events (SAEs)|Number of participants who experience one or more common terminology criteria for adverse events (CTCAE) grade 3 or higher|Number of participants who experience one or more adverse events (AEs) leading to dose modification|Number of participants who experience one or more adverse events (AEs) leading to discontinuation",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COV-01|2020-002594-10,24-Nov-20,20-Sep-21,20-Sep-21,19-Oct-20,,13-Jan-21,"Research Site, Anniston, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, S. El Monte, California, United States|Research Site, Gainesville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT04590586
NCT04306393,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,NOSARSCOVID,Recruiting,No Results Available,SARS (Severe Acute Respiratory Syndrome)|Coronavirus,Drug: Nitric Oxide Gas,Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment,"Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NO-SARS-COVID-19,21-Mar-20,21-Mar-21,21-Mar-22,12-Mar-20,,14-Jul-20,"University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04306393
NCT04382586,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,,Recruiting,No Results Available,COVID-19 Pulmonary Complications|COVID-19,Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo,Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale,BeiGene,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BGB-3111-219,6-Jul-20,Apr-21,Apr-21,11-May-20,,8-Oct-20,"Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System, Inc. / Chilton Medical Center, Pompton Plains, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Instituto Dor de Pesquisa E Ensino, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04382586
NCT04490278,CoV-PICS: A Virtual Post-ICU Clinic,,Recruiting,No Results Available,Post ICU Syndrome,Other: Medical Record Review - Inpatient Treatment|Other: Online Questionnaires,Acceptance with virtual CoV-PICS Visits - AIM|Acceptance with virtual CoV-PICS Visits - IAM|Acceptance with virtual CoV-PICS Visits - FIM|PICS Symptoms - Daily living|PICS Systems - Cognitive|PICS Systems - Nutrition|PICS Systems - PROMIS|PICS Symptoms - Memory,Washington University School of Medicine,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,202007053,29-Sep-20,30-Jul-21,30-Jul-21,29-Jul-20,,5-Oct-20,"Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04490278
NCT04516746,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Biological: AZD1222|Biological: Placebo,"The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age|The safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age|The reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age (Substudy only)|The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of SARS-CoV-2 infection|The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of symptomatic COVID-19 using CDC criteria|The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of University of Oxford defined symptomatic COVID-19|The efficacy of 2 IM doses of AZD12222 compared to placebo for the prevention of severe or critical symptomatic COVID-19.|The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19-related Emergency Department visits|Antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or placebo (Substudy and Illness Visits only)|Anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or placebo (Sub-study and Illness Visits only)|The efficacy of 2 IM doses of AZD1222 compared to placebo in the prevention of COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection",AstraZeneca|Iqvia Pty Ltd,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,30000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D8110C00001,28-Aug-20,23-Mar-21,21-Feb-23,18-Aug-20,,12-Jan-21,"Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Berkeley, California, United States|Research Site, El Centro, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, Atlantis, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Fairway, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Bloomington, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lackland Air Force Base, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellingham, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudad Autónoma de Buenos Aire, Argentina|Research Site, Quillota, Chile|Research Site, Region Metropolitana, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Floridablanca, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Callao, Peru|Research Site, Cercado De Lima, Peru|Research Site, Cercardo De Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru",,https://ClinicalTrials.gov/show/NCT04516746
NCT04606498,Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study,PURIFY-OBS-1,Recruiting,No Results Available,Covid19,Other: Observational,Time spent on medications used to increase blood pressure|Time spent on mechanical ventilation|Time spent in the intensive care unit (ICU)|Time spent in the hospital|Time spent on dialysis|Mortality,Henry M. Jackson Foundation for the Advancement of Military Medicine|Uniformed Services University of the Health Sciences,All,"18 Years and older   (Adult, Older Adult)",,200,Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Other,PURIFY-OBS-1,18-Dec-20,31-Dec-21,1-Feb-22,28-Oct-20,,12-Jan-21,"VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Southeast Georgia Health System - Brunswick Campus, Brunswick, Georgia, United States|Eisenhower Army Medical Center (EAMC), Fort Gordon, Georgia, United States|Uniformed Services University, Bethesda, Maryland, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baylor Scott & White, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04606498
NCT04350593,Dapagliflozin in Respiratory Failure in Patients With COVID-19,DARE-19,Recruiting,No Results Available,COVID-19,Drug: Dapagliflozin 10 MG|Drug: Placebo,"Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:|Hierarchical composite outcome measures including time to death from any cause, time to new/worsened organ dysfunction, clinical status at day 30 and time to hospital discharge|Time to hospital discharge|Total number of days alive, out of hospital, and/or free from mechanical ventilation|Total number of days alive, not in the ICU, and free from mechanical ventilation (as defined in the primary outcome measure)|Time to death from any cause|Time to new/worsened organ dysfunction|Time to acute kidney injury (defined as doubling of s-Creatinine compared to baseline)",Saint Luke's Health System|AstraZeneca|George Clinical Pty Ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1690C00081|ESR-20-20653,22-Apr-20,Jan-21,Mar-21,17-Apr-20,,31-Dec-20,"Heart Group of the Eastern Shore, Fairhope, Alabama, United States|Baptist Hospital of Miami, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|Ascension - St. Vincent, Indianapolis, Indiana, United States|Lahey Health, Burlington, Massachusetts, United States|McLaren Health Care, Auburn Hills, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|St. Francis Hospital, Roslyn, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Clinical Trials Network of Tennessee, Memphis, Tennessee, United States|DHR Health Institute for Research and Development, Edinburg, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Fundación Favaloro, Buenos Aires, Argentina|Hospital Español, Buenos Aires, Argentina|Hospital Fernández, Buenos Aires, Argentina|Hospital Pirovano, Buenos Aires, Argentina|Hospital Santojanni, Buenos Aires, Argentina|Sanatorio Anchorena, Buenos Aires, Argentina|Sanatorio Güemes, Buenos Aires, Argentina|Hospital San Roque, Córdoba, Argentina|Sanatorio Privado Duarte Quiros, Córdoba, Argentina|Centro de Pesquisa Dr. Marco Mota, Maceió, Alagoas, Brazil|Hospital EMEC e Hospital da Cidade, Feira de Santana, Bahia, Brazil|Hospital e Clínica São Roque, Ipiaú, Bahia, Brazil|Hospital Regional Deputado Luis Eduardo Magalhães, Porto Seguro, Bahia, Brazil|Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Unimed de Fortaleza, Fortaleza, Ceará, Brazil|Hospital de Messejana dr Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil|Hospital Coração do Brasil, Brasília, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espírito Santo, Brazil|Liga de Hipertensão Arterial, Goiania, Goias, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|Hospital São Domingos - Unimed Uberaba, Uberaba, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Mãe de Deus, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital São José - Criciuma, Criciuma, Santa Catarina, Brazil|IPEMI- Instituto de Pesquisas Médicas de Itajaí, Itajai, Santa Catarina, Brazil|Hospital Municipal São José, Joinville, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Clínica do Coração, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, São Paulo, Brazil|Unimed Ribeirao Preto, Ribeirão Preto, São Paulo, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, São Paulo, Brazil|Centro Integrado de Pesquisas, São José do Rio Preto, São Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, São Paulo, Brazil|Fundação Pio XII, Barretos, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|InCor - Instituto do Coração do Hospital das Clínicas FMUSP, São Paulo, Brazil|Halton Healthcare Services, Oakville, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|CIMS Hospital Pvt. Ltd, Sola, Ahmedabad, India|All India Institute of Medical Science, New Delhi, Delhi, India|Lokmanya Tilak General Hospital, Mumbai, Maharashtra, India|Max Smart Super Speciality Hospital, Saket, New Delhi, India|Max Super Speciality Hospital (A unit of Devki Devi Foundation), Saket, New Delhi, India|Dayanand Medical College & Hospital, Ludhiāna, Punjab, India|Grupo Medico del Prado, Acapulco, Mexico|Icaro, Chihuahua, Mexico|Hospital General de Cuernavaca, Cuernavaca, Mexico|JM Research, Cuernavaca, Mexico|Instituto de Investigaciones Aplicadas, Durango, Mexico|Hospital Civil, Guadalajara, Mexico|Hospital San Javier, Guadalajara, Mexico|Invesclinica Mx, Guanajuato, Mexico|CIMEZAP, Jalisco, Mexico|Medica Sur, Mexico City, Mexico|Clinica Nova, Monterrey, Mexico|Hospital San Jose, Monterrey, Mexico|Estudios Clinicos Internacionales, Puebla, Mexico|Hospital SMIQ, Queretaro, Mexico|Investigacion Medica, Sonora, Mexico|Sanatorio Santa Cruz, Toluca, Mexico|Addenbrooke's Hospital, Cambridge, Cb2 0qq, United Kingdom",,https://ClinicalTrials.gov/show/NCT04350593
NCT04425629,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",,Recruiting,No Results Available,COVID-19,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,"Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Cumulative incidence of patients with at least one (≥1) COVID-19 related medically attended visit or all-cause death|Concentration of REGN10933 in serum over time|Concentration of REGN10987 in serum over time|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of ADA to REGN10987|Incidence of neutralizing antibody (NAb) to REGN10933|Incidence of NAb to REGN10987|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in saliva samples|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in nasal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR|Change from baseline in viral load at each visit, as measured by RT-qPCR in NP swabs|Change from baseline in viral load at each visit, as measured by RT-qPCR in saliva samples|Change from baseline in viral load at each visit, as measured by RT-qPCR in nasal swabs|Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Time-weighted average change from baseline in viral load (log10 copies/mL) from day 1 to post-baseline study days|Proportion of participants with ≥1 COVID-19 related medically-attended visit|Proportion of participants with ≥2 COVID-19 related medically-attended visit|Total number of COVID-19 related medically-attended visits|Proportion of participants admitted to a hospital due to COVID-19|Proportion of participants with ≥1 outpatient or telemedicine visit due to COVID-19|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Proportion of participants with high viral load at each visit|Proportion of participants with viral loads below the limit of detection at each visit|Proportion of participants with viral loads below the lower limit of quantitation at each visit|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of participants requiring mechanical ventilation due to COVID-19|Number of days of hospitalization due to COVID-19|Proportion of participants with all-cause mortality|Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only)|Duration of symptoms consistent with COVID-19|Cumulative incidence of participants with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death|Proportion of participants with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death|Cumulative incidence of participants with ≥1 COVID-19-related hospitalization or all-cause death|Proportion of participants with ≥1 COVID-19-related hospitalization or all-cause death|Proportion of participants with ≥1 COVID-19-related medically-attended visit or all-cause death|Proportion of participants with ≥1 COVID-19 related medically-attended visit by type of visit|Proportion of participants requiring supplemental oxygen due to COVID-19|Time to all-cause death|All-cause death|Viral load over time in participants with COVID-19-related medically-attended visits|Viral load over time in participants without COVID-19-related medically-attended visits",Regeneron Pharmaceuticals,All,"Child, Adult, Older Adult",Phase 2|Phase 3,6420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R10933-10987-COV-2067|2020-003690-21,16-Jun-20,10-Apr-21,28-Aug-21,11-Jun-20,,11-Jan-21,"Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site 1, Long Beach, California, United States|Regeneron Study Site 2, Long Beach, California, United States|Regeneron Study Site 3, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Ridgewood, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Bucuresti, Romania",,https://ClinicalTrials.gov/show/NCT04425629
NCT04545060,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,COMET-ICE,Recruiting,No Results Available,Covid19,Biological: VIR-7831|Drug: Placebo,"Proportion of participants who have progression of COVID-19 through Day 29|Occurence of of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESI)|Incidence and titers (if applicable) of serum ADA to VIR-7831|Cmax|Clast|Tmax|Tlast|AUCinf|AUClast|%AUCextrap|t1/2|Vz|Vss|CL|Proportion of participants who have progression of COVID-19 as defined by hospitalization >24 hrs or death at Day 8, Day 15, or Day 22|Proportion of participants who progress to develop severe and/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22, or Day 29|Severity and duration of participant-reported symptoms of COVID-19 related illness using the FLU-PRO patient-reported outcome instrument|Detection of SARS-CoV-2 in nasal secretions by PCR at baseline and during follow-up period through Day 29|29-day, 60-day, and 90-day all-cause mortality","Vir Biotechnology, Inc.|GlaxoSmithKline",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1360,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VIR-7831-5001|GSK Study 214367,27-Aug-20,Jan-21,Jul-21,10-Sep-20,,7-Jan-21,"Investigative Site, Anniston, Alabama, United States|Investigative Site, Cullman, Alabama, United States|Investigative Site, Mesa, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Northridge, California, United States|Investigative Site, Oxnard, California, United States|Investigative Site, Rolling Hills Estates, California, United States|Investigative Site, Sacramento, California, United States|Investigative Site, Doral, Florida, United States|Investigative Site, Gainesville, Florida, United States|Investigative Site, Hialeah, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miramar, Florida, United States|Investigative Site, North Miami, Florida, United States|Investigative Site, Palmetto Bay, Florida, United States|Investigative Site, Pembroke Pines, Florida, United States|Investigative Site, Pompano Beach, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Decatur, Georgia, United States|Investigative Site, Idaho Falls, Idaho, United States|Investigative Site, Lake Charles, Louisiana, United States|Investigative Site, Marrero, Louisiana, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Caro, Michigan, United States|Investigative Site, Hazelwood, Missouri, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Santa Fe, New Mexico, United States|Investigative Site, Bronx, New York, United States|Investigative Site, Asheboro, North Carolina, United States|Investigative Site, Charlotte, North Carolina, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Smithfield, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Austin, Texas, United States|Investigative Site, Baytown, Texas, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, El Paso, Texas, United States|Investigative Site, Forney, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Humble, Texas, United States|Investigative Site, Laredo, Texas, United States|Investigative Site, McAllen, Texas, United States|Investigative Site, Mesquite, Texas, United States|Investigative Site, Sugar Land, Texas, United States|Investigative Site, Kirkland, Washington, United States|Investigative Site, Seattle, Washington, United States|Investigative Site, Vienna, Austria|Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Investigative Site, Maringá, Parana, Brazil|Investigative Site, Natal, Rio Grande Do Norte, Brazil|Investigative Site, Passo Fundo, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Chapecó, Santa Catarina, Brazil|Investigative Site, Santo André, Sao Paulo, Brazil|Investigative Site, Vila Assuncao, Sao Paulo, Brazil|Investigative Site, Campinas, São Paulo, Brazil|Investigative Site, Sarnia, Ontario, Canada|Investigative Site, Toronto, Ontario, Canada|Investigative Site, Québec, Quebec, Canada|Investigative Site, Santiago, Region Metropolitana, Chile|Investigative Site, Argenteuil, France|Investigative Site, Limoges, France|Investigative Site, Melun, France|Investigative Site, Valenciennes, France|Investigative Site, Bellavista, Callao, Peru|Investigative Site, El Agustino, Lima, Peru|Investigative Site, Huaral, Lima, Peru|Investigative Site, San Isidro, Lima, Peru|Investigative Site, Bella Vista, Peru|Investigative Site, Lima, Peru|Investigative Site, Terrassa, Barcelona, Spain|Investigative Site, Albacete, Spain|Investigative Site, Centelles, Spain|Investigative Site, Girona, Spain|Investigative Site, Granada, Spain|Investigative Site, Vigo, Spain|Investigative Site, Belfast, United Kingdom",,https://ClinicalTrials.gov/show/NCT04545060
NCT04557046,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,ASPIRE,Recruiting,No Results Available,Covid19,Diagnostic Test: Nasal Swab|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Throat swab|Diagnostic Test: Fingerstick|Diagnostic Test: Saliva specimen,Performance Evaluation,LumiraDx UK Limited,All,"Child, Adult, Older Adult",Not Applicable,400,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,S-CLIN-PROT-00032,26-Jun-20,30-Nov-20,31-Dec-20,21-Sep-20,,22-Oct-20,"Children's Pediatric Associates of Altamonte Springs, Altamonte Springs, Florida, United States|Chappel Group, Kissimmee, Florida, United States|Good Samaritan Minute Clinic, Georgia Tech, Atlanta, Georgia, United States|Gvozden Pediatrics, Millersville, Maryland, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Physicians Quality Care of Jackson, Jackson, Tennessee, United States|Village Health Partners, Plano, Texas, United States",,https://ClinicalTrials.gov/show/NCT04557046
NCT04364737,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,,Recruiting,No Results Available,COVID-19|Coronavirus|Coronavirus Infection,Biological: Convalescent Plasma|Other: Saline solution,Score on the WHO 11-point ordinal scale for clinical improvement at 14 days|Score on the WHO 11-point ordinal scale for clinical improvement at 28 days,"NYU Langone Health|National Center for Advancing Translational Science (NCATS)|Albert Einstein College of Medicine|Yale University|The University of Texas Health Science Center, Houston|The University of Texas Health Science Center at Tyler|University of Miami",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-00541,17-Apr-20,31-Jan-23,30-Apr-23,28-Apr-20,,28-Aug-20,"Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States|The University of Texas Health Science Center, Houston, Texas, United States|The University of Texas Health Science Center, Tyler, Texas, United States",,https://ClinicalTrials.gov/show/NCT04364737
NCT04643964,Brief Video Interventions for Depression,,Recruiting,No Results Available,Depressive Symptoms,Behavioral: Entrée: Cognitive skills|Behavioral: Entrée: Behavioral skills|Behavioral: Entrée: Interpersonal skills|Behavioral: Sampler skills,"Change in the Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR)|Change in the Ways of Responding Questionnaire (WOR)|Change in the Styles of Emotion Response Questionnaire (SERQ)|Change in the University of California, Los Angeles (UCLA) Loneliness Scale, Version 3",Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,501,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020B0326,Nov-20,Nov-20,Nov-20,25-Nov-20,,25-Nov-20,"Department of Psychology, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04643964
NCT04426695,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",,Recruiting,No Results Available,COVID-19,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,Incidence of death or required mechanical ventilation|Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average change from baseline in viral load as measured by RT-qPCR in NP swab samples|Change from baseline in viral load as measured by RT-qPCR in NP swabs|Time to sustained negative RT-qPCR in NP swab samples|Incidence of deaths due to any cause|Incidence of required mechanical ventilation|Proportion of patients who died or went on mechanical ventilation|Proportion of patients who died|Proportion of patients who went on mechanical ventilation|Time to discharge|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987|Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933|Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987|Assessment of PK parameter: Clearance (CL) for REGN10933|Assessment of PK parameter: Clearance (CL) of REGN10987|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987|Assessment of PK parameter: Mean residence time (MRT) of REGN10933|Assessment of PK parameter: Mean residence time (MRT) of REGN10987|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987,Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,6900,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R10933-10987-COV-2066|2020-002537-15,11-Jun-20,16-Apr-21,16-Apr-21,11-Jun-20,,15-Jan-21,"Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Chandler, Arizona, United States|Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site 1, Tucson, Arizona, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Mission Hills, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regneron Study Site, Hartford, Connecticut, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pensacola, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Glenview, Illinois, United States|Regeneron Study Site, Urbana, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Grand Rapids, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Chesterfield, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Englewood, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Pennington, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site 1, Buffalo, New York, United States|Regeneron Study Site 2, Buffalo, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, West Islip, New York, United States|Regeneron Study Site, White Plains, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Concord, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site 1, Amarillo, Texas, United States|Regeneron Study Site 2, Amarillo, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Lubbock, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Sugar Land, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site 1, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Garibaldi Salvador, Bahia, Brazil|Regeneron Study Site, Salvador, Bahia, Brazil|Regeneron Study Site, Fortaleza, Ceara, Brazil|Regeneron Study Site, Curitiba, Paraná, Brazil|Regeneron Study Site, Porto Alegre, Rio Grande Do Sul, Brazil|Regeneron Study Site, Passo Fundo, RS, Brazil|Regeneron Study Site, Chapeco, Santa Catarina, Brazil|Regeneron Study Site, Criciuma, Santa Catarina, Brazil|Regeneron Study Site, Botucatu, Sao Paolo, Brazil|Regeneron Study Site, Campinas, Sao Paolo, Brazil|Regeneron Study Site, São Paulo, Brazil|Regeneron Study Site, São Paulo, Brazil|Regeneron Study Site, São Paulo, Brazil|Regeneron Study Site 1, Las Condes, Santiago De Chile, Chile|Regeneron Study Site 2, Las Condes, Santiago De Chile, Chile|Regeneron Study Site, Región Metropolitana, Santiago, Chile|Regeneron Study Site, Santiago de Chile, Chile|Regeneron Study Site, Culiacan, Mexico|Regeneron Study Site, Monterrey, Mexico|Regeneron Study Site 1, Mérida, Mexico|Regeneron Study Site 2, Mérida, Mexico|Regeneron Study Site, Sertoma, Mexico|Regeneron Study Site, Veracruz, Mexico|Regeneron Study Site, Zapopan, Mexico|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucuresti, Romania",,https://ClinicalTrials.gov/show/NCT04426695
NCT04583969,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,,Recruiting,No Results Available,COVID-19,Biological: Lenzilumab|Other: Placebo|Drug: Remdesivir,"Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in lactate dehydrogenase (LDH) concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in National Early Warning Score (NEWS) from baseline|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation/high flow oxygen use|Incidence of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of ventilator/ extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Time to discharge or to a National Early Warning Score (NEWS) of < / = 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0013B,19-Oct-20,8-Jan-21,1-Jul-21,12-Oct-20,,30-Dec-20,"Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|Kern Medical Center, Bakersfield, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States|West Virginia University - Infectious Diseases Clinic, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT04583969
NCT04504032,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),,Recruiting,No Results Available,COVID-19,Drug: Rivaroxaban|Drug: Placebo,Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs)|Number of Participants With AEs Leading to Study Discontinuation|Number of Participants With Serious Adverse Events (SAEs)|Proportion of Participants With Disease Progression|Median Time to Disease Resolution|Proportion of Participants Who Achieve Disease Resolution|Mean Gates Medical Research Institute Ordinal Scale Score|Change From Baseline in Gates Medical Research Institute Ordinal Scale Score|Mean World Health Organization Ordinal Scale Score|Change From Baseline in World Health Organization Ordinal Scale Score|Incidence of Hospitalization|Number of Days of Hospitalization,Bill & Melinda Gates Medical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Gates MRI - COD-01-T01-01,2-Sep-20,Dec-20,Dec-20,7-Aug-20,,9-Dec-20,"Woodland Research Northwest LLC - ERG - PPDS, Rogers, Arkansas, United States|Science 37, Inc, Los Angeles, California, United States|Allergy and Asthma Medical Group and Research Center - CRN - PPDS, San Diego, California, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|LCC Medical Research - Miami - BTC - PPDS, Miami, Florida, United States|Adult Medicine of Lake County, Mount Dora, Florida, United States|Providea Health Partners LLC, Evergreen Park, Illinois, United States|Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States|Encompass Care, North Las Vegas, Nevada, United States|Riverside Medical Group - Circuit- PPDS, Secaucus, New Jersey, United States|NYC Health + Hospitals/Lincoln, Bronx, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Harlem Hospital Center, New York, New York, United States|Premier Family Physicians - Austin - Hunt - PPDS, Austin, Texas, United States|Village Health Partners - Plano - Hunt - PPDS, Plano, Texas, United States|South Texas Allergy and Asthma Medical Professionals, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04504032
NCT04511819,Losmapimod Safety and Efficacy in COVID-19,LOSVID,Recruiting,No Results Available,COVID-19,Drug: Losmapimod oral tablet|Drug: Placebo oral tablet,Day 28 Mortality|Clinical Status Assessment|Respiratory Failure Assessment|Treatment Survival|Treatment-Emergent Adverse Events,Fulcrum Therapeutics,All,"50 Years and older   (Adult, Older Adult)",Phase 3,410,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FIS-001-2020,28-Aug-20,Jun-21,Jun-21,13-Aug-20,,14-Jan-21,"University of California Irvine - Irvine Medical Center, Irvine, California, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|United Medical Memorial Hospital, Houston, Texas, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil|Irmandade de Santa Casa de Misericordia de Porto Alegre, Centro Histórico, Porto Alegre - RS, Brazil|Maestri e Kormann Consultoria Medico-cientifica LTDA, Blumenau, SC, Brazil|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|JM Research Cuernavaca, Cuernavaca, Morelos, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada, S.C., Culiacán, Sinaloa, Mexico",,https://ClinicalTrials.gov/show/NCT04511819
NCT04640168,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),,Recruiting,No Results Available,COVID-19,Drug: Baricitinib|Drug: Dexamethasone|Other: Placebo|Drug: Remdesivir,"The proportion of subjects not meeting criteria for one of the following two ordinal scale categories at any time: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Days of invasive mechanical ventilation/ extracorporeal membrane oxygenation (ECMO) (if applicable)|Days of non-invasive ventilation/high flow oxygen (if applicable)|Days of supplemental oxygen (if applicable)|Desirability of Outcome Ranking (DOOR)|Duration of hospitalization|Incidence of discontinuation or temporary suspension of study product administration|Subject 14-day mortality|Subject 28-day mortality|Subject clinical status|The proportion of subjects meeting criteria for one of the 8 ordinal scale categories|Time to an improvement of one category from baseline using an ordinal scale|Time to an improvement of two categories from baseline using an ordinal scale|Time to recovery",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1500,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-4,24-Nov-20,30-Apr-21,30-Jun-21,23-Nov-20,,12-Jan-21,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|VA Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Michigan - Infectious Disease Clinic at Taubman Center, Ann Arbor, Michigan, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|CHI Health Creighton University Medical Center - Bergan Mercy - Pulmonary Medicine, Omaha, Nebraska, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National University Health System - Alexandra Hospital - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04640168
NCT04666441,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,,Recruiting,No Results Available,COVID-19,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,"Time-weighted average daily change from baseline in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average daily change from baseline in viral load (log10 copies/mL)|Time-weighted average daily change from baseline in viral load (log10 copies/mL) in patients with high viral load|Proportion of patients with high viral load|Proportion of patients with viral loads below the limit of detection|Proportion of patients with viral loads below the lower limit of quantitation|Time-weighted average daily change from baseline in cycle threshold (Ct) as measured by RT-qPCR in NP samples|Time-weighted average daily change from baseline in Ct from day 1 to day 5, as measured by RT-qPCR in NP samples|Change from baseline in Ct as measured by RT-qPCR in NP samples|Change from baseline in viral load as measured by RT-qPCR in NP samples|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions (grade ≥2)|Proportion of patients with injection-site reactions (grade ≥2)|Proportion of patients with hypersensitivity reactions (grade ≥2)|Concentrations of REGN10933 in serum|Concentrations of REGN10987 in serum",Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R10933-10987-COV-20145,15-Dec-20,1-Mar-21,24-Apr-21,14-Dec-20,,13-Jan-21,"Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04666441
NCT04583956,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Biological: Risankizumab,"Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in National Early Warning Score (NEWS) from baseline|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation/high flow oxygen use|Incidence of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Time to discharge or to a National Early Warning Score (NEWS) of < / = 2 and maintained for 24 hours, whichever occurs first|Ventilator/ extracorporeal membrane oxygenation (ECMO) use",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0013A,14-Oct-20,8-Jan-21,1-Jul-21,12-Oct-20,,12-Jan-21,"Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|Kern Medical Center, Bakersfield, California, United States|Hoag Hospital Newport Beach, Newport Beach, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology, New Haven, Connecticut, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|University of Louisville - Division of Infectious Diseases, Louisville, Kentucky, United States|Louisiana State University Health Shreveport - Infectious Diseases, Shreveport, Louisiana, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States|Englewood Hospital, Englewood, New Jersey, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States|St. Charles Health System - St. Charles Bend Hospital, Bend, Oregon, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Kent County Memorial Hospital, Warwick, Rhode Island, United States|Baptist Hospitals of Southeast Texas Site, Beaumont, Texas, United States|West Virginia University - Infectious Diseases Clinic, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT04583956
NCT04604184,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,,Recruiting,No Results Available,COVID-19,Drug: BI 764198|Drug: Placebo,Patients alive and free of mechanical ventilation|Patients alive and discharged free of oxygen|Patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation|Time to response|Number of ventilator free days|Mortality,Boehringer Ingelheim,All,"50 Years and older   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1434-0009|2020-003211-96,3-Nov-20,27-Feb-21,5-May-21,27-Oct-20,,12-Jan-21,"University of California Irvine, Orange, California, United States|Rapides Regional Medical Center, Alexandria, Louisiana, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Mercy Health St. Vincent Medical Center, Toledo, Ohio, United States|Providence Regional Medical Center, Everett, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Hospital Municipal de San Juan, Rio Piedras, Puerto Rico|Hospital Universitario Infanta Leonor, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04604184
NCT04501978,ACTIV-3: Therapeutics for Inpatients With COVID-19,TICO,Recruiting,No Results Available,Covid19,Biological: LY3819253|Drug: Placebo|Biological: Remdesivir|Biological: VIR-7831|Biological: BRII-196/BRII-198,"Pulmonary ordinal outcome (disease severity stratum 1)|Pulmonary+ ordinal outcome (disease severity stratum 1)|Time from randomization to sustained recovery|All-cause mortality|Composite of time to sustained recovery and mortality|Days alive outside short-term acute care hospital|Pulmonary ordinal outcome|Pulmonary+ ordinal outcome|Incidence of clinical organ failure|Composite of death or serious clinical COVID-19 related events|Composite of cardiovascular events and thromboembolic events|Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death|Incidence of infusion reactions|Composite of SAEs or death|Change in SARS-CoV-2 neutralizing antibody levels|Change in overall titers of antibodies|Change in neutralizing antibody levels|Incidence of home use of supplemental oxygen above pre-morbid oxygen use|Incidence of no home use of supplemental oxygen above pre-morbid oxygen use","National Institute of Allergy and Infectious Diseases (NIAID)|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)|University of Copenhagen|Medical Research Council|Kirby Institute|Washington D.C. Veterans Affairs Medical Center|AIDS Clinical Trials Group|National Heart, Lung, and Blood Institute (NHLBI)|US Department of Veterans Affairs|Prevention and Early Treatment of Acute Lung Injury (PETAL)|Cardiothoracic Surgical Trials Network (CTSN)|Eli Lilly and Company|Vir Biotechnology, Inc.|GlaxoSmithKline|Brii Biosciences Limited",All,"18 Years and older   (Adult, Older Adult)",Phase 3,10000,NIH|Other|U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",014 / ACTIV-3,4-Aug-20,Jul-22,Jul-22,6-Aug-20,,12-Jan-21,"Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States|Southern Arizona VA Health Care System (Site 074-009), 3601 S. 6th Ave., Tucson, Arizona, United States|Community Regional Medical Center (Site 203-005), 2823 Fresno Street, Fresno, California, United States|Keck Hospital of USC (Site 301-020), 1500 San Pablo Street, Los Angeles, California, United States|Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd., Los Angeles, California, United States|Mount Zion Hospital, UCSF Medical Center (Site 203-007), 1600 Divisadero St., San Francisco, California, United States|San Francisco VA Healthcare System (Site 074-002), 4150 Clement St., San Francisco, California, United States|Moffitt-Long Hospital, UCSF Medical Center (Site 203-001), 505 Parnassus Ave., San Francisco, California, United States|Stanford University Hospital & Cinics (Site 203-003), 300 Pasteur Dr., Stanford, California, United States|University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue, Aurora, Colorado, United States|Denver Public Health (Site 017-004), 605 Bannock St., MC2600 (Infectious Disease Clinic), Denver, Colorado, United States|National Jewish Health (Site 204-003), 1400 Jackson Street, Denver, Colorado, United States|MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW, Washington, District of Columbia, United States|Bay Pines VA Healthcare System (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104, Bay Pines, Florida, United States|Miami VA Healthcare System (Site 074-003), 1201 NW 16 Street, Miami, Florida, United States|The Emory Clinic (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE, Atlanta, Georgia, United States|Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States|University of Kentucky Hospital (Site 210-004), 1000 South Limestone St., Lexington, Kentucky, United States|Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway, New Orleans, Louisiana, United States|University of Maryland (Site 301-019), 22 South Greene Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 202-002), 55 Fruit Street, Boston, Massachusetts, United States|Baystate Medical Center (Site 201-001), 759 Chestnut Street, Springfield, Massachusetts, United States|University of Michigan (Site 205-001), 1500 East Medical Center Drive, Ann Arbor, Michigan, United States|Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd., Detroit, Michigan, United States|Hennepin Healthcare (Site 027-001), 701 Park Avenue, Minneapolis, Minnesota, United States|University of Mississippi Medical Center (Site 202-005), 2500 North State Street, Jackson, Mississippi, United States|Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive, Lebanon, New Hampshire, United States|Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road, Bronx, New York, United States|Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street, Bronx, New York, United States|Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center (Site 207-003), 234 Goodman Ave., Cincinnati, Ohio, United States|Cleveland Clinic Fairview Hospital (Site 207-005), 18101 Lorain Avenue, Cleveland, Ohio, United States|Cleveland Clinic Foundation (Site 207-001), 9500 Euclid Avenue, Cleveland, Ohio, United States|Cleveland Clinic Marymount Hospital (Site 207-006), 12300 McCraken Road, Garfield Heights, Ohio, United States|Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd., Portland, Oregon, United States|Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive, Nashville, Tennessee, United States|UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor, Dallas, Texas, United States|Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave., Dallas, Texas, United States|Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd., Houston, Texas, United States|Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street, Murray, Utah, United States|University of Utah Health (Site 211-002), 419 Wakara Way, Suite 207, Salt Lake City, Utah, United States|University of Virginia (Site 301-021), 1215 Lee Street, Charlottesville, Virginia, United States|Virginia Commonwealth University Health System (Site 210-005), 1250 East Marshall Street, Richmond, Virginia, United States|Harborview Medical Center (Site 208-001), 325 9th Avenue, Seattle, Washington, United States|University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street, Seattle, Washington, United States|WVU Medicine (Site 301-023), One Medical Center Drive, Morgantown, West Virginia, United States|Aalborg University Hospital (Site 625-005), Hobrovej 18, Aalborg, Denmark|Department of Infectious Diseases (Site 625-002), Aarhus University Hospital, Skejby, Palle Juul-Hensens Boulevard 99, Aarhus N, Denmark|Righospitalet (Site 625-006), Blegdamsvej 9,, Copenhagen Ø, Denmark|Herlev Hospital (Site 625-012), Medicinsk Afdeling, Herlev Ringvej 75, Herlev, Denmark|Nordsjællands Hospital (Site 625-009), Dyrehavevej 29, Hillerød, Denmark|Hvidovre Hospital (Site 625-001), Department of Infectious Diseases, Kettegård allé 30, Hvidovre, Denmark|Medicinsk Afdeling (Site 625-011), Kolding Sygehus, Sygehusvej 24, Kolding, Denmark|Odense Universitetshospital (Site 625-004), Infektionsmedicinsk Forskningsenhed,J.B. Winsløwsgade 4, Odense, Denmark|Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng, Singapore, Singapore|Germans Trias i Pujol Hospital (Site 626-003), Unidad de enfermedades infecciosas, Carretera de Canyet s/n, Badalona, Barcelona, Spain|Hospital Del Mar (Site 626-025), Paseo Maritimo 25-29, Barcelona, Spain|Hospital Clínic de Barcelona (Site 626-004), Carrer de Villaroel 170, Barcelona, Spain|Hospital General Universitario Gregorio Marañón (Site 626-001), Dr. Esquerdo, 46, Madrid, Spain|Hospital Clinico San Carlos (Site 626-017), Enfermedades infecciosas, C/Martin Lagos CN, Madrid, Spain|UCICEC (Clinical Trial Unit) Hospital Universitario La Paz (Site 626-012), Paseo de la Castellana 261, 2° planta Hospital Maternal, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04501978
NCT04377620,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),,Recruiting,No Results Available,COVID-19,Drug: Placebo|Drug: Ruxolitinib,Proportion of participants who have died due to any cause|Number of Ventilator free days|Number of ICU free days|Oxygen free days|Vasopressor free days|Hospital free days|Improvement in the COVID-19 ordinal scale|Change in SOFA Score|Number of treatment-related adverse events,Incyte Corporation,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",INCB 18424-369,24-May-20,30-Apr-21,30-Apr-21,6-May-20,,19-Dec-20,"Honor Health Research Institute, Scottsdale, Arizona, United States|Sharp Memorial Hospital, San Diego, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Teradan Clinical Trials, Brandon, Florida, United States|University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Northshore University Health System, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Healthpartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|Mercy Research, Springfield, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Njms Clinical Research Unit, Newark, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Kettering Cancer Care, Dayton, Ohio, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Allegheny Health Network, Wexford, Pennsylvania, United States|St David'S Medical Center, Austin, Texas, United States|University of Texas Health Science Center At Houston - McGovern Medical School, Houston, Texas, United States|University of Texas Health Science Cente, San Antonio, Texas, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States|Sbih City Hospital 15, Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT04377620
NCT04422769,Needs of Persons With Spinal Cord Injury (SCI),,Recruiting,No Results Available,Spinal Cord Injuries,,NIH Toolbox Instrumental Support Survey - change in instrumental support|UCLA (University of California - Los Angeles) 3-item Loneliness Scale - change in social isolation,Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,202005026,22-May-20,31-Dec-20,31-Dec-20,9-Jun-20,,25-Sep-20,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04422769
NCT04547140,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),,Recruiting,No Results Available,COVID-19,Biological: Liquid Alpha1-Proteinase Inhibitor (Human)|Drug: Placebo|Drug: Standard Medical Treatment,Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression,Grifols Therapeutics LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GC2006,Jan-21,Apr-21,Sep-21,14-Sep-20,,14-Jan-21,"Birmingham VA, Birmingham, Alabama, United States|CHI Health Center, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|University of Utah, Salt Lake City, Utah, United States|AngioCor Blumenau, Blumenau, Santa Catarina, Brazil|Hospital Sao Jose, Criciúma, Santa Catarina, Brazil|Hospital das Clinicas da Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04547140
NCT04488081,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,I-SPY_COVID,Recruiting,No Results Available,COVID-19,Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast,Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality,"QuantumLeap Healthcare Collaborative|University of California, San Francisco|University of Pennsylvania|University of Minnesota|Emory University|University of Alabama at Birmingham|University of California, San Diego|University of Colorado, Denver|University of Southern California|Yale University|Columbia University|Wake Forest University Health Sciences|Sanford Health|Montefiore Medical Center",All,"18 Years and older   (Adult, Older Adult)",Phase 2,1500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I-SPY-COVID,31-Jul-20,24-Jul-22,1-Nov-22,27-Jul-20,,29-Sep-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT04488081
NCT04480424,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),,Recruiting,No Results Available,COVID-19,Biological: GAMUNEX-C|Drug: Standard Medical Treatment,All-Cause Mortality Rate Through Day 29|Time to Actual ICU Discharge|Duration of Mechanical Ventilation|Time to Actual Hospital Discharge|Duration of Any Oxygen Use|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale|Overall Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Number of Participants who Develop ARDS Distributed by Severity|Change from Baseline in Sequential Organ Failure Assessment (SOFA) Score|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours,Grifols Therapeutics LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GC2007,17-Sep-20,Apr-21,May-21,21-Jul-20,,24-Nov-20,"University of Louisville, Louisville, Kentucky, United States|McLaren Flint, Flint, Michigan, United States|McLaren Health Care-Macomb, Mount Clemens, Michigan, United States|McLaren Health Care Oakland, Pontiac, Michigan, United States|CHI Health, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|CHRISTUS Health, Tyler, Texas, United States|MultiCare Deaconness Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT04480424
NCT04472494,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Biological: Abatacept|Other: Placebo,Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28|Change from baseline in the Ordinal 8-point Outcome Scale on Day 28|All-cause mortality on Day 28|Proportion of participants alive and free of respiratory failure on Day 28|Proportion of participants returned to room air by Day 28|Proportion of participants alive and discharged home by Day 28|Proportion of participants with Serious Adverse Events (SAEs)|Proportion of participants with serious infections,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 2,129,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IM101-873|U1111-1250-4217,24-Aug-20,13-Jan-21,14-Jan-21,15-Jul-20,,17-Nov-20,"Norton Infectious Disease Institute, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Atlantic Health System, Morristown, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, Dallas, Texas, United States|Local Institution, Guaynabo, Puerto Rico|Local Institution, Monterrey Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04472494
NCT04505774,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),,Recruiting,No Results Available,Covid19,Drug: theraputic heparin|Drug: prophylactic heparin,21 Day Organ Support (respiratory or vasopressor) Free Days|Key Platform Secondary Thrombotic Endpoint|Other Platform Secondary Endpoints of Morbidity and Hospitalization|All cause mortality,"Matthew Neal MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACTIV-4 ACUTE,4-Sep-20,Mar-21,Dec-21,10-Aug-20,,5-Jan-21,"University of Alabama, Birmingham, Alabama, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC San Diego Hillcrest, San Diego, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|UCSF San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Cook County Health, Chicago, Illinois, United States|University of Illinois at Chicago Health (UIH), Chicago, Illinois, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Boston University, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, ACCS Research, Saint Louis, Missouri, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|VA New York Harbor Healthcare System, New York, New York, United States|NYU Langone, New York, New York, United States|Duke University Hospital, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The MetroHealth System, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott and White Medical Center - Temple, Temple, Texas, United States|Swedish Hospital, Seattle, Washington, United States|University of Wisconsin Hospital; Meriter Hospital (UW affiliated), Madison, Wisconsin, United States|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT04505774
NCT04421027,A Study of Baricitinib (LY3009104) in Participants With COVID-19,COV-BARRIER,Recruiting,No Results Available,COVID-19,Drug: Baricitinib|Drug: Placebo,"Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])|Percentage of Participants with at Least 1-Point Improvement on NIAID-OS or Live Discharge from Hospital|Number of Ventilator-Free Days|Time to Recovery|Overall Improvement on the NIAID-OS|Duration of Hospitalization|Percentage of Participants with a Change in Oxygen Saturation from <94% to ≥94% from Baseline|Mortality|Duration of Stay in the Intensive Care Unit (ICU) in Days|Time to Clinical Deterioration (one-category increase on the NIAID-OS)|Time to Resolution of Fever, in Participants with Fever at Baseline|Mean Change from Baseline on the National Early Warning Score (NEWS)|Time to Definitive Extubation|Time to Independence from Non-Invasive Mechanical Ventilation|Time to Independence from Oxygen Therapy in Days|Number of Days with Supplemental Oxygen Use|Number of Days of Resting Respiratory Rate <24 Breaths per Minute",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",17830|I4V-MC-KHAA|2020-001517-21,7-Sep-19,19-May-21,20-Jun-21,9-Jun-20,,19-Dec-20,"Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Valleywise Health, Phoenix, Arizona, United States|St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|White Oak Medical Center, Adventist Healthcare, Silver Spring, Maryland, United States|South Shore Hospital, Weymouth, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Renown Regional Med. Center, Reno, Nevada, United States|SUNY Downstate, Brooklyn, New York, United States|East Carolina University, Greenville, North Carolina, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States|Swedish Medical Center, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Sanatorio Sagrado Corazón, Ciudad de Buenos Aires, AR, Argentina|ClÃ-nica Zabala, Ciudad de Buenos Aires, AR, Argentina|Hospital Z.G.A.D ""Evita Pueblo"", Berazategui, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Caba, Buenos Aires, Argentina|Fundacion Sanatorio Guemes, Caba, Buenos Aires, Argentina|Casa Hospital San Juan de Dios, Ramos Mejía, Buenos Aires, Argentina|Hospital Interzonal General de Agudos ""Eva Peron"", San Martin, Buenos Aires, Argentina|Clinica Adventista Belgrano, Caba, Ciudad Autónoma De Buenos Aire, Argentina|Centros de Investigaciones Cli-nicas. Clinica Viedma, Viedma, Rio Negro, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Hospital San Roque, Cordoba, Argentina|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro Hospitalar de Reabilitacao Ana Carolina Moura Xavier, Curitiba, Parana, Brazil|CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva, Curitiba, Paraná, Brazil|CPCLIN, Natal, Rio Grande Do Norte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Carlos Fernando Malzoni Matao, Matao, Sao Paulo, Brazil|Pesquisare, Santo Andre, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo André, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, São Paulo, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, São Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|CECIP - Centro de Estudos do Interior Paulista, Jaú, São Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda, São Bernardo do Campo, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiencia, São Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica, São Paulo, Brazil|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Unity Hospital, Surat, Gujarat, India|Medanta-The Medicity, Gurgaon, Haryana, India|Government Medical College (GMC) Aurangabad, Aurangabad, Maharashtra, India|Government Medical College, Nagpur, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|Aakash Healthcare Super Speciality Hospital, New Delhi, India|Ospedale SS Annunziata, Chieti Scalo, Chieti, Italy|INMI Lazzaro Spallanzani, Roma, Rome, Italy|Ospedale Luigi Sacco, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Nuovo Ospedale di Prato S. Stefano, Prato, Italy|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Edogawa Medicare Hospital, Edogawa-ku, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|Hospital General Agustín O'Horán, Yucatan, Merida, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran- Medicina Critica, Federal District, Mexico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|The Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Barnet Hospital, Barnet, Herts, United Kingdom|St. George's University Hospitals NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04421027
NCT04583592,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),,Recruiting,No Results Available,COVID-19,Drug: Camostat Mesilate|Drug: Placebo,Disease Progression at Day 28|Survival Rate|Time to Fever Resolution|Time to Disease Progression|Resolution of Viral Shedding|Rate of Adverse Events and Serious Adverse Events|Cumulative Rate of Grade 3 and 4 Adverse Events|Rate of Discontinuation|Change in Laboratory Parameter - Platelet Count|Change in Laboratory Parameter - Potassium Level|Change in Laboratory Parameter - Aspartate Aminotransferase (AST)|Change in Laboratory Parameter - Alanine Aminotransferase (ALT)|Change in Laboratory Parameter - Alkaline Phosphatase (ALP)|Change in Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)|Change in Laboratory Parameter - Albumin|Change in Laboratory Parameter - Bilirubin|Change in Vital Signs - Heart Rate|Change in Vital Signs - Blood Pressure|Change in Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2),Sagent Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NI03-CV19-001,9-Nov-20,Feb-21,Feb-21,12-Oct-20,,14-Jan-21,"Cullman Clinical Trials, Cullman, Alabama, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Synergy Healthcare, LLC, Bradenton, Florida, United States|Clinical Research of Brandon, LLC, Brandon, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|A+ Research, Miami, Florida, United States|NextPhase Research Alliance (at CANO HEALTH), Miami, Florida, United States|Ezy Medical Research, Miami, Florida, United States|Eminat LLC, Plantation, Florida, United States|Invictus Clinical Research Group, LLC, Pompano Beach, Florida, United States|Visionaries Clinical Research, LLC, Atlanta, Georgia, United States|Family Care Research, Boise, Idaho, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Oakland Medical Research Center, Troy, Michigan, United States|Cary Research Group, Cary, North Carolina, United States|Onsite Solutions, Charlotte, North Carolina, United States|STAT Research, Springboro, Ohio, United States|Toledo Institute of Clinical Research, Inc., Toledo, Ohio, United States|Pharma Corp Clin Trials, Charleston, South Carolina, United States|Advanced Medical Trials, Georgetown, Texas, United States|Next Innovative Clinical Research, Houston, Texas, United States|Rio Grand Valley Clinical Research Institute, Pharr, Texas, United States",,https://ClinicalTrials.gov/show/NCT04583592
NCT04396106,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),,Recruiting,No Results Available,COVID-19,Drug: AT-527|Other: Placebo,Proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.|Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|Time to clinical recovery|Proportions (active vs. placebo) of subjects with respiratory failure or death,"Atea Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,190,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AT-03A-001,26-May-20,Mar-21,May-21,20-May-20,,17-Dec-20,"Atea Study Site, Scottsdale, Arizona, United States|Atea Study Site, Davis, California, United States|Atea Study Site, Los Angeles, California, United States|Atea Study Site, Washington, District of Columbia, United States|Atea Study Site, Orlando, Florida, United States|Atea Study Site, Atlanta, Georgia, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Boston, Massachusetts, United States|Atea Study Site, Butte, Montana, United States|Atea Study Site, Charlotte, North Carolina, United States|Atea Study Site, Cincinnati, Ohio, United States|Atea Study Site, Columbus, Ohio, United States|Atea Study Site, Charleston, South Carolina, United States|Atea Study Site, Columbia, South Carolina, United States|Atea Study Site, Brussels, Belgium|Atea Study Site, Mechelen, Belgium|Atea Study Site, Belo Horizonte, Brazil|Atea Study Site, Brasília, Brazil|Atea Study Site, Campo Largo, Brazil|Atea Study Site, Porto Alegre, Brazil|Atea Study Site, São Paulo, Brazil|Atea Study Site, Chisinau, Moldova, Republic of|Atea Study Site, Bucharest, Romania|Atea Study Site, Bloemfontein, South Africa|Atea Study Site, Cape Town, South Africa|Atea Study Site, Centurion, South Africa|Atea Study Site, George, South Africa|Atea Study Site, Worcester, South Africa|Atea Study Site, Brovary, Ukraine|Atea Study Site, Kyiv, Ukraine",,https://ClinicalTrials.gov/show/NCT04396106
NCT04411680,Study of Sargramostim in Patients With COVID-19,iLeukPulm,Recruiting,No Results Available,COVID-19|Sars-CoV2,Drug: Sargramostim|Drug: Standard of care,Change in oxygenation parameter of P(A-a)O2 gradient by Day 6|Percent of patients who have been intubated by Day 14|Change in ordinal scale|All cause 28-day mortality|Number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions (ADRs),"Partner Therapeutics, Inc.|United States Department of Defense",All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PTX-001-002,18-Aug-20,Jan-21,Mar-21,2-Jun-20,,14-Jan-21,"St. Jude Medical Center, Fullerton, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|California Pacific Medical Center - Van Ness Campus, San Francisco, California, United States|TidalHealth Peninsula Regional, Inc, Salisbury, Maryland, United States|University of Missouri Health Care, Columbia, Missouri, United States|Great Plains Health, North Platte, Nebraska, United States|Richmond University Medical Center, Staten Island, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04411680
NCT04634409,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,BLAZE-4,Recruiting,No Results Available,COVID-19,Drug: LY3819253|Drug: LY3832479|Drug: Placebo,"Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27|Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3832479","Eli Lilly and Company|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.",All,18 Years to 64 Years   (Adult),Phase 2,700,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",18160|J2X-MC-PYAH,29-Oct-20,31-Dec-20,15-Mar-21,18-Nov-20,,22-Dec-20,"The Institute for Liver Health, Mesa, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Surprise, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Inland Empire CT, LLC, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Cleveland Clinic of Weston Florida, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Prime Global Research, LLC, Bronx, New York, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, LLC, Dayton, Ohio, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase R and D, Knoxville, Tennessee, United States|Central Texas Clinical Rch, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|1960 Family Practice, PA, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC - Hato Rey Site, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04634409
NCT04397718,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,HITCH,Recruiting,No Results Available,COVID-19,Drug: Degarelix|Other: Saline,"A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.|Time to clinical improvement|Inpatient mortality|Duration of hospitalization|Duration of intubation for mechanical ventilation.|Time to normalization of temperature.|Maximum severity of COVID19 illness.|A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.",VA Office of Research and Development,Male,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,198,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",COVID19-8900-15,6-Jul-20,6-Jul-21,6-Jul-21,21-May-20,,4-Dec-20,"Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, Los Angeles, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Philadelphia MultiService Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04397718
NCT04427501,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,BLAZE-1,Recruiting,No Results Available,COVID-19,Drug: LY3819253|Drug: LY3832479|Drug: Placebo,"Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load|Percentage of Participants Who Experience COVID-Related Hospitalization or Death|Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold|Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization or Death","Eli Lilly and Company|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,2450,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",17947|J2W-MC-PYAB,17-Nov-19,20-Sep-20,30-Apr-21,11-Jun-20,,8-Jan-21,"Arizona Clin Trials-Mesa, Mesa, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Surprise, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|Orange Grove Banner Clinic, Tucson, Arizona, United States|Arizona Clin Trials-Tucson, Tucson, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Valley Research, Fresno, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|University of CA, Irvine, Orange, California, United States|Inland Empire CT, LLC, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Cleveland Clinic of Weston Florida, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Northwestern University, Chicago, Illinois, United States|J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Care Access Research - Bronx, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OH State Univ College of Med, Columbus, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, LLC, Dayton, Ohio, United States|Ascension St. John Tulsa OK, Tulsa, Oklahoma, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase R and D, Knoxville, Tennessee, United States|Central Texas Clinical Rch, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Centex-Houston, Houston, Texas, United States|BioPharma Clinc Site, Houston, Texas, United States|Centex-Wesfield, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC - Hato Rey Site, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04427501
NCT04313023,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,,Recruiting,No Results Available,COVID-19,Drug: PUL-042 Inhalation Solution|Drug: Placebo,Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality,"Pulmotect, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PUL-042-501,9-Jun-20,Apr-21,May-21,18-Mar-20,,13-Jan-21,"University of California Irvine, Orange, California, United States|Premier Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04313023
NCT04505098,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults,MITIGATE,Recruiting,No Results Available,Covid19|Atherosclerosis|Cardiovascular Diseases|Upper Respiratory Tract Infections,Drug: Icosapent ethyl,Percentage of patients with moderate or severe confirmed viral URIs|Worst clinical status due to a confirmed viral URI,Kaiser Permanente|Amarin Corporation,All,"50 Years and older   (Adult, Older Adult)",Phase 4,16500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,1597940,7-Aug-20,7-Aug-21,28-Feb-23,10-Aug-20,,5-Oct-20,"Kaiser Permanente Northern California, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT04505098
NCT04501952,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,,Recruiting,No Results Available,COVID-19,Drug: RDV|Drug: Placebo to Match RDV,Composite Endpoint of All-cause Medically Attended Visits (MAVs; Medical Visits Attended in Person by the Participant and a Health Care Professional) or Death by Day 28.|Proportion of Participants Experiencing Treatment-Emergent Adverse Events|All-cause Mortality at Day 28|Rate of Hospitalization by Day 28|Composite Endpoint of All-cause MAVs or Death by Day 14|Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7|Time to Alleviation (Mild or Absent) of Baseline Coronavirus Disease 2019 (COVID-19) Symptoms as Reported on the COVID-19-adapted InFLUenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)|Proportion of Participants Progressing to Requiring Oxygen Supplementation by Day 28,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1264,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GS-US-540-9012|2020-003510-12,18-Sep-20,Apr-21,Apr-21,6-Aug-20,,6-Jan-21,"Arizona Liver Health, Chandler, Arizona, United States|Arizona Clinical Trials, Tucson, Arizona, United States|St Joseph Hospital Eureka, Eureka, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|Mills Clinical Research, Los Angeles, California, United States|UC Davis Health, Sacramento, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Centura Health Porter Place, Denver, Colorado, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|CTMD Research, Inc, Palm Springs, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|St. Josephs Comprehensive Research Institute, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast, Vero Beach, Florida, United States|Triple O Research Institute PA, West Palm Beach, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States|University of Maryland Baltimore, Baltimore, Maryland, United States|Be Well Medical Center, Berkley, Michigan, United States|Memorial Hospital of Gulfport, Gulfport, Mississippi, United States|AB Clinical Trials, Las Vegas, Nevada, United States|New York Presbyterian Hospital, Flushing, New York, United States|Nuvance Health, Lagrangeville, New York, United States|Northwell Health, New Hyde Park, New York, United States|Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Rosedale Infectious Diseases, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Cherokee Nation WW Hastings Hospital, Tahlequah, Oklahoma, United States|Central Texas Clinical Research, Austin, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Care United Research, LLC, Forney, Texas, United States|University of Texas, Houston, Texas, United States|The Crofoot Research Center, Inc, Houston, Texas, United States|Laguna Clinical Research Associates, Laredo, Texas, United States|Diagnostic Clinic of Longview - Center for Clinical Research, Longview, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04501952
NCT04312997,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,,Recruiting,No Results Available,COVID-19,Drug: PUL-042 Inhalation Solution|Drug: Placebo,Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality,"Pulmotect, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PUL-042-502,16-Jun-20,Mar-21,Apr-21,18-Mar-20,,13-Jan-21,"University of California Irvine, Orange, California, United States|Premeir Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|DBC Research Corp., Tamarac, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04312997
NCT04539262,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",,Recruiting,No Results Available,COVID-19,Drug: Remdesivir (RDV)|Drug: Placebo,Time-weighted Average Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation|Proportion of Participants Progressing From Early Stage Coronavirus Disease 2019 (COVID-19) to Hospitalization or Death by Day 14|Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and its Metabolites (GS-441524 and GS-704277)|PK Parameter: AUClast of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: CLss/F of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: t1/2 of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Vz/F of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Cmax of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Tmax of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Clast of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Tlast of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: AUCtau of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: λz of RDV and its Metabolites (GS-441524 and GS-704277)|PK Parameter: Ctau of RDV and its Metabolites (GS-441524 and GS-704277)|Change in SARS-CoV-2 Viral Load From Baseline to Day 4|Change in SARS-CoV-2 Viral Load From Baseline to Day 7|Change in SARS-CoV-2 Viral Load From Baseline to Day 14|Time to Negative SARS-CoV-2 Polymerase Chain Reaction (PCR),Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,282,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GS-US-553-9020,14-Sep-20,Mar-21,Apr-21,4-Sep-20,,9-Dec-20,"The Institute for Liver Health, Mesa, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Saint Josephs Clinical Research, Anaheim, California, United States|Franco Felizarta, MD, Bakersfield, California, United States|Aurora FDRC Inc., Costa Mesa, California, United States|Elevated Health, Huntington Beach, California, United States|Western Clinical Research, Placentia, California, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Westchester Research Center at Westchester General Hospital, Miami, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Triple O Research Institute, PA, West Palm Beach, Florida, United States|Family Care Research, Boise, Idaho, United States|CTU Covid Research Center, New Orleans, Louisiana, United States|STAT Research, Vandalia, Ohio, United States|Baylor Research Institute, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04539262
NCT04368728,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",,Recruiting,No Results Available,SARS-CoV-2 Infection|COVID-19,Biological: BNT162b1|Biological: BNT162b2|Other: Placebo,"Percentage of participants in Phase 1 reporting local reactions|Percentage of participants in Phase 1 reporting systemic events|Percentage of participants in Phase 1 reporting adverse events|Percentage of participants in Phase 1 reporting serious adverse events|Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values|Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events|In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions|In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events|Percentage of participants in Phase 2/3 reporting adverse events|Percentage of participants in Phase 2/3 reporting serious adverse events|Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination|Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination|Percentage of participants 12-15 years of age in Phase 3 reporting adverse events|In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions|In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events|In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point|Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels|In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs|Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels|In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point|In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels|Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination|Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination|Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination|Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination|GMR of SARS CoV 2 neutralizing titers in the 2 age groups (12-15 years of age to 16-25 years of age)",BioNTech SE|Pfizer,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,43998,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",C4591001|2020-002641-42,29-Apr-20,30-Jul-21,27-Jan-23,30-Apr-20,,12-Jan-21,"North Alabama Research Center, LLC, Athens, Alabama, United States|Birmingham Clinical Research Unit, Birmingham, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Optimal Research, LLC, Huntsville, Alabama, United States|Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States|Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States|Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States|Whiteriver Indian Hospital, Whiteriver, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, United States|Long Beach Clinical Trials Services Inc., Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|Paradigm Clinical Research Center, Redding, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|Kaiser Permanente Santa Clara, Santa Clara, California, United States|Bayview Research Group, Valley Village, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Clinical Research Consulting, LLC, Milford, Connecticut, United States|Yale Center for Clinical Investigations (CSRU), New Haven, Connecticut, United States|Alliance for Multispecialty Research, Coral Gables, Florida, United States|DeLand Clinical Research Unit, DeLand, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Acevedo Clinical Research Associates, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|IACT Health, Columbus, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Optimal Research, LLC, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Alliance for Multispecialty Research, LLC, Newton, Kansas, United States|Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|LSUHSC-Shreveport Clinical Trials Office, Shreveport, Louisiana, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Pharmaron CPC, Inc., Baltimore, Maryland, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Michigan Center for Medical Research, Farmington Hills, Michigan, United States|MedPharmics, LLC, Gulfport, Mississippi, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research, Bozeman, Montana, United States|Methodist Physicians Clinic / CCT Research, Fremont, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Wake Research-Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Amici Clinical Research, Raritan, New Jersey, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Johns Hopkins Center for American Indian Health, Gallup, New Mexico, United States|Johns Hopkins Center for American Indian Health, Shiprock, New Mexico, United States|Meridian Clinical Research, LLC, Binghamton, New York, United States|Meridian Clinical Research LLC, Endwell, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|Duke University Medicine Circle- Duke Early Phase Clinical Research Unit, Durham, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|PriMED Clinical Research, Dayton, Ohio, United States|Senders Pediatrics, South Euclid, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Kaiser Permanente Northwest-Center for Health Research, Portland, Oregon, United States|Lehigh Valley Health Network/Network Office of Research and Innovation, Allentown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Main Street Physician's Care, Little River, South Carolina, United States|Main Street Physician's Care, Loris, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Trinity Clinical Research, Tullahoma, Tennessee, United States|Benchmark Research, Austin, Texas, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Ventavia Research Group, LLC, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Ventavia Research Group, LLC, Keller, Texas, United States|SMS Clinical Research, LLC, Mesquite, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|Benchmark Research., San Angelo, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States|Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia, United States|Virginia Research Center LLC, Midlothian, Virginia, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Wenatchee Valley Hospital, Wenatchee, Washington, United States|Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Caba, Argentina|Hospital Santo Antonio/ Associacao Obras Sociais Irma Dulce, Salvador, BA, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca), Sao Paulo, Brazil|CRS Clinical Research Services Berlin GmbH, Berlin, Germany|Medizentrum Essen Borbeck, Essen, Germany|IKF Pneumologie GmbH & Co KG, Frankfurt am Main, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany|Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Stuhr, Germany|Newtown Clinical Research Centre, Johannesburg, Gauteng, South Africa|Jongaie Research, Pretoria, Gauteng, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital, Cape Town, Western CAPE, South Africa|Ankara Universitesi Tip Fakultesi, Ibni Sina Hastanesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Medipol Mega Universite Hastanesi, Istanbul, Turkey|Acibadem Atakent Hastanesi, Istanbul, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi, Sakarya, Turkey",,https://ClinicalTrials.gov/show/NCT04368728
NCT04431453,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",CARAVAN,Recruiting,No Results Available,COVID-19,Drug: Remdesivir,Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Plasma Concentrations of Remdesivir (RDV) and Metabolites|Change From Baseline in Oxygenation Use|Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Clinical Improvement on a 7-point Ordinal Scale|Time (days) to Discharge From Hospital|Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result|Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load|Bilirubin Concentrations in < 14-day-old Participants|Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale|Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)|Proportion of Participants With Concomitant Use of Medications other than RDV for Treatment of Coronavirus Disease 2019 (COVID-19),Gilead Sciences,All,"up to 18 Years   (Child, Adult)",Phase 2|Phase 3,52,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5823|2020-001803-17,21-Jul-20,Feb-21,Feb-21,16-Jun-20,,10-Dec-20,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Ronald Reagan University of California, Los Angeles Medical Center, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Tampa General Hospital (Inpatient Visits), Tampa, Florida, United States|Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Spectrum Health/Helen De Vos Children's Hospital, Grand Rapids, Michigan, United States|Children's Minnesota, Minneapolis, Minnesota, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|NYC Health + Hospitals/Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Northwell Health-Cohen Children's Medical Center, New Hyde Park, New York, United States|Carolinas Medical Center-Levine Children's Hospital, Charlotte, North Carolina, United States|Lehigh Valley Hospital/Lehigh Valley Health Network (LVH/LVHN), Allentown, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Azienda Ospedaliero Universitaria Meyer, Florence, Italy|University Hospital of Parma, Parma, Italy|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04431453
NCT04658121,SARS-CoV-2/COVID-19 PREVALENCE STUDY,,Not yet recruiting,No Results Available,COVID-19,,"To estimate the prevalence of SARS-CoV-2 IgG seropositivity among individuals in communities surrounding selected NIAID clinical research sites|To estimate prevalence of SARS-CoV-2 infection based on results of SARS-CoV-2 RNA testing|To estimate prevalence of SARS-CoV-2 infection by presence versus absence of symptoms consistent with COVID-19|To estimate seroprevalence of SARS-CoV-2|To assess correlation between demographic, clinical and social factors with SARS-CoV-2 infection and seroprevalence|To estimate potential size of populations for referral to COVID-19 prevention and treatment studies|To assess knowledge, attitudes, and behavior about SARS-CoV-2 and COVID-19 through a study questionnaire|To compare performance characteristics of PCR-based and serologic SARS-CoV-2 tests using saliva and/or oral fluid and DBS samples",COVID-19 Prevention Network,All,"2 Months and older   (Child, Adult, Older Adult)",,3920,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,CoVPN 5002,15-Dec-20,30-Mar-21,30-Mar-21,8-Dec-20,,8-Dec-20,"Children's Hospital Colorado CRS, Aurora, Colorado, United States|U of Miami, IDRU at Jackson Memorial Hospital CRS, Miami, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|UIC Project Wish CRS, Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|John's Hopkins CRS, Baltimore, Maryland, United States|New Jersey Medical School CRS, Newark, New Jersey, United States|Harlem Prevention, New York, New York, United States|Bronx Prevention Center, New York, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati CRS, Cincinnati, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|St. Louis University VTEU-CAIMED-PHSU, Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04658121
NCT04404192,PH94B in the Treatment of Adjustment Disorder With Anxiety,,Not yet recruiting,No Results Available,Adjustment Disorder With Anxious Mood,Drug: PH94B,Hamilton Anxiety Scale|Sheehan Disability Scale|Adjustment Disorder New Module (ADNM)|Clinical Global Impression - Improvement rating (CGI-I),"VistaGen Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PH94B-CL-029,Nov-20,Jul-21,Sep-21,27-May-20,,27-May-20,"The Medical Research Network, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04404192
NCT04494646,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),,Recruiting,No Results Available,Covid19,Drug: Bardoxolone methyl|Drug: Placebo,Incidence of Serious Adverse Events in Phase 2|Proportion of participants who have recovered in Phase 3|Average number of renal replacement therapy (RRT)-free days|Average number of mechanical ventilation-free days|Incidence of All-Cause Mortality|Proportion of participants who experienced deterioration from baseline,"NYU Langone Health|Reata Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,440,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-00591,8-Sep-20,30-Jan-21,28-Feb-21,31-Jul-20,,3-Nov-20,"HSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Coney Island Hospital, Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|NYU Bellevue Hospital Center, New York, New York, United States|NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04494646
NCT04417257,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,RESOLUTION,Recruiting,No Results Available,COVID-19 Disease,Drug: LAU-7b|Drug: Placebo oral capsule,"Proportion of patients alive and free of respiratory failure (Ordinal Scale scores 1-4)|The safety of LAU-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo|Health status of the patient on the 7-point Ordinal Scale compared to placebo|Rate of all-causes death, depicted by a change from baseline in the Ordinal Scale score to category 7|Rate of COVID-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo|Rate of COVID-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo|Rate of COVID-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo|Mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo|Time to an improvement of one category on the ordinal scale patient health status, compared to placebo|Time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo|Time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo|Time to death, defined here as a time to reach category 7 on the ordinal scale patient health status, censored to Day 29 if it happens later than Day 29, compared to placebo|Duration of hospitalization (days) within the study period Days 1-29, compared to placebo|Time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo|The change from baseline in the score obtained on the EQ-5D-5L quality-of-life survey",Laurent Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LAU-20-01,29-Jun-20,30-Apr-21,30-May-21,4-Jun-20,,5-Jan-21,"Chandler Regional Medical Center / Mercy Gilbert Medical Center, Chandler, Arizona, United States|Baptist Medical Center Beaches, Jacksonville Beach, Florida, United States|St Lukes Hospital, Boise, Idaho, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Anne Arundel Medical Center, 2001 Medical Parkway, Belcher Pavillion, Annapolis, Maryland, United States|Wayne State University, Harper University Hospital, Detroit, Michigan, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|St-Paul's Hospital, Vancouver, British Columbia, Canada|Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi, Chicoutimi, Quebec, Canada|CIUSSSS de l'Est-de-l'Ile-de-Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CISSS Ds Laurentides, Saint-Jérôme, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04417257
NCT04359680,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,,Recruiting,No Results Available,COVID-19|Viral Respiratory Illnesses,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.|The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.,Romark Laboratories L.C.,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,4000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",RM08-3007,13-May-20,30-Apr-21,30-Apr-21,24-Apr-20,,29-Oct-20,"HealthStar Research LLC, Hot Springs, Arkansas, United States|So Cal Clinical Research, Huntington Beach, California, United States|Long Beach Clinical Trials, LLC, Long Beach, California, United States|Meris Clinical Research, Brandon, Florida, United States|Invesclinica US LLC, Fort Lauderdale, Florida, United States|The Chappel Group Research, Kissimmee, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|DMI Research, Pinellas Park, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States|Chicago Medical Research Institute, Inc., Chicago, Illinois, United States|Quad Clinical Research, Chicago, Illinois, United States|Chicago Medical Research, LLC, Hazel Crest, Illinois, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Beacom Family Health Connection, Fremont, Nebraska, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|RH Medical Urgent Care Professional PLLC, Bronx, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|The New York Center for Travel and Tropical Medicine, New York, New York, United States|Centex Studies, Inc., Houston, Texas, United States|SMS Clinical Research LLC, Mesquite, Texas, United States|LinQ Research LLC, Pearland, Texas, United States|Rio Grande Valley Clinical Research Institute, Pharr, Texas, United States|BFHC Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04359680
NCT04358003,Plasma Adsorption in Patients With Confirmed COVID-19,,Recruiting,No Results Available,Respiratory Failure|ARDS,Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol),All-cause mortality|Change in Sequential Organ Failure Assessment [SOFA] scores,Marker Therapeutics AG|Terumo BCT,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MH-007/B,20-May-20,1-Aug-21,1-Dec-21,22-Apr-20,,17-Aug-20,"UNM Health Science Center, Albuquerque, New Mexico, United States|Providence Portland Medical Center, Portland, Oregon, United States|UT Southwestern/Clements Hospital, Dallas, Texas, United States|UTMB, Galveston, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04358003
NCT04382651,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,MAS-COVID,Recruiting,No Results Available,"COVID-19 Pneumonia, Impaired Respiratory Function",Drug: MAS825|Drug: Matching placebo,APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CMAS825F12201,7-Jun-20,6-Jan-21,14-Apr-21,11-May-20,,16-Dec-20,"Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Bend, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04382651
NCT04652518,LYT-100 in Post-acute COVID-19 Respiratory Disease,,Recruiting,No Results Available,Covid19,Drug: LYT-100|Other: Placebo,Change in distance walked on the six-minute walk test (6MWT)|Change in Modified Borg Dyspnoea Scale (mBDS) score|Quality of Life assessment as collected using the SF-36,PureTech|Clinipace Worldwide|Novotech (Australia) Pty Limited,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,168,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LYT-100-2020-02,11-Dec-20,Aug-21,Dec-21,3-Dec-20,,13-Jan-21,"University of Southern California - Keck School of Medicine, Los Angeles, California, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|Site Coordinator, Austin, Texas, United States|Institutul de Pneumoftiziologie ""Marius Nasta"" (""Marius Nasta"" Pneumoftiziology Institute), Bucharest, Romania|National Institute for Infectious Diseases ""Prof. Dr. Matei Balş"" (Arensia Eploratory Medicine), Bucharest, Romania|Spitalul Clinic De Pneumoftiziologie ""Leon Daniello"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova, Craiova, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes - Timisoara, Timişoara, Romania",,https://ClinicalTrials.gov/show/NCT04652518
NCT04644120,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19),,Recruiting,No Results Available,CoronaVirus Disease-2019 (COVID-19),Drug: ABBV-47D11|Drug: Placebo for ABBV-47D11,Number of Participants With Study-Drug Related Grade 3 or Higher Adverse Events (AEs)|Number of Participants With Study-Drug Related Grade 3 or Higher Infusion-Related Reactions|Maximum Observed Serum Concentration (Cmax) of ABBV-47D11|Time to Cmax (Tmax) of ABBV-47D11|Area Under the Serum Concentration-Time Curve (AUC) From Day 1 (0 hour) to Day 29 (672 hour) (AUC0-672h) of ABBV-47D11|Terminal Phase Elimination Half-Life (t1/2) of ABBV-47D11|AUC From Time 0 to Infinity (AUCinf) of ABBV-47D11|Detection of Anti-Drug Antibodies (ADA)|Detection of Neutralizing Anti-Drug Antibodies (nADA)|AUC for Change From Baseline (Day 1) in SARS-CoV-2 Ribose Nucleic Acid (RNA) Reverse Transcription-Polymerase Chain Reaction (RT-PCR)|Time to Negative SARS-CoV-2 by RT-PCR|Negative SARS-CoV-2 RNA by RT-PCR,AbbVie,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",M20-404|2020-005203-39,10-Dec-20,2-Aug-21,2-Aug-21,25-Nov-20,,12-Jan-21,"Glendale Adventist Medical Center /ID# 225188, Glendale, California, United States|University of Miami /ID# 225038, Miami, Florida, United States|University of Illinois Hospital and Health Sciences System /ID# 224323, Chicago, Illinois, United States|Pikeville Medical Center /ID# 224539, Pikeville, Kentucky, United States|Wayne State University /ID# 224740, Detroit, Michigan, United States|Henry Ford Health System /ID# 224320, Detroit, Michigan, United States|Michigan State University /ID# 224907, East Lansing, Michigan, United States|Saint Peter's University Hospital /ID# 225183, New Brunswick, New Jersey, United States|Saint Michaels Medical Center /ID# 225258, Newark, New Jersey, United States|The Christ Hospital /ID# 224541, Cincinnati, Ohio, United States|Prisma Health Upstate /ID# 224556, Greenville, South Carolina, United States|St. David's Healthcare Partnership, L.P., LLP /ID# 225053, Austin, Texas, United States|Hadassah Ein Kerem Hospital /ID# 225827, Jerusalem, Yerushalayim, Israel|Sheba Medical Center /ID# 225857, Ramat Gan, Israel|Universitair Medisch Centrum Utrecht /ID# 225919, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT04644120
NCT04511650,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",RESCUE,Recruiting,No Results Available,COVID-19|Acute Respiratory Distress Syndrome,Drug: Razuprotafib Subcutaneous Solution|Drug: Placebo Subcutaneous Solution,Proportion of subjects alive and free of respiratory failure at Day 7|Proportion of subjects alive and free of respiratory failure at Day 28|Length hospitalized and free of respiratory failure from baseline to Day 7|Length hospitalized and free of respiratory failure from baseline to Day 28|Length of hospitalization from baseline to Day 7|Length of hospitalization from baseline to Day 28|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|All-cause mortality at Day 7|All-cause mortality at Day 28|Length of ICU stay from baseline to Day 28|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 7|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 28|Time to return to prehospitalization oxygen requirement|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 7|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 28|Change in PaO2:FiO2 ratio from baseline to Day 7|Change in PaO2:FiO2 ratio from baseline to Day 28|Number of participants with any serious adverse event from baseline to Day 7|Number of participants with any treatment emergent adverse event from baseline to Day 28|Number of participants with any treatment emergent adverse event from baseline to Day 7|Number of participants with any serious adverse event from baseline to Day 28,Aerpio Therapeutics|Medical Technology Enterprise Consortium (MTEC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,180,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AKB-9778-CI-6001,21-Oct-20,Feb-21,Feb-21,13-Aug-20,,17-Nov-20,"University of Southern California, Los Angeles, California, United States|University of California- Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Snake River Research, Idaho Falls, Idaho, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT04511650
NCT04348656,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),CONCOR-1,Recruiting,No Results Available,COVID-19,Biological: Convalescent plasma,Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE),Hamilton Health Sciences Corporation|Canadian Blood Services|Héma-Québec|University of Toronto|Université de Montréal|Weill Cornell Medicine/New York-Presbyterian|New York Blood Centre|McMaster University,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CONCOR-1,14-May-20,31-Oct-20,31-Dec-20,16-Apr-20,,5-Nov-20,"Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Peter Lougheed Center, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Sturgeon Community Hospital, St. Albert, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Campbellton Regional Hospital, Campbellton, New Brunswick, Canada|Edmundston Regional Hospital, Edmundston, New Brunswick, Canada|Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada|Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Bluewater Health, Sarnia, Ontario, Canada|Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hôpital Charles-Le Moyne, Longueuil, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Québec, Quebec City, Quebec, Canada|Centre hospitalier régional de St-Jérôme, Saint-Jérôme, Quebec, Canada|Ciussse De L'Estrie CHUS, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT04348656
NCT04148430,A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy,,Recruiting,No Results Available,B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma,Drug: Anakinra,Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities|Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-168,30-Oct-19,Oct-22,Oct-22,1-Nov-19,,17-Nov-20,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04148430
NCT04497987,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,BLAZE-2,Recruiting,No Results Available,COVID-19|SARS-CoV2,Drug: LY3819253|Drug: Placebo|Drug: LY3832479,"Percentage of Participants with COVID-19 within 21 Days of Detection|Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection|Percentage of Participants with SARS-CoV-2|Percentage of Participants Who are Hospitalized or Have Died due to COVID-19|Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Percentage of Participants Who Die Due to COVID-19|Pharmacokinetics (PK): Mean Concentration of LY3819253 Administered Alone|PK: Mean Concentration of LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253","Eli Lilly and Company|National Institute of Allergy and Infectious Diseases (NIAID)|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,5000,Industry|NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",18063|J2X-MC-PYAD|CoVPN #3501,2-Aug-20,8-Mar-21,29-Jun-21,4-Aug-20,,24-Dec-20,"Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States|Care Access Research, Phoenix, Arizona, United States|Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States|Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Belmont Village Lincoln Park, Lincoln Park, Illinois, United States|Family Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Care Access Rch Lake Charles, Lake Charles, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States|Care Access, Boston, Massachusetts, United States|St. Paul IDA-CARe, Saint Paul, Minnesota, United States|Care Access, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Hospital & Medical Center, Omaha, Nebraska, United States|Care Access Research - Bronx, Bronx, New York, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Donahoe Manor, Bedford, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04497987
NCT04336332,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,1-Apr-20,30-Apr-21,30-Apr-21,7-Apr-20,,8-May-20,"Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04336332
NCT04414124,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,,Recruiting,No Results Available,Mild-to-moderate COVID-19,Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone,Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)|Change from baseline to end of intake in overall composite COVID-19 symptom score|Time to resolution of fever|Proportion of patients with decreased oxygen saturation|Effect of COVID-19 symptoms on physical activities|Proportion of patients requiring hospitalization,Kaleido Biosciences,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,K031-120,2-Jul-20,Oct-20,Dec-20,4-Jun-20,,14-Aug-20,"Healthstar Research, Hot Springs, Arkansas, United States|Axon Clinical Research, Riverside, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Vista Health Research, Miami, Florida, United States|Bio-Medical Research, Miami, Florida, United States|Mount Vernon Clinical Research, Atlanta, Georgia, United States|Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Carolina Institute For Clinical Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|TruCare Internal Medicine and Infectious Diseases, DuBois, Pennsylvania, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Global Medical Research, DeSoto, Texas, United States|Centex Studies, Houston, Texas, United States|Infectious Diseases Associates of Central Virginia, Lynchburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04414124
NCT04697927,A Study of Risk Factors for the COVID-19 Virus Infection,,Recruiting,No Results Available,COVID-19 Infections in Cancer Patients,Other: Questionnaires,develop a comprehensive registry database,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",,10000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-418,30-Dec-20,Dec-22,Dec-22,6-Jan-21,,8-Jan-21,"Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Rockville Centre, New York, United States",,https://ClinicalTrials.gov/show/NCT04697927
NCT04401475,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",,Recruiting,No Results Available,COVID-19|ARDS,Biological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IV,"the proportion of patients that are alive without any need for oxygen support defined as a score of 3 or less on the WHO COVID-19 nine-point scale|Time to therapeutic response (primary efficacy endpoint).|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 28|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of ≤ 2) at Day 28.|The proportion of patients that are alive and free of respiratory failure (WHO scale ≤ 4) at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of ≤ 2) at Day 60.|The proportion of patients that are alive and free of respiratory failure (WHO scale ≤ 4) at Day 60.|Time to clinical improvement by 2 points on the WHO ordinal scale described above.|Time to clinical improvement by 1 point on the WHO ordinal scale described above.|Change in the NEWS-2 Scale at 28 days.|Time to News-2 = 0.|The proportion of patients that experience disease progression, defined as an increase of one point or more in the WHO 9-point ordinal scale, at Day 28.|Ventilator-free days.|Duration of ventilation.|Mortality rate at 28-days and 60-days post-treatment initiation.|Duration of hospitalization.|Time to independence from supplementary oxygen therapy.|Time to normalization of oxygen saturation, defined as SaO2/SpO2 > 94% sustained a minimum of 24 hours.|Change in Sequential Organ Failure Assessment (SOFA) score, while hospitalized.|Radiological response to treatment based on Thoracic Computerized Tomography Scan (CT-Scan) or Chest X-Ray.|Change in cytokines, including IL-6, and C-reactive protein (CRP) levels.|Time to resolution of fever for at least 48 hours without antipyretics.|The decision by the attending physician to initiate treatment with another targeted immunomodulator (i.e. dexamethasone).|Change in the Berlin ARDS severity scale.|Change in Acute Kidney Injury Network (AKIN) classification.|Change in troponin levels.",Edesa Biotech Inc.|JSS Medical Research Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,396,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EB05-04-2020,25-Nov-20,Apr-21,Apr-21,26-May-20,,12-Jan-21,"St. Jude Medical Center/ Providence, Fullerton, California, United States|St. Joseph Hospital, Orange - Providence, Orange, California, United States|University of Miami Hospital, Coral Gables, Florida, United States|Methodist Medical Center IL, Peoria, Illinois, United States|Providence Regional Medical Center - Everett, Everett, Washington, United States|UW Medicine Valley Medical Center, Renton, Washington, United States|West Virginia University Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States|North York General Hospital, Toronto, Ontario, Canada|Hôpital Maisonneuve Rosemont, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04401475
NCT04351152,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,,Recruiting,No Results Available,Coronavirus Disease 2019 (COVID-19) Pneumonia,Biological: Lenzilumab|Drug: Standard of Care,"Time to Recovery|Incidence of Invasive Mechanical Ventilation and/or Death|Incidence of severe acute respiratory distress syndrome (ARDS)|Duration of Intensive Care Unit (ICU) Stay|Ventilator-free Days|Duration of Hospitalization|Time to Improvement in 1 or 2 Categories using 8-point Ordinal Scale|Time to Death|Number of Subjects Alive and Off Oxygen|Percentage of Participants Experiencing Adverse Events|Percentage of Participants Experiencing Serious Adverse Events|Proportion of Subjects Discharged from Hospital|All-cause Mortality and Proportion of Subjects Alive|Time to improvement in oxygenation for > 48 hours|Incidence of Non-invasive Ventilation (or Use of High-flow Oxygen Device)|Time to Clinical Improvement, Defined as NEWS2 < 2 Maintained for 24 Hours|Change from Baseline to Day 28 in Clinical status Based on the 8-point Ordinal Scale|Duration of Time on Low-flow or High-flow Supplemental Oxygen","Humanigen, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HGEN003-06,30-Apr-20,Sep-20,Sep-20,17-Apr-20,,5-Aug-20,"Mayo Clinic, Phoenix, Arizona, United States|University of Southern California (USC) Medical Center, Los Angeles, California, United States|USC - Los Angeles County Medical Center, Los Angeles, California, United States|Baptist Medical Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Atrium Health, Charlotte, North Carolina, United States|St. David's Healthcare, Austin, Texas, United States|St. David's North Austin Medical Center, Austin, Texas, United States|Texas Health, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT04351152
NCT04373460,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,CSSC-004,Recruiting,No Results Available,SARS-CoV 2,Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor,Cumulative incidence of hospitalization or death prior to hospitalization|Cumulative incidence of treatment-related serious adverse events|Cumulative incidence of treatment-related grade 3 or higher adverse events|Change in serum SARS-CoV-2 antibody titers|Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity,Johns Hopkins University|State of Maryland|Bloomberg Foundation|United States Department of Defense|National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years and older   (Adult, Older Adult)",Phase 2,1344,Other|U.S. Fed|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB00247590,3-Jun-20,21-Dec-22,31-Jan-23,4-May-20,,14-Jan-21,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|Mayo Clinic, Phoenix, Phoenix, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Netowrk, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Network, Norwalk Hospital, Norwalk, Connecticut, United States|University of Miami, Coral Gables, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|MedStar Washington Hospital Center, Hyattsville, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04373460
NCT04389840,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,,Recruiting,No Results Available,COVID-19|Acute Lung Injury|SARS-CoV-2,Drug: Dociparastat sodium|Drug: Placebo,Proportion of participants who are alive and free of invasive mechanical ventilation|All-cause mortality,Chimerix,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,524,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CMX-DS-004,3-Jun-20,Feb-21,Mar-21,15-May-20,,5-Oct-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States|Our Lady of the Lake, Baton Rouge, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Texas Health Harris Methodist Hospital Fort Worth, Dallas, Texas, United States|Sentara Clinical Trials, Norfolk, Virginia, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04389840
NCT04341116,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),,Recruiting,No Results Available,Coronavirus Disease 2019 COVID-19,Drug: TJ003234|Drug: Placebo,Proportion (%) of subjects recovered|Proportion (%) of subjects recovered on Day 30|All-cause mortality rate by Day 30|Time to recovery among subjects alive by Day 30|Length of hospitalization|Incidence of treatment-emergent Adverse events by Day 30,I-Mab Biopharma Co. Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,384,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TJ003234COV201,11-Apr-20,Dec-21,Dec-21,10-Apr-20,,14-Dec-20,"Olive View-UCLA Medical Center, Sylmar, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|The GW Medical Faculty Associates, Washington, District of Columbia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|UNM Hospitals, Albuquerque, New Mexico, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univeristy Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04341116
NCT04447469,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,,Recruiting,No Results Available,COVID,Drug: mavrilimumab|Other: Placebo,Cohort 1: Proportion of Participants Alive and Without Respiratory Failure at Day 15|Cohort 2: Mortality Rate at Day 15|Cohort 1: Time to Return to Room Air by Day 15|Cohort 1: Time to 2-point Clinical Improvement by Day 15|Cohort 1: Mortality Rate at Day 29|Cohort 1: Time to 1-Point Clinical Improvement by Day 15|Cohort 2: Mortality Rate at Day 29|Cohort 2: Proportion of Participants Alive and Without Respiratory Failure at Day 15|Cohorts 1 and 2: Proportion of Participants Alive and Without Respiratory Failure At Day 29|Cohorts 1 and 2: Time to Return to Room Air by Day 29|Cohort 2: Time to 2-point Clinical Improvement by Day 15|Cohorts 1 and 2: Time to 1-point Clinical Improvement by Day 29|Cohorts 1 and 2: Time to 2-point Clinical Improvement by Day 29|Cohort 1: Respiratory Failure-Free Survival by Day 15|Cohort 1: Respiratory Failure-Free Survival by Day 29|Cohort 1: Proportion of Participants Who Return to Room Air by Day 15|Cohorts 1 and 2: Proportion of Participants Who Return to Room Air by Day 29|Cohort 1: Mortality Rate at Day 15|Cohorts 1 and 2: Overall Survival by Day 29|Cohorts 1 and 2: Clinical Status Over Time|Cohorts 1 and 2: Number of Days Alive and Out of Hospital Through Day 90,"Kiniksa Pharmaceuticals, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,573,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KPL-301-C203,27-Jul-20,Feb-21,Apr-21,25-Jun-20,,17-Nov-20,"UCLA Medical Center, Los Angeles, California, United States|Sharp Health Care, San Diego, California, United States|Affinity Health, Oak Brook, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Allina Health System, Minneapolis, Minnesota, United States|Mercy Hospital, Springfield, Missouri, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Texas Health Sciences, Houston, Texas, United States|UPECLIN - Unidade de Pesquisa Clínica, Botucatu, Brazil|IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará, Fortaleza, Brazil|Hospital Bruno Born, Lajeado, Brazil|Centro de Pesquisas Clínicas, Natal, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil|Hospital Cardio Pulmonar, Salvador, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Clinica Las Condes, Santiago, Chile|Hospital Essalud Alberto Sabogal Sologuren, Bellavista, Peru|Essalud - Hospital de Emergencias Grau, Lima Cercado, Peru|Hospital Nacional Cayetano Heredia, San Martín De Porres, Peru|Clinica Providencia, San Miguel, Peru|IATROS International, Bloemfontein, South Africa|Tiervlei Trial Center, Cape Town, South Africa|TASK Eden, George, South Africa|Into Research - Little Company of Mary Medical Center, Pretoria, South Africa|Limpopo Clinical Research Initiative, Rustenburg, South Africa",,https://ClinicalTrials.gov/show/NCT04447469
NCT04575584,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),,Recruiting,No Results Available,Coronavirus Disease (COVID-19),Drug: Molnupiravir|Drug: Placebo,Time-to-sustained recovery|Percentage of participants with an adverse event (AE)|Percentage of participants who discontinued study intervention due to an AE|Percentage of participants with all-cause mortality|Pulmonary score on a scale|Pulmonary+ score on a scale|National Early Warning Score on a scale|WHO 11-point outcomes score on a scale,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4482-001|2020-003367-26|MK-4482-001|PHRR201210-003189,19-Oct-20,30-May-21,2-Dec-21,5-Oct-20,,8-Jan-21,"Kaiser Foundation Hospital - South Bay ( Site 1832), Harbor City, California, United States|UC Davis Medical Center ( Site 1809), Sacramento, California, United States|University Of Florida ( Site 1810), Gainesville, Florida, United States|Wellstar Kennestone Hospital ( Site 1801), Marietta, Georgia, United States|Loretto Hospital ( Site 1838), Chicago, Illinois, United States|LSU-HSC Shreveport ( Site 1824), Shreveport, Louisiana, United States|Henry Ford Health System ( Site 1821), Detroit, Michigan, United States|University of Mississippi Medical Center ( Site 1846), Jackson, Mississippi, United States|University of Nebraska Medical Center ( Site 1835), Omaha, Nebraska, United States|Carolinas Medical Center ( Site 1850), Charlotte, North Carolina, United States|Vidant Medical Center ( Site 1865), Greenville, North Carolina, United States|Sanford Health ( Site 1851), Fargo, North Dakota, United States|Temple University ( Site 1836), Philadelphia, Pennsylvania, United States|Houston Methodist Hospital ( Site 1863), Houston, Texas, United States|Swedish Medical Center ( Site 1812), Edmonds, Washington, United States|Valley Medical Center ( Site 1815), Renton, Washington, United States|Swedish Medical Center ( Site 1861), Seattle, Washington, United States|Chronos Pesquisa Clínica ( Site 0105), Brasilia, Distrito Federal, Brazil|Santa Casa de Misericordia de Belo Horizonte ( Site 0100), Belo Horizonte, Minas Gerais, Brazil|Hospital de Clinicas da Universidade Federal do Parana ( Site 0104), Curitiba, Parana, Brazil|Hospital Tacchini ( Site 0107), Bento Goncalves, Rio Grande Do Sul, Brazil|FUNFARME Hospital de Base Centro Integrado de Pesquisa ( Site 0101), Sao Jose do Rio Preto, Sao Paulo, Brazil|University Health Network - Toronto General Hospital ( Site 0201), Toronto, Ontario, Canada|Hospital Clinico Fusat ( Site 0300), Rancagua, Libertador General Bernardo O Higgins, Chile|Clinica Universidad de los Andes ( Site 0301), Santiago, Region M. De Santiago, Chile|Hospital Sotero del Rio [Santiago, Chile] ( Site 0304), Santiago, Region M. De Santiago, Chile|Complejo Hospitalario San Jose ( Site 0306), Santiago, Region M. De Santiago, Chile|Servicio de Salud Sur Hospital Lucio Cordova ( Site 0305), Santiago, Region M. De Santiago, Chile|Hospital Pablo Tobon Uribe ( Site 0404), Medellin, Antioquia, Colombia|Clinica de la Costa Ltda. ( Site 0402), Barranquilla, Atlantico, Colombia|Oncomedica S.A. ( Site 0406), Monteria, Cordoba, Colombia|Hospital Universitario San Ignacio ( Site 0401), Bogota, Distrito Capital De Bogota, Colombia|Fundacion Cardiovascular de Colombia ( Site 0403), Bucaramanca, Santander, Colombia|Fundacion Valle del Lili ( Site 0400), Cali, Valle Del Cauca, Colombia|Groupe Hospitalier Pellegrin ( Site 0511), Bordeaux, Gironde, France|Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504), Paris, Ile-de-France, France|C.H.U. de Toulouse, Hopital de Purpan ( Site 0501), Toulouse, Midi-Pyrenees, France|Centre Hospitalier de Tourcoing ( Site 0502), Tourcoing, Nord, France|CHU Hopital Saint Antoine ( Site 0505), Paris, France|Hopital Bichat - Claude Bernard ( Site 0503), Paris, France|Rambam Medical Center ( Site 2102), Haifa, Israel|Hadassah Medical Center. Ein Kerem ( Site 2103), Jerusalem, Israel|Chaim Sheba Medical Center ( Site 2100), Ramat Gan, Israel|Chungnam National University Hospital ( Site 2202), Daejeon, Taejon-Kwangyokshi, Korea, Republic of|Inha University Hospital ( Site 2204), Incheon, Korea, Republic of|The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 2205), Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0802), Ciudad de mexico, Distrito Federal, Mexico|Hospital Regional de Alta Especialidad del Bajio ( Site 0807), Leon, Guanajuato, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800), Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0803), Monterrey, Nuevo Leon, Mexico|Lung Center of the Philippines ( Site 0902), Quezon City, National Capital Region, Philippines|Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 1001), Lodz-Baluty, Lodzkie, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1004), Lublin, Lubelskie, Poland|Centrum Medyczne Pratia, Mazowiecki Szpital Specjalistyczny, Oddział Obserwacyjno - Zakaźny ( Site 1, Ostroleka, Mazowieckie, Poland|Centrum Medyczne w Lancucie Sp.zo.o. ( Site 1000), Lancut, Podkarpackie, Poland|Krasnogorsk City Hospital Number 1 ( Site 1119), Krasnogorsk, Moskovskaya Oblast, Russian Federation|City Clinical Hospital #40 ( Site 1109), Moscow, Moskva, Russian Federation|FSBI Central Hospital with Policlinics ( Site 1105), Moscow, Moskva, Russian Federation|Moscow Clinical Hospital #52 ( Site 1103), Moscow, Moskva, Russian Federation|City Hospital #40 ( Site 1113), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Pokrovskaya hospital ( Site 1116), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Hospital #1 ( Site 1112), Smolensk, Smolenskaya Oblast, Russian Federation|Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1100), Kazan, Tatarstan, Respublika, Russian Federation|IATROS International ( Site 1202), Bloemfontein, Free State, South Africa|Hospital Universitari Vall d Hebron ( Site 1305), Barcelona, Spain|Hospital Clinic ( Site 1304), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ( Site 1303), Barcelona, Spain|Hospital Universitario Gregorio Maranon ( Site 1302), Madrid, Spain|Hospital Universitario Ramon y Cajal ( Site 1301), Madrid, Spain|Hospital Universitario La Paz ( Site 1300), Madrid, Spain|Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|CNPE of Kharkiv RC Regional Clinical Infectious Diseases Hospital ( Site 1606), Kharkiv, Kharkivska Oblast, Ukraine|Сommunal non-com. Institution Oleksandrivska clinical hospital Kyiv ( Site 1600), Kyiv, Kyivska Oblast, Ukraine|Odesa City Clinical Infectious Hospital ( Site 1611), Odesa, Odeska Oblast, Ukraine|Communal Non-Commercial Enterprise Central City Hospital ( Site 1615), Rivne, Rivnenska Oblast, Ukraine|Volyn Regional Clinical Hospital ( Site 1613), Lutsk, Volynska Oblast, Ukraine|Royal Free London NHS Foundation Trust ( Site 1700), London, London, City Of, United Kingdom|King's College Hospital ( Site 1705), London, London, City Of, United Kingdom|North Manchester General Hospital ( Site 1701), Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT04575584
NCT04403880,Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19,,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Other: Sample collection,"Humoral responses to peptide antigens derived from SARS-CoV-2 structural proteins and regions of the spike protein not present in vaccines|SARS-CoV-2-specific antibody binding response rate|SARS-CoV-2-specific antibody binding response magnitude|SARS-CoV-2-specific antibody binding response epitope specificity|SARS-CoV-2-specific antibody neutralization response rate|SARS-CoV-2-specific antibody neutralization response magnitude|SARS-CoV-2-specific antibody neutralization response epitope specificity|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response rate|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response magnitude|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response epitope specificity|SARS-CoV-2-specific CD4+ and CD8+ T cell responses|SARS-CoV-2-specific CD4+ and CD8+ T cell response rate|SARS-CoV-2-specific CD4+ and CD8+ T cell response magnitude|SARS-CoV-2-specific CD4+ and CD8+ T cell response functional profiling|SARS-CoV-2-specific memory B cell characterization|SARS-CoV-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants|Detection of viral RNA in nasopharyngeal or nasal swab samples|Response rate of SARS-CoV-2-specific binding antibodies in nasal samples|Response magnitude of SARS-CoV-2-specific binding antibodies in nasal samples",HIV Vaccine Trials Network|National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network,All,"18 Years and older   (Adult, Older Adult)",,727,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Other,HVTN 405/HPTN 1901|5UM1AI068614-14,13-May-20,Aug-21,Aug-21,27-May-20,,7-Dec-20,"Alabama Vaccine CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Bridge HIV CRS, San Francisco, California, United States|George Washington University CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|Adolescent & Young Adult Research at The CORE Center (AYAR at CORE), Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health Clinical Research Site CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Bronx Prevention Research Center CRS, Bronx, New York, United States|Harlem Prevention Center CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Vanderbilt Vaccine CRS, Nashville, Tennessee, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|Malawi CRS, Lilongwe, Malawi|Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo, Mozambique|CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista, Callao, Peru|San Miguel CRS, San Miguel, Lima, Peru|Asociacion Civil Selva Amazonica (ACSA) CRS, Iquitos, Maynas, Peru|Via Libra CRS, Lima, Peru|Barranco CRS, Lima, Peru|Josha Research CRS, Bloemfontein, South Africa|Emavundleni CRS, Cape Town, South Africa|Groote Schuur HIV CRS, Cape Town, South Africa|Khayelitsha CRS / (CIDRI UCT), Cape Town, South Africa|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa|Chatsworth CRS, Chatsworth, South Africa|Botha's Hill CRS, Durban, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Vulindlela CRS, Durban, South Africa|Isipingo CRS, Isipingo, South Africa|Kliptown Soweto CRS, Johannesburg, South Africa|Soweto HVTN CRS, Johannesburg, South Africa|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa|Synexus Stanza Clinical Research Centre CRS, Pretoria, South Africa|Rustenburg CRS, Rustenburg, South Africa|Setshaba Research Centre CRS, Soshanguve, South Africa|Tembisa Clinic 4 CRS, Tembisa, South Africa|The Aurum Institute Tembisa Clinical Research Centre CRS, Tembisa, South Africa|Tongaat CRS, Tongaat, South Africa|Verulam CRS, Verulam, South Africa|National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya, Tanzania|Matero Reference Clinic CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Lusaka CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Ndola CRS, Ndola, Zambia|St Mary's CRS, Chitungwiza, Zimbabwe|Zengeza CRS, Chitungwiza, Zimbabwe|Seke South CRS, Harare, Zimbabwe",,https://ClinicalTrials.gov/show/NCT04403880
NCT04575597,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),,Recruiting,No Results Available,Coronavirus Disease (COVID-19),Drug: Molnupiravir|Drug: Placebo,Percentage of participants who are hospitalized and/or die|Percentage of participants with an adverse event (AE)|Percentage of participants who discontinued study intervention due to an AE|Time to sustained resolution or improvement of each targeted COVID-19 sign/symptom|Time to progression of each targeted COVID-19 sign/symptom|WHO 11-point outcomes score on a scale,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4482-002|2020-003368-24|MK-4482-002|PHRR201209-003186,19-Oct-20,28-May-21,30-Nov-21,5-Oct-20,,31-Dec-20,"Phoenix Medical Group ( Site 1822), Peoria, Arizona, United States|Ruane Clinical Research Group, Inc. ( Site 2406), Los Angeles, California, United States|Men's Health Foundation ( Site 1820), Los Angeles, California, United States|UC Davis Medical Center ( Site 1833), Sacramento, California, United States|Emerson Clinical Research Institute ( Site 1828), Washington, District of Columbia, United States|Midway Immunology and Research Center ( Site 1837), Fort Pierce, Florida, United States|Indago Research & Health Center, Inc ( Site 1809), Hialeah, Florida, United States|Advanced Research For Health Improvement LLC ( Site 1816), Immokalee, Florida, United States|Advanced Research For Health Improvement LLC ( Site 1813), Naples, Florida, United States|Bliss Healthcare Services ( Site 1847), Orlando, Florida, United States|Javara Inc. ( Site 1869), Albany, Georgia, United States|IACT Health ( Site 1818), Columbus, Georgia, United States|Javara Inc. ( Site 1868), Fayetteville, Georgia, United States|Loretto Hospital ( Site 1886), Chicago, Illinois, United States|University of Nebraska Medical Center ( Site 2414), Omaha, Nebraska, United States|Saint Hope Foundation, Inc. ( Site 1830), Bellaire, Texas, United States|The Crofoot Research Center, Inc. ( Site 1812), Houston, Texas, United States|Javara Inc. ( Site 1866), Sugar Land, Texas, United States|Swedish Medical Center First Hill ( Site 1807), Seattle, Washington, United States|Multicare Health System ( Site 1811), Spokane, Washington, United States|Multicare Health System ( Site 1814), University Place, Washington, United States|Chronos Pesquisa Clínica ( Site 0155), Brasilia, Distrito Federal, Brazil|Santa Casa de Misericordia de Belo Horizonte ( Site 0150), Belo Horizonte, Minas Gerais, Brazil|Hospital de Clinicas da Universidade Federal do Parana ( Site 0154), Curitiba, Parana, Brazil|Hospital Tacchini ( Site 0157), Bento Goncalves, Rio Grande Do Sul, Brazil|Instituto de Infectologia Emilio Ribas ( Site 0153), Sao Paulo, Brazil|University Health Network - Toronto General Hospital ( Site 0201), Toronto, Ontario, Canada|Clinica Universidad de los Andes ( Site 0302), Santiago, Region M. De Santiago, Chile|Fundacion Arturo Lopez Perez ( Site 0305), Santiago, Region M. De Santiago, Chile|Espacio EME ( Site 0304), Santiago, Region M. De Santiago, Chile|Clinica Bicentenario Spa ( Site 0306), Santiago, Region M. De Santiago, Chile|Hospital Pablo Tobon Uribe ( Site 0405), Medellin, Antioquia, Colombia|Clinica de la Costa Ltda. ( Site 0403), Barranquilla, Atlantico, Colombia|Oncomedica S.A. ( Site 0407), Monteria, Cordoba, Colombia|Caja de Compensación Familiar CAFAM. Sede Centro de Atención en Salud CAFAM Floresta ( Site 0406), Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia ( Site 0402), Bucaramanca, Santander, Colombia|Fundacion Valle del Lili ( Site 0401), Cali, Valle Del Cauca, Colombia|Groupe Hospitalier Pellegrin ( Site 0511), Bordeaux, Gironde, France|C.H.U. de Toulouse Hopital Purpan ( Site 0501), Toulouse, Midi-Pyrenees, France|Centre Hospitalier de Tourcoing ( Site 0502), Tourcoing, Nord, France|CHU Hopital Saint Antoine ( Site 0505), Paris, France|Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504), Paris, France|Hopital Bichat Claude Bernard ( Site 0503), Paris, France|Universitaetsklinikum Frankfurt ( Site 2302), Frankfurt a main, Hessen, Germany|Universitaetsklinikum Essen ( Site 2305), Essen, Nordrhein-Westfalen, Germany|ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 2301), Berlin, Germany|Hadassah Medical Center. Ein Kerem ( Site 2100), Jerusalem, Israel|Lung Center of the Philippines ( Site 0902), Quezon City, National Capital Region, Philippines|Central Scientific Research Institute of Epidemiology ( Site 1104), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1105), Moscow, Moskva, Russian Federation|Medical Research Institute LLC ( Site 1116), Saint Petersburg, Sankt-Peterburg, Russian Federation|St.Petersburg Outpatient Clinic #109 ( Site 1119), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Limited liability company ""Scientific research center Eco-safety"" ( Site 1117), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Smolensk State Medical University ( Site 1110), Smolensk, Smolenskaya Oblast, Russian Federation|Strategic Medical System LLC ( Site 1114), Saint-Petersburg, Russian Federation|IATROS International ( Site 1212), Bloemfontein, Free State, South Africa|Mzansi Ethical Research Centre ( Site 1225), Mpumalanga, Gauteng, South Africa|Jongaie Research ( Site 1223), Pretoria-West, Gauteng, South Africa|Wentworth Provincial Hospital ( Site 1216), Durban, Kwazulu-Natal, South Africa|Be Part Yoluntu Centre ( Site 1218), Paarl, Western Cape, Western Cape, South Africa|Hospital General Universitario Gregorio Maranon ( Site 1302), Madrid, Madrid, Comunidad De, Spain|Hospital Clinic ( Site 1304), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ( Site 1303), Barcelona, Spain|Hospital Universitario Ramon y Cajal ( Site 1301), Madrid, Spain|Hospital Universitario La Paz ( Site 1300), Madrid, Spain|Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Non profit municipal enterprise City hospital student of Kharkiv city council ( Site 1621), Kharkiv, Kharkivska Oblast, Ukraine|LLC ""Adonis plus"" ( Site 1619), Kyiv, Kyivska Oblast, Ukraine|Kyiv railway clinical hospital 2 of Branch Health center ( Site 1602), Kyiv, Kyivska Oblast, Ukraine|ARTEM. State Holding Company ( Site 1618), Kyiv, Kyivska Oblast, Ukraine|Layton Medical Centre ( Site 1705), Blackpool, Lancashire (England), United Kingdom|Royal Free London NHS Foundation Trust ( Site 1700), London, London, City Of, United Kingdom|King's College Hospital ( Site 1707), London, London, City Of, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust ( Site 1704), Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT04575597
NCT04409509,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),,Recruiting,No Results Available,Coronavirus Disease 2019 (COVID-19),"Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo",The incidence of tracheal intubation or death prior to tracheal intubation|Proportion of subjects with death from all causes|Proportion of subjects intubated|Number and proportion of subjects with ≥ 2-point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale|Number and proportion of subjects within each of the categories of the NIAID|Proportion of subjects requiring continuous positive airway pressure (CPAP)|Proportion of subjects requiring bilevel positive airway pressure (BiPAP)|Proportion of subjects requiring high-flow nasal cannula (HFNC)|Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO)|Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score|Change from Baseline in SOFA score and in the individual components of SOFA score|Length of hospital stay|Number and proportion of subjects experiencing Adverse Events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects with adverse events of special interest (AESIs)|Number and proportion of subjects with CSL312 induced anti-CSL312 antibodies|Maximum plasma concentration (Cmax) of CSL312|Time to maximum plasma concentration (Tmax) of CSL312|Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last) of CSL312|Terminal half-life (T1/2) of CSL312,CSL Behring,All,"18 Years and older   (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSL312_COVID-19,1-Jul-20,Dec-20,Dec-20,1-Jun-20,,30-Sep-20,"Nova Clinical Research, LLC, Bradenton, Florida, United States|Theia Clinical Research, LLC, Saint Petersburg, Florida, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Inspira Health Center Vineland, Vineland, New Jersey, United States|Sisters of Charity Hospital/ St. Joseph's Campus, Buffalo, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Monument Health Clinical Research, Rapid City, South Dakota, United States|PharmaTex Research, Amarillo, Texas, United States|UT Health Science Center, McGovern Medical School, Houston, Texas, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04409509
NCT04575038,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,CRISIS2,Recruiting,No Results Available,COVID-19 Infection,Drug: Brequinar|Drug: Placebo,SARS-CoV-2 viral load|Rates of AEs and SAEs including laboratory assessments|Viral shedding duration|Hospital Admission,"Clear Creek Bio, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCB-CRISIS-02,19-Nov-20,31-Jan-21,28-Feb-21,5-Oct-20,,17-Dec-20,"Central Alabama Research, Homewood, Alabama, United States|Ark Clinical Research, Long Beach, California, United States|Doral Medical Research, Doral, Florida, United States|IACT Health, Columbus, Georgia, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Wilmington Health, Wilmington, North Carolina, United States|Remington-Davis, Inc., Columbus, Ohio, United States|VitaLink - Gaffney, Gaffney, South Carolina, United States|Self Regional Healthcare Research Center - Self Medical Group, Greenwood, South Carolina, United States|VitaLink Research, Spartanburg, South Carolina, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Centex Studies, Inc. - McAllen, McAllen, Texas, United States|Synexus Clinical Research US, Inc. - Olympus Family Medicine, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04575038
NCT04518410,ACTIV-2: A Study for Outpatients With COVID-19,,Recruiting,No Results Available,Coronavirus|Covid19,Drug: LY3819253|Drug: Placebo,Duration of COVID-19 symptoms (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2)|Cumulative incidence of death from any cause or hospitalization (Phase 3)|Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3)|Cumulative incidence of death from any cause or hospitalization (Phase 2)|Duration of COVID-19 symptoms (Phase 3)|Presence of SARS-CoV-2 RNA (Phases 2 and 3)|Level of SARS-Cov-2 RNA (Phases 2 and 3)|COVID-19 severity ranking (Phases 2 and 3)|Incidence of ≥1 worsening symptom of COVID-19 (Phases 2 and 3)|Duration of fever (Phases 2 and 3)|Time to self-report return to usual (pre-COVID-19) health (Phases 2 and 3)|Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3)|Oxygen saturation level (Phase 2)|Level of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)|Level of SARS-CoV-2 RNA from saliva (Phase 2)|Level of SARS-CoV-2 RNA from self-collected nasal swabs (Phase 2)|Level of SARS-CoV-2 RNA (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA in saliva (Phase 2)|Post-treatment level of SARS-CoV-2 RNA (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 3 (Phase 3)|Concentration of investigational agent (Phase 2 - LY3819253)|Level of anti-drug antibodies (Phase 2 - LY3819253)|AUC (Phase 2 - LY3819253)|Total body clearance (CL) (Phase 2 - LY3819253)|Elimination half-life (Phase 2 - LY3819253)|Cmax (Phase 2 - LY3819253)|Cmin (Phase 2 - LY3819253),National Institute of Allergy and Infectious Diseases (NIAID)|Eli Lilly and Company|AIDS Clinical Trials Group,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,2000,NIH|Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A5401/ACTIV-2|38742,19-Aug-20,Dec-21,Dec-21,19-Aug-20,,15-Jan-21,"Pinnacle Research Group (Site 1082), 321 E 10th Street, Anniston, Alabama, United States|University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States|Jasper Summit Research, LLC. (Site 1056), 1280 Summit, Jasper, Alabama, United States|Atella Clinical Research (Site 1111), 5451 La Palma Avenue, La Palma, California, United States|Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C, Loma Linda, California, United States|University of Southern California (Site 1057), 1300 N Mission Rd., Rm 349, Los Angeles, California, United States|UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100, Los Angeles, California, United States|Central Valley Research, LLC (Site 1085), 400 E Orangeburg Ave., Ste. 5, Modesto, California, United States|Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210, Northridge, California, United States|University of California Irvine (Site 1083), 843 Health Sciences Road, Orange, California, United States|FOMAT Medical Research (Site 1136), 300 South A Street, Oxnard, California, United States|Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive, Rancho Mirage, California, United States|University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd., Sacramento, California, United States|University of California San Diego (Site 1002), 220 Dickinson Street, San Diego, California, United States|Zion Medical Center (Site 1063), 4647 Zion Avenue, San Diego, California, United States|University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84, San Francisco, California, United States|Harbor UCLA (Site 1022), 1124 West Carson Street, Torrance, California, United States|University of Colorado (Site 1007), 12401 East 17th Avenue, Aurora, Colorado, United States|Bradenton Research Center Inc. (Site 1109), 3924 9th Ave. W, Bradenton, Florida, United States|Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350, Bradenton, Florida, United States|Midland Florida Clinical Research Center LLC (Site 1130), 665 Peachwood Drive, DeLand, Florida, United States|Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave., Doral, Florida, United States|Holy Cross Health (Site 1072), 4725 North Federal Highway, Fort Lauderdale, Florida, United States|NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway, Gulf Breeze, Florida, United States|AGA Clinical Trials (Site 1026), 900 West 49th Street, Hialeah, Florida, United States|University of Florida Jacksonville (Site 1039), 655 West 8th Street, Jacksonville, Florida, United States|QC Trials (Site 1117), 300 W. 41st Street, Ste. 203, Miami Beach, Florida, United States|Lakes Research (Site 1037), 5801 NW 151 Street, Miami Lakes, Florida, United States|Miami Clinical Research (Site 1089), 2400 SW 69th Ave., Miami, Florida, United States|IMIC, Inc. (Site 1141), 18320 Franjo Rd, Palmetto Bay, Florida, United States|Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place, Vero Beach, Florida, United States|Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4, West Palm Beach, Florida, United States|The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast, Atlanta, Georgia, United States|Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive, Atlanta, Georgia, United States|IACT Health (Site 1035), 800 Talbotton Road, Columbus, Georgia, United States|Snake River Research, PLLC (Site 1120), 2900 Cortez Ave., Idaho Falls, Idaho, United States|Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201, Burr Ridge, Illinois, United States|Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd., Chicago, Illinois, United States|Northwestern University (Site 1025), 645 North Michigan Ave, Chicago, Illinois, United States|Rush University Medical Center (Site 1017), 600 Paulina St., Chicago, Illinois, United States|University of Chicago (Site 1064), 5841 S. Maryland Ave., Chicago, Illinois, United States|Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave., Chicago, Illinois, United States|University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard, Kansas City, Kansas, United States|MedPharmics (Site 1065), 3800 Houma Blvd., Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904, New Orleans, Louisiana, United States|Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 1016), 55 Fruit Street, Boston, Massachusetts, United States|Memorial Hospital at Gulfport (Site 1104), 4500 13th Street, Gulfport, Mississippi, United States|MedPharmics, LLC. (Site 1032), 15190 Community Rd., Gulfport, Mississippi, United States|Hannibal Clinic (Site 1129), 100 Medical Drive, Hannibal, Missouri, United States|Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital (Site 1115), 931 Highland Blvd, Ste. 3103, Bozeman, Montana, United States|Mercury Street Medical Group (Site 1074), 300 W. Mercury St., Butte, Montana, United States|Quality Clinical Research (Site 1112), 10040 Regency Circle, Omaha, Nebraska, United States|Las Vegas Medical Research (Site 1048), 8530 W. Sunset Rd., Las Vegas, Nevada, United States|Lincoln Hospital (Site 1092), 249 East 149th Street, Bronx, New York, United States|Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South, Bronx, New York, United States|Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd, Flushing, New York, United States|Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway, Jamaica, New York, United States|Columbia Partnership for Prevention and Control of HIV/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604, New York, New York, United States|Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street, New York, New York, United States|Canton-Potsdam Hospital (Site 1076), 50 Leroy Street, Potsdam, New York, United States|University of Rochester (Site 1010), 601 Elmwood Ave, Rochester, New York, United States|SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C, Stony Brook, New York, United States|University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor, Chapel Hill, North Carolina, United States|Duke University Medical Center (Site 1041), 40 Duke Medicine Circle, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Health (Site 1084), 801 Broadway N, Fargo, North Dakota, United States|The Christ Hospital (Site 1119), 2123 Auburn Avenue, Cincinnati, Ohio, United States|Case Western Reserve University (Site 1033), 2061 Cornell Road, Cleveland, Ohio, United States|Ohio State University Medical Center (Site 1020), 480 Medical Center Drive, Columbus, Ohio, United States|Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way, Ohio City, Ohio, United States|STAT Research (Site 1107), 66 Remick Blvd., Springboro, Ohio, United States|Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street, Tulsa, Oklahoma, United States|Kaiser Permanente Center for Health Research (Site 1079), 3800 N. Interstate Ave., Portland, Oregon, United States|Doylestown Hospital (Site 1122), 595 W State Street, Doylestown, Pennsylvania, United States|University of Pennsylvania (Site 1031), 3400 Spruce Street, Philadelphia, Pennsylvania, United States|The University of Pittsburgh (Site 1018), 3471 5th Ave., Pittsburgh, Pennsylvania, United States|Medtrial, LLC (Site 1134), 1718 Saint Julian Pl., Ste. 2, Columbia, South Carolina, United States|Sanford USD Medical Center (Site 1078), 1305 W. 18th St., Sioux Falls, South Dakota, United States|Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183, Nashville, Tennessee, United States|Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560, Bellaire, Texas, United States|PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd., Brownsville, Texas, United States|Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive, Galveston, Texas, United States|Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street, Houston, Texas, United States|University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112, Houston, Texas, United States|Dynamic Medical Research Group (Site 1081), 8314 Southwest Fwy, Houston, Texas, United States|SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave., Mesquite, Texas, United States|Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road, Falls Church, Virginia, United States|EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77, Kirkland, Washington, United States|University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave., Seattle, Washington, United States|Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road, Milwaukee, Wisconsin, United States|Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04518410
NCT04508023,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",PREVENT-HD,Recruiting,No Results Available,Coronavirus Disease 2019 (COVID-19),Drug: Rivaroxaban|Other: Placebo|Other: Standard of Care (SOC),"Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, All-cause Hospitalization and All-cause Mortality|Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Mortality|Time to First Occurrence of All-cause Hospitalization|Time to First Occurrence of Symptomatic VTE|Time to First Occurrence of an Emergency Room (ER) Visit|Time to First Occurrence of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Hospitalization|Percentage of Participants who are Hospitalized or Dead From Any Cause|Time to All-cause Mortality up to Day 35|Time to First Occurrence of International Society on Thrombosis and Hemostasis (ISTH) Critical Site and Fatal Bleeding|Time to First Occurrence of ISTH Major Bleeding Events|Time to First Occurrence of Clinically Relevant Non-major Bleeding","Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 3,4000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR108849|39039039DVT3004,13-Aug-20,3-Mar-21,16-Apr-21,11-Aug-20,,11-Jan-21,"University of Arizona, Tucson, Arizona, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Florida Hospital Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northshore Universite Healthsystem, Evanston, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Lenox Hill Hospital -Northwell Health, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Health Physicians Group, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT04508023
NCT04539275,COVID-19 (VA CURES-1),VA CURES-1,Recruiting,No Results Available,COVID-19,Drug: Convalescent Plasma|Other: Masked Saline Placebo,"Proportion of participants developing acute hypoxemic respiratory failure or all-cause death|Time (in days) to recovery|Time (in days) to death or respiratory failure|Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm|Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm|Subject 28-day all-cause mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Participant's clinical status by ordinal scale|Mean change in the ordinal scale|Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first|Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29|Duration of hospitalization|Number of hospitalizations related to COVID-19|Cumulative incidence of Serious Adverse Events (SAEs)|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Incidence of discontinuation or temporary suspension of study product administrations (for any reason)|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in total bilirubin|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in prothrombin time (PT)",VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 3,702,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",COVID19-8900-22,16-Nov-20,20-Jun-22,18-Jul-22,4-Sep-20,,24-Nov-20,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Orlando VA Medical Center, Orlando, FL, Orlando, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States|VA Southern Nevada Healthcare System, North Las Vegas, NV, Las Vegas, Nevada, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04539275
NCT04519502,Maternal Morbidity and Mortality During the COVID-19 Pandemic,MFMU COVID-19,Recruiting,No Results Available,COVID-19|Pregnancy Complications,,Maternal Mortality and Morbidity Composite|Cesarean Delivery|Severe maternal morbidity or mortality|Adverse maternal outcomes|Adverse neonatal outcomes|Neonatal infection|Maternal in-patient hospitalization days|Maternal ICU admission|Duration of labor and delivery|Neonatal length of stay|Neonatal ICU length of stay,The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Female,"Child, Adult, Older Adult",,26400,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Retrospective,HD36801 - MFMU COVID-19|U01HD036801,23-Jun-20,31-Mar-21,31-Dec-21,19-Aug-20,,21-Aug-20,"University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University-St. Luke's Hospital, New York, New York, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Brown Univeristy, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04519502
NCT04472728,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,COVA,Recruiting,No Results Available,Covid-19|SARS-CoV2,Drug: BIO101|Drug: Placebo,End-of-Part 1 interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.|For part-2 sample size interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.|For the final analysis: Proportion of subjects with all cause mortality or respiratory failure.|Interim analysis; indication of activity of BIO101: Oxygen saturation by pulse oximetry (SpO2) SpO2 / Fraction of inspired oxygen (FiO2) ratio|Interim analysis; indication of activity of BIO101: Inflammatory markers|Interim analysis; indication of activity of BIO101: Renin Angiotensin System biomarkers|Key secondary endpoint for final analysis: Proportion of participants with positive or negative events|Additional secondary endpoints for final analysis: Respiratory function|Additional secondary endpoints for final analysis:proportion of patients who experienced positive event|Additional secondary endpoints for final analysis:proportion of patients who experienced negative events|Additional secondary endpoint for final analysis: The National Early Warning Score 2 (NewS2):|Additional secondary endpoint for final analysis: Population Pharmacokinetics study (pop-PK)|Additional secondary endpoint : Population Pharmacokinetics study (pop-PK)|Secondary endpoint: Population Pharmacokinetics study (pop-PK),Biophytis,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,310,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIO101-CL05,16-Jun-20,Jul-21,Sep-21,15-Jul-20,,10-Dec-20,"University of California, Irvine, Irvine, California, United States|Barnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches, Louisiana, United States|Beaumont Health, Royal Oak, Michigan, United States|CHU Saint-Pierre, Brussel, Belgium|AZ-Sint Maarten, Mechelen, Belgium|CHU CLU Namur (Saint-Elisabeth) Place Louise Godin, Namur, Belgium|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Municipal de Barueri Dr. Francisco Moran, Barueri, São Paulo, Brazil|Hospital e Maternidade Celso Pierro - PUCCAMP, Campinas, São Paulo, Brazil|Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São José Do Rio Preto, São Paulo, Brazil|Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar, São Paulo, Brazil|Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital, Paris, Paris Cedex 13, France|Centre Hospitalier Argenteuil, Argenteuil, France|Centre Hospitalier Universitaire Bordeaux, Bordeaux, France|Centre Hospitalier Rene Dubos, Cergy-Pontoise, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, Paris, France|FDI Clinical Research - San Juan City Hospital, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04472728
NCT04614948,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,ENSEMBLE 2,Recruiting,No Results Available,Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol,Biological: Ad26.COV2.S|Other: Placebo,"Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 and who were Seronegative at Baseline|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of their Serostatus|Number of Participants with First Occurrence of COVID-19 Requiring Medical Intervention|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants with Molecularly Confirmed, Moderate to Severe/Critical COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed Mild COVID-19|Number of Participants with First Occurrence of Molecularly confirmed COVID-19 Defined by the US FDA Harmonized Case Definition|Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|Serologic Conversion Between Baseline (Day 1) and 14 days, 6 months, and 1 year after the 2nd vaccination Using an Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants with First Occurrence of SARS-CoV-2 Infection (Serologically and/or Molecularly Confirmed)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs) Leading to Study Discontinuation|Number of Participants with Solicited Local Adverse Events (AEs) During 7 Days Following Each Vaccination|Number of Participants with Solicited Systemic AEs During 7 Days Following Each Vaccination|Number of Participants with Unsolicited Local Adverse Events (AEs) During 28 Days Post-vaccination|SARS-CoV-2 Binding Antibodies Assessed by ELISA|SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)",Janssen Vaccines & Prevention B.V.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CR108916|2020-003643-29|VAC31518COV3009,15-Nov-20,10-May-22,11-May-23,4-Nov-20,,22-Dec-20,"Achieve Clinical Research, LLC, Vestavia Hills, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Synexus Clinical Research US, Inc, Cerritos, California, United States|eStudySite, Chula Vista, California, United States|Catalina Research Institute, Montclair, California, United States|Benchmark Research, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Paradigm Clinical Research Centers, Inc., Wheat Ridge, Colorado, United States|JEM Research, LLC, Atlantis, Florida, United States|Prestige Clinical Research Center, Inc., Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Health Awareness inc., Jupiter, Florida, United States|Altus Research, Inc, Lake Worth, Florida, United States|Compass Research, Melbourne, Melbourne, Florida, United States|Behavioral Clinical Research , Inc, North Miami, Florida, United States|Clinical NeuroScience Solutions, Inc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Accel Research Sites, Eatonton, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centennial Medical Group, Elkridge, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Hassman Research Institute, LLC., Berlin, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Medpharmics, LLC, Albuquerque, New Mexico, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Allergy Asthma Immunology of Rochester, PC (AAIR) - Research Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|American Health Network, LLC, Charlotte, North Carolina, United States|Wilmington Health Associates, Wilmington, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinical NeuroScience Solutions, Inc, Memphis, Tennessee, United States|Centennial Medical Center, Nashville, Tennessee, United States|Tekton Research Inc., Austin, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc., McAllen, Texas, United States|Endeavor Clinical Trials, LLC, San Antonio, Texas, United States|JBR Clinical Research, Salt Lake City, Utah, United States|Alliance for Multispeciality Research, Norfolk, Virginia, United States|Anima, Alken, Belgium|Institute of Tropical Medicine Antwerp, Antwerpen, Belgium|Hopital Erasme, Brussel, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|Az Sint-Maarten, Mechelen, Belgium|Private Practice RESPISOM Namur, Namur, Belgium|Fundacion Cardiomet CEQUIN, Armenia, Colombia|IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S., Barranquilla, Colombia|Caja de Compensacion Familiar Cafam, Bogota, Colombia|Asistencia Cientifica de Alta Complejidad S.A.S, Bogota, Colombia|CAIMED Aguazul, Casanare, Colombia|Centro Medico Imbanaco de Cali S.A., Casanare, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|Hospital General de Medellin Luz Castro de Gutierrez E.S.E, Medellin, Colombia|T Y C Inversiones S A S Grupsalud, Santa Marta, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Yopal - Casanare, Colombia|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Grenoble - Hôpital Albert Michallon, La Tronche, France|CHU de Montpellier, Hopital Saint-Eloi, Montpellier, France|Hopital Saint-Antoine, Paris Cedex 12, France|Hopital Cochin, Paris, France|Groupe Hospitalier Sud Hôpital Haut-Leveque Service d'hematologie, Pessac, France|CHU Saint-Etienne - Hôpital Nord, Saint-Etienne Cedex 2, France|Hopital Purpan, Toulouse Cedex 09, France|Centre Hospitalier Universitaire de Tours, Tours Cedex, France|Hôpital de Brabois Adultes, Vandoeuvre les Nancy, France|Uniklinik Köln, Köln, Germany|Klinikum rechts der Isar der TU Munchen, München, Germany|Riverside Medical Center, Bacolod, Philippines|West Visayas State University Medical Center, Iloilo City, Philippines|Tropical Disease Foundation, Makati, Philippines|Makati Medical Center, Manila, Philippines|Medical Center Manila, Manila, Philippines|TREAD Research Tygerberg Hospital, Cape Town, South Africa|Centre of Tuberculosis Research Innovation, Cape Town, South Africa|Worthwhile Clinical trials, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Dr AA Mahomed Medical Centre, Moloto, South Africa|VX Pharma, Pretoria, South Africa|Dr J.M. Engelbrecht Trial Site, Somerset West, South Africa|Be Part Yoluntu Centre, Western Cape, South Africa|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Univ. de La Paz, Madrid, Spain|Hosp. Quiron Madrid Pozuelo, Madrid, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Powys Teaching Local Health Board - Bronllys Hospital, Brecon, United Kingdom|Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Bristol NHS Trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Royal Free Hospital, Hampstead, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Guy's and St Thomas' Hospital, London,, United Kingdom|Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|University of Oxford, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT04614948
NCT04372589,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),ATTACC,Recruiting,No Results Available,COVID-19|Pneumonia,Drug: Heparin,Mortality and days free of organ support|Arterial and venous thrombotic conditions|Intubation and mortality|All-cause mortality|Intubation|Hospital-free days|Ventilator-free days|Myocardial infarction|Ischaemic stroke|Venous thromboembolism|Vasopressor-free days|Renal replacement free days|Hospital re-admission|Acute kidney injury|Systemic arterial thrombosis or embolism|ECMO support|Mechanical circuit thrombosis|WHO ordinal scale|Major bleeding|Heparin-induced thrombocytopenia (HIT),"University of Manitoba|University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,3000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATTACC|OZM-113,20-May-20,Jan-21,Jan-21,4-May-20,,22-Dec-20,"Emory University Hospital Midtown, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic, Jefferson, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Henry Ford University, Dearborn, Michigan, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States|Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Santa Casa de Misericordia de Itabuna, Itabuna, BA, Brazil|Hospital Unimed do Cariri, Juazeiro do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Instituto Goiano de Oncologia e Hematologia - INGOH, Goiania, Goias, Brazil|Centro de Pesquisas Clínicas Humap - UFMS, Campo Grande, Mato Grosso Do Sul, Brazil|Hospital Felício Rocho, Belo Horizonte, MG, Brazil|Clinica de Campo Grande S/A, Campo Grande, MS, Brazil|Unimed Campo Grande, Campo Grande, MS, Brazil|Hospital Agamenon Magalhaes, Recife, Pernanbuco, Brazil|Hospital das Clinicas da UFPR, Curitiba, PR, Brazil|Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil|Parana Medical Research Center, Maringa, PR, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil|Hospital Universitario de Canoas, Canoas, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil|Instituto de Medicina Vascular, Porto Alegre, RS, Brazil|AngioCor Blumenau, Blumenau, Santa Catarina, Brazil|Instituto de Cardiologia de Santa Catarina, Sao Jose, Santa Catarina, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo Andre, Sao Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil|Casa de Saúde Santa Marcelina, Sao Paulo, SP, Brazil|Instituto de Molestias Cardio Vasculares de Tatui, Tatui, SP, Brazil|Hospital 9 de Julho, São Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Instituto de Infectologia Emilio Ribas, São Paulo, Brazil|Instituto do Coração do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente Israelita Hospital Albert Einstein, São Paulo, Brazil|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Center Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Hôpital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier de l'université de Montréal (CHUM), Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Quebec-University Laval, Québec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Hospital de Infectolog´ñia Centro Médico Nacional La Raza, Azcapotzalco, Mexico City, Mexico|Hospital General Regional 1 Carlos MacGregor Sánchez Navarro, Benito Juárez, Mexico City, Mexico|Hospital General regional 2 El Marqués, Querétaro, Mexico",,https://ClinicalTrials.gov/show/NCT04372589
NCT04505722,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,ENSEMBLE,Recruiting,No Results Available,Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol,Biological: Ad26.COV2.S|Other: Placebo,"Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) with Seronegative Status|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of their Serostatus|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease COVID-19 Regardless of Their Serostatus|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19)|Number of Participants with First Occurrence of COVID-19 Requiring Medical Intervention|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants with Molecularly Confirmed, Moderate to Severe/Critical COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed Mild COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed COVID-19 Defined by the US Food and Drug Administration (FDA) Harmonized case Definition|Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|Serologic Conversion Between Baseline and (Day 1; Pre-vaccination), Day 71, 6 Months and 1- Year Post-vaccination using an Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants with First Occurrence of SARS-CoV-2 Infection (Serologically and/or Molecularly Confirmed)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs) Leading to Study Discontinuation|Number of Participants with Solicited Local Adverse Events (AEs) During 7 Days Following Vaccination|Number of Participants with Solicited Systemic AEs During 7 Days Following Vaccination|Number of Participants with Unsolicited Local Adverse Events (AEs) During 28 Days Post-vaccination|SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)|SARS-CoV-2 Binding Antibodies Assessed by ELISA",Janssen Vaccines & Prevention B.V.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CR108876|VAC31518COV3001,7-Sep-20,10-Mar-23,10-Mar-23,10-Aug-20,,3-Dec-20,"Synexus Clinical Research US, Inc, Birmingham, Alabama, United States|University of Alabama Birmingham, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States|Optimal Research, Huntsville, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|Synexus Clinical Research US, Inc, Glendale, Arizona, United States|VA Medical Center, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|East Bay AIDS Center (EBAC) CRS, Oakland, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSD Antiviral Research Center AVRC, San Diego, California, United States|Wr-McCr, Llc, San Diego, California, United States|VA Medical Center, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Denver, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale Medical Group, New Haven, Connecticut, United States|Alliance for Multispeciality Research, Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|North Florida South Georgia Veteran Health System, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|University of Miami- Jackson Memorial Hospital, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|James A Haley VA Hospital GNS, Tampa, Florida, United States|Synexus Clinical Research US, Inc, The Villages, Florida, United States|Emory University of Medicine, Atlanta, Georgia, United States|The Hope Clinic at Emory University, Decatur, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Jesse Brown VAMC Department of Surgery, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The Core Center, Chicago, Illinois, United States|University of IL Chicago, Chicago, Illinois, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Optimal Research, Peoria, Illinois, United States|Synexus Clinical Research US, Inc, Evansville, Indiana, United States|Indiana University Adult Cystic Fibrosis Center, Indianapolis, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Investigative Clinical Research, L.L.C., Annapolis, Maryland, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States|Fenway Health, Boston, Massachusetts, United States|University of Michigan Neuorsurgery A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|MediSync Clinical Research, Petal, Mississippi, United States|The Center For Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Meridian Clinical Research - Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Bronx Veterans Affairs Medical Center, Bronx, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Bronx Prevention Research Center CRS, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|New York Blood Center, New York, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Tryon Medical Group, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Durham VAMC, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc, Akron, Ohio, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Synexus Clinical Research US, Inc, Columbus, Ohio, United States|Corvallis Clinic PC, Corvallis, Oregon, United States|Clinical Research Institute of Southern Oregon, P.C., Medford, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|VA Medical Center, Columbia, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Avera Health, Harrisburg, South Dakota, United States|PMG Research of Bristol, Bristol, Tennessee, United States|AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Clinical Research Associates Inc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Optimal Research, LLC, Austin, Texas, United States|AIDS Arms Incorporated Trinity Health and Wellness Center, Dallas, Texas, United States|Synexus Clinical Research US, Inc, Dallas, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University Of Texas Medical School At Houston, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Gordon Crofoot, MD, Houston, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Health Research of Hampton Roads, Inc, Newport News, Virginia, United States|Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States|CIPREC, Buenos Aires, Argentina|Helios Salud Sa, Buenos Aires, Argentina|CEMEDIC, Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma Buenos Aires, Argentina|Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina|Clínica y Maternidad Suizo Argentina, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina|CEMIC Saavedra, Ciudad de Buenos Aires, Argentina|Hospital J. M. Ramos Mejía, Ciudad de Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Faculdade de Medicina Barretos FACISB, Barretos, Brazil|Hospital Das Clinicas Da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil|L2IP - Instituto de Pesquisas Clínicas, Brasília, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Fundação Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil|Hospital São José, Criciúma, Brazil|Oncovida - Centro de Onco-Hematologia de Mato Grosso, Cuiabá, Brazil|Hospital Nossa Senhora Das Gracas, Curitiba, Brazil|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, Brazil|IEC - Instituto Evandro Chagas, Para, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirão Preto, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Brasil de Pesquisa Clinica, Rio de Janeiro, Brazil|FIO CRUZ- Fundação Oswaldo Cruz - Inst de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil|Hospital Geral De Nova Igaucu Brazil, Rio de Janeiro, Brazil|Fundação Bahiana De Infectologia, Salvador, Brazil|Obras Sociais Irma Dulce, Salvador, Brazil|Hospital da Universidade Federal de Santa Maria CEP/UFSM, Santa Maria, Brazil|Universidade Municipal de Sao Caetano do Sul, Sao Caetano do Sul, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|Centro de Referência E Treinamento Dst/Aids, Sao Paulo, Brazil|CPQuali Pesquisa Clinica LTDA ME, São Paulo, Brazil|Instituto de infectologia Emilio Ribas, São Paulo, Brazil|Hospital Sirio Libanes, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil|Cepic - Centro Paulista De Investigacao Clinica, São Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil|Bioclinica Santiago Bulnes, Santiago, Chile|Facultad de Medicina Universidad de Chile, Santiago, Chile|Hospital Padre Hurtado, Santiago, Chile|Clinica del Maule, Talca, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Centro de Estudios Clínicos V Región Ltda, Viña del Mar, Chile|Clinica de la Costa, Barranquilla, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Colombia|Hospital Universidad del Norte, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Asistencia Cientifica de Alta Complejidad S.A.S, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Medplus Medicina Prepagada S.A., Bogota, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Fundación Valle del Lili, Cali, Colombia|Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca, Floridablanca, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Programa de Estudio y Control de Enfermedades Tropicales, Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medellín, Colombia|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Salud Publica, Cuernavaca, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico|Unidad de Atención Medica e Investigacion en Salud (UNAMIS), Merida, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital General Dr. Manuel Gea González, Mexico City, Mexico|Centro Medico Nacional Siglo XXI IMSS, Mexico, Mexico|CAIMED Investigacion en salud S.A de C.V., Mexico, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico|Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez', Monterrey, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Infectolab, Tijuana, Mexico|Centro de Invetigaciones Medicas, Callao, Peru|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Centro de Investigaciones Tecnologicas, Biomedica y medio ambientales (CITBM), Callao, Peru|Asociacion Civil Selva Amazonica (ACSA), Iquitos, Peru|Asociacion Civil Impacta Salud y Educacion - Barranco, Lima - Barranco, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil Via Libre, Lima, Peru|Instituto de Investigacion Nutricional, Lima, Peru|Asociacion Civil Impacta Salud y Educacion- San Miguel CRS, Lima, Peru|Josha Research, Bloemfontein, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|Family Clinical Research Unit FAM-CRU, Cape Town, South Africa|TASK Central, Cape Town, South Africa|Desmond Tutu HIV Foundation, Cape Town, South Africa|University of Cape Town IDM/CIDRI Research Site, Cape Town, South Africa|Desmond Tutu Hiv Foundation - University of Cape Town, Cape Town, South Africa|Masiphumelele Research Centre, Cape Town, South Africa|Ndlovu Elandsdoorn Site, Dennilton, South Africa|SA Medical Research Council, Durban, South Africa|SA Medical Research Council, Durban, South Africa|South African Medical Research Council Isipingo Clinical Research Site, Isipingo Rail, South Africa|CRISMO Bertha Gxowa Research Centre, Johannesburg, South Africa|Shandukani Research Centre, Johannesburg, South Africa|The Aurum Institute Klerksdorp Clinical Research Centre, Klerksdorp, South Africa|Qhakaza Mbokodo Research Centre, KwaZulu-Natal, South Africa|South African Medical Research Council Chatsworth Clinical Research Site, KwaZulu-Natal, South Africa|Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Nelson Mandela Academic Clinical Research Unit 'NeMACRU', Mthatha, South Africa|PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa|MeCRU Clinical Research Unit, Pretoria, South Africa|Synexus Watermeyer, Pretoria, South Africa|The Aurum Institute Rustenburg Clinical Research Site, Rustenburg, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit (PHRU), Kliptown, Soweto, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|The Aurum Institute: Tembisa - Clinic 4, Tembisa, South Africa|CAPRISA Vulindlela Clinic, Vulindlela, South Africa|University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa|SATVI, Brewelskloof Hospital, Worcester, South Africa",,https://ClinicalTrials.gov/show/NCT04505722
NCT04381988,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,,Recruiting,No Results Available,COVID-19|Cancer,Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy,cumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or death,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,132,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",20-176,7-May-20,May-21,May-21,11-May-20,,13-May-20,"Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States",,https://ClinicalTrials.gov/show/NCT04381988
NCT04642638,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure",,Recruiting,No Results Available,Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|COVID-19 Disease,Drug: INO-4800|Device: CELLECTRA® 2000|Drug: Placebo,Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Assay|Phase 2: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay|Phase 3: Percentage of Participants With Virologically-confirmed COVID-19 Disease|Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Injection Site Reactions|Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Systemic Adverse Events (AEs)|Phase 2 and 3: Percentage of Participants With Serious Adverse Events (SAEs)|Phase 2 and 3: Percentage of Participants With Adverse Events of Special Interest (AESIs)|Phase 3: Percentage of Participants With Death From All Causes|Phase 3: Percentage of Participants With Non-Severe COVID-19 Disease|Phase 3: Percentage of Participants With Severe COVID-19 Disease|Phase 3: Percentage of Participants With Death From COVID-19 Disease|Phase 3: Percentage of Participants With Virologically-Confirmed SARS-CoV-2 Infections|Phase 3: Days to Symptom Resolution in Participants With COVID-19 Disease|Phase 3: Change From Baseline in Antigen-specific Cellular Immune Response Measured by IFN-gamma ELISpot Assay|Phase 3: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay,Inovio Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,6578,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",COVID19-311|INNOVATE,30-Nov-20,Sep-22,Sep-22,24-Nov-20,,12-Jan-21,"Synexus Clinical Research US, Inc - Phoenix Southeast, Chandler, Arizona, United States|Central Phoenix Synexus Clinical Research, Phoenix, Arizona, United States|AMR Tempe, Tempe, Arizona, United States|Optimal Research, LLC, San Diego, California, United States|AMR South Florida, Coral Gables, Florida, United States|Clinical Research Trials of Florida, Inc, Tampa, Florida, United States|AMR Lexington, Lexington, Kentucky, United States|Walter Reed Army Institute of Research, Silver Spring, Maryland, United States|Ascension St. John Hospital, Detroit, Michigan, United States|AMR Kansas City, Kansas City, Missouri, United States|AMR, Clinical Research Consortium- Las Vegas, Las Vegas, Nevada, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tekton Research, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States",,https://ClinicalTrials.gov/show/NCT04642638
NCT04495907,COVID-19 Progression in End-Stage Kidney Disease,COPE,Recruiting,No Results Available,SARS-CoV-2 Infection (Asymptomatic)|SARS-CoV-2 Infection (Symptomatic),,SARS-CoV-2 IgG|Anti-SARS-CoV-2 IgG,Davita Clinical Research,All,"18 Years to 80 Years   (Adult, Older Adult)",,1000,Industry,Observational,Observational Model: Cohort|Time Perspective: Other,20-M-0047-00,6-Aug-20,Mar-21,Jun-21,3-Aug-20,,7-Jan-21,"DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04495907
NCT04404361,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,,Recruiting,No Results Available,COVID,Drug: Pacritinib|Drug: Placebo,Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization,CTI BioPharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,364,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PAC319,22-May-20,31-Jul-21,31-Oct-21,27-May-20,,4-Dec-20,"St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California, United States|Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|St. Vincent Medical Group, Inc, Indianapolis, Indiana, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Ascension Providence Hospital - Novi Campus, Novi, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Overlook Medical Center, Morristown, New Jersey, United States|Chilton Medical Center, Pompton Plains, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints, Racine, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04404361
NCT04405570,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",,Recruiting,No Results Available,SARS-CoV 2,Drug: EIDD-2801|Drug: Placebo (PBO),"Virologic Efficacy|Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach|Number of Participants With any Adverse Events (AEs), Grade 2 or higher as Assessed by Kaplan Meier Approach","Ridgeback Biotherapeutics, LP",All,"18 Years and older   (Adult, Older Adult)",Phase 2,204,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EIDD-2801-2003,16-Jun-20,30-Jan-21,28-Feb-21,28-May-20,,9-Dec-20,"Benchmark Research, Colton, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|FOMAT Medical Research, Oxnard, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|NOLA Research, New Orleans, Louisiana, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Duke, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Care United Research, LLC, Forney, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Fred Hutch, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04405570
NCT04606563,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,ARBs CORONA II,Recruiting,No Results Available,Covid19|SARS-CoV Infection,Drug: Losartan,"Mortality|Hospital Mortality|ICU Admission|days alive and free of vasopressors, ventilation, and renal replacement therapy|SOFA score|Acute cardiac injury|Severe adverse events",University of British Columbia|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Phase 3,1372,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H20-01984,9-Oct-20,30-Jun-21,30-Jun-21,28-Oct-20,,28-Oct-20,"University of Nebraska, Omaha, Nebraska, United States|Brown University, Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States|St. Luc University Hospital, Brussels, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|University of Calgary - Foothills, Calgary, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queens University, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|Université de Sherbrooke, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire d'Angers, Angers, France|Chiba University, Chiba, Japan|Hospital Clínico San Carlos, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04606563
NCT04375397,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,iNSPIRE,Recruiting,No Results Available,CoronaVirus Induced Disease-2019 (COVID-19),Drug: Ibrutinib|Drug: Placebo,Percentage of Participants Alive and Without Respiratory Failure|Change in the World Health Organization (WHO)-8 Point Ordinal Scale From Baseline|Median Reduction in Days Spent on Supplemental Oxygen|All-Cause Mortality|Percentage of Participants Experiencing Respiratory Failure or Death|Mechanical Ventilation-Free Survival|Days on Mechanical Ventilation|Duration of hospitalization|Time to Discharge|Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio|Oxygenation Index|Number of Participants With Adverse Events|Number of Participants With Abnormal Laboratory Findings,"AbbVie|Janssen Research & Development, LLC|Pharmacyclics LLC (An AbbVie Company)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,46,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M20-310,6-Jun-20,19-Mar-21,25-Aug-21,5-May-20,,15-Jan-21,"Desert Regional Medical Center /ID# 224276, Palm Springs, California, United States|Stanford Univ School Medicine /ID# 221954, Stanford, California, United States|Medstar Washington Hospital Center /ID# 221886, Washington, District of Columbia, United States|GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States|Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States|University of Miami /ID# 223227, Miami, Florida, United States|Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States|Brigham & Women's Hospital /ID# 221847, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 222994, Boston, Massachusetts, United States|University of Tennessee Health Care System /ID# 223472, Memphis, Tennessee, United States|Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04375397
NCT04649151,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",TeenCove,Recruiting,No Results Available,SARS-CoV-2,Biological: mRNA-1273|Biological: Placebo,"Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI)|Number of Participants Who have Reached the Acceptable Threshold for the Serum Ab Level at Day 57|Comparison of the Geometric Mean of the Serum Neutralizing Antibody (nAb) level against the Geometric Mean of the Serum nAb level in Study mRNA-1273-P301 (NCT04470427)|Geometric Mean Value of SARS-CoV-2 Spike Protein (S2P)-specific binding antibody (bAb)|Geometric Mean Value of SARS-CoV-2-specific nAb|Number of Participants with a SARS-CoV-2 Infection Starting on Day 57|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo","ModernaTX, Inc.|Biomedical Advanced Research and Development Authority",All,12 Years to 17 Years   (Child),Phase 2|Phase 3,3000,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",mRNA-1273-P203,9-Dec-20,30-Jun-22,30-Jun-22,2-Dec-20,,14-Jan-21,"Velocity Clinical Research - Banning, Banning, California, United States|Paradigm Clinical Research, La Mesa, California, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Velocity Clinical Research - Boise, Meridian, Idaho, United States|Velocity Clinical Research - Valparaiso, Valparaiso, Indiana, United States|Johnson County Clinical Trials, Lenexa, Kansas, United States|Medpharmics - Metairie, Metairie, Louisiana, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Medpharmics - Gulfport, Gulfport, Mississippi, United States|Medpharmics - Albuquerque, Albuquerque, New Mexico, United States|Child Healthcare Associates, Liverpool, New York, United States|Velocity Clinical Research - Cincinnati, Cincinnati, Ohio, United States|Lynn Health Sciences Institute, Oklahoma City, Oklahoma, United States|Velocity Clinical Research - Providence, Warwick, Rhode Island, United States|Coastal Pediatric Associates, Charleston, South Carolina, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|Kool Kids Pediatrics, Houston, Texas, United States|Tekton Research, San Antonio, Texas, United States|Tekton Research, San Antonio, Texas, United States|Velocity Clinical Research - Salt Lake City - Jordan Valley, West Jordan, Utah, United States",,https://ClinicalTrials.gov/show/NCT04649151
NCT04611802,"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2",,Recruiting,No Results Available,SARS-CoV Infection|Covid19,Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant|Other: Placebo,"Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)|Participants with Symptomatic Moderate or Severe COVID-19|Participants with Any Symptomatic COVID-19|Neutralizing Antibody Activity Expressed as Geometric Mean Titers (GMTs)|Neutralizing Antibody Activity Expressed as Geometric Mean Fold Rises (GMFRs)|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs|Serum IgG Antibody Levels Expressed as GMFRs|Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as GMTs|hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs at Later Time Points|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMFRs at Later Time Points|hACE2 Receptor Binding Inhibition Assay Expressed as GMTs at Later Time Points|hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs at Later Time Points|Neutralizing Antibody Activity Expressed as GMTs at Later Time Points|Neutralizing Antibody Activity Expressed as GMFRs at Later Time Points|Description of Course, Treatment and Severity of COVID-19|Reactogenicity Incidence and Severity|Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49.|Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49.|Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12.|Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12.|Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12.|Incidence and Severity of SAEs from Month 12 to Month 24.|Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24.|Incidence and Severity of AESIs from Month 12 to Month 24.|Deaths Due to Any Cause|Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points|Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Any Time Point",Novavax|Department of Health and Human Services,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2019nCoV-301,27-Dec-20,31-Mar-21,30-Dec-22,2-Nov-20,,8-Jan-21,"Accel Research Sites, Birmingham, Alabama, United States|Centers for American Indian Health, Chinle, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|AMR Tempe Clinical Research Consortium, Tempe, Arizona, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Anaheim Clinical Trials, Anaheim, California, United States|Advanced Clinical Research - Rancho Paseo, Banning, California, United States|eStudy Site, Chula Vista, California, United States|eStudySite - Corporate Offices, La Mesa, California, United States|Wr-Pri, Llc, Los Alamitos, California, United States|National Research Institute, Los Angeles, California, United States|Transitional Research Group, Inc., North Hollywood, California, United States|Empire Clinical Research, Pomona, California, United States|University of California Davis Health, Sacramento, California, United States|Benchmark Research, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|Woodland Clinic Medical Group, Woodland, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Howard University Hospital Howard/ University College of Medicine, Washington, District of Columbia, United States|University Clinical Research-Deland, LLC dba Accel Research Sites, DeLand, Florida, United States|SIMED Health, LLC / SIMED Research, Gainesville, Florida, United States|M D Clinical, Hallandale Beach, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Meridien Research/Accel Research, Lakeland, Florida, United States|Miami Veterans Affairs Medical Center, Miami, Florida, United States|Suncoast Research Associates, LLC, Miami, Florida, United States|Clinical Neuroscience Solutions Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Jedidiah Clinical Research, Tampa, Florida, United States|Synexus Clinical Research US, Inc., The Villages, Florida, United States|Comprehensive Clinical Trials, Llc, West Palm Beach, Florida, United States|Atlanta - Morehouse School of Medicine, Atlanta, Georgia, United States|Emory Ponce Clinical Research Site, Atlanta, Georgia, United States|Ponce CRS Emory University, Atlanta, Georgia, United States|Synexus Clinical Research US, Inc., Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|IACT Health (DBA John B. Amos Cancer Center), Columbus, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Synexus, Chicago, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Providea Health Partners LLC, Mokena, Illinois, United States|Synexus USA, Evansville, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Meridian Clinical Research, Sioux City, Iowa, United States|Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States|Meridian Clinical Research, LLC, Baton Rouge, Louisiana, United States|Med Pharmics, LLC, Metairie, Louisiana, United States|Willis-Knighton Physician Network, Shreveport, Louisiana, United States|University Of Maryland School Of Medicine CVD, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|VA Medical Center, Ann Arbor, Michigan, United States|Wayne State University/ Children's Hospital of Michigan, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|MedPharmics, LLC-Biloxi, Gulfport, Mississippi, United States|The Curators of University of Missouri, Columbia, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research Associates, LLC, Omaha, Nebraska, United States|University Of Nebraska Medical Center, Omaha, Nebraska, United States|Synexus Clinical Research US, Inc., Henderson, Nevada, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Stony Brook Responder Vaccine Program, Commack, New York, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Rochester Clinical Research, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte, North Carolina, United States|M3-Emerging Medical Research, LLC, Durham, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Womack Army Medical Center, Fort Bragg, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Synexus Clinical Research, US, Inc., Akron, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc., Cincinnati, Ohio, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Medical Research International, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|CRISOR, LLC - Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|The Miriam Hospital (TMH), Providence, Rhode Island, United States|Velocity Clinical Research, Providence, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Medical University of South Carolina, SCTR Research Nexus, Charleston, South Carolina, United States|American Indian Clinical Trials Research Network, Eagle Butte, South Dakota, United States|PMG Research of Bristol, Bristol, Tennessee, United States|WR Clinsearch, LLC, Chattanooga, Tennessee, United States|PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States|Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc, McAllen, Texas, United States|Research Your Health, Plano, Texas, United States|Synexus, US - San Antonio, San Antonio, Texas, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Health Research of Hampton Roads, Inc, Newport News, Virginia, United States|MultiCare Institute for Research & Innovation, Cheney, Washington, United States|University of Washington VTEU, Seattle, Washington, United States|PanAmerican Clinical Research Mexico S.A de C.V, Guadalajara, Jalisco, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico City, Mexico|PanAmerican Clinical Research Mexico, Juriquilla, Queretaro, Mexico|Unidad de Atencion Medica e Investigacion en Salud (UNAMIS), Merida, Yucatan, Mexico|Instituto Nacional de Salud Publica (INSP) - Cuernavaca - Centro de Investigacion en Salud Poblacional (CISP), Cuernavaca, Mexico|CAIMED Investigacion en Salud S.A de C.V, Mexico City, Mexico|Faicic S. de R.L. de C.V., Veracruz, Mexico|Ponce Medical School Foundation Inc. / CAIMED Cneter, Ponce, Puerto Rico|Ponce Health Sciences University, Ponce, Puerto Rico|University of Puerto Rico Medical Sciences Campus Maternal Infant Studies Center, San Juan, Puerto Rico|UPR Maternal Infant Studies Center/ CEMI, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04611802
NCT04402957,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),,Recruiting,No Results Available,COVID|Severe Acute Respiratory Syndrome|Sars-CoV2|Acute Kidney Injury,Drug: LSALT peptide|Drug: Placebo,Development of Acute Respiratory Distress Syndrome (ARDS) and Other Organ Injuries|Ventilation-free days|Time on nasal cannula or oxygen masks|28 day mortality - all cause and attributable|ICU and hospitalization length of stay (days)|SARS-CoV2 testing|Need and duration for extracorporeal membrane oxygenation (ECMO)|Vasopressor free days|Radiographic pulmonary assessments|Change in modified Medical Research Council (mMRC) dyspnea and Sequential Organ Failure Assessment (SOFA) scores|Incidence of non-lung disorders|Measures of liver dysfunction|Measures of kidney dysfunction|Measures of cardiac dysfunction|Measures of coagulopathies|Changes in immunogenic responses|Healthcare outcomes|Molecular changes in pro-inflammatory pathways|Pharmacokinetics of LSALT peptide,Arch Biopartners Inc.,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB002,14-Oct-20,31-Jan-21,30-Jun-21,27-May-20,,7-Jan-21,"VA San Diego Healthcare System, San Diego, California, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|LSU Health Shreveport, Shreveport, Louisiana, United States|University of Calgary, Calgary, Alberta, Canada|Ankara City Hospital, Ankara, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04402957
NCT04466683,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,PREVENT,Recruiting,No Results Available,Covid-19|Sars-CoV2|Pneumonia,Radiation: Low dose radiation 35 cGy|Radiation: High dose radiation 100 cGy,Step 1 Dose selection|Clinical benefit of Step 2 Radiation dose|Changes of the cost of care for the control arm versus the radiation arms,Ohio State University Comprehensive Cancer Center|Varian Medical Systems,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PREVENT,28-Aug-20,31-Dec-21,31-Dec-22,10-Jul-20,,25-Sep-20,"Boca Raton Regional Hospital Lynn Cancer Institute, Boca Raton, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Lowell General Hospital Cancer Center, Lowell, Massachusetts, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Ohio State University James Cancer Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04466683
NCT04431414,A Study of Immune Responses to the Virus That Causes COVID-19,CoVPN 5001,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Other: Sample collection,"Response rate of SARS-CoV-2-specific B cells in peripheral blood samples|Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples|Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples|Response rate of SARS-CoV-2-specific antibody binding in serum samples|Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples|Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples|Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples|Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples|Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples|Frequency of leukocyte populations in peripheral blood|Transcriptional profiles of peripheral blood leukocytes|Concentration of serum cytokines and other soluble factors|Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells|Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells|Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells|Quantitation of viral RNA in nasal swabs",COVID-19 Prevention Network|National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years and older   (Adult, Older Adult)",,800,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,CoVPN 5001|5UM1AI068614-14,20-Jul-20,Jan-21,Jan-21,16-Jun-20,,30-Dec-20,"Alabama CRS, Birmingham, Alabama, United States|Bridge HIV CRS, San Francisco, California, United States|University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS, Miami, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health (FH) CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|Fundacion Huesped CRS, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejía CRS, Buenos Aires, Argentina|Gaborone CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Kisumu Crs, Kisumu, Kenya|Malawi CRS, Lilongwe, Malawi|Merida CRS, Mérida, Mexico|Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo, Mozambique|CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista, Peru|Asociacion Civil Selva Amazonica (ASCA) CRS, Iquitos, Peru|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|Via Libre CRS, Lima, Peru|Groote Schuur HIV CRS, Cape Town, South Africa|Khayelitsha CRS / (CIDRI UCT), Cape Town, South Africa|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa|Chatsworth CRS, Chatsworth, South Africa|Botha's Hill CRS, Durban, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Vulindlela CRS, Durban, South Africa|Ndlovu Research Centre CoVPN CRS, Elandsdoorn, South Africa|Isipingo CRS, Isipingo, South Africa|Kliptown Soweto CRS, Johannesburg, South Africa|Soweto HVTN CRS, Johannesburg, South Africa|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa|MeCRU CRS, Medunsa, South Africa|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa|Rustenburg CRS, Rustenburg, South Africa|Setshaba Research Centre CRS, Soshanguve, South Africa|Tembisa Clinic 4 CoVPN CRS, Tembisa, South Africa|Tongaat CRS, Tongaat, South Africa|Verulam CRS, Verulam, South Africa|National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya, Tanzania|Matero Reference Clinic CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Lusaka CoVPN CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Ndola CoVPN CRS, Ndola, Zambia|St Mary's CRS, Chitungwiza, Zimbabwe|Milton Park CRS, Harare, Zimbabwe|Seke South CRS, Harare, Zimbabwe",,https://ClinicalTrials.gov/show/NCT04431414
NCT04389450,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",,Recruiting,No Results Available,COVID|ARDS,Biological: PLX-PAD|Biological: Placebo,Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation,Pluristem Ltd.,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PLX-COV-01,1-Oct-20,May-21,Mar-22,15-May-20,,29-Oct-20,"University of California Irvine, Irvine, California, United States|University of Southern California (USC) - Keck School of Medicine (KSOM), Los Angeles, California, United States|University Of California Davis,4860 Y Street, Sacramento, California, United States|Baptist Health Medical Center, Jacksonville, Florida, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|Sarah Cannon Research Institute, LLC (Mercer University School of Medicine), Macon, Georgia, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper Research Institute, Camden, New Jersey, United States|Holy Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, New York, New York, United States|Maimonides Medical Center, New York, New York, United States|Mercy Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04389450
NCT04439071,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),FITE19,Recruiting,No Results Available,Pneumonia|COVID-19|Coronavirus,Drug: PTC299|Other: SOC|Drug: Placebo,"Time from Randomization to Respiratory Improvement|Percentage of Participants Requiring Invasive Ventilation|Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline|Time from Randomization to Defervescence in Participants Presenting With Fever at Enrollment (Temperature of ≥37.6℃ Axilla, ≥38.0℃ Oral, or ≥38.6°C Tympanic or Rectal)|Time from Randomization to Respiratory Rate ≤ 24 Breaths per Minute on Room Air|Time from Randomization to Cough Reported as Mild or Absent|Time from Randomization to Dyspnea Reported as Mild or Absent|Reduction of Immune Responses|Reduction in Viral Load|Duration of Hospitalization|Number of Mortalities|Number of Participants with Treatment-Emergent Adverse Events (TEAEs)",PTC Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,380,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PTC299-VIR-015-COV19|2020-001872-13,9-Jul-20,31-Jul-21,31-Jul-21,19-Jun-20,,12-Jan-21,"University of California, Irvine, Orange, California, United States|Augusta University, Augusta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Salisbury VA Medical Center, Salisbury, North Carolina, United States|University Hospitals Cleveland, Cleveland, Ohio, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Columbia VA Health Care System, Columbia, South Carolina, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|Hospital Vera Cruz, Belo Horizonte, MG, Brazil|Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, SP, Brazil|Hospital Guilherme Alvaro, Santos, SP, Brazil|Hospital Santa Casa de Misecórdia de Sorocoba, Sorocaba, SP, Brazil|Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brazil|Escola Paulista de Medicina (UNIFESP), São Paulo, SP, Brazil|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04439071
NCT04588363,COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C,PRISM,Recruiting,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|Multisystem Inflammatory Syndrome in Children (MIS-C)|Coronavirus Disease 2019 (COVID-19),Other: SARS-CoV-2 and/or MIS-C Exposure,"Proportion of Participants With Either COVID-19-Related Death, Rehospitalization, Major Complications after SARS-CoV-2 Illness and/or MIS-C at 6 Months Post Illness Presentation|Proportion of Participants with Coronavirus Disease 2019 (COVID-19)-Related Death after Multisystem Inflammatory Syndrome in Children (MIS-C) at 1 Year Post Illness Presentation|All-Cause Mortality|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mortality|Hospitalization for Participants Enrolled as an Outpatient or Rehospitalization after First Admission in Hospitalized Participants|Coagulation Abnormality by D-Dimer Biomarker|Coagulation Abnormality by Fibrinogen Biomarker|Coagulation Abnormality by Prothrombin Time (PT) and Activated Partial Thromboplastin Time (PTT) Biomarkers|Coagulation Abnormality by International Normalised Ratio (INR) Biomarker|Coronary Artery Abnormalities|Pulmonary Hypertension|Cardiovascular System Dysregulation by B-type natriuretic peptide (BNP) Biomarker|Cardiovascular System Dysregulation by Troponin I Biomarker|Cardiovascular System Dysregulation by Echocardiogram|Cardiovascular System Dysregulation by Electrocardiogram (ECG)|Pulmonary Abnormalities|Pulmonary Function Characteristics|Renal/Metabolic Biomarkers: Serum Creatinine and Blood Urea Nitrogen (BUN)|Renal/Metabolic Biomarker: Estimated glomerular filtration rate (eGFR)|Hepatic/Metabolic Biomarkers: Serum Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase ( ALT/SGPT)and Aspartate Aminotransferase (AST/SGOT)|Hepatic/Metabolic Biomarker: Total Bilirubin|Neurologic Abnormalities|Other End Organ and/or functional abnormalities Occurring After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection/ Coronavirus Disease 2019 (COVID-19) and/or Multisystem Inflammatory Syndrome in Children (MIS-C)|Health Related Quality of Life",National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence|Clinical Trials in Organ Transplantation in Children,All,"up to 20 Years   (Child, Adult)",,250,NIH|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DAIT PRISM-01|NIAID CRMS ID#: 38772,19-Nov-20,Nov-21,Nov-22,19-Oct-20,,8-Jan-21,"Loma Linda University Health, Loma Linda, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital at Montefiore, Bronx, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|NewYork-Presbyterian Queens Hospital, Flushing, New York, United States|Cohen Children's Medical Center - Northwell Health, New Hyde Park, New York, United States|Hassenfeld Children's Hospital at NYU Langone, New York, New York, United States|NewYork-Presbyterian Komansky Children's Hospital, New York, New York, United States|Mount Sinai Kravis Children's Hospital, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Pediatric Rheumatology, Charleston, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Eccles Primary Children's: University of Utah Health, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04588363
NCT04412057,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,,Recruiting,No Results Available,COVID-19 Pneumonia|Acute Lung Injury|ARDS,Drug: CERC-002|Drug: Placebo,Proportion of patient alive and free of respiratory failure|Proportion of subjects who are alive,"Aevi Genomic Medicine, LLC, a Cerecor company|Cerecor Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CERC-002-CVID-201,9-Jun-20,Oct-20,Nov-20,2-Jun-20,,1-Oct-20,"Hoag Memorial Hospital, Newport Beach, California, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Parkview Research Center, Fort Wayne, Indiana, United States|MedPharmics, LLC, Metairie, Louisiana, United States|LSUHSC - Shreveport, Shreveport, Louisiana, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|AnMed Health Medical Center, Anderson, South Carolina, United States|Lowcountry Infectious Diseases, P.A., Charleston, South Carolina, United States|BRCR Global Texas, McAllen, Texas, United States",,https://ClinicalTrials.gov/show/NCT04412057
NCT04362176,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,PassItOn,Recruiting,No Results Available,COVID-19|Coronavirus|SARS-CoV-2,Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo,"COVID-19 7-point Ordinal Clinical Progression Outcomes Scale|All-location, all-cause 14-day mortality|All-location, all-cause 28-day mortality|Survival through 28 days|Time to hospital discharge through 28 days|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 3|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 8|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 29|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days through Day 28|Hospital-free days through Day 28",Vanderbilt University Medical Center|Dolly Parton|National Center for Advancing Translational Science (NCATS),All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",200738|3UL1TR002243-04S3,24-Apr-20,Apr-21,Apr-21,24-Apr-20,,11-Dec-20,"University of Arizona, Phoenix, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Scripps Health, La Jolla, California, United States|University of Colorado Denver, Aurora, Colorado, United States|MedStar Health Research Institute/MedStar Washington Hospital Center, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore (University of Maryland Medical Center), Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellelsey Hospital, Newton, Massachusetts, United States|Mercy Health Muskegon, Muskegon, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|University at Buffalo/Buffalo General Medical Center, Buffalo, New York, United States|Rochester General Hospital, Rochester, New York, United States|The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Utah Valley Hospital, Provo, Utah, United States|University of Utah Health, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04362176
NCT04405739,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),,Recruiting,No Results Available,SARS-CoV 2,Drug: EIDD-2801|Drug: Placebo (PB0),Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801|Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS|Number of Participants With any Adverse Events(AEs) as assessed by DAIDS,"Ridgeback Biotherapeutics, LP",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EIDD-2801-2004,16-Jun-20,12-Feb-21,12-Mar-21,28-May-20,,5-Jan-21,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cook County Hospital, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Christ Medical Center, Park Ridge, Illinois, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Howard County General Hospital, Columbia, Maryland, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04405739
NCT04569786,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),,Recruiting,No Results Available,Coronavirus Disease (COVID-19),Biological: V590|Other: Placebo,Percentage of Participants with at Least 1 Solicited Injection Site Adverse Event|Percentage of Participants with at Least 1 Solicited Systemic Adverse Event|Percentage of Participants with at Least 1 Unsolicited Adverse Event|Percentage of Participants with at Least 1 Medically Attended Adverse Event|Percentage of Participants with at Least 1 Serious Adverse Event|Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by Plaque Reduction Neutralization Test (Panels A - H)|Geometric Mean Titers for SNAs as Measured by PRNT (Panels A-H)|Geometric Mean Concentration of Total Anti-SARS-CoV-2 Spike SNAs as Measured by Enzyme-Linked Immunosorbent Assay (Panels A-H)|Percentage of Participants with Vaccine Viremia as Measured by Reverse Transcription-Polymerase Chain Reaction|Percentage of Participants with Vaccine Shedding in Saliva or Urine as Measured by RT-PCR|Percentage of Participants with Vaccine Shedding in Stool as Measured by RT-PCR,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,252,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",V590-001,29-Oct-20,10-Jan-22,10-Jan-22,30-Sep-20,,21-Dec-20,"Celerion ( Site 0002), Tempe, Arizona, United States|Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States|QPS Miami Research Associates ( Site 0005), South Miami, Florida, United States|Bio-Kinetic Clinical Applications (QPS) ( Site 0006), Springfield, Missouri, United States|Celerion ( Site 0001), Lincoln, Nebraska, United States|Alliance for Multispecialty Reseach, LLC ( Site 0004), Knoxville, Tennessee, United States|Worldwide Clinical Trials ( Site 0007), San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04569786
NCT04336215,Rutgers COVID-19 Cohort Study,,Recruiting,No Results Available,Coronavirus|SARS-CoV-2,Other: Non-Interventional,Prevalence|Incidence,"Rutgers, The State University of New Jersey",All,"20 Years and older   (Adult, Older Adult)",,750,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020000679,7-Apr-20,1-Sep-20,21-Oct-21,7-Apr-20,,15-Apr-20,"Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04336215
NCT04574219,Virtual Parental Presence on Induction,VPPIA,Recruiting,No Results Available,Anxiety|Surgery,Other: Use of Facetime with child and parents during induction,"Virtual presence cause delays in operating room|Parent satisfaction with virtual presence|Operating room provider satisfaction|Operating room induction nurse satisfaction|Assessment of parental presence with either Facetime, Skype or Teams|Anxiety of child|Child behavior induction compliance|Parent anxiety|Patient previous induction experience|Parental Coaching - Prior|Parental Coaching - Day","Children's Hospital Medical Center, Cincinnati|The Hospital for Sick Children",All,4 Years to 12 Years   (Child),Not Applicable,184,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2020-0371,3-Nov-20,Oct-22,Dec-22,5-Oct-20,,7-Jan-21,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04574219
NCT04380961,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,,Recruiting,No Results Available,Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC),"Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Percentage of Participants with All-cause Mortality|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants with Related Adverse Events|Percentage of Participants with Severe or Life Threatening Bacterial, Invasive Fungal, Viral or Opportunistic Infections|Percentage of Participants with Grade 3 and 4 Neutropenia|Percentage of Participants with Grade 3 and 4 Lymphocytopenia|Percentage of Participants with Increased Alanine Aminotransferase (ALT) Greater than or equal to 3 Times Upper Limit of Normal (ULN) Combined with Increased Bilirubin > 2 Times ULN|Time to Improvement of at least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Time from Study Intervention to end of Oxygen Supplementation|Time from Study Intervention to Hospital Discharge Among the Surviving Participants|Total Length of Hospitalization|Number of Ventilation Free Days|Participant's Clinical Status at Day 7, 14, 21, 28 as Assessed by 6-Point Ordinal Clinical Recovery Scale|Total Time on Invasive Mechanical Ventilation|Percentage of Participants with a Worse Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale over Time|Percentage of Participants on Extracorporeal Membrane Oxygenation (ECMO) Over Time|Total Time on ECMO|Percentage of Alive Participants at Day 28, Week 8 and Week 16|Percentage of Alive Participants that Required Readmission at Week 8 and Week 16","Janssen Pharmaceutica N.V., Belgium",All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 2,270,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR108820|CNTO136COV2001|2020-003056-32,24-Apr-20,28-Sep-21,28-Sep-21,8-May-20,,23-Dec-20,"UCSF Fresno, Fresno, California, United States|MemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|Sutter Institute for Medical Research, Roseville, California, United States|Sutter Medical Foundation, Sacramento, California, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|The Corporation of Mercer University, Macon, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Illinois College of Medicine at Peoria, Peoria, Illinois, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center - Infectious Disease, Newark, New Jersey, United States|SUNY Upstate Medical University, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor All Saints Medical Center at Fort Worth, Fort Worth, Texas, United States|Instituto de infectologia Emilio Ribas, São Paulo, Brazil|Private Healthcare Institution 'Clinical Hospital 'RZD-Medcine' n.a. N.A.Semashko', Moscow, Russian Federation|Clinical Infectious Diseases Hospital n. a. S.P. Botkin, St. Petersburg, Russian Federation|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Gral. Univ. de Elche, Elche, Spain|Hosp. Clinico San Carlos, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Gral. Univ. Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT04380961
NCT04452565,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",NATADEX,Recruiting,No Results Available,Coronavirus Infection|Severe Acute Respiratory Infection|Severe Acute Respiratory Syndrome Coronavirus 2,Drug: Drug: NA-831|Combination Product: NA-831 and Atazanavir|Combination Product: NA-831and Dexamethasone|Combination Product: Atazanavir and Dexamethasone,1. Time (Hours) to recovery|Time fever resolution,"NeuroActiva, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,525,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",NATADEX,15-Oct-20,31-Dec-20,15-Feb-21,30-Jun-20,,7-Sep-20,"Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Institute-Testing Site, Sacramento, California, United States|Coronavirus Research Institute-Testing Site, San Diego, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Fort Lauderdale, Florida, United States|Coronavirus Research Institute-Testing Site, Tampa, Florida, United States|Coronavirus Research Institute- Testing Site, Chicago, Illinois, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site, Baltimore, Maryland, United States|Coronavirus Research Institute-Testing Site, Bethesda, Maryland, United States|Coronavirus Research Institute-Testing Site, Boston, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Worcester, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Ann Arbor, Michigan, United States|Coronavirus Research Institute-Testing Site, Detroit, Michigan, United States|Coronavirus Research Institute-Testing Site, Newark, New Jersey, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|Coronavirus Research Institute-Testing Site, New York, New York, United States|Coronavirus Research Institute- Testing Site, Rochester, New York, United States|Coronavirus Research Institute-Testing Site, Durham, North Carolina, United States|Coronavirus Research Institute-Testing Site, Philadelphia, Pennsylvania, United States|Coronavirus Research Institute- Testing Site, Fort Sam Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Galveston, Texas, United States|Coronavirus Research Institute-Testing Site, Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Kirkland, Washington, United States|Coronavirus Research Institute-Testing Site, Seattle, Washington, United States|Coronavirus Research Institute-Testing Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT04452565
NCT04369469,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,,Recruiting,No Results Available,"COVID-19 Severe Pneumonia|Acute Lung Injury|Acute Respiratory Distress Syndrome|Pneumonia, Viral",Biological: Ravulizumab|Other: Best Supportive Care,Survival (based on all-cause mortality) at Day 29|Number of days free of mechanical ventilation at Day 29|Duration of intensive care unit stay at Day 29|Change from baseline in Sequential Organ Failure Assessment at Day 29|Change from baseline in SpO2/FiO2 at Day 29|Duration of hospitalization at Day 29|Survival (based on all-cause mortality) at Day 60 and Day 90,Alexion Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,270,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALXN1210-COV-305,11-May-20,May-21,Jul-21,30-Apr-20,,12-Jan-21,"Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|LAC/USC Health Center, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Alternative Research Associates, LLC, Hialeah, Florida, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Jupiter Medical Center, Jupiter, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Norton Healthcare, Louisville, Kentucky, United States|Overton Brooks VA Medical Center, Shreveport, Louisiana, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Mayo Clinic Health System in Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|Hôpital Raymond Poincaré, Garches, Hauts De Seine, France|Hôpital Henri Mondor, Créteil, Val De Marne, France|Hôpital Bicêtre, Le Kremlin-Bicêtre cedex, Val De Marne, France|Hôpital Saint-Louis, Paris cedex, France|Medical Hospital, Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo-To, Japan|Jikei University Hospital, Minato-Ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-Ku, Tokyo, Japan|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04369469
NCT04445402,Pediatrics HOT COVID-19 Database in NY Tristate,,Recruiting,No Results Available,Pediatric Cancer|Immune System Disorder|COVID-19|Hemoglobinopathies,,Number of tristate area pediatric HOT patients tested for COVID-19 that completed 1 year follow-up|Change in PROMIS T-score|Number of collected and analyzed stool samples,Columbia University,All,"up to 21 Years   (Child, Adult)",,1500,Other,Observational,Observational Model: Other|Time Perspective: Prospective,AAAT0268,30-Apr-20,1-May-21,1-May-22,24-Jun-20,,24-Jun-20,"Connecticut Children's Hospital, Hartford, Connecticut, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Steven Halpern, Morristown, New Jersey, United States|Archana Sharma, New Brunswick, New Jersey, United States|Mount Sinai Beth Israel, Newark, New Jersey, United States|St. Joseph's Regional Medical Center, New Jersey, Paterson, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Maimondes Medical Center, Brooklyn, New York, United States|Mount Sinai, New York, New York, United States|NYU Langone Health, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Stephen Roberts, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Cohen Children's Northwell Health, Queens, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Westchester Medical Center, Valhalla, New York, United States",,https://ClinicalTrials.gov/show/NCT04445402
NCT04530448,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,,Recruiting,No Results Available,COVID|Coronavirus|Coronavirus Infection|AKI|Acute Kidney Injury,Drug: Sodium bicarbonate|Other: Standard of Care,pH|Number of Days Alive Free of Stage 2-3 AKI|Stage 2-3 AKI|Vent-Free|Hospital-Free,West Virginia University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WVU Protocol #2005006707,5-Oct-20,Jan-21,Mar-21,28-Aug-20,,19-Oct-20,"WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT04530448
NCT04439825,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,,Not yet recruiting,No Results Available,Mood,Drug: Botulinum Neurotoxin|Drug: Placebo,Self- perception of mood before treatment and after achieving an optimal cosmetic result as determined by the PI.|Happiness levels before treatment and after achieving an optimal cosmetic result as determined by the PI.|Measurement of the Glabellar Wrinkle Severity Scores before treatment. The onset of effect and maximum efficacy compared to previous BOTOX Cosmetic injections will also be assessed by questionnaires.,DeNova Research,All,"10 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1,45,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BTX-PST-COVID,15-Jul-20,15-Sep-20,15-Oct-20,19-Jun-20,,22-Jul-20,"DeNova Research, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04439825
NCT04663776,Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform,,Recruiting,No Results Available,Covid19|Influenza|Respiratory Tract Infections|Acute Respiratory Tract Infection|Acute Respiratory Distress Syndrome,,Incidence of inﬂuenza-like illness (ILI) and COVID-like illness (CLI) in a study participant.|Incidence of COVID-like illness (CLI) in a study participant.|Disease Prevalence,Boston Children's Hospital|Google LLC.,All,"18 Years and older   (Adult, Older Adult)",,100000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,P00036213,4-Nov-20,8-Dec-21,8-Dec-21,11-Dec-20,,11-Dec-20,"Boston Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04663776
NCT04497922,Virtual White Boards for Patient Satisfaction,,Not yet recruiting,No Results Available,"Satisfaction, Patient|Covid19|Emergencies|Satisfaction|Information Disclosure",Device: e-ink screen|Behavioral: Treatment as usual,emergency department satisfaction: likert scale|Quality of emergency department stay: likert scale|Preference for virtual white board,Brigham and Women's Hospital|E-ink corporation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2020P002382,20-Aug-20,15-Apr-21,17-Apr-21,4-Aug-20,,5-Aug-20,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04497922
NCT04347239,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),,Recruiting,No Results Available,Coronavirus Disease 2019,Drug: Placebos|Drug: Leronlimab (700mg),All-cause mortality at Day 28|All-cause mortality at Day 14|Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)|Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)|Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.,"CytoDyn, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,390,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CD12_COVID-19,15-Apr-20,31-Dec-20,1-Apr-21,15-Apr-20,,16-Nov-20,"Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|St. Jude Medical Center, Fullerton, California, United States|UCLA, Los Angeles, California, United States|James A. Haley Veterans' Hospital, Tampa, Florida, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Barnabas, Livingston, New Jersey, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|New York Community Hospital of Brooklyn, Brooklyn, New York, United States|Novant Health, Winston-Salem, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04347239
NCT04610515,Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),INSPIRE,Recruiting,No Results Available,Covid19|ME/CFS|SARS COV2|Novel Coronavirus Infection|Neurocognitive Disorders|Cardiovascular Diseases,,Incident myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)|Ambulatory care and/or ED visits post enrollment|Hospitalizations post enrollment|Death during hospital admission|Hospital-free survival|ICU-free survival,"Rush University Medical Center|Yale University|University of Washington|Thomas Jefferson University|University of California, Los Angeles|University of California, San Francisco|University of Texas Southwestern Medical Center|The University of Texas Health Science Center, Houston",All,"18 Years and older   (Adult, Older Adult)",,4800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,75D30120C08008,15-Dec-20,14-Nov-22,14-Nov-22,30-Oct-20,,15-Jan-21,"UCLA, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Yale, New Haven, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04610515
NCT04442230,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),,Recruiting,No Results Available,Coronavirus Infection,Biological: NasoVAX|Other: Placebo,Proportion of patients with clinical worsening|Maximal severity of COVID-19 after treatment|All-cause mortality,"Altimmune, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,96,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALT-601-201,10-Oct-20,Feb-21,Feb-21,22-Jun-20,,14-Dec-20,"Miami Dade Medical Research Institute, Miami, Florida, United States|Infinite Clinical Trials, Morrow, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|Columbia University, New York, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Centex Studies, Houston, Texas, United States|Centex Studies, McAllen, Texas, United States",,https://ClinicalTrials.gov/show/NCT04442230
NCT04448756,Study of M5049 in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia,ANEMONE,Recruiting,No Results Available,Coronavirus Disease 2019,Drug: M5049|Drug: Placebo,"Percentage of Participants Alive and not Requiring Supplemental Oxygenation|Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs)|Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings|Clinical Status of Participants on a 9-Point Ordinal Scale|Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours on Room Air|Percentage of Participants With All-Cause Mortality|Clinical Deterioration: Time to Intensive Care Unit (ICU) Admission|Clinical Deterioration: Time to Invasive Mechanical Ventilation|Clinical Deterioration: Time to Non-Invasive Mechanical Ventilation|Total Length of Stay in Intensive Care Unit (ICU)|Total Length of Hospitalization Stay|Percentage Change From Baseline in Inflammatory Biomarkers|Percentage Change From Baseline in Cytokine Biomarkers|Percentage of Participants With Relapse|Percentage of Participants who are Re-Hospitalized|Maximum Observed Concentration (Cmax) of M5049|Time to Reach the Maximum Observed Concentration (tmax) of M5049|Terminal Rate Constant (Lambda z) of M5049|Apparent Elimination Half-Life (t1/2) of M5049|Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t) of M5049|Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h) of M5049|Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity) of M5049|Apparent Total Body Clearance (CL/F) of M5049|Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of M5049|Dose-Normalized Maximum Observed Concentration (Cmax/Dose) of M5049|Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t/Dose) of M5049|Dose-Normalized Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h/Dose) of M5049|Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity/Dose) of M5049|Accumulation Ratio for Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose [Racc(AUC0- 12h)] of M5049|Accumulation Ratio for Maximum Observed Concentration [Racc(Cmax)] of M5049","EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MS200569_0026|2020-002248-22,29-Jul-20,6-Jun-21,6-Jun-21,26-Jun-20,,24-Dec-20,"University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States|LAC-USC Medical Center, Los Angeles, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Saint Louis University - Saint Louis University Hospital, Saint Louis, Missouri, United States|Holy Name Hospital - Dept of Multiple Sclerosis Comp Care Center, Teaneck, New Jersey, United States|Christus Spohn Hospital Corpus Christi-Memorial, Corpus Christi, Texas, United States|Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil|Hospital Dia do Pulmão, Blumenau, Brazil|Hospital São José - Sociedade Literária e Caritativa Santo Agostinho, Criciúma, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|HMCG - Hospital e Maternidade Dr. Christovão da Gama, Santo André, Brazil|Pesquisare, Santo André, Brazil|Hospital Leforte Morumbi, Sao Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital Bandeirantes / Hospital Leforte Liberdade, São Paulo, Brazil|Instituto de Infectologia Emílio Ribas, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04448756
NCT04419623,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,,Recruiting,No Results Available,COVID-19|Sars-CoV2|Cancer|Solid Tumor|Carcinoma|Blood Cancer,Drug: Part 1 - TL-895|Drug: Part 2 - TL-895|Drug: Part 2 - Placebo,Part 1 - Recommended dose of TL-895|Part 2 - Change in the need for artificial ventilation or death|Part 2 - Change in respiratory failure events that require invasive ventilation or death,"Telios Pharma, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,146,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TL-895-202,9-Jul-20,Jul-21,Jul-21,5-Jun-20,,25-Sep-20,"University of Miami, Miami, Florida, United States|Georgia Cancer Center, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Barbara Ann Karmanos Cancer Institute - Wertz Clinic, Detroit, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States|OhioHealth - Riverside Methodist Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04419623
NCT04535167,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.",,Recruiting,No Results Available,Viral Disease,Drug: PF-07304814|Drug: Placebo,"Frequency of treatment-emergent adverse events (TEAEs)|Number of participants who withdraw due to treatment-emergent adverse events (TEAEs)|Frequency of treatment-emergent adverse events (TEAEs), causally related to study intervention|Frequency of treatment-emergent serious adverse events|Frequency of treatment-emergent infusion site reactions|Magnitude of abnormal hematologic laboratory findings|Frequency of abnormal chemistry values|Frequency of abnormal hematologic laboratory findings|Magnitude of abnormal urinalysis findings|Change from baseline in PR values|Change from baseline in RR values|Change from baseline in QTc values|Change from baseline in QTcF values|Change from baseline in QRS values|Change from baseline in pulse rate measurements|Change from baseline in temperature values|Change from baseline in respiratory rate values|Change from baseline in systolic blood pressure|Change from baseline in diastolic blood pressure|Change from baseline in pulse oximetry/SpO2 measurement|Change in concentration at 24 hours (C24[end of infusion]) of PF-07304814 and PF-00835231|Change in concentration, dose normalised, at 24 hours (C24 (dn) [end of infusion]) of PF-07304814 and PF-00835231|Change in concentration at 120 hours (C120[end of infusion]) of PF-07304814 and PF-00835231|Change in maximum observed concentration (Cmax) of PF-07304814 and PF-00835231|Change in maximum observed concentration, dose normalised (Cmax [dn]) of PF-07304814 and PF-00835231|Change in concentration at steady state (Css) of PF-07304814 and PF-00835231|Change in concentration at steady state, dose normalised (Css [dn]) of PF-07304814 and PF-00835231|Change in terminal half life (t1/2) of PF-07304814 and PF-00835231|Change in clearance (CL) of PF-07304814|Change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity (AUCinf) of PF-07304814 and PF-00835231|Change in area-under-the-curve plasma concentration from 0 to last quantifiable concentration (AUClast) of PF-07304814 and PF-00835231|Change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity, dose normalised (AUCinf [dn]) of PF-07304814 and PF-00835231|Change in steady state volume of distribution (Vss) of PF-00835231|Cumulative amount of unchanged drug excreted into urine (Ae)|Percent of dose excreted as unchanged drug (Ae%) over dosing period",Pfizer,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",C4611001|2020-003905-73,9-Sep-20,20-Apr-21,20-Apr-21,1-Sep-20,,30-Oct-20,"El Camino Health, Mountain View, California, United States|Palo Alto Medical Foundation, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UC Davis Health Investigational Drug Pharmacy, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Iowa, Iowa City, Iowa, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|University of Texas Physicians - Texas Medical Center, Houston, Texas, United States|Multicare Health System-Tacoma General Hospital, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT04535167
NCT04402060,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,,Recruiting,No Results Available,COVID|Covid-19|Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Ards|Acute Respiratory Distress Syndrome,Drug: APL-9|Other: Vehicle Control,Cumulative incidence of treatment-emergent serious adverse events and treatment-emergent adverse events.|Hospital length of stay|Any cause of mortality|Sequential Organ Failure Assessment|Total duration of mechanical ventilation and/or oxygen therapy|Total duration of oxygen therapy,"Apellis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,66,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",APL9-COV-201,28-May-20,Jan-21,Jan-21,26-May-20,,19-Dec-20,"University of California at San Francisco - Fresno, Fresno, California, United States|California Pacific Medical Center, San Francisco, California, United States|Baptist Medical Center Beaches, Jacksonville Beach, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran Health Physicians, Fort Wayne, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audobon Hospital, Louisville, Kentucky, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Ascension Providence Hospital, Southfield, Michigan, United States|Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo, Buffalo, New York, United States|Columbia University, New York, New York, United States|Texas A&M College of Medicine - Scott and White, Temple, Texas, United States|Hospital Angelina Caron, Campina Grande Do Sul, Paraná, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Estadual Mario Covas, Santo André, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos LTDA EPP, São Bernardo Do Campo, Sao Paulo, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, Sao Paulo, Brazil|Hospital Santa Marcelina, São Paulo, Sao Paulo, Brazil|UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP, Botucatu, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04402060
NCT03738774,Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID),APICS,Recruiting,No Results Available,Post Intensive Care Syndrome,,Number of deaths or hospital readmissions within three months of discharge|Number of ER visits|Healthcare utilization|Cognitive Functional outcome as assessed by Montreal Cognitive Assessment (MoCA) - Blind Instrument|Physical function outcome as assessed by Activity of Daily Living (ADL-Katz Index)|Physical function outcome as assessed by Instrumental Activity of Daily Living (IADL-Lawton)|Mental health Functional outcome as assessed by Hospital Anxiety and Depression Scale (HADS)|Functional outcomes-Post Traumatic Stress Disorder (PTSD)|Coping or social support|Health related quality of life|Number of deaths within 6 Months after discharge|Return to work,Vanderbilt University Medical Center|United States Department of Defense,All,"18 Years and older   (Adult, Older Adult)",,200,Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB181120,2-Jan-19,Dec-21,Jul-22,13-Nov-18,,22-Dec-20,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Vanderbilt University, Nashville, Tennessee, United States|Intermountain Medical Center, Murray, Utah, United States|George Wahlen Salt Lake City Veterans Administration Hospital, Salt Lake City, Utah, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03738774/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03738774
NCT04312009,Losartan for Patients With COVID-19 Requiring Hospitalization,,Recruiting,No Results Available,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection,Drug: Losartan|Other: Placebo,Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea scale|Change in SF-12 Physical Composite Score|Change in SF-12 Mental Composite Score|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15,University of Minnesota|Bill and Melinda Gates Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SURG-2020-28675|INV-017069,13-Apr-20,1-Apr-21,1-Apr-21,17-Mar-20,,21-Dec-20,"University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Henry Ford Hospital, Detroit, Michigan, United States|M Health Fairview Ridges Hospital, Burnsville, Minnesota, United States|M Health Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|North Memorial Health Hospital, Robbinsdale, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper University Hospital, Camden, New Jersey, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04312009
NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus,"Drug: Cannabis, Medical",Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms|Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events,"OMNI Medical Services, LLC|OMNI Medical Services Inc",All,"7 Years and older   (Child, Adult, Older Adult)",Phase 2,200000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00033337,1-Dec-18,31-Dec-25,31-Dec-25,9-May-19,,9-Dec-20,"OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03944447
NCT04365101,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,CYNKCOVID,Recruiting,No Results Available,"Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2|Pneumonia|Pneumonia, Viral|Lung Diseases|Respiratory Tract Disease|Respiratory Tract Infections|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Virus Disease|Immunologic Disease|ARDS|Immunologic Factors|Physiological Effects of Drugs|Antiviral Agents|Anti-infective Agents|Analgesics|Antimetabolites, Antineoplastic",Biological: CYNK-001,Phase 1: Frequency and Severity of Adverse Events (AE)|Phase 1: Rate of clearance of SARS-CoV-2|Phase 1: Rate of clinical improvement|Phase 2: Time to Clearance of SARS-CoV-2|Phase 2: Time to Clinical Improvement by NEWS2 Score|Rate of Clearance of SARS-CoV-2|Phase 2: Frequency and Severity of Adverse Events (AE)|Overall Clinical Benefit by time to medical discharge|Overall Clinical Benefit by hospital utilization|Overall Clinical Benefit by measuring mortality rate|Impact of CYNK-001 on sequential organ failure assessment (SOFA) score|Time to Pulmonary Clearance|Supplemental oxygen-free days|Proportion of subjects requiring ventilation,Celularity Incorporated|IDRI|Lung Biotechnology PBC|California Institute for Regenerative Medicine (CIRM),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,86,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CYNK-001-COVID-19,13-May-20,30-Dec-20,30-Jun-21,28-Apr-20,,23-Nov-20,"Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arkansas, Little Rock, Arkansas, United States|UC Irvine, Irvine, California, United States|UC Davis Medical Center, Sacramento, California, United States|Scripps Health, San Diego, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Atlantic Health, Morristown, New Jersey, United States|Atlantic Health, Summit, New Jersey, United States|Multicare Health System, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT04365101
NCT04348370,BCG Vaccine for Health Care Workers as Defense Against COVID 19,BADAS,Recruiting,No Results Available,Coronavirus|Coronavirus Infection|Coronavirus as the Cause of Diseases Classified Elsewhere,Biological: BCG Vaccine|Biological: Placebo Vaccine,Incidence of COVID 19 Infection|Disease Severity,Texas A&M University|Baylor College of Medicine|M.D. Anderson Cancer Center|Cedars-Sinai Medical Center|Harvard University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,1800,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",2020-0432F,20-Apr-20,May-21,Nov-21,16-Apr-20,,27-May-20,"Cedars-Sinai Medical Center, Los Angeles, California, United States|Texas A&M Family Care Clinic, Bryan, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04348370
NCT04333732,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,CROWN CORONA,Recruiting,No Results Available,COVID 19,Drug: MR or M-M-R II ® vaccine|Drug: Placebo,Symptomatic COVID-19|Severity of COVID-19 over the study period|Effectiveness of preventing/reducing SARS-CoV-2 infection,Washington University School of Medicine|COVID -19 Therapeutics Accelerator,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",202004099|INV-017499,4-Sep-20,Aug-21,Aug-21,3-Apr-20,,23-Nov-20,"Washington University School of Medicine, Saint Louis, Missouri, United States|Unity Health Toronto, Toronto, Ontario, Canada|University of Ghana Medical Centre, Accra, Greater Accra Region, Ghana|St James's Hospital, Dublin, Leinster, Ireland|Radboud University Medical Center, Nijmegen, Netherlands|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Infectious Diseases Institute Kampala, Uganda, Kampala, Uganda|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia|University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe",,https://ClinicalTrials.gov/show/NCT04333732
NCT04357730,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,,Recruiting,No Results Available,Severe Acute Respiratory Syndrome|Respiratory Failure|Acute Respiratory Distress Syndrome,Drug: Alteplase 50 MG [Activase],PaO2/FiO2 improvement from pre-to-post intervention|Achievement of PaO2/FiO2 ≥ 200 or 50% increase in PaO2/FiO2|National Early Warning Score 2 (NEWS2)|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale|48 hour in-hospital mortality|14 days in-hospital mortality|28 days in-hospital mortality|ICU-free days|In-hospital coagulation-related event-free (arterial and venous) days|Ventilator-free days|Successful extubation|Successful weaning from paralysis|Survival to discharge,"Denver Health and Hospital Authority|Genentech, Inc.|University of Colorado, Denver|National Jewish Health|Beth Israel Deaconess Medical Center|Long Island Jewish Medical Center|Scripps Health|St. Mary's Medical Center|University of Miami|Ben Taub Hospital|Methodist Dallas Medical Center",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-0880,14-May-20,Sep-21,Nov-21,22-Apr-20,,19-Nov-20,"Scripps Memorial Hospital La Jolla, La Jolla, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Miami Hospital, Miami, Florida, United States|St. Mary's Medical Center, West Palm Beach, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Long Island Jewish Medical Center, New York, New York, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Ben Taub Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04357730
NCT04668339,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,,Recruiting,No Results Available,Covid19|SARS-CoV Infection|Corona Virus Infection,"Biological: ARCT-021 single dose priming|Biological: ARCT-021 two lower dose priming|Biological: ARCT-021 two higher dose priming|Biological: Placebo (two doses), priming|Biological: Randomized booster|Biological: Placebo booster","Percentages of participants reporting solicited local adverse events|Percentages of participants reporting solicited systemic adverse events|Percentages of participants reporting adverse events|Percentages of participants reporting serious adverse events|Percentages of participants reporting medically attended adverse events|Percentages of participants reporting new onset of chronic disease|Percentages of participants with abnormal chemistry and hematology values|SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs|Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels|SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs|Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs|Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels","Arcturus Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ARCT-021-04,7-Jan-21,30-Apr-22,30-Apr-22,16-Dec-20,,12-Jan-21,"Arcturus Investigational Site 103, Chandler, Arizona, United States|Arcturus Investigational Site 107, Tucson, Arizona, United States|Arcturus Investigational Site 112, San Diego, California, United States|Arcturus Investigational Site 104, Melbourne, Florida, United States|Arcturus Investigational Site 105, Orlando, Florida, United States|Arcturus Investigational Site 106, Pinellas Park, Florida, United States|Arcturus Investigational Site 109, The Villages, Florida, United States|Arcturus Investigational Site 101, Peoria, Illinois, United States|Arcturus Investigational Site 110, Rockville, Maryland, United States|Arcturus Investigational Site 102, Anderson, South Carolina, United States|Arcturus Investigational Site 111, Austin, Texas, United States|Arcturus Investigational Site 108, Dallas, Texas, United States|Arcturus Investigational Site 201, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04668339
NCT03852537,Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,,Recruiting,No Results Available,Pneumonia,Drug: Methylprednisolone|Other: Usual Care,Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",18-010925,2-Dec-19,Jul-21,Jul-22,25-Feb-19,,22-Apr-20,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03852537
NCT04476914,Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,,Recruiting,No Results Available,Respiratory Failure|SARS-CoV 2|Corona Virus Infection|Post Intensive Care Unit Syndrome|Family Members|Post Traumatic Stress Disorder|Anxiety|Depression,,Symptoms of Post-Traumatic Stress Disorder (PTSD)|Symptoms of Anxiety|Symptoms of Depression|Family Satisfaction with Communication and Decision Making,"University of Colorado, Denver|University of Washington|Tulane University|University of Vermont|Penn State University|Columbia University|South Shore Hospital|Evergreen Hospital|Brigham and Women's Hospital",All,"18 Years and older   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-1021,29-Jun-20,31-Dec-20,31-Dec-20,20-Jul-20,,28-Sep-20,"Eastern Colorado Veterans Affairs Health Care System, University Of Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Brigham and Women's Medical Center, Boston, Massachusetts, United States|South Shore Medical Center, Weymouth, Massachusetts, United States|Columbia Milstein and Allen Hospitals, New York, New York, United States|Penn State Hershey Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04476914
NCT04684836,Comparative Effectiveness of Telemedicine in Primary Care,,Not yet recruiting,No Results Available,Asthma|Chronic Obstructive Pulmonary Disease (COPD|Congestive Heart Failure|Diabetes|Hypertension,"Other: Exposure to telemedicine, after the onset of the pandemic",Number of avoidable emergency department (ED) admissions|Number of unplanned hospital admissions from the ED|Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index|Continuity of care as assessed by the Breslau Usual Provider of Care measure|Continuity of care as assessed by attendance at follow-up appointment|Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)|Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure|Days at home|Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18)|Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ),Weill Medical College of Cornell University|Patient-Centered Outcomes Research Institute,All,"19 Years and older   (Adult, Older Adult)",,216000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-12023014,Feb-21,Apr-22,Dec-23,28-Dec-20,,28-Dec-20,"University of Florida, Gainesville, New York, United States|Mount Sinai, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04684836
NCT04546581,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),,Recruiting,No Results Available,COVID|COVID-19|SARS-CoV-2|SARS (Severe Acute Respiratory Syndrome),Drug: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo|Drug: Remdesivir,"Ordinal Outcome Scale - Day 7|All-cause mortality through Day 28|Ordinal Outcome Scale|Change in National Early Warning Score (NEWS)|Time to Worsening|Discharge Status|Days Alive Outside the Hospital|Pulmonary-only Components of the Primary Ordinal Outcome|Thrombotic Components of the Primary Ordinal Outcome|Time to recovery|Clinical Organ Dysfunction|Safety and Tolerability - Adverse Events|Safety and Tolerability - Infusion Reactions, Interruptions, or Cessation|Safety and Tolerability - Serious Adverse Events|Safety and Tolerability - Prevalence of Adverse Events|Change in Neutralizing Antibody Level",University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|The International Network for Strategic Initiatives in Global HIV Trials,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INSIGHT 013,8-Oct-20,Jul-21,Jul-21,14-Sep-20,,9-Dec-20,"Penrose Hospital, Colorado Springs, Colorado, United States|St. Francis Health Services, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|Saint Anthony North Health Campus, Westminster, Colorado, United States|Washington VA Medical Center, Washington, District of Columbia, United States|Redmond Regional Medical Center, Rome, Georgia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Hennepin Healthcare Research Institute/HCMC, Minneapolis, Minnesota, United States|University of Missouri, Columbia, Missouri, United States|Cox Medical Centers, Springfield, Missouri, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|Hendrick Medical Center, Abilene, Texas, United States|CHRISTUS Spohn Shoreline Hospital, Corpus Christi, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|CJW Chippenham Medical Center, Richmond, Virginia, United States|Henrico Doctors' Hospital (HCA), Richmond, Virginia, United States|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|CHIP, Department of Infectious Diseases, Section 2100, Copenhagen, Denmark|Herlev-Gentofte Hospital, Hellerup, Denmark|Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Kolding Sygehus, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Democritus University of Thrace, Alexandroupoli, Thrace, Greece|3rd Dept of Medicine, Medical School, NKUA, Athens, Greece|1st Respiratory Medicine Dept, Athens University Medical School, Athens, Greece|Attikon University General Hospital, Athens, Greece|Dept. of Critical Care & Pulmonary Medicine, Evangelismos General Hospital, Athens, Greece|NCGM, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|Institute of Human Virology-Nigeria (IHVN), Abuja, Nigeria|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Royal Free Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04546581
NCT04345614,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,,Recruiting,No Results Available,Pneumonia,Drug: Auxora|Drug: Placebo,Number of days from the Start of the First Infusion of Study Drug (SFISD) to recovery|Proportion of patients requiring invasive mechanical ventilation or dying|Proportion of patients requiring invasive mechanical ventilation|Differences in outcomes as measured by an 8-point ordinal scale|Proportion of patients who have died at day 30 (mortality)|Number of days in the hospital|Number of days in the Intensive Care Unit (ICU)|Incidence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)|CM4620-IE serum concentration,"CalciMedica, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CM4620-204,8-Apr-20,Mar-21,Apr-21,14-Apr-20,,23-Nov-20,"Long Beach Memorial, Long Beach, California, United States|University of Southern California / LA County, Los Angeles, California, United States|Sharp Memorial San Diego, San Diego, California, United States|Baton Rouge General, Baton Rouge, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai Grace, Detroit, Michigan, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Texas Tech University Medical Center, El Paso, Texas, United States|John Peter Smith Hospital, Fort Worth, Texas, United States|Ben Taub (Baylor), Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital San Cristobal, Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04345614
NCT03808922,Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study,,Recruiting,No Results Available,Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19,Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL,Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes),"Ansun Biopharma, Inc.",All,"Child, Adult, Older Adult",Phase 3,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAS181-3-01|2018-004318-16,23-May-19,30-Apr-21,28-Dec-21,18-Jan-19,,27-Oct-20,"City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|University of California Davis Health System, Sacramento, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Universtiy of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health, Winston-Salem, North Carolina, United States|The Lindner Center- The Christ Hospital, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Mercy Health, Youngstown, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Kent Hospital, Warwick, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|Texas Health, Fort Worth, Texas, United States|Therapeutic Concepts, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert Medical College Pulmonary Clinic, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Wesley Hospital, Auchenflower, Queensland, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Shanghai Pulmonary Hospital, Yangpu, Shanghai, China|West China Hospital, Nanchong, Sichuan, China|Shulan(Hangzhou)Hospital co., LTD, Hangzhou, Zhejiang, China|Rigshospitalet, Copenhagen, Denmark|Hôpital Henri Mondor, Créteil, Ile-de-France, France|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT03808922
NCT04659135,ASCO Survey on COVID-19 in Oncology (ASCO) Registry,,Recruiting,No Results Available,Neoplasms|Coronavirus,,Changes to Cancer Treatments|All-cause mortality at 30 days|COVID-19 Symptoms|COVID-19 Treatments|Patient vital status|Overall survival|Patient cancer status (for patients who had active cancer at covid-19 dx)|Patient cancer status (for patients who are disease-free at COVID-19 diagnosis),American Society of Clinical Oncology,All,"Child, Adult, Older Adult",,2000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Pro00014181,19-Apr-20,Dec-22,Dec-22,9-Dec-20,,9-Dec-20,"Anchorage Oncology Center, Anchorage, Alaska, United States|AIS Cancer Center, Bakersfield, California, United States|Long Beach Memorial Medical Center, Fountain Valley, California, United States|Orange Coast Medical Center, Fountain Valley, California, United States|Saddleback Memorial Medical Center, Fountain Valley, California, United States|Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|PIH Health, Whittier, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Hartford HealthCare Cancer Institute, Hartford, Connecticut, United States|Bayhealth Medical Center, Dover, Delaware, United States|Florida Precision Oncology, A Division of 21st Centry Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, LLC, Sarasota, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Hawaii Cancer Care, Honolulu, Hawaii, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|Edward-Elmhurst Healthcare, Naperville, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Michiana Hematology Oncology, Mishawaka, Indiana, United States|MidAmerica Oncology Associates, Overland Park, Kansas, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Baptist Health Madisonville, Madisonville, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|LifeBridge Health, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Great Lakes Cancer Management Specialists, Grosse Pointe Woods, Michigan, United States|Lakeland Hospitals, Saint Joseph, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mosaic Cancer Care, Saint Joseph, Missouri, United States|Nebraska Hematology Oncology, Lincoln, Nebraska, United States|Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Bayonne Medical Center, Bayonne, New Jersey, United States|CarePoint Health - Christ Hospital, Jersey City, New Jersey, United States|Penn Medicine, Princeton Health, Plainsboro, New Jersey, United States|Hematology Oncology Associates of Central New York, East Syracuse, New York, United States|Northwell Health Cancer Institute, Lake Success, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Levine Cancer Institute Atrium Health, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Carteret Health Care, Morehead City, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Florida Cancer Specialists, Massillon, Ohio, United States|Columbia Memorial Hospital, Astoria, Oregon, United States|Samaritan Health Services Corvallis, Corvallis, Oregon, United States|Penn Medicine, Lancaster General Health, Lancaster, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Monument Health, Rapid City, South Dakota, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|BSA Harrington Cancer Center, Amarillo, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04659135/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04659135
NCT04480333,"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",NEUROSIVIR,Recruiting,No Results Available,Covid19|Corona Virus Infection|Severe Acute Respiratory Syndrome|Severe Acute Respiratory Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Severe Acute Respiratory Syndrome of Upper Respiratory Tract|Neurodegeneration|Neuroinflammatory Response,Drug: Drug: NA-831 - 0.10 mg/kg|Drug: Placebo- 0.10 mg/kg|Drug: Drug: NA-831 - 0.20 mg/kg|Drug: Placebo- 0.20 mg/kg|Drug: Drug: GS-5734 - 1.00 mg/kg|Drug: Placebo- 1.00 mg/kg|Drug: Drug: GS-5734 - 2.00 mg/kg|Drug: Placebo- 2.00 mg/kg|Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|Combination Product: Placebo 0.10 mg + 1.00 mg/kg|Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|Combination Product: Placebo 0.20 mg + 2.00 mg/kg,Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-∞)|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment,"NeuroActiva, Inc.",All,21 Years to 50 Years   (Adult),Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NEUROSIVIR,15-Sep-20,31-Dec-20,31-Mar-21,21-Jul-20,,21-Jul-20,"Coronavirus Research Institute, Sunnyvale, California, United States",,https://ClinicalTrials.gov/show/NCT04480333
NCT04660422,Advance Care Planning: Communicating With Outpatients for Vital Informed Decision,ACP-COVID,Recruiting,No Results Available,Advanced Care Planning|Shared Decision Making|Video Decision Aids|Communication Skills|Advance Directives|Natural Language Processing|Covid19,Other: VitalTalk communication skills training|Other: ACP Decisions Video Program|Other: Intervention training:|Other: Medical Record Review,Rate for Advanced Care Planning (ACP) documentation|Rate of orders for resuscitation preferences|Rate of palliative care consultation|Rate of referral to hospice|Advanced Care Planning (ACP) documentation rates among under-represented minority groups.,Dana-Farber Cancer Institute|National Institute on Aging (NIA),All,65 Years and older   (Older Adult),,13150,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Other,20-600|UH3AG060626-03S1,15-Dec-20,14-May-21,14-May-21,9-Dec-20,,5-Jan-21,"Northwell Health, New Hyde Park, New York, United States",,https://ClinicalTrials.gov/show/NCT04660422
NCT04385160,Myeloproliferative Neoplasms (MPN) and COVID-19,MPN-COVID,Recruiting,No Results Available,Myeloproliferative Neoplasm|COVID,,pulmonary embolism (PE)|fatal or non fatal thrombotic event|Continuous Positive Airway Pressure (CPAP)|invasive ventilation|admission in Intensive Care Unit (ICU)|death|treatments and interventions applied for MPN|treatments and interventions applied for COVID-19|thrombotic events association to patients characteristic and treatments,Fondazione per la Ricerca Ospedale Maggiore|European Leukemia Net,All,"18 Years and older   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Other,FROM - O-MPN-COVID-2020,13-May-20,15-Jul-20,1-Sep-20,12-May-20,,23-Jul-20,"New York-Presbyterian/Weill Cornell Medical Center, New York, New York, United States|Hopital Saint-Louis, Paris, France|University Medical Center RWTH, Aachen, Germany|University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany|Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy|A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria, Alessandria, Italy|ASST-Papa Giovanni XXIII, Bergamo, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST-Spedali Civili, Brescia, Italy|AOU Ospedale Careggi, Firenze, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Ospedale Policlinico ""G.B. Rossi"" Borgo Roma, Verona, Italy|Ospedale San Bortolo, Vicenza, Italy|Sobas Wroclaw Medical University ·, Wrocław, Poland|Hospital Clínic De Barcelona, Barcelona, Barcellona, Spain|Hospital del Mar, Barcelona, Barcellona, Spain|Institut Català d' Oncologia - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet - Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital General de La Palma, Breña Alta, Santa Cruz De Tenerife, Spain|Servicio de Hematología Hospital General Universitario de Albacete, Albacete, Spain|Hospital General de Elche, Alicante, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|ICO Girona Hospital Josep Trueta Servei d'hematologia, Girona, Spain|FEA Hematología Hospital Universitario de Móstoles, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Moncloa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario, Valencia, Spain|Guy's and St. Thomas' NHS Foundation Trust., London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04385160
NCT04452318,Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,,Recruiting,No Results Available,Healthy Participants,Drug: REGN10933 + REGN10987|Drug: Placebo,"Proportion of participants who have a positive SARS-CoV-2 RT-qPCR (based on central lab test) and signs and symptoms (strict-term) of SARS-CoV-2 infection during the Efficacy assessment period (EAP)|Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infection (either symptomatic or asymptomatic) during the EAP|Proportion of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (strict term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (broad term) during the EAP|Number of days of symptomatic SARS-CoV-2 infection (strict-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Number of days of symptomatic SARS-CoV-2 infection (broad-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Time-weighted average of viral shedding (log10 copies/mL) from the first positive SARS CoV-2 RT-qPCR Nasopharyngeal (NP) swab sample (with an onset during the EAP) until the visit within the window including 22 days after the positive test during the EAP|Maximum SARS-CoV-2 RT-qPCR log10 viral copies/mL in Nasopharyngeal (NP) swab samples among individuals with ≥1 RT-qPCR positive that has an onset during the EAP|Area under the curve (AUC) in viral shedding (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR NP swab sample until the first confirmed negative test, that has an onset during the EAP|Number of medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset during the EAP|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days missed for daily responsibilities due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Incidence of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Proportion of baseline seropositive subjects (based on central lab test) with TEAEs and severity of TEAEs|Concentrations of REGN10933 in serum over time and selected PK parameters|Concentrations of REGN10987 in serum over time and selected PK parameters|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933 over time|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987 over time|Proportion of participants who subsequently develop signs and symptoms (strict-term) of symptomatic SARS-CoV-2 infection during EAP|Proportion of participants who subsequently develop signs and symptoms (broad-term) of symptomatic SARS-CoV-2 infection during EAP|Number of days of symptomatic SARS CoV-2 infection (strict-term)|Number of days of symptomatic SARS CoV-2 infection (broad-term)|Time-weighted average change from baseline in viral shedding in NP swab samples until the visit within the window including day 23|Area under the curve (AUC) in viral shedding (log10 copies/mL) in NP swab samples until the first confirmed negative test|Maximum SARS-CoV-2 RT-qPCR log10 viral copies/mL in NP swab samples|Number of medically attended visits in emergency rooms or urgent care centers related to RT-qPCR confirmed SARS-CoV-2 infection|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection|Number of days missed for daily responsibilities due to a RT-qPCR confirmed SARS-CoV-2 infection|Proportion of participants with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods",Regeneron Pharmaceuticals,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,2000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R10933-10987-COV-2069,13-Jul-20,15-Jun-21,15-Aug-21,30-Jun-20,,10-Nov-20,"Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Northridge, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Eatonton, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 2, Chicago, Illinois, United States|Regeneron Study Site 3, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site 1, Boston, Massachusetts, United States|Regeneron Study Site 2, Boston, Massachusetts, United States|Regeneron Study Site 3, Boston, Massachusetts, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Gulfport, Mississippi, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Hazelwood, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Fayetteville, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Gaffney, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Yakima, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucharest, Romania",,https://ClinicalTrials.gov/show/NCT04452318
NCT04681040,Risk Stratification of COVID-19 Using Urine Biomarkers,,Recruiting,No Results Available,Covid19|Urine|Biomarker|Acute Respiratory Failure With Hypoxia,,"Risk Stratification of COVID-19 Participants Using Urine Biomarkers|Prediction of COVID-19 Treatment by Urine L-FABP|Increase of O2 support, hospital days, worsening of chest X-ray and CT, and survival rate, at 14 and/or 30 days.|Comparison of Risk Stratification with Other Biomarkers","National Center for Global Health and Medicine, Japan",All,"20 Years and older   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NCGM-G-003654-00,19-Dec-20,31-Mar-22,31-Aug-22,23-Dec-20,,28-Dec-20,"MD Mount Sinai, Baltimore, Maryland, United States|Hospital das Clinicas Ribeirao Preto, Ribeirão Preto, San Paulo, Brazil|Danish National Biobank, København, Denmark|Shonan General Hospital, Kamakura, Kanagawa, Japan|National Center Global Health and Medicine, Shinjuku, Tokyo, Japan|Yamanashi Prefectural Central Hospital, Kōfu, Yamanashi, Japan|Unilab Group, Manila, Philippines",,https://ClinicalTrials.gov/show/NCT04681040
NCT04352634,The Covid-19 HEalth caRe wOrkErS (HEROES) Study,HEROES,Recruiting,No Results Available,Covid-19|Mental Health Disorder|Stress Disorder|Anxiety|Depression|SARS-CoV-2,Other: Exposure to the SARS-CoV-2 and its consequences,"Anxiety and depressive symptoms|Experiences, fears and concerns about the Covid-19|Training and resource prioritization|Suicide ideation (presence)|Suicide ideation (frequency)|Acute stress symptoms|Psycho/social support and network|Resilience",University of Chile,All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HEROES Covid-19,26-Apr-20,31-Dec-21,31-Dec-21,20-Apr-20,,14-Jul-20,"Columbia University, New York, New York, United States|Universidad del Chubut, Rawson, Chubut, Argentina|National Institute of Health Named After Academician S. Avdalbekyan, Yerevan, Armenia|University of Sydney, Sidney, New South Wales, Australia|Salud Global, Sucre, Chuquisaca, Bolivia|University of Chile, Santiago, Chile|Universidad Nacional de Costa Rica, Heredia, Costa Rica|Society for Emergecy and Disaster Medicine CzMA JEP, Kladno, Bohemia, Czechia|Hochschule Emden/Leer, Emden, Niedersachsen, Germany|Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias Médicas Universidad de San Carlos de Guatemala -USAC-, Guatemala City, Guatemala|University of Cagliari, Cagliari, CA, Italy|University of Cagliari, Cagliari, Italy|The Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon|Logotipo del comercio Instituto Jalisciense De Salud Mental (SALME), Guadalajara, Jalisco, Mexico|Maastricht University, Maastricht, Limburg, Netherlands|University of Ibadan, Ibadan, Oyo State, Nigeria|Ponce Health Sciences University, Ponce, Puerto Rico|King Abdullah International medical research center, Riyadh, Central, Saudi Arabia|Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain|Razi Hospital La Manouba, Tunis, La Manouba, Tunisia|Koc University, Istanbul, Sariyer, Turkey|PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon, Maracay, Aragua, Venezuela",,https://ClinicalTrials.gov/show/NCT04352634
NCT04323800,Convalescent Plasma to Stem Coronavirus (CSSC-001),CSSC-001,Recruiting,No Results Available,Coronavirus|Convalescence,Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma,Efficacy of treatment at Day 28|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2|Cumulative incidence of disease severity,Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB00245634,10-Jun-20,31-Dec-22,Jan-23,27-Mar-20,,9-Nov-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami, Coral Gables, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04323800
NCT04322682,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),COVID-19,Recruiting,No Results Available,Corona Virus Infection,Drug: Colchicine|Drug: Placebo oral tablet,Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation,"Montreal Heart Institute|National Heart, Lung, and Blood Institute (NHLBI)|Bill and Melinda Gates Foundation|The Government of Quebec|DACIMA Software",All,"40 Years and older   (Adult, Older Adult)",Phase 3,6000,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MHIPS-2020-001|3R01HL146206-02S1,23-Mar-20,Mar-21,Mar-21,26-Mar-20,,12-Jan-21,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|University of Arkansas for medical Sciences, Little Rock, Arkansas, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Prisma Health, Greenville, South Carolina, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, São Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04322682
NCT04422275,Coronavirus Smell Therapy for Anosmia Recovery,Co-STAR,Not yet recruiting,No Results Available,Anosmia,Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil,University of Pennsylvania Smell Identification Test (UPSIT)|Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).|Global Rating of Smell.|Global Rating of Smell Change.,Washington University School of Medicine,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PA-18-334,1-Jun-21,1-Jun-23,31-Dec-23,9-Jun-20,,11-Jun-20,"Washington University, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT04422275
NCT04573062,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,,Recruiting,No Results Available,Post-Coronavirus Disease 19,,Screening Phase,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,1200,NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,10000089|000089-N,20-Jan-21,31-Dec-24,31-Dec-24,5-Oct-20,,15-Jan-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04573062
NCT04441047,Universal Anti-Viral Vaccine for Healthy Elderly Adults,ALLOPRIME,Not yet recruiting,No Results Available,Virus Diseases,Drug: AlloStim,frequency of vaccine events|Proportion of subjects with positive T-cell response|Proportion of subjects able to suppress viral propagation,"Immunovative Therapies, Ltd.|Mirror Biologics, Inc.",All,65 Years and older   (Older Adult),Phase 1|Phase 2,40,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MBI-001-ALLOPRIME,6-Jan-21,7-Jul-21,31-Dec-21,22-Jun-20,,20-Nov-20,"Medical Oncology and Hematology, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04441047
NCT04326309,Audio Data Collection for Identification and Classification of Coughing,,Recruiting,No Results Available,COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy,,Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application,HealthMode Inc.,All,"18 Years and older   (Adult, Older Adult)",,1000,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,HM070102,25-Mar-20,25-Sep-22,25-Sep-22,30-Mar-20,,30-Mar-20,"Virtual Facility, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT04326309
NCT04436276,A Study of Ad26.COV2.S in Adults (COVID-19),,Recruiting,No Results Available,Healthy,Biological: Ad26.COV2.S|Biological: Placebo,"Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination|Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination|Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination|Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination|Cohorts 1, 2, and 3: Number of Participants With SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)|Cohorts 1, 2, and 3: Number of Participants with SARS-CoV-2 Binding Antibodies Assessed by ELISA|Cohorts 1, 2, and 3: Number of Participants with T-helper (Th)-1 and Th-2 Immune Responses as Assessed by Flow Cytometry",Janssen Vaccines & Prevention B.V.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1045,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",CR108828|2020-001483-28|VAC31518COV1001,15-Jul-20,3-Dec-21,2-Feb-24,18-Jun-20,,6-Jan-21,"Optimal Research, San Diego, California, United States|Optimal Research, Melbourne, Florida, United States|Optimal Research, Peoria, Illinois, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Optimal Research, Rockville, Maryland, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States|Optimal Research, Austin, Texas, United States|SGS Life Science Services, Antwerpen, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|ATC Pharma, Luik, Belgium|Clinical Pharmacology Unit, Merksem, Belgium|Universiteit Antwerpen, Wilrijk, Belgium",,https://ClinicalTrials.gov/show/NCT04436276
NCT02735707,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab|Drug: Vitamin C|Drug: Therapeutic anticoagulation|Drug: Simvastatin|Biological: Convalescent plasma|Other: Protocolised mechanical ventilation strategy|Drug: Eritoran|Drug: Apremilast|Drug: Aspirin|Drug: Clopidogrel|Drug: Prasugrel|Drug: Ticagrelor,All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,11-Apr-16,Dec-21,Dec-23,13-Apr-16,,12-Oct-20,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT02735707
NCT04383730,Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19),ISCA,Recruiting,No Results Available,Critically Illness|Sedation|Invasive Mechanical Ventilation|Acute Respiratory Distress Syndrome,Drug: Intravenous sedation|Drug: Inhaled sedation,"Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event|All-cause mortality|Ventilator-free days|ICU-free days|Duration of invasive mechanical ventilation|Duration of controlled mechanical ventilation|Physiological measures of lung function|Development of complications|Duration of vasopressor use|Duration of renal replacement therapy|Duration (in days) of any adjuvant therapies|Duration of continuous neuromuscular blockade|Type of sedation practices|Duration of sedation practices|Modalities of sedation practices","University Hospital, Clermont-Ferrand|Hospital Clínico Universitario de Valencia|University Hospital Schleswig-Holstein|Groupe Hospitalier Pitie-Salpetriere",All,"18 Years and older   (Adult, Older Adult)",,400,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,ISCA Study,26-Jun-20,30-Nov-20,31-Dec-20,12-May-20,,1-Dec-20,"Beth Israel Deaconess Medical Center, Inc., Boston, Massachusetts, United States|CHU, Clermont-Ferrand, France|Centre Hospitalier, Dunkerque, France|Pitié-Salpêtrière Hospital - APHP, Paris, France|CH Privé de la Loire, Saint-Étienne, France|University Medical Center Schleswig-Holstein, Kiel, Germany|Universitätsklinikum, Oldenburg, Germany|Hospital Clínico Universitario de Valencia, Valencia, Spain|Cantonal Hospital, Münsterlingen, Switzerland|Universitätsspital, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT04383730
NCT04377412,Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic,MindCOVID,Recruiting,No Results Available,Anxiety|Depression|Pregnancy Related,Other: Pandemic control measures,Anxiety|Depression,"Żelazna Medical Centre, LLC|University of Medicine, Tirana|Royal Prince Alfred Hospital, Sydney, Australia|Charles University, Czech Republic|Hôpital Necker-Enfants Malades|Charite University, Berlin, Germany|Chinese University of Hong Kong|Meir Medical Center|Università degli Studi di Brescia|American University of Beirut Medical Center|Karolinska Institutet|Pomeranian Medical University Szczecin|Nicolaus Copernicus University|Centre of Postgraduate Medical Education|Polish Academy of Sciences|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland|Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal ""iMaterna"", Madrid|Taiji Clinic, Taipei|Wayne State University|Chang Gung University|University of Tromso",Female,"18 Years and older   (Adult, Older Adult)",,8500,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,Maternal axiety and COVID-19,1-May-20,31-Aug-20,31-Oct-20,6-May-20,,6-May-20,"Wayne State University, Detroit, Michigan, United States|University of Medicine Tirana, Tirana, Albania|Royal Prince Alfred Hospital, Sydney, Australia|Charles University, Prague, Czechia|Université de Paris, Paris, France|Charité - University Medicine Berlin, Berlin, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Meir Medical Center, Kafr Saba, Israel|University of Brescia, Brescia, Italy|American University of Beirut, Beirut, Lebanon|The Arctic University of Norway, Tromsø, Norway|Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland|Pomeranian Medical University, Szczecin, Poland|Centre of Postgraduate Medical Education, Warsaw, Poland|11. Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal ""iMaterna"", Madrid, Spain|Karolinska Institutet, Stockholm, Sweden|Taiji Clinic, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT04377412
NCT03648372,"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)",,Recruiting,No Results Available,Neoplasms|Lymphoma|Hematologic Neoplasms|Coronavirus Disease,Drug: TAK-981|Drug: Standard of care,"Phase 1: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)|Phase 1: Number of Participants Based on Severity of TEAEs|Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)|Phase 1: Number of Participants With Clinically Significant Laboratory Values|Phase 2: Overall Response Rate (ORR)|COVID-19 Expansion: Number of Participants With Greater Than or Equal to (>=) 2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples|Phase 2: Number of Participants Reporting one or More TEAEs|Phase 2: Number of Participants Based on Severity of TEAEs|Phase 2, Cmax: Maximum Observed Plasma Concentration for TAK-981|Phase 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981|Phase 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-981|Phase 2, AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981|Phase 2, Terminal Disposition Phase Half-life (t1/2z) for TAK-981|Phase 2, Total Clearance (CL) After Intravenous Administration for TAK-981|Phase 2, Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981|Phase 2: ORR|Phase 2: Duration of Response (DOR)|Phase 2: Disease Control Rate (DCR)|Phase 2: Time to Response (TTR)|Phase 2: Time to Progression (TTP)|Phase 2: Progression-free Survival (PFS)|Phase 2: Overall Survival (OS)|Phase 2: Number of Participants With TAK-981-Small Ubiquitin-like Modifier (TAK-981-SUMO) Adduct Formation and SUMO Pathway Inhibition in Skin/Blood|COVID-19 Expansion: Number of Participants Reporting one or More TEAEs|COVID-19 Expansion: Number of Participants Based on Severity of TEAEs|COVID-19 Expansion: Duration of TEAEs|COVID-19 Expansion: Change from Baseline in National Early Warning Score (NEWS)|COVID-19 Expansion: Percentage of Participants Reporting Each Hospitalization Severity Rating|COVID-19 Expansion: Change From Baseline in SARS-CoV-2 Viral Load in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Percentage of Participants Requiring Oxygen Supplementation; Assisted or Positive Pressure Non-invasive Ventilation; and Invasive Ventilation, on Days 3, 5, 8, 11, 15, and 30|COVID-19 Expansion: Percentage of Participants That met Intensive Care Unit (ICU) Criteria|COVID-19 Expansion: Duration of Hospitalization|COVID-19 Expansion: Time to Viral Ribonucleic Acid (RNA) Negativity in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Time to Discharge or to a NEWS of Less Than or Equal to (<=) 3 and Maintained for 24 Hours|COVID-19 Expansion: Number of Deaths in Hospital due to any Cause in First 30 Days and in 90 Days","Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,242,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAK-981-1002|U1111-1214-4537|2020-003947-27,1-Oct-18,1-Dec-22,1-Oct-23,27-Aug-18,,3-Dec-20,"University of California San Diego Moores Cancer Center, La Jolla, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03648372
NCT04414826,Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness,,Recruiting,No Results Available,Loneliness,Behavioral: Mindfulness Alone (MO) Intervention|Behavioral: Mindfulness + Compassion Intervention (MC),Revised University of California Los Angeles Loneliness Scale - 8 (ULS-8)|Perceived Stress Scale (PSS),University of Texas at Austin,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-04-0088,25-May-20,May-21,May-21,4-Jun-20,,4-Jun-20,"Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04414826
NCT03452774,SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry,,Recruiting,No Results Available,"Cancer, Metastatic|Cancer|Cancer of Pancreas|Cancer of Liver|Cancer of Stomach|Cancer Liver|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Cervix|Cancer of Colon|Cancer of Larynx|Cancer, Lung|Cancer, Breast|Cancer, Advanced|Cancer Prostate|Cancer of Neck|Cancer of Skin|Neuroendocrine Tumors|Carcinoma|Mismatch Repair Deficiency|BRCA Gene Rearrangement|Non Hodgkin Lymphoma|Leukemia|Non Small Cell Lung Cancer|Cholangiocarcinoma|Glioblastoma|Central Nervous System Tumor|Melanoma|Urothelial Carcinoma|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Testicular Cancer|Breast Cancer|COVID",Other: Clinical Trial Matching,"Proportion of patients Eligible for CTE versus Actual CTE|Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Identification of Barriers to CTE|Real World Data Analytics|Virtual Tumor Board Utilization|Time from Intervention to Actual CTE (months)","Massive Bio, Inc.",All,"Child, Adult, Older Adult",,1500,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,SYNERGY-AI,1-Jan-18,Dec-21,Dec-22,2-Mar-18,,28-Apr-20,"Massive Bio, Inc, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03452774
NCT04683744,Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation,,Recruiting,No Results Available,Colorectal Cancer Screening,Other: Semi-structured interviews-Patients|Other: Semi-structured interviews-Health system,"Identify facilitators and barriers to implementing decision aids, provider notifications, and personal risk calculation using an electronic health record to promote colorectal cancer screening.|Identify the challenges and facilitators of effective cancer screening and prevention in primary care during the COVID-19 pandemic among leadership, providers, and staff.|Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake",Indiana University|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Other,2012926551|CDR-2018C3-14715,Jan-21,Jul-23,Jul-23,24-Dec-20,,24-Dec-20,"Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT04683744
NCT04684602,Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions,,Recruiting,No Results Available,Autoimmune Diseases|Cardiovascular Disorders|Diabetes Complications|Integumentary Disease|Musculoskeletal Disorders|Neurodegenerative Disorders|Neurologic Disorders|Pulmonary Disorders|Sexual Dysfunction|Urologic Disorders|Viral Illness,Biological: PrimePro™/ PrimeMSK™,"Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.",Thomas Advanced Medical LLC|HeartStem Institute|NuStem,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5000,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICSS-2020-032,9-Jul-20,9-Jul-30,9-Dec-30,24-Dec-20,,24-Dec-20,"Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City, California, United States",,https://ClinicalTrials.gov/show/NCT04684602
NCT04278404,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",POPS or POP02,Recruiting,No Results Available,Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Fibrinolysis; Hemorrhage|Attention Deficit Hyperactivity Disorder|Multisystem Inflammatory Syndrome in Children (MIS-C)|Kawasaki Disease|Coagulation Disorder|Down Syndrome,"Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,5-Mar-20,24-Apr-24,24-Apr-24,20-Feb-20,,14-Oct-20,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|University of California, Los Angeles, California, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas-Southwestern Medical Center, Dallas, Texas, United States|University of Texas--Memorial Hermann Texas Medical Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04278404
NCT04240886,Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds,AEGIS,Recruiting,No Results Available,Invasive Fungal Infections,Drug: fosmanogepix,All-Cause Mortality|Global Response,Amplyx Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APX001-202|2019-001386-33,4-Jan-20,Jul-21,Oct-21,27-Jan-20,,14-Jan-21,"Clinical Trial Site, Duarte, California, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Brussels, Belgium|Clinical Trial Site, Brussels, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Yvoir, Belgium|Clinical Trial Site, Mainz, Germany|Clinical Trial Site, Haifa, Israel|Clinical Trial Site, Tel Aviv, Israel|Clinical Trial Site, Tel HaShomer, Israel",,https://ClinicalTrials.gov/show/NCT04240886
NCT03474965,Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients,,Recruiting,No Results Available,Sickle Cell Disease (SCD),Drug: Crizanlizumab,"PK (AUCd15) after 1st dose|PD (AUCd15) after 1st dose|PK (AUCtau) after multiple dose|PD (AUCtau) after multiple dose|PK (Cmax) after 1st dose and multiple dose|PK pre-dose concentrations|Frequency of any adverse events (AEs) as a measure of safety and tolerability|Annualized rate Vaso Occusive Crisis (VOC) events leading to healthcare visit in clinic/ER/hospital|Annualized rate Vaso Occusive Crisis (VOC) events treated at home (based on documentation by health care provider following phone contact with the patient)|Annualized rate each subcategory of VOC event (uncomplicated pain crisis, acute chest syndrome, hepatic sequestration, splenic sequestration, priapism)|Annualized rate hospitalizations and ER visits (both overall and VOC-related)|Annualized rate days of ER/hospitalization (both overall and VOC-related)|Annualized rate of dactylitis events|Number, seriousness, severity, and causality assessments of treatement emergent adverse events and other data as considered appropiate.|Absolute change from baseline in hemoglobin|Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab|Electrocardiogram (ECGs) at relevant PK time points|Growth and sexual maturation assessments (Tanner stage)|PK pre-dose concentrations prior to each study drug dose.|Percentage P-selectin inhibition prior to dosing",Novartis Pharmaceuticals|Novartis,All,6 Months to 17 Years   (Child),Phase 2,100,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSEG101B2201|2017-001747-12,1-Oct-18,5-Jun-23,20-Nov-24,23-Mar-18,,23-Dec-20,"University of Alabama 1600 7th ave, Birmingham, Alabama, United States|Phoenix Childrens Hospital CVAL489A2302, Phoenix, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|Children s National Hospital, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States|Childrens Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H Lurie Childrens Hospital of Chicago CTBM100C2407, Chicago, Illinois, United States|University of Chicago Hospital, Chicago, Illinois, United States|Childrens Hospital Boston, Boston, Massachusetts, United States|Institute for Pediatric Cancer and Blood Disorders, Hackensack, New Jersey, United States|UMDNJ, New Brunswick, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Duke University Medical Center Oncology, Durham, North Carolina, United States|East Carolina University SC, Greenville, North Carolina, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Medical Uni of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hosptial, Memphis, Tennessee, United States|Cook Childrens Medical Center Oncology, Fort Worth, Texas, United States|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Laeken, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Heidelberg, Baden Wuerttemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Vellore, India|Novartis Investigative Site, Modena, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Padova, Italy|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Aarau, Aargau, Switzerland|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03474965
NCT04666597,Pandemic-adapted Caries Care Multicentre Case Series,,Recruiting,No Results Available,Dental Caries in Children,Procedure: Modified CariesCare International management,Outcome at the tooth surface and at the individual level|Parents' satisfaction and dentists' process acceptability|Children behaviour change related with oral health caring,"Universidad El Bosque, Bogotá|King's College London|University of Leeds|University of Sheffield",All,3 Years to 8 Years   (Child),,420,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00010617,15-Nov-20,2-Mar-22,2-Mar-22,14-Dec-20,,14-Dec-20,"Indiana University, Indianapolis, Indiana, United States|Tufts University, Boston, Massachusetts, United States|Universidad de Buenos Aires, Buenos Aires, Argentina|Universidad Nacional de Córdoba, Córdoba, Argentina|University of Sao Paulo, São Paulo, Brazil|Universidad El Bosque, Bogotá, Bogotá DC, Colombia|Viva 1A IPS Health Provider, Barranquilla, Colombia|Fundación Universitaria de Colegios de Colombia, Bogotá, Colombia|Corporación Universitaria Rafael Núñez, Cartagena, Colombia|Universidad de Cartagena, Cartagena, Colombia|ACFF Colombian Chapter Manizales Demonstration Territory, Manizales, Colombia|Universidad Cooperativa de Colombia, Medellín, Colombia|Universidad Iberoamericamericana, Santo Domingo, Dominican Republic|Universite Cote d' Azur, Nice, France|Universidad de Guadalajara, Guadalajara, Mexico|ACTA, Amsterdam, Netherlands|Universidad Peruana Cayetano Heredia, Lima, Peru|University of Porto, Porto, Portugal|University of Moscow, Moscow, Russian Federation|University of Sheffield, Sheffield, United Kingdom|Universidad Católica de Uruguay, Buenos aires, Sanmartin, Uruguay",,https://ClinicalTrials.gov/show/NCT04666597